

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 415 987 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

06.05.2004 Bulletin 2004/19(21) Application number: **01976786.2**(22) Date of filing: **19.10.2001**

(51) Int Cl.⁷: **C07D 213/74**, C07D 213/75,
C07D 215/48, C07D 239/47,
C07D 401/12, C07D 401/14,
C07D 413/12, C07D 405/12,
C07D 409/12, A61K 31/47,
A61P 35/00

(86) International application number:

PCT/JP2001/009221

(87) International publication number:

WO 2002/032872 (25.04.2002 Gazette 2002/17)

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**(30) Priority: **20.10.2000 JP 2000320420****20.12.2000 JP 2000386195****22.02.2001 JP 2001046685**(71) Applicant: **Eisai Co., Ltd.****Tokyo 112-0002 (JP)**


(72) Inventors:

- FUNAHASHI, Yasuhiro
Nakamura-ku, Nagoya-shi, Aichi 453-0831 (JP)
- TSURUOKA, Akihiko
Tsukuba-shi, Ibaraki 305-0031 (JP)
- MATSUKURA, Masayuki
Tsukuba-shi, Ibaraki 300-2635 (JP)
- HANEDA, Toru
Ushiku-shi, Ibaraki 300-1216 (JP)
- FUKUDA, Yoshio
Tsukuba-shi, Ibaraki 305-0035 (JP)
- KAMATA, Junichi
Tsukuba-shi, Ibaraki 305-0005 (JP)
- TAKAHASHI, Keiko
Ushiku-shi, Ibaraki 300-1237 (JP)
- MATSUSHIMA, Tomohiro
Ushiku-shi, Ibaraki 300-1237 (JP)
- MIYAZAKI, Kazuki
Tsukuba-shi, Ibaraki 305-0061 (JP)


- **NOMOTO, Ken-ichi**
Tsukuba-shi, Ibaraki 305-0032 (JP)
- **WATANABE, Tatsuo**
Inzai-shi, Chiba 270-1323 (JP)
- **OBAISHI, Hiroshi**
Tsukuba-shi, Ibaraki 305-0035 (JP)
- **YAMAGUCHI, Atsumi**
Tsukuba-shi, Ibaraki 305-0045 (JP)
- **SUZUKI, Sachi**
Tsuchiura-shi, Ibaraki 300-0032 (JP)
- **NAKAMURA, Katsuji**
Tsukuba-shi, Ibaraki 305-0035 (JP)
- **MIMURA, Fusayo**
Tsukuba-shi, Ibaraki 300-3257 (JP)
- **YAMAMOTO, Yuji**
Tsukuba-shi, Ibaraki 305-0061 (JP)
- **MATSUI, Junji**
Toride-shi, Ibaraki 302-0006 (JP)
- **MATSUI, Kenji**
Tsukuba-shi, Ibaraki 305-0035 (JP)
- **YOSHIBA, Takako**
Tsukuba-shi, Ibaraki 300-3253 (JP)
- **SUZUKI, Yasuyuki**
Kagamigahara-shi, Gifu 509-0124 (JP)
- **ARIMOTO, Itaru**
Tsukuba-shi, Ibaraki 305-0061 (JP)

(74) Representative: **HOFFMANN - EITLE****Patent- und Rechtsanwälte****Arabellastrasse 4****81925 München (DE)**(54) **NITROGENOUS AROMATIC RING COMPOUNDS**

(57) Compounds represented by the following general formula:



[wherein A⁹ is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X⁹ is -O-, -S-, etc.; Y⁹ is an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T⁹¹ is a group represented by the following general formula:



(wherein E^9 is a single bond or $-N(R^{92})-$, R^{91} and R^{92} each independently represent a hydrogen atom, an optionally substituted C_{1-6} alkyl group, etc. and Z^9 represents a C_{1-8} alkyl group, a C_{3-8} alicyclic hydrocarbon group, a C_{6-14} aryl group, etc.)), salts thereof or hydrates of the foregoing.

Description**Technical Field**

[0001] The present invention relates to novel compounds which are effective for prevention and treatment of various diseases associated with abnormal angiogenesis, and to medical compositions such as angiogenesis inhibitors and antitumor agents comprising the novel compounds.

Background Art

[0002] Angiogenesis is an essential biological phenomenon for fetal vascular formation and morphological and functional development of organs. New blood vessels are assembled through several processes including endothelial cell migration, proliferation and tube formation, and the participation of mast cells, lymphocytes, interstitial cells and the like has been shown to be important in this process (J. Folkman and Y. Shing, J. Biol. Chem., 267, 10931, 1992). In adult individuals, physiological angiogenesis occurs during the female estrous cycle, but pathological increase in angiogenesis in adult individuals is known to be connected with onset or progression of various diseases. Specific diseases associated with abnormal angiogenesis include cancer, rheumatoid arthritis, atherosclerosis, diabetic retinopathy, angioma, psoriasis, and the like (J. Folkman, N. Engl. J. Med., 333, 1757, 1995). In particular, the literature has indicated angiogenesis dependency for solid tumor growth, and angiogenesis inhibitors are therefore promising as new therapeutic agents for intractable solid tumors (J. Folkman, J. Natl. Cancer Inst., 82, 4, 1990).

[0003] The prior art includes compounds based on a urea structure, described in WO99/00357 and WO00/43366. WO99/00357 mentions biphenylurea derivatives which have an inhibiting action on *raf* kinase and an antitumor effect, but their angiogenesis-inhibiting effect is not disclosed. WO00/43366 describes quinoline derivatives and quinazoline derivatives which exhibit a weak karyomorphism-altering effect on A375 human melanoma cells *in vitro* and an anti-proliferative effect on endothelial cells stimulated by vascular epithelial growth factor (VEGF), and which thus have an antitumor effect, but their effect on angiogenic factors other than VEGF is not disclosed.

Disclosure of the Invention


[0004] As mentioned above, it is ardently desired to provide angiogenesis-inhibiting compounds which are useful as drugs. However, clinically effective compounds that exhibit excellent angiogenesis-inhibiting effects and high usefulness as medicines have not yet been discovered.

[0005] It is an object of the present invention to investigate and discover angiogenesis-inhibiting compounds which (1) exhibit antitumor activity through a powerful angiogenesis-inhibiting effect or a powerful angiogenesis-inhibiting and cancer cells growth-inhibiting effect, (2) are highly useful as drug materials in terms of their properties, biokinetics and safety, and (3) are useful for amelioration, prevention and treatment of various diseases associated with abnormal increase in angiogenesis.

[0006] As a result of much diligent research in light of the circumstances described above, the present inventors have succeeded in synthesizing novel compounds represented by the following general formula (I) and their salts or hydrates, and have completed the present invention upon discovering that the compounds of general formula (I) and their salts or hydrates exhibit an excellent angiogenesis-inhibiting effect.


[0007] Specifically, the invention relates to:

<1> a compound represented by the following general formula:




[wherein A^g is an optionally substituted C_{6-14} aryl group or an optionally substituted 5- to 14-membered heterocyclic group; X^g is a single bond, -O-, -S-, a C_{1-6} alkylene group, -SO₂-, -SO₂- or -N(R^{g3})- (wherein R^{g3} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{2-7} acyl group); Y^g is an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted C_{1-8} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl- C_{1-6} alkyl group, an optionally substituted 5- to 14-membered heteroaryl- C_{1-6} alkyl group, -(CH₂)_gSO₂- (wherein g is an integer of 1 to 8), -(CH₂)_{fa}-CH=CH-(CH₂)_{fb}- (wherein fa and fb each represent 0, 1, 2 or 3), -(CH₂)_{fa}-CH=CH-(CH₂)_{fb}-SO₂- (wherein fa and fb each represent 0, 1, 2 or 3), -(CH₂)_{fa}-C≡C-(CH₂)_{fb}- (wherein fa and fb each represent 0, 1, 2 or 3) or -(CH₂)_{fa}-C≡C-(CH₂)_{fb}-SO₂- (wherein fa and fb each represent 0, 1, 2 or 3);


and T⁹¹ is (1) a group represented by the following general formula:



{wherein E_g is a single bond or -N(R⁹²)- (wherein R⁹² is a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group); R⁹¹ is a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and Z⁹ is a hydrogen atom, an optionally substituted C₁₋₈ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted C₆₋₁₄ aryl-C₁₋₆ alkyl group, -OR²⁰⁰, -SR²⁰⁰, -COR²⁰⁰, -SO₂R²⁰⁰ (wherein R²⁰⁰ is a hydrogen atom, an optionally substituted C₁₋₈ alkyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted C₆₋₁₄ aryl-C₁₋₆ alkyl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered heterocyclic-C₁₋₆ alkyl group), an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered heterocyclic-C₁₋₆ alkyl group}, or (2) a group represented by the following general formula:




{wherein R⁹¹ and Z⁹ have the same definitions as R⁹¹ and Z⁹ above; and Z⁹¹ and Z⁹² may be the same or different and each is (1) a single bond, (2) an optionally oxo-substituted C₁₋₆ alkylene group also optionally having one or more atoms selected from -O-, -S- and a nitrogen atom within or at the end of the chain, or (3) an optionally substituted C₂₋₆ alkenyl group}}, a salt thereof or a hydrate of the foregoing;
<2> a compound represented by the following general formula:



[wherein A is an optionally substituted 5- to 14-membered aromatic heterocyclic group; X is an oxygen atom, a sulfur atom, -SO- or -SO₂; Y is an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C₁₋₆ alkylene group; E is a single bond or -NR²-; R¹ and R² are each independently a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and Z is a group represented by the formula -Z¹¹-Z¹² (wherein Z¹¹ is a single bond, an oxygen atom, a sulfur atom, -CO-, -SO₂- or an optionally substituted C₁₋₆ alkylene group and Z¹² is a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic hetero-


cyclic group or a group represented by the formula:



(wherein Z^{31} , Z^{33} and Z^{34} are each independently a methylene group, -CO-, -NH- or -O-, and Z^{32} is a single bond, a methylene group, -CO-, -NH- or -O-), with the proviso that A may be an optionally substituted with 1 to 6 groups, each selected from the group consisting of (1) a cyano group, (2) a halogen atom, (3) a nitro group and (4) the formula $-V^{X1}-V^{X2}-V^{X22}-V^{X3}$ (wherein V^{X1} , V^{X2} and V^{X22} are each independently a single bond, an oxygen atom, a sulfur atom, -CO-, -SO-, -SO₂-, -NR^{X1}-, -CONR^{X1}-, -NR^{X1}CO-, -SO₂NR^{X1}-, -NR^{X1}-SO₂-, -O-CO-, -C(O)O-, -NR^{X1}C(O)O-, -NR^{X1}C(O)NR^{X2}-, -O-C(O)NR^{X1}-, -O-C(O)O-, an optionally substituted C₁₋₆ alkylene group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and V^{X3} , R^{X1} and R^{X2} are each independently a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C₁₋₆ alkoxy group)], a salt thereof or a hydrate of the foregoing;


<3> a compound according to <2>, a salt of the compound or a hydrate of the foregoing, wherein X is an oxygen atom or a sulfur atom;

<4> a compound according to <2> or <3>, a salt of the compound or a hydrate of the foregoing, wherein Z is an optionally substituted cyclopropyl group, an optionally substituted 2-thiazolyl group or a group represented by the formula:




(wherein Z^{13} is a nitrile group, a methylsulfonyl group or a -NHCOCH₃ group);

<5> a compound according to any one of <2> to <4>, a salt of the compound or a hydrate of the foregoing, wherein E is a group represented by the formula -NR²- (wherein R² has the same definition as R² in <2>), and Y is an optionally substituted phenyl group, an optionally substituted pyridyl group or a group represented by the formula:




(wherein W¹¹ and W¹² are each independently an optionally substituted carbon atom or a nitrogen atom);


<6> a compound according to any one of <2> to <4>, a salt of the compound or a hydrate of the foregoing, wherein E is a single bond, and Y is a further optionally substituted group represented by the formula:




(wherein W^{13} is an optionally substituted carbon atom or a nitrogen atom);
 <7> a compound according to any one of <2> to <6>, a salt of the compound or a hydrate of the foregoing, wherein
 A is a group represented by the formula:



[wherein W is an optionally substituted carbon atom or a nitrogen atom; R^{a13} is a hydrogen atom, a halogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{1-6} alkoxy group, an amino group or a nitro group; R^{a12} is a cyano group or a group represented by the formula:




(wherein Va^{11} is $-CO-$ or $-SO_2-$; and Va^{12} , Va^{13} and Va^{14} are each independently a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group); and R^{a11} is a group represented by the formula $-Va^{21}-Va^{22}-Va^{23}$ (wherein Va^{21} is an optionally substituted C_{1-6} alkylene group, a single bond or a group represented by the formula:




; Va^{22} is a single bond, an oxygen atom, a sulfur atom, $-CO-$, $-SO-$, $-SO_2-$, $-CONR^{a14}-$, $-SO_2NR^{a14}-$, $-NR^{a14}SO_2-$, $-NR^{a14}CO-$ or $-NR^{a14}-$ (wherein R^{a14} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{3-8} alicyclic hydrocarbon group); and Va^{23} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group)];

<8> a compound according to any one of <2> to <6>, a salt of the compound or a hydrate of the foregoing, wherein A is a group represented by the formula:




(wherein W is an optionally substituted carbon or a nitrogen atom; and Ra¹¹, Ra¹² and Ra¹³ have the same definitions as Ra¹¹, Ra¹² and Ra¹³ in <7>);

<9> a compound according to any one of <2> to <6>, a salt of the compound or a hydrate of the foregoing, wherein A is a further optionally substituted group represented by the formula:




[wherein W is an optionally substituted carbon atom or a nitrogen atom; and Ab¹¹ is (1) an optionally substituted 5- to 14-membered heterocyclic group or (2) a group represented by the formula:




(wherein V^{b11} and V^{b12} are each independently a single bond, -SO₂-, -NHCO- or a group represented by the formula -(CH₂)_b-CO- (wherein b is an integer of 0 to 6); R^{b13} is a single bond, an optionally substituted C₁₋₆ alkylene group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group or an optionally substituted 5- to 14-membered heterocyclic group; and R^{b11} and R^{b12} are each independently a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted 5- to 14-membered heterocyclic group)];


<10> a compound according to any one of <2> to <6>, a salt of the compound or a hydrate of the foregoing, wherein A is a group represented by the formula:




[wherein W is an optionally substituted carbon or a nitrogen atom; R^{c13} is (1) a hydrogen atom, (2) a cyano group, (3) a halogen atom, (4) a formyl group, (5) an optionally substituted C_{1-6} alkyl group, (6) a group represented by the formula:




(wherein V^{c21} is -CO- or a methylene group; V^{c22} and V^{c23} are each independently a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C_{6-14} aryl group), or (7) a group represented by the formula - V^{c21} -O- V^{c22} (wherein V^{c21} and V^{c22} have the same definitions as V^{c21} and V^{c22} above); R^{c12} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{3-8} alicyclic hydrocarbon group; and R^{c11} is a group represented by the formula - V^{c11} - V^{c12} - V^{c13} (wherein V^{c11} is a single bond, an oxygen atom, an optionally substituted benzene ring, an optionally substituted 5- to 14-membered aromatic heterocyclic group or -CO-; V^{c12} is a single bond, an oxygen atom or an optionally substituted C_{1-6} alkylene group; and V^{c13} is (1) an optionally substituted C_{1-6} alkyl group, (2) an optionally substituted C_{2-6} alkenyl group, (3) an optionally substituted C_{2-6} alkynyl group, (4) an optionally substituted C_{3-8} alicyclic hydrocarbon group, (5) a hydroxyl group, (6) a carboxyl group, (7) an optionally substituted C_{2-} alkoxy-carbonyl group, (8) an optionally substituted 5- to 14-membered heterocyclic group, (9) an optionally substituted 5- to 14-membered aromatic heterocyclic group, (10) an optionally substituted C_{6-14} aryl group, (11) a group represented by the formula - $NR^{c21}R^{c22}$ (wherein R^{c21} and R^{c22} are each independently a hydrogen atom or an optionally substituted C_{1-6} alkyl group), or (12) a hydrogen atom)];
<11> a compound represented by the following general formula:



[wherein R^1 , R^2 and Z^{12} have the same definitions as R^1 , R^2 and Z^{12} in <2>, but Z^{12} is not a pyrazolyl group; Y^{a1} is a group represented by the formula:




(wherein W^{31} and W^{32} are each independently an optionally substituted carbon atom or a nitrogen atom; R^{300} and R^{301} are each independently a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{1-6} alkoxy group, an optionally substituted C_{2-7} alkoxycarbonyl group, a formyl group, a group represented by the formula




(wherein V^{300} and V^{301} are each independently a hydrogen atom or an optionally substituted C_{1-6} alkyl group), or an optionally substituted C_{2-7} acyl group); and R^{a11} and R^{a12} have the same definitions as R^{a11} and R^{a12} in <7>, with the exception of the following compounds (1) and (2): (1) a compound wherein R^{a12} is a group represented by the formula:



(wherein V^{a12} and V^{a13} have the same definitions as V^{a12} and V^{a13} in <7>), R^1 and R^2 are hydrogen atoms and Z^{12} is a C_{6-14} aryl group, a 6- to 14-membered heterocyclic group or a 6- to 14-membered aromatic heterocyclic group; (2) a compound wherein R^{a12} is a group selected from the group consisting of the formulas:




(wherein V^{a11} , V^{a12} , V^{a13} and V^{a14} have the same definitions as V^{a11} , V^{a12} , V^{a13} and V^{a14} in <7>), R^2 is a hydrogen atom and Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a 5- to 14-membered aromatic heterocyclic group, (d) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (e) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (f) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (g) a C_{3-8} alicyclic hydrocarbon group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group], a salt thereof or a hydrate of the foregoing; <12> a compound according to <11>, a salt of the compound or a hydrate of the foregoing, wherein R^{a11} is a methyl group, a 2-methoxyethyl group or a group represented by the formula:



(wherein R^{a53} is a methyl group, a cyclopropylmethyl group or a cyanomethyl group; R^{a51} is a hydrogen atom, a fluorine atom or a hydroxyl group; and R^{a52} is a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group);

<13> a compound according to <11> or <12>, a salt of the compound or a hydrate of the foregoing, wherein Z^{12} is a methyl group, an ethyl group, a cyclopropyl group, a 2-thiazolyl group or a 4-fluorophenyl group;


<14> a compound according to any one of <11> to <13>, a salt of the compound or a hydrate of the foregoing, wherein Y^{a1} is a group represented by the formula:





(wherein R^{a61} is a hydrogen atom, a methyl group, a trifluoromethyl group, a chlorine atom or a fluorine atom);

<15> a compound according to any one of <11> to <14>, a salt of the compound or a hydrate of the foregoing, wherein R^{a12} is a cyano group or a group represented by the formula $-\text{CONHR}^{a62}$ (wherein R^{a62} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{1-6} alkoxy group or an optionally substituted C_{3-8} cycloalkoxy group);


<16> a compound represented by the following general formula:



[wherein Z^{21} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group or an optionally substituted C_{3-8} alicyclic hydrocarbon group; R^{a120} is a cyano group or a group represented by the formula:




(wherein V^{a15} is an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group or an optionally substituted C_{3-8} alicyclic hydrocarbon group, and V^{a11} , V^{a12} , V^{a13} and V^{a14} have the same definitions as V^{a11} , V^{a12} , V^{a13} and V^{a14} in <7>; R^{300} and R^{301} have the same definitions as R^{300} and R^{301} in <11>; and R^{a11} has the same definition as R^{a11} in <7>, with the exception of a compound wherein R^{a120} is a group selected from the group consisting of the formulas:




(wherein V^{a11} , V^{a12} , V^{a13} and V^{a14} have the same definitions as V^{a11} , V^{a12} , V^{a13} and V^{a14} in <7>, and V^{a15} is as defined above), and Z^{21} is (a) a C_{3-8} alicyclic hydrocarbon group, (b) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (c) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (d) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group], a salt thereof or a hydrate of the foregoing;


<17> a compound represented by the following general formula:



[wherein Z^{22} is an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group; R^{300} and R^{301} have the same definitions as R^{300} and R^{301} in <11>; V^{d13} is a group selected from the group consisting of the formulas:




(wherein V^{a12} and V^{a13} have the same definitions as V^{a12} and V^{a13} in <7>; V^{d11} is an optionally substituted C_{1-6} alkylene group or a group represented by the formula:



; and V^{d12} is (1) a group represented by the formula $-NR^{d11}R^{d12}$ (wherein R^{d11} and R^{d12} are each a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group), or (2) an optionally substituted 5- to 14-membered


bered heterocyclic group], a salt thereof or a hydrate of the foregoing;
 <18> a compound represented by the following general formula:




[wherein R^1 , R^2 and Z^{12} have the same definitions as R^1 , R^2 and Z^{12} in <2>; W^{11} is an optionally substituted carbon atom or a nitrogen atom; R^{300} has the same definition as R^{300} in <11>; R^{a11} has the same definition as R^{a11} in <7>; and R^{a120} has the same definition as R^{a120} in <16>, with the exception of the following compounds (1) and (2):
 (1) a compound wherein R^{a120} is a group represented by the formula:



(wherein V^{a12} and V^{a13} have the same definitions as V^{a12} and V^{a13} in <7>), R^1 and R^2 are hydrogen atoms and Z^{12} is a C_{6-14} aryl group, a 6- to 14-membered heterocyclic group or a 6- to 14-membered aromatic heterocyclic group; (2) a compound wherein R^{a120} is a group selected from the group consisting of the formulas:




(wherein V^{a11} , V^{a12} , V^{a13} and V^{a14} have the same definitions as V^{a11} , V^{a12} , V^{a13} and V^{a14} in <7>, and V^{a15} has the same definition as V^{a15} in <16>), R^2 is a hydrogen atom and Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a 5- to 14-membered aromatic heterocyclic group, (d) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (e) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (f) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (g) a C_{3-8} alicyclic hydrocarbon group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group],
 a salt thereof or a hydrate of the foregoing;
 <19> a compound represented by the following general formula:




[wherein W^{41} and W are each independently an optionally substituted carbon atom or a nitrogen atom, but W_{41}


and W are not both nitrogen atoms; X^{y1} is an optionally substituted group selected from the group consisting of the following formulas:




(wherein Z^{12} has the same definition as Z^{12} in <2>, and W^{11} is an optionally substituted carbon atom or a nitrogen atom); and A^{b11} has the same definition as A^{b11} in <9>], a salt thereof or a hydrate of the foregoing;
<20> a compound represented by the following general formula:



[wherein R^{c13} has the same definition as R^{c13} in <10>; X^{y2} is an optionally substituted group selected from the group consisting of the following formulas:





(wherein Z^{12} , R^1 and R^2 have the same definitions as Z^{12} , R^1 and R^2 in <2>, and W^{11} is an optionally substituted carbon atom or a nitrogen atom); and R^{c11} and R^{c12} have the same definitions as R^{c11} and R^{c12} in <10>, with the exception of the following compounds (1) and (2): (1) a compound wherein R^1 and R^2 are hydrogen atoms and Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a C_{1-6} alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group, a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (d) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (e) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (f) a C_{3-8} alicyclic hydrocarbon group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group; (2) a compound wherein X^{y2} is a group represented by the formula:



(wherein Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a 5- to 14-membered aromatic heterocyclic group, (d) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10}


10 $V^{f12}-V^{f1}O-$ 

20 ; and V^{f12} is (1) a hydrogen atom, (2) a hydroxyl group, (3) an optionally substituted 5- to 14-membered heterocyclic group, (4) an optionally substituted 5- to 14-membered aromatic heterocyclic group, (5) an optionally substituted C_{6-14} aryl group or (6) a group represented by the formula $-NR^{f21}R^{f22}$ (wherein R^{f21} and R^{f22} are each independently
25 <22> a compound represented by the following general formula:




(wherein V^{f11} and V^{f12} have the same definitions as V^{f11} and V^{f12} in <21>, but V^{f12} is not a hydrogen atom)), a salt thereof or a hydrate of the foregoing;

<23> a compound represented by the following general formula:



[wherein Z^{12} , R^1 and R^2 have the same definitions as Z^{12} , R^1 and R^2 in <2>; R^{300} and R^{301} have the same definitions as R^{300} and R^{301} in <11>; and A^{32} is a group selected from the group consisting of the formulas:



(wherein R^{c13} has the same definition as R^{c13} in <10>; W , R^{a11} , R^{a12} and R^{a13} have the same definitions as W , R^{a11} , R^{a12} and R^{a13} in <7>; A^{b11} has the same definition as A^{b11} in <9>; and R^{c11} and R^{c12} have the same definitions as R^{c11} and R^{c12} in <10>]], a salt thereof or a hydrate of the foregoing;

<24> a compound according to <1> or <2>, a pharmacologically acceptable salt of the compound or a hydrate of the foregoing, wherein said compound is a compound selected from N-(4-(6-cyano-7-(3-(4-pyridyl)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(1,3-thiazol-2-yl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-cyanophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylurea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(1,3-thiazol-2-yl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-cyclopropylurea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylmethylurea, N-(4-(6-cyano-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yloxy)-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(3-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(3-(1-(4-ethylpiperazino))propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(3-cyanopropoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-(methylsulfonyl)ethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-(methylsulfonyl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(3-methoxycarbonylpropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(3-carboxypropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(2-(2-hydroxyethoxy)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxyphenyl)-N'-phenylurea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-phenylurea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(2-

oxo-1,2,3,4-tetrahydro-6-quinolyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-acetamidophenyl)urea, N-(4-(6-cyano-7-benzoyloxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-phenylurea, 4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 7-(2-methoxyethoxy)-4-(4-((1,3-thiazol-2-ylamino)carbonyl)aminophenoxy)-6-quinolinecarboxamide, 4-(4-((anilino)carbonyl)amino)-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 7-methoxy-4-(4-((1,3-thiazol-2-ylamino)carbonyl)aminophenoxy)-6-quinolinecarboxamide, 4-(4-((2,4-difluoroanilino)carbonyl)amino)-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(5-((anilino)carbonyl)amino)-2-pyridyloxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-(anilino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-(anilino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(4-((2,4-difluoroanilino)carbonyl)amino)-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(4-((4-fluoroanilino)carbonyl)amino)-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 7-(2-methoxyethoxy)-4-(4-((1,3-thiazol-2-ylamino)carbonyl)amino)-3-fluorophenoxy)-6-quinolinecarboxamide and 4-(4-((4-fluoroanilino)carbonyl)amino)-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide;


<25> a compound according to <1> or <2>, a pharmacologically acceptable salt of the compound or a hydrate of the foregoing, wherein said compound is a compound selected from N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea, N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea, N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(4-fluorophenyl)urea, N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(4-fluorophenyl)urea, N-(4-[6-cyano-7-(2-hydroxy-3-pyrrolidin-1-yl-propoxy)-quinolin-4-yl-oxy]-2-methylphenyl)-N'-cyclopropyl-urea, 4-(4-(4-fluoroanilino)carbonyl)-4-methylaminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-(2-pyridyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, 6-carbamoyl-4-(1-ethylcarbamoyl-1H-indol-5-yloxy)-7-methoxyquinoline, 6-carbamoyl-7-methoxy-4-(1-propylcarbamoyl-1H-indol-5-yloxy)quinoline, 6-carbamoyl-7-methoxy-4-[1-(1-methyl)ethylcarbamoyl-1H-indol-5-yloxy]quinoline, N4-(4-[4-((anilino)carbonyl)amino]-3-chlorophenoxy)-2-pyridyl)-1-methyl-4-piperidinecarboxamide, N1-phenyl-3-chloro-5-[(2-[(1-methyl-4-piperidyl)carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide, N4-[4-(3-chloro-4-[(4-fluoroanilino)carbonyl]amino)phenoxy]-2-pyridyl]-1-methyl-4-piperidinecarboxamide, 1-(2-chloro-4-[6-[4-(2-diethylaminoethoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl)-3-cyclopropylurea, 1-[2-chloro-4-[6-[4-((2R)-2-hydroxy-3-diethylaminopropoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea, 1-(2-chloro-4-[6-[4-((2R)-2-hydroxy-3-pyrrolidinopropoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl)-3-cyclopropylurea and 1-(2-chloro-4-[6-[4-(2-diethylaminopropoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl)-3-cyclopropylurea;

<26> a compound according to <1> or <2>, a pharmacologically acceptable salt of the compound or a hydrate of the foregoing, wherein said compound is a compound selected from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide;


<27> a medicament (a drug) comprising as an active ingredient, a compound according to any one of <1> to <6>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<28> an angiogenesis inhibiting activity-based medicament (an angiogenesis inhibiting activity-based drug) comprising as an active ingredient, a compound according to any one of <1> to <6>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<29> a pharmaceutical composition comprising a compound represented by the general formula:



10 [wherein A is an optionally substituted 5- to 14-membered aromatic heterocyclic group; X is an oxygen atom, a sulfur atom, -SO- or -SO₂; Y is an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C₁₋₆ alkylene group; E is a single bond or -NR²-; R¹ and R² are each independently a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and Z is a group represented by the formula -Z¹¹-Z¹² (wherein Z¹¹ is a single bond, an oxygen atom, a sulfur atom, -CO-, -SO₂- or an optionally substituted C₁₋₆ alkylene group and Z¹² is a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or a group represented by the formula:



(wherein Z³¹, Z³³ and Z³⁴ are each independently a methylene group, -CO-, -NH- or -O-, and Z³² is a single bond, a methylene group, -CO-, -NH- or -O-)), with the proviso that A may be optionally substituted with 1 to 6 groups, each selected from the group consisting of (1) a cyano group, (2) a halogen atom, (3) a nitro group and (4) the formula -VX¹-VX²-VX²²-VX³ (wherein VX¹, VX² and VX²² are each independently a single bond, an oxygen atom, a sulfur atom, -CO-, -SO-, -SO₂-, -NR^{X1}-, -CONR^{X1}-, -NR^{X1}CO-, -SO₂NR^{X1}-, -NR^{X1}SO₂-, -O-CO-, -C(O)O-, -NR^{X1}C(O)O-, -NR^{X1}C(O)NR^{X2}-, -O-C(O)NR^{X1}-, -O-C(O)O-, an optionally substituted C₁₋₆ alkylene group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and VX³, R^{X1} and R^{X2} are each independently a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C₁₋₆ alkoxy group)], a pharmacologically acceptable salt thereof or a hydrate of the foregoing, together with a pharmacologically acceptable carrier;

<30> a prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective, comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<31> an angiogenesis inhibitor comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<32> an antitumor agent comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<33> a therapeutic agent for angioma (an angioma treatment agent) comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<34> a cancer metastasis inhibitor comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<35> a therapeutic agent for retinal neovascularization or diabetic retinopathy (a retinal neovascularization treat-

ment agent or diabetic retinopathy treatment agent) comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<36> a therapeutic agent for an inflammatory disease (an inflammatory disease treatment agent) comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<37> a therapeutic agent for an inflammatory disease selected from deformant arthritis, rheumatoid arthritis, psoriasis and delayed hypersensitivity reaction (an inflammatory disease treatment agent for deformant arthritis, rheumatoid arthritis, psoriasis or delayed hypersensitivity reaction) comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<38> a therapeutic agent for atherosclerosis (an atherosclerosis treatment agent) comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<39> a therapeutic agent for a pancreatic cancer, a gastric cancer, a colon cancer, a breast cancer, a prostate cancer, a lung cancer, a renal cancer, a brain tumor, a blood cancer or an ovarian cancer (a pancreatic cancer treatment agent, a gastric cancer treatment agent, a colon cancer treatment agent, a breast cancer treatment agent, a prostate cancer treatment agent, a pulmonary cancer treatment agent, a renal cancer treatment agent, a brain tumor treatment agent, a blood cancer treatment agent or an ovarian cancer treatment agent) comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<40> an angiogenesis inhibition-based antitumor agent comprising as an active ingredient, a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<41> a prophylactic or therapeutic method for a disease for which angiogenesis inhibition is effective, comprising administering to a patient, a pharmacologically effective dose of a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing;

<42> The use of a compound according to <1> or <2>, a pharmacologically acceptable salt thereof or a hydrate of the foregoing for the manufacture of a prophylactic or a therapeutic agent for a disease for which angiogenesis inhibition is effective.

Best Mode for Carrying Out the Invention

[0008] The present invention will now be explained in greater detail.

[0009] Several of the structural formulas given for compounds throughout the present specification will represent a specific isomer for convenience, but the invention is not limited to such specific isomers and encompasses all isomers and isomer mixtures, including geometric isomers, asymmetric carbon-derived optical isomers, stereoisomers and tautomers, implied by the structures of the compounds. Moreover, the compounds of the invention also include those that have been metabolized in the body by oxidation, reduction, hydrolysis, conjugation or the like, and still exhibit the desired activity, while the invention further encompasses all compounds which undergo metabolism such as oxidation, reduction, hydrolysis, etc. in the body to produce the compounds of the invention. Solvates, including those with water, are also encompassed by the invention.

[0010] The terms used throughout the present specification will now be defined.

[0011] The term "halogen atom" as used throughout the present specification refers to halogen atoms such as fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.

[0012] The term "C₁₋₆ alkyl group" as used throughout the present specification refers to a linear or branched alkyl group of 1 to 6 carbons, and as specific examples there may be mentioned methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, n-hexyl, i-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl, preferably methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, n-hexyl and i-hexyl, more preferably methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, 1,1-dimethylpropyl and 1,2-dimethylpropyl, even more preferably methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl, and most preferably methyl, ethyl, n-propyl and i-propyl.

[0013] The term "C₁₋₆ alkylene group" as used throughout the present specification refers to a divalent group derived by removing one hydrogen atom from the aforementioned "C₁₋₆ alkyl group", and as specific examples there may be mentioned methylene, ethylene, methylethylene, propylene, ethylethylene, 1,1-dimethylethylene, 1,2-dimethylethylene, trimethylene, 1-methyltrimethylene, 1-ethyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, tetramethylene, pentamethylene and hexamethylene.

[0014] The term "C₂₋₆ alkenyl group" as used throughout the present specification refers to a linear or branched alkenyl group of 2 to 6 carbons, and it is a substituent with a double bond in a "C₁₋₆ alkyl group" of 2 or more carbons. As specific examples there may be mentioned ethenyl, 1-propen-1-yl, 2-propen-1-yl, 3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl, 1-methyl-1-propen-1-yl, 2-methyl-1-propen-1-yl, 1-methyl-2-propen-1-yl, 2-methyl-2-propen-1-yl, 1-methyl-1-buten-1-yl, 2-methyl-1-buten-1-yl, 3-methyl-1-buten-1-yl, 1-methyl-2-buten-1-yl, 2-methyl-2-buten-1-yl, 3-methyl-2-buten-1-yl, 1-methyl-3-buten-1-yl, 2-methyl-3-buten-1-yl, 3-methyl-3-buten-1-yl, 1-ethyl-1-buten-1-yl, 2-ethyl-1-buten-1-yl, 3-ethyl-1-buten-1-yl, 1-ethyl-2-buten-1-yl, 2-ethyl-2-buten-1-yl, 3-ethyl-2-buten-1-yl, 1-ethyl-3-buten-1-yl, 2-ethyl-3-buten-1-yl, 3-ethyl-3-buten-1-yl, 1,1-dimethyl-1-buten-1-yl, 1,2-dimethyl-1-buten-1-yl, 1,3-dimethyl-1-buten-1-yl, 2,2-dimethyl-1-buten-1-yl, 3,3-dimethyl-1-buten-1-yl, 1,1-dimethyl-2-buten-1-yl, 1,2-dimethyl-2-buten-1-yl, 1,3-dimethyl-2-buten-1-yl, 2,2-dimethyl-2-buten-1-yl, 3,3-dimethyl-2-buten-1-yl, 1,1-dimethyl-3-buten-1-yl, 1,2-dimethyl-3-buten-1-yl, 1,3-dimethyl-3-buten-1-yl, 2,2-dimethyl-3-buten-1-yl, 3,3-dimethyl-3-buten-1-yl, 1-penten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-penten-2-yl, 2-penten-2-yl, 3-penten-2-yl, 4-penten-2-yl, 1-penten-3-yl, 2-penten-3-yl, 1-methyl-1-penten-1-yl, 2-methyl-1-penten-1-yl, 3-methyl-1-penten-1-yl, 4-methyl-1-penten-1-yl, 1-methyl-2-penten-1-yl, 2-methyl-2-penten-1-yl, 3-methyl-2-penten-1-yl, 4-methyl-2-penten-1-yl, 1-methyl-3-penten-1-yl, 2-methyl-3-penten-1-yl, 3-methyl-3-penten-1-yl, 4-methyl-3-penten-1-yl, 1-methyl-4-penten-1-yl, 2-methyl-4-penten-1-yl, 3-methyl-4-penten-1-yl, 4-methyl-4-penten-1-yl, 1-methyl-1-penten-2-yl, 2-methyl-1-penten-2-yl, 3-methyl-1-penten-2-yl, 4-methyl-1-penten-2-yl, 1-methyl-2-penten-2-yl, 2-methyl-2-penten-2-yl, 3-methyl-2-penten-2-yl, 4-methyl-2-penten-2-yl, 1-methyl-3-penten-2-yl, 2-methyl-3-penten-2-yl, 3-methyl-3-penten-2-yl, 4-methyl-3-penten-2-yl, 1-methyl-4-penten-2-yl, 2-methyl-4-penten-2-yl, 3-methyl-4-penten-2-yl, 4-methyl-4-penten-2-yl, 1-methyl-1-penten-3-yl, 2-methyl-1-penten-3-yl, 3-methyl-1-penten-3-yl, 4-methyl-1-penten-3-yl, 1-methyl-2-penten-3-yl, 2-methyl-2-penten-3-yl, 3-methyl-2-penten-3-yl, 4-methyl-2-penten-3-yl, 1-hexen-1-yl, 1-hexen-2-yl, 1-hexen-3-yl, 1-hexen-4-yl, 1-hexen-5-yl, 1-hexen-6-yl, 2-hexen-1-yl, 2-hexen-2-yl, 2-hexen-3-yl, 2-hexen-4-yl, 2-hexen-5-yl, 2-hexen-6-yl, 3-hexen-1-yl, 3-hexen-2-yl, 3-hexen-3-yl, preferably ethenyl, 1-propen-1-yl, 2-propen-1-yl, 3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl, 1-methyl-1-propen-1-yl, 2-methyl-1-propen-1-yl, 1-methyl-2-propen-1-yl, 2-methyl-2-propen-1-yl, 1-methyl-1-buten-1-yl, 2-methyl-1-buten-1-yl, 3-methyl-1-buten-1-yl, 1-methyl-2-buten-1-yl, 2-methyl-2-buten-1-yl, 3-methyl-2-buten-1-yl, 1-methyl-3-buten-1-yl, 2-methyl-3-buten-1-yl, 3-methyl-3-buten-1-yl, 1-ethyl-1-buten-1-yl, 2-ethyl-1-buten-1-yl, 3-ethyl-1-buten-1-yl, 1-ethyl-2-buten-1-yl, 2-ethyl-2-buten-1-yl, 3-ethyl-2-buten-1-yl, 1-ethyl-3-buten-1-yl, 2-ethyl-3-buten-1-yl, 3-ethyl-3-buten-1-yl, 1,1-dimethyl-1-buten-1-yl, 1,2-dimethyl-1-buten-1-yl, 1,3-dimethyl-1-buten-1-yl, 2,2-dimethyl-1-buten-1-yl, 3,3-dimethyl-1-buten-1-yl, 1,1-dimethyl-2-buten-1-yl, 1,2-dimethyl-2-buten-1-yl, 1,3-dimethyl-2-buten-1-yl, 2,2-dimethyl-2-buten-1-yl, 3,3-dimethyl-2-buten-1-yl, 1,1-dimethyl-3-buten-1-yl, 1,2-dimethyl-3-buten-1-yl, 1,3-dimethyl-3-buten-1-yl, 2,2-dimethyl-3-buten-1-yl and 3,3-dimethyl-3-buten-1-yl, more preferably ethenyl, 1-propen-1-yl, 2-propen-1-yl, 3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl, 1-methyl-1-propen-1-yl, 2-methyl-1-propen-1-yl, 1-methyl-2-propen-1-yl, 2-methyl-2-propen-1-yl, 1-methyl-1-buten-1-yl, 2-methyl-1-buten-1-yl, 3-methyl-1-buten-1-yl, 1-methyl-2-buten-1-yl, 2-methyl-2-buten-1-yl, 3-methyl-2-buten-1-yl, 1-methyl-3-buten-1-yl, 2-methyl-3-buten-1-yl and 3-methyl-3-buten-1-yl, and most preferably ethenyl, 1-propen-1-yl, 2-propen-1-yl, 3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl and 2-buten-2-yl.

[0015] The term "C₂₋₆ alkynyl group" as used throughout the present specification refers to a linear or branched alkynyl group of 2 to 6 carbons, and it is a substituent with a triple bond in a "C₁₋₆ alkyl group" of 2 or more carbons. As specific examples there may be mentioned ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 3-propyn-1-yl, 1-butyne-1-yl, 1-butyne-2-yl, 1-butyne-3-yl, 1-butyne-4-yl, 2-butyne-1-yl, 2-butyne-2-yl, 1-methyl-1-propyn-1-yl, 2-methyl-1-propyn-1-yl, 1-methyl-2-propyn-1-yl, 2-methyl-2-propyn-1-yl, 1-methyl-1-butyne-1-yl, 2-methyl-1-butyne-1-yl, 3-methyl-1-butyne-1-yl, 1-methyl-2-butyne-1-yl, 2-methyl-2-butyne-1-yl, 3-methyl-2-butyne-1-yl, 1-methyl-3-butyne-1-yl, 2-methyl-3-butyne-1-yl, 3-methyl-3-butyne-1-yl, 1-ethyl-1-butyne-1-yl, 2-ethyl-1-butyne-1-yl, 3-ethyl-1-butyne-1-yl, 1-ethyl-2-butyne-1-yl, 2-ethyl-2-butyne-1-yl, 3-ethyl-2-butyne-1-yl, 1-ethyl-3-butyne-1-yl, 2-ethyl-3-butyne-1-yl, 3-ethyl-3-butyne-1-yl, 1,1-dimethyl-1-butyne-1-yl, 1,2-dimethyl-1-butyne-1-yl, 1,3-dimethyl-1-butyne-1-yl, 2,2-dimethyl-1-butyne-1-yl, 3,3-dimethyl-1-butyne-1-yl, 1,1-dimethyl-2-butyne-1-yl, 1,2-dimethyl-2-butyne-1-yl, 1,3-dimethyl-2-butyne-1-yl, 2,2-dimethyl-2-butyne-1-yl, 3,3-dimethyl-2-butyne-1-yl, 1,1-dimethyl-3-butyne-1-yl, 1,2-dimethyl-3-butyne-1-yl, 1,3-dimethyl-3-butyne-1-yl, 2,2-dimethyl-3-butyne-1-yl, 3,3-dimethyl-3-butyne-1-yl, 1-pentyn-1-yl, 2-pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl, 1-pentyn-2-yl, 2-pentyn-2-yl, 3-pentyn-2-yl, 4-pentyn-2-yl, 1-pentyn-3-yl, 2-pentyn-3-yl, 1-methyl-1-pentyn-1-yl, 2-methyl-1-pentyn-1-yl, 3-methyl-1-pentyn-1-yl, 4-methyl-1-pentyn-1-yl, 1-methyl-2-pentyn-1-yl, 2-methyl-2-pentyn-1-yl, 3-methyl-2-pentyn-1-yl, 4-methyl-2-pentyn-1-yl, 1-methyl-3-pentyn-1-yl, 2-methyl-3-pentyn-1-yl, 3-methyl-3-pentyn-1-yl, 4-methyl-3-pentyn-1-yl, 1-methyl-4-pentyn-1-yl, 2-methyl-4-pentyn-1-yl, 3-methyl-4-pentyn-1-yl, 4-methyl-4-pentyn-1-yl, 1-methyl-1-pentyn-2-yl, 2-methyl-1-pentyn-2-yl, 3-methyl-1-pentyn-2-yl, 4-methyl-1-pentyn-2-yl, 1-methyl-2-pentyn-2-yl, 2-methyl-2-pentyn-2-yl, 3-methyl-2-pentyn-2-yl, 4-methyl-2-pentyn-2-yl, 1-methyl-3-pentyn-2-yl, 2-methyl-3-pentyn-2-yl, 3-methyl-3-pentyn-2-yl, 4-methyl-3-pentyn-2-yl, 1-methyl-4-pentyn-2-yl, 2-methyl-4-pentyn-2-yl, 3-methyl-4-pentyn-2-yl, 4-methyl-4-pentyn-2-yl, 1-methyl-1-pentyn-3-yl, 2-methyl-1-pentyn-3-yl, 3-methyl-1-pentyn-3-yl, 4-methyl-1-pentyn-3-yl,

1-methyl-2-pentyn-3-yl, 2-methyl-2-pentyn-3-yl, 3-methyl-2-pentyn-3-yl, 4-methyl-2-pentyn-3-yl, 1-hexyn-1-yl, 1-hexyn-2-yl, 1-hexyn-3-yl, 1-hexyn-4-yl, 1-hexyn-5-yl, 1-hexyn-6-yl, 2-hexyn-1-yl, 2-hexyn-2-yl, 2-hexyn-3-yl, 2-hexyn-4-yl, 2-hexyn-5-yl, 2-hexyn-6-yl, 3-hexyn-1-yl, 3-hexyn-2-yl and 3-hexyn-3-yl, preferably ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 3-propyn-1-yl, 1-butyn-1-yl, 1-butyn-2-yl, 1-butyn-3-yl, 1-butyn-4-yl, 2-butyn-1-yl, 2-butyn-2-yl, 1-methyl-1-propyn-1-yl, 2-methyl-1-propyn-1-yl, 1-methyl-2-propyn-1-yl, 2-methyl-2-propyn-1-yl, 1-methyl-1-butyn-1-yl, 2-methyl-1-butyn-1-yl, 3-methyl-1-butyn-1-yl, 1-methyl-2-butyn-1-yl, 2-methyl-2-butyn-1-yl, 3-methyl-2-butyn-1-yl, 1-methyl-3-butyn-1-yl, 2-methyl-3-butyn-1-yl, 3-methyl-3-butyn-1-yl, 1-ethyl-1-butyn-1-yl, 2-ethyl-1-butyn-1-yl, 3-ethyl-1-butyn-1-yl, 1-ethyl-2-butyn-1-yl, 2-ethyl-2-butyn-1-yl, 3-ethyl-2-butyn-1-yl, 1-ethyl-3-butyn-1-yl, 2-ethyl-3-butyn-1-yl, 3-ethyl-3-butyn-1-yl, 1,1-dimethyl-1-butyn-1-yl, 1,2-dimethyl-1-butyn-1-yl, 1,3-dimethyl-1-butyn-1-yl, 2,2-dimethyl-1-butyn-1-yl, 3,3-dimethyl-1-butyn-1-yl, 1,1-dimethyl-2-butyn-1-yl, 1,2-dimethyl-2-butyn-1-yl, 1,3-dimethyl-2-butyn-1-yl, 2,2-dimethyl-2-butyn-1-yl, 3,3-dimethyl-2-butyn-1-yl, 1,1-dimethyl-3-butyn-1-yl, 1,2-dimethyl-3-butyn-1-yl, 1,3-dimethyl-3-butyn-1-yl, 2,2-dimethyl-3-butyn-1-yl and 3,3-dimethyl-3-butyn-1-yl, more preferably ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 3-propyn-1-yl, 1-butyn-1-yl, 1-butyn-2-yl, 1-butyn-3-yl, 1-butyn-4-yl, 2-butyn-1-yl, 2-butyn-2-yl, 1-methyl-1-propyn-1-yl, 2-methyl-1-propyn-1-yl, 1-methyl-2-propyn-1-yl, 2-methyl-2-propyn-1-yl, 1-methyl-1-butyn-1-yl, 2-methyl-1-butyn-1-yl, 3-methyl-1-butyn-1-yl, 1-methyl-2-butyn-1-yl, 2-methyl-2-butyn-1-yl, 3-methyl-2-butyn-1-yl, 1-methyl-3-butyn-1-yl, 2-methyl-3-butyn-1-yl and 3-methyl-3-butyn-1-yl, even more preferably ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 3-propyn-1-yl, 1-butyn-1-yl, 1-butyn-2-yl, 1-butyn-3-yl, 1-butyn-4-yl, 2-butyn-1-yl and 2-butyn-2-yl, and most preferably ethynyl, 1-propyn-1-yl, 2-propyn-1-yl and 3-propyn-1-yl.

[0016] The term "C₃₋₈ cycloalkyl group" as used throughout the present specification refers to a cyclic alkyl group of 3 to 8 carbons, and as specific examples there may be mentioned cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, with cyclopropyl being preferred.

[0017] The term "C₃₋₈ cycloalkenyl group" as used throughout the present specification refers to a cyclic alkenyl group of 3 to 8 carbons, and as specific examples there may be mentioned cyclopentenyl and cyclohexenyl.

[0018] The term "C₃₋₈ cycloalkynyl group" as used throughout the present specification refers to a cyclic alkynyl group of 3 to 8 carbons, and as a specific example there may be mentioned cyclohexynyl.

[0019] The term "C₃₋₈ cycloalkyloxy group" as used throughout the present specification corresponds to the aforementioned C₃₋₈ cycloalkyl group having an oxygen atom bonded at the end, and as specific examples there may be mentioned cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.

[0020] The term "C₃₋₈ alicyclic hydrocarbon group" as used throughout the present specification refers to a cyclic hydrocarbon of 3 to 8 carbons, and it is a substituent whose definition includes that of the aforementioned "C₃₋₈ cycloalkyl group", "C₃₋₈ cycloalkenyl group" and "C₃₋₈ cycloalkynyl group", with cyclopropyl being preferred.

[0021] The term "C₁₋₆ alkoxy group" as used throughout the present specification refers to a substituent wherein the aforementioned "C₁₋₆ alkyl group" is bonded to an oxygen atom, and as specific examples there may be mentioned methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy, sec-pentyloxy, t-pentyloxy, neopentyloxy, 1-methylbutoxy, 2-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, n-hexyloxy, i-hexyloxy, 1-methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 2,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and 1-ethyl-2-methylpropoxy, preferably methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy, sec-pentyloxy, t-pentyloxy, neopentyloxy, 1-methylbutoxy, 2-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, n-hexyloxy and i-hexyloxy, more preferably methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy, sec-pentyloxy, t-pentyloxy, neopentyloxy, 1-methylbutoxy, 2-methylbutoxy, 1,1-dimethylpropoxy and 1,2-dimethylpropoxy, even more preferably methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy and t-butoxy, and most preferably methoxy, ethoxy, n-propoxy and i-propoxy.

[0022] The term "C₂₋₇ acyl group" as used throughout the present specification refers to a substituent wherein a carbonyl group is bonded to the end of the aforementioned "C₁₋₆ alkyl group", "C₂₋₆ alkenyl group" or "C₂₋₆ alkynyl group" or phenyl group, and as specific examples there may be mentioned acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, acryloyl, methacryloyl, crotonyl and benzoyl, preferably acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, acryloyl, methacryloyl, crotonyl and benzoyl, more preferably acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl and benzoyl, even more preferably acetyl, propionyl, butyryl, isobutyryl and benzoyl, and most preferably acetyl, propionyl and benzoyl.

[0023] The term "C₂₋₇ alkoxycarbonyl group" as used throughout the present specification refers to a substituent wherein a carbonyl group is bonded to the aforementioned "C₁₋₆ alkoxy group", and as specific examples there may be mentioned methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl, sec-propoxycarbonyl, n-butoxycarbonyl, i-butoxycarbonyl, 1,2-dimethylpropoxycarbonyl and 2-ethylpropoxycarbonyl.

[0024] The term "n-" as used throughout the present specification indicates a normal type or primary substituent, "sec-" indicates a secondary substituent, "t-" indicates a tertiary substituent and "i-" indicates an iso type substituent.

[0025] The term "C₁₋₆ alkylendioxy group" as used throughout the present specification refers to a substituent having

oxygen atoms at each end of a divalent group derived by removing one more hydrogen atom from a "C₁₋₆ alkyl group", and as specific examples there may be mentioned methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, pentylenedioxy and hexylenedioxy.

[0026] The term "C₆₋₁₄ aryl group" as used throughout the present specification refers to an aromatic ring group of 6 or 14 carbons, and as specific examples there may be mentioned benzene, pentalene, indene, naphthalene, azulene, heptalene, biphenylene, indacene, acenaphthylene, fluorene, phenalene, phenanthrene and anthracene, and preferably benzene, pentalene, indene, naphthalene and azulene.

[0027] The term "hetero atom" as used throughout the present specification refers to, specifically, an oxygen atom, sulfur atom, nitrogen atom, phosphorus, arsenic, antimony, silicon, germanium, tin, lead, boron, mercury or the like, and preferably an oxygen atom, sulfur atom or nitrogen atom.

[0028] The term "5- to 14-membered aromatic heterocyclic group" as used throughout the present specification refers to an aromatic cyclic group having 5 to 14 atoms forming the cyclic ring and including at least one hetero atom such as nitrogen, sulfur or oxygen among the atoms forming the cyclic ring. As specific examples there may be mentioned nitrogen-containing aromatic heterocycles such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, tetrazole, indole, isoindole, indolizine, purine, indazole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as furan, pyran, cyclopentapyran, benzofuran and isobenzofuran; and aromatic heterocycles comprising 2 or more hetero atoms selected from among nitrogen, sulfur and oxygen, such as thiazole, thiadiazole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine and oxazole. As examples of the "5- to 14-membered aromatic heterocyclic group" there may be mentioned preferably, pyridine, pyridone, pyrimidine, imidazole, indole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinazoline, cinnoline, acridine, phenacene, thiophene, benzothiophene, furan, pyran, benzofuran, thiazole, benzthiazole, phenothiazine, pyrrolopyrimidine, furopyridine and thienopyrimidine, more preferably pyridine, thiophene, benzothiophene, thiazole, benzothiazole, quinoline, quinazoline, cinnoline, pyrrolopyrimidine, pyrimidine, furopyridine and thienopyrimidine.

[0029] The term "5- to 14-membered non-aromatic heterocyclic group" as used throughout the present specification refers to a non-aromatic cyclic group having 5 to 14 atoms forming the cyclic ring and including at least one hetero atom such as nitrogen, sulfur or oxygen among the atoms forming the cyclic ring. As specific examples there may be mentioned non-aromatic heterocycles such as pyrrolidinyl, pyrrolinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, imidazolyl, pyrazolidinyl, imidazolidinyl, morpholinyl, tetrahydropyranyl, azetidyl, oxetanyl, oxathiolanyl, pyridone, 2-pyrrolidone, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, phthalimide and succinimide. As examples of the "5- to 14-membered non-aromatic heterocyclic group" there may be mentioned preferably, pyrrolidinyl, piperidinyl and morpholinyl, and more preferably pyrrolidinyl, piperidinyl, morpholinyl and pyrrole.

[0030] The term "5- to 14-membered heterocyclic group" as used throughout the present specification refers to an aromatic or non-aromatic cyclic group having 5 to 14 atoms forming the cyclic ring and including at least one hetero atom such as nitrogen, sulfur or oxygen among the atoms forming the cyclic ring, which is a "5- to 14-membered aromatic heterocyclic group" in the former case and a "5- to 14-membered non-aromatic heterocyclic group" in the latter case. Specific examples of the "5- to 14-membered heterocyclic group" therefore include specific examples of the "5- to 14-membered aromatic heterocyclic group" and specific examples of the "5- to 14-membered non-aromatic heterocyclic group".

[0031] As the "5- to 14-membered heterocyclic group" there may be mentioned preferably pyrrolidinyl, piperidinyl, morpholinyl, pyrrole, pyridine, pyridone, pyrimidine, imidazole, indole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinazoline, cinnoline, acridine, phenacene, thiophene, benzothiophene, furan, pyran, benzofuran, thiazole, benzothiazole, phenothiazine and carbostyryl, more preferably pyrrolidinyl, piperidinyl, morpholinyl, pyrrole, pyridine, thiophene, benzothiophene, thiazole, benzothiazole, quinoline, quinazoline, cinnoline and carbostyryl, and even more preferably thiazole, quinoline, quinazoline, cinnoline and carbostyryl.

[0032] The term "6- to 14-membered aromatic heterocyclic group" as used throughout the present specification refers to those substituents defined by "5- to 14-membered aromatic heterocyclic group" which have 6 to 14 atoms forming the cyclic ring. As specific examples there may be mentioned pyridine, pyridone, pyrimidine, indole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinazoline, cinnoline, acridine, benzothiophene, benzofuran, thiazole, benzothiazole and phenothiazine.

[0033] The term "6- to 14-membered heterocyclic group" as used throughout the present specification refers to those substituents defined by "5- to 14-membered heterocyclic group" which have 6 to 14 atoms forming the cyclic ring. As specific examples there may be mentioned piperidinyl, piperazinyl, N-methylpiperazinyl, morpholinyl, tetrahydropyranyl, 1,4-dioxane and phthalimide.

[0034] The term "C₆₋₁₄ aryl-C₁₋₆ alkyl group [= aralkyl group]" as used throughout the present specification refers to a "C₁₋₆ alkyl group" substituted at substitutable positions with a "C₆₋₁₄ aryl group", and as specific examples there may be mentioned benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl, 1-naphthylmethyl, 2-naphthylmethyl, 1-naphthylethyl, 2-naphthylethyl, 1-naphthylpropyl and 2-naphthylpropyl, preferably benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl, 1-naphthylmethyl, 2-naphthylmethyl, 1-naphthylethyl, 2-naphthylethyl, 1-naphthylpropyl and 2-naphthylpropyl, more preferably benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl, 1-naphthylmethyl, 2-naphthylmethyl, even more preferably benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, and most preferably benzyl and phenethyl.

[0035] The term "5- to 14-membered heterocyclic-C₁₋₆ alkyl group" as used throughout the present specification refers to a "C₁₋₆ alkyl group" substituted at substitutable positions with a "5- to 14-membered heterocyclic group", and as specific examples there may be mentioned 2-pyridylmethyl, 3-pyridylmethyl and 2-quinolinomethyl.

[0036] A "leaving group" in the sense used throughout the present specification may be any group commonly known as a leaving group in chemical synthesis, with no special restrictions, and as specific examples there may be mentioned halogen atoms such as chlorine, bromine and iodine; alkylthio groups such as methylthio, ethylthio and propylthio; arylthio groups such as phenylthio, tolylthio and 2-pyridylthio; alkylsulfonyloxy groups such as methanesulfonyloxy, trifluoromethanesulfonyloxy, ethanesulfonyloxy and propanesulfonyloxy; arylsulfonyloxy groups such as benzenesulfonyloxy and p-toluenesulfonyloxy; alkanoyloxy groups such as acetoxy and trifluoroacetoxy; alkoxy groups such as methoxy, ethoxy and propoxy; alkylamino groups such as methylamino, ethylamino, propylamino and butylamino; dialkylamino groups such as dimethylamino, diethylamino, dipropylamino, methylethylamino, ethylpropylamino and methylpropylamino; and substituted phosphoryloxy groups such as diphenoxyphosphoryloxy. Preferred are halogen atoms such as chlorine, bromine and iodine, and trifluoromethanesulfonyloxy.

[0037] The term "optionally substituted" as used throughout the present specification is synonymous with "optionally having one or more substituents in any desired combination at substitutable positions", and as specific examples of substituents there may be mentioned (1) halogens, (2) hydroxyl, (3) thiol, (4) nitro, (5) nitrile, (6) oxo, (7) azido, (8) guanidino, (9) hydrazino, (10) isocyano, (11) cyanate, (12) isocyanate, (13) thiocyanate, (14) isothiocyanate, (15) nitroso, (16) carbamido (ureido), (17) formyl, (18) C₁₋₆ imidoyl, (19) optionally halogenated or hydroxylated C₁₋₆ alkyl groups, C₂₋₆ alkenyl groups, C₂₋₆ alkynyl groups, C₃₋₆ cycloalkyl groups, C₃₋₆ cycloalkenyl groups, C₃₋₆ cycloalkynyl groups, C₁₋₆ alkoxy groups, C₂₋₆ alkenyloxy groups, C₂₋₆ alkynyloxy groups, C₂₋₆ alkynyloxy groups, C₃₋₆ cycloalkyloxy groups, C₁₋₆ alkylthio groups, C₂₋₆ alkenylthio groups, C₂₋₆ alkynylthio groups, C₃₋₆ cycloalkylthio groups or C₁₋₆ alkylenedioxy groups, (20) C₆₋₁₄ aryl groups, (21) 5- to 14-membered heterocyclic groups, (22) carboxyl, (23) trifluoromethyl, (24) C₆₋₁₄ aryl-C₁₋₆ alkyl groups, (25) 5- to 14-membered heterocyclic C₁₋₆ alkyl groups or (26) the group represented by the formula -V^{XX1}-V^{XX2}-V^{XX3}-V^{XX4} (wherein V^{XX1}, V^{XX2} and V^{XX3} are each independently 1) a single bond, 2) oxygen, 3) sulfur, 4) -CO-, 5) -SO-, 6) -SO₂-, 7) -NR^{XX1}-, 8) -CONR^{XX1}-, 9) -NR^{XX2}CO-, 10) -SO₂NR^{XX1}-, 11) -NR^{XX1}SO₂-, 12) -O-CO-, 13) -C(O)O-, 14) -NR^{XX1}C(O)O-, 15) -NR^{XX1}C(O)NR^{XX2}-, 16) -O-C(O)NR^{XX1}-, 17) -O-C(O)O-, 18) a C₁₋₆ alkylene group, 19) a C₂₋₆ alkenyl group, 20) a C₁₋₆ alkynyl group, 21) a C₃₋₈ alicyclic hydrocarbon group, 22) a C₆₋₁₄ aryl group, 23) a 5- to 14-membered heterocyclic group or 24) a 5- to 14-membered aromatic heterocyclic group; and V^{XX4}, R^{XX1} and R^{XX2} are each independently 1) hydrogen, 2) a C₁₋₆ alkyl group, 3) a C₂₋₆ alkenyl group, 4) a C₁₋₆ alkynyl group, 5) a C₃₋₈ alicyclic hydrocarbon group, 6) a C₆₋₁₄ aryl group, 7) a 5- to 14-membered heterocyclic group, 8) a 5- to 14-membered aromatic heterocyclic group or 9) a C₁₋₆ alkoxy group.)

[0038] Thus, "optionally substituted" means optionally substituted with a substituent, specific examples of which are hydroxyl; thiol; nitro; morpholino; thiomorpholino; halogens such as fluorine, chlorine, bromine and iodine; nitrile; azide; formyl; alkyl groups such as methyl, ethyl, propyl, isopropyl and butyl; alkenyl groups such as vinyl, allyl and propenyl; alkynyl groups such as ethynyl, butynyl and propargyl, alkoxy groups corresponding to lower alkyl groups, such as methoxy, ethoxy, propoxy and butoxy; halogenoalkyl groups such as fluoromethyl, difluoromethyl, trifluoromethyl and fluoroethyl; hydroxyalkyl groups such as hydroxymethyl, hydroxyethyl and hydroxypropyl; guanidino; formimidoyl; acetimidoyl; carbamoyl; thiocarbamoyl; carbamoylalkyl groups such as carbamoylmethyl and carbamoylethyl; alkylcarbamoyl groups such as methylcarbamoyl and dimethylcarbamoyl; carbamide; alkanoyl groups such as acetyl; amino; alkylamino groups such as methylamino, ethylamino and isopropylamino; dialkylamino groups such as dimethylamino, methylethylamino and diethylamino; aminoalkyl groups such as aminomethyl, aminoethyl and aminopropyl; carboxy; alkoxycarbonyl groups such as methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl; alkoxycarbonylalkyl groups such as methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl and propoxycarbonylethyl; alkoxyalkyl groups such as methyloxyethyl, methyloxyethyl, ethyloxyethyl and ethyloxyethyl; alkylthioalkyl groups such as methylthiomethyl, methylthioethyl, ethylthiomethyl and ethylthioethyl; aminoalkylaminoalkyl groups such as aminomethylaminomethyl and aminoethylaminomethyl; alkylcarboxyloxy groups such as methylcarboxyloxy, ethylcarboxyloxy and isopropylcarboxyloxy; arylalkoxyalkoxyalkyl groups such as oxymethyl and benzyloxyethyloxyethyl; hydroxyalkoxyalkyl groups such as hydroxyethyloxyethyl and hydroxyethyloxyethyl; arylalkoxyalkyl groups such as benzyloxyethyl, benzyloxyethyl and benzyloxypropyl; quaternary ammonio groups such as trimethylammonio, methylethylmethylammonio and triethylammonio; cycloalkyl groups such as cyclopropyl,

cyclobutyl, cyclopentyl and cyclohexyl; cycloalkenyl groups such as cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl; aryl groups such as phenyl, pyridinyl, thienyl, furyl and pyrrolyl; alkylthio groups such as methylthio, ethylthio, propylthio and butylthio; arylthio groups such as phenylthio, pyridinylthio, thienylthio, furylthio and pyrrolylthio; aryl lower alkyl groups such as benzyl, trityl and dimethoxytrityl; substituted sulfonyl groups such as sulfonyl, mesyl and p-toluenesulfonyl; aroyl groups such as benzoyl; halogenoaryl groups such as fluorophenyl and bromophenyl; and oxyalkoxy groups such as methylenedioxy.

[0039] The term "C₁₋₆ imido group" as used throughout the present specification refers to, for example, formimidoyl, hexaneimidoyl, succinimidoyl, or the like.

[0040] Throughout the present specification, when ring A is a 5- to 14-membered heterocyclic group, it is preferably one selected from among pyridine, pyrimidine, pyridopyrimidine, isoquinoline, phthalazine, quinoline, quinazoline, pyrimidopyrimidine, quinoxaline, pyridopyridine, pyrrolopyridine, pyrrolopyrimidine, indole, pyrazolopyridine, pyrazolopyrimidine, thienopyridine, thienopyrimidine, benzothiazole, thiazolopyridine, thiazolopyrimidine, benzimidazole, imidazopyridine, imidazopyrimidine, thiazole, imidazole, pyrazole, benzofuran, furopyridine, furopyrimidine, benzoxazole, oxazolopyridine, oxazolopyrimidine, pyridopyrimidin-7-one, pyrazine, pyridazine, pyridone, pyrimidine, oxyindole, pyrazoloquinazoline, pyrazoloquinoline, pyrroloquinazoline, pyrroloquinoline, isoindolin-1-one, isoazaindolin-1-one, isoflavone, benzopyran-4-one, benzimidazolin-2-one, 1,3-dioxo-1,3-dihydroisoindole, 2,3-dihydro-pyrrolopyridin-2-one, 2,3-dihydro-pyrroloquinolin-2-one, imidazol-2-one, benzene, naphthalene, oxazole, isoxazole, isothiazole and quinazolin-4-one. There may be mentioned as preferred groups, quinoline, pyridine, pyrrolopyrimidine, pyrimidine, quinazoline, pyridopyridine, pyridopyrimidine, pyrazolopyrimidine, thiazolopyridine, furopyridine and thienopyrimidine, and as more preferred groups, quinoline, pyridine, pyrrolopyrimidine, thienopyrimidine, pyrimidine and furopyridine, although there is no limitation to these.


[0041] In cases where Y is a group with a hetero atom, such as a 5- to 14-membered heterocyclic group, the invention naturally encompasses compounds wherein a substituent such as X or T⁹¹ is bonded at the hetero atom.

[0042] Production methods for the compounds of the invention will now be described. Various methods may be imagined for production of compounds of the invention represented by general formulas (I) and (II) with synthesis carried out by ordinary chemical synthesis means, and the following are representative examples of methods for their production.

[Representative production methods]

[Production Method 1]

[0043]




[0044] In formula (a-01), U represents a leaving group. The other symbols have the same definitions as above.

[0045] The leaving group may be, for example, a halogen or a trifluoromethanesulfonyl group. There are no particular restrictions on the solvent used for the reaction, though it is preferably one with low reactivity for the starting materials, and as examples there may be mentioned 1-methylpyrrolidone, dimethylformamide, chlorobenzene, and the like. An organic or inorganic base may also be added. The reaction time may be from 10 minutes to 30 hours, and the reaction temperature from room temperature to reflux temperature.


[0046] In the following formulas for the representative production methods Z, R³⁰⁰, R³⁰¹, W, W¹¹, R¹, R² and Y have the same definitions as above; X^{sa1} is an oxygen or sulfur atom; R^{sa4} has the same definition as R² above; R^{sa5} is an optionally substituted C₁₋₆ alkyl group or optionally substituted C₁₋₆ aryl group; compound (a-6) is compound (a-61) or compound (a-62); R^{sa70} is an optionally substituted C₁₋₆ alkyl group; G₁ is an optionally substituted nitrogen atom or oxygen atom; U is a leaving group; n and s are each integers of 0 to 6; R^{sa90} is a nitro or amino group; R^{sa82} is an amino-protecting group such as t-butoxycarbonyl or benzyl; and R^{sa1}, R^{sa2}, R^{sa3}, R^{sa50}, R^{sa60}, R^{sa71} and R^{sa80} independently are defined as substituents selected from among the substituents for ring A mentioned above.

[Production method 2-1]


[0047] Representative production method for compound (G2) represented by:



(wherein the symbols have the same definitions given above):



(wherein the symbols have the same definitions given above.)



(wherein the symbols have the same definitions given above.)

<Step A-1> <Step A-2>

5 **[0048]** Steps of cyclization from an aniline derivative (a-1) to a quinolone derivative (a-3). The synthesis may be carried out by the known method reported in Tetrahedron, 53, 1743(1997).

<Step A-1>

10 **[0049]** Specifically, an aniline derivative having any desired substituents (a-1) may be reacted with an orthoester derivative such as trimethyl orthoformate or triethyl orthoformate and Meldrum acid in an alcohol such as ethanol to obtain compound (a-2). The reaction temperature may be from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours.

15 <Step A-2>

[0050] Compound (a-2) is then heated in a mixed solvent of phenyl ether, biphenyl, etc. or Dowtherm A to obtain compound (a-3). The reaction temperature may be from 40°C to reflux temperature, and the reaction time from 10 minutes to 30 hours.

20

<Step A-3>

[0051] Chlorination step. Compound (a-3) may be reacted with a chlorinating agent such as phosphorus oxychloride or thionyl chloride to obtain compound (a-4). The reaction solvent used may be phosphorus oxychloride, thionyl chloride, benzene, toluene or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours.

25

<Step A-4>

30 **[0052]** Step of reacting compound (a-4) with compound (a-42) to obtain a nitro compound (a-5). The reaction solvent may be 1-methylpyrrolidone, dimethylformamide, chlorobenzene, 2,6-lutidine, or the like. The reaction may be conducted with addition of a base, for example, an organic base such as diisopropylethylamine or 2,6-lutidine, or an inorganic base such as potassium carbonate. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

35

<Step A-42>

[0053] Step of reacting compound (a-4) with compound (a-43) to obtain an amino compound (a-61). The reaction solvent used may be 1-methylpyrrolidone, dimethylsulfoxide, or the like. A base such as sodium hydride may be used for the reaction. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

40

<Step A-5>

45 **[0054]** Step of reduction reaction of the nitro compound (a-5) to an amino compound (a-61). This may be carried out under conditions commonly employed for reduction of nitro groups to amino groups. Specifically, there may be mentioned reduction with iron-ammonium chloride, iron-hydrochloric acid or iron-acetic acid, or catalytic reduction with palladium hydroxide-hydrogen. The reaction solvent may be methanol, ethanol, tetrahydrofuran, dimethylformamide or the like, and catalytic reduction may be conducted at ordinary pressure or under pressurization. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

50

<Step A-6>

[0055] Step of alkylation of the amino compound (a-61). The amino compound (a-61) may be reacted with an aldehyde derivative or ketone derivative and the resultant imine reduced with a reducing agent such as sodium cyanoborohydride to obtain compound (a-62).

55

[0056] Alternatively, the amino compound (a-61) may be reacted with an acid chloride derivative or acid anhydride in the presence of a base and then reduced with a reducing agent such as lithium aluminum hydride to obtain compound

(a-62).

<Step A-7>

[0057] Step of reacting a carbamate derivative (a-81) with the amino derivative (a-61) or compound (a-62) to obtain a urea derivative (a-10). The reaction solvent used may be chloroform, toluene, acetonitrile, dimethylformamide, dimethylsulfoxide or the like. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from below freezing to reflux temperature. The reaction may also be conducted with addition of an organic base such as sodium hydride, triethylamine or pyridine or an inorganic base such as potassium carbonate or sodium carbonate.

<Step A-8>

[0058] Step of reacting an isocyanate derivative (a-82) with the amino derivative (a-61) or compound (a-62) to obtain compound (a-7). The reaction solvent used may be chloroform, toluene, acetonitrile, dimethylformamide, dimethylsulfoxide or the like. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from below freezing to reflux temperature. The reaction may also be conducted with addition of an organic base such as sodium hydride, triethylamine or pyridine or an inorganic base such as potassium carbonate or sodium carbonate.

<Step A-9>

[0059] Step of reacting compound (a-7) and compound (a-83) in the presence of a base such as pyridine to obtain a urea derivative (a-10). The reaction solvent used may be dimethylsulfoxide, dimethylformamide, tetrahydrofuran or the like, the reaction time from 10 minutes to 30 hours and the reaction temperature from 0°C to reflux temperature.

<Step A-10>


[0060] Step of reacting a carbamating reagent (a-84) such as phenylchloroformate with the amino compound (a-61) or compound (a-62) to obtain a carbamate derivative (a-9). The reaction may be conducted using a base such as pyridine. The reaction solvent used may be dimethylsulfoxide, dimethylformamide, tetrahydrofuran or the like, the reaction time from 10 minutes to 30 hours, and the reaction temperature from 0°C to reflux temperature.

<Step A-11>

[0061] Step of reacting an amine derivative (a-85) with the carbamate derivative (a-9) to obtain a urea derivative (a-10). The reaction may be conducted using a base such as triethylamine. The reaction solvent used may be dimethylsulfoxide, dimethylformamide or the like, the reaction time from 10 minutes to 30 hours, and the reaction temperature from room temperature to reflux temperature.

[Production Method 2-2]

[0062] Alternative production method to compound (a-10):




(wherein the symbols have the same definitions given above.)

<Step A-12>

[0063] Step of reacting a phenol derivative (a-12) having urea as a part of its structure, with a 4-chloroquinoline derivative (a-4) to obtain the target compound (a-11) by one direct step. The reaction solvent used may be 1-methylpyrrolidone, dimethylformamide, chlorobenzene, or the like. The reaction may be conducted with addition of a suitable base, for example, an organic base such as diisopropylethylamine, or an inorganic base such as potassium carbonate or sodium hydride. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

[Production Method 2-3]

[0064] Alternative production method to compound (a-5) and compound (a-61):



(wherein the symbols have the same definitions given above.)

<Step 2A-1>


[0065] Step of reacting a pyridine derivative (2a-1) with compound (a-5) to obtain compound (2a-2). The reaction may be conducted using a base such as potassium carbonate. The reaction solvent used may be dimethylformamide or the like, the reaction time from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

<Step 2A-2>

[0066] Step of converting a quinolone (a-5) to a thioquinolone (2a-3). A sulfide reagent such as sodium sulfide, phosphorus pentasulfide or the like may be reacted with the quinolone (a-5) to obtain the corresponding thioquinolone. The reaction solvent used may be diglyme, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours.

<Step 2A-3>

[0067] Step of reacting the thioquinolone (2a-3) with compound (2a-4) to obtain compound (2a-5). The reaction solvent used may be dimethylformamide or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours. An appropriate base such as pyridine may also be used.



(wherein the symbols have the same definitions given above.)

<Step 2A-4>

[0068] Step of reacting a hydroxypyridine derivative (2a-6) with compound (a-4) to obtain compound (2a-7). The solvent used may be 1-methylpyrrolidone, dimethylformamide, chlorobenzene, or the like. The reaction may be conducted with addition of a suitable base, for example, an organic base such as diisopropylethylamine, or an inorganic base such as potassium carbonate. The reaction time may be from 10 minutes to 30 hours, and the reaction temperature from room temperature to reflux temperature.

<Step 2A-5>


[0069] Step of palladium coupling reaction between compound (2a-7) and an imine derivative to obtain compound (2a-8). The reaction may be conducted using a solvent such as toluene, a catalyst, for example, a palladium derivative such as tris(dibenzylideneacetone)dipalladium(0) or a phosphine derivative such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, and a base such as t-butoxypotassium. The reaction temperature may be from about 50°C to reflux temperature, and the reaction time from about 1 hour to 10 hours.

<Step 2A-6>

[0070] Step of obtaining an amino derivative (2a-9) from compound (2a-8). The reaction is conducted using ethanol, water or the like, with the action of an acid such as hydrochloric acid. The reaction temperature may be from 0°C to about 100°C, and the reaction time from 10 minutes to about 10 hours.

<Step 2A-7>

[0071] Step of dechlorination of compound (2a-9) to obtain compound (2a-10). This may be accomplished by catalytic reduction or the like using palladium carbon-hydrogen. The reaction solvent may be methanol, ethanol, tetrahydrofuran, or the like, and catalytic reduction may be conducted at ordinary pressure or under pressurization. Triethylamine or the like may also be used as a base. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.




(wherein the symbols have the same definitions given above.)

<Step 2A-8>

[0072] A step of converting a quinolone compound (a-3) into a 4-aminoalkoxyquinoline (2a-11). An N-alkylphthalimide derivative may be reacted with compound (a-3) and deprotection accomplished with hydrazine hydrate or the like to obtain the target compound (2a-11). The solvent used may be dimethylformamide, tetrahydrofuran or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours. Potassium carbonate or the like may also be used as the base.

[Production Method 2-4]

[0073] Alternative production method to compound (a-4):



(wherein the symbols have the same definitions given above.)

<Step 3A-1>

[0074] Step of obtaining an enamine (3a-1). Diethyl ethoxymethylenemalonate may be reacted with an aniline derivative (a-1) to obtain compound (3a-1). The reaction proceeds without a solvent. The reaction temperature may be about 100°C, and the reaction time from 30 minutes to several hours.

<Step 3A-2>


[0075] Step of cyclization. Compound (3a-1) may be heated from about 200°C to about 260°C in a biphenyl ether/biphenyl mixed solvent for cyclization to obtain the target compound (3a-2). The reaction time may be from 30 minutes to 10 hours.

<Step 3A-3>


[0076] Step of chlorination. The same procedure as in <Step A-3> may be carried out to obtain the chlorinated compound (3a-3) from compound (3a-2).

[Production Method 3]

[0077] Representative production method for compound (G3) represented by:



(wherein the symbols have the same definitions given above)




(wherein the symbols have the same definitions given above.)

<Step B-1>

[0078] Step of reacting compound (a-4) with an indole derivative (b-2) to obtain compound (b-1). The reaction may be conducted under the same conditions as for <Step A-4> above.

<Step B-2>

[0079] Step of obtaining a urea derivative (b-3) from compound (b-1). The reagent used may be the aforementioned isocyanate derivative (a-82) or carbamate derivative (a-81). The reaction may be conducted under the same conditions as for <Step A-7>, <Step A-8> and <Step A-9> above.




(wherein the symbols have the same definitions given above.)


<Step B-3>

[0080] Step of introducing a substituent at the 3-position of the indole. Compound (b-4) may be reacted with a halogenating agent such as N-chlorosuccinimide or N-bromosuccinimide, or with phosphorus oxychloride or a thionyl chloride/dimethylformamide mixed reagent to obtain compound (b-5). The reaction solvent used may be 2-propanol, tetrahydrofuran, acetonitrile, dimethylformamide or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 10 minutes to 30 hours.

[Production Method 4-1]

[0081] Representative production method for compound (G4-1) represented by:

(wherein the symbols have the same definitions given above)



(wherein the symbols have the same definitions given above.)

[0082] General formula (G4-1) may be synthesized according to the process described in WO97/02266, PCT/EP96/02728 or Journal of Medicinal Chemistry, 1996, Vol.39, No.12, 2285-2292.

<Step C-1>

[0083] Step of synthesizing an imidate. Ethyl cyanoacetate may be reacted with hydrochloric acid in a solvent such as dioxane to obtain the target imidate compound (c-2). The reaction temperature is preferably from near 0°C to room temperature, and the reaction time may be from a few hours to several days.

<Step C-2>

[0084] Step of synthesizing an amidine. Compound (c-2) may be reacted with ammonia gas in ethanol to obtain the target amidine compound (c-3). The reaction temperature may be from near 0°C to room temperature, and the reaction time may be several hours.

<Step C-3>


[0085] Step of synthesizing a pyrrole derivative. Compound (c-3) may be reacted with an α -haloketone derivative (c-31) in ethanol to obtain the target pyrrole derivative (c-4). The reaction temperature may be from room temperature to reflux temperature, and the reaction time from a few hours to several days.

<Step C-4>

[0086] Ring-closing reaction of pyrrole ring to pyrrolopyrimidine ring. Compound (c-4) may be reacted with formamide and formic acid to obtain the target compound (c-5). The solvent used may be dimethylformamide. The reaction temperature may be from near 100°C to reflux temperature, and the reaction time from a few hours to several days.

<Step C-5>

[0087] Step of chlorination. The same procedure as in <Step A-3> may be carried out to obtain the target chlorinated compound (c-6).



(wherein the symbols have the same definitions given above.)

<Step C-6>

[0088] Reaction for introduction of substituent at 5-position of a pyrrole derivative (c-70). Compound (c-70) may be reacted with compound (c-71) in the presence of 2,6-lutidine, in darkness under a nitrogen atmosphere, to obtain the target compound (c-8). The reaction solvent used may be dichloromethane or the like, the reaction temperature from 0°C to room temperature, and the reaction time from 1 hour to 30 hours.

<Step C-7>


[0089] The same procedure as in <Step C-4> may be carried out to obtain compound (c-9).

<Step C-8>


[0090] The same procedure as in <Step A-3> may be carried out to obtain compound (c-10).

[Production Method 4-2]

[0091] Representative production method for compound (G4-2) represented by:



(wherein the symbols have the same definitions given above.)



(wherein the symbols have the same definitions given above.)

<Step 2C-1>

[0092] Step of chlorination. Compound (2c-1) may be reacted with thionyl chloride to obtain the target compound (2c-2). The reaction solvent used may be thionyl chloride, the reaction temperature may be reflux temperature, and the reaction time from a few hours to several days.

<Step 2C-2>

[0093] Rearrangement from carboxylic acid to a carbamate derivative (2c-3). The carboxylic acid derivative (2c-2) may be reacted with tert-butanol, benzyl alcohol, trimethylsilyl alcohol or the like in the presence of diphenylphosphoryl azide and triethylamine to obtain the target carbamate derivative (2c-3). The reaction solvent used may be tert-butanol, benzyl alcohol, dimethylformamide, toluene or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours.

<Step 2C-3>

[0094] Iodination reaction. The target compound (2c-4) may be obtained by using a base to generate an anion at the 3-position of pyridine, reacting iodine therewith to obtain an iodinated compound, and then conducting decarbamating reaction. The reaction solvent for the iodination may be tetrahydrofuran, diethyl ether or the like, the reaction temperature from -78°C to room temperature, and the reaction time from 10 minutes to 30 hours. The base used may be n-butyllithium or the like, and a base such as N,N,N',N'-tetramethylethylenediamine may also be added as appropriate. The reaction solvent used for the decarbamating reaction may be water, an alcohol or the like, as an acid there may be used aqueous hydrobromic acid, aqueous hydrochloric acid or the like, the reaction temperature may be from room temperature to reflux temperature, and the reaction time may be from 1 minute to several hours.

<Step 2C-4>

[0095] The same procedure as in <Step A-4> may be carried out to obtain the target compound (2c-5).

<Step 2C-5>

[0096] Coupling reaction between the iodo compound (2c-5) and an acetylene derivative. The iodo compound may be reacted with (trimethyl)acetylene in the presence of tetrakis(triphenylphosphine) palladium, copper (I) iodide or the like to obtain the target compound (2c-6). The reaction solvent used may be dimethylformamide or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours.


<Step 2C-6>

[0097] Cyclization reaction. Compound (2c-6) may be heated in the presence of copper (I) iodide to obtain the target

cyclized compound (2c-7). The reaction solvent used may be dimethylformamide or the like, the reaction temperature from 80°C to reflux temperature, and the reaction time from 5 minutes to 10 hours.

[Production Method 4-3]

[0098] Alternative production method to compound (2c-7) in Production Method 4-2:



(wherein the symbols have the same definitions given above.)

<Step 2C-7>


[0099] Conversion of ketone (2c-8) to thioketone (2c-90). Synthesis may be carried out by the same procedure as in <Step 2A-2>.

<Step 2C-8>


[0100] Synthesis may be carried out by the same procedure as in <Step 2A-3>.

[Production Method 5-1]

[0101] Representative production method for compound (G5-1) represented by:



(wherein the symbols have the same definitions given above.)



(wherein the symbols have the same definitions given above.)

<Step D-1>

[0102] The same procedure as in <Step A-4> may be carried out to obtain the target compound (d-2).

<Step D-2>


[0103] Step of amination of chloro group. The 2-chloropyrimidine derivative (d-2) may be reacted with ammonia to obtain the target amino compound (d-3). The reaction solvent used may be ethanol, tetrahydrofuran or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 10 minutes to 30 hours.

<Step D-3>

[0104] Reduction of nitro compound (d-3) to amino compound (d-4). The same procedure as in <Step A-5> may be carried out to obtain the target amino compound (d-4).

<Step D-4>

[0105] The same procedure as in <Step A-7> may be carried out to obtain the target urea compound (d-5).



(wherein the symbols have the same definitions given above.)

<Step D-6>

[0106] The same procedure as in <Step A-4> may be carried out to obtain the target compound (d-8).

<Step D-7>

[0107] Step of dechlorination and nitro group reduction. The target compound (d-9) may be obtained under common catalytic reduction conditions with palladium hydroxide-hydrogen or the like. The reaction solvent used may be methanol, ethanol, tetrahydrofuran, dimethylformamide or the like, and catalytic reduction may be conducted at ordinary


pressure or under pressurization. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

<Step D-8>


[0108] The same procedure as in <Step A-7> may be carried out to obtain the target urea compound (d-10).

[Production Method 5-2]

[0109] Representative production method for compound (G5-2) represented by:



(wherein the symbols have the same definitions given above.)



(wherein the symbols have the same definitions given above.)

<Step 2D-1>


[0110] Decarbamating reaction. Compound (2d-1) may be reacted with an acid to obtain the target amine derivative (2d-2). The solvent used may be water, dioxane, tetrahydrofuran, methanol, ethanol or the like, the reaction temperature from room temperature to reflux temperature and the reaction time from 10 minutes to 30 hours. The acid used may be hydrochloric acid, hydrobromic acid, trifluoroacetic acid, or the like.

<Step 2D-2>


[0111] Compound (2d-2) may be used in the same procedure from <Step D-6> to <Step D-8> of Production Method 5-1 to obtain a urea derivative (2d-3).

[Production Method 6]

[0112] Alternative production method for compounds (G6-1), (G6-2) and (G6-3) represented by:



(G6-1)




(G6-2)



(G6-3)

(wherein the symbols have the same definitions given above.)



(wherein the symbols have the same definitions given above.)

<Step E-1>


[0113] Coupling reaction between iodo compound and ethyl acrylate. Compound (e-1) may be reacted with ethyl acrylate in the presence of a catalyst such as palladium acetate and a tertiary amine such as tributylamine, to obtain the target compound (e-2). The reaction solvent used may be dimethylformamide or the like, the reaction temperature from 100°C to reflux temperature, and the reaction time from 5 minutes to 30 hours.

<Step E-2>

[0114] Reduction of double bond, followed by cyclization and nitro group reduction. Compound (e-2) may be reacted in the presence of palladium carbon-hydrogen for reduction of the double bond, cyclization and nitro group reduction. The reaction solvent used may be methanol, ethanol, tetrahydrofuran, dimethylformaldehyde or the like, and catalytic reduction may be conducted at ordinary pressure or under pressurization. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

<Step E-3>

[0115] Isomerization of double bond by light irradiation followed by cyclization. The reaction solvent used may be methanol or the like, with light irradiation performed in the presence of 2'-acetonaphthone to obtain the target compound (e-4). The reaction time may be from 10 minutes to 30 hours.



(wherein the symbols have the same definitions given above.)

<Step 2E-1>

[0116] Nitration reaction. Compound (2e-1) may be reacted with sulfuric acid and fuming nitric acid to obtain the target compound (2e-2). The reaction solvent used may be sulfuric acid, fuming nitric acid or the like, the reaction temperature from 0°C to room temperature, and the reaction time from 10 minutes to 30 hours.

<Step 2E-2>

[0117] Rearrangement of nitro group. Compound (2e-2) may be reacted with sulfuric acid to obtain the target compound (2e-3). The reaction solvent used may be sulfuric acid or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 10 minutes to 30 hours.

<Step 2E-3>


[0118] The target nitro compound (2e-4) may be obtained by nucleophilic substitution of compound (2e-3) using any desired nitro group-containing nucleophilic agent and 1-methylpyrrolidone, dimethylformamide, chlorobenzene or the like as the reaction solvent. The reaction may be conducted with addition of an appropriate base, for example, an organic base such as diisopropylethylamine, or an inorganic base such as potassium carbonate. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.

<Step 2E-4>

[0119] Reduction of nitro group to amino group. The same procedure as in <Step A-5> may be carried out to obtain the target compound (2e-5).

<Step 2E-5>

[0120] Condensation of a carboxylic acid and the diamine (2e-5). The diamine compound (2e-5) may be reacted with a carboxylic acid to obtain the target compound (2e-6). The reaction solvent used may be pyrophosphoric acid or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours. Polyphosphoric acid, phosphorus pentoxide or the like may be used as a dehydrating agent.



(wherein the symbols have the same definitions given above.)

<Step 3E-1>

[0121] This synthesis may be carried out according to the process described in Journal of Heterocyclic Chemistry, 35, 1313(1998). An α -haloketone derivative (3e-1) may be reacted with malononitrile to synthesize compound (3e-2). The reaction solvent used may be dimethylformamide or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 30 minutes to about 30 hours. Diethylamine may be used as the base.

<Step 3E-2>


[0122] Step of forming furopyrimidine ring. Compound (3e-2) may be heated at about 200°C in formamide with addition of acetic anhydride to obtain the target compound (3e-3). The reaction time may be about a few hours.

<Step 3E-3>

[0123] Bromination reaction. Compound (3e-3) may be reacted with dibromomethane and isoamyl nitrite to obtain the target bromo compound (3e-4). The reaction solvent used may be dibromomethane, the reaction temperature from room temperature to reflux temperature, and the reaction time from 30 minutes to 30 hours.

<Step 3E-4>

[0124] The same procedure as in <Step A-4> may be carried out to obtain compound (3e-5).



(wherein the symbols have the same definitions given above.)

<Step 3E-5>


[0125] The same procedure as in <Step A-1> may be carried out to obtain compound (3e-7).

<Step 3E-6>



[0126] The same procedure as in <Step A-2> may be carried out to obtain compound (3e-8).

<Step 3E-7>

[0127] The same procedure as in <Step A-3> may be carried out to obtain compound (3e-9).




(wherein the substituent R^{sa100} is optionally substituted phenylamino or optionally substituted benzyl amino). Synthesis of this compound is described in Journal of Medicinal Chemistry, 40, 3601(1997).



(wherein the substituent R^{sa101} is fluorine, optionally substituted amino, optionally substituted C_{1-6} alkoxy or optionally substituted C_{2-7} acylamino). Synthesis of this compound is described in Journal of Medicinal Chemistry, 39, 1823(1996).


[Production Method 7]

[0128] Representative production method for compound (II) represented by:



(wherein the symbols have the same definitions given above.)


(1) Compound (a-01) represented by the formula:



(wherein the symbols have the same definitions given above) may be synthesized utilizing common hitherto known organic reactions. As compound (a-01) there may be used compounds (c-6), (c-10), (2c-4), (d-1), (d-2), (d-7), (3e-4), (2e-4), (3e-9), (4e-1), (4e-2) or (4e-3) described in the aforementioned production methods 4-1, 4-2, 5-1, 5-2 and 6.

[0129] Compound (II) may be produced using compound (a-01) under the reaction conditions described in <Step A-4> to <Step A-11> in Production Method 2-1 above, the reaction conditions described in Production Method 2-2 above, the reaction conditions described in Production Method 2-3 above and the reaction conditions described in Production Method 3 above.

(2)




(wherein the symbols have the same definitions given above.)


[0130] The urea derivative (II) may be obtained using compound (a-03) or (a-04) with an appropriate combination of the conditions in <Step A-5> to <Step A-11> in Production Method 2-1. Specifically, compound (a-03) or (a-04) may be, for example, (2c-7), (2c-92), (e-4), (3e-5), (e-3) or (e-6).

[Production Method 8-1]

[0131] Representative synthesis method for compound represented by:



(wherein the symbols have the same definitions given above.)



(wherein the symbols have the same definitions given above.)

<Step O-1>

[0132] Step of reductive amination. An aldehyde derivative may be reductively reacted with compound (o-1) to obtain the target compound (o-2). The reaction solvent used may be acetic acid, tetrahydrofuran, dichloroethane, dichloromethane, methanol or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 30 minutes to 30 hours. The reducing agent used may be sodium triacetoxymethylborohydride, sodium borohydride, or the like.

<Step O-2>

[0133] Carbamating step. Compound (o-2) may be reacted with a chloroformate derivative to obtain the target compound (o-3). The reaction solvent used may be tetrahydrofuran, dichloromethane or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 30 minutes to 30 hours. Pyridine, triethylamine or the like may be used as the base.

<Step O-3>


[0134] Step of reducing nitro group to amino group. The same procedure as in <Step A-5> may be carried out to obtain compound (o-4).

<Step O-4>

[0135] Intramolecular cyclization step. The target compound (o-5) may be obtained by reacting the amino group and carbamate group in the molecule. The reaction solvent used may be tetrahydrofuran, dimethylformamide, dimethylsulfoxide, acetonitrile or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 30 minutes to 30 hours. Sodium hydride, pyridine, triethylamine or the like may be used as the base.

[Production Method 8-2]

[0136] Alternative production method for compound (o-5).



(wherein the symbols have the same definitions given above.)

<Step O-5>


[0137] Step of reducing nitro group to amino group. The same procedure as in <Step A-5> may be carried out to obtain the target diamine compound (o-6).

<Step O-6>

[0138] Intramolecular cyclization step. The target compound (o-5) may be obtained by condensing the two amino groups in the molecule using phosgene, triphosgene, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, (1H-1,2,3-benzotriazol-1-yloxy)(tri(dimethylamino))phosphonium hexafluorophosphate, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1,1-carbonyldiimidazole or the like as the condensing agent. The reaction solvent used may be tetrahydrofuran, dimethylformamide, dimethylsulfoxide, acetonitrile or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 30 minutes to 30 hours. Sodium hydride, pyridine, triethylamine or the like may be appropriately used as the base.

[Production Method 9]

[0139] Conversion of substituent on ring A of compound (II) represented by




(wherein the symbols have the same definitions given above.)

[0140] This may be accomplished by appropriately employing common organic reactions such as oxidation, reduction, esterification, amidation, protection, deprotection, hydrolysis, dehydration, rearrangement, nucleophilic reaction, nucleophilic substitution or aromatic electrophilic substitution.

[0141] Specifically, the substituent conversion on ring A may be carried out by the methods shown below, for example. In addition, (1) the following reactions may be appropriately combined, (2) their products may be used as intermediates as well as final products, and (3) the reactions may be used not only for conversion of substituents directly bonded to ring A, but also for conversion of substituents at positions not directly bonded to but within substituents on ring A.

[Production Method 10]

[0142]



(wherein G₁ is an optionally substituted nitrogen atom or oxygen atom, and the remaining symbols have the same definitions given above.)

<Step H-1>

[0143] Reduction of ester compound (h-1) to alcohol compound (h-2). The reducing agent used may be lithium borohydride, lithium aluminum hydride or the like, the reaction solvent diethyl ether, tetrahydrofuran or the like, the reaction temperature from 0°C to reflux temperature and the reaction time from 10 minutes to 30 hours.

<Step H-2>

[0144] Oxidation of alcohol compound (h-2) to aldehyde compound (h-3). The oxidizing agent used may be manganese dioxide, pyridium chlorochromate (PCC), pyridium dichromate (PDC) or the like, the reaction solvent chloroform, dichloromethane, toluene or the like, the reaction temperature from 0°C to reflux temperature and the reaction time from 30 minutes to 30 hours.

<Step H-3>

[0145] Reductive amination reaction. Compound (h-4) may be obtained by reaction of an amino derivative with the aldehyde derivative (h-3) to form an imine, followed by reduction with sodium cyanoborohydride or the like. The reaction solvent used may be methanol, tetrahydrofuran or the like, the reaction time from 10 minutes to 30 hours and the reaction temperature from 0°C to reflux temperature.



15

20

<Step H-5>

25

30

35




<Step H-7>

45

50

[Production Method 10-2]

[0150]

(wherein the symbols have the same definitions given above.)

<Step 2H-1>


[0151] Step of hydrolyzing ester in compound (2h-1) to obtain compound (2h-2). A base such as potassium hydroxide, sodium hydroxide, calcium carbonate, sodium carbonate or the like may be used for the reaction. The reaction time may be from 10 minutes to 30 hours, and the reaction temperature from 0°C to reflux temperature. The solvent used may be water, tetrahydrofuran or the like.

<Step 2H-2>

[0152] Synthesis of amide derivative (2h-3) by condensation of carboxylic acid and amine derivative. Compound (2h-3) may be obtained by reacting compound (2h-2) and an amine derivative in the presence of a condensing agent. As condensing agents there may be used 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, (1H-1,2,3-benzotriazol-1-yloxy)(tri(dimethylamino))phosphonium hexafluorophosphate, or the like. The reaction time may be from 10 minutes to 30 hours, and the reaction temperature from 0°C to reflux temperature. The solvent used may be dimethylformamide, tetrahydrofuran, or the like.

<Step 2H-3>

[0153] Synthesis of ester (2h-4) by condensation of carboxylic acid and an alcohol. Compound (2h-3) may be obtained by reaction of compound (2h-2) and an alcohol derivative in the presence of a condensing agent. As the condensing agent there may be used 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, or the like. The reaction time may be from 10 minutes to 30 hours, and the reaction temperature from 0°C to reflux temperature. The solvent used may be dimethylformamide, tetrahydrofuran, or the like.




(wherein the symbols have the same definitions given above.)

<Step 2H-4>

[0154] Step of obtaining compound (2h-6) by hydrolysis of ester in compound (2h-5). The same procedure as in <Step 2H-1> may be carried out to synthesize compound (2h-6) from compound (2h-5).

<Step 2H-5>

[0155] Synthesis of amide derivative (2h-7) by condensation of carboxylic acid derivative (2h-6) and amino derivative. The same procedure as in <Step 2H-2> may be carried out to synthesize compound (2h-7) from compound (2h-6).




(wherein the symbols have the same definitions given above.)

<Step 2H-6>

[0156] Step of obtaining nitrile derivative (2h-9) by dehydration of carbamoyl compound (2h-8). The reaction solvent used may be tetrahydrofuran, diethyl ether or the like, the dehydrating agent used may be thionyl chloride, trifluoroacetic anhydride, dicyclohexyl carbodiimide or the like, and the base used may be pyridine, triethylamine or the like. The reaction temperature may be from 0°C to reflux temperature, and the reaction time from 30 minutes to 30 hours.

[Production Method 10-3]



[0157]



(wherein the symbols have the same definitions given above.)

<Step 3H-1>

[0158] Step of acylating amino group. Compound (3h-1) may be reacted with an acid chloride, acid anhydride or the like to obtain the target compound (3h-2). The reaction solvent used may be tetrahydrofuran or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 10 minutes to 30 hours. Triethylamine or the like may be used as the base.




(wherein the symbols have the same definitions given above.)

<Step 3H-20>

[0159] Acylation step. Compound (3h-3) may be reacted with an acid chloride, acid anhydride or the like to obtain the target compound (3h-4). The reaction solvent used may be tetrahydrofuran, pyridine or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 10 minutes to 30 hours. Triethylamine, pyridine or the like may be used as the base.

<Step 3H-21>


[0160] Cyclization reaction. The reaction solvent used may be dimethylformamide or the like, the reaction temperature from 100°C to reflux temperature, and the reaction time from 10 minutes to 30 hours. Potassium carbonate or the like may be used as the base.



(wherein the symbols have the same definitions given above.)

<Step 3H-3>

[0161] Sulfonamidation step. Compound (3h-5) may be reacted with a sulfonyl chloride derivative to obtain the target compound (3h-6). The reaction solvent used may be tetrahydrofuran, dimethylformamide or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 10 minutes to 30 hours. Triethylamine, pyridine or the like may be used as the base.




(wherein the symbols have the same definitions given above.)

<Step 3H-4>

[0162] De-benzoyloxycarbonylation step. Compound (3h-8) may be obtained from compound (3h-7) by ordinary catalytic reduction (palladium-carbon, palladium hydroxide-carbon and hydrogen, etc.). The solvent used may be tetrahydrofuran, methanol, ethanol or the like. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from 0°C to reflux temperature. Trifluoroacetic acid, hydrochloric acid or the like may be added as an acid.

[Production Method 11]

[0163]




(wherein the symbols have the same definitions given above.)

<Step I-1>

[0164] Rearrangement of carboxylic acid to amino derivative (i-2). A carboxylic acid derivative (i-1) may be reacted with benzyl alcohol in the presence of diphenylphosphoryl azide and triethylamine to obtain compound (i-2) from compound (i-1). The reaction solvent used may be benzyl alcohol, dimethylformamide, toluene or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours.

<Step I-2>

[0165] The same procedure as in <Step A-4>, <Step A-5> and <Step A-7> may be carried out to synthesize compound (i-3) from compound (i-2).




(wherein the symbols have the same definitions given above.)

<Step I-3>

[0166] Step of rearrangement of carbamoyl group to amino group. An amino compound (i-5) may be obtained from compound (i-4) by reaction with a base such as bromine water, sodium hydroxide or the like. The reaction solvent used maybe water or the like, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 10 hours.

[Production Method 12-1]

[0167]




(wherein the symbols have the same definitions given above.)

<Step M-1>

[0168] Conversion of methylthio group to methylsulfonyl group. Compound (m-1) may be reacted with a peracid to obtain the target compound (m-2). The peracid used may be 3-chloroperbenzoic acid, the reaction solvent methylene chloride, chloroform or the like, the reaction time from 10 minutes to 30 hours and the reaction temperature from 0°C to room temperature.

[Production Method 12-2]


[0169]



(wherein the symbols have the same definitions given above.)

<Step 2M-1>


[0170] Step of introducing substituent into aromatic ring by electrophilic reaction. An electrophilic reagent may be reacted with compound (2m-1) to obtain compound (2m-2). The electrophilic reagent used for the reaction may be, as specific examples, Vilsmeier reagent (which may be prepared from dimethylformamide or N-methylformanilide and phosphorus oxychloride), N-chlorosuccinimide, N-bromosuccinimide, a combination of acyl chloride and a Lewis acid (for example, aluminum chloride, titanium tetrachloride, etc.) or a reagent represented by the formula



These allow introduction of formyl, chloro, bromo, acyl and dimethylaminomethyl groups, respectively. The reaction solvent used maybe dimethylformamide, acetonitrile, dichloromethane, toluene or the like. The reaction temperature may be from 0°C to reflux temperature, and the reaction time from 10 minutes to 30 hours.

[Production Method 13]


[0171]



(wherein the symbols have the same definitions given above.)

<Step Q-1>

[0172] Step of deprotection of hydroxyl-protecting group of compound (q-1). The reaction may be conducted in the same manner as the conventional method for deprotection of a phenol group protected with a benzyl group. Specifically, the reagent used may be, for example, trifluoroacetic acid-thioanisole, palladium hydroxide-hydrogen, platinum oxide-hydrogen, or the like. The reaction solvent used may be trifluoroacetic acid, dimethylformamide or the like, the reaction time from 10 minutes to 30 hours and the reaction temperature from room temperature to reflux temperature.




(wherein R^{sa90} is an amino or nitro group, and the other symbols have the same definitions given above.)

<Step Q-2>

[0173] Step of deprotection of hydroxyl-protecting group of compound (q-3). The reaction may be conducted under the same conditions as in <Step Q-1> above.

[Production Method 14]

[0174]




(wherein the symbols have the same definitions given above.)


<Step R-1>

[0175] Step of reacting compound (r-1) with an electrophilic reagent such as an alkyl halide derivative (r-2) to obtain compound (r-3). The reaction solvent used may be dimethylformamide, dimethylsulfoxide, tetrahydrofuran or the like, the reaction time from 10 minutes to 30 hours, and the reaction temperature from 0°C to reflux temperature. The reaction may also employ a base, and specifically, for example, potassium carbonate, cesium carbonate or the like.

[0176] As specific examples for the alkyl halide derivative ($R^{sa71}\text{-U}$) in the reaction there may be mentioned (1) alkylthio halide derivatives represented by the formula: $R^{sa80}\text{S}-(\text{CH}_2)_s\text{-Cl}$ (wherein s is an integer of 1-6, and the other symbols have the same definitions given above), (2) alkyl halide derivatives represented by the formula: $\text{Br}-(\text{CH}_2)_s\text{-Cl}$ (wherein s is an integer of 1-6), (3) propylene oxide derivatives represented by the formula:

(wherein U is a leaving group), (4) compounds represented by the formula:

(wherein U is a leaving group, R^{sa82} is an amino-protecting group such as t -butoxycarbonyl or benzyl, and s is an integer of 1-6), and (5) alkyl halide derivatives substituted with C_{1-6} alkoxy groups.




(wherein R^{sa73} is hydrogen or 2-(trimethylsilyl)ethoxymethyl, and the other symbols have the same definitions given above.

<Step R-2>

[0177] Step of reaction with a phenol derivative (r-4) to introduce the substituent R^{sa71} . The substituent R^{sa71} may

be introduced by the same procedure as in <Step R-1>.




(wherein the symbols have the same definitions given above.)

<Step R-3>

[0178] Step of triflating the hydroxyl group. Compound (r-6) may be reacted with a triflating reagent such as paranitrophenyl triflate or the like to obtain the target compound (r-7). The reaction solvent used may be dimethylformamide or the like, the reaction temperature from 0°C to reflux temperature and the reaction time from 10 minutes to 30 hours. Potassium carbonate or the like may be used as a base.

<Step R-4>

[0179] Step of converting the triflate group to a cyano group. Compound (r-7) may be reacted with a cyanating reagent such as zinc cyanide ($\text{Zn}(\text{CN})_2$) or the like to obtain the target compound (r-8). The catalyst used may be tetrakis-riphenylphosphine palladium. The reaction solvent used may be dimethylformamide, the reaction temperature from room temperature to reflux temperature, and the reaction time from 10 minutes to 30 hours.



(wherein the symbols have the same definitions given above.)

<Step R-5>

[0180] Step of reacting compound (r-3) which has a thioether group in substituent $\text{R}^{\text{sa}71}$, with an oxidizing agent such as 3-chloroperbenzoic acid to obtain compound (2r-2). The reaction solvent used may be methylene chloride, chloroform or the like, the reaction time from 10 minutes to 30 hours and the reaction temperature from 0°C to room temperature.

<Step R-6>


[0181] Step of reacting a nucleophilic agent with compound (r-3) having a leaving group, for example, a halogen atom such as chlorine, bromine or iodine or a methanesulfonyloxy group, or an epoxide group or the like in substituent $\text{R}^{\text{sa}71}$, to obtain compound (2r-1) or compound (2r-4). Specific examples of nucleophilic agents which may be used include nitrogen-containing aromatic derivatives such as triazole or imidazole, amine derivatives such as morpholine

or pyrrolidine, and alcohol derivatives, phenol derivatives, thiol derivatives and the like.

[0182] The reaction solvent used may be dimethylformamide, tetrahydrofuran, or the like, the reaction time from 10 minutes to 30 hours and the reaction temperature from 0°C to reflux temperature, and potassium carbonate, sodium hydride or the like may be used as a base.

<Step R-7>

[0183]



(wherein R^{sa82} is an amino-protecting group such as t-butoxycarbonyl or benzyl, and the remaining symbols have the same definitions given above.)


[0184] Compound (r-90) or compound (r-91) wherein the amino group protected with a protecting group may be subjected to amino-deprotection reaction, and the deprotected amino group then alkylated.

(1) Amino-deprotecting step. The deprotecting reagent used may be trifluoroacetic acid, hydrochloric acid or the like. When the protecting group is benzyl, the deprotecting reaction may be conducted by common catalytic reduction (palladium hydroxide-hydrogen or the like). The solvent used may be trifluoroacetic acid, methanol, ethanol or the like. The reaction time may be from 10 minutes to 30 hours and the reaction temperature from 0°C to reflux temperature.


(2) Step of alkylating deprotected amino group. The deprotected amino derivative may be reacted with an aldehyde derivative or ketone derivative to form an imine, which is then reduced with a reducing agent such as sodium cyanoborohydride to obtain compound (2r-3). The reaction solvent used may be methanol, tetrahydrofuran or the like, the reaction time from 10 minutes to 30 hours, and the reaction temperature from 0°C to reflux temperature.

[Production Method 15]

[0185] Alternative synthesis method for compound represented by:



(wherein the symbols have the same definitions given above.)




(wherein the symbols have the same definitions given above.)

<Step P-1>


[0186] Compound (p-1) may be reacted with an alcohol derivative (p-2) in the presence of a base such as sodium hydride to obtain compound (p-3). The synthesis may be carried out by reaction in a solvent such as 1-methylpyrrolidone or N,N-dimethylformamide. The reaction time may be from 10 minutes to 30 hours, and the reaction temperature from 0°C to reflux temperature.

[Production Method 16]

[0187] Alternative synthesis method for compound represented by:



(wherein the symbols have the same definitions given above.)



(wherein the symbols have the same definitions given above.)

<Step P-2>

[0188] Reaction for obtaining carbamate derivative. It may be obtained by reacting an amino derivative with phenyl chloroformate. The reaction solvent used may be tetrahydrofuran, dimethylformamide or the like, the reaction temperature from 0°C to reflux temperature, and the reaction time from 30 minutes to 30 hours.

[0189] The reaction is carried out while appropriately protecting the reactive functional groups such as amino, hydroxyl and carboxyl.

[0190] As amino-protecting groups there may be used any groups conventionally known as protecting groups for amino groups in organic synthesis, with no particular restrictions, and as specific examples there may be mentioned substituted or unsubstituted lower alkanoyl groups such as formyl, acetyl, chloroacetyl, dichloroacetyl, propionyl, phenylacetyl, phenoxyacetyl and thienylacetyl; substituted or unsubstituted lower alkoxy carbonyl groups such as benzyloxycarbonyl, t-butoxycarbonyl and p-nitrobenzyloxycarbonyl; substituted lower alkyl groups such as methyl, t-butyl, 2,2,2-trichloroethyl, trityl, p-methoxybenzyl, p-nitrobenzyl, diphenylmethyl and pivaloyloxymethyl; substituted silyl groups such as trimethylsilyl and t-butyldimethylsilyl; substituted silylalkoxyalkyl groups such as trimethylsilylmethoxymethyl, trimethylsilylethoxymethyl, t-butyldimethylsilylmethoxymethyl and t-butyldimethylsilylethoxymethyl; or substituted or unsubstituted benzylidene groups such as benzylidene, salicylidene, p-nitrobenzylidene, m-chlorobenzylidene, 3,5-di(t-butyl)-4-hydroxybenzylidene and 3,5-di(t-butyl)benzylidene.

[0191] These protecting groups may be removed by ordinary methods such as hydrolysis or reduction, depending on the type of protecting group used.

[0192] As hydroxyl-protecting groups there may be used any groups conventionally known as protecting groups for hydroxyl groups in organic synthesis, with no particular restrictions, and as specific examples there may be mentioned lower alkylsilyl groups such as trimethylsilyl and t-butyldimethylsilyl; lower alkoxy methyl groups such as methoxymethyl and 2-methoxyethoxymethyl; tetrahydropyranyl; aralkyl groups such as benzyl, p-methoxybenzyl, 2,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl and trityl; acyl groups such as formyl and acetyl; lower alkoxy carbonyl groups such as t-butoxycarbonyl, 2-iodoethoxycarbonyl and 2,2,2-trichloroethoxycarbonyl; alkenyloxycarbonyl groups such as 2-pro-

penyloxy carbonyl, 2-chloro-2-propenyloxy carbonyl, 3-methoxycarbonyl-2-propenyloxy carbonyl, 2-methyl-2-propenyloxy carbonyl, 2-butenyloxy carbonyl and cinnamyloxy carbonyl; and aralkyloxy carbonyl groups such as benzyloxy carbonyl, p-methoxybenzyloxy carbonyl, o-nitrobenzyloxy carbonyl and p-nitrobenzyloxy carbonyl.

[0193] These protecting groups may be removed by ordinary methods such as hydrolysis or reduction, depending on the type of protecting group used.

[0194] As carboxyl-protecting groups there may be used any groups conventionally known as protecting groups for carboxyl groups in organic synthesis, with no particular restrictions, and as specific examples there may be mentioned linear or branched lower alkyl groups of 1-4 carbons such as methyl, ethyl, isopropyl and t-butyl; halogeno lower alkyl groups such as 2-iodoethyl and 2,2,2-trichloroethyl; lower alkoxy methyl groups such as methoxymethyl, ethoxymethyl and isobutoxymethyl; lower aliphatic acyloxy methyl groups such as butyryloxy methyl and pivaloyloxy methyl; 1-lower alkoxy carbonyloxyethyl groups such as 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl, aralkyl groups such as benzyl, p-methoxybenzyl, o-nitrobenzyl and p-nitrobenzyl; benzhydryl, phthalidyl, and the like.

[0195] These protecting groups may be removed by ordinary methods such as hydrolysis or reduction, depending on the type of protecting group used.

[0196] There are no particular restrictions on esters of the carboxyl groups so long as they are ones commonly used in organic synthesis, and they include physiologically acceptable esters which are hydrolyzed under physiological conditions. As specific examples there may be mentioned alkyl groups of 1 to 6 carbons, aryl groups of 6 to 12 carbons, aralkyl groups of 7 to 20 carbons such as benzyl, heteroarylalkyl groups of 7 to 20 carbons, 4-methoxybenzyl, alkanoyloxyalkyl groups such as acetoxymethyl, propionyloxymethyl or pivaloxymethyl, alkoxy carbonyloxyalkyl groups such as methoxycarbonyloxymethyl ethoxycarbonyloxymethyl or 2-methoxycarbonyloxyethyl, (5-methyl-2-oxo-1,3-dioxo-4-yl)-methyl, and the like.

[0197] The solvents to be used for the invention are not particularly restricted so long as they do not impede the reaction and are solvents commonly used in organic synthesis, and as examples there may be mentioned lower alcohols such as methanol, ethanol, propanol and butanol, polyalcohols such as ethyleneglycol and glycerin, ketones such as acetone, methylethyl ketone, diethyl ketone and cyclohexanone, ethers such as diethyl ether, isopropyl ether, tetrahydrofuran, dioxane, 2-methoxyethanol and 1,2-dimethoxyethane, nitriles such as acetonitrile and propionitrile, esters such as methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate and diethyl phthalate, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, trichloroethylene and tetrachloroethylene, aromatic compounds such as benzene, toluene, xylene, monochlorobenzene, nitrobenzene, indene, pyridine, quinoline, collidine and phenol, hydrocarbons such as pentane, cyclohexane, hexane, heptane, octane, isooctane, petroleum benzene and petroleum ether, amines such as ethanolamine, diethylamine, triethylamine, pyrrolidine, piperidine, piperazine, morpholine, aniline, dimethylaniline, benzylamine and toluidine, amides such as formamide, N-methylpyrrolidone, N,N-dimethylimidazolone, N,N-dimethylacetamide and N,N-dimethylformamide, phosphoric/phosphorous amides such as hexamethylphosphoric triamide and hexamethylphosphorous triamide, and water, as well as other commonly used solvents, either alone or in mixtures of two or more, with no particular restrictions on the solvent ratio.

[0198] There are no particular restrictions on bases used so long as they are commonly known as bases for organic synthesis, and as specific examples there may be mentioned sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydride, potassium hydride, t-butoxypotassium, pyridine, dimethylaminopyridine, trimethylamine, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine, N-methylpiperidine, N,N-dimethylaniline, 1,8-diazabicyclo[5.4.0]undeca-7-ene (DBU), pyridine, 4-dimethylaminopyridine, picoline, lutidine, quinoline, isoquinoline, sodium hydroxide, potassium hydroxide, lithium hydroxide, butyllithium, and sodium or potassium alcoholates such as sodium methylate, potassium methylate and sodium ethylate.

[0199] As specific examples of halogenating agents to be used there may be mentioned halogenating agents conventionally used for synthesis of acid halides, for example, phosgene, diphosgene (phosgene dimer), triphosgene (phosgene trimer), thionyl chloride, thionyl bromide, phosphorus trichloride, phosphorus tribromide, phosphorus oxychloride, phosphorus pentachloride, trichloromethyl chloroformate and oxalyl chloride, as well as Vilsmeier reagents obtained by reacting these halogenating agents with acid amides or phosphoric amides.

[0200] There are no particular restrictions on reducing agents so long as they are ones commonly used in organic synthesis, and as examples there may be mentioned contact hydrogenating catalysts such as NaBH_4 , LiBH_4 , $\text{Zn}(\text{BH}_4)_2$, $\text{Me}_4\text{NBH}(\text{OAc})_3$, NaBH_3CN , Selectride, Super Hydride (LiBHEt_3), LiAlH_4 , DIBAL, $\text{LiAlH}(\text{t-BuO})_3$, Red-al and binap, as well as platinum, palladium, rhodium, ruthenium, nickel, and the like.

[0201] After completion of the reaction, purification may be accomplished by any desired ordinary treatment method, such as column chromatography using silica gel or an adsorption resin, or recrystallization from a suitable solvent.

[0202] Throughout the present specification, the term "pharmacologically acceptable salt" is not particularly restrictive on the type of salt, and as examples of such salts there may be mentioned inorganic acid addition salts such as hydrochloric acid salts, sulfuric acid salts, carbonic acid salts, bicarbonate salts, hydrobromic acid salts and hydriodic acid salts; organic carboxylic acid addition salts such as acetic acid salts, maleic acid salts, lactic acid salts, tartaric

acid salts and trifluoroacetic acid salts; organic sulfonic acid addition salts such as methanesulfonic acid salts, hydroxymethanesulfonic acid salts, hydroxyethanesulfonic acid salts, benzenesulfonic acid salts, toluenesulfonic acid salts and taurine salts; amine addition salts such as trimethylamine salts, triethylamine salts, pyridine salts, procaine salts, picoline salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, N-methylglucamine salts, diethanolamine salts, triethanolamine salts, tris(hydroxymethylamino)methane salts and phenethylbenzylamine salts; and amino acid addition salts such as arginine salts, lysine salts, serine salts, glycine salts, aspartic acid salts and glutamic acid salts.

[0203] The dosage of a medicine according to the invention will differ depending on the severity of symptoms, patient age, gender and weight, administration form and type of disease, but administration may usually be from 100 µg to 10 g per day for adults, either at once or in divided doses.

[0204] There are no particular restrictions on the form of administration of a medicine according to the invention, and it may usually be administered orally or parenterally by conventional methods.

[0205] Common excipients, binders, glossy agents, coloring agents, taste correctors and the like, and if necessary stabilizers, emulsifiers, absorption promoters, surfactants and the like, may also be used for formulation, with inclusion of components ordinarily used as starting materials for formulation of pharmaceutical preparations by common methods.

[0206] Examples of such components which may be used include animal and vegetable oils (soybean oil, beef tallow, synthetic glycerides, etc.), hydrocarbons (liquid paraffin, squalane, solid paraffin, etc.), ester oils (octyldodecyl myristate, isopropyl myristate, etc.), higher alcohols (cetostearyl alcohol, behenyl alcohol, etc.), silicone resins, silicone oils, surfactants (polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylenesorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylenepolyoxypropylene block copolymer, etc.), water-soluble polymers (hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethyleneglycol, polyvinylpyrrolidone, methyl cellulose, etc.), alcohols (ethanol, isopropanol, etc.), polyhydric alcohols (glycerin, propyleneglycol, dipropyleneglycol, sorbitol, etc.), sugars (glucose, sucrose, etc.), inorganic powders (silicic anhydride, aluminium magnesium silicate, aluminium silicate, etc.), purified water and the like. For pH adjustment there may be used inorganic acids (hydrochloric acid, phosphoric acid, etc.), alkali metal salts of inorganic acids (sodium phosphate, etc.), inorganic bases (sodium hydroxide, etc.), organic acids (lower fatty acids, citric acid, lactic acid, etc.), alkali metal salts of organic acids (sodium citrate, sodium lactate, etc.), and organic bases (arginine, ethanolamine, etc.). If necessary, preservatives, antioxidants and the like may also be added.

[0207] The compounds of the invention exhibit powerful *in vitro* inhibition of 1) invasive tube formation by vascular endothelial cells induced by a combination of angiogenic factors, 2) tube formation by vascular endothelial cells specifically induced by single angiogenic factors, and 3) receptor kinases for various angiogenic factors. Among these compound groups having such activity there were also found compounds that inhibit proliferation of cancer cells. Invasion and tube formation by endothelial cells are an important process in angiogenesis, and therefore compounds with inhibiting action against them exhibit angiogenesis-inhibiting effects. In addition, angiogenesis in the body is known to depend not on a single angiogenic factor but rather on the additive and synergistic effect of multiple angiogenic factors ((1) Koolwijk P, van Erck MGM, de Vree WJA, Vermeer MA, Weich HA, Hane maaier R, van Hinsbergh VWM. Cooperative effect of TNF-alpha, bFGF and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. 1996, 132, P1177-1188.; (2) Tallquist MD, Soriano P, Klinghoffer RA. Growth factor signaling pathways in vascular development. Oncogene 1999, 18, P7917-7932.). Thus, the compounds of the invention which inhibit tube formation induced by multiple angiogenic factors produced by cancer cells and the like are expected to exhibit powerful angiogenesis inhibition *in vivo*, and should be highly useful as angiogenesis inhibitors.

[0208] The biochemical activity of the compounds of the invention and their function and effect as medicines (angiogenesis-inhibiting activity, antitumor activity, etc.) may be evaluated by the methods described below.

[0209] The following is a list of abbreviations used in the pharmacological test examples described below.

<List of Abbreviations>

[0210]

DNA: Deoxyribonucleic Acid

VEGFR2: Vascular Endothelial Growth Factor Receptor 2 human placenta: human placenta

Hepes: N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]

MgCl₂: Magnesium chloride

MnCl₂: Manganese chloride

Na₃VO₄: Sodium Orthovanadate (V)

ATP: Adenosine 5'-Triphosphate

EDTA: Ethylenediaminetetraacetic acid
 HTRF: Homogenous Time-Resolved Fluorescence
 FGFR1: Fibroblast Growth Factor Receptor 1
 PDGFR β : Platelet-Derived Growth Factor Receptor β
 5 HGFR: Hepatocyte Growth Factor Receptor
 EGFR: Epidermal Growth Factor Receptor
 Tris: Tris(hydroxymethyl)aminomethane
 NaCl: Sodium chloride
 BSA: Bovine Serum Albumin
 10 HRP: Horseradish peroxidase
 EGTA: N,N,N',N'-Tetraacetic acid
 SDS: Sodium Dodecyl Sulfate
 NP-40: Nonidet P-40
 PCR: Polymerase Chain Reaction
 15 RT-PCR: Reverse Transcription-Polymerase Chain Reaction
 RNA: Ribonucleic Acid
 cDNA: complementary DNA
 cRNA: complementary RNA
 dNTP: dATP, dCTP, dGTP, dTTP
 20 UTP: Uridine 5'-Triphosphate
 CTP: Cytidine 5'-Triphosphate
 dATP: 2'-Deoxyadenosine 5'-Triphosphate
 dCTP: 2'-Deoxycytidine 5'-Triphosphate
 dGTP: 2'-Deoxyguanosine 5'-Triphosphate
 25 dUTP: 2'-Deoxyuridine 5'-Triphosphate
 GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase
 FBS: Fetal Bovine Serum
 PBS: Phosphate Buffered Saline
 MTT: (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Thiazolyl blue
 30 DMSO: Dimethyl Sulfoxide
 PDGF: Platelet-Derived Growth Factor
 EGF: Epidermal Growth Factor
 FGF2: Fibroblast Growth Factor 2
 VEGF: Vascular Endothelial Growth Factor
 35 HGF: Hepatocyte Growth Factor
 TNF- α : Tumor Necrosis Factor alpha
 FCS: Fetal Bovine Serum (Fetal Calf Serum)
 EGM-2: Endothelial cell Growth Medium-2

40 Pharmacological Test Example 1: Inhibition against invasive tube formation by vascular endothelial cells in response to stimulation by angiogenic factor mixture

[0211] Human Umbilical Vein Endothelial Cells (HUVECs) were isolated according to a reported method (Shinseik-
 agaku Jikken Koza [New Biochemistry Experiment Lectures], "Saibo Baiyo Gijutsu" [Cell Culturing Techniques], p.
 45 197-202), and were cultured in a 5% CO₂ incubator (37°C) using EGM-2 medium (purchased from Clonetics Corp.)
 until the cells reached confluency. After adding 0.4 ml of bovine fibrinogen (purchased from Sigma Co.) to the inner
 well of a Transwell culturing plate (purchased from Coster Inc.), it was hardened with 0.7 units/ml of thrombin (purchased
 from Sigma Co.). The HUVECs were recovered using trypsin-EDTA and then suspended in human endothelial serum
 free medium basal growth medium (hereinafter abbreviated as SFM, purchased from GIBCO BRL), and 0.4 ml of the
 50 cell suspension (1.4 x 10⁵ cells) was seeded onto the hardened fibrin gel and cultured for approximately 4 hours in a
 5% CO₂ incubator (37°C). After 4 hours, there was added to the outer chamber of the Transwell 1.5 ml of an SFM
 solution containing a mixture of angiogenic factors {10 ng/ml EGF (purchased from GIBCO BRL), 30 ng/ml FGF2
 (purchased from GIBCO BRL), 75 ng/ml VEGF (purchased from Wako Pure Chemical Industries Co., Ltd.), 50 ng/ml
 HGF (purchased from R&D Co.) and 7.5 ng/ml TNF- α (purchased from Genzyme Corp.) [The concentrations of the
 55 angiogenic factors differed slightly according to the HUVEC lot.]} and a diluted test substance, and culturing was carried
 out in a 5% CO₂ incubator (37°C). On the 2nd and 4th days after adding the test substance, the medium was exchanged
 with 1.5 ml of freshly prepared SFM solution containing the angiogenic factor mixture and test substance. Upon aspi-
 rating off the culture supernatant in the inner well on the 6th day after the initial addition of the test substance, 0.4 ml

EP 1 415 987 A1

of a 3.3 mg/ml MTT solution dissolved in PBS (purchased from Sigma Corp.) was added and culturing was performed for approximately 1 hour in a 5% CO₂ incubator (37°C). The number of tubes formed in the fibrin gel stained with MTT was scored based on microscope observation. Specifically, the number of tubes formed in the absence of the test substance was designated as +++, while - was assigned if absolutely no tubes formed. The number of tubes formed in the presence of the test substance was scored on the 5-level scale of +++, ++, +, +/-, - to evaluate the strength of inhibition of the test substance.

Table 1

[Pharmacological Test Example 1: Inhibition against invasive tube formation by vascular endothelial cells in response to stimulation by angiogenic factor mixture]			
Example No.	0.01 μ M	0.1 μ M	1.0 μ M
25	++	+/-	+/-
53	+++	+/-	-
55	+++	+/-	+/-
72	+++	-	-
74	++	-	-
75	+++	+/-	-
81	++	-	-
100	++	+/-	+/-
153	+/-	-	-
172	+	+/-	+/-
189	+/-	-	-
212	+/-	-	-
245	+/-	-	-
298	+/-	-	-
316	+/-	-	-
348	+/-	-	-
368	-	-	-
374	+/-	-	-
404	-	-	-
415	+/-	-	-
422	+	-	-

Pharmacological Test Example 2: Inhibition against sandwich tube formation by vascular endothelial cells in response to stimulation by angiogenic factor

[0212] Human Umbilical Vein Endothelial Cells (HUVECs) were isolated by the same method as in Pharmacological Test Example 1, and were cultured in a 5% CO₂ incubator (37°C) using EGM-2 medium (purchased from Clonetics Corp.) until the cells reached confluency.

[0213] An ice-cooled mixture of collagen:5x RPMI 1640:reconstitution buffer (all purchased from Nitta Gelatin, Inc.) at 7:2:1 was dispensed at 0.4 ml into each well of a 24-well plate, and then stationed for 40 minutes in a 5% CO₂ incubator (37°C) for gelling. The HUVECs were recovered using trypsin-EDTA and then suspended in human endothelial serum free medium (SFM, purchased from GIBCO BRL) containing added angiogenic factors [20 ng/ml FGF2 (purchased from GIBCO BRL) and 10 ng/ml EGF (purchased from GIBCO BRL), or 25 ng/ml VEGF (purchased from Wako Pure Chemical Industries Co., Ltd.) and 10 ng/ml EGF, or 30 ng/ml HGF (purchased from R&D Co.) and 10 ng/ml EGF], and the cell suspension was added at 0.4 ml to each well (with the cell counts differing slightly according to the HUVEC lot), and cultured overnight in a 5% CO₂ incubator (37°C). On the following day, the medium on the upper

EP 1 415 987 A1

layer was aspirated off, and then 0.4 ml of an ice-cooled mixture of collagen:5x RPMI 1640:reconstitution buffer (all purchased from Nitta Gelatin, Inc.) at 7:2:1 was superposed into each well prior to stationing for 4 hours in a 5% CO₂ incubator (37°C) for gelling. After adding 1.5 ml of an SFM solution containing each of the aforementioned angiogenic factors and a diluted test substance onto the upper layer, culturing was performed in a 5% CO₂ incubator (37°C). Upon aspirating off the culture supernatant in each well on the 4th day after addition of the test substance, 0.4 ml of a 3.3 mg/ml MTT solution dissolved in PBS (purchased from Sigma Corp.) was added to each well and culturing was performed for approximately 2 hours in a 5% CO₂ incubator (37°C). The tubes formed in the collagen gel of each well were stained by the MTT, the tube images were loaded into a computer (Macintosh), and the total length of the tubes was determined by image analysis software "MacScope" (purchased from Mitani Corp.). The ratio of the total length of the tubes formed in the well containing the test substance with respect to the total length of the tubes formed in the well containing no test substance was expressed as a percentage, and the concentration of each test substance required for 50% inhibition of tube formation (IC₅₀) was determined from the ratio value.

Table 2

[Pharmacological Test Example 2: Inhibition against sandwich tube formation by vascular endothelial cells in response to stimulation by VEGF]

Example No.	IC ₅₀ (nM)	Example No.	IC ₅₀ (nM)
1	310	12	44
19	28	23	100
53	9.9	55	35
59	170	65	5.9
70	58	72	22
74	5.9	75	1.4
81	1.8	100	6.3
108	4.9	116	8.1
121	42	127	7.5
129	40	137	10
153	0.02	155	1.4
157	0.9	159	0.6
186	23	189	0.3
198	1.5	202	15
204	0.9	211	0.3
215	22	224	26
249	1.6	253	40
256	36	265	0.6
266	0.6	283	36
289	4.6	296	34
298	0.7	299	1.0
300	7.5	304	0.3
308	5.2	314	4.2
316	1.0	320	2.5
325	1.0	326	1.0
327	56	346	25
368	5.4	372	44

Table 2 (continued)

[Pharmacological Test Example 2: Inhibition against sandwich tube formation by vascular endothelial cells in response to stimulation by VEGF]

Example No.	IC ₅₀ (nM)	Example No.	IC ₅₀ (nM)
374	3.0	381	4.7
382	4.6	386	10
404	2.8	405	28
408	39	415	3.8
419	10	422	4.8
433	5.6	436	22
440	1.4	441	3.6
442	7.2	444	5.5
445	6.2	446	4.0
450	4.5	454	3.7
455	7.8	463	26
490	26	492	7.2
493	9.0	494	9.3
497	4.6	503	6.4
504	4.6	505	8.9
518	1.3	520	1.5
521	0.5	578	13

Pharmacological Test Example 3: Measurement of inhibition against receptor tyrosine kinase activity

[0214] This assay is used to determine inhibition of a test substance on tyrosine kinase activity. DNA coding for the cytoplasmic domain of VEGFR2 is obtained by total cDNA synthesis (Edwards M, International Biotechnology Lab 5 (3), 19-25, 1987) or by cloning. Expression in an appropriate expression system can produce a polypeptide with tyrosine kinase activity. The cytoplasmic domain of VEGFR2 obtained by expression of recombinant protein in, for example, insect cells has been found to exhibit intrinsic tyrosine kinase activity. For VEGFR2 (Genbank Accession No. L04947), the 1.7 kb DNA fragment described by Terman et al. (Oncogene, 6(9), 1677-1683, 1991), coding for the cytoplasmic domain, beginning with lysine 791 and including the termination codon, was isolated from a human placental cDNA library (purchased from Clontech Laboratories, Inc.) and cloned in a Baculovirus expression vector (pFastBacHis, purchased from GIBCO BRL). The recombinant construct was transfected into insect cells (*Spondoptea frugiperda*9 (Sf9)) to prepare a recombinant Baculovirus. (Instructions for preparation and use of recombinant Baculovirus may be found in standard texts, such as "Bac-To-Bac Baculovirus Expression System" (GIBCO BRL).) The cytoplasmic fragment starting from lysine 398 (FGFR1, Genbank Accession No. X52833), the cytoplasmic fragment starting from lysine 558 (PDGFR β , Genbank Accession No. M21616) or the cytoplasmic fragment starting from lysine 974 (HGFR, Genbank Accession No. J02958) may be cloned and expressed by the same method for use in assays for other tyrosine kinases. EGFR was purchased from Sigma Co. (Product No. E-2645).

[0215] For expression of the VEGFR2 tyrosine kinase, Sf9 cells were infected with the VEGFR2 recombinant virus and collected after 48 hours. The collected cells were rinsed with ice-cooled phosphate buffered saline (PBS) and then resuspended using 20 ml of ice-cooled Lysis Buffer (50 mM Tris-HCl (pH 8.5), 5 mM 2-mercaptoethanol, 100 mM KCl, 1 mM phenylmethylsulfonyl fluoride, 1% (v/v) NP-40) per 1.5×10^8 cells. The suspension was centrifuged at 12,000 rpm for 30 minutes at 4°C and the supernatant was obtained.

[0216] The supernatant was added to a Ni-NTA agarose column (3 ml, purchased from Qiagen) equilibrated with Buffer A {20 mM Tris-HCl (pH 8.5), 5 mM 2-mercaptoethanol, 500 mM KCl, 20 mM imidazole, 10% (v/v) glycerol}. The column was washed with 30 ml of Buffer A, and then with 6 ml of Buffer B {20 mM Tris-HCl (pH 8.5), 5 mM 2-mercaptoethanol, 1M KCl, 10% (v/v) glycerol}, and finally with 6 ml of Buffer A. After washing, it was eluted with 6 ml of Buffer C {20 mM Tris-HCl (pH 8.5), 5 mM 2-mercaptoethanol, 100 mM KCl, 100 mM imidazole, 10% (v/v) glycerol}. The eluate

was placed on a dialysis membrane (purchased from Spectrum Laboratories) and dialyzed with a dialysis buffer {20 mM Tris-HCl (pH 7.5), 10% (v/v) glycerol, 1 mM dithiothreitol, 0.1 mM Na₃VO₄, 0.1 mM EGTA}. After dialysis, it was supplied for SDS-electrophoresis, and the recombinant protein (His6-VEGFR2, cytoplasmic domain of VEGFR2 fused with 6 histidine residues at the N-terminus) detected at a molecular weight of approximately 100 kDa with Coumassie Brilliant Blue staining was assayed using BSA (bovine serum albumin, purchased from Sigma Co.) as the standard substance, and stored at -80°C until use. Using the same method for the cytoplasmic domains of FGFR1, PDGFR β and HGFR yielded respective recombinant proteins fused with 6 histidine residues at the N-termini (His6-FGFR1, His6-PDGFR β or His6-HGFR).

[0217] The tyrosine kinase reaction was conducted as follows. In the case of VEGFR2, for example, 10 μ l of a kinase reaction solution {200 mM Hepes (pH 7.4), 80 mM MgCl₂, 16 mM MnCl₂, 2 mM Na₃VO₄}, 250 ng of biotin-bound poly (Glu4:Tyr1) (biotin-poly(GT), purchased from CIS Diagnostics Co.) (6 μ l of a 15-fold dilution with distilled water), 15 ng of His6-VEGFR2 (10 μ l of a 240-fold dilution with 0.4% BSA solution) and the test substance dissolved in dimethylsulfoxide (4 μ l of a 100-fold dilution with 0.1% BSA solution) were added into each well of a 96-well round-bottom plate (NUNC Co., Product No. 163320), to a total of 30 μ l. Next, 10 μ l of 4 μ M ATP (diluted with distilled water) was added prior to incubation at 30°C for 10 minutes, and then 10 μ l of 500 mM EDTA (pH 8.0) was added.

[0218] The tyrosine phosphorylated biotin-poly(GT) was measured by the Homogenous Time-Resolved Fluorescence (HTRF) method (Analytical Biochemistry, 269, 94-104, 1999). Specifically, the kinase reaction solution was transferred to a 96-well black half-plate (Product No. 3694, Coster, Inc.), 7.5 ng of europium cryptate-labeled anti-phosphotyrosine antibody (Eu(K)-PY20, purchased from CIS Diagnostics Co.) (25 μ l of a 250-fold dilution with 20 mM Hepes (pH 7.0), 0.5 M KF, 0.1% BSA solution) and 250 ng of XL665-labeled streptavidin (XL665-SA, purchased from CIS Diagnostics Co.) (25 μ l of a 62.5-fold dilution with 20 mM Hepes (pH 7.0), 0.5 M KF and 0.1% BSA solution) were added thereto, the mixture was allowed to stand at room temperature for 30 minutes, and then the fluorescent intensity was measured at 665 nm and 620 nm under irradiation with an excitation wavelength of 337 nm using a Discovery HTRF Microplate Analyzer (Packard Co.). The tyrosine phosphorylation rate for the biotin-poly(GT) was expressed as the delta F% value as described in the HTRF Standard Experiment Methods text by CIS Diagnostics Co. The delta F% value in the presence of the test substance was determined as a ratio (%) with the delta F% value with addition of His6-VEGFR2 in the absence of the test substance defined as 100% and the delta F% value in the absence of both the test substance and His6-VEGFR2 defined as 0%. This ratio (%) was used to calculate the test substance concentration required for 50% inhibition of VEGFR2 kinase activity (IC₅₀).

[0219] Measurement of inhibition against FGFR1, EGFR and HGFR kinase activity was conducted using 15 ng of His6-FGFR1, 23 ng of EGFR and 30 ng of His6-HGFR, respectively, according to the tyrosine kinase reaction and HTRF method described above.

[0220] Measurement of inhibition against PDGFR β kinase activity was conducted using 50 ng of His6-PDGFR β according to the tyrosine kinase reaction described above, followed by detection of tyrosine phosphorylated biotin-poly (GT) by the following method.

[0221] Specifically, the kinase reaction solution was added to a 96-well streptavidin-coated plate (Product No. 15129, Pierce Chemical) and incubated at room temperature for 30 minutes. After rinsing 3 times with 150 μ l of a rinsing solution {20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.05% Tween-20, 0.1% BSA}, 70 μ l of anti-phosphotyrosine (PY20)-HRP conjugate (Product No. P-11625, Transduction Laboratories) {2000-fold dilution with 20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.05% Tween-20, 1% BSA} was added thereto and incubation was performed at room temperature for 1 hour. After incubation, it was rinsed 3 times with 150 μ l of the rinsing solution, and 100 μ l of TMB Membrane Peroxidase Substrate (Product No. 50-5077-03, Funakoshi Co., Ltd.) was added to initiate the reaction. After stationing at room temperature for 10 minutes, 100 μ l of 1 M phosphoric acid was added to suspend the reaction, and the absorbance at 450 nm was measured with a microplate reader (BIO KINETICS READER EL304, Bio-Tek Instruments). The absorbance ratio in the presence of the test substance was determined with respect to 100% as the absorbance with addition of His6-PDGFR β and no test substance, and 0% as the absorbance without addition of the test substance or His6-PDGFR β . This absorbance ratio was used to calculate the test substance concentration required for 50% inhibition of PDGFR β kinase activity (IC₅₀).

Table 3

[Pharmacological Test Example 3: Inhibition against VEGFR2 kinase]			
Example No.	IC ₅₀ (nM)	Example No.	IC ₅₀ (nM)
1	51	10	4.9
14	2.7	15	8.7
21	4.3	30	22

EP 1 415 987 A1

Table 3 (continued)

[Pharmacological Test Example 3: Inhibition against VEGFR2 kinase]			
Example No.	IC ₅₀ (nM)	Example No.	IC ₅₀ (nM)
31	17	33	6.9
34	3.4	25	5.5
36	14	37	22
43	18	54	15
55	29	65	15
99	8.6	100	9.6
111	21	116	4.2
121	8.7	143	70
159	25	173	356
178	12	182	71
183	29	184	59
187	14	208	9.2
252	31	253	23
259	16	260	11
262	9.5	265	6.2
266	5.4	283	26
314	5.3	316	6.4
346	4.6	348	4.6
350	43	353	2.2
356	1.4	364	8.1
365	5.4	368	3.0
374	8.4	375	16
381	2.6	382	9.0
387	4.1	394	15
398	3.5	404	6.5
410	2.2	413	3.2
435	22	437	9.9
441	2.8	449	2.2
463	5.9	465	13
556	14		

Pharmacological Test Example 4: Inhibition on cancer cell and normal cell growth

[0222] Cancer cells (for example, KP-4 human pancreatic cancer cells) or normal cells (for example, IEC-18 rat ileal epithelial cells) were subcultured in RPMI 1640 medium containing 10% FBS (purchased from Nissui Pharmaceutical Co., Ltd.) every 3-4 days, and cells in the growth phase were used. After recovering the cells using trypsin-EDTA, the cells were counted and a 0.1 ml cell suspension of each diluted with 10% FBS-containing RPMI 1640 medium (to 2 x 10³ cells/well for KP-4 and 8 x 10² cells/well for IEC18) was spread onto a 96-well plate for cell culturing. Culturing was performed overnight in a 5% CO₂ incubator (37°C), and then a 0.1 ml solution of the test substance diluted with 10% FBS-containing RPMI 1640 was added and culturing was continued in a 5% CO₂ incubator (37°C). On the 3rd

day after addition of the test substance, 0.05 ml of a 3.3 mg/ml MTT solution (purchased from Sigma Co.) was added, and culturing was continued in the 5% CO₂ incubator (37°C) for approximately 2 hours. After aspirating off of the culture supernatant and DMSO dissolution of the formazan produced in each well, the absorbance of each well was measured using an MTP-32 plate reader (Corona Electric) at a measuring wavelength of 540 nm and a reference wavelength of 660 nm. The absorbance ratio in the substance-added well was determined as a percentage with respect to the absorbance of the well without addition of the test substance, and this ratio was used to calculate the test substance concentration required for 50% inhibition of cell growth (IC₅₀).

Pharmacological Test Example 5: Effect of L6 (Rat myoblasts) on PDGF-dependent growth

[0223] L6 (rat myoblasts) were subcultured in 10% FBS-containing D-MEM medium (purchased from Nissui Pharmaceutical Co., Ltd.) every 3-4 days, and cells in the growth phase were used. The cells were recovered using trypsin-EDTA and rinsed once with 10% FBS-free D-MEM medium, and the cells were counted. After spreading 0.1 ml of a cell suspension diluted with 10% FBS-free D-MEM medium onto a Type I collagen-coated 96-well tissue culturing plate at 5 x 10³ cells/well, culturing was performed overnight in a 5% CO₂ incubator (37°C). On the following day, 0.05 ml of a solution of the test substance diluted with 10% FBS-free D-MEM medium was added, with almost simultaneous addition of 0.05 ml of a 40 nM PDGF solution (10 nM final concentration), and culturing was continued in the 5% CO₂ incubator (37°C). On the 3rd day after addition of the test substance, 0.01 ml of WST-1 solution (purchased from Wako Pure Chemical Industries Co., Ltd.) was added to each well, and culturing was continued in the 5% CO₂ incubator (37°C) for approximately 3 hours until coloration. The absorbance of each well was measured using an MTP-32 plate reader (Corona Electric) at a measuring wavelength of 415 nm and a reference wavelength of 660 nm. The absorbance ratio in the substance-added well was determined as a percentage with respect to the absorbance of the well without addition of the test substance, and this ratio was used to calculate the test substance concentration required for 50% inhibition of cell growth (IC₅₀).

Pharmacological Test Example 6: Analysis of mRNA expression by DNA microarray/quantitative PCR

1. Extraction of total RNA from sample

[0224] The cells were cultured at 37°C either in 5% CO₂ or under low (1%) oxygen conditions. In the case of HUVEC, for example, EGM-2 medium (purchased from Clonetics Corp.) was used for culturing at 37°C under 5% CO₂ conditions. At a prescribed time after reaction with the test substance, the cells were lysed using TRIZOL reagent (purchased from GIBCO BRL) according to the manufacturer's protocol. Specifically, it was accomplished as follows. A 1 ml portion of TRIZOL reagent is added per 10 cm² culturing area, and pipetting is carried out several times to collect the cells. After centrifuging the sample, the obtained supernatant is allowed to stand at room temperature for 5 minutes, and then chloroform (purchased from Junsei Chemical Co., Ltd.) is added in a proportion of 0.2 ml with respect to 1 ml of TRIZOL reagent used. The solution is vigorously shaken and stirred for 15 seconds and allowed to stand at room temperature for 2-3 minutes, and then centrifuged (12,000 x g, 10 min, 4°C). After centrifugation, the aqueous layer is transferred to a fresh tube, isopropyl alcohol (purchased from Wako Pure Chemical Industries Co., Ltd.) is added in a proportion of 0.5 ml to 1 ml of TRIZOL reagent used, and the mixture is allowed to stand at room temperature for 10 minutes and then centrifuged (12,000 x g, 10 min, 4°C). The obtained precipitate is rinsed with 75% ethanol (purchased from Wako Pure Chemical Industries Co., Ltd.) and then air-dried and supplied as total mRNA for the following procedure.

2. Quantitation of RNA

[0225] The RNA may be quantitated by techniques such as Northern blotting analysis, DNA microarray, RT-PCR, quantitative PCR and the like, with DNA microarray and quantitative PCR being preferred. Explanations of these techniques are provided below, but are not intended to be limitative on the invention.

- 1) Quantitation with a DNA microarray (Schena M. et al., Science, 270 (5235), 467-70, 1995 and Lockhart, D.J. et al., Nature Biotechnology, 14 (13), 1675-1680, 1996) is carried out in the following manner.

[1] cDNA synthesis and biotin labeling

[0226] The initially obtained RNA was used as template to synthesize double-stranded cDNA with a SuperScript Choice System (purchased from GIBCO BRL) and T7-d(T)₂₄ primer, and then this cDNA was used as template for synthesis of biotinylated cRNA.

[0227] Specifically, 5 µg T7-d(T)₂₄ primer, 1 × first strand buffer, 10 mM DTT, 500 µM dNTP mix and 20 unit/µl

SuperScript II Reverse Transcriptase were added to 10 µg of RNA, and reaction was conducted at 42°C for 1 hour to synthesize single-stranded cDNA. Next, 1 × second strand buffer, 200 µM dNTP mix, 67 U/ml DNA ligase, 270 U/ml DNA polymerase I and 13 U/ml RNaseH were added and reaction was conducted at 16°C for 2 hours to synthesize double-stranded cDNA. Finally, 67 U/ml T4 DNA polymerase I was added for reaction at 16°C for 5 minutes, after

which 10 µl of 0.5 M EDTA (purchased from Sigma Co.) was added to suspend the reaction.
[0228] The obtained cDNA was purified with phenol/chloroform (purchased from Ambion, Inc.), and an RNA Transcript Labeling Kit (purchased from Enzo Diagnostics, Inc.) was used for labeling with biotinylated UTP and CTP according to the manufacturer's protocol. The reaction product was purified with an RNeasy column (purchased from Qiagen), and then heating was performed for 35 minutes at 94°C in 200 mM Tris acetate (pH 8.1), 150 mM magnesium acetate and 50 mM potassium acetate, for fragmentation of the cRNA.

[2] DNA microarray (GeneChip) hybridization and measurement

[0229] The fragmented cRNA is hybridized with a GeneChip (purchased from Affymetrix Corp.) Hu6800/Human Cancer G110 Array or an equivalent product, in 100 mM MES, 1M sodium salt, 20 mM EDTA, 0.01% Tween20, for example, at 45°C for 16 hours. After hybridization, the GeneChip is rinsed and dyed according to protocol EukGE-WS2 included with the Affymetrix fluidics station or the optimum protocol for the array used. The dyeing is carried out using streptavidin-phycoerythrin (purchased from Molecular Probe) and biotinylated anti-streptavidin goat antibody (purchased from Vector Laboratories). The dyed GeneChip is scanned using an HP argon-ion laser confocal microscope (purchased from Hewlett Packard Co.), and the fluorescent intensity is measured. The fluorescence was measured with excitation at 488 nm and emission at 570 nm.

[0230] All of the quantitative data analysis was carried out using GeneChip software (purchased from Affymetrix Corp.) or Genespring (purchased from Silicon Genetics). For RNA quantitation, the average of the difference (perfect match hybridization signal - mismatch signal) is determined for each probe family, and the gene expression is judged as having significantly "increased" or "decreased" if the value is 5 or greater and the RNA quantities are disparate under 2 conditions, and preferably if they are disparate by a factor of 1.8 or greater.

2) Quantitation by quantitative PCR is conducted in the following manner.

[0231] Quantitative PCR is accomplished in the following manner using SYBR Green (purchased from Applied Biosystems) and an ABI Prism 7700 Sequence Detection System (purchased from Perkin-Elmer Applied Biosystems) or an equivalent apparatus.

[0232] The procedure is carried out by the two stages of reverse transcription and PCR reaction. In the reverse transcription of the first stage, dNTP, oligo d(T)₁₆ primer, RNase Inhibitor and Multiscribe Reverse Transcriptase (purchased from Perkin-Elmer Applied Biosystems) are added to the obtained RNA, the temperature is kept at 25°C for 10 minutes, and then heating is effected at 48°C for 30 minutes. The reaction is suspended by heating at 95°C for 5 minutes.

[0233] The obtained cDNA is then supplied to the PCR reaction of the second stage. The PCR reaction is carried out in a reaction system comprising, for example, 4 ng cDNA, 1 × SYBR PCR buffer, 3 mM MgCl₂, 200 µM each dATP, dCTP and dGTP, 400 µM dUTP, 200 nM primer pair, 0.01 U/µl AmpErase UNG and 0.025 U/µl Ampli Taq Gold DNA Polymerase (purchased from Perkin-Elmer Applied Biosystems). The reaction was conducted under conditions with 50°C for 2 minutes and 95°C for 10 minutes followed by 40 cycles of 95°C for 20 seconds, 55°C for 20 seconds and 72°C for 30 seconds. The primers and probes are designed using Primer Expression (purchased from Perkin-Elmer Applied Biosystems) or equivalent software. The different test substances are compared while compensating the quantitative values based on the mRNA level of a housekeeping gene having low transcription level fluctuation, preferably GAPDH, in each specimen.

Pharmacological Test Example 7: Evaluation of *in vivo* angiogenesis-inducing activity using mouse dorsal air sac model

[1] Construction of VEGF (Vascular Endothelial Growth Factor) expression vector

[0234] PCR was conducted using a human placenta cDNA library (purchased from Toyobo Co., Ltd.) as the template and the VEGF sequences 5'CCGGATCCATGAACCTTTCTGCTG3' and 5'GTGAATTCTGTATCGATCGTT3' as primers. After completion of the PCR reaction, the 5' ends were phosphorylated and an approximately 600 bp DNA band was separated by 1.2% agarose gel electrophoresis. After polymerization by self-ligation, the cDNA was cut with *EcoRI* and *BamHI* and inserted into the *EcoRI* and *BamHI* sites of vector pUC19. This was used to transform *E. coli* JM83, and plasmids were recovered from the transformed clones. A VEGF cDNA fragment was cut out of the plasmids with *HindIII* and *EcoRI* and then inserted into an expression vector containing the neomycin resistance gene.

[2] Preparation of VEGF high-expressing strain

[0235] After overnight culturing of KP-1 human pancreatic cancer cells (3×10^6 cells) with 10% FCS-containing RPMI 1640 medium, an Effectene Transfection Reagent Kit (purchased from Qiagen) was used for introduction of 3 μ g of VEGF expression vector into the KP-1 cells. After culturing in 10% FCS-containing RPMI 1640 medium also containing 600 μ g/ml of Geneticin, the high-expressing drug-resistant cells were selected as VEGF high-expressing KP-1 cells (KP-1/VEGF).

[3] Measurement of VEGF level in culture supernatant

[0236] The KP-1/VEGF cells were prepared to 5×10^5 cells/ml, and 0.5 ml thereof was dispensed into each well of a 24-well plate and cultured at 37°C for 24 hours. The culture supernatants were collected and the VEGF levels thereof measured using a VEGF measuring kit (purchased from IBL Co., Ltd.) for confirmation of high expression.

[4] Evaluation of *in vivo* angiogenesis-inducing activity using mouse dorsal air sac model

[0237] Millipore rings (purchased from Nihon Millipore) were sealed with 0.45 μ m Durapore™ filter membranes (purchased from Nihon Millipore) to create chambers. KP-1/VEGF human pancreatic cancer cells (3×10^6) suspended in 0.17 ml of collagen gel were injected into each chamber through the injection port, and the chambers were sealed. Approximately 10 ml of air was then injected in the dorsal skin of 6-week-old C57BL/6N female mice under anesthesia to produce pouches, and the prepared chambers were transplanted therein. About 6 hours after completing transplantation, a test substance suspended in 0.5% methyl cellulose was orally administered (0.1 ml/10 g body weight), and this was continued once a day for the next 4 days.

[0238] On the 4th day after transplanting the chambers, 0.2 ml of ^{51}Cr (Amersham Pharmacia)-labeled mouse erythrocytes (2.5×10^6 cpm/ml) were injected through the caudal veins of each of the mice with the transplanted chambers. After a prescribed period, the skin in contact with the chamber was excised and frozen, the section in direct contact with the chamber was precisely cut off, and the radioactivity was measured with a γ -counter. The blood volume was calculated from the radioactivity and used as an index of the *in vivo* angiogenesis-inducing activity. The angiogenesis volume was recorded as this measured blood volume minus the blood volume obtained with transplantation of a chamber containing only collagen gel. The experiment was conducted using 10 mice in the control (solvent-administered) group and 5 mice in each compound-administered group.

Pharmacological Test Example 8: Evaluation of antitumor activity on KP-1/VEGF cells in subcutaneous xenograft models

[0239] VEGF high-expressing pancreatic cancer cells (KP-1/VEGF) suspended in PBS at a concentration of 1×10^7 cells/ml were transplanted under the right flank skin of 6-week-old female Balb/c (nu/nu) mice in a volume of 0.1 ml. When the tumor volume reached approximately 100 mm³, the test substance was orally administered over a period of 2 weeks with a schedule of 5 days per week. The test substance was suspended in 0.5% methyl cellulose for an administered volume of 0.1 ml/10 g body weight. The tumor size was measured twice a week using a micrometer caliper. The tumor volume was determined by measuring the long and short diameters of the tumor with a micrometer caliper, and calculating $1/2 \times (\text{long diameter} \times \text{short diameter} \times \text{short diameter})$. The experiment was conducted using 10 mice in the control (solvent-administered) group and 5 mice in each test substance-administered group.

Pharmacological Test Example 9: Evaluation of tumor growth, cancerous ascites accumulation and survival period in orthotopic transplantation models of pancreatic cancer

[0240] After abdominal section of 6- to 7-week-old female Balb/c (nu/nu) mice under anesthesia and exposure of the pancreases, VEGF high-expressing pancreatic cancer cells (KP-1/VEGF) suspended in PBS at a concentration of 1×10^7 cells/ml were directly transplanted into each pancreas head at a volume of 0.1 ml. Upon the 4th week after transplantation, the test substance was orally administered over a period of 10 weeks with a schedule of 5 days per week. The test substance was suspended in 0.5% methyl cellulose for an administered volume of 0.1 ml/10 g body weight. Body weight was periodically measured twice per week during the test period, and the presence of ascites accumulation was recorded based on appearance. The survival period was based on tabulating the number of mice which died up until completion of the experiment. Tumor weight was measured in individuals suitable for postmortem autopsy. The experiment was conducted using 8 to 10 mice per group.

Industrial Applicability

[0241] According to the present invention, it is possible to provide novel compounds that exhibit (1) powerful inhibiting action against invasive tube formation by vascular endothelial cells induced by an angiogenic factor mixture comprising Epidermal Growth Factor (EGF)/VEGF/Fibroblast Growth Factor 2 (FGF2)/Hepatocyte Growth Factor (HGF)/Tumor Necrosis Factor alpha (TNF- α), (2) powerful inhibiting action against tube formation by vascular endothelial cells specifically induced by single angiogenic factors (for example, VEGF, FGF, HGF and other such factors), and 3) powerful inhibiting action against receptor kinases for various angiogenic factors. It is further possible to provide novel compounds which are highly useful as medicines.

[0242] Among the group of compounds with the action of (1) to (3) described above there may also be provided a group of compounds with tumor cell growth-inhibiting action.

[0243] Incidentally, angiogenesis in the body is known to depend not on a single angiogenic factor but rather on the additive and synergistic effect of multiple angiogenic factors ((1) Koolwijk P, van Erck MGM, de Vree WJA, Vermeer MA, Weich HA, Hane maaijer R, van Hinsbergh VWM. Cooperative effect of TNF-alpha, bFGF and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. 1996, 132, P1177-1188.; (2) Tallquist MD, Soriano P, Klinghoffer RA. Growth factor signaling pathways in vascular development. Oncogene 1999, 18, P7917-7932.).

[0244] Thus, the compounds of the invention which inhibit tube formation induced by multiple angiogenic factors produced by cancer cells and the like are expected to exhibit powerful angiogenesis inhibition *in vivo*, and should be highly useful as angiogenesis inhibitors. Moreover, the compounds of the invention may be useful as prophylactic or therapeutic agents for diseases for which angiogenesis inhibition is effective, and specifically as angiogenesis inhibitors, antitumor agents, angioma treatment agents, cancer metastasis inhibitors, retinal neovascularization treatment agents, diabetic retinopathy treatment agents, general inflammatory disease treatment agents, inflammatory disease treatment agents for deformant arthritis, rheumatoid arthritis, psoriasis, delayed hypersensitivity reaction and the like, or atherosclerosis treatment agents, and particularly as antitumor agents, based on their angiogenesis inhibition.

(Examples)

[0245] The present invention will now be explained in further and more concrete detail through the following examples, with the implied understanding that these examples are in no way limitative on the invention.

[Production Examples]Production Example 1

2-(3-Chloropropyl)-1,2,3-triazole (Production Example 1-A)

1-(3-Chloropropyl)-1,2,3-triazole (Production Example 1-B)

[0246] A suspension of sodium hydride (1.55 g, 30.8301 mmol, 60% in oil) in hexane was allowed to stand, and after removing the supernatant, dimethylformamide (25 ml) was added thereto to form a suspension and 1H-1,2,3-triazole (1.5 ml, 25.8867 mmol) was added dropwise while cooling on ice. This was stirred at room temperature for 5 minutes to thorough dissolution, and then 1-bromo-3-chloropropane (2.82 ml, 28.4754 mmol) was added and the mixture was stirred at room temperature for 8 hours. After adding water while cooling on ice, the mixture was extracted with diethyl ether and then with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the isomers were separated by NH silica gel column chromatography (hexane-ethyl acetate) and purified to obtain low polarity 2-(3-chloropropyl)-1,2,3-triazole (0.429 g, 2.9466 mmol, 11.38%) and high polarity 1-(3-chloropropyl)-1,2,3-triazole (0.910 g, 6.2504 mmol, 24.15%) as colorless oils.

2-(3-chloropropyl)-1,2,3-triazole (Production Example 1-A)

¹H-NMR Spectrum (CDCl₃) δ (ppm) : 2.42 (2H, tt, J = 6.4 Hz, 6.4 Hz), 3.54 (2H, t, J = 6.4 Hz), 4.64 (2H, t, J = 6.4 Hz), 7.61 (2H, s).

1-(3-chloropropyl)-1,2,3-triazole (Production Example 1-B)

¹H-NMR Spectrum (CDCl₃) δ (ppm) : 2.41 (2H, m), 3.52 (2H, d, J = 6.0 Hz), 4.60 (2H, d, J = 6.4 Hz), 7.61 (1H, d, J = 0.8 Hz), 7.72 (1H, d, J = 0.8 Hz).

Production Example 2

1-Chloro-3-(4-pyridyl)propane

[0247] 3-(4-Pyridyl)-1-propanol (2.68 g, 19.3724 mmol) was dissolved in dichloromethane (100 ml), triphenylphosphine (5.6 g, 21.3096 mmol) was added, and then N-chlorosuccinimide (2.6 g, 19.3724 mmol) was gradually added while cooling on ice prior to stirring overnight. After distilling off the solvent under reduced pressure, the residue was dissolved in ethyl acetate and extracted with 1N hydrochloric acid. Upon neutralization with saturated sodium bicarbonate water, the mixture was extracted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (2.375 g, 15.2605 mmol, 78.77%) as a yellowish-brown oil. This was used without further purification for the following reaction. ¹H-NMR Spectrum (CDCl₃) δ(ppm) : 2.11 (2H, m), 2.80 (2H, t, J = 7.6 Hz), 3.54 (2H, t, J = 6.4 Hz), 7.14 (2H, dd, J = 1.6 Hz, 4.4 Hz), 8.52 (2H, dd, J = 1.6 Hz, 4.4 Hz).

Production Example 3

4-Amino-3-fluorophenol

[0248] 3-Fluoro-4-nitrophenol (5.0 g, 31.83 mmol) was dissolved in ethyl acetate (50 ml) and tetrahydrofuran (75 ml), and then palladium carbon (2.0 g) was added and the mixture was stirred for 8.5 hours at room temperature under a hydrogen atmosphere. The catalyst was filtered off, the filtrate was washed with ethanol, the solvent was distilled off under reduced pressure and the obtained crystals were washed with addition of hexane:ethanol = 1:1. The crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (1.62 g, 12.74 mmol, 40.61%) as light yellow crystals. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.35 (1H, brs), 6.32 (1H, dd, J = 2.4 Hz, 8.4 Hz), 6.39-6.45 (1H, m), 6.57 (1H, dd, J = 8.4 Hz, 10.4 Hz).

Production Example 4

N-(2,4-Difluorophenyl)-N'-(2-fluoro-4-hydroxyphenyl)urea

[0249] 4-Amino-3-fluoronitrophenol (500 mg, 3.9333 mmol) was dissolved in tetrahydrofuran (15 ml), 2,4-difluoro isocyanate (0.56 ml, 4.7199 mmol) was added dropwise, and the mixture was heated to reflux for 1 hour under a nitrogen atmosphere. After allowing the mixture to cool, the solvent was distilled off under reduced pressure, and the obtained crystals were washed with addition of hexane:ethanol = 1:1. The crystals were filtered out, washed with hexane:ethanol = 1:1 and dried by aspiration to obtain the title compound (960 mg, 3.4016 mmol, 86.48%) as light violet crystals. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 6.54 (1H, m), 6.60 (1H, ddd, J = 2.4 Hz, 2.4 Hz, 8.8 Hz), 7.00 (1H, m), 7.27 (1H, ddd, J = 2.8 Hz, 9.0 Hz, 11.6 Hz), 7.69 (1H, m), 8.07 (1H, ddd, J = 6.0 Hz, 9.0 Hz, 9.0 Hz), 8.53 (1H, s), 8.72 (1H, s), 9.56 (1H, s).

Production Example 5

7-Benzyloxy-6-cyano-4-(4-nitrophenoxy)quinoline

[0250] To the 7-benzyloxy-4-chloro-6-cyanoquinoline (2.60 g, 8.83 mmol) described in WO98/13350 there were added 4-nitrophenol (2.46 g, 17.7 mmol) and lutidine (2.06 ml, 17.7 mmol), and the mixture was heated and stirred at 155-158°C for 2 hours. After returning the reaction system to room temperature, it was dissolved in tetrahydrofuran, saturated sodium bicarbonate water was added and stirred therewith for 10 minutes, the mixture was concentrated under reduced pressure, the precipitated solid was filtered out and subjected to silica gel column chromatography (Fuji Silysia NH Type, eluent - hexane:ethyl acetate = 50:50 → ethyl acetate alone), the fraction containing the target substance was concentrated and the obtained solid was washed with diethyl ether. It was then dried under reduced pressure to obtain the title compound (1.84 g, 4.63 mmol, 52.6%). ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 5.48 (2H, s), 6.89 (1H, d, J=6.1Hz), 7.30-7.60 (8H, m), 7.78 (1H, s), 8.36-8.41 (2H, m), 8.80 (1H, s), 8.85 (1H, d, J=6.1Hz).

Production Example 64-(4-Aminophenoxy)-7-(benzyloxy)-6-cyanoquinoline

[0251] Iron powder (0.6 g), ammonium chloride (1.4 g), ethanol (100 ml) and water (30 ml) were added to the 7-benzyloxy-6-cyano-4-(4-nitrophenoxy)quinoline obtained in Production Example 5, and the mixture was stirred at 90°C for 2.5 hours. The reaction system was returned to room temperature and then filtered with celite, the filtrate was subjected to liquid separation, and the organic layer was washed with water and saturated brine in that order, dried over sodium sulfate and then concentrated to dryness under reduced pressure to obtain 1.31 g of a crude product containing the target substance. The crude product was used directly for the following reaction. (Production Example 7).
¹H-NMR Spectrum(CDCl₃) δ(ppm): 3.75 (2H, br), 5.35 (2H, s), 6.46 (1H, d, J=5.2Hz), 6.75-6.78 (2H, m), 6.94-6.97 (2H, m), 7.35 (1H, d, J=7.6Hz), 7.42 (2H, t, J=6.8Hz), 7.50-7.55 (3H, m), 8.63 (1H, d, J=5.2Hz), 8.72 (1H, s).

Production Example 77-Benzyloxy-6-cyano-4-(3-fluoro-4-nitrophenoxy)quinoline

[0252] The 7-benzyloxy-4-chloro-6-cyanoquinoline (8.82 g, 30.0 mmol) described in WO98/13350 was suspended in 1-methylpyrrolidone (30 ml), and then 3-fluoro-4-nitrophenol (5.18 g, 33.0 mmol) and N,N-diisopropylethylamine (3.88 g, 30.0 mmol) were added and the mixture was heated and stirred at 110°C for 4 hours. After returning the reaction system to room temperature, water was added and a solid precipitated. The obtained solid was filtered out, washed with water, methanol and ethyl acetate and dried at 60°C to obtain the title compound (4.98 g, 12.0 mmol, 40%) as colorless crystals.
¹H-NMR Spectrum (CDCl₃) δ(ppm) : 5.37 (2H, s), 6.73 (1H, d, J = 5.2 Hz), 7.07-7.13 (2H, m), 7.33-7.45 (3H, m), 7.50-7.56 (2H, m), 7.60 (1H, s), 8.21-8.27 (1H, m), 8.55 (1H, s), 8.83 (1H, d, J = 5.2 Hz).

Production Example 87-Benzyloxy-6-cyano-4-(3-fluoro-4-aminophenoxy)quinoline

[0253] The 7-benzyloxy-6-cyano-4-(3-fluoro-4-nitrophenoxy)quinoline (5.30 g, 12.8 mmol) obtained in Production Example 7, iron (3.57 g, 64.0 mmol) and ammonium chloride (6.85 g, 128 mmol) were suspended in an ethanol (120 ml)-water (30 ml) mixed solvent, and the suspension was heated and stirred at 100°C for 3 hours. After completion of the reaction, the reaction mixture was filtered with celite and washed in an ethyl acetate (500 ml)-N,N-dimethylformamide DMF (50 ml) mixed solvent. The organic layer was washed with water and saturated brine, dried over magnesium sulfate and concentrated. The obtained solid was recrystallized from an ethyl acetate-hexane mixed solvent and then dried to obtain the title compound (2.53 g, 6.56 mmol, 51%) as light brown crystals.
¹H-NMR Spectrum (CDCl₃) δ(ppm) : 3.80 (2H, brs), 5.35 (2H, s), 6.48 (1H, d, J = 5.3 Hz), 6.78-6.90 (3H, m), 7.32-7.44 (3H, m), 7.51 (1H, s), 7.52-7.56 (2H, m), 8.66 (1H, d, J = 5.3 Hz), 8.69 (1H, s).

Production Example 96-Cyano-7-(2-methoxyethoxy)-4-(4-nitrophenoxy)quinoline

[0254] A mixture of 4-chloro-6-7-(2-methoxyethoxy)quinoline (3 g), 4-nitrophenol (3.17 g) and 2,6-lutidine (2.7 ml) was heated and stirred in an oil bath at 155°C for 1.5 hours. After completion of the reaction, ethyl acetate was added, and the precipitated solid was filtered out. The solid was washed with 1N sodium hydroxide water and then with water and dried to obtain 1.8 g of the title compound.
¹H-NMR(DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.41-4.44 (2H, m), 6.85 (1H, d, J= 5.2 Hz), 7.54 (2H, d, J= 9.2 Hz), 7.68 (1H, s), 8.37 (2H, d, J= 9.2 HZ), 8.74 (1H, s), 8.83 (1H, d, J= 5.2 Hz).

Production Example 104-(4-Aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline

[0255] 6-Cyano-7-(2-methoxyethoxy)-4-(4-nitrophenoxy)quinoline (1.8 g), iron (1.8 g) and ammonium chloride (3.6 g) were suspended in an ethanol (30 ml)-water (7 ml) mixed solvent and the suspension was heated and stirred at 80°C for 2 hours. After completion of the reaction, the reaction mixture was filtered with celite and washed in ethyl

acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate and concentrated. The obtained solid was washed with ether and dried to obtain 1.2 g of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.78 (2H, m), 4.38-4.41 (2H, m), 5.19 (2H, brd), 6.45 (1H, d, J= 5.2 Hz), 6.65 (2H, d, J= 8.8 Hz), 6.93 (2H, d, J= 8.8 Hz), 7.59 (1H, s), 8.68 (1H, d, J= 5.2 HZ), 8.71 (1H, s).

Production Example 11

6-Cyano-4-(3-fluoro-4-nitrophenoxy)-7-(2-methoxyethoxy)quinoline

[0256] 4-Chloro-6-cyano-7-(2-methoxyethoxy)quinoline (1.7 g) and 3-fluoro-4-nitrophenol (2.0 g) were suspended in chlorobenzene (20 ml), and the suspension was heated to reflux for 6 hours. After completion of the reaction, the solvent was distilled off, ethyl acetate was added, and a solid precipitated. The solid was filtered out and washed with ether, washed with 1N sodium hydroxide water and with water, and then dried to obtain 1.55 g of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 3.38 (3H, s), 3.78-3.81 (2H, m), 4.44-4.47 (2H, m), 7.02 (1H, d, J= 5.2 Hz), 7.33-7.37 (1H, m), 7.69 (1H, dd, J=2.8 Hz, J=12 Hz), 7.72 (1H, s), 8.33 (1H, t, J= 8.8 HZ), 8.75 (1H, s), 8.88 (1H, d, J= 5.2 Hz).

Production Example 12

4-(4-Amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline

[0257] The title compound (1.23 g) was obtained from the nitro compound (1.55 g) obtained in Production Example 11, in the same manner as Production Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.38 (3H, s), 3.78-3.81 (2H, m), 4.42-4.44 (2H, m), 5.25-5.27 (2H, brd), 6.54 (1H, d, J= 5.2 Hz), 6.87-6.89 (2H, m), 7.10-7.14 (1H, m), 7.62 (1H, s), 8.72 (1H, d, J= 5.2 HZ), 8.74 (1H, s).

Production Example 13

6-Cyano-7-methoxy-4-(4-nitrophenoxy)quinoline

[0258] A mixture of 4-chloro-6-cyano-7-methoxyquinoline (0.35 g) obtained in the same manner as Production Example 7, 4-nitrophenol (0.36 g) and 2,6-lutidine (0.25 ml) was heated and stirred in an oil bath at 170°C. After completion of the reaction, water and ethyl acetate were added to the reaction mixture for extraction. The organic layer was washed with an aqueous saturated sodium bicarbonate solution and saturated brine, dried over magnesium sulfate and concentrated. The obtained residue was passed through an NH silica gel column (Fuji Silysia Chemical), eluted with a solvent (ethyl acetate:hexane = 1:2) and concentrated to obtain 0.2 g of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 4.06 (3H, s), 6.87 (1H, d, J= 5.6 Hz), 7.54 (2H, d, J= 8.8Hz), 7.65 (1H, s), 8.36 (2H, d, J= 8.8Hz), 8.75 (1H, s), 8.84(1H, d, J= 5.6Hz).

Production Example 14

4-(4-Aminophenoxy)-6-cyano-7-methoxyquinoline

[0259] The title compound (0.17 g) was obtained from 6-cyano-7-methoxy-4-(4-nitrophenoxy)quinoline (0.2 g) in the same manner as Production Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 4.06 (3H, s), 5.15-5.20 (2H, m), 6.46 (1H, d, J= 5.6 Hz), 6.66 (2H, d, J= 8.8Hz), 6.93 (2H, d, J= 8.8 Hz), 7.56 (1H, s), 8.69 (1H, d, J= 5.6Hz), 8.71(1H, s).

Production Example 15

6-Cyano-4-(3-fluoro-4-nitrophenoxy)-7-methoxyquinoline

[0260] The title compound (0.33 g) was obtained from 4-chloro-6-cyano-7-methoxyquinoline (0.5 g) obtained in the same manner as Production Example 7, in the same manner as Production Example 13.

¹H-NMR(DMSO-d₆) δ(ppm): 4.07 (3H, s), 7.00 (1H, d, J= 5.2 Hz), 7.30-7.34 (1H, m), 7.65 (1H, dd, J= 2.8 Hz, J= 12 Hz), 7.66 (1H, s), 8.30 (1H, t, J= 8.8 Hz), 8.72(1H, s), 8.87 (1H, d, J= 5.2Hz).

Production Example 164-(4-Amino-3-fluorophenoxy)-6-cyano-7-methoxyquinoline

[0261] The title compound (0.24 g) was obtained from 6-cyano-4-(3-fluoro-4-nitrophenoxy)-7-methoxyquinoline (0.32 g) in the same manner as Production Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 4.06 (3H, s), 5.26 (2H, brs), 6.54 (1H, d, J= 5.2 Hz), 6.85-6.91 (2H, m), 7.11 (1H, dd, J= 2.0 Hz, J= 11.2 Hz), 7.59 (1H, s), 8.72 (1H, d, J= 5.2Hz), 8.73 (1H, s).

Production Example 17Phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl) oxyphenyl)carbamate

[0262] The 4-(4-aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (3.354 g, 10.0 mmol) obtained in Production Example 10 was dissolved in dimethylformamide (35 ml) under a nitrogen atmosphere, and then the solution was cooled in an ice water bath, pyridine (2.43 ml, 30.0 mmol) and phenyl chloroformate (1.38 ml, 11.0 mmol) were added in that order, and the mixture was stirred at room temperature for 3 hours. Water (40 ml) was added to the reaction solution and the precipitated crystals were filtered out. The filtrate was extracted with ethyl acetate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The drying agent was filtered off, and the crystals obtained by concentration under reduced pressure were combined with the previous crystals, suspended in hexane-ethyl acetate (5:1) and stirred overnight, after which the crystals were filtered out and dried under reduced pressure to obtain the title compound (4.334 g, 9.52 mmol, 95.2%) as light brown crystals.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 3.53 (3H, s), 3.91 (2H, t, J=4.4Hz), 4.38 (2H, t, J=4.4Hz), 6.49 (1H, d, J=5.2Hz), 7.07 (1H, br), 7.17-7.32 (5H, m), 7.40-7.45 (2H, m), 7.44 (1H, s), 7.59 (2H, d, J=8.8Hz), 8.67 (1H, d, J=5.6Hz), 8.70 (1H, s).

Production Example 18Phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-quinolyl)oxy-2-fluorophenyl)carbamate

[0263] The 4-(4-amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (2500 mg) obtained in Production Example 12 was dissolved in 20 ml of dimethylformamide and 1.7 ml of pyridine, and the solution was cooled to 0°C under a nitrogen atmosphere. After adding 0.97 ml of phenyl chlorocarbonate to the solution, it was stirred at room temperature for 2 hours. Ethyl acetate and water were added to the reaction solution for distribution, and the organic layer was washed with water and saturated brine in that order, dried over anhydrous sodium sulfate and then concentrated under reduced pressure to obtain 3.7 g of a residue. This was dissolved in tetrahydrofuran, and then n-hexane was added and the precipitated solid was filtered out to obtain 2.2 g of the title compound as light brown crystals (67% yield).

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 3.36 (3H, s), 3.89-3.94 (2H, m), 4.34-4.39 (2H, m), 6.52 (1H, d, J=5.6Hz), 7.01-7.06 (2H, m), 7.21-7.30 (4H, m), 7.40-7.45 (2H, m), 7.49 (1H, s), 8.26 (1H, brs), 8.66 (1H, s), 8.70 (1H, d, J=5.6Hz).

Production Example 19Phenyl N-(4-(6-cyano-7-methoxy-4-quinolyl)oxyphenyl) carbamate

[0264] The 4-(4-aminophenoxy)-6-cyano-7-methoxyquinoline (747 mg) obtained in Production Example 14 was dissolved in 7 ml of dimethylformamide and 0.34 ml of pyridine, and the solution was cooled to 0°C under a nitrogen atmosphere. After adding 0.34 ml of phenyl chlorocarbonate to the solution, it was stirred at room temperature for 2 hours. Ethyl acetate and water were added to the reaction solution, and the precipitated solid was filtered out to obtain 590 mg of the title compound as light brown crystals (56% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.04 (3H, s), 6.52 (1H, d, J=5.6Hz), 7.20-7.30 (5H, m), 7.40-7.46 (2H, m), 7.60 (1H, s), 7.62-7.68 (2H, m), 8.72 (1H, d, J=5.6Hz), 8.75 (1H, s), 10.4 (1H, brs).

Production Example 206-Chloro-4-(4-nitrophenoxy)pyrimidine

[0265] After adding 4,6-dichloropyrimidine (750 mg) to a suspension of 4-nitrophenol (700 mg) and sodium hydride

(60%) (200 mg) in dimethylformamide (13 ml) at 0°C, the mixture was heated and stirred at 80°C for 1.5 hours. The reaction solution was poured into saturated brine and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and then concentrated. The obtained residue was passed through an NH silica gel column (Fuji Silysia Chemical), eluted with a solvent (ethyl acetate-hexane = 1-4) and concentrated to obtain 700 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 7.08 (1H, d, J= 0.8 Hz), 7.30-7.37 (2H, m), 8.32-8.36 (2H, m), 8.60 (1H, d, J= 0.8 Hz).

Production Example 21

4-(4-Amino-3-fluorophenoxy)-7-hydroxyquinoline-6-carbonitrile

[0266] After adding 26 ml of trifluoroacetic acid and 2.6 ml of thioanisole to 2.6 g of 7-benzyloxy-6-cyano-4-(3-fluoro-4-nitrophenoxy)quinoline 2.6 g, the mixture was stirred at 70-72°C for 15 hours and returned to room temperature, and then the reaction system was concentrated, saturated sodium bicarbonate water and methanol were added to the residue, and the precipitated yellow crystals were filtered out. Drying yielded 2.61 g of crystals. To 640 mg of the crystals there were added 950 mg of iron, 1.8 g of ammonium chloride, 10 ml of ethanol, 10 ml of tetrahydrofuran, and 10 ml of water, the mixture was refluxed for 1 hour, the reaction system was filtered with celite, ethyl acetate and water were added to the filtrate for liquid separation and extraction, and the organic layer was concentrated to dryness to obtain 355 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 5.22 (2H, s), 6.42 (1H, d, J=5.8Hz), 6.80-6.90 (2H, m), 7.08 (2H, d, J=12.0Hz), 8.60-8.65 (2H, m), 11.60 (1H, brs)

Production Example 22

Phenyl 3-methylsulfonylphenylcarbamate

[0267] 1-Amino-3-methylthiobenzene (1.27 ml, 10 mmol) was dissolved in tetrahydrofuran (10 ml), and then triethylamine (1.46 ml, 10.5 mmol) and phenyl chloroformate (1.32 ml, 10.5 mmol) were added dropwise in that order at room temperature under a nitrogen atmosphere and the mixture was stirred overnight. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent and drying under reduced pressure, the residue was dissolved in dichloromethane (50 ml), and 3-chloroperbenzoic acid (4.93 g, 20 mmol) was gradually added while cooling in an ice water bath. An aqueous saturated solution of sodium thiosulfate was added to the reaction solution, and then the insoluble portion was filtered off, and extraction with ethyl acetate was followed by washing with an aqueous saturated solution of sodium carbonate and drying over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane = 1:1) to obtain the title compound (2.545 g, 8.74 mmol, 87.4%) as white crystals.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 3.07 (3H, s), 7.18-7.29 (4H, m), 7.40-7.44 (2H, m), 7.55 (1H, t, J=8.0Hz), 7.68 (1H, d, J=8.0Hz), 7.80 (1H, d, J=8.0Hz), 8.05 (1H, s).

Production Example 23

4-[(2,2-Dimethyl-4,6-dioxo[1,3]dioxane-5-ylidenemethyl)-amino]-2-methoxybenzonitrile

[0268] 4-Amino-2-chlorobenzonitrile (3 g) was dissolved in 1-methyl-2-pyrrolidone (10 ml), and then sodium methoxide (2.12 g) was added and the mixture was heated and stirred for 7 hours at 100°C. The reaction solution was poured into an aqueous saturated solution of ammonium chloride and extracted with ethyl acetate, and the organic layer was dried over magnesium sulfate and concentrated. The obtained residue was subjected to NH silica gel column chromatography and eluted with a solvent (ethyl acetate:n-hexane = 1:2) to obtain an aniline compound (1.26 g). The aniline compound (1.26 g) was heated to reflux in ethanol together with ethoxymethylene-Meldrum acid (1.7 g). The solid which precipitated after 2 hours was filtered out, washed with ethanol and then dried to obtain the title compound (1.9 g).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.66 (6H, s), 3.94 (3H, s), 7.21-7.26 (1H, m), 7.46-7.50 (1H, m), 7.72 (1H, d, J=8.4Hz), 8.70 (1H, s).

Production Example 247-Methoxy-4-oxo-1,4-dihydroquinoline-6-carbonitrile

[0269] 4-[(2,2-Dimethyl-4,6-dioxo[1,3]dioxane-5-ylidenemethyl) amino]-2-methoxybenzonitrile (1.9 g) was heated for cyclization in the same manner as Production Example 457-3, to obtain the title compound (1.08 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.96 (3H, s), 6.02 (1H, d, J=7.6Hz), 7.06 (1H, s), 7.89 (1H, d, J=7.6Hz), 8.30 (1H, s).

Production Example 256-Methoxycarbonyl-7-methoxy-4-(5-indolyloxy)quinoline

[0270] After mixing methyl 4-chloro-7-methoxyquinoline-6-carboxylate (described in WO0050405, p.34, 8.5 g, 33.77 mmol), 5-hydroxyindole (7 g), diisopropylethylamine (8.9 ml) and N-methylpyrrolidone (8.9 ml), the mixture was heated and stirred at 130°C for 5 hours and then at 150°C for 8 hours. After standing to cool, the solution was adsorbed onto silica gel and purified with a silica gel column (hexane-ethyl acetate system). Ethanol, diethyl ether and hexane were added to the obtained yellow oil, and crystals precipitated after a period of standing. The crystals were filtered out, washed with diethyl ether and hexane and then dried by aspiration to obtain light yellow crystals (3.506 g, 10.06 mmol, 29.80%).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 3.86(3H,s), 3.97(3H,s), 6.38(1H,d,J = 5.2Hz), 6.46(1H,s), 6.98(1H,d,J = 8.8Hz), 7.44-7.52(4H,m), 8.60-8.65(2H,m), 11.29(1H,s).

Production Example 267-(2-Methoxyethoxy)-4-oxo-1,4-dihydro-6-quinolinecarboxylic acid

[0271] The 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carbonitrile (8.0 g) described in WO9813350 was used to obtain the title compound (6.3 g) by the same procedure as in Production Example 152-1.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.33(3H, s), 3.71-3.73 (2H, m), 4.21-4.22 (2H, m), 6.28(1H, d, J=7.2Hz), 7.15 (1H, s), 8.59(1H, d, J=7.2Hz), 8.40(1H, s)

[Examples]

Example 1N-(4-(6-Cyano-7-(3-(4-pyridyl)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0272] The sodium 6-cyano-4-(4-((4-methoxyanilino) carbonyl) aminophenoxy)-7-quinolinolate (200 mg) synthesized in Example 87 was dissolved in dimethylformamide (4 ml), and then potassium carbonate (130 mg, 0.9400 mmol), potassium iodide (3 mg) and 1-chloro-3-(4-pyridyl)propane (80 mg, 0.5159 mmol) were added and the mixture was heated and stirred at 80°C for 5 hours and 30 minutes. After allowing the mixture to stand and adding saturated brine, it was extracted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by NH silica gel column chromatography (ethyl acetate-methanol system). The obtained crystals were suspended in ethanol, the suspension was diluted with diethyl ether, and the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (60 mg) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.17 (2H, d), 2.84 (2H, t, J = 7.8 Hz), 3.70 (3H, s), 4.28 (2H, t, J = 6.2 Hz), 6.51 (1H, d, J = 5.2 Hz), 6.86 (2H, d, J = 9.0 Hz), 7.22 (2H, d, J = 9.0 Hz), 7.29 (2H, d, J = 6.0 Hz), 7.35 (2H, d, J = 9.0 Hz), 7.57 (1H, s), 7.58 (2H, d, J = 9.0 Hz), 8.46 (2H, d, J = 6.0 Hz), 8.49 (1H, s), 8.71 (1H, d, J = 5.2 Hz), 8.74 (1H, s), 8.76 (1H, s).

Example 2N-(4-(6-Cyano-7-(4-picolyl)oxy)-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0273] The sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl) aminophenoxy)-7-quinolinolate (100 mg) synthesized in Example 87 was dissolved in dimethylformamide (2 ml), and then potassium carbonate (97 mg, 0.7018 mmol),

potassium iodide (3 mg) and 4-picolyl chloride (40 mg, 0.2462 mmol) were added and the mixture was heated and stirred at 80°C for 3 hours. After allowing the mixture to stand and adding water, it was extracted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by NH silica gel column chromatography (ethyl acetate-methanol system). The obtained crystals were suspended in acetone, the suspension was diluted with diethyl ether, and the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (30 mg) as light yellow crystals. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.70 (3H, s), 5.54 (2H, s), 6.53 (1H, d, J = 5.2 Hz), 6.86 (2H, d, J = 8.8 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.36 (2H, d, J = 8.8 Hz), 7.52 (2H, d, J = 6.4 Hz), 7.59 (2H, d, J = 8.8 Hz), 7.66 (1H, s), 8.55 (1H, brs), 8.63 (2H, d, J = 6.0 Hz), 8.72 (1H, d, J = 5.2 Hz), 8.81 (1H, brs), 8.82 (1H, s).

Example 3

N-(4-(6-Cyano-7-(3-picolylloxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0274] The sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl) aminophenoxy)-7-quinolinolate (200 mg) synthesized in Example 87 was used for reaction in the same manner as Example 2 to obtain the title compound (68 mg).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.70 (3H,s), 5.50 (2H,s), 6.54 (1H, d, J = 5.0 Hz), 6.86 (2H, d, J = 8.8 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.35 (2H, d, J = 8.8 Hz), 7.49 (2H, dd, J = 4.8 Hz, 7.6 Hz), 7.58 (2H, d, J = 8.8 Hz), 7.74 (1H, s), 7.95 (1H, d, J = 7.6 Hz), 8.49 (1H, s), 8.59 (1H, dd, J = 1.6, Hz, 4.8 Hz), 7.83-8.80 (3H, m).

Example 4

N-(4-(6-Cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (Example 4-A)

N-(4-(6-Cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (Example 4-B)

[0275] The N-(4-(6-cyano-7-(2-chloroethoxy)-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (210 mg, 0.4403 mmol) synthesized in Example 90 was dissolved in N,N-dimethylformamide (2.5 ml), and then potassium carbonate (180 mg, 1.3209 mmol), potassium iodide (15 mg) and 1H-1,2,3-triazole (0.078 ml, 1.3209 mmol) were added and the mixture was heated and stirred at 60°C for 20 minutes and then at 65°C for 3 hours. After cooling, tetrahydrofuran and ethyl acetate were added, the mixture was washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the isomers were separated by silica gel column chromatography (ethyl acetate-methanol system). The crystals of the low polarity isomer were suspended in ethanol and then washed with ethanol, filtered and dissolved in dimethylsulfoxide, after which the solution was diluted with ethanol and the precipitated crystals were filtered out, washed with ethanol and then with diethyl ether and dried by aspiration. The crystals of the high polarity isomer were suspended in ethanol, washed with ethanol, filtered out, washed with ethanol and then with diethyl ether and dried by aspiration. These yielded colorless crystals of low polarity N-(4-(6-cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (37 mg, 0.0703 mmol, 16.02%) and high polarity N-(4-(6-cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (62 mg, 0.1182 mmol, 26.85%).

Low polarity isomer (Example 4-A)

[0276] ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.81 (2H, t, J = 4.6 Hz), 4.92 (2H, t, J = 4.6 Hz), 6.52 (1H, d, J = 5.2 Hz), 7.11 (2H, t, J = 8.8 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.46 (2H, dd, J = 5.0 Hz, 8.8 Hz), 7.59 (2H, d, J = 8.8 Hz), 7.65 (1H, s), 7.80 (2H, s), 8.71 (1H, s), 8.72 (1H, d, J = 5.2 Hz), 8.77 (1H, s), 8.86 (1H, s).

High polarity isomer (Example 4-B)

[0277] ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.72 (2H, t, J = 4.8 Hz), 4.93 (2H, t, J = 4.8 Hz), 6.53 (1H, d, J = 5.2 Hz), 7.11 (2H, t, J = 8.4 Hz), 7.23 (2H, d, J = 8.8 Hz), 7.46 (2H, dd, J = 4.4 Hz, 8.4 Hz), 7.59 (2H, d, J = 8.8 Hz), 7.64 (1H, s), 7.77 (1H, s), 8.18 (1H, s), 8.73 (1H, d, J = 5.2 Hz), 8.73 (1H, s), 8.75 (1H, s), 8.83 (1H, s).

Example 5

N-(4-(6-Cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (Example 5-A)

N-(4-(6-Cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (Example 5-B)

[0278] The N-(4-(6-cyano-7-(2-chloroethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (300 mg, 0.6136 mmol) synthesized in Example 91 was used for reaction in the same manner as Example 4 to obtain low polarity N-(4-(6-cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (87 mg, 0.1652 mmol, 26.93%) and high polarity N-(4-(6-cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (83 mg, 0.1576 mmol, 25.69%) as colorless crystals.

Low polarity isomer (Example 5-A)

[0279] ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.70 (3H, s), 4.81 (2H, t, J = 5.0 Hz), 4.92 (2H, t, J = 5.0 Hz), 6.52 (1H, d, J = 5.4 Hz), 6.86 (2H, d, J = 8.8 Hz), 7.21 (2H, d, J = 9.2 Hz), 7.35 (2H, d, J = 8.8 Hz), 7.57 (2H, d, J = 9.2 Hz), 7.65 (1H, s), 7.80 (2H, s), 8.49 (1H, s), 8.71 (1H, s), 8.72 (1H, d, J = 5.4 Hz), 8.73 (1H, s).

High polarity isomer (Example 5-B)

[0280] ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.70 (3H, s), 4.72 (2H, t, J = 5.2 Hz), 4.93 (2H, t, J = 5.2 Hz), 6.53 (1H, d, J = 5.2 Hz), 6.85 (2H, d, J = 9.0 Hz), 7.21 (2H, d, J = 9.0 Hz), 7.35 (2H, d, J = 9.0 Hz), 7.57 (2H, d, J = 9.0 Hz), 7.64 (1H, s), 7.77 (1H, s), 8.18 (1H, s), 8.49 (1H, s), 8.72 (1H, d, J = 5.2 Hz), 8.73 (1H, s), 8.75 (1H, s).

Example 6

N-(4-(6-Cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxy-3-fluorophenyl)-N'-(2,4-difluorophenyl)urea (Example 6-A)
N-(4-(6-Cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxy-3-fluorophenyl)-N'-(2,4-difluorophenyl)urea (Example 6-B)

[0281] Sodium hydride (35 mg, 0.8774 mmol, 60% in oil) was suspended in N,N-dimethylformamide (2.5 ml), and then 1H-1,2,3-triazole (0.051 ml, 0.8774 mmol) was added while cooling on ice and the mixture was stirred at room temperature for 15 minutes to complete dissolution. After then adding N-(4-(6-cyano-7-(2-chloroethoxy)-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea (225 mg, 0.4386 mmol) and potassium iodide (10 mg), the mixture was heated and stirred at 50°C for 10 hours. Upon cooling, tetrahydrofuran and ethyl acetate were added, the mixture was washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the isomers were separated by silica gel column chromatography (hexane/ethyl acetate/methanol system). The crystals of the low polarity isomer were dissolved in dimethylsulfoxide, the solution was diluted with ethanol, and the precipitated crystals were filtered out, washed with ethanol and then with diethyl ether and dried by aspiration. The crystals of the high polarity isomer were further purified by NH silica gel column chromatography (hexane/ethyl acetate system), and the obtained crystals were suspended in ethanol, washed with ethanol and hexane, and then filtered out, washed with hexane and dried by aspiration. This yielded pink crystals of low polarity N-(4-(6-cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxy-3-fluorophenyl)-N'-(2,4-difluorophenyl)urea (15 mg, 0.0275 mmol, 6.27%) and colorless crystals of high polarity N-(4-(6-cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxy-3-fluorophenyl)-N'-(2,4-difluorophenyl)urea (30 mg, 0.0550 mmol, 12.54%).

Low polarity isomer (Example 6-A)

[0282] ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.82 (2H, t, J = 4.8 Hz), 4.92 (2H, t, J = 4.82 Hz), 6.63 (1H, d, J = 5.0 Hz), 7.05 (1H, m), 7.14 (1H, d, J = 9.6 Hz), 7.32 (1H, m), 7.40 (1H, m), 7.66 (1H, s), 7.80 (2H, s), 8.11 (1H, m), 8.26 (1H, t, J = 9.6 Hz), 8.70 (1H, s), 8.75 (1H, d, J = 5.0 Hz), 8.99 (1H, s), 9.07 (1H, s).

High polarity isomer (Example 6-B)

[0283] ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.73 (2H, t, J = 5.2 Hz), 4.93 (2H, t, J = 5.2 Hz), 6.63 (1H, d, J = 5.2 Hz), 7.05 (1H, m), 7.15 (1H, m), 7.32 (1H, ddd, J = 2.8 Hz, 8.8 Hz, 11.6 Hz), 7.40 (1H, dd, J = 2.8 Hz, 11.6 Hz), 7.66 (1H, s), 7.77 (1H, s), 8.11 (1H, m), 8.18 (1H, s), 8.26 (1H, t, J = 8.8 Hz), 8.74 (1H, s), 8.75 (1H, d, J = 5.2 Hz), 8.99 (1H, d, J = 2.2 Hz), 9.07 (1H, d, J = 2.2 Hz).

Example 7N-(4-(6-Cyano-7-(3-(morpholin-4-yl)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0284] The sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate (100 mg) synthesized in Example 87 was dissolved in dimethylformamide (2.5 ml), and then potassium carbonate (65 mg, 0.4690 mmol) and 1-chloro-3-(morpholin-4-yl)propane (38 mg, 0.2345 mmol, J. Am. Chem. Soc. 67, 736 (1945)) were added and the mixture was heated and stirred at 80°C for 2 hours. After allowing the mixture to stand and adding saturated brine, it was extracted with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by NH silica gel column chromatography (ethyl acetate-methanol system). The obtained crystals were suspended in ethyl acetate, the suspension was diluted with diethyl ether, and the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (120 mg) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 1.99 (2H, m), 2.38 (4H, brs), 2.49 (2H, m), 3.57 (4H, t, J = 4.6 Hz), 3.70 (3H, s), 4.33 (2H, t, J = 6.2 Hz), 6.51 (1H, d, J = 5.6 Hz), 6.86 (2H, d, J = 9.2 Hz), 7.22 (2H, d, J = 9.2 Hz), 7.35 (2H, d, J = 9.2 Hz), 7.58 (2H, d, J = 9.2 Hz), 7.59 (1H, s), 8.49 (1H, s), 8.71 (1H, d, J = 5.6 Hz), 8.74 (1H, s), 8.75 (1H, s).

Example 8N-(4-(6-Cyano-7-(3-(1,2,3-triazol-2-yl)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0285] The title compound was obtained from the sodium 6-cyano-4-(4-((4-methoxyanilino) carbonyl)aminophenoxy)-7-quinolinolate synthesized in Example 87 and 2-(3-chloropropyl)1,2,3-triazole, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.41 (2H, m), 3.70 (3H, s), 4.29 (2H, t, J = 6.0 Hz), 4.68 (2H, t, J = 6.6 Hz), 6.52 (1H, d, J = 5.2 Hz), 6.86 (2H, d, J = 8.8 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.35 (2H, d, J = 8.8 Hz), 7.54 (1H, s), 7.58 (2H, d, J = 8.8 Hz), 7.78 (2H, s), 8.49 (1H, s), 8.71 (1H, d, J = 5.2 Hz), 8.74 (1H, s), 8.77 (1H, s).

Example 9N-(4-(6-Cyano-7-(3-(1,2,3-triazol-1-yl)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0286] The title compound was obtained from the sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate synthesized in Example 87 and 1-(3-chloropropyl)-1,2,3-triazole, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.41 (2H, m), 3.70 (3H, s), 4.28 (2H, t, J = 6.0 Hz), 4.63 (2H, t, J = 6.6 Hz), 6.52 (1H, d, J = 5.4 Hz), 6.86 (2H, d, J = 8.8 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.35 (2H, d, J = 8.8 Hz), 7.57 (1H, s), 7.58 (2H, d, J = 8.8 Hz), 7.73 (1H, s), 8.19 (1H, s), 8.49 (1H, s), 8.72 (1H, d, J = 5.4 Hz), 8.74 (1H, s), 8.77 (1H, s).

Example 10N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0287] 4-(4-Aminophenoxy)-7-(2-methoxyethoxy)-6-cyanoquinoline (109 mg, 0.325 mmol) was dissolved in toluene (5 ml) while heating, and then 4-fluorophenyl isocyanate (0.057 ml, 0.488 mmol) was added and the mixture was heated to reflux for 1 hour. After cooling, the precipitated crystals were filtered out, washed with ethyl acetate and dried under reduced pressure to obtain the title compound (148 mg, 0.311 mmol, 96.4%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.41-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 7.11 (2H, t, J=9.0Hz), 7.23 (2H, d, J=9.0Hz), 7.46 (2H, q, J=4.8Hz), 7.57-7.62 (3H, m), 8.71-8.76 (3H, m), 8.82 (1H, s).

Example 11N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-pyridyl)urea

[0288] Phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (104 mg, 0.228 mmol) was dissolved in dimethylsulfoxide (1 ml), and then 2-aminopyridine (43 mg, 0.457 mmol) was added and the mixture was heated at 85°C for 3 hours while stirring. After cooling, ethyl acetate and water were added for distribution, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtering off the drying

agent and concentrating under reduced pressure, ethyl acetate-hexane was added to the residue and the precipitated crystals were filtered out and dried under reduced pressure to obtain the title compound (86 mg, 0.189 mmol, 82.7%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.42 (2H, m), 6.53 (1H, d, J=5.2Hz), 6.99 (1H, m), 7.18 (1H, d, J=8.4Hz), 7.26 (2H, d, J=9.2Hz), 7.56 (1H, d, J=8.4Hz), 7.62 (1H, s), 7.68-7.77 (3H, m), 8.26 (1H, d, J=5.2Hz), 8.72 (1H, d, J=5.2Hz), 8.77 (1H, s), 9.89 (1H, brs).

Example 12

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(1,3-thiazol-2-yl)urea

[0289] The title compound (37 mg, 0.08 mmol, 34.4%) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (106 mg, 0.233 mmol) by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.79 (2H, m), 4.40-4.43 (2H, m), 6.53 (1H, d, J=5.6Hz), 7.10 (1H, d, J=3.2Hz), 7.72 (1H, d, J=8.8Hz), 7.37 (1H, m), 7.57-7.67 (3H, m), 8.72 (1H, d, J=5.2Hz), 8.77 (1H, s), 9.53 (1H, brs).

Example 13

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-hydroxyphenyl)urea

[0290] The title compound (52 mg, 0.110 mmol, 43.0%) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (117 mg, 0.257 mmol) by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.77-3.79 (2H, m), 4.41-4.43 (2H, m), 6.51 (1H, d, J=5.2Hz), 6.67 (2H, d, J=8.0Hz), 7.15-7.25 (3H, m), 7.57 (2H, d, J=8.0Hz), 7.62 (1H, s), 8.37 (1H, s), 8.70-8.76 (3H, m), 9.05 (1H, s).

Example 14

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-methoxyphenyl)urea

[0291] The title compound (50 mg, 0.103 mmol, 39.2%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (120 mg, 0.263 mmol) by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.72 (3H, s), 3.76-3.79 (2H, m), 4.39-4.43 (2H, m), 6.50-6.57 (2H, m), 6.93 (1H, d, J=8.0Hz), 7.14-7.19 (2H, m), 7.24 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.8Hz), 7.62 (1H, s), 8.69-8.73 (2H, m), 8.76 (1H, s), 8.80 (1H, s).

Example 15

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-hydroxyphenyl)urea

[0292] The title compound (25 mg, 0.053 mmol, 23.7%) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (102 mg, 0.234 mmol) by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.79 (2H, m), 4.40-4.43 (2H, m), 6.36 (1H, d, J=9.2Hz), 6.52 (1H, d, J=5.2Hz), 6.79 (1H, d, J=8.0Hz), 7.00-7.06 (2H, m), 7.23 (2H, d, J=9.2Hz), 7.58 (2H, d, J=8.8Hz), 7.62 (1H, s), 8.59 (1H, s), 8.71 (1H, d, J=4.8Hz), 8.76 (1H, s), 9.31 (1H, brs).

Example 16

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-hydroxyphenyl)urea

[0293] The title compound (78 mg, 0.166 mmol, 69.9%) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (108 mg, 0.237 mmol) by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.6Hz), 6.69-6.85 (3H, m), 7.22 (2H, d, J=8.8Hz), 7.57-7.62 (3H, m), 7.99 (1H, d, J=8.0Hz), 8.34 (1H, br), 8.71 (1H, d,

J=5.2Hz), 8.76 (1H, s), 9.62 (1H, brs).

Example 17

5 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(1H-2-imidazolyl)urea

[0294] After dissolving 2-aminoimidazole (132 mg, 1.0 mmol) in a dimethylformamide (2 ml) and water (1 ml) mixed solvent, triethylamine (0.42 ml, 3.0 mmol) and phenyl chloroformate (0.14 ml, 1.1 mmol) were added at room temperature, and the mixture was stirred for 10 minutes. After further adding 4-(4-aminophenoxy)-7-(2-methoxyethoxy)-6-cyanoquinoline (168 mg, 0.5 mmol), the mixture was stirred overnight. The reaction solution was diluted with ethyl acetate (30 ml) and then washed with water (10 ml x 2) and saturated brine (10 ml), and the organic layer was dried over anhydrous sodium sulfate. The drying agent was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent - ethyl acetate:ethanol = 95:5) to obtain the title compound (20 mg, 0.045 mmol, 8.98%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.53 (1H, d, J=5.2Hz), 6.70 (1H, s), 7.24 (2H, d, J=8.8Hz), 7.57-7.67 (3H, m), 8.72 (1H, d, J=5.6Hz), 8.76 (1H, s).

Example 18

20 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea

[0295] The title compound (136 mg, 0.277 mmol, 87.7%) was obtained as white crystals from 4-(4-aminophenoxy)-7-(2-methoxyethoxy)-6-cyanoquinoline (106 mg, 0.316 mmol) by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 7.04 (1H, m), 7.23-7.34 (3H, m), 7.57-7.62 (3H, m), 8.06 (1H, m), 8.52 (1H, s), 8.71 (1H, d, J=5.6Hz), 8.76 (1H, s), 9.16 (1H, s).

Example 19

30 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-cyanophenyl)urea

[0296] The title compound (38 mg, 0.079 mmol, 33.1%) was obtained as light yellow crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (109 mg, 0.239 mmol) by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 7.26 (2H, d, J=8.8Hz), 7.41 (1H, d, J=6.4Hz), 7.49 (1H, t, J=8.0Hz), 7.55-7.62 (3H, m), 7.68 (1H, dd, J=1.2, 8.8Hz), 7.97 (1H, s), 8.71 (1H, d, J=6.4Hz), 8.76 (1H, s), 9.00 (1H, s), 9.05 (1H, s).

Example 20

40 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-fluorophenyl)urea

[0297] The title compound (75 mg, 0.159 mmol, 48.8%) was obtained as white crystals from 4-(4-aminophenoxy)-7-(2-methoxyethoxy)-6-cyanoquinoline (109 mg, 0.325 mmol) by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 7.01 (1H, m), 7.13 (1H, t, J=8.0Hz), 7.20-7.27 (3H, m), 7.55-7.63 (3H, m), 8.14 (1H, t, J=8.0Hz), 8.56 (1H, brs), 8.72 (1H, d, J=6.4Hz), 8.76 (1H, s), 9.22 (1H, s).

Example 21

50 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfonyl)phenyl)urea

[0298] Diisopropylethylamine (0.057 ml, 0.328 mmol) and phenyl N-[3-(methylsulfonyl)phenyl]carbamate (96 mg, 0.328 mmol) were reacted with 4-(4-aminophenoxy)-7-(2-methoxyethoxy)-6-cyanoquinoline (100 mg, 0.298 mmol), and the title compound (120 mg, 0.225 mmol, 75.6%) was obtained as white crystals by the same procedure as in Example 34.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.19 (3H, s), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.53 (1H, d, J=5.6Hz), 7.26 (2H, d, J=8.8Hz), 7.50-7.69 (6H, m), 8.16 (1H, brs), 8.72 (1H, d, J=5.2Hz), 8.76 (1H, s), 8.95 (1H, s), 9.15 (1H, s).

Example 22N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfanyl)phenyl)urea

[0299] The title compound (210 mg, 0.420 mmol, 98.9%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (193 mg, 0.424 mmol) by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.43 (3H, s), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 6.83 (1H, d, J=7.2Hz), 7.14-7.24 (4H, m), 7.48 (1H, s), 7.58-7.61 (3H, m), 8.71 (1H, d, J=5.2Hz), 8.75 (1H, s), 9.62 (1H, s), 9.76 (1H, s).

Example 23N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylurea

[0300] The title compound (145 mg, 0.347 mmol, 80.9%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (195 mg, 0.428 mmol) by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.4 (2H, brs), 0.63 (2H, d, J=6.8Hz), 2.53 (1H, m), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.42 (1H, s), 6.48 (1H, d, J=5.2Hz), 6.97 (2H, d, J=9.2Hz), 7.53 (2H, d, J=9.2Hz), 7.60 (1H, s), 8.44 (1H, s), 8.70 (1H, d, J=4.8Hz), 8.74 (1H, s).

Example 24N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluoro-2-hydroxyphenyl)urea

[0301] The title compound (132 mg, 0.270 mmol, 78.9%) was obtained as light yellow crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (156 mg, 0.343 mmol) by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.6Hz), 6.57 (1H, m), 6.62 (1H, m), 7.23 (2H, d, J=8.8Hz), 7.57 (2H, d, J=8.8Hz), 7.62 (1H, s), 7.98 (1H, m), 8.12 (1H, s), 8.71 (1H, d, J=5.6Hz), 9.40 (1H, s), 10.47 (1H, s).

Example 25N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(1,3-thiazol-2-yl)urea

[0302] Phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (200 mg) and 2-aminothiazole (85 mg) were dissolved in 1 ml of dimethylformamide, and then 0.12 ml of triethylamine was added thereto and the mixture was heated and stirred at 90°C for 2 hours. After cooling, water was added and the precipitated solid was filtered out and washed with ethyl acetate to obtain 110 mg of the title compound as light brown crystals (57% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.37 (3H, s), 3.75-3.80 (2H, m), 4.40-4.45 (2H, m), 6.63 (1H, d, J=5.6Hz), 7.14 (1H, d, J=3.2Hz), 7.16-7.20 (1H, m), 7.39 (1H, d, J=3.2Hz), 7.42-7.47 (1H, m), 7.64 (1H, s), 8.21-8.27 (1H, m), 8.74-8.76 (2H, m)

Example 26N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-cyclopropylurea

[0303] The title compound (83 mg, 0.190 mmol, 61.3%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (147 mg, 0.310 mmol) by the same procedure as in Example 25.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.40 (2H, br), 0.61-0.66 (2H, m), 2.53 (1H, m), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.58 (1H, d, J=5.6Hz), 6.79 (1H, d, J=2.0Hz), 7.08 (1H, dd, J=2.0, 10.4Hz), 7.32 (1H, dd, J=2.4, 11.6Hz), 7.62 (1H, s), 8.18-8.22 (2H, m), 8.71-8.74 (2H, m).

Example 27N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylmethylurea

[0304] The title compound (144 mg, 0.333 mmol, 96.6%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (157 mg, 0.345 mmol) by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.16-0.18 (2H, m), 0.39-0.43 (2H, m), 0.94 (1H, m), 2.97 (2H, t, J=6.4Hz), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.22 (1H, m), 6.49 (1H, d, J=5.6Hz), 7.17 (2H, d, J=8.8Hz), 7.52 (2H, d, J=8.8Hz), 7.61 (1H, s), 8.60 (1H, s), 8.70 (1H, d, J=5.2Hz), 8.75 (1H, s).

Example 28N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-cyclopropylmethylurea

[0305] The title compound (83 mg, 0.190 mmol, 61.3%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (147 mg, 0.310 mmol) by the same procedure as in Example 25.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.16-0.18 (2H, m), 0.41-0.46 (2H, m), 0.94 (1H, m), 2.99 (2H, t, J=6.0Hz), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.58 (1H, d, J=5.6Hz), 6.71 (1H, t, J=5.6Hz), 7.08 (1H, d, J=9.2Hz), 7.33 (1H, dd, J=2.8, 11.6Hz), 7.63 (1H, s), 8.24 (1H, t, J=9.2Hz), 8.38 (1H, s), 8.55-8.59 (2H, m).

Example 29N-(4-(6-Cyano-7-(3-(morpholin-4-yl)propoxy)-4-quinolyloxy)-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0306] N-(4-(6-Cyano-7-hydroxyquinolin-4-yloxy)-2-fluorophenyl)-N-(2,4-difluorophenyl)urea (100 mg, 0.2220 mmol) was used for reaction in the same manner as Example 7 to obtain the title compound (35 mg, 0.0606 mmol, 27.30%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 1.99 (2H, m), 2.38 (4H, brs), 2.50 (2H, t, J = 7.2 Hz), 3.57 (4H, t, J = 4.6 Hz), 4.33 (2H, t, J = 6.4 Hz), 6.62 (1H, d, J = 5.4 Hz), 7.06 (1H, m), 7.15 (1H, m), 7.32 (1H, ddd, J = 2.8 Hz, 8.8 Hz, 11.6 Hz), 7.41 (1H, dd, J = 2.8 Hz, 11.6 Hz), 7.61 (1H, s), 8.12 (1H, m), 8.27 (1H, dt, J = 2.0 Hz, 9.2 Hz), 8.74 (1H, s), 8.74 (1H, d, J = 5.4 Hz), 8.99 (1H, m), 9.07 (1H, m).

Example 30N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyloxy)phenyl)-N'-(4-fluorophenyl)urea

[0307] The title compound (69 mg, 0.131 mmol, 51.9%) was obtained as light brown crystals from sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (110 mg, 0.252 mmol) by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 0.95 (6H, t, J=7.2Hz), 1.89-1.95 (2H, m), 2.44-2.49 (4H, m), 2.58-2.62 (2H, m), 4.31 (2H, t, J=6.0Hz), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.4Hz), 7.23 (2H, d, J=8.8Hz), 7.44-7.48 (2H, m), 7.56-7.57 (2H, m), 7.60 (1H, s), 8.71 (1H, d, J=5.2Hz), 8.74-8.76 (2H, m), 8.85 (1H, s).

Example 31N-(4-(6-Cyano-7-(3-(4-morpholino)propyl)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0308] The title compound (73 mg, 0.135 mmol, 53.5%) was obtained as light brown crystals from sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (110 mg, 0.252 mmol) by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.99 (2H, t, J=6.4Hz), 2.30-2.60 (6H, m), 3.55-3.58 (4H, m), 4.31-4.34 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.23 (2H, d, J=9.2Hz), 7.44-7.48 (2H, m), 7.57-7.60 (3H, m), 8.70-8.75 (3H, m), 8.82 (1H, s).

Example 32N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2-pyridyl)urea

[0309] The title compound (210 mg, 84% yield) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (250 mg) and 2-aminopyridine (100 mg), in the same manner as Example 25.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.36 (3H, s), 3.75-3.80 (2H, m), 4.39-4.45 (2H, m), 6.64 (1H, d, J=5.2Hz), 7.00-7.05 (1H, m), 7.15-7.19 (1H, m), 7.37-7.47 (2H, m), 7.64 (1H, s), 7.50-7.80 (1H, m), 8.25-8.30 (1H, m), 8.31-8.37 (1H, m), 8.74 (1H, d, J=5.2Hz), 8.76 (1H, s), 9.87 (1H, s)

Example 33N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(3-(methylsulfanyl)phenyl)urea

[0310] The title compound (100 mg, 61% yield) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (160 mg) and 3-(methylthio)aniline (88 mg), in the same manner as Example 25.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.43 (3H, s), 3.36 (3H, s), 3.75-3.80 (2H, m), 4.40-4.45 (2H, m), 6.62 (1H, d, J=5.6Hz), 6.86-6.89 (1H, m), 7.11-7.17 (2H, m), 7.20-7.25 (1H, m), 7.37-7.43 (1H, m), 7.47 (1H, s), 7.63 (1H, s), 8.21-8.28 (1H, m), 8.66 (1H, brs), 8.73-8.76 (2H, m), 9.11-9.13 (1H, m)

Example 34N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(3-(methylsulfonyl)phenyl)urea

[0311] 4-(4-Amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (106 mg) and phenyl N-(3-(methylsulfonyl)phenyl)carbamate (96 mg) were added to 5 ml of toluene, and then 0.06 ml of diisopropylethylamine was added and the mixture was heated to reflux for 3 hours. After cooling, ethyl acetate was added and the precipitated insoluble portion was filtered out. The filtrate was concentrated, the resulting residue was dissolved in tetrahydrofuran, toluene was added, and the precipitated solid was filtered out to obtain 13 mg of the title compound as light brown crystals (8% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.20 (3H, s), 3.35 (3H, s), 3.75-3.80 (2H, m), 4.38-4.43 (2H, m), 6.63 (1H, d, J=5.2Hz), 7.14-7.17 (1H, m), 7.39-7.45 (1H, m), 7.51-7.61 (2H, m), 7.62-7.70 (2H, m), 8.16-8.27 (2H, m), 8.73-8.76 (3H, m), 9.47-9.49 (1H, m)

Example 35N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2-fluorophenyl)urea

[0312] 4-(4-Amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (100 mg) was added to 4.5 ml of toluene, and the mixture was heated to reflux. After then adding 2-fluorophenyl isocyanate (0.05 ml), the mixture was further heated to reflux for 1 hour. After cooling, the precipitated solid was filtered out and washed with ethyl acetate/toluene = 1/1 to obtain 100 mg of the title compound as light brown crystals (72% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.37 (3H, s), 3.75-3.80 (2H, m), 4.40-4.45 (2H, m), 6.62 (1H, d, 5.6Hz), 6.97-7.05 (1H, m), 7.11-7.18 (1H, m), 7.21-7.28 (1H, m), 7.38-7.45 (1H, m), 7.64 (1H, s), 8.14-8.20 (1H, m), 8.26-8.33 (1H, m), 8.73-8.76 (2H, m), 9.06 (1H, brs), 9.14 (1H, brs)

Example 36N-(4-(6-Cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea

[0313] 4-(4-Aminophenoxy)-6-cyano-7-methoxyquinoline (180 mg) was added to 5.5 ml of toluene, and the mixture was heated to reflux. After then adding 2,4-difluorophenyl isocyanate (0.12 ml), the mixture was further heated to reflux for 1 hour. After cooling, the precipitated solid was filtered out and washed with ethyl acetate/toluene = 1/1 to obtain 195 mg of the title compound as light brown crystals (70% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.05 (3H, s), 6.52 (1H, d, J = 5.2 Hz), 7.01-7.08 (1H, m), 7.21-7.34 (3H, m), 7.56-7.62 (3H, m), 8.02-8.10 (1H, m), 8.52 (1H, s), 8.72 (1H, d, J=5.2Hz), 8.76 (1H, s), 9.18 (1H, s).

Example 37N-(4-(6-Cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-phenylurea

[0314] 4-(4-Aminophenoxy)-6-cyano-7-methoxyquinoline (148 mg) was added to 5.5 ml of toluene, and the mixture was heated to reflux. After then adding phenyl isocyanate (0.08 ml), the mixture was further heated to reflux for 1 hour. After cooling, the precipitated solid was filtered out and washed with ethyl acetate/toluene = 1/1 to obtain 150 mg of the title compound as light brown crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.05 (3H, s), 6.50-6.54 (1H, m), 6.96 (t, 1H, 7.2Hz), 7.23 (2H, d, J=9.2Hz), 7.27 (2H, d, J=7.2Hz), 7.44 (2H, d, J=7.2Hz), 7.56-7.62 (3H, m), 8.68-8.77 (3H, m), 8.83 (1H, brs).

Example 38N-(4-(6-Cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-(1-butyl)urea

[0315] 4-(4-Aminophenoxy)-6-cyano-7-methoxyquinoline (150 mg) was added to 2.5 ml of toluene and 2.5 ml of acetonitrile, and the mixture was heated to reflux. After then adding n-butyl isocyanate (0.12 ml), the mixture was further heated to reflux for 1 hour. After cooling, the precipitated solid was filtered out and washed with ethyl acetate/toluene = 1/1 to obtain 110 mg of the title compound as light brown crystals (55% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 0.88 (3H, t, J=7.6Hz), 1.25-1.45 (4H, m), 3.04-3.11 (2H, m), 4.05 (3H, s), 6.13 (1H, t, J=5.6Hz), 6.49 (1H, d, J=5.6Hz), 7.16 (2H, d, J=9.2Hz), 7.52 (2H, d, J=9.2Hz), 7.58 (1H, s), 8.55 (1H, s), 8.71 (1H, d, J=5.6Hz), 8.75 (1H, s)

Example 39N-(4-(6-Cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0316] 4-(4-Aminophenoxy)-6-cyano-7-methoxyethoxyquinoline (150 mg) was added to 5.0 ml of toluene and 2.5 ml of acetonitrile, and the mixture was heated to reflux. After then adding 4-fluorophenyl isocyanate (0.12 ml), the mixture was further heated to reflux for 1 hour. After cooling, the precipitated solid was filtered out and washed with ethyl acetate/toluene = 1/1 to obtain 150 mg of the title compound as light brown crystals (68% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.05 (3H, s), 6.52 (1H, d, J=5.6Hz), 7.08-7.14 (2H, m), 7.23 (2H, d, J=8.8Hz), 7.43-7.49 (2H, m), 7.56-7.61 (3H, m), 8.71-8.76 (3H, m), 8.85 (1H, s)

Example 40N-(4-(6-Cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-(2-pyridyl)urea

[0317] Phenyl N-(4-(6-cyano-7-methoxy-4-quinolyl)oxyphenyl)carbamate (150 mg) and 2-aminopyridine (69 mg) were dissolved in 1 ml of dimethylsulfoxide, and the solution was heated and stirred at 80°C for 1.5 hours. After cooling, water was added, and the precipitated solid was filtered out and washed with ethyl acetate to obtain 82 mg of the title compound as light brown crystals (54% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.05 (3H, s), 6.54 (1H, d, J=5.6Hz), 6.98-7.03 (1H, m), 7.26-7.30 (2H, m), 7.45-7.52 (1H, m), 7.60 (1H, s), 7.63-7.78 (3H, m), 8.25-8.30 (1H, m), 8.73 (1H, d, J=5.6Hz), 8.78 (1H, s), 9.59 (1H, s), 10.67 (1H, s)

Example 41N-(4-(6-Cyano-7-methoxyethoxy-4-quinolyl)oxyphenyl)-N'-(3-pyridyl)urea

[0318] The title compound (32 mg, 32% yield) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-methoxy-4-quinolyl)oxyphenyl)carbamate (100 mg) and 3-aminopyridine (46 mg), in the same manner as Example 40. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.05 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.22-7.34 (3H, m), 7.57-7.63 (3H, m), 7.91-7.96 (1H, m), 8.17-8.20 (1H, m), 8.59-8.63 (1H, m), 8.73 (1H, d, J=5.2Hz), 8.76 (1H, s), 8.91 (1H, brs), 9.00 (1H, brs).

Example 42N-(4-(6-Cyano-7-methoxyethoxy-4-quinolyl)oxyphenyl)-N'-(4-pyridyl)urea

[0319] The title compound (45 mg, 30% yield) was obtained as light brown crystals from phenyl N-(4-(6-cyano-7-methoxy-4-quinolyl)oxyphenyl)carbamate (150 mg) and 4-aminopyridine (69 mg), in the same manner as Example 40.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.05 (3H, s), 6.54 (1H, d, J=5.2Hz), 7.26 (2H, d, J=9.0Hz), 7.43 (2H, d, J=7.0Hz), 7.57-7.64 (3H, m), 8.35 (2H, d, J=7.0Hz), 8.71-8.77 (2H, m), 9.05 (1H, brs), 9.16 (1H, brs).

Example 43N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0320] The title compound (10 mg) was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate (131 mg) by the same procedure as in Example 7.

¹H-NMR(CDCl₃) δ(ppm): 2.02-2.15 (2H, m), 2.27 (6H, s), 2.54 (2H, t, J=7.4 Hz), 3.80 (3H, s), 4.28(2H, t, J=7.4 Hz), 6.42 (1H, d, J=5.3 Hz), 6.80 (1H, brs), 6.90 (2H, d, J=9.3 Hz), 7.03(1H, brs), 7.08 (2H, d, J=9.3 Hz), 7.28 (2H, d, J=9.3 Hz), 7.46(1H, s), 7.48 (2H, d, J= 9.3 HZ), 8.62 (1H, d, J=5.3 Hz), 8.66 (1H, s)

Example 44N-[4-(6-Cyano-7-(2-(dimethylamino)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0321] The title compound (110 mg) was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate (145 mg), by the same procedure as in Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.28 (6H, s), 2.76 (2H, t, J=5.3 Hz), 3.70 (3H, s), 4.37(2H, t, J=5.3Hz), 6.51 (1H, d, J=5.4 Hz), 6.86 (2H, d, J=8.7 Hz), 7.21 (2H, d, J=8.7 Hz), 7.35 (2H, d, J=8.7 Hz), 7.58 (2H, d, J= 8.7 Hz), 7.62(1H, s), 8.50 (1H, s), 8.72 (1H, d, J= 5.4 Hz), 8.75(2H, s)

Example 45N-(4-(6-Cyano-7-(3-(1-pyrrolidino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0322] N-(4-(6-Cyano-7-(3-chloropropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (140 mg) was dissolved in dimethylformamide, pyrrolidine (163 μl) was added, and the mixture was heated and stirred at 80°C for 6 hours. The reaction solution was poured into saturated brine and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated. The residue was passed through NH silica gel (Fuji Silysia Chemical) and eluted with a solvent (ethyl acetate), and then further eluted with another solvent (ethyl acetate:methanol = 10:1) and concentrated to obtain 31 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 1.67-1.73 (4H, m), 1.96-2.04 (2H, m), 2.44-2.49 (4H, m), 2.61 (2H, t, J= 6.8 Hz), 3.72 (3H, s), 4.34 (2H, t, J=6.4 Hz), 6.53 (1H, d, J=5.2 Hz), 6.88 (2H, d, J=8.8 Hz), 7.23 (2H, d, J=9.2 Hz), 7.37 (2H, d, J=8.8 Hz), 7.60 (1H, s), 7.61 (2H, d, J=9.2 Hz), 8.63 (1H, brs), 8.73 (1H, d, J= 5.2 HZ), 8.76 (1H, s), 8.88 (1H, brs).

Example 46N-(4-(6-Cyano-7-(3-(1-piperidino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0323] The title compound (67 mg) was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate (156 mg), by the same procedure as in Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 1.30-1.57(6H, m), 1.93-2.03(2H, m), 2.31-2.53(6H, m), 3.72(3H, s), 4.33(2H, t, J=6.5 Hz), 6.52 (1H, d, J=4.9 Hz), 6.87 (2H, d, J=8.9 Hz), 7.23 (2H, d, J=8.9 Hz), 7.38 (2H, d, J=8.9 Hz), 7.57-7.63(3H, m), 8.53 (1H, brs), 8.72 (1H, d, J=4.9 Hz), 8.76(1H, s), 8.79(1H, brs)

Example 47N-(4-(6-Cyano-7-(2-(1-pyrrolidino)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0324] The title compound (54 mg) was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate (188 mg), by the same procedure as in Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 1.68-1.74(4H, m), 2.58-2.65(4H, m), 2.93(2H, t, J=6.4 Hz), 3.72(3H, s), 4.40(2H, t, J=6.4 Hz), 6.53(1H, d, J=5.7 Hz), 6.88 (2H, d, J=9.1 Hz), 7.24 (2H, d, J=9.1 Hz), 7.37 (2H, d, J=9.1 Hz), 7.60 (2H, d, J=9.1 Hz), 7.62(1H, s), 8.52(1H, s), 8.73 (1H, d, J=5.7 Hz), 8.77 (2H, s)

Example 48N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0325] The title compound (45 mg) was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate (134 mg), by the same procedure as in Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 0.97(6H, t, J=7.8Hz), 1.88-1.96(2H, m), 2.43-2.53(4H, m), 2.61(2H, t, J=7.8 Hz), 3.72(3H, s), 4.33(2H, t, J=7.8 Hz), 6.53(1H, d, J=5.2 Hz), 6.88 (2H, d, J=8.8 Hz), 7.24 (2H, d, J=8.8 Hz), 7.38 (2H, d, J=8.8 Hz), 7.53-7.63(3H, m), 8.55(1H, s), 8.73 (1H, d, J=5.2 Hz), 8.76 (1H, s), 8.80(1H, s)

Example 49N-(4-(6-Cyano-7-(3-(dimethylamino)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0326] The title compound (35 mg) was obtained from sodium 6-cyano-4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-quinolinolate (100 mg), by the same procedure as in Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 1.94-2.01(2H, m), 2.43(2H, t, J=7.2 Hz), 2.50(6H, s), 4.33(2H, t, J=7.2 Hz), 6.64(1H, d, J=5.2 Hz), 7.04-7.46 (4H, m), 7.61 (1H, s), 8.09-8.34(2H, m), 8.74-8.78(2H, m), 9.06(1H, brs), 9.14 (1H, brs).

Example 50N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0327] The title compound (43 mg) was obtained from sodium 6-cyano-4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-quinolinolate (95 mg), by the same procedure as in Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 0.97(6H, t, J=7.8Hz), 1.88-1.98(2H, m), 2.45-2.52(4H, m), 2.61(2H, t, J=7.8 Hz), 4.33(2H, t, J=7.8 Hz), 6.63(1H, d, J=5.9 Hz), 7.03-7.45(4H, m), 7.60 (1H, s), 8.09-8.17(1H m), 8.28(1H, t, J=11.5Hz), 8.74-8.78 (2H, m), 9.03(1H, brs), 9.11(1H, brs).

Example 51N-(4-(6-Cyano-7-(4-(dimethylamino)butoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0328] N-(4-(6-Cyano-7-(4-chlorobutoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (120 mg) was dissolved in dimethylformamide (3 ml), and then a 50% dimethylamine solution (93 μl) was added and the mixture was heated and stirred at 70°C for 5 hours. The reaction solution was poured into saturated brine and extracted with ethyl acetate, and the organic layer was dried over magnesium sulfate and concentrated. The residue was passed through NH silica gel (Fuji Silysia Chemical) and eluted with a solvent (ethyl acetate), and then further eluted with another solvent (ethyl acetate:methanol = 10:1) and concentrated. The obtained solid was passed through Merck Silica Gel using tetrahydrofuran, and after eluting the insoluble portion with tetrahydrofuran and ethyl acetate, it was further eluted with solvents (tetrahydrofuran:methanol:triethylamine = 10:1:1, ethyl acetate:methanol:triethylamine = 10:1:1) and concentrated to obtain 10 mg of the title compound as a solid.

¹H-NMR(DMSO-d₆) δ(ppm): 1.71-1.78 (2H, m), 1.82-1.91 (2H, m), 2.42 (6H, s), 2.64-2.72 (2H, m), 3.72 (3H, s), 4.33 (2H, t, J=6.0 Hz), 6.54 (1H, d, J=5.2 Hz), 6.88 (2H, d, J=8.8 Hz), 7.23 (2H, d, J=8.8 Hz), 7.37 (2H, d, J=8.8 Hz), 7.60 (2H, d, J=8.8 Hz), 7.61 (1H, s), 8.64 (1H, brs), 8.73 (1H, d, J= 5.2 Hz), 8.78 (1H, s), 8.91 (1H, brs).

Example 52N-(4-(6-Cyano-7-(4-morpholinobutoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0329] The title compound (11 mg) was obtained from N-(4-(6-cyano-7-(4-chlorobutoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (110 mg), in the same manner as Example 51.

¹H-NMR(DMSO-d₆) δ(ppm): 1.65-1.77 (2H, m), 1.84-1.93 (2H, m), 2.32-2.48 (6H, m), 3.51-3.66 (4H, m), 3.72 (3H, s), 4.33 (2H, t, J=6.0 Hz), 6.53 (1H, d, J=4.8 Hz), 6.88 (2H, d, J=8.4 Hz), 7.24 (2H, d, J=8.4 Hz), 7.37 (2H, d, J=8.4 Hz), 7.60 (2H, d, J=8.4 Hz), 7.61 (1H, s), 8.57 (1H, brs), 8.73 (1H, d, J= 4.8 Hz), 8.78 (1H, s), 8.82 (1H, brs).

Example 53N-(4-(6-Cyano-7-(3-(1-(4-ethyl)piperazino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0330] The title compound (16 mg) was obtained from N-(4-(6-cyano-7-(3-chloropropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (150 mg), in the same manner as Example 51.

¹H-NMR(DMSO-d₆) δ(ppm): 0.98 (3H, t, J= 7.2Hz), 1.91-2.06 (2H, m), 2.26-2.48 (12H, m), 3.72 (3H, s), 4.33 (2H, t, J= 6.0 Hz), 6.53 (1H, d, J= 5.2 Hz), 6.88 (2H, d, J= 8.8 Hz), 7.23 (2H, d, J= 8.8 Hz), 7.37 (2H, d, J= 8.8 Hz), 7.59 (1H, s), 7.60 (2H, d, J= 8.8 Hz), 8.58 (1H, brs), 8.73 (1H, d, J= 5.2 HZ), 8.76 (1H, s), 8.83 (1H, brs).

Example 54N-(4-(6-Cyano-7-(2-(4-morpholino)ethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0331] The title compound (10 mg) was obtained from sodium 6-cyano-4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-quinolinolate (200 mg), by the same procedure as in Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.56 (4H, t, J= 4.4 Hz), 2.83 (2H, t, J= 5.6 Hz), 3.59 (4H, t, J= 4.4 Hz), 4.43 (2H, t, J= 5.6 Hz), 6.64 (1H, d, J=5.2 Hz), 7.04-7.10 (1H, m), 7.14-7.19 (1H, m), 7.30-7.36 (1H, m), 7.42 (1H, dd, J= 2.8 Hz, J= 12 Hz), 7.66 (1H, s), 8.10-8.16 (1H, m), 8.28 (1H, t, J= 9.2 HZ), 8.75 (1H, s), 8.76 (1H, d, J= 5.2 Hz), 9.02-9.05 (1H, m), 9.09-9.13 (1H, m).

Example 55N-(4-(6-Cyano-7-(3-cyanopropoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0332] The title compound (15 mg) was obtained from sodium 6-cyano-4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-quinolinolate (300 mg), in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.14-2.21 (2H, m), 2.73 (2H, t, J= 7.2 Hz), 4.38 (2H, t, J= 6.4 Hz), 6.65 (1H, d, J=5.2 Hz), 7.04-7.11 (1H, m), 7.15-7.19 (1H, m), 7.31-7.37 (1H, m), 7.43 (1H, dd, J= 2.8 Hz, J= 11.6 Hz), 7.67 (1H, s), 8.10-8.16 (1H, m), 8.29 (1H, t, J= 9.2 HZ), 8.77 (1H, d, J= 5.2 Hz), 8.79 (1H, s), 9.03-9.06 (1H, m), 9.11-9.14 (1H, m).

Example 56N-(4-(6-Cyano-7-(2-(methylthio)ethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0333] The title compound (95 mg) was obtained from sodium 6-cyano-4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-quinolinolate (130 mg), in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.25 (3H, s), 2.99 (2H, t, J= 6.0 Hz), 4.49 (2H, t, J= 6.0 Hz), 6.64 (1H, d, J=5.2 Hz), 7.04-7.11 (1H, m), 7.15-7.19 (1H, m), 7.30-7.37 (1H, m), 7.43 (1H, dd, J= 2.4 Hz, J= 11.6 Hz), 7.66 (1H, s), 8.09-8.17 (1H, m), 8.29 (1H, t, J= 9.2 Hz), 8.76 (1H, d, J= 5.2 Hz), 8.77 (1H, s), 9.01-9.05 (1H, m), 9.09-9.13 (1H, m).

Example 57N-(4-(6-Cyano-7-(2-(methylsulfonyl)ethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0334] N-(4-(6-Cyano-7-(2-(methylthio)ethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea (84 mg) was dissolved in a methanol (1 ml) and methylene chloride (5 ml) mixed solvent, 2 equivalents of meta-perbenzoic acid was added while stirring at 0°C, and the mixture was stirred for 30 minutes. The reaction solution was poured into

a saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate, and the organic layer was dried over magnesium sulfate and then concentrated. The residue was passed through NH silica gel (Fuji Silysia Chemical), eluted with a solvent (ethyl acetate:hexane = 10:1) and concentrated to obtain 21 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 3.02 (3H, s), 3.79 (2H, t, J= 4.8 Hz), 4.67 (2H, t, J= 4.8 Hz), 6.67 (1H, d, J=5.2 Hz), 7.04-7.10 (1H, m), 7.15-7.19 (1H, m), 7.31-7.34 (1H, m), 7.43 (1H, dd, J= 2.8 Hz, J= 12 Hz), 7.73 (1H, s), 8.10-8.16 (1H, m), 8.28 (1H, t, J= 9.2 Hz), 8.79 (1H, d, J= 5.2 Hz), 8.81 (1H, s), 9.02-9.05 (1H, m), 9.11-9.14 (1H, m).

Example 58

N-(4-(6-Cyano-7-(2-(methylthio)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0335] The title compound (112 mg) was obtained from sodium 6-cyano-4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-quinolinolate (300 mg), in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.25 (3H, s), 2.99 (2H, t, J= 6.0 Hz), 4.49 (2H, t, J= 6.0 Hz), 6.54 (1H, d, J=5.2 Hz), 7.13 (2H, t, J= 8.8 Hz), 7.25 (2H, d, J= 8.8 Hz), 7.46-7.51 (2H, m), 7.61 (2H, d, J= 8.8 Hz), 7.65 (1H, s), 8.74 (1H, d, J= 5.2 Hz), 8.78 (1H, s), 8.82 (1H, brs), 8.91 (1H, brs).

Example 59

N-(4-(6-Cyano-7-(2-(methylsulfonyl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0336] The title compound (11 mg) was obtained from N-(4-(6-cyano-7-(2-(methylthio)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (100 mg), in the same manner as Example 56.

¹H-NMR(DMSO-d₆) δ(ppm): 3.20 (3H, s), 3.79 (2H, t, J= 5.6 Hz), 4.69 (2H, t, J= 5.6 Hz), 6.57 (1H, d, J=5.2 Hz), 7.13 (2H, t, J= 8.8 Hz), 7.25 (2H, d, J= 8.8 Hz), 7.46-7.52 (2H, m), 7.62 (2H, d, J= 8.8 Hz), 7.72 (1H, s), 8.76 (1H, d, J= 5.2 Hz), 8.82 (1H, s), 8.90 (1H, brs), 8.99 (1H, brs).

Example 60

N-(4-(6-Chloro-5,7-dimethoxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0337] The title compound (173 mg) was obtained from 4-(4-amino-3-fluorophenoxy)-6-chloro-5,7-dimethoxyquinoline (235 mg) and 2,4-difluorophenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.93 (3H, s), 4.07 (3H, s), 6.67 (1H, d, J= 5.2 Hz), 6.91-6.96 (1H, m), 7.00 (1H, s), 7.03-7.09 (1H, m), 7.20 (1H, dd, J= 2.8 Hz, J= 8.0 Hz), 7.30-7.37 (1H, m), 8.08-8.20 (2H, m), 8.69 (1H, d, J= 5.2 Hz), 9.01 (1H, brd, J= 2.0 Hz), 9.04 (1H, brd, J= 2.0 Hz).

Example 61

N-(4-(6-Cyano-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0338] The title compound (130 mg) was obtained from 4-(4-amino-3-fluorophenoxy)-6-cyano-7-methoxyquinoline (238 mg) and 2,4-difluorophenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 4.08 (3H, s), 6.64 (1H, d, J= 5.2 Hz), 7.04-7.10 (1H, m), 7.15-7.19 (1H, m), 7.31-7.37 (1H, m), 7.43 (1H, dd, J= 2.8 Hz, J= 12 Hz), 7.63 (1H, s), 8.13 (1H, dt, J= 6.4 Hz, J= 9.2 Hz), 8.29 (1H, t, J= 9.2 Hz), 8.77 (1H, d, J= 5.2 Hz), 8.78 (1H, s), 9.05 (1H, brs), 9.13 (1H, brs).

Example 62

N-(4-(6-Cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0339] The title compound (55 mg) was obtained from 4-amino(4-aminophenoxy)-6-cyano-7-methoxyquinoline (170 mg) and 4-methoxyphenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.72 (3H, s), 4.07 (3H, s), 6.54 (1H, d, J= 5.2 Hz), 6.88 (2H, d, J= 8.8 Hz), 7.24 (2H, d, J= 8.8 Hz), 7.37 (2H, d, J= 8.8 Hz), 7.60 (2H, d, J= 8.8 Hz), 7.61 (1H, s), 8.62 (1H, brs), 8.74 (1H, d, J= 5.2 Hz), 8.78 (1H, s), 8.87 (1H, brs).

Example 63N-(4-(6-Cyano-7-(2-(4-morpholino)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0340] The title compound was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate, in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.50-2.55 (4H, m), 2.87 (2H, t, J= 5.6 Hz), 3.57 (4H, t, J= 4.4 Hz), 3.60 (3H, s), 4.38 (2H, t, J= 5.6 Hz), 6.85 (2H, d, J= 8.8 Hz), 7.02 (1H, s), 7.06 (1H, d, J= 5.2 Hz), 7.21 (2H, d, J= 8.8 Hz), 7.36 (2H, d, J= 8.8 Hz), 7.58 (2H, d, J= 8.8 Hz), 8.65 (1H, s), 8.68 (1H, brs), 8.73 (1H, d, J= 5.2 Hz), 8.92 (1H, brs)

Example 64N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclohexylurea

[0341] The title compound (25 mg) was obtained from 4-(4-aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (60 mg) and cyclohexyl isocyanate, in the same manner as Example 10.

¹H-NMR (DMSO-d₆) δ(ppm) : 1.12-1.24 (3H, m), 1.26-1.38 (2H, m), 1.51-1.59 (1H, m), 1.63-1.72 (2H, m), 1.78-1.86 (2H, m), 3.38 (3H, s), 3.42-3.52 (1H, m), 3.78-3.80 (2H, m), 4.42-4.44 (2H, m), 6.18 (1H, brd, J= 8.0 Hz), 6.50 (1H, d, J= 5.2 Hz), 7.18 (2H, d, J= 9.2 Hz), 7.53 (2H, d, J= 9.2 Hz), 7.63 (1H, s), 8.55 (1H, brs), 8.72 (1H, d, J= 5.2 Hz), 8.77 (1H, s).

Example 65N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-phenylurea

[0342] 4-(4-Aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (600 mg) was suspended in toluene (15 ml), and the suspension was heated to reflux for dissolution, after which phenyl isocyanate (292 μl) was added dropwise and the mixture was heated to reflux for 30 minutes. After cooling, the precipitated solid was filtered out, washed with ether and ethyl acetate and dried to obtain 760 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 3.38 (3H, s), 3.78-3.81 (2H, m), 4.42-4.45 (2H, m), 6.54 (1H, d, J= 5.2 Hz), 6.98 (1H, t, J= 7.2 Hz), 7.24-7.31 (4H, m), 7.47 (2H, d, J= 7.2 Hz), 7.62 (2H, d, J= 8.8 Hz), 7.64 (1H, s), 8.74 (1H, d, J= 5.2 Hz), 8.79 (1H, s), 8.85 (1H, brs), 8.99 (1H, brs).

Example 66N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

[0343] 4-(4-Amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (352 mg) was suspended in toluene (20 ml) and the suspension was heated to reflux for dissolution, after which 2,4-difluorophenyl isocyanate (236 μl) was added dropwise and the mixture was heated to reflux for 30 minutes. After cooling, the precipitated solid was filtered out, washed with ether and ethyl acetate and dried to obtain 380 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm) : 3.38 (3H, s), 3.78-3.81 (2H, m), 4.42-4.46 (2H, m), 6.64 (1H, d, J= 5.2 Hz), 7.04-7.11 (1H, m), 7.15-7.19 (1H, m), 7.31-7.37 (1H, m), 7.43 (1H, dd, J= 2.8 Hz, J= 8.0 Hz), 7.66 (1H, s), 8.13 (1H, dt, J= 6 Hz, J= 9.2 Hz), 8.28 (1H, t, J= 9.2 Hz), 8.76 (1H, d, J= 5.2 Hz), 8.77 (1H, s), 9.05 (1H, brs), 9.13 (1H, brs).

Example 67N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(methoxyphenyl)urea

[0344] The title compound (570 mg) was obtained from 4-(4-amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (620 mg) and 4-methoxyphenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.38 (3H, s), 3.73 (3H, s), 3.78-3.81 (2H, m), 4.43-4.45 (2H, m), 6.63 (1H, d, J= 5.2 Hz), 6.89 (2H, d, J= 8.8 Hz), 7.13-7.17 (1H, m), 7.37 (2H, d, J= 8.8 Hz), 7.41 (1H, dd, J= 2.8 Hz, J= 11.6 Hz), 7.65 (1H, s), 8.28 (1H, t, J= 8.8 Hz), 8.60 (1H, brs), 8.76 (1H, d, J= 5.2 Hz), 8.77 (1H, s), 8.94 (1H, brs).

Example 68N-(4-(6-Cyano-7-(methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0345] The title compound (450 mg) was obtained from 4-(4-aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (890 mg) and 4-methoxyphenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.70 (3H, s), 3.76-3.79 (2H, m), 4.40-4.42 (2H, m), 6.51 (1H, d, J= 5.6 Hz), 6.86 (2H, d, J= 8.8 Hz), 7.22 (2H, d, J= 8.8 Hz), 7.35 (2H, d, J= 8.8 Hz), 7.58 (2H, d, J= 8.8 Hz), 7.62 (1H, s), 8.53 (1H, brs), 8.71 (1H, d, J= 5.6 Hz), 8.76 (1H, s), 8.80 (1H, brs).

Example 69N-((4-Pyrimidyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0346] Palladium hydroxide (20 mg) was added to solution of 6-chloro-4-(4-nitrophenoxy)pyrimidine (300 mg) in an ethyl acetate (10 ml)-methanol (10 ml) mixed solvent, and the mixture was stirred for 13 hours at room temperature under a hydrogen atmosphere at normal pressure. The reaction solution was filtered, the filtrate was concentrated, and the residue was passed through NH silica gel (Fuji Silysia Chemical). Elution was performed with a solvent (ethyl acetate:hexane = 1:2) to obtain 70 mg of 4-(4-aminophenoxy)pyrimidine. The title compound (107 mg) was obtained from the obtained 4-(4-aminophenoxy)pyrimidine (70 mg) and 4-methoxyphenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.72 (3H, s), 6.87 (2H, d, J= 8.8 Hz), 7.09 (1H, dd, J= 1.6 Hz, J= 5.6 Hz), 7.12 (2H, d, J= 8.8 Hz), 7.36 (2H, d, J= 8.8 Hz), 7.51 (2H, d, J= 8.8 Hz), 8.56 (1H, s), 8.66 (1H, d, J= 5.6 Hz), 8.74-8.76 (2H, m).

Example 70N-(4-(6-Cyano-7-(3-methoxycarbonylpropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0347] The title compound was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate, in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.09 (2H, tt, J= 6.4 Hz, J= 6.4 Hz), 2.56 (2H, t, J= 6.4 Hz), 3.62 (3H, s), 3.71 (3H, s), 4.31 (2H, t, J= 6.4 Hz), 6.52 (1H, d, J= 5.2 Hz), 6.86 (2H, d, J= 8.8 Hz), 7.22 (2H, d, J= 8.8 Hz), 7.35 (2H, d, J= 8.8 Hz), 7.57 (2H, d, J= 8.8 Hz), 7.59 (1H, s), 8.50 (1H, s), 8.72 (1H, d, J= 5.2 Hz), 8.74 (1H, s), 8.75 (1H, s).

Example 71N-(4-(6-Cyano-7-(3-carboxypropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0348] N-(4-(6-Cyano-7-(3-methoxycarbonylpropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (100 mg) was added to a methanol (16 ml) and 2N aqueous sodium hydroxide (3 ml) mixed solvent, and the mixture was heated and stirred at 80°C for 35 minutes. The reaction solution was filtered, and then 1.2 ml of aqueous 5N hydrochloric acid was added. The precipitated solid was filtered out and washed with methanol and then ether to obtain 50 mg of the target substance as a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 2.05 (2H, tt, J= 6.4 Hz, J= 6.4 Hz), 2.47 (2H, t, J= 6.4 Hz), 3.70 (3H, s), 4.31 (2H, t, J= 6.4 Hz), 6.52 (1H, d, J= 5.2 Hz), 6.86 (2H, d, J= 8.8 Hz), 7.22 (2H, d, J= 8.8 Hz), 7.35 (2H, d, J= 8.8 Hz), 7.57 (2H, d, J= 8.8 Hz), 7.59 (1H, s), 8.50 (1H, s), 8.71 (1H, d, J= 5.2 Hz), 8.75 (1H, s), 8.76 (1H, s).

Example 72N-(4-(6-Cyano-7-(2-(2-hydroxyethoxy)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0349] The title compound was obtained from sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl)aminophenoxy)-7-quinolinolate, in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 3.54-3.57 (4H, m), 3.72 (3H, s), 3.87-3.90 (2H, m), 4.41-4.45 (2H, m), 4.62-4.65 (1H, m), 6.54 (1H, d, J=5.2 Hz), 6.87 (2H, d, J=8.8 Hz), 7.24 (2H, d, J=8.8 Hz), 7.38 (2H, d, J=8.8 Hz), 7.60 (2H, d, J=8.8 Hz), 7.64 (1H, s), 8.62 (1H, brs), 8.74 (1H, d, J= 5.2 Hz), 8.78 (1H, s), 8.87 (1H, brs).

Example 73N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyloxy)phenyl)-N'-(3-(methylsulfonyl)phenyl)urea

[0350] The title compound (8.8 mg, 0.015 mmol, 6.0%) was obtained as light brown crystals from N-4-((6-cyano-7-hydroxy-4-quinolyl)oxy)phenyl-N'-(3-(methylsulfonyl)phenyl)urea (119 mg, 0.25 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.95 (6H, t, J=7.2Hz), 1.87-1.95 (2H, m), 2.40-2.70 (6H, m), 3.18 (3H, s), 4.29-4.33 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.25 (2H, d, J=8.8Hz), 7.49-7.68 (6H, m), 8.16 (1H, brs), 8.71 (1H, d, J=5.2Hz), 8.75 (1H, s), 9.02 (1H, brs), 9.21 (1H, brs).

Example 74N-(4-(6-Cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfonyl)phenyl)urea

[0351] The title compound (81 mg, 0.135 mmol, 53.7%) was obtained as light yellow crystals from N-4-((6-cyano-7-hydroxy-4-quinolyl)oxy)phenyl-N'-(3-(methylsulfonyl)phenyl)urea (119 mg, 0.25 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.95-2.04 (2H, m), 2.34-2.60 (6H, m), 3.18 (3H, s), 3.54-3.60 (4H, m), 4.30-4.36 (2H, m), 6.52 (1H, d, J=5.2Hz), 7.25 (2H, d, J=8.8Hz), 7.50-7.68 (6H, m), 8.16 (1H, s), 8.72 (1H, d, J=5.2Hz), 8.75 (1H, s), 8.95 (1H, s), 9.15 (1H, s).

Example 75N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyloxy)phenyl)-N'-phenylurea

[0352] The title compound (70 mg, 0.137 mmol, 27.5%) was obtained as light brown crystals from sodium 4-(4-((anilino)carbonyl) amino)phenoxy)-6-cyano-7-quinolinolate (210 mg, 0.50 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.95 (6H, t, J=7.2Hz), 1.85-1.95 (2H, m), 2.40-2.55 (4H, m), 2.60 (2H, t, J=6.8Hz), 4.31 (2H, t, J=6.0Hz), 6.51 (1H, d, J=5.2Hz), 6.96 (1H, m), 7.22-7.30 (4H, m), 7.45 (2H, d, J=8.0Hz), 7.56-7.61 (3H, m), 8.70-8.72 (2H, m), 8.75 (1H, s), 8.84 (1H, s).

Example 76N-(4-(6-Cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-phenylurea

[0353] The title compound (67 mg, 0.128 mmol, 51.0%) was obtained as light yellow crystals from sodium 4-(4-((anilino)carbonyl) amino)phenoxy)-6-cyano-7-quinolinolate (105 mg, 0.25 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.92-2.02 (2H, m), 2.35-2.57 (6H, m), 3.55-3.57 (4H, m), 4.30-4.34 (2H, m), 6.51 (1H, d, J=5.6Hz), 6.96 (1H, t, J=7.2Hz), 7.22-7.30 (4H, m), 7.45 (2H, d, J=7.6Hz), 7.58-7.61 (3H, m), 8.69-8.72 (2H, m), 8.75 (1H, s), 8.83 (1H, s).

Example 77N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(1H-[d]imidazol-2-yl)urea

[0354] The title compound (71 mg, 0.14 mmol, 64.7%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (101 mg, 0.222 mmol), by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.79 (2H, m), 4.40-4.43 (2H, m), 6.54 (1H, d, J=5.2Hz), 7.04-7.07 (2H, m), 7.26 (2H, d, J=8.8Hz), 7.34-7.37 (2H, m), 7.62 (1H, s), 7.73 (2H, d, J=8.8Hz), 8.72 (1H, d, J=5.2Hz), 8.77 (1H, s).

Example 78N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-oxo-1,2,3,4-tetrahydro-6-quinoliny)urea

[0355] The title compound (70 mg, 0.134 mmol, 60.9%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.38-2.43 (2H, m), 2.81-2.85 (2H, m), 3.36 (3H, s), 3.75-3.79 (2H, m), 4.40-4.43 (2H, m), 6.51 (1H, d, J=5.2Hz), 6.76 (1H, d, J=8.4Hz), 7.16 (1H, dd, J=2.0, 8.4Hz), 7.22 (2H, dd, J=8.8Hz), 7.30 (1H, s), 7.58 (2H, d, J=8.8Hz), 7.62 (1H, s), 8.52 (1H, s), 8.71 (1H, d, J=5.2Hz), 8.75 (2H, s), 9.95 (1H, s).

5 Example 79

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-acetamidephenyl)urea

10 **[0356]** The title compound (100 mg, 0.197 mmol, 89.6%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.00 (3H, s), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 7.23 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.8Hz), 7.46 (2H, d, J=8.8Hz), 7.58 (2H, d, J=8.8Hz), 7.62 (1H, s), 8.59 (1H, s), 8.72 (1H, d, J=5.2Hz), 8.76 (1H, s), 8.77 (1H, s), 9.80 (1H, s).

15 Example 80

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-acetamidephenyl)urea

20 **[0357]** The title compound (95 mg, 0.186 mmol, 84.9%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.02 (3H, s), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.6Hz), 7.15-7.20 (3H, m), 7.23 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.8Hz), 7.62 (1H, s), 7.76 (1H, s), 8.71-8.76 (4H, m), 9.90 (1H, s).

25 Example 81

N-(4-(6-Cyano-7-benzyloxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea

30 **[0358]** N-(2,4-Difluorophenyl)-N'-(2-fluoro-4-hydroxyphenyl)urea (227 mg, 0.8058 mmol) and 4-chloro-6-cyano-7-benzyloxyquinoline (250 mmol, 0.8482 mmol) were used for reaction in the same manner as the second method in Example 86, and after cooling, extraction and washing with water, the solvent was distilled off under reduced pressure and the obtained crystals were suspended in diethyl ether, washed and filtered. They were then dissolved in tetrahydrofuran and filtered with silica gel, and the solvent was distilled off under reduced pressure. These crystals were then suspended in diethyl ether, washed with water and filtered, and then washed with diethyl ether and dried by aspiration to obtain the title compound (70 mg, 0.1295 mmol, 16.07%) as light brown crystals.
35 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 5.45 (2H, s), 6.63 (1H, d, J = 5.4 Hz), 7.05 (1H, m), 7.15 (1H, m), 7.29-7.46 (5H, m), 7.54 (2H, d, J = 7.6 Hz), 7.71 (1H, s), 8.11 (1H, dt, J = 6.0 Hz, 9.2 Hz), 8.27 (1H, d, J = 9.2 Hz), 8.74 (1H, d, J = 5.4 Hz), 8.77 (1H, s), 8.99 (1H, s), 9.07 (1H, s).

40 Example 82

N-(4-(7-(Benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-(2-thiazolyl)urea

45 **[0359]** The title compound (3.19 g, 6.46 mmol, 91%) was obtained as light brown crystals from 4-(4-aminophenoxy)-7-(benzyloxy)-6-cyanoquinoline (2.61 g, 7.10 mmol) and phenyl N-(2-thiazolyl)carbamate (1.88 g, 8.54 mmol), by the same procedure as in Example 34. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 5.47 (2H, s), 6.55 (1H, d, J = 5.3 Hz), 7.12 (1H, d, J = 3.5 Hz), 7.29 (2H, d, J = 8.7 Hz), 7.36-7.58 (6H, m), 7.65 (2H, d, J = 8.7Hz), 7.72 (1H, s), 8.74 (1H, d, J = 5.3 Hz), 8.80 (1H, s), 9.18 (1H, s).

50 Example 83

N-(4-(6-Cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(2-thiazolyl)urea

55 **[0360]** The N-(4-(7-(benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-(2-thiazole)urea (3.09 g, 7.66 mmol) obtained in Example 82 was dissolved in trifluoroacetic acid (25 ml) and thioanisole (4.50 ml, 38.3 mmol), and the mixture was stirred at 65°C for 15 hours. The reaction solution was concentrated under reduced pressure, and then a 5% aqueous sodium bicarbonate solution and diethyl ether were added to the resulting residue, the mixture was stirred, and the crystals were filtered out and washed with water and diethyl ether and then dried under reduced pressure. The crude

product was suspended in a hexane-ethyl acetate mixed solvent and subjected to sonication, after which the crystals were filtered, washed with diethyl ether and blow-dried at room temperature to obtain the title compound (1.94 g, 4.80 mmol, 63%) as yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 6.44 (1H, d, J = 5.2 Hz), 7.12 (1H, d, J = 3.7 Hz), 7.28 (2H, d, J = 7.8 Hz), 7.39 (1H, d, J = 3.7 Hz), 7.42 (1H, s), 7.64 (2H, d, J = 7.8 Hz), 8.65 (1H, d, J = 5.2 Hz), 8.68 (1H, s), 9.14 (1H, s).

Example 84

N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyloxy)phenyl)-N'-(2-thiazolyl)urea

[0361] The title compound (26 mg, 0.0503 mmol, 20%) was obtained as colorless crystals from the N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(2-thiazolyl)urea (101 mg, 0.250 mmol) obtained in Example 83, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 1.05 (6H, t, J = 7.2 Hz), 2.03-2.12 (2H, m), 2.58 (4H, q, J = 7.2 Hz), 2.71 (2H, t, J = 7.0 Hz), 4.28 (2H, t, J = 6.2 Hz), 6.47 (1H, d, J = 5.3 Hz), 6.92 (1H, d, J = 3.7 Hz), 7.17 (2H, d, J = 8.8 Hz), 7.43 (1H, d, J = 3.7 Hz), 7.47 (1H, s), 7.67 (2H, d, J = 8.8 Hz), 8.65 (1H, d, J = 5.3 Hz), 8.67 (1H, s).

Example 85

N-(4-(6-Cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(2-thiazolyl)urea

[0362] The title compound (19 mg, 0.0358 mmol, 14%) was obtained as colorless crystals from the N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(2-thiazolyl)urea (101 mg, 0.250 mmol) obtained in Example 83, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 2.08-2.16 (2H, m), 2.46-2.52 (4H, m), 2.62 (2H, t, J = 7.0 Hz), 3.70-3.76 (4H, m), 4.30 (2H, t, J = 6.2 Hz), 6.47 (1H, d, J = 5.3 Hz), 6.92 (1H, d, J = 3.7 Hz), 7.17 (2H, d, J = 8.8 Hz), 7.42 (1H, d, J = 3.7 Hz), 7.48 (1H, s), 7.67 (2H, d, J = 8.8 Hz), 8.66 (1H, d, J = 5.3 Hz), 8.69 (1H, s).

Example 86

N-(4-(6-Cyano-7-benzyloxy-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0363] After adding toluene (60 ml) and acetonitrile (30 ml) to 4-amino(4-aminophenoxy)-7-(benzyloxy)-6-cyanoquinoline (1.0 g) and refluxing the mixture to dissolution, 4-methoxyphenyl isocyanate (0.53 ml) was added while continuing reflux. After stirring for 1 hour with reflux, additional 4-methoxyphenyl isocyanate (0.30 ml) was added. This was further stirred for 40 minutes with reflux and returned to room temperature. The precipitated crystals were filtered out and washed with a mixed solvent of toluene:acetonitrile = 1:1 to obtain the title compound (0.60 g) as light brown crystals. The crystals which precipitated from the washing solution were filtered out to obtain more of the title compound (0.20 g) as light brown crystals.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 3.73 (3H, s), 5.98 (2H, s), 6.56 (1H, d, J=5.2Hz), 6.89 (2H, d, J=9.3Hz), 7.24 (2H, d, J=9.3Hz), 7.33-7.65 (9H, m), 7.72 (1H, s), 8.74 (1H, d, J=5.2Hz), 8.82 (1H, s), 8.89 (1H, brs), 9.19 (1H, brs).

Example 86-2

N-(4-(6-Cyano-7-benzyloxy-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0364] After adding 1-methylpyrrolidone (3.4 ml) and diisopropylethylamine (3.6 ml, 20.78 mmol) to N-(4-hydroxyphenyl)-N'-(4-methoxyphenyl)urea (4.25 g, 16.46 mmol), the mixture was heated and stirred at 130°C to complete dissolution, and then 4-chloro-6-cyano-7-benzyloxyquinoline (5.10 g, 17.32 mmol) was added and the mixture was stirred at 130°C for 1.5 hours and at 150°C for 1 hour. Upon addition of diisopropylethylamine (1.2 ml, 6.93 mmol), the mixture was further stirred for 1 hour. After cooling and adding tetrahydrofuran and ethyl acetate, the mixture was washed with saturated sodium bicarbonate water and saturated brine and dried over magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained crystals were washed with diethyl ether/hexane, acetonitrile/diethyl ether/hexane, methanol and dimethylsulfoxide/water, in that order. The obtained crystals were dissolved in tetrahydrofuran, filtered with silica gel (200 cc silica gel) and flushed with 3000 ml of tetrahydrofuran, and the solvent was distilled off under reduced pressure. The crystals were then washed with diethyl ether, acetonitrile and diethyl ether:ethanol = 5:1 and dried by aspiration to obtain the title compound (3.70 g, 7.1627 mmol, 43.52%) as brown crystals.

Example 87Sodium 6-cyano-4-(4-((4-methoxyanilino)carbonyl) aminophenoxy)-7-quinolinolate

[0365] Trifluoroacetic acid (122 ml) and thioanisole (11.7 ml) were added to N-(4-(6-cyano-7-benzyloxy-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (12.2 g), and the mixture was stirred at 50°C overnight and at 40°C for 24 hours. Upon confirming disappearance of the starting materials, the reaction system was concentrated under reduced pressure, tetrahydrofuran and saturated sodium bicarbonate water were added, and the precipitated yellow crystals were filtered and dried under reduced pressure to obtain the title compound (6.8 g). Ether was further added to the filtrate and the precipitated yellow crystals were filtered out and dried under reduced pressure to obtain more of the title compound (2.0 g).

¹H-NMR Spectrum (CDCl₃) δ(ppm): 3.72 (3H, s), 6.56 (1H, d, J=6.1Hz), 6.88 (2H, d, J=8.7Hz), 7.23 (2H, d, J=8.7Hz), 7.37 (2H, d, J=8.7Hz), 7.44 (1H, s), 7.60 (2H, d, J=8.7Hz), 8.57 (1H, s), 8.67 (1H, d, J=6.1Hz), 8.70 (1H, s), 8.82 (1H, s).

Example 88Sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl) aminophenoxy)-7-quinolinolate

[0366] 4-(4-Aminophenoxy)-7-(benzyloxy)-6-cyanoquinoline (7.776 g, 21.2 mmol) was dissolved in a toluene (400 ml) and acetonitrile (200 ml) mixed solvent, and then 4-fluorophenyl isocyanate (3.68 ml, 31.7 mmol) was added and the mixture was heated to reflux at 120°C for 1 hour. The reaction solution was concentrated under reduced pressure, the residue was suspended in tetrahydrofuran (150 ml), and then hexane (150 ml) was added, sonication was performed, and the precipitated crystals were filtered out and dried under reduced pressure to obtain N-(4-(7-(benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (9.81 g, 19.4 mmol, 91.9%) as light brown crystals. These were dissolved in trifluoroacetic acid (100 ml) and thioanisole (9.13 ml, 77.7 mmol) under a nitrogen atmosphere, and the solution was stirred at 60°C for 12 hours. The reaction solution was concentrated under reduced pressure, and after adding tetrahydrofuran (50 ml) and then 1N aqueous sodium hydroxide (150 ml) and water (150 ml) to the residue, the mixture was stirred and the precipitated crystals were filtered out and washed with water, diethyl ether and ethyl acetate and dried at 70°C to obtain the title compound (3.646 g, 8.36 mmol, 43.0%) as yellow crystals.

negative ESI-MS 413 (M-Na)⁻

Example 89Sodium 6-cyano-4-(4-(2,4-difluoroanilino)carbonyl) amino-3-fluorophenoxy)-7-quinolinolate

[0367] A mixture of the 7-benzyloxy compound (1.1 g) obtained in Example 81, trifluoroacetic acid (10 ml) and thioanisole (1 ml) was heated and stirred in an oil bath at 63-67°C for 16 hours. After completion of the reaction, the reaction solution was concentrated, a saturated aqueous sodium bicarbonate solution was added, and the precipitated solid was filtered out. The obtained solid was washed with water, ether and ethyl acetate and dried to obtain the title compound in a quantitative amount.

¹H-NMR(DMSO-d₆) δ(ppm): 6.54 (1H, d, J=5.6 Hz), 7.04-7.10 (1H, m), 7.14-7.17 (1H, m), 7.31-7.36 (1H, m), 7.40 (1H, dd, J=2.8 Hz, J=12 Hz), 7.44 (1H, s), 8.10-8.16 (1H, m), 8.27 (1H, t, J= 8.8 HZ), 8.67 (1H, s), 8.68 (1H, d, J= 5.2 Hz), 8.99-9.03(1H, m), 9.07-9.11(1H, m).

Example 90N-(4-(6-Cyano-7-(2-chloroethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0368] N-(4-(6-Cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (400 mg, 0.9166 mmol) was dissolved in dimethylformamide (5.0 ml), and then 1-bromo-2-chloroethane (0.12 ml, 1.4479 mmol) and potassium carbonate (200 mg, 1.4479 mmol) were added and the mixture was heated and stirred at 55°C for 4 hours. After cooling, tetrahydrofuran and ethyl acetate were added, the mixture was washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was subjected to NH silica gel column chromatography (ethyl acetate-methanol system). The obtained crystals were suspended in diethyl ether, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (331 mg, 0.6941 mmol, 75.72%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.07 (2H, t, J = 5.2 Hz), 4.59 (2H, t, J = 5.2 Hz), 6.54 (1H, d, J = 5.6 Hz), 7.12 (2H, t, J = 9.0 Hz), 7.24 (2H, d, J = 9.0 Hz), 7.44-7.48 (2H, m), 7.59 (2H, d, J = 9.0 Hz), 7.65 (1H, s), 8.72 (1H, s), 8.73

(1H, d, J = 5.6 Hz), 8.78 (1H, s), 8.82 (1H, s).

Example 91

5 N-(4-(6-Cyano-7-(2-chloroethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0369] The title compound (501 mg, 1.0247 mmol, 87.39%) was obtained as yellow crystals from N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (500 mg, 1.1725 mmol), in the same manner as Example 90.

10 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.70 (3H, s), 4.06 (2H, t, J = 5.0 Hz), 4.59 (2H, t, J = 5.0 Hz), 6.53 (1H, d, J = 5.6 Hz), 6.86 (2H, d, J = 9.2 Hz), 7.22 (2H, d, J = 9.2 Hz), 7.35 (2H, d, J = 9.2 Hz), 7.58 (2H, d, J = 9.2 Hz), 7.65 (1H, s), 8.55 (1H, m), 8.73 (1H, d, J = 5.6 Hz), 8.78 (1H, m), 8.88 (1H, s).

Example 92

15 N-(4-(6-Cyano-7-(2-chloroethoxy)-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea

[0370] The title compound (227 mg, 0.4426 mmol, 66.45%) was obtained as light yellow crystals from N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea (300 mg, 0.6661 mmol), in the same manner as Example 90.

20 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.07 (2H, t, J = 5.0 Hz), 4.59 (2H, t, J = 5.0 Hz), 6.64 (1H, d, J = 5.4 Hz), 7.06 (1H, m), 7.16 (1H, m), 7.32 (1H, ddd, J = 2.8 Hz, 8.8 Hz, 11.6 Hz), 7.41 (1H, dd, J = 2.8 Hz, 11.6 Hz), 7.67 (1H, s), 7.93 (1H, s), 8.12 (1H, m), 8.27 (1H, dt, J = 4.0 Hz, 9.2 Hz), 8.76 (1H, d, J = 5.4 Hz), 8.77 (1H, s), 8.97-9.09 (1H, m).

25 Example 93

N-(4-(6-Cyano-7-(4-chlorobutoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0371] N-(4-(6-Cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (200 mg), potassium carbonate (65 mg) and 1-bromo-4-chlorobutane (81 μl) were suspended in dimethylformamide (3 ml), and the suspension was heated and stirred for 1 hour and 50 minutes. The reaction solution was poured into saturated brine and extracted with ethyl acetate. After drying the organic layer over magnesium sulfate, it was passed through NH silica (Fuji Silysia Chemical) and washed in ethyl acetate, and the filtrate was concentrated. The obtained solid was washed with ether and dried to obtain 110 mg of the title compound.

35 ¹H-NMR(DMSO-d₆) δ(ppm): 1.96-2.00 (4H, m), 3.72 (3H, s), 3.77-3.80 (2H, m), 4.33-4.37 (2H, m), 6.53 (1H, d, J=5.2 Hz), 6.88 (2H, d, J=8.8 Hz), 7.23 (2H, d, J=8.8 Hz), 7.38 (2H, d, J=8.8 Hz), 7.60 (2H, d, J=8.8 Hz), 7.62 (1H, s), 8.65 (1H, brs), 8.73 (1H, d, J= 5.2 HZ), 8.77 (1H, s), 8.90 (1H, brs).

Example 94

40 N-(4-(6-Cyano-7-(3-chloropropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea

[0372] The title compound (310 mg) was obtained from N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea (500 mg) and 1-chloro-3-iodopropane (188μl), by the same procedure as in Example 93.

45 ¹H-NMR(DMSO-d₆) δ(ppm): 2.28-2.35 (2H, m), 3.72 (3H, s), 3.86-3.90 (2H, m), 4.41-4.45 (2H, m), 6.54 (1H, d, J=5.2 Hz), 6.88 (2H, d, J=8.8 Hz), 7.24 (2H, d, J=8.8 Hz), 7.38 (2H, d, J=8.8 Hz), 7.61 (2H, d, J=8.8 Hz), 7.65 (1H, s), 8.66 (1H, brs), 8.74 (1H, d, J= 5.2 HZ) , 8.79 (1H, s), 8.91 (1H, brs).

Example 95

50 N-(4-(7-(Benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfonyl)phenyl)urea

[0373] After dissolving 4-(4-aminophenoxy)-7-(benzyloxy)-6-cyanoquinoline (919 mg, 2.5 mmol) in dimethylsulfoxide (10 ml), phenyl N-(3-(methylsulfonyl)phenyl)carbamate (801 mg, 2.75 mmol) was added and the mixture was heated at 85°C for 2 hours. The reaction solution was diluted with ethyl acetate and then washed with 1N aqueous sodium hydroxide (10 ml), water (20 ml x 2) and saturated brine (10 ml) and dried over anhydrous sodium sulfate. After filtering off the drying agent, the filtrate was concentrated under reduced pressure and the residue was suspended in ethyl acetate (30 ml), after which hexane (30 ml) was added, sonication was performed and the precipitated crystals were

filtered out and dried under reduced pressure to obtain the title compound (1.43 g, 2.5 mmol, quantitative) as light brown crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.18 (3H, s), 5.44 (2H, s), 6.53 (1H, d, J=5.2Hz), 7.24 (2H, d, J=8.8Hz), 7.37 (1H, d, J=8.0Hz), 7.44 (2H, t, J=7.2Hz), 7.45-7.69 (8H, m), 8.16 (1H, s), 8.71 (1H, d, J=5.2Hz), 8.78 (1H, s), 9.12 (1H, s), 9.31 (1H, s).

Example 96

N-(4-(7-(Benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-phenylurea

[0374] The title compound (1.126 g, 2.3 mmol, 92.5%) was obtained as light brown crystals from 4-(4-aminophenoxy)-7-(benzyloxy)-6-cyanoquinoline (919 mg, 2.5 mmol) and phenyl isocyanate (0.298 ml, 2.75 mmol), by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 5.45 (2H, s), 6.53 (1H, dd, J=1.6, 5.2Hz), 6.96 (1H, dd, J=6.0, 7.2Hz), 7.23 (2H, d, J=7.6Hz), 7.27 (2H, dd, J=7.2, 7.6Hz), 7.37 (1H, d, J=7.2Hz), 7.42-7.47 (4H, m), 7.54 (2H, d, J=8.0Hz), 7.60 (2H, dd, J=1.2, 8.8Hz), 7.70 (1H, s), 8.71 (1H, dd, J=1.6, 5.2Hz), 8.78 (1H, d, J=1.2Hz), 8.88 (1H, brs), 9.02 (1H, brs).

Example 97

N-(4-((6-Cyano-7-hydroxy-4-quinolyl)oxy)phenyl)-N'-(3-(methylsulfonyl)phenyl)urea

[0375] After dissolving N-(4-(7-(benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfonyl)phenyl)urea (1.43 g, 2.5 mmol) in trifluoroacetic acid (10 ml) and thioanisole (1.17 ml, 10 mmol) under a nitrogen atmosphere, the solution was stirred at 65°C for 19 hours. The reaction solution was concentrated under reduced pressure, and after adding 5% aqueous sodium bicarbonate (30 ml) and ethyl acetate (50 ml) to the obtained residue and stirring, the precipitated crystals were filtered out, washed with water and ethyl acetate and dried under reduced pressure. The organic layer of the filtrate was separated, washed with saturated brine and dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a yellow crystalline residue. This was combined with the previous crystals, suspended in ethyl acetate (40 ml) and subjected to sonication, and then the crystals were filtered out, washed with diethyl ether and dried at 60°C to obtain the title compound (862 mg, 1.8 mmol, 72.7%) as yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.18 (3H, s), 6.43 (1H, d, J=5.2Hz), 7.22-7.25 (3H, m), 7.43 (1H, s), 7.48-7.68 (5H, m), 8.16 (1H, s), 8.63 (1H, d, J=5.2Hz), 8.67 (1H, s), 9.36 (1H, s), 9.55 (1H, s).

Example 98

Sodium 4-(4-((anilinocarbonyl)amino)phenoxy)-6-cyano-7-quinolinolate

[0376] The title compound (811 mg, 1.94 mmol, 83.8%) was obtained as yellow crystals from N-(4-(7-(benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-phenylurea (1.126 g, 2.31 mmol), by the same procedure as in Example 87.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 6.26 (1H, d, J=5.2Hz), 6.96 (1H, m), 7.18-7.29 (5H, m), 7.45 (2H, d, J=8.4Hz), 7.57 (2H, d, J=8.0Hz), 8.50-8.51 (2H, m), 8.74 (1H, s), 8.86 (1H, s).

Example 99

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-phenylurea

[0377] The title compound was obtained from 4-(4-amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline and phenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.38 (3H, s), 3.78-3.81 (2H, m), 4.42-4.45 (2H, m), 6.64 (1H, d, J= 5.2 Hz), 7.00 (1H, t, J= 7.2 Hz), 7.15-7.19 (1H, m), 7.31 (2H, t, J= 7.2 Hz), 7.42 (1H, dd, J=2.8 Hz, J=12 Hz), 7.48 (2H, d, J= 7.2 Hz), 7.66 (1H, s), 8.28 (1H, t, J= 8.8 Hz), 8.72 (1H, brs), 8.76 (1H, d, J= 5.2 Hz), 8.78(1H, s), 9.15(1H, brs).

Example 100

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0378] The title compound was obtained from 4-(4-amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline and 4-fluoro phenyl isocyanate, in the same manner as Example 10.

¹H-NMR(DMSO-d₆) δ(ppm): 3.38 (3H, s), 3.78-3.81 (2H, m), 4.42-4.45 (2H, m), 6.64 (1H, d, J=5.2 Hz), 7.12-7.18 (3H, m), 7.42 (1H, dd, J=2.8 Hz, J=12 Hz), 7.46-7.51 (2H, m), 7.65 (1H, s), 8.25 (1H, t, J=9.2 Hz), 8.71 (1H, brs), 8.76 (1H, d, J= 5.2 HZ), 8.77 (1H, s), 9.18 (1H, brs).

5 Example 101

N-(1H-Benzo[d]imidazol-6-yl)-N'-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)urea (Example 101-A)

N-(1H-Benzo[d]imidazol-5-yl)-N'-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)urea (Example 101-B)

10 **[0379]** A mixture of the title compounds (Example 101-A) and (Example 101-B) (77.5 mg, 0.157 mmol, 71.4%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11. The mixture of (Example 101-A) and (Example 101-B)

15 ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.53 (1H, d, J=5.6Hz), 6.99-7.62 (6H, m), 7.82 (2/5H, s), 7.91 (3/5H, s), 8.08 (3/5H, s), 8.13 (2/5H, s), 8.59-8.79 (5H, m), 12.26 (3/5H, s), 12.29 (2/5H, s).

Example 102

20 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)urea

[0380] The title compound (104.2 mg, 0.204 mmol, 93.0%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 6.81 (2H, s), 7.22 (2H, d, J=8.0Hz), 7.31 (1H, s), 7.58 (2H, d, J=8.0Hz), 7.62 (1H, s), 8.53 (1H, s), 8.71-8.76 (3H, m), 10.41 (1H, s), 10.50 (1H, s).

Example 103

30 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)urea

[0381] The title compound (101 mg, 0.197 mmol, 89.9%) was obtained as gray crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.37 (3H, s), 3.76-3.39 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 6.91 (1H, dd, J=2.0, 8.8Hz), 7.17 (1H, d, J=8.4Hz), 7.24 (2H, d, J=8.8Hz), 7.48 (1H, s), 7.59 (2H, d, J=8.8Hz), 7.62 (1H, s), 8.71-8.77 (3H, m), 8.81 (1H, s), 11.53 (1H, s).

Example 104

40 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)urea

[0382] The title compound (111 mg, 0.217 mmol, 98.8%) was obtained as gray crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.37 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.52 (1H, d, J=5.2Hz), 6.99 (1H, d, J=8.4Hz), 7.07 (1H, dd, J=2.0, 8.4Hz), 7.24 (2H, d, J=8.8Hz), 7.56-7.63 (4H, m), 8.72 (1H, d, J=5.2Hz), 8.74 (1H, s), 8.76 (1H, s), 8.82 (1H, s), 11.46 (1H, s).

Example 105

50 N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-oxo-2,3-dihydro-1H-5-indolyl)urea

[0383] The title compound (69 mg, 0.135 mmol, 61.7%) was obtained as gray crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (100 mg, 0.220 mmol), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.36 (3H, s), 3.45 (2H, s), 3.76-3.79 (2H, s), 4.40-4.43 (2H, m), 6.51 (1H, d, J=5.2Hz), 6.72 (1H, d, J=8.4Hz), 7.17 (1H, dd, J=2.0, 8.4Hz), 7.22 (2H, d, J=8.8Hz), 7.37 (1H, s), 7.58 (2H, d, J=8.8Hz), 7.62 (1H, s), 8.49 (1H, s), 8.71 (1H, d, J=5.2Hz), 8.74 (1H, s), 8.75 (1H, s), 10.23 (1H, s).

Example 106N-(4-(6-Cyano-7-(3-hydroxypropoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0384] The title compound (64 mg, 0.135 mmol, 54.2%) was obtained as light yellow crystals from sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (109 mg, 0.250 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.97 (2H, t, J=6.0Hz), 3.63 (2H, m), 4.34 (2H, t, J=6.0Hz), 4.63 (1H, t, J=5.2Hz), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.23 (2H, d, J=8.8Hz), 7.44-7.47 (2H, m), 7.57-7.60 (3H, m), 8.70-8.75 (3H, m), 8.82 (1H, s).

Example 107N-(4-(6-Cyano-7-(3-(methylsulfonyl)propoxy)-4-quinolyloxy)phenyl)-N'-(4-fluorophenyl)urea

[0385] The title compound (37 mg, 0.074 mmol, 29.5%) was obtained as light brown crystals from sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (109 mg, 0.250 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.08-2.12 (5H, m), 2.69 (2H, t, J=7.2Hz), 4.36 (2H, t, J=6.0Hz), 6.52 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.23 (2H, d, J=8.8Hz), 7.44-7.48 (2H, m), 7.57-7.60 (3H, m), 8.71-8.76 (3H, m), 8.82 (1H, s).

Example 108N-(4-(6-Cyano-7-(3-(methylsulfonyl)propoxy)-4-quinolyloxy)phenyl)-N'-(4-fluorophenyl)urea

[0386] The title compound (70 mg, 0.131 mmol, 52.4%) was obtained as light brown crystals from sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (109 mg, 0.250 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.27 (2H, m), 3.04 (3H, s), 3.21-3.37 (2H, m), 4.41 (2H, t, J=6.4Hz), 6.53 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.23 (2H, d, J=8.8Hz), 7.44-7.48 (2H, m), 7.57-7.61 (3H, m), 8.71-8.73 (2H, m), 8.77 (1H, s), 8.82 (1H, s).

Example 109N-(4-(6-Cyano-7-(3-(2-oxotetrahydro-1H-1-pyrrolyl)propoxy)-4-quinolyloxy)phenyl)-N'-(4-fluorophenyl)urea

[0387] The title compound (11.2 mg, 0.021 mmol, 8.3%) was obtained as light yellow crystals from sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (109 mg, 0.250 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.93 (2H, m), 2.03 (2H, t, J=6.0Hz), 2.19 (2H, t, J=8.0Hz), 3.37-3.42 (4H, m), 4.27 (2H, t, J=6.0Hz), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.23 (2H, d, J=8.8Hz), 7.44-7.48 (2H, m), 7.55 (1H, s), 7.58 (2H, d, J=8.8Hz), 8.70-8.73 (2H, m), 8.75 (1H, s), 8.82 (1H, s).

Example 110N-(4-(6-Cyano-7-(3-(1,3-dioxo-2,3-dihydro-1H-2-isoindolyl)propoxy)-4-quinolyloxy)phenyl)-N'-(4-fluorophenyl)urea

[0388] The title compound (416 mg, 0.692 mmol, 69.2%) was obtained as light yellow crystals from sodium 6-cyano-4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (436 mg, 1.00 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.17 (2H, t, J=5.6Hz), 3.84 (2H, t, J=6.4Hz), 4.32 (2H, t, J=6.0Hz), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.23 (2H, d, J=9.2Hz), 7.44-7.48 (2H, m), 7.52 (1H, s), 7.58 (2H, d, J=8.8Hz), 7.78-7.84 (4H, m), 8.69-8.73 (3H, m), 8.82 (1H, s).

Example 111N-(3-(6-Cyano-4-(3-fluoro-4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolyl)oxypropyl)methanesulfonamide

[0389] The title compound (73 mg, 0.129 mmol, 51.3%) was obtained as light brown crystals from sodium 6-cyano-4-(3-fluoro-4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-quinolinolate (114 mg, 0.25 mmol), by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.02 (2H, t, J=6.4Hz), 2.91 (3H, s), 3.20 (2H, q, J=6.4Hz), 4.34 (2H, t, J=6.4Hz), 6.62 (1H, d, J=5.2Hz), 7.12-7.38 (4H, m), 7.40 (1H, dd, J=2.8, 11.6Hz), 7.44-7.48 (2H, m), 7.61 (1H, s), 8.24 (1H, t, J=9.2Hz), 8.62 (1H, d, J=2.0Hz), 8.74 (1H, s), 8.75 (1H, s), 9.09 (1H, s).

Example 1124-(4-((4-Fluoroanilino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0390] The N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (360 mg, 0.762 mmol) obtained in Example 10 was dissolved in dimethylsulfoxide (4.5 ml), and then 5N aqueous sodium hydroxide (1.5 ml) was added and the mixture was heated at 80°C while stirring for 60 minutes. The reaction solution was cooled in an ice water bath, 2N hydrochloric acid (3.75 ml) was added for neutralization, and then the mixture was diluted with water (21 ml) and the precipitated crude crystals were filtered out. These were suspended in ethanol (20 ml) and subjected to sonication, and upon filtering out the crystals they were dried under reduced pressure to obtain the title compound (214 mg, 0.436 mmol, 57.3%) as gray crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 3.34 (3H, s), 3.78-3.81 (2H, m), 4.38-4.41 (2H, m), 6.46 (1H, d, J=5.6Hz), 7.11 (2H, d, J=8.8Hz), 7.23 (2H, d, J=8.4Hz), 7.46 (2H, m), 7.54 (1H, s), 7.58 (2H, d, J=8.8Hz), 7.80 (1H, s), 7.82 (1H, s), 8.64 (1H, d, J=5.6Hz), 8.75 (1H, s), 8.78 (1H, s), 8.83 (1H, s).

Example 1137-(2-Methoxyethoxy)-4-(4-((1,3-thiazol-2-ylamino)carbonyl)aminophenoxy)-6-quinolinecarboxamide

[0391] The title compound (181 mg, 0.377 mmol, 42.6%) was obtained as gray crystals from the N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(1,3-thiazol-2-yl)urea (409 mg, 0.886 mmol) obtained in Example 12, by the same procedure as in Example 112.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 3.35 (3H, s), 3.78-3.81 (2H, m), 4.39-4.42 (2H, m), 6.47 (1H, d, J=5.2Hz), 7.11 (1H, brs), 7.26 (2H, d, J=8.8Hz), 7.37 (1H, d, J=3.2Hz), 7.55 (1H, s), 7.62 (2H, d, J=8.8Hz), 7.80 (1H, s), 7.82 (1H, s), 8.65 (1H, d, J=5.2Hz), 8.78 (1H, s), 9.10 (1H, s).

Example 1144-4-((Anilino)carbonyl)amino-3-fluorophenoxy-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0392] The title compound (21 mg, 0.043 mmol, 19.1%) was obtained as brown crystals from the N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-phenylurea (106 mg, 0.224 mmol) obtained in Example 99, by the same procedure as in Example 112. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 3.35 (3H, s), 3.78-3.81 (2H, m), 4.39-4.42 (2H, m), 6.55 (1H, d, J=5.2Hz), 6.98 (1H, t, J=7.6Hz), 7.13 (1H, d, J=8.4Hz), 7.29 (2H, t, J=7.6Hz), 7.39 (1H, dd, J=2.4, 12.0Hz), 7.45 (2H, d, J=8.4Hz), 7.56 (1H, s), 7.82 (2H, brs), 8.25 (1H, m), 8.63 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.76 (1H, s), 9.06 (1H, s).

Example 1154-(4-((4-Fluoroanilino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0393] The title compound (201 mg, 0.450 mmol, 49.2%) was obtained as gray crystals from the N-(4-(6-cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (391 mg, 0.913 mmol) obtained in Example 39, by the same procedure as in Example 112.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 4.02 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.24 (2H, d, J=8.8Hz), 7.44-7.48 (2H, m), 7.51 (1H, s), 7.59 (2H, d, J=8.8Hz), 7.75 (1H, s), 7.87 (1H, s), 8.68-8.70 (2H, m), 8.85 (1H, s), 8.95 (1H, s).

Example 1164-(4-((Cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0394] The title compound (71 mg, 0.163 mmol, 45.4%) was obtained as light brown crystals from the N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylurea (150 mg, 0.358 mmol) obtained in Example 23, by the same procedure as in Example 112.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.40-0.44 (2H, m), 0.62-0.66 (2H, m), 2.43-2.48 (1H, m), 3.36 (3H, s), 3.80-3.83 (2H, m), 4.40-4.43 (2H, m), 6.43-6.46 (2H, m), 7.18 (2H, d, J=8.8Hz), 7.53-7.67 (3H, m), 7.81 (1H, s), 7.83 (1H, s), 8.46 (1H, s), 8.65 (1H, d, J=5.6Hz), 8.79 (1H, s).

Example 117N-4-((6-Cyano-7-methoxy-4-quinolyl)oxy)phenyl)-N'-(1,3-thiazol-2-yl)urea

[0395] The title compound (390 mg, 0.934 mmol, 93.4%) was obtained as white crystals from 4-(4-aminophenoxy)-6-cyano-7-methoxyquinoline (291 mg, 1.0 mmol) and 2-phenoxy-carbamoylamino-1,3-thiazole (264 mg, 1.2 mmol), by the same procedure as in Example 36.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.05 (3H, s), 6.52 (1H, d, J=5.2Hz), 7.11 (1H, br), 7.27 (2H, d, J=8.8Hz), 7.37 (1H, d, J=3.2Hz), 7.59 (1H, s), 7.62 (2H, d, J=8.8Hz), 8.72 (1H, d, J=5.2Hz), 8.77 (1H, s), 9.12 (1H, s).

Example 1187-Methoxy-4-(4-((1,3-thiazol-2-ylamino)carbonyl)aminophenoxy)-6-quinolinecarboxamide

[0396] The title compound (195 mg, 0.448 mmol, 52.8%) was obtained as gray crystals from the N-4-((6-cyano-7-methoxy-4-quinolyl)oxy)phenyl-N'-(1,3-thiazol-2-yl)urea (354 mg, 0.848 mmol) obtained in Example 117, by the same procedure as in Example 112.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.02 (3H, s), 6.47 (1H, d, J=5.2Hz), 7.10 (1H, br), 7.25 (2H, d, J=8.8Hz), 7.36 (1H, d, J=3.6Hz), 7.50 (1H, s), 7.62 (2H, d, J=8.8Hz), 7.73 (1H, s), 7.85 (1H, s), 8.64 (1H, d, J=5.2Hz), 8.67 (1H, s), 9.45 (1H, s).

Example 1194-(4-((2,4-Difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide

[0397] The title compound (36 mg, 0.448 mmol, 29.4%) was obtained as light pink crystals from the N-(4-(6-cyano-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea (118 mg, 0.254 mmol) obtained in Example 61, by the same procedure as in Example 112.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.02 (3H, s), 6.56 (1H, d, J=5.2Hz), 7.06 (1H, m), 7.12 (1H, m), 7.33 (1H, m), 7.39 (1H, dd, J=2.8, 11.6Hz), 7.51 (1H, s), 7.73 (1H, s), 7.84 (1H, s), 8.11 (1H, m), 8.25 (1H, t, J=9.2Hz), 8.65 (1H, s), 8.66 (1H, d, J=5.2Hz), 8.99 (1H, s), 9.06 (1H, s).

Example 120N-4-((6-Cyano-7-methoxy-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[0398] The title compound (293 mg, 0.783 mmol, 59.8%) was obtained as white crystals from 4-(4-aminophenoxy)-6-cyano-7-methoxyquinoline (381 mg, 1.308 mmol), by the same procedure as in Example 36.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.40-0.44 (2H, m), 0.62-0.67 (2H, m), 2.53-2.58 (1H, m), 4.07 (3H, m), 6.44 (1H, d, J=2.0Hz), 6.51 (1H, d, J=5.6Hz), 7.19 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 7.60 (1H, s), 8.48 (1H, s), 8.73 (1H, d, J=5.6Hz), 8.77 (1H, s).

Example 1214-(4-((Cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0399] The title compound (79 mg, 0.201 mmol, 26.9%) was obtained as gray crystals from the N-4-((6-cyano-7-meth-

oxy-4-quinolyl)oxy)phenyl-N'-cyclopropylurea (279 mg, 0.745 mmol) obtained in Example 120, by the same procedure as in Example 112.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.40-0.43 (2H, m), 0.62-0.64 (2H, m), 2.42-2.45 (1H, m), 4.02 (3H, s), 6.42-6.44 (2H, m), 7.16 (2H, d, J=8.0Hz), 7.49 (1H, s), 7.53 (2H, d, J=8.0Hz), 7.72 (1H, s), 7.84 (1H, s), 8.45 (1H, s), 8.63 (1H, d, J=5.6Hz), 8.67 (1H, s).

Example 122

N-(4-(5,6-Dimethyl-4-7H-pyrrolo[2,3-d]pyrimidyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0400] 4-(4-Aminophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidine was dissolved in toluene (16 mg)(0.8 ml) and acetonitrile (0.5 ml) under reflux, and then 4-fluorophenyl isocyanate (7.9 μM) was added. The mixture was stirred for 1 hour and returned to room temperature, and then the reaction system was concentrated, diethyl ether was added to the residue, and the resulting crystals were filtered out. The crystals were washed with diethyl ether to obtain the title compound (5 mg).

MS m/z 392(M + H)

¹H-NMR(DMSO-d₆)δ(ppm): 2.29(3H, s), 2.31(3H, s), 7.00-7.16 (4H, m), 7.38-7.50 (4H, m), 8.10(1H, s), 8.50(2H, s), 11.75(1H, s)

[0401] The intermediates were synthesized in the following manner.

Production Example 122-1

4-(Nitrophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidine

[0402] After adding para-nitrophenol (121 mg), potassium carbonate (133 mg) and dimethylformamide (1 ml) to the 4-chloro-5,6-7H-pyrrolo[2,3-d]-pyrimidine (88 mg) described in Journal of Medicinal Chemistry, 1996, Vol.39, No.12, 2285-2292, the mixture was stirred at 135-140°C for 72 hours. This was returned to room temperature, water was added, extraction was performed with a tetrahydrofuran and ethyl acetate mixed solution, and then the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated to dryness. The obtained crystals were washed with diethyl ether to obtain the title compound (90 mg).

MS m/z 285(M + H)

¹H-NMR(DMSO-d₆)δ(ppm): 2.28(3H, s), 2.32(3H, s), 7.50(2H, d, J=9.5 Hz), 8.20(1H, s), 8.30(2H, d, J=9.5 Hz), 11.98 (1H, s)

Production Example 122-2

4-(Aminophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidine

[0403] After adding iron powder (0.1 g), ammonium chloride (0.2 g), ethanol (4 ml) and water (1 ml) to the 4-(nitrophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidine (80 mg) synthesized by the intermediate synthesis method described above, the mixture was stirred at 75-82°C for 1.5 hours. After returning the reaction system to room temperature and adding tetrahydrofuran (3 ml) and ethyl acetate (3 ml), the mixture was filtered with celite, the filtrate was subjected to liquid separation, and the organic layer was washed with water and saturated brine in that order, dried over sodium sulfate, concentrated to dryness under reduced pressure and washed with diethyl ether to obtain the title compound (22 mg).

MS m/z 255(M + H)

¹H-NMR(DMSO-d₆)δ(ppm): 2.27(3H, s), 2.29(3H, s), 4.90-5.00 (2H, m), 6.52-6.88 (4H, m), 8.06(1H, s), 11.66(1H, s)

Example 123

4-(4-(3,4-Dihydroquinazolin-2-one-3-yl)phenoxy)-6,7-dimethoxyquinoline

[0404] 6,7-Dimethoxy-4-(4-(2-aminophenyl)methylaminophenoxy)quinoline (40 mg, 0.0996 mmol) was dissolved in dimethylformamide (0.5 ml), 1,1'-carbonyldiimidazole (19 mg, 0.1196 mmol) was added, and the mixture was stirred at 70°C for 8 hours. After cooling to room temperature, the reaction solution was diluted with tetrahydrofuran, water was added, and the mixture was extracted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, after which the solvent was distilled off under reduced pressure. The residue was purified with a silica gel column (ethyl acetate-methanol system) and recrystallized with hexane-diethyl ether to obtain the title com-

pound (3 mg, 0.0070 mmol, 7.05%) as colorless crystals.

¹H-NMR (CDCl₃) δ(ppm) : 4.06 (6H, s), 4.89 (2H, s), 6.57 (1H, d, J = 5.2 Hz), 6.77 (1H, d, J = 7.6 Hz), 6.87 (1H, brs), 7.03 (1H, t, J = 7.6 Hz), 7.14 (1H, d, J = 7.6 Hz), 7.23 (3H, m, covered by CDCl₃), 7.44 (1H, s), 7.48 (2H, d, J=8.8 Hz), 7.55 (1H, s), 8.52 (1H, d, J = 5.2 Hz).

[0405] The intermediates were synthesized in the following manner.

Production Example 123-1

6,7-Dimethoxy-4-(4-(2-nitrophenylmethylimino)phenoxy)quinoline

[0406] 6,7-Dimethoxy-4-(4-aminophenoxy)quinoline (500 mg, 1.6873 mmol) was dissolved in tetrahydrofuran (64 ml), and after adding 2-nitrobenzaldehyde (320 mg, 2.1091 mmol) and acetic acid (0.58 ml), sodium triacetoxyborohydride (720 mg, 3.3746 mmol) was further added and the mixture was stirred at room temperature for 11 hours and 30 minutes. Water and saturated sodium bicarbonate were added, the mixture was extracted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained crystals were washed with hexane-diethyl ether, filtered out, washed with hexane and dried by aspiration at room temperature to obtain the title compound (453 mg) as light yellow crystals.

¹H-NMR (CDCl₃) δ(ppm) : 4.06 (6H, s), 6.54 (1H, d, J = 5.2 Hz), 7.25 (2H, d, J = 8.4 Hz), 7.40 (2H, d, J = 8.4 Hz), 7.44 (1H, s), 7.57 (1H, s), 7.65 (1H, dd, J = 7.6, 8.0 Hz), 7.77 (1H, dd, J = 7.6, 7.6 Hz), 8.10 (1H, d, J = 8.0 Hz), 8.33 (1H, d, J = 7.6 Hz), 8.51 (1H, d, J = 5.2 Hz), 9.01 (1H, s).

Production Example 123-2

6,7-Dimethoxy-4-(4-(2-nitrophenylmethylamino)phenoxy)quinoline

[0407] After adding tetrahydrofuran (2 ml), ethanol (2 ml) and chloroform (1 ml) to 6,7-dimethoxy-4-(4-(2-nitrophenylmethyl-imino)phenoxy)quinoline (200 mg, 0.4657 mmol) and heating the mixture to complete dissolution, sodium borohydride (35 mg, 0.9314 mmol) was added and the mixture was heated to reflux for 1 hour and 30 minutes. After cooling to room temperature, water was added, the mixture was extracted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified with an NH silica gel column (hexane-ethyl acetate system) to obtain the title compound (151 mg, 0.3500 mmol, 75.15%) as a yellow oil.

¹H-NMR (CDCl₃) δ(ppm) : 4.04 (6H, s), 4.46 (1H, brs), 4.76 (2H, d, J = 4.8 Hz), 6.42 (1H, d, J = 5.2 Hz), 7.64 (2H, d, J = 8.8 Hz), 6.99 (2H, d, J = 8.8 Hz), 7.40 (1H, s), 7.47 (1H, dd, J = 7.2, 7.2 Hz), 7.57 (1H, s), 7.62 (1H, dd, J = 7.2, 7.6 Hz), 7.71 (1H, d, J = 7.6 Hz), 8.10 (1H, d, J = 7.2 Hz), 8.45 (1H, d, J = 5.2 Hz).

Production Example 123-3

6,7-Dimethoxy-4-(4-(2-aminophenylmethylamino)phenoxy)quinoline

[0408] 6,7-Dimethoxy-4-(4-(2-nitrophenylmethylamino)phenoxy)quinoline (150 mg, 0.35 mmol) was dissolved in ethanol (2.8 ml) and water (0.7 ml), and then iron powder (78 mg, 1.4 mmol) and ammonium chloride (150 mg, 2.8 mmol) were added and the mixture was heated to reflux for 1 hour. After cooling to room temperature, the reaction solution was diluted with tetrahydrofuran and water, and the insoluble portion was filtered off. The filtrate was distilled off under reduced pressure, and then the residue was purified with a silica gel column (ethyl acetate system), the obtained amorphous substance was solidified with hexane and ethyl acetate, and the obtained crystals were washed with hexane-ethyl acetate, filtered out, washed with hexane and dried by aspiration at room temperature to obtain the title compound (80 mg, 0.1993 mmol, 56.93%) as milky white crystals.

¹H-NMR (CDCl₃) δ(ppm) : 3.78 (1H, brs), 4.05 (3H, s), 4.06 (3H, s), 4.15 (2H, brs), 4.26 (2H, s), 6.44 (1H, d, J = 5.2 Hz), 6.74-6.81 (4H, m), 7.06 (2H, d, J = 8.8 Hz), 7.16-7.22 (2H, m), 7.42 (1H, s), 7.60 (1H, s), 8.46 (1H, d, J = 5.2 Hz).

Example 124

N-(4-(2-Phenylpyridin-4-yl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0409] 4-(2-Phenylpyridin-4-yl)oxyaniline (110 mg, 0.42 mM) was added to ethyl acetate (10 ml), and then parafluorophenyl isocyanate (0.56 ml, 4.9 mM) was added while stirring, which was continued for 30 minutes. After adding n-hexane (20 ml) to the reaction solution, the solvent was partially distilled off under reduced pressure and the precipitating

solid was filtered out to obtain the target substance (98 mg) as a gray solid.

$^1\text{H-NMR}$ (DMSO- d_6) δ (ppm) : 6.81 (1H, dd, J= 5.6 Hz, J= 2.4 Hz), 7.10-7.20 (4H, m), 7.42-7.52 (6H, m), 7.57 (2H, d, J= 8.8 Hz) 8.01 (2H, d, J= 8.4 Hz), 8.53 (1H, d, J= 5.6 Hz), 8.74 (1H, s), 8.80 (1H, s).

[0410] The starting material and intermediate were synthesized in the following manner.

Production Example 124-1

4-(2-Phenylpyridin-4-yl)oxyaniline

[0411] 4-Chloro-2-phenylpyridine 1.0 g (5.5 mM), paranitrophenol (1.68 g, 12 mM), Hunig's base (diisopropylethylamine, 5 ml) and 1-methylpyrrolidone (10 ml) were stirred at 160°C for 20 hours. Water was added, extraction was performed with ethyl acetate, and the organic layer was washed 5 times with water. The solvent was distilled off under reduced pressure and the residue was purified by silica gel chromatography (hexane:ethyl acetate = 4:1) to obtain 490 mg of 4-(4-nitrophenoxy)-2-phenylpyridine as a light yellow solid.

$^1\text{H-NMR}$ (DMSO- d_6) δ (ppm): 7.08-7.14 (1H, m), 7.40-7.53 (5H, m), 7.74 (1H, s), 8.07-8.13 (2H, m) 8.34 (2H, d, J= 8.8 Hz), 8.68 (1H, dd, J= 5.6 Hz, J= 1.2Hz).

[0412] 4-(4-nitrophenoxy)-2-phenylpyridine (490 mg), iron powder (1 g), ammonium chloride (2 g), ethanol (10 ml), dimethylformamide (10 ml) and water (5 ml) were stirred at 100°C for 10 minutes. The mixture was filtered with celite, water was added to the filtrate, and extraction was performed with ethyl acetate. The organic layer was washed 5 times with water, and then the solvent was distilled off under reduced pressure to obtain 4-(2-phenylpyridin-4-yl)oxyaniline (460 mg) as a brown oil.

$^1\text{H-NMR}$ (DMSO- d_6) δ (ppm): 5.12-5.16 (2H, m), 6.65 (2H, d, J= 8.8Hz), 6.74 (1H, dd, J= 5.6Hz, J= 2.4Hz), 6.89 (2H, d, J= 8.8Hz), 7.38 (1H, d, J= 2.4Hz), 7.40-7.52 (3H, m), 7.98 (2H, d, J= 8.0 Hz), 8.48 (1H, d, J= 5.6 Hz).

Example 125

N-(4-(3-Phenylpyridin-4-yl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0413] Ethyl acetate (10 ml) was added to 4-(3-phenylpyridin-4-yl)oxyaniline (84 mg, 0.32 mM), and then parafluorophenyl isocyanate (0.54 ml, 4.7 mM) was added while stirring, which was continued for 40 minutes. After adding NH type silica gel to the reaction solution, the solvent was distilled off under reduced pressure to adsorb the reaction product onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, for column purification (chloroform:methanol = 10:1). After adding ethyl acetate and n-hexane to the obtained residue, the solvent was distilled off under reduced pressure to obtain the target compound (82 mg) as a light yellow amorphous substance.

$^1\text{H-NMR}$ (DMSO- d_6) δ (ppm): 6.69 (1H, dd, J= 5.6 Hz, J= 1.6 Hz), 7.06-7.15 (4H, m), 7.37-7.54 (7H, m), 7.64 (2H, d, J= 7.6 Hz), 8.38 (1H, dd, J= 5.6 Hz, J= 1.6Hz), 8.51 (1H, d, J= 1.6 Hz), 8.70 (1H, s), 8.75 (1H, s).

[0414] The starting material and intermediate were synthesized in the following manner.

Production Example 125-1

4-(3-Phenylpyridin-4-yl)oxyaniline

[0415] 4-Chloro-3-phenylpyridine (200 mg, 1.06 mM), paranitrophenol (440 mg, 3.18 mM), Hunig's base (isoPr₂EtN, diisopropylethylamine, 1 ml) and 1-methylpyrrolidone (2 ml) were stirred at 160°C for 2 hours. Water was added, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography (hexane:ethyl acetate = 4:1, and then 2:1) to obtain 4-(4-nitrophenoxy)-3-phenylpyridine (150 mg) as a light yellow oil.

$^1\text{H-NMR}$ (CDCl₃) δ (ppm): 6.98 (1H, d, J= 5.6Hz), 7.12 (2H, d, J= 9.2Hz), 7.37-7.48 (3H, m), 7.50-7.56 (2H, m) 8.24 (2H, d, J= 9.3 Hz), 8.55 (1H, d, J= 5.6 Hz), 8.71 (1H, s).

[0416] 4-(4-Nitrophenoxy)-3-phenylpyridine (150 mg), iron powder (300 mg), ammonium chloride (600 mg), ethanol (5 ml), dimethylformamide (5 ml) and water (2.5 ml) were stirred at 100°C for 15 minutes. The mixture was filtered with celite, water was added to the filtrate, and extraction was performed with ethyl acetate. The organic layer was washed 5 times with water, and then the solvent was distilled off under reduced pressure to obtain 4-(3-phenylpyridin-4-yl)oxyaniline (84 mg) as a yellow oil.

$^1\text{H-NMR}$ (CDCl₃) δ (ppm): 6.65-6.74 (3H, m), 6.88 (2H, d, J= 8.8Hz), 7.36-7.50 (3H, m), 7.64 (2H, d, J= 8.8Hz), 8.34 (1H, dd, J= 5.6Hz, J= 0.8Hz), 8.54 (1H, s).

Example 126

N-(3-(6,7-Dimethoxyquinolin-4-yl)oxypropyl)-N'-(4-fluorophenyl)urea

[0417] 6,7-Dimethoxy-4-(3-aminopropoxy)quinoline 150 mg (0.57 mM) and ethyl acetate (20 ml) were stirred at room temperature, and then 4-fluorophenyl isocyanate (0.078 ml, 0.68 mM) was added and the mixture was further stirred for 15 minutes. The precipitated solid was filtered out to obtain the target substance (92 mg) as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 2.03 (2H, tt, J= 6.0Hz, J= 6.0Hz), 3.36 (2H, t, J= 6.0Hz), 3.89 (3H, s), 3.91 (3H, s), 4.27 (2H, t, J= 6.0Hz), 6.29 (1H, t, J= 6.0Hz), 6.88 (1H, d, J= 5.2Hz), 7.00-7.07 (2H, m), 7.31 (1H, s), 7.34-7.41 (3H, m), 8.47 (1H, s), 8.51 (1H, d, J= 5.2Hz).

[0418] The starting material and intermediate were synthesized in the following manner.

Production Example 126-16,7-Dimethoxy-4-(3-aminopropoxy)quinoline

[0419] 6,7-Dimethoxy-4-hydroxyquinoline (4.0 g, 19.5 mM), N-(3-bromopropyl)phthalimide (5.8 g, 21.5 mM), potassium carbonate (5.4 g, 39 mM) and DMF dimethylformamide (20 ml) were stirred at 60°C for 1.5 hours. Water, ethyl acetate and tetrahydrofuran were added to the reaction solution for extraction. The solid which precipitated after standing for a period was filtered out to obtain N-(3-(6,7-dimethoxyquinolin-4-yloxy)propyl)phthalimide (1.1 g).

¹H-NMR(DMSO-d₆) δ(ppm) : 2.22 (2H, tt, J= 6.0Hz, J= 6.0Hz), 3.82 (3H, s), 3.86 (2H, t, J= 6.0Hz), 3.90 (3H, s), 4.29 (2H, t, J= 6.0Hz), 6.82 (1H, d, J= 5.2Hz), 7.27 (1H, s), 7.31 (1H, s), 7.77-7.84 (4H, m), 8.49 (1H, d, J= 5.2Hz).

[0420] N-(3-(6,7-Dimethoxyquinolin-4-yloxy)propyl)phthalimide (600 mg, 1.53 mM), hydrazine monohydrate (300 mg, 6.12 mM), ethanol (5 ml), methanol (5 ml) and tetrahydrofuran (5 ml) were stirred for 2 hours under reflux. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography (Fuji Silysia NH Type Silica Gel, chloroform:methanol = 20:1) to obtain the target substance (150 mg) as a brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 1.93 (2H, tt, J= 6.0Hz, J= 6.0Hz), 2.77 (2H, t, J= 6.0Hz), 3.88 (3H, s), 3.91 (3H, s), 4.29 (2H, t, J= 6.0Hz), 6.89 (1H, d, J= 5.2Hz), 7.31 (1H, s), 7.34 (1H, s), 8.51 (1H, d, J= 5.2Hz).

Example 127

N-(4-(6-Cyano-7-((1-methylpiperidin-3-yl)methoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0421] After dissolving 6-cyano-4-(4-(4-fluoroanilino)carbonyl)amino-3-fluorophenoxy)quinolin-7-ol sodium salt (222 mg), potassium carbonate (162 mg) and 3-chloromethyl-1-methylpiperidine hydrochloride (86 mg) in dimethylformamide (1.7 ml) and stirring the mixture overnight at 70-80°C, water was added, and extraction was performed with a tetrahydrofuran and ethyl acetate mixed solvent prior to concentration under reduced pressure and purification of the residue with NH Silica (Fuji Silysia Chemical). The obtained solid was washed with ether and dried to obtain the title compound (10 mg).

MS Spectrum: 544(M+1)

¹H-NMR Spectrum: (DMSO-d₆) 1.30-2.70 (12H, m), 4.17 (2H, d, J=6.7Hz), 6.61 (1H, d, J=5.0Hz), 7.06-7.18 (3H, m), 7.36-7.50 (3H, m), 7.60 (1H, s), 8.20-8.28 (1H, m), 8.63 (1H, s), 8.74 (1H, d, J=5.0Hz), 8.75 (1H, s), 9.10 (1H, s)

Example 128

N-(3-(5,6-Dimethyl-4-7H-pyrrolo[2,3-d]pyrimidyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[0422] After dissolving 4-amino(3-aminophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidine (27 mg) in toluene (1 ml) and acetonitrile (0.5 ml) under reflux, 4-fluorophenyl isocyanate (13.3 μM) was added. Upon stirring for 1 hour, the mixture was returned to room temperature and the precipitated crystals were filtered out to obtain the title compound (26 mg).

MS(ESI) m/z 392(M + 1)

¹H-NMR(DMSO-d₆)δ(ppm): 2.31(3H, s), 2.46-2.50(3H, m), 6.78-7.48 (8H, m), 8.14(1H, s), 8.52(1H, s), 8.82(1H, s), 11.79(1H, s)

[0423] The intermediates were synthesized in the following manner.

Production Example 128-14-(3-Nitrophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine

[0424] After adding 3-nitrophenol (243 mg), potassium carbonate (268 mg) and dimethylformamide (2 ml) to the 4-chloro-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (177 mg) described in Journal of Medicinal Chemistry, 1996, Vol. 39, No.12, 2285-2292, the mixture was stirred at 120-130°C for 72 hours. This was returned to room temperature, water was added, extraction was performed with a tetrahydrofuran and ethyl acetate mixed solution, and then the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated to dryness. The

obtained crystals were washed with diethyl ether to obtain the title compound (130 mg).

MS(ESI) m/z 285(M + 1)

¹H-NMR(DMSO-d₆)δ(ppm): 2.31(3H, s), 2.46-2.50(3H, m), 7.70-8.18(5H, m), 11.89(1H, s)

Production Example 128-24-(3-Aminophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine

[0425] After adding iron powder (0.12 g), ammonium chloride (0.24 g), ethanol (5 ml) and water (1 ml) to the 4-(3-nitrophenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (110 mg) synthesized by the intermediate synthesis method described above, the mixture was stirred at 80-90°C for 3 hours. After returning the reaction system to room temperature and adding tetrahydrofuran (3 ml) and ethyl acetate (3 ml), the mixture was filtered with celite, the filtrate was subjected to liquid separation and extraction with ethyl acetate, and the organic layer was washed with water and saturated brine in that order. It was then dried over sodium sulfate, concentrated to dryness under reduced pressure and washed with diethyl ether to obtain the title compound (37 mg).

¹H-NMR(DMSO-d₆)δ(ppm): 2.27(3H, s), 2.29(3H, s), 5.15-5.24 (2H, m), 6.28 (1H, d, J=8.1Hz), 6.32(1H, s), 6.40 (1H, d, J=8.1Hz), 7.01 (1H, t, J=8.1Hz), 8.12(1H, s), 11.72 (1H, s).

Example 129N-6-((6,7-Dimethoxy-4-quinolyl)oxy)-3-pyridyl-N'-phenylurea

[0426] 6-((6,7-Dimethoxy-4-quinolyl)oxy)-3-pyridylamine (59.5 mg, 200 mmol) and phenyl isocyanate (26.2 mg, 220 mmol) were stirred in N,N-dimethylformamide (1 ml) at room temperature for 18 hours. After diluting the reaction solution with ethyl acetate, it was washed with water and saturated brine, the organic layer was dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out and washed with ethyl acetate and then blow-dried to obtain the title compound (68 mg, 163 mmol, 82%) as colorless crystals.

¹H-NMR Spectrum: (DMSO-d₆) 3.90 (3H, s), 3.95 (3H, s), 6.55 (1H, d, J = 5.2 Hz), 6.96-7.02 (1H, m), 7.26-7.32 (3H, m), 7.40 (1H, s), 7.41 (1H, s), 7.47 (2H, d, J = 8.4 Hz), 8.14 (1H, dd, J = 2.8, 8.8 Hz), 8.35 (1H, d, J = 2.8 Hz), 8.55 (1H, d, J = 5.2 Hz), 8.89 (1H, s), 8.99 (1H, s).

[0427] The intermediates were synthesized in the following manner.

Production Example 129-16,7-Dimethoxy-4-((5-nitro-2-pyridyl)oxy)quinoline

[0428] 6,7-Dimethoxy-1,4-dihydro-4-quinolinone (4.10 g, 20.0 mmol), 2-bromo-5-nitropyridine (4.46 g, 22.0 mmol) and potassium carbonate (5.53 g, 40.0 mmol) were heated and stirred at 70°C for 3 hours in N,N-dimethylformamide (20 ml). The reaction solution was diluted with ethyl acetate, the insoluble portion was filtered off, and after washing with water and saturated brine and drying the organic layer over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent: ethyl acetate), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (2.23 g, 6.81 mmol, 34%) as yellow crystals.

¹H-NMR Spectrum: (CDCl₃) 3.95 (3H, s), 4.06 (3H, s), 7.07 (1H, d, J = 5.2 Hz), 7.16 (1H, s), 7.26 (1H, d, J = 8.8 Hz), 7.49 (1H, s), 8.60 (1H, dd, J = 2.8, 8.8 Hz), 8.74 (1H, d, J = 5.2 Hz), 9.08 (1H, d, J = 2.8 Hz).

Production Example 129-26-((6,7-Dimethoxy-4-quinolyl)oxy)-3-pyridinamine

[0429] 6,7-Dimethoxy-4-((5-nitro-2-pyridyl)oxy)quinoline (654 mg, 2.00 mmol), iron powder (559 mg, 10.0 mmol) and ammonium chloride (1.07 g, 20.0 mmol) were heated and stirred in ethanol (20 ml)-water (5 ml) at 80°C for 20 minutes. After completion of the reaction, the reaction mixture was filtered with celite and washed in ethyl acetate. After washing the organic layer with water and saturated brine and drying over anhydrous magnesium sulfate, the drying agent was filtered out and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out and washed with ethyl acetate and then blow-dried to obtain the title compound (380 mg, 1.28 mmol, 64%) as light yellow crystals.

¹H-NMR Spectrum: (CDCl₃) 3.73 (2H, s), 4.02 (3H, s), 4.04 (3H, s), 6.61 (1H, d, J = 5.2 Hz), 6.96 (1H, d, J = 8.8 Hz), 7.18 (1H, dd, J = 2.8, 8.8 Hz), 7.41 (1H, s), 7.53 (1H, s), 7.85 (1H, d, J = 2.8 Hz), 8.54 (1H, d, J = 5.2 Hz).

Example 130N-6-((6,7-Dimethoxy-4-quinolyl)oxy)-3-pyridyl-N'-(4-fluorophenyl)urea

[0430] The title compound (67 mg, 154 mmol, 77%) was obtained as colorless crystals from 4-fluorophenyl isocyanate (30.1 mg, 220 mmol), by the same procedure as in Example 129.

¹H-NMR Spectrum: (DMSO-d₆) 3.89 (3H, s), 3.95 (3H, s), 6.79 (1H, d, J = 5.0 Hz), 7.11-7.16 (2H, m), 7.29 (1H, d, J = 8.6 Hz), 7.39 (1H, s), 7.41 (1H, s), 7.45-7.51 (2H, m), 8.13 (1H, dd, J = 2.6, 8.6 Hz), 8.34 (1H, d, J = 2.6 Hz), 8.55 (1H, d, J = 5.0 Hz), 8.93 (1H, s), 8.99 (1H, s).

Example 131N-6-((6,7-Dimethoxy-4-quinolyl)oxy)-3-pyridyl-N'-(1,3-thiazol-2-yl)urea

[0431] The 6-((6,7-dimethoxy-4-quinolyl)oxy)-3-pyridinamine (89.1 mg, 300 mmol) obtained in Example 129 and phenyl N-(2-thiazolyl)carbamate (79.3 mg, 360 mmol) were stirred in dimethyl sulfoxide (1 ml) at 85°C for 1 hour. After diluting the reaction solution with ethyl acetate, it was washed with water and saturated brine, the organic layer was dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out and washed with ethyl acetate and then blow-dried to obtain the title compound (88 mg, 208 mmol, 69%) as colorless crystals.

¹H-NMR Spectrum: (DMSO-d₆) 3.89 (3H, s), 3.95 (3H, s), 6.81 (1H, d, J = 5.2 Hz), 7.12 (1H, d, J = 3.6 Hz), 7.31 (1H, d, J = 8.8 Hz), 7.36-7.40 (2H, m), 7.42 (1H, s), 8.18 (1H, dd, J = 2.8, 8.8 Hz), 8.37 (1H, d, J = 2.8 Hz), 8.56 (1H, d, J = 5.2 Hz), 9.30 (1H, s).

Example 1324-(5-((Anilinoacarbonyl)amino)-2-pyridyloxy)-7-methoxy-6-quinolinecarboxamide

[0432] The title compound (59 mg, 137 mmol, 78%) was obtained as colorless crystals from 4-((5-amino-2-pyridyl)oxy)-7-methoxy-6-quinolinecarboxamide (55.0 mg, 177 mmol), by the same procedure as in Example 129.

¹H-NMR Spectrum: (DMSO-d₆) 4.04 (3H, s), 6.86 (1H, d, J = 5.2 Hz), 6.96-7.02 (1H, m), 7.26-7.34 (3H, m), 7.47 (2H, d, J = 7.6 Hz), 7.54 (1H, s), 7.74 (1H, s), 7.86 (1H, s), 8.15 (1H, dd, J = 2.8, 8.8 Hz), 8.36 (1H, d, J = 2.8 Hz), 8.55 (1H, s), 8.75 (1H, d, J = 5.2 Hz), 8.90 (1H, s), 9.01 (1H, s).

[0433] The intermediates were synthesized in the following manner.

Production Example 132-17-Methoxy-4-((5-nitro-2-pyridyl)oxy)-6-quinolinecarboxamide

[0434] The title compound (93.0 mg, 273 mmol, 5%) was obtained as yellow crystals from 7-methoxy-4-oxo-1,4-dihydro-6-quinolinecarboxamide (1.09 g, 5.00 mmol) derived by hydrolysis of the 7-methoxy-4-oxo-1,4-dihydro-6-quinolinecarboxamide described in WO98/13350, by the same procedure as in Example 129.

¹H-NMR Spectrum: (CDCl₃) 4.15 (3H, s), 5.92 (1H, s), 7.21 (1H, d, J = 5.2 Hz), 7.35 (1H, d, J = 9.2 Hz), 7.63 (1H, s),

7.79 (1H, s), 8.62 (1H, dd, J = 2.8, 8.8 Hz), 8.94 (1H, d, J = 5.2 Hz), 8.96 (1H, s), 9.02 (1H, d, J = 5.2 Hz).

Production Example 132-2

4-((5-Amino-2-pyridyl)oxy)-7-methoxy-6-quinolinecarboxamide

[0435] 7-Methoxy-4-((5-nitro-2-pyridyl)oxy)-6-quinolinecarboxamide (93.0 mg, 273 mmol), iron powder (76.0 mg, 1.36 mmol) and ammonium chloride (146 mg, 2.73 mmol) were heated and stirred in ethanol (4 ml)-water (1 ml) at 80°C for 20 minutes. After completion of the reaction, the reaction mixture was filtered with celite and washed in an ethyl acetate-tetrahydrofuran mixed solvent. After washing the organic layer with water and saturated brine and drying over anhydrous magnesium sulfate, the drying agent was filtered out and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 20:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (61.0 mg, 197 mmol, 72%) as yellow crystals.

¹H-NMR Spectrum: (DMSO-d₆) 4.03 (3H, s), 6.60 (1H, d, J = 5.4 Hz), 7.04 (1H, d, J = 8.4 Hz), 7.18 (1H, dd, J = 2.6, 8.4 Hz), 7.50 (1H, s), 7.68 (1H, d, J = 2.6 Hz), 7.73 (1H, s), 7.86 (1H, s), 8.61 (1H, s), 8.67 (1H, d, J = 5.4 Hz).

Example 133

N-(4-(6-Cyano-7-((3-methylsulfonyl)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0436] The title compound (67 mg) was obtained from 6-cyano-4-{4-[4-fluoroanilinocarbonyl]amino-3-fluorophenoxy}quinolin-7-ol sodium salt (100 mg) in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.24-2.32(2H, m), 3.05(3H, s), 3.30-3.35(2H, m), 4.42 (2H, t, J= 6 Hz), 6.63 (1H, d, J= 5.6 Hz), 7.11-7.15 (3H, m), 7.40 (1H, dd, J= 2.8 Hz, J= 8.0 Hz), 7.44-7.48 (2H, m), 7.63(1H, s), 8.21-8.26(1H, m), 8.64(1H, br), 8.75 (1H, d, J= 5.6Hz), 8.77 (1H, s), 9.10(1H, br).

Example 134

N-(4-(6-Cyano-7-((3-methylthio)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0437] The title compound (30 mg) was obtained from 6-cyano-4-{4-[4-fluoroanilinocarbonyl]amino-3-fluorophenoxy}quinolin-7-ol sodium salt (100 mg), in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.09(3H, s), 2.06-2.14(2H, m), 2.67(2H, t, J= 7.2 Hz), 4.37 (2H, t, J= 6 Hz), 6.62 (1H, d, J= 5.2 Hz), 7.10-7.15 (3H, m), 7.39 (1H, dd, J= 2.8 Hz, J= 7.6 Hz), 7.44-7.48 (2H, m), 7.60(1H, s), 8.21-8.26(1H, m), 8.65(1H, br), 8.74 (1H, d, J= 5.2 Hz), 8.75 (1H, s), 9.12(1H, brd, J= 3.2 Hz).

Example 135

N-(4-(6-Cyano-7-(3-(ethoxycarbonyl)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0438] The title compound (850 mg) was obtained from 6-cyano-4-{4-[4-fluoroanilinocarbonyl]amino-3-fluorophenoxy}quinolin-7-ol sodium salt (1.0 g), in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 1.17(3H, t, J= 7.2 Hz), 2.05-2.13(2H, m), 2.53(2H, t, J= 7.2 Hz), 4.07(2H, q, J= 7.2 Hz), 4.31 (2H, t, J= 6.4 Hz), 6.61 (1H, d, J= 5.2 Hz), 7.10-7.15 (3H, m), 7.40 (1H, dd, J= 2.8 Hz, J= 7.6 Hz), 7.44-7.48 (2H, m), 7.60(1H, s), 8.22-8.27(1H, m), 8.64(1H, br), 8.74 (1H, d, J= 5.2 Hz), 8.74 (1H, s), 9.10(1H, br).

Example 136

N-(4-(6-Cyano-7-(3-carboxypropoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0439] N-(4-(6-Cyano-7-(3-(ethoxycarbonyl)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea (800 mg) was dissolved in methanol (45 ml), 2N NaOH water (15 ml) was added, and the mixture was heated and stirred for 40 minutes at 80°C. After completion of the reaction, the reaction solution was poured into ice water and neutralized with 1N HCl, and the precipitated solid was filtered out. The obtained solid was washed with water and dried to obtain 230 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 2.01-2.08(2H, m), 2.46(2H, t, J= 7.6 Hz), 4.30 (2H, t, J= 6.4 Hz), 6.61 (1H, d, J= 5.2 Hz),

7.10-7.15 (3H, m), 7.39 (1H, dd, J= 2.8 Hz, J= 8.0 Hz), 7.44-7.48 (2H, m), 7.59(1H, s), 8.21-8.26(1H, m), 8.66(1H, br), 8.73 (1H, d, J= 5.2 Hz), 8.74 (1H, s), 9.13(1H, br).

Example 137

N-(4-(6-Cyano-7-(3-((cyclopropylamino)carbonyl)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0440] N-(4-(6-Cyano-7-(3-carboxypropoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea (100 mg) was dissolved in dimethylformamide (3 ml), and then 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (44 mg) and 1-hydroxy-1H-benzotriazole (35 mg) were added while stirring on ice and the mixture was stirred at room temperature for 30 minutes. Cyclopropylamine (16 µl) was then added and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction solution was poured into 1N sodium hydroxide water and extracted with ethyl acetate, and the obtained organic layer was washed with saturated brine and dried over magnesium sulfate. The organic layer was concentrated, and the obtained solid was washed with ether and a small amount of ethyl acetate to obtain 38 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm): 0.34-0.38(2H, m), 0.54-0.59(2H, m), 1.99-2.06(2H, m), 2.25(2H, t, J= 7.2 Hz), 2.56-2.63 (1H, m), 4.27(2H, t, J= 6.4 Hz), 6.60 (1H, d, J= 5.2 Hz), 7.10-7.15 (3H, m), 7.39 (1H, dd, J= 2.8 Hz, J= 8.0 Hz), 7.44-7.49 (2H, m), 7.59(1H, s), 7.95(1H, brd, J= 3.6 Hz), 8.21-8.25(1H, m), 8.67(1H, br), 8.73 (1H, d, J= 5.2 Hz), 8.74 (1H, s), 9.15(1H, br).

Example 138

N-(4-(6-Cyano-7-(3-((piperidino)carbonyl)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0441] The title compound (33 mg) was obtained from N-(4-(6-cyano-7-(3-carboxypropoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea (100 mg) by the same procedure as in Example 137.

¹H-NMR(DMSO-d₆) δ(ppm): 1.38-1.60(6H, m), 2.01-2.09(2H, m), 2.53(2H, t, J= 7.2 Hz), 3.39-3.46(4H, m), 4.31(2H, t, J= 6.0 Hz), 6.61 (1H, d, J= 5.2 Hz), 7.10-7.15 (3H, m), 7.40 (1H, dd, J= 2.4 Hz, J= 8.0 Hz), 7.43-7.49 (2H, m), 7.61 (1H, s), 8.20-8.27(1H, m), 8.70(1H, br), 8.73 (1H, d, J= 5.2 Hz), 8.74 (1H, s), 9.17(1H, br).

Example 139

N-(4-(6-Cyano-7-(3-((dimethylamino)sulfonyl)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0442] The title compound (35 mg) was obtained from 6-cyano-4-{4-[4-fluoroanilinocarbonyl]amino-3-fluorophenoxy} quinolin-7-ol sodium salt (100 mg), in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 2.19-2.27(2H, m), 2.80(6H, s), 3.26-3.31(2H, m), 4.41(2H, t, J= 6.4 Hz), 6.63 (1H, d, J= 5.2 Hz), 7.10-7.16 (3H, m), 7.40 (1H, dd, J= 2.8 Hz, J= 7.6 Hz), 7.44-7.49 (2H, m), 7.61(1H, s), 8.21-8.27(1H, m), 8.68 (1H, br), 8.75 (1H, d, J= 5.2 Hz), 8.77 (1H, s), 9.15(1H, br).

Example 140

N-(4-(6-Cyano-7-(3-((cyclopropylamino)sulfonyl)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[0443] The title compound (31 mg) was obtained from 6-cyano-4-{4-[4-fluoroanilinocarbonyl]amino-3-fluorophenoxy} quinolin-7-ol sodium salt (100 mg), in the same manner as Example 7.

¹H-NMR(DMSO-d₆) δ(ppm): 0.51-0.63(4H, m), 2.17-2.25(2H, m), 3.15-3.22(1H, m), 3.26-3.33(2H, m), 4.42(2H, t, J= 6.0 Hz), 6.63 (1H, d, J= 5.2 Hz), 7.10-7.16 (3H, m), 7.40 (1H, dd, J= 2.8 Hz, J= 8.0 Hz), 7.44-7.48 (2H, m), 7.56(1H, brd, J= 2.8 Hz), 7.61(1H, s), 8.21-8.27(1H, m), 8.63-8.66(1H, m), 8.75 (1H, d, J= 5.2 Hz), 8.77 (1H, s), 9.11-9.13(1H, m).

Example 141

N-(4-(7-Benzyloxy-6-cyano-4-quinolyl)oxy-2-fluorophenyl)-N'-(2-thiazolyl)urea

[0444] Phenyl N-(4-(6-cyano-7-benzyloxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (6.93 g) and 2-aminothiazole (2.75 g) were dissolved in dimethylformamide (70 ml), and then diisopropylethylamine (4.8 ml) was added and the mixture was heated and stirred at 90°C for 2 hours. After cooling, water was added and the precipitated solid was filtered out and washed with ethyl acetate to obtain 5.53 g of the title compound as light brown crystals (79% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 5.46 (2H, s), 6.63 (1H, d, J=5.2Hz), 7.13-7.19 (2H, m), 7.33-7.48 (5H, m), 7.54 (2H, d, J=6.8Hz), 7.72 (1H, s), 8.21-8.27 (1H, m), 8.73-8.78 (2H, m)

[0445] The intermediates were synthesized in the following manner.

5 Production Example 141-1

Phenyl N-(4-(6-cyano-7-benzyloxy-4-quinolyl)oxy-2-fluorophenyl)carbamate

[0446] The 7-benzyloxy-6-cyano-4-(3-fluoro-4-aminophenoxy) quinoline (9.45 g) synthesized in Production Example 8 was dissolved in dimethylformamide (70 ml) and pyridine (5.9 ml), and the mixture was cooled to 0°C under a nitrogen atmosphere. After adding phenyl chlorocarbonate (3.4 ml), the mixture was stirred for 2 hours. Water was added to the reaction solution, and the precipitated crystals were filtered out and triturated in tetrahydrofuran and toluene to obtain 6.93 g of the title compound as light brown crystals (56% yield).

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 5.36 (2H, s), 6.53 (1H, d, J=5.3), 6.98-7.05 (2H, m), 7.17-7.47 (9H, m), 7.51-7.58 (3H, m), 8.67-8.71 (2H, m)

Example 142

N-[4-(6-Cyano-7-[3-(morpholin-4-yl)propoxy]-4-quinolyl)oxy-2-fluorophenyl]-N'-(2-thiazolyl)urea

[0447] N-(4-(6-Cyano-7-hydroxyquinolyl)oxy-2-fluorophenyl)-N'-(2-thiazolyl)urea (150 mg) was dissolved in dimethylformamide (3 ml), and then potassium carbonate (150 mg) and 1-chloro-3-(morpholin-4-yl)propane (70 mg) were added and the mixture was heated and stirred at 60°C for 2 hours. After cooling, water was added, extraction was performed with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (20 mg).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 1.94-2.04 (2H, m), 2.34-2.52 (6H, m), 3.54-3.61 (4H, m), 4.34 (2H, t, J=6.2Hz), 6.61 (1H, d, J=5.6Hz), 7.12-7.20 (2H, m), 7.37-7.47 (2H, m), 7.61 (1H, s), 8.21-8.27 (1H, m), 8.73-8.76 (2H, m)

[0448] The intermediates were synthesized in the following manner.

Production Example 142-1

N-(4-(6-Cyano-7-hydroxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2-thiazolyl)urea

[0449] The N-(4-(7-benzyloxy-6-cyanoquinolyl)oxy-2-fluorophenyl)-N'-(2-thiazolyl)urea (5.53 g) synthesized in Example 141 was dissolved in TFA (55 ml), and then thioanisole (5.5 ml) was added and the mixture was heated and stirred at 70°C for 6 hours. After cooling the reaction solution and concentrating it under reduced pressure, sodium bicarbonate water and methanol were added and the precipitated crystals were filtered. These were washed with diethyl ether to obtain 3.63 g of the title compound (80% yield).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 6.50 (1H, d, J=5.6Hz), 7.12-7.19 (2H, m), 7.35-7.45 (3H, m), 8.19-8.27 (1H, m), 8.61-8.66 (2H, m)

Example 143

N-(4-(6-Cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2-thiazolyl)urea

[0450] The N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2-thiazolyl)urea (150 mg) synthesized in Example 142 was dissolved in dimethylformamide (2.5 ml), and then potassium carbonate (150 mg) and 1-chloro-3-(diethylamino)propane (80 mg) were added and the mixture was heated and stirred at 60°C for 2 hours. After cooling, water was added, extraction was performed with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (10 mg). ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 0.95 (6H, t, J=7.0Hz), 1.85-1.96 (2H, m), 2.40-2.65 (6H, m), 4.32 (2H, t, J=6.0Hz), 6.62 (1H, d, J=5.2Hz), 7.12-7.20 (2H, m), 7.36-7.48 (2H, m), 7.59 (1H, s), 8.20-8.24 (1H, m), 8.73-8.77 (2H, m)

Example 144N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-methylisoxazol-5-yl)urea

[0451] The 4-(4-aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (100 mg) synthesized in Production Example 10 and phenyl N-(3-methylisoxazol-5-yl)carbamate (81 mg) were added to toluene (5 ml), then diisopropylethylamine (0.88 ml) was added and the mixture was heated and stirred at 100°C for 2 hours. After cooling, the precipitated crystals were filtered and washed with an ethyl acetate:toluene (1:1) mixed solvent to obtain the title compound (102 mg).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.16 (3H, s), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.44 (2H, m), 5.95 (1H, s), 6.52 (1H, d, J=5.2Hz), 7.26 (2H, d, J=9.2Hz), 7.58-7.64 (3H, m), 8.71 (1H, d, J=5.2Hz), 8.76 (1H, s), 9.04 (1H, brs).

[0452] The intermediates were synthesized in the following manner.

Production Example 144-1N-(3-Methylisoxazol-5-yl)carbamate

[0453] 5-Amino-3-methylisoxazole (1 g) purchased from Aldrich Co. was dissolved in tetrahydrofuran (40 ml) and pyridine (1.5 ml), and after cooling to 0°C under a nitrogen atmosphere, phenyl chlorocarbonate (1.4 ml) was added and the mixture was stirred at room temperature for 1.5 hours. Water was added, extraction was performed twice with ethyl acetate, and then the organic layers were combined, washed with water and saturated brine in that order, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was recrystallized from ethyl acetate and n-hexane to obtain the title compound (450 mg, 20% yield).

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 2.27 (3H, s), 6.03 (1H, s), 7.16-7.30 (3H, m), 7.37-7.44 (2H, m), 7.81 (1H, brs)

Example 145N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(5-methylisoxazol-3-yl)urea

[0454] The 4-(4-aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (100 mg) synthesized in Production Example 10 and phenyl N-(5-methylisoxazol-3-yl)carbamate (72 mg) were added to toluene (5 ml), and then diisopropylethylamine (0.50 ml) was added and the mixture was heated to reflux for 2 hours. After cooling, the precipitated crystals were filtered and washed with an ethyl acetate/toluene (1/1) mixed solvent to obtain the title compound (120 mg).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.36 (3H, s), 3.37 (3H, s), 3.75-3.78 (2H, m), 4.37-4.43 (2H, m), 6.50-6.54 (2H, m), 7.26 (2H, d, J=8.8Hz), 7.56-7.63 (3H, m), 8.72 (1H, d, J=5.6Hz), 8.76 (1H, s), 8.99 (1H, brs), 9.51 (1H, brs)

[0455] The intermediates were synthesized in the following manner.

Production Example 145-1N-(5-Methylisoxazol-3-yl)carbamate

[0456] 3-Amino-5-methylisoxazole (1.00 g) purchased from Aldrich Co. was dissolved in tetrahydrofuran (20 ml) and pyridine (1.5 ml), and after cooling to 0°C under a nitrogen atmosphere, phenyl chlorocarbonate (1.4 ml) was added and the mixture was stirred at room temperature for 2 hours. Water was added, extraction was performed twice with ethyl acetate, and then the organic layers were combined, washed with water and saturated brine in that order, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was triturated with diethyl ether and n-hexane to obtain the title compound (1.54 g) (68% yield).

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 2.42 (3H, s), 6.56 (1H, s), 7.15-7.30 (3H, m), 7.36-7.43 (2H, m), 8.18 (1H, brs)

Example 146N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2-oxo-1,2,3,4-tetrahydro-6-quinoliny)urea

[0457] The title compound (64 mg) was obtained from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl) carbamate (65 mg), in the same manner as Example 25.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.38-2.45 (2H, m), 2.81-2.90 (2H, m), 3.36 (3H, s), 3.75-3.79 (2H, m), 4.40-4.43 (2H, m), 6.61 (1H, d, J=5.2), 6.77 (1H, d, J=8.4Hz), 7.10-7.18 (2H, m), 7.30 (1H, brs), 7.36-7.42 (1H, m), 7.63 (1H, s), 8.23-8.29 (1H, m), 8.60 (1H, brs), 8.73-8.76 (2H, m), 8.92-8.94 (1H, m), 9.97 (1H, brs)

Example 1474-(4-(Anilincarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0458] The N-(4-(6-cyano-7-methoxy-4-quinolyl)oxyphenyl)-N'-phenylurea (100 mg) synthesized in Example 37 was dissolved in dimethylsulfoxide (3 ml) at 80°C, and then 5N aqueous sodium hydroxide was added and the mixture was heated and stirred for 2 hours. The reaction solution was neutralized with 1N hydrochloric acid, and the precipitated crystals were filtered out and washed with ethanol to obtain the title compound (60 mg).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.03 (3H, s), 6.56 (1H, d, J=6.0Hz), 6.96 (1H, t, J=7.6Hz), 7.22-7.30 (4H, m), 7.45 (2H, d, J=7.6Hz), 7.52 (1H, s), 7.59-7.62 (2H, m), 7.76 (1H, brs), 7.87 (1H, brs), 8.69-8.73 (2H, m), 8.76 (1H, brs), 8.90 (1H, brs)

Example 1484-(4-(Anilincarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0459] The title compound (54 mg) was obtained from the N-(4-(6-cyano-7-(methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-phenylurea (95 mg) synthesized in Example 65, in the same manner as Example 147.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.35 (3H, s), 3.75-3.81 (2H, m), 4.37-4.41 (2H, m), 6.46 (1H, d, J=5.2), 6.96 (1H, t, J=7.6), 7.21-7.30 (4H, m), 7.45 (2H, d, J=8.4Hz), 7.55 (1H, s), 7.59 (2H, d, J=8.8Hz), 7.81 (1H, brs), 7.82 (1H, brs), 8.65 (1H, d, J=5.2), 8.77-8.79 (2H, m), 8.91 (1H, brs)

Example 1494-(4-((2,4-Difluorophenyl)carbonyl)amino-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0460] The title compound (35 mg) was obtained from the N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea (100 mg) synthesized in Example 66, in the same manner as Example 147.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.34 (3H, s), 3.78-3.81 (2H, m), 4.39-4.42 (2H, m), 6.56 (1H, d, J=5.2Hz), 7.03-7.17 (2H, m), 7.28-7.43 (2H, m), 7.56 (1H, s), 7.81 (2H, brs), 8.08-8.16 (1H, m), 8.28-8.29 (1H, m), 8.67 (1H, d, J=5.2), 8.76 (1H, s), 9.00-9.09 (2H, m)

Example 1504-(4-((4-Fluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0461] The title compound (25 mg) was obtained from the N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea (58 mg) synthesized in Example 100, in the same manner as Example 147.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.34 (3H, s), 3.78-3.81 (2H, m), 4.39-4.42 (2H, m), 6.56 (1H, d, J=5.2Hz), 7.10-7.17 (3H, m), 7.36-7.50 (3H, m), 7.56 (1H, s), 7.82 (2H, brs), 8.19-8.26 (1H, m), 8.64-8.69 (2H, m), 8.76 (1H, s), 9.13-9.15 (1H, m)

Example 1517-(2-Methoxyethoxy)-4-(4-((1,3-thiazol-2-ylamino)carbonyl)amino-3-fluorophenoxy)-6-quinolinecarboxamide

[0462] The title compound (18 mg) was obtained from the N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(1,3-thiazol-2-yl)urea (100 mg) synthesized in Example 25, in the same manner as Example 147.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.34 (3H, s), 3.78-3.81 (2H, m), 4.39-4.42 (2H, m), 6.57 (1H, d, J=5.2Hz), 7.12-7.19 (2H, m), 7.39 (1H, d, J=3.6Hz), 7.41-7.46 (1H, m), 7.57 (1H, s), 7.82 (1H, brs), 8.21-8.25 (1H, m), 8.68 (1H, d, J=5.2Hz), 8.76 (1H, s), 9.06 (1H, brs)

Example 1524-(4-((4-Fluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide

[0463] The title compound (25 mg) was obtained from 6-carbamoyl-4-(4-amino-3-fluorophenoxy)-7-methoxyquinoline (50 mg), in the same manner as Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.02 (3H, s), 6.55 (1H, d, J=5.6Hz), 7.09-7.18 (3H, m), 7.35-7.41 (1H, m), 7.43-7.49 (2H, m), 7.51 (1H, s), 7.74 (1H, brs), 7.85 (1H, brs), 8.18-8.26 (1H, m), 8.61-8.68 (3H, m), 9.09-9.12 (1H, m)

[0464] The starting compounds were synthesized in the following manner.

5 Production Example 152-1

7-Methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid

[0465] Glycerol (20 ml) and potassium hydroxide (KOH, 3.0 g) were added to the 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carbonitrile (2 g) of Production Example 24, and after heating and stirring at 160°C for 3 hours, water (40 ml) was added and the mixture was heated at 80°C for 30 minutes. After cooling, 2N hydrochloric acid was added to acidity and the precipitated insoluble portion was filtered out, washed with water and then dried under reduced pressure to obtain the title compound (1.6 g).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.87 (3H, s), 6.14 (1H, d, J=6.0Hz), 7.04 (1H, s), 7.98 (1H, d, J=6.0), 8.40 (1H, s)

15 Production Example 152-2

7-Methoxy-4-chloroquinoline-6-carbonyl chloride

[0466] Thionyl chloride (10 ml) and a small amount of dimethylformamide (DMF) were added to 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid (2.0 g), and the mixture was heated to reflux for 2 hours. After concentrating under reduced pressure, azeotropic distillation was performed twice with toluene to obtain the title compound (2.7 g).

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 4.20 (3H, s), 7.80-7.90 (1H, m), 8.41 (1H, s), 8.90-9.00 (2H, m)

25 Production Example 152-3

7-Methoxy-4-chloroquinoline-6-carboxamide

[0467] 7-Methoxy-4-chloroquinoline-6-carbonyl chloride (2.7 g) was dissolved in tetrahydrofuran (150 ml), and the solution was cooled to 0°C. After adding 30% ammonia water (5 ml), the mixture was stirred at room temperature for 30 minutes. Water was added, extraction was performed 3 times with ethyl acetate, and then the organic layers were combined, washed with water and saturated brine, dried over sodium sulfate and dried under reduced pressure to obtain the title compound (1.35 g).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.03 (3H, s), 7.56-7.66 (2H, m), 7.79 (1H, brs), 7.88 (1H, brs), 8.46-8.49 (1H, m), 8.78-8.82 (1H, m)

35 Production Example 152-4

6-Carbamoyl-4-(3-fluoro-4-nitrophenoxy)-7-methoxyquinoline

[0468] The title compound (1.1 g) was obtained from 7-methoxy-4-chloroquinoline-6-carboxamide (1.23 g), in the same manner as Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.03 (3H, s), 6.96 (1H, d, J=5.2Hz), 7.25-7.30 (1H, m), 7.57 (1H, s), 7.61-7.66 (1H, m), 7.74 (1H, brs), 7.84 (1H, brs), 8.25-8.32 (1H, m), 8.49 (1H, s), 8.80 (1H, d, J=5.2Hz)

45 Production Example 152-5

6-Carbamoyl-4-(4-amino-3-fluorophenoxy)-7-methoxyquinoline

[0469] The title compound (540 mg) was obtained from 6-carbamoyl-4-(3-fluoro-4-nitrophenoxy)-7-methoxyquinoline (1.08 g), in the same manner as Production Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 4.01 (3H, s), 5.19-5.23 (2H, m), 6.44 (1H, d, J=5.2), 6.83-6.89 (2H, m), 7.05-7.10 (1H, m), 7.47 (1H, s), 7.71 (1H, brs), 7.83 (1H, brs), 8.60-8.66 (2H, m)

Example 153

1-(2-Chloro-4-{6-[4-(2-diethylaminoethoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl)-3-cyclopropylurea

[0470] 1-[2-Chloro-4-[6-[4-(2-diethylaminoethoxy)-phenyl]-7-(2-trimethylsilylanyloxy)methyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-phenyl)-3-cyclopropylurea (40 mg, 0.0601 mmol) was dissolved in 1 ml of tetrahydrofuran, and then 0.5 ml (8.3 equivalents) of tetrabutylammonium fluoride (1M tetrahydrofuran solution) was added dropwise and the mixture was refluxed for 2 hours. After returning to room temperature, 3 ml of water was added, the mixture was allowed to stand for 3 hours, and the precipitating crystals were filtered out, washed with water and ether:hexane = 1:1 and dried under reduced pressure to obtain 22 mg of the title compound.

MS Spectrum(ESI):535(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.40-0.54(2H,m),0.70-0.80(2H,m), 1.06(6H,t, J=7.8Hz) 2.55-2.70(5H,m), 2.88(2H,t, J=7.8Hz), 4.18(2H,t, J=7.8Hz), 7.01(1H, d, J=1.7Hz), 7.12(2H, d, J=8.4Hz), 7.23(1H, d, J=2.5Hz), 7.27(1H, dd, J=8.8Hz, J'=2.5Hz), 7.41(1H, d, J=2.5Hz),7.97(2H, d, J=8.4Hz), 8.01(1H, s), 8.24(1H, d, J=8.8Hz), 8.36(1H, s),12.68 (1H, brs)

[0471] The intermediates were synthesized in the following manner.

Production Example 153-12-Amino-5-(4-benzyloxyphenyl)-1H-pyrrole-3-carboxylic acid ethyl ester

[0472] After adding 700 ml of ethanol to 50.7 g of ethyl 2-amidinoacetate hydrochloride (a publicly known compound described in Liebigs Ann. Chem., 1895(1977)), the mixture was stirred at room temperature, 22.3 g of sodium ethoxide (1 equivalent with respect to ethyl 2-amidinoacetate hydrochloride) was added, and the mixture was stirred for 15 minutes under a nitrogen atmosphere. To this there was added 49.9 g of 1-(4-benzyloxyphenyl)-2-bromoethanone (publicly known compound described in Journal of Heterocyclic Chemistry, vol.2, 310(1965) and Journal of Medicinal Chemistry, vol.17, 55(1974)), and the mixture was stirred for 36 hours at room temperature under a nitrogen atmosphere. Water was added, ethyl acetate was used for liquid separation and extraction, and then the organic layer was dried over sodium sulfate and concentrated to dryness to obtain 56.7 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 1.32 (3H, t, J=7.3Hz),4.10(2H,q, J=7.3Hz),5.08(2H, s,), 5.62(2H, s), 6.30 (1H, d, J=2.2Hz), 6.95 (2H, d, J=7.9Hz),7.28-7.47 (7H, m), 10.67(1H,brs)

Production Example 153-26-(4-Benzyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol

[0473] After adding 84 ml of formic acid, 338 ml of formamide and 169 ml of dimethylformamide to 56.7 g of the ethyl 2-amino-5-(4-benzyloxyphenyl)-1H-pyrrole-3-carboxylate synthesized in Production Example 153-1, the mixture was stirred at 140°C for 48 hours and then allowed to stand at room temperature for 24 hours. The precipitated solid was filtered out and dried under reduced pressure to obtain 41 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 5.12(2H, s), 6.78(1H, s),7.03(2H, d, J=7.0Hz), 7.28-7.47(5H, m), 7.73(2H, d, J=7.0Hz), 7.82(1H, s),11.80(1H,brs), 12.20(1H,brs)

Production Example 153-36-(4-Benzyloxyphenyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine

[0474] After adding 200 ml of phosphorus oxychloride to 20 g of the 6-(4-benzyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol synthesized in Production Example 153-2, the mixture was stirred at 140°C for 3 hours and the reaction mixture was cooled to room temperature and the reaction mixture was concentrated. Ice water was added to the residue, and liquid separation and extraction were performed with an ethyl acetate:tetrahydrofuran (5:1) mixed solvent. The organic layer was washed with water and saturated brine, dried over sodium sulfate and concentrated to dryness to obtain 12 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 5.18(2H, s),6.97(1H, d, J=2.4Hz),7.12(2H, d, J=7.5Hz), 7.30-7.50(5H, m), 7.94(2H, d, J=7.5Hz), 8.70(1H, s), 12.90(1H,brs)

Production Example 153-4

6-(4-Benzyloxyphenyl)-4-chloro-7-(2-trimethylsilanylethoxy-methyl)-7H-pyrrolo[2,3-d]pyrimidine

[0475] After adding 0.381 g (1.3 equivalents) of sodium hydride (60% dispersion, Aldrich) to a solution of 2.46 g of the 6-(4-benzyloxyphenyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine synthesized in Production Example 153-3 in dimethylformamide (30 ml), the mixture was stirred at room temperature for 40 minutes, 1.68 ml (1.3 equivalents) of 2-(chloromethoxy)ethyltrimethylsilane was added, the mixture was stirred at room temperature overnight, and then 20 ml of water and 1 ml of acetic acid were added and liquid separation and extraction were performed with an ethyl acetate:tetrahydrofuran (5:1) mixed solvent. The organic layer was dried over sodium sulfate, concentrated and subjected to NH silica gel column chromatography (ethyl acetate) to obtain 2.83 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) -0.10 (9H, s), 0.84(2H,t, J=8.0Hz), 3.62(2H,t, J=8.0Hz), 5.20(2H, s), 5.61(2H, s), 6.81 (1H, s), 7.19(2H, d, J=7.7Hz), 7.33-7.52(5H, m), 7.88(2H, d, J=7.7Hz), 8.70(1H, s)

Production Example 153-5

4-[6-(4-Benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine

[0476] After adding 12 ml of dimethylsulfoxide to the 6-(4-benzyloxyphenyl)-4-chloro-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine synthesized in Production Example 153-4, 141 mg (1.5 equivalents) of sodium hydride (60% dispersion, Aldrich) and 507 mg (1.5 equivalents) of 4-amino-3-chlorophenol were added while stirring, and stirring was then continued at room temperature for 10 minutes and then at 135-140°C for 4 hours. The mixture was returned to room temperature, water was added, and liquid separation and extraction were performed with an ethyl acetate:tetrahydrofuran (5:1) mixed solvent. The organic layer was dried over sodium sulfate, concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 1.20 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) -0.90(9H, s), 0.85(2H,t, J=8.0Hz), 3.61(2H,t, J=8.0Hz), 5.18(2H, s), 5.34(2H, s), 5.59 (2H, s), 6.64(1H, s), 6.85(1H, d, J=8.0Hz), 6.95-6.99(1H, m), 7.15-7.20(3H, m), 7.30-7.55(5H, m), 7.71(2H, d, J=8.0Hz), 8.41(1H, d, J=1.4Hz)

Production Example 153-6

1-[4-[6-(4-Benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-3-cyclopropylurea

[0477] After dissolving 334 mg of the 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine synthesized in Production Example 153-5 in 4 ml of dimethylformamide, 0.066 ml (1.4 equivalents) of pyridine and 0.102 ml (1.4 equivalents) of phenyl chlorocarbonate were added, and after stirring at room temperature for 2.5 hours, 0.09 ml (2.2 equivalents) of cyclopropylamine was added and the mixture was stirred overnight. Water was added, liquid separation and extraction were performed with ethyl acetate, and the organic layer was washed with saturated brine, dried over sodium sulfate, concentrated and subjected to silica gel column chromatography (hexane-ethyl acetate) to obtain 330 mg of the title compound.

MS Spectrum (ESI) : 656(M+1), 678(M+23),

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.40-0.46(2H,m), 0.63-0.70(2H,m), 0.87(2H,t, J=7.8Hz), 2.43-2.62(1H, m), 3.62(2H,t, J=7.8Hz), 5.20(2H, s), 5.60(2H, s), 6.75(1H, s), 7.15-7.53 (9H, m), 7.73(2H, d, J=8.6Hz), 7.94(1H, s), 7.93(1H, s), 8.18(1H, d, J=9.0Hz), 8.41(1H, d, J=1.8Hz)

Production Example 153-7

1-[2-Chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl]-3-cyclopropylurea

[0478] After dissolving 260 mg of the 1-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-3-cyclopropylurea synthesized in Production Example 153-6 in 10 ml of ethanol and 5 ml of tetrahydrofuran, 100 mg of platinum oxide was added and the mixture was stirred overnight at room temperature and normal pressure under a hydrogen atmosphere. It was then filtered with celite and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane-ethyl acetate) to obtain 160 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.40-0.46(2H,m), 0.63-0.70(2H,m), 0.86(2H,t, J=8.1Hz), 2.53-2.62(1H, m), 3.62(2H,t, J=8.1Hz), 5.58(2H, s,), 6.67(1H, s,), 6.90(2H, d, J=8.2Hz), 7.13-7.22 (2H, m), 7.43-7.47(1H, m), 7.60 (2H, d, J=8.2Hz), 7.93(1H, s), 8.17(1H, d, J=9.1Hz), 8.40(1H, s), 9.38(1H,brs)

5 Production Example 153-8

1-{2-Chloro-4-[6-[4-(2-diethylamino-2-hydroxypropoxy)-phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-phenyl}-3-cyclopropylurea

10 **[0479]** After dissolving 113 mg of the 1-{2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl}-3-cyclopropylurea synthesized in Production Example 153-7 in 1 ml of dimethylformamide, 120 mg (3.5 equivalents) of 2-chloroethyldiethylamine hydrochloride and 138 mg (5 equivalents) of potassium carbonate were added and the mixture was stirred at 80°C for 15 hours. The mixture was then returned to room temperature, water was added, and liquid separation and extraction were performed with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 40 mg of the title compound.

MS Spectrum(ESI):665(M+1),

1H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.40-0.47(2H,m), 0.63-0.70(2H,m), 0.87(2H,t, J=8.9Hz), 0.99(6H,t, J=8.0Hz) 2.52-2.62(5H,m), 2.80(2H,t, J=8.0Hz), 3.62(2H,t, J=8.9Hz), 4.10(2H,t, J=8.0Hz), 5.60(2H, s,), 6.72(1H, s), 7.08(2H, d, J=8.1Hz), 7.17(1H, d, J=3.2Hz), 7.21(1H, dd, J=3.2, 8.4Hz), 7.46(1H, d, J=3.2Hz), 7.71(2H, d, J=8.1Hz), 7.94(1H, s,), 8.18(1H, d, J=8.4Hz), 8.40(1H, s,)

Example 154

25 1-(2-Chloro-4-{6-[4-(2-(1-pyrrolidino)ethoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl)-3-cyclopropylurea

[0480] The title compound (13 mg) was obtained from 25 mg of 1-{2-chloro-4-[6-[4-(2-pyrrolidinoethoxy)-phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-phenyl}-3-cyclopropylurea, in the same manner as Example 153.

30 MS Spectrum(ESI):533(M+1),

1H-NMR Spectrum: (DMSO-d₆) 0.40-0.45(2H,m), 0.60-0.70(2H,m), 1.65-1.72(4H,m), 2.47-2.60(5H,m, covered by DMSO peak), 2.70(2H,t, J=7.6Hz), 4.12(2H,t, J=7.6Hz), 6.82(1H, s), 7.02(2H, d, J=8.5Hz), 7.13(1H, d, J=2.6Hz), 7.17(1H, dd, J=2.6, 8.5Hz), 7.41(1H, d, J=2.6Hz), 7.87(2H, d, J=8.5Hz), 7.91(1H, s), 8.14(1H, d, J=8.5Hz), 8.26(1H, s), 12.59 (1H, brs)

Production Example 154-1

1-{2-Chloro-4-[6-[4-(2-(1-pyrrolidino)ethoxy)-phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl}-3-cyclopropylurea

40 **[0481]** The title compound (27 mg) was obtained from 86 mg of the 1-{2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl}-3-cyclopropylurea synthesized in Production Example 153-7, using 104 mg of 1-(2-chloroethyl)pyrrolidine hydrochloride and 126 mg of potassium carbonate, in the same manner as Production Example 153-8.

45 MS Spectrum(ESI):663(M+1),

1H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.40-0.44(2H,m), 0.61-0.69(2H,m), 0.85(2H,t, J=8.0Hz), 1.61-1.76(4H, m), 2.44-2.61(5H,m, covered by DMSO peak), 2.86(2H,t, J=8.0Hz), 3.61(2H,t, J=8.0Hz), 4.13(2H,t, J=8.0Hz), 5.79 (2H, s), 6.72(1H, s), 7.09(2H, d, J=8.7Hz), 7.15(1H, d, J=8.7Hz), 7.20(1H, dd, J=2.5, 8.7Hz), 7.44(1H, d, J=2.5Hz), 7.71(2H, d, J=8.7Hz), 7.93(1H, s), 8.16(1H, d, J=8.7Hz), 8.39(1H, s)

Example 155

1-(2-Chloro-4-{6-[4-(2-(1-pyrrolidino)propoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl)-3-cyclopropylurea

55 **[0482]** The title compound (11 mg) was obtained from 28 mg of 1-{2-chloro-4-[6-[4-(2-(1-pyrrolidino)propoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl}-3-cyclopropylurea, in the same manner as Example 153.

MS Spectrum(ESI):547(M+1),

Production Example 155-1

1-[2-Chloro-4-[6-[4-(3-(1-pyrrolidino)propoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0483] The title compound (28 mg) was obtained from 96 mg of the 1-[2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl]-3-cyclopropylurea synthesized in Production Example 153-7, using 146 mg of 1-(3-chloropropyl)pyrrolidine, 150 mg of potassium carbonate and 15 mg of potassium iodide, in the same manner as Production Example 153-8.

MS Spectrum(ESI):677(M+1),

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.39-0.47(2H,m), 0.63-0.70(2H,m), 0.87(2H,t, J=8.0Hz), 1.63-1.73(4H, m), 1.88-1.96(2H,m), 2.40-2.62(7H, m, covered by DMSO peak), 3.61(2H,t, J=8.1Hz), 4.09(2H,t, J=6.6Hz), 5.60(2H, s), 6.72(1H, s), 7.08(2H, d, J=8.9Hz), 7.16(1H, d, J=2.6Hz), 7.21(1H, dd, J=2.4, 8.9Hz), 7.46(1H, d, J=2.6Hz), 7.71(2H, d, J=8.9Hz), 7.95(1H, s), 8.18(1H, d, J=8.9Hz), 8.40(1H, s)

Example 156

1-[2-Chloro-4-[6-[4-((2R)-2-hydroxy-3-diethylaminopropoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0484] The title compound (11 mg) was obtained from 22 mg of 1-[2-chloro-4-[6-[4-((2S)-2-hydroxy-3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea, in the same manner as Example 153.

MS Spectrum(ESI):565(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.40-0.47(2H,m), 0.63-0.70(2H,m), 0.96(6H,t, J=6.6Hz) 2.45-2.63(7H,m, covered by DMSO peak), 3.80-4.10(3H,m), 6.93(1H, s), 7.04(2H, d, J=8.6Hz), 7.15(1H, d, J=2.2Hz), 7.19(1H, dd, J=2.2, 8.6Hz), 7.43(1H, d, J=2.2Hz), 7.88(2H, d, J=8.6Hz), 7.93(1H, s), 8.16(1H, d, J=8.6Hz), 8.28(1H, s), 12.60(1H, brs)

Production Example 156-1

1-[2-Chloro-4-[6-[4-((2S)-2-hydroxy-3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0485] After dissolving 75 mg of the 1-[2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl]-3-cyclopropylurea synthesized in Production Example 153-7 in 1 ml of dimethylformamide, 91 mg (3 equivalents) of (2S)-(+)-glycidyl p-toluenesulfonate and 92 mg (5 equivalents) of potassium carbonate were added, and the mixture was stirred at 75°C for 8 hours. After returning it to room temperature, the reaction system was filtered with a Kiriya funnel, 0.1 ml of diethylamine was added to the filtrate, and the mixture was stirred at 70°C for 8 hours. Water was then added, and liquid separation and extraction were performed with ethyl acetate and tetrahydrofuran. The organic layer was concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 24 mg of the title compound.

MS Spectrum(ESI):695(M+1),

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.39-0.47(2H,m), 0.63-0.70(2H,m), 0.86(2H,t, J=8.3Hz), 0.97(6H,t, J=7.0Hz), 2.38-2.60(7H,m), 3.61(2H,t, J=8.3Hz), 3.83-4.11(3H,m), 4.82(1H, brs), 5.59(2H, s), 6.73(1H, s), 7.08(2H, d, J=8.5Hz), 7.18(1H, d, J=2.7Hz), 7.21(1H, dd, J=2.7, 8.5Hz), 7.45(1H, d, J=2.7Hz), 7.71(2H, d, J=8.5Hz), 7.94(1H, s), 8.18(1H, d, J=8.5Hz), 8.40(1H, s),

Example 157

1-[2-Chloro-4-[6-[4-((2R)-2-hydroxy-3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0486] The title compound (11 mg) was obtained from 22 mg of 1-[2-chloro-4-[6-[4-((2R)-2-hydroxy-3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea, in the same manner as Example 153.

MS Spectrum(ESI):565(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.40-0.47(2H,m), 0.63-0.70(2H,m), 0.96(6H,t, J=6.6Hz) 2.45-2.63(7H,m, covered by DMSO peak), 3.80-4.10(3H,m), 6.93(1H, s), 7.04(2H, d, J=8.6Hz), 7.16(1H, d, J=2.2Hz), 7.19(1H, dd, J=2.2, 8.6Hz),

7.43(1H, d, J=2.2Hz), 7.89(2H, d, J=8.6Hz), 7.94(1H, s), 8.16(1H, d, J=8.6Hz), 8.28(1H, s) 12.60(1H, brs)

Production Example 157-1

5 1-[2-Chloro-4-[6-[4-((2R)-2-hydroxy-3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0487] The title compound (62 mg) was obtained from 127 mg of 1-[2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl]-3-cyclopropylurea, using 154 mg of (2R)-(-)-glycidyl p-toluenesulfonate, 155 mg of potassium carbonate and 0.15 ml of diethylamine, in the same manner as Production Example 153-9.

MS Spectrum(ESI):695(M+1),

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.39-0.47(2H, m), 0.63-0.70(2H, m), 0.86(2H, t, J=8.3Hz), 0.97(6H, t, J=7.0Hz) 2.38-2.60(7H, m, covered by DMSO peak), 3.61(2H, t, J=8.3Hz), 3.83-4.11(3H, m), 4.82(1H, brs), 5.60(2H, s), 6.73(1H, s), 7.09(2H, d, J=8.5Hz), 7.16(1H, d, J=2.7Hz), 7.20(1H, dd, J=2.7, 8.5Hz), 7.45(1H, d, J=2.7Hz), 7.71(2H, d, J=8.5Hz), 7.94(1H, s), 8.18(1H, d, J=8.5Hz), 8.40(1H, s)

Example 158

20 1-(2-Chloro-4-[6-[4-((2S)-2-hydroxy-3-pyrrolidinopropoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl)-3-cyclopropylurea

[0488] The title compound (14 mg) was obtained from 30 mg of 1-[2-chloro-4-[6-[4-(2-hydroxy-3-pyrrolidinopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea, in the same manner as Example 153.

MS Spectrum(ESI):563(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.40-0.47(2H, m), 0.60-0.70(2H, m), 1.62-1.74(4H, m), 2.40-2.70(7H, m, covered by DMSO peak), 3.88-4.10(3H, m), 4.92(1H, brs) 6.94(1H, s), 7.04(2H, d, J=8.6Hz), 7.15(1H, d, J=2.4Hz), 7.20(1H, dd, J=2.4, 8.6Hz), 7.44(1H, d, J=2.4Hz), 7.88(2H, d, J=8.6Hz), 7.94(1H, s), 8.16(1H, d, J=8.6Hz), 8.28(1H, s) 12.60(1H, brs)

Production Example 158-1

35 1-[2-Chloro-4-[6-[4-(2S)-2-hydroxy-3-pyrrolidinopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0489] The title compound (30 mg) was obtained from 81 mg of 1-[2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl]-3-cyclopropylurea, using 98 mg of (2S)-(+)-glycidyl p-toluenesulfonate, 99 mg of potassium carbonate and 0.1 ml of pyrrolidine, in the same manner as Production Example 153-9.

MS Spectrum(ESI):693(M+1),

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.40-0.46(2H, m), 0.62-0.70(2H, m), 0.87(2H, t, J=8.4Hz), 1.62-1.72(4H, m), 2.40-2.68(7H, m, covered by DMSO peak), 3.62(2H, t, J=8.4Hz), 3.90-4.10(3H, m), 4.92(1H, brs), 5.60(2H, s), 6.72(1H, s), 7.10(2H, d, J=8.8Hz), 7.17(1H, d, J=2.4Hz), 7.21(1H, dd, J=2.4, 8.8Hz), 7.46(1H, d, J=2.4Hz), 7.71(2H, d, J=8.8Hz), 7.95(1H, s), 8.18(1H, d, J=8.8Hz), 8.41(1H, s)

Example 159

50 1-(2-Chloro-4-[6-[4-((2R)-2-hydroxy-3-pyrrolidinopropoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl)-3-cyclopropylurea

[0490] The title compound (24 mg) was obtained from 70 mg of 1-[2-chloro-4-[6-[4-(2-hydroxy-3-pyrrolidinopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea, in the same manner as Example 153.

MS Spectrum(ESI):563(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.40-0.47(2H, m), 0.60-0.70(2H, m), 1.73-1.87(4H, m), 2.49-2.60(7H, m, covered by DMSO peak), 3.94-4.19(3H, m), 4.92(1H, brs) 6.94(1H, d, J=1.2Hz), 7.06(2H, d, J=8.6Hz), 7.15-7.22(2H, m), 7.43(1H, d, J=2.4Hz), 7.91(2H, d, J=8.6Hz), 7.96(1H, s), 8.17(1H, d, J=8.6Hz), 8.29(1H, s) 12.61(1H, brs)

Production Example 159-1

1-[2-Chloro-4-[6-[4-((2R)-2-hydroxy-3-pyrrolidinopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0491] The title compound (72 mg) was obtained from 128 mg of 1-[2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea, using 155 mg of (2R)-(-)-glycidyl p-toluenesulfonate, 156 mg of potassium carbonate and 0.13 ml of pyrrolidine, in the same manner as Production Example 153-9.

MS Spectrum(ESI):693(M+1),

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.40-0.46(2H,m), 0.60-0.70(2H,m), 0.87(2H,t, J=8.4Hz), 1.62-1.72(4H, m), 2.40-2.68(7H,m, covered by DMSO peak), 3.61(2H,t, J=8.4Hz), 3.90-4.10(3H,m), 4.92(1H, brs,), 5.60(2H, s,), 6.72(1H, s), 7.09(2H, d, J=8.8Hz), 7.16(1H, d, J=2.4Hz), 7.20(1H, dd, J=2.4, 8.8Hz), 7.45(1H, d, J=2.4Hz), 7.71(2H, d, J=8.8Hz), 7.95(1H, s), 8.18(1H, d, J=8.8Hz), 8.40(1H, s)

Example 160

1-[2-Chloro-4-[6-[4-(2-diethylaminopropoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0492] The title compound (2 mg) was obtained from 17 mg of 1-[2-chloro-4-[6-[4-(2-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea, in the same manner as Example 153.

MS Spectrum(ESI):549(M+1),

Production Example 160-1

4-[4-(4-Amino-3-chlorophenoxy)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol

[0493] After dissolving 255 mg of the 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine synthesized in Production Example 153-5 in 10 ml of ethanol and 3 ml of tetrahydrofuran, 100 mg of platinum oxide was added and the mixture was stirred overnight at room temperature under normal pressure in a hydrogen atmosphere. After filtering with celite, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane-ethyl acetate) to obtain 105 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H, s), 0.83(2H,t, J=7.8Hz), 3.52(2H,t, J=7.8Hz), 5.33(2H, s), 5.54(2H, s), 6.55(1H, s), 6.83(1H, d, J=8.8Hz), 6.88(2H, d, J=8.8Hz), 6.94(1H, dd, J=2.4, 8.8Hz), 7.17(1H, d, J=2.4Hz), 7.58(2H, d, J=8.8Hz), 8.35(1H, s), 9.84(1H, brs)

Production Example 160-2

2-Chloro-4-[6-[4-(3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenylamine

[0494] After dissolving 47 mg of the 4-[4-(4-amino-3-chlorophenoxy)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol synthesized in Production Example 160-1 in 0.5 ml of dimethylformamide, there were added 56 mg (3.1 equivalents) of (3-chloropropyl)diethylamine hydrochloride and 94 mg (7 equivalents) of potassium carbonate, and the mixture was stirred at 80°C for 24 hours. It was then returned to room temperature, water was added, and liquid separation and extraction were performed with an ethyl acetate:tetrahydrofuran (5:1) mixed solvent. The organic layer was dried over sodium sulfate, concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 49 mg of the title compound.

Ms Spectrum(ESI):596(M+1),

Production Example 160-3

1-[2-Chloro-4-[6-[4-(3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]-3-cyclopropylurea

[0495] After dissolving the 2-chloro-4-[6-[4-(3-diethylaminopropoxy)phenyl]-7-(2-trimethylsilanylethoxymethyl)-7H-

pyrrolo[2,3-d]pyrimidin-4-yloxy]phenylamine synthesized in Production Example 160-2 in 0.6 ml of dimethylsulfoxide, 23 mg of phenyl cyclopropylcarbamate was added and the mixture was stirred at 80°C for 1.5 hours. After further adding 75 mg of phenyl cyclopropylcarbamate and stirring at 100°C for 5 hours, 70 mg of the same reagent was added prior to stirring overnight. The mixture was then returned to room temperature, water was added, and liquid separation and extraction were performed with an ethyl acetate:tetrahydrofuran (5:1) mixed solvent. The organic layer was dried over sodium sulfate, concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 18 mg of the title compound.

MS Spectrum(ESI):679(M+1),

Example 161

1-(4-Fluorophenyl)-3-[4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylsulfanyl)thiazol-5-yl]urea

[0496] After adding 323 mg of iron powder, 12 ml of ethanol and 2.4 ml of water to 4-(5-nitrothiazol-2-ylsulfanyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine, the mixture was stirred at 80°C for 10 minutes and then returned to room temperature, after which 7.5 ml of potassium carbonate was added, the mixture was filtered with celite, and ethyl acetate and water were added to the filtrate for liquid separation and extraction. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 310 mg of a solid. The solid was dissolved in 10 ml of tetrahydrofuran, 10 ml of toluene and 10 ml of acetonitrile under reflux, and then 0.1 ml of 4-fluorophenyl isocyanate was added and the mixture was stirred for 2 hours. It was then returned to room temperature, and the reaction system was concentrated, subjected to silica gel column chromatography and dried to obtain 33 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 6.71(1H, s,), 7.12(2H, m), 7.36-7.52(5H, m), 7.62(1H, s), 7.92(2H, d, J=8.1Hz), 8.55(1H, s), 9.12(1H, s), 10.24(1H, s), 12.82(1H, brs)

[0497] The intermediates were synthesized in the following manner.

Production Example 161-1

6-Phenyl-7H-pyrrolo[2,3-d]pyrimidine-4-thiol

[0498] After adding 6.19 g of phosphorus pentasulfide, 6.24 g of sodium bicarbonate and 25 ml of diglyme to 2.45 g of the 6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol described in WO97/02266 and PCT/EP96/02728, and stirring the mixture for 1 hour, an additional 3 g of phosphorus pentasulfide and 3 g of sodium bicarbonate were added and the mixture was stirred for 1 hour. There were further added another 3 g of phosphorus pentasulfide and 3 g of sodium bicarbonate, and the mixture was stirred for 1 hour. It was then returned to room temperature, water was added, the mixture was stirred for 10 minutes, and the precipitated crystals were filtered out, washed with water and dried to obtain 2.5 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 7.05 (1H, d, J=2.1Hz), 7.32 (1H, t, J=7.9Hz), 7.43 (2H, t, J=7.9Hz), 7.88 (2H, d, J=7.9Hz), 8.05(1H, s), 12.68(1H, brs), 13.36(1H, brs)

Production Example 161-2

4-(5-Nitrothiazol-2-ylsulfanyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine

[0499] After adding 1.06 g of 2-bromo-5-nitrothiazole and 15 ml of dimethylformamide to 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine-4-thiol, the mixture was stirred at room temperature for 3 hours, and then 0.45 ml of pyridine was added and the mixture was stirred overnight. Water was added, and the precipitated crystals were filtered out, blow-dried and dried under reduced pressure to obtain 1.20 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 7.26(1H, J=2.4Hz), 7.36-7.54(3H, m), 8.01 (2H, d, J=7.8Hz), 8.90(1H, s,), 8.94(1H, s,), 13.11(1H, brs),

Example 162

1-[5-(6-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylsulfanyl)-3-thiazol-2-yl]urea

[0500] After adding 265 mg of phenyl 2-thiazoylcarbamate and 10 ml of dimethylsulfoxide to 354 mg of 5-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylsulfanyl)-2-thiophenylamine, the mixture was stirred at 80°C for 2 hours. Ethyl acetate and water were added for liquid separation and extraction, the organic layer was concentrated and subjected to silica

gel column chromatography and dried, and the obtained solid was washed with ether to obtain 170 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 6.55(1H, brs), 6.94(1H, d, J=4.2Hz), 7.05(1H, d, J=1.9Hz), 7.26(1H, d, J=4.2Hz), 7.28-7.50(4H, m), 7.82-7.90(3H, m), 8.49(1H, s), 10.42(1H, brs), 12.54(1H, brs)

[0501] The intermediates were synthesized in the following manner.

Production Example 162-1

4-(5-Nitro-2-thiophenylsulfanyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine

[0502] After adding 1.05 g of 2-bromo-5-nitrothiophene, 0.95 g of potassium carbonate and 15 ml of dimethylformamide to the 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine-4-thiol synthesized in Production Example 161-1 and stirring the mixture overnight at room temperature, water was added and the precipitated crystals were filtered out, blow-dried and dried under reduced pressure to obtain 1.30 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 7.08(1H, s), 7.40 (1H, t, J=8.0Hz), 7.48 (2H, t, J=8.0Hz), 7.56 (1H, d, J=4.1Hz), 7.98 (2H, d, J=8.0Hz), 8.16 (1H, d, J=4.1Hz), 8.70(1H, s), 12.68(1H, brs)

Production Example 162-2

5-(6-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylsulfanyl)-thiophen-2-ylamine

[0503] After adding 543 mg of iron powder, 1.06 g of ammonium chloride, 10 ml of dimethylformamide, 20 ml of ethanol and 5 ml of water to the 4-(5-nitro-2-thiophenylsulfanyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine synthesized in Production Example 162-1, the mixture was stirred at 90°C for 2 hours, 30 ml of tetrahydrofuran was added, and then the mixture was returned to room temperature and filtered with celite, and ethyl acetate and water were added to the filtrate for liquid separation and extraction. The organic layer was dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 435 mg of the title compound.

MS Spectrum(ESI):325(M+1)

¹H-NMR Spectrum: (DMSO-d₆) 5.98 (1H, d, J=4.2Hz), 6.24(2H, s), 6.27 (1H, d, J=2.0Hz), 7.00 (1H, d, J=4.2Hz), 7.30-7.50(3H, m), 7.80 (2H, d, J=7.6Hz), 8.46(1H, s), 12.63(1H, brs)

Example 163

4-{4-[3-(4-Fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid ethyl ester

[0504] After dissolving 90 mg of ethyl 4-(4-aminophenoxy)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate in 3 ml of toluene and 1 ml of acetonitrile at 110°C, 16.6 µl of 4-fluorophenyl isocyanate was added and the mixture was stirred for 1 hour under reflux. After standing at room temperature, the precipitated crystals were filtered out and dried to obtain 110 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 1.31(3H, t, J=7.9 Hz), 4.32(2H, q, J=7.9 Hz), 7.07-7.54(9H, m), 8.42(1H, s), 8.72(1H, s), 8.76(1H, s), 13.03(1H, brs)

[0505] The intermediates were synthesized in the following manner.

Production Example 163-1

4-(4-Nitrophenoxy)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid ethyl ester

[0506] After adding 390 mg of 4-nitrophenol, 703 mg of potassium carbonate and 8.7 ml of dimethylformamide to 577 mg of the 4-chloroethoxycarbonyl-7H-pyrrolo[2,3-d]pyrimidine described in WO9702266(A1) and stirring the mixture at 120°C for 4 hours, 40 mg of 4-nitrophenyl was further added and the mixture was stirred for 1.5 hours. After returning the mixture to room temperature, water was added, liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran mixed solvent, and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain a solid which was then washed with ether to obtain 520 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 1.33 (3H, t, J=7.9 Hz), 4.35(2H, q, J=7.9 Hz), 7.28(1H, s), 7.56-7.64(2H, m), 8.30-8.38 (2H, m), 8.46(1H, s), 13.21(1H, brs)

Production Example 163-24-(4-Aminophenoxy)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid ethyl ester

[0507] After adding 110 mg of iron powder, 220 mg of ammonium chloride, 10 ml of ethanol and 2 ml of water to 4-(4-nitrophenoxy)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid ethyl ester, the mixture was stirred at 80-85°C for 2.5 hours. After returning the mixture to room temperature, 20 ml of tetrahydrofuran was added, the mixture was stirred for 5 minutes and filtered with celite, and 100 ml of ethyl acetate and 50 ml of water were added to the filtrate for liquid separation and extraction. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 90 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 1.31(3H, t, J=7.9 Hz), 4.31(2H, q, J=7.9 Hz), 5.10(2H, s), 6.56-6.62(2H, m), 6.86-9.92(3H, m), 8.40(1H, s), 12.98(1H, brs)

Example 1644-{4-[3-(4-Fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid

[0508] After adding 7 ml of ethanol, 7 ml of water and 31 mg of lithium hydroxide monohydrate to 75 mg of the 4-{4-[3-(4-fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid ethyl ester synthesized in Example 163 and stirring the mixture at 40-45°C for 24 hours, it was neutralized with 2N HCl and concentrated to dryness to obtain 40 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 6.83(1H, s), 7.06-7.16(2H, m), 7.19(2H, m), 7.44-7.48(2H, m), 7.51(2H, d, J=8.0 Hz), 8.39(1H, s), 8.72(1H, s), 8.76(1H, s), 12.88(1H, brs)

Example 1654-{4-[3-(4-Fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic(3-diethylaminopropyl)amide

[0509] After adding 1 ml of dimethylformamide, 47 µl of triethylamine, 18.5 µl of diphenylphosphoryl azide and 8.2 µl of 1-methylpiperazine to 12 mg of the 4-{4-[3-(4-fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid synthesized in Example 164, the mixture was stirred overnight at room temperature. Water was added, and the mixture was subjected to liquid separation and extraction with an ethyl acetate-tetrahydrofuran mixed solvent and to NH silica gel column chromatography (ethyl acetate-methanol) to obtain 27 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 2.18(3H, s), 2.28-2.48(4H, m), 3.58-3.70(4H, m), 6.56(1H, s), 7.06-7.56(8H, m), 8.36(1H, d, J=1.7 Hz), 8.78(1H, s), 8.84(1H, s), 12.67(1H, brs)

Example 1664-{4-[3-(4-Fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic(3-diethylaminopropyl)amide

[0510] After adding 0.8 ml of dimethylformamide, 21 µl of triethylamine, 9.5 µl of diphenylphosphoryl azide (DPPA) and 6.5 µl of 4-(3-aminopropyl)morpholine to 12 mg of the 4-{4-[3-(4-fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid synthesized in Production Example 164, the mixture was stirred at room temperature for 2 days. Saturated aqueous ammonium chloride solution was added, liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran mixed solvent, and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 9 mg of the title compound.

MS Spectrum(ESI): 534(M+1)

¹H-NMR Spectrum: (DMSO-d₆) 1.62-1.74(2H, m), 2.20-2.42(6H, m), 2.88-2.98(2H, m), 3.46-3.62(4H, m), 7.06-7.56(9H, m), 8.34(1H, s), 8.84-8.90(2H, m), 12.68(1H, brs)

Example 1671-(4-Fluorophenyl)-3-[4-(6-hydroxymethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0511] After adding 9 ml of tetrahydrofuran to 55 mg of the 4-{4-[3-(4-fluorophenyl)ureido]phenoxy}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid ethyl ester synthesized in Example 163 and stirring the mixture, 25 mg of lithium aluminum hydride was added at room temperature and the mixture was stirred for 2 days. Water was then added, liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran mixed solvent, and the organic layer was filtered

with celite and concentrated to dryness to obtain 35 mg of the title compound.

MS Spectrum(ESI):394(M+1),416(M+23)

¹H-NMR Spectrum: (DMSO-d₆) 4.55(2H, d, J=6.7 Hz), 5.32(1H, t, J=6.7 Hz), 6.84(1H, s), 7.06-7.55(8H, m), 8.22(1H, s), 8.74(1H, s), 8.76(1H, s), 12.11(1H, brs)

Example 168

1-(4-Fluorophenyl)-3-[4-(6-formyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0512] After adding 3 ml of chloroform and 50 mg of manganese dioxide to 18 mg of 1-(4-fluorophenyl)-3-[4-(6-hydroxymethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea, the mixture was stirred overnight at room temperature. Tetrahydrofuran and ethyl acetate were added to the reaction system, and the mixture was filtered with celite and concentrated to dryness to obtain 16 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 6.82(1H, s), 7.03-7.60(8H, m), 8.46(1H, s), 8.71(1H, s), 8.75(1H, s), 9.86(1H, s), 13.08(1H, brs)

Example 169

1-(4-Fluorophenyl)-3-[4-(6-morpholin-4-ylmethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0513] After adding 0.5 ml of tetrahydrofuran, 10 µl of morpholine and 26 mg of triacetoxyborohydride to the 1-(4-fluorophenyl)-3-[4-(6-formyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea synthesized in Example 168, the mixture was stirred overnight at room temperature. The reaction system was subjected to liquid separation and extraction with a tetrahydrofuran-ethyl acetate mixed solvent, and then dried over anhydrous sodium sulfate and concentrated to dryness to obtain 5 mg of the title compound.

MS Spectrum(ESI):463(M+1)

Example 170

1-(4-Fluorophenyl)-3-[4-[6-(4-methyl-1-piperazylmethyl)-1-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl]urea

[0514] After adding 0.4 ml of tetrahydrofuran, 11 µl of 1-methylpiperazine and 23 mg of sodium triacetoxyborohydride to the 1-(4-fluorophenyl)-3-[4-(6-formyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea synthesized in Example 168, the mixture was stirred overnight at room temperature. The reaction system was subjected to liquid separation and extraction with a tetrahydrofuran-ethyl acetate mixed solvent, and then dried over anhydrous sodium sulfate and concentrated to dryness to obtain 5 mg of the title compound.

MS Spectrum(ESI):476(M+1)

Example 171

1-(4-Fluorophenyl)-3-[4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0515] After dissolving 40 mg of 4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine in 4.5 ml of toluene and 4.5 ml of acetonitrile at 110°C, 4-fluorophenyl isocyanate (16.6 µl) was added and the mixture was stirred for 1 hour. After returning the mixture to room temperature, the precipitated crystals were filtered out and dried to obtain 37 mg of the title compound.

MS Spectrum(ESI):440(M+1),462(M+23)

¹H-NMR Spectrum: (DMSO-d₆) 7.02(1H, s), 7.06-7.52 (11H, m), 7.94 (2H, d, J=8.0Hz), 8.28(1H, s), 8.77(1H, s), 8.79(1H, s), 12.68(1H, brs)

[0516] The intermediates were synthesized in the following manner.

Production Example 171-1

4-(4-Nitrophenoxy)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine

[0517] After adding 123 mg of 4-nitrophenol, 136 mg of potassium carbonate and 1.5 ml of dimethylformamide to 113 mg of the 4-chloro-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine described in WO97/02266 and PCT/EP96/02728, and stirring the mixture for 15 hours at 130-135°C, and additional 60 mg of 4-nitrophenol and 75 mg of potassium carbonate

were added and the mixture was stirred for 6 hours. After returning the mixture to room temperature, water was added, liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran mixed solvent, and the solid obtained by concentration to dryness was washed with ether to obtain 112 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 7.13(1H, s), 7.37 (1H, t, J=7.7 Hz), 7.47 (2H, t, J=7.7 Hz), 7.56-7.61 (2H, m), 7.74-8.00 (2H, m), 8.30-8.38 (3H, m), 12.82(1H, brs)

Production Example 171-2

4-(6-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine

[0518] After adding 110 mg of iron powder, 220 mg of ammonium chloride, 10 ml of ethanol and 2 ml of water to 110 mg of 4-(4-nitrophenoxy)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine, the mixture was stirred at 80-85°C for 2.5 hours. After returning the mixture to room temperature, 20 ml of tetrahydrofuran was added, and the mixture was stirred for 5 minutes and filtered with celite, after which 100 ml of ethyl acetate and 50 ml of water were added to the filtrate for liquid separation and extraction. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 90 mg of the title compound.

MS spectrum(ESI) m/z 303(M + 1)

¹H-NMR Spectrum: (DMSO-d₆) 5.04(2H, brs) 6.57-6.61(2H, m), 6.84-6.90(3H, m), 7.34 (1H, t, J=7.7 Hz), 7.45 (2H, t, J=7.7 Hz), 7.87 (2H, t, J=7.7 Hz), 8.26(1H, s) 12.61(1H, brs)

Example 172

1-(3-Fluorophenyl)-3-[4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0519] The title compound (24 mg) was obtained by reacting 3-fluorophenyl isocyanate (14 μl) with 36 mg of 4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine, in the same manner as Example 171. MS Spectrum(ESI):440 (M+1), 462(M+23)

¹H-NMR Spectrum: (DMSO-d₆) 7.02(1H, s,), 7.08-7.54 (11H, m), 7.94 (2H, d, J=8.0Hz), 8.28(1H, s,), 8.88(1H, s,), 9.00 (1H, s,), 12.68(1H, brs)

Example 173

1-Cyclopropyl-3-[4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0520] After adding 30 mg of phenyl cyclopropylcarbamate and 0.5 ml of dimethylsulfoxide to 40 mg of 4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine, the mixture was stirred at 80°C for 4 hours. The mixture was returned to room temperature, water was added, liquid separation and extraction were performed with ethyl acetate, and the solid obtained by concentration to dryness was washed with ether to obtain 6 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 0.30-0.40(2H, m), 0.55-0.65(2H, m), 2.43-2.57(1H, m, covered by DMSO peak), 6.20(1H, brs), 6.60(2H, d, J=8.90 Hz), 6.83(1H, s), 6.87-6.91 (1H, m), 7.10-7.16 (1H, m), 7.30-7.50 (3H, m), 7.90 (2H, d, J=8.1Hz), 8.26(1H, d, J=0.4 Hz), 8.92(1H, brs,), 12.60(1H, brs)

Example 174

1-[4-(6-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]-3-(thiazol-2-yl)urea

[0521] After adding 492 mg of phenyl 2-thiazoylcarbamate to 520 mg of 4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine, the mixture was stirred at 80°C for 4 hours. The precipitated crystals were filtered out and washed with ethyl acetate and tetrahydrofuran to obtain 275 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 7.03(1H, d, J=2.0Hz), 7.10(1H, d, J=3.0Hz), 7.18-7.50(7H, m), 7.54 (2H, d, J=8.7Hz), 7.74 (2H, d, J=8.0Hz), 8.29(1H, s,), 9.10(1H, s,), 12.69(1H, brs)

Example 175

1-(4-Fluorophenyl)-3-[2-fluoro-4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0522] The title compound (26 mg) was obtained from 36 mg of 2-fluoro-4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine, in the same manner as Example 171.

¹H-NMR Spectrum: (DMSO-d₆) 7.05-7.18 (4H, m), 7.30-7.50 (6H, m), 7.94 (2H, d, J=8.1Hz), 8.21(1H, t, J=10.4Hz), 8.32 (1H, s), 8.55(1H, d, J=1.9Hz), 9.09(1H, s), 12.73(1H, brs)

[0523] The intermediates were synthesized in the following manner.

5 Production Example 175-1

4-(3-Fluoro-4-nitrophenoxy)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine

[0524] After adding 328 mg of 3-fluoro-4-nitrophenol, 0.22 ml of 2,6-lutidine and 0.9 ml of N-methylpyrrolidine to 360 mg of the 4-chloro-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine described in WO97/02266 and PCT/EP96/02728 and stirring the mixture overnight at 130°C, it was returned to room temperature, water was added, the precipitated solid was filtered out and washed with water and diethyl ether, and the collected solid was dried to obtain 112 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 7.14(1H, s), 7.34-7.44 (2H, m), 7.48 (2H, t, J=7.8 Hz), 7.73 (1H, dd, J=2.5 Hz, 11.8 Hz), 7.89(2H, d, J=7.8 Hz), 8.28(1H, t, J=8.5 Hz), 8.40(1H, d, J=1.3 Hz), 12.87(1H, brs)

Production Example 175-2

4-(6-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine

[0525] The title compound (118 mg) was obtained from 125 mg of the 4-(3-fluoro-4-nitrophenoxy)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine synthesized by the intermediate synthesis method described above, in the same manner as Production Example 171-2.

¹H-NMR Spectrum: (DMSO-d₆) 5.10(2H, s), 6.78-7.04 (4H, m), 7.37 (1H, t, J=7.9 Hz), 7.47(2H, t, J=7.9 Hz), 7.92(2H, d, J=7.9 Hz), 8.38(1H, s), 12.67(1H, brs)

Example 176

1-(3-Fluorophenyl)-3-[2-fluoro-4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0526] The title compound (27 mg) was obtained from 33 mg of 2-fluoro-4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine, in the same manner as Example 171.

¹H-NMR Spectrum: (DMSO-d₆) 6.78(1H, dt, J=3.3, 9.5Hz), 7.06-7.52 (8H, m), 7.97 (2H, t, J=8.2Hz), 8.11(1H, t, J=9.5Hz), 8.42(1H, s), 8.62(1H, s), 8.62(1H, s), 9.28(1H, s), 12.73(1H, brs)

Example 177

1-[2-Fluoro-4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]-3-(thiazol-2-yl)urea

[0527] The title compound (27 mg) was obtained from 42 mg of 2-fluoro-4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine, in the same manner as Example 171.

¹H-NMR Spectrum: (DMSO-d₆) 7.06-7.16 (3H, m), 7.12-7.44 (3H, m), 7.47 (2H, t, J=8.1Hz), 7.96 (2H, d, J=8.1Hz), 8.12 (1H, t, J=9.1Hz), 8.32(1H, s), 8.96(1H, brs), 10.78(1H, brs), 12.73(1H, brs)

Example 178

5-[6-(4-Hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]indole-1-carboxylic ethylamide

[0528] After dissolving 30 mg of 5-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilanyloxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]indole-1-carboxylic ethylamide in 1 ml of trifluoroacetic acid and 0.1 ml of thioanisole, the mixture was stirred at 50-55°C. The mixture was then returned to room temperature, saturated sodium bicarbonate water was added to alkalinity, and liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran (5:1) mixed solvent. The organic layer was concentrated, 1 ml of tetrahydrofuran and 1 ml of 2N aqueous sodium hydroxide were added to the residue, and the mixture was stirred at room temperature for 5 minutes. After neutralization with 1N hydrochloric acid, liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran (5:1) mixed solvent. The organic layer was concentrated and the residue was subjected to silica gel column chromatography (hexane-ethyl acetate) to obtain 5 mg of the title compound.

MS Spectrum(ESI): 468(M+55); (M+Na+MeOH)

¹H-NMR Spectrum: (DMSO-d₆) 1.18(3H, t, J=6.7Hz), 3.20-3.50(2H, m, covered by H₂O peak), 6.67(1H, d, J=3.5Hz), 6.78(1H, s,), 6.83(2H, d, J=8.4Hz), 7.12(1H, dd, J=2.2, 8.4Hz), 7.44(1H, d, J=2.2Hz), 7.74(2H, d, J=8.4Hz), 7.89(1H, d, J=3.3Hz), 8.16-8.22(2H, m), 8.25(1H, d, J=8.4Hz), 9.80(1H, brs.), 12.45(1H, brs),

Example 179

6-(4-Benzyloxyphenyl)-4-(1H-5-indolyloxy)-7H-pyrrolo[2,3-d]pyrimidine

[0529] After dissolving 1.5 ml of tetrahydrofuran in 22 mg of 5-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-indole-1-carboxylic ethylamide, a 1M solution of tetrabutylammonium fluoride in tetrahydrofuran was added and the mixture was refluxed for 2 hours. After returning it to room temperature, water was added and the precipitated crystals were filtered out and subjected to silica gel column chromatography (hexane-ethyl acetate) to obtain 2 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 5.17(2H, s), 6.40-6.43(1H, m), 6.80(1H, s,), 6.93(1H, dd, J=2.5, 8.8Hz), 7.10(2H, d, J=8.8Hz), 7.30-7.50(8H, m), 7.83(2H, d, J=8.8Hz), 8.20(1H, s), 11.19(1H, brs), 12.51(1H, brs),

[0530] The intermediates were synthesized in the following manner.

Production Example 179-1

6-(4-Benzyloxyphenyl)-4-(1H-5-indolyloxy)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine

[0531] After adding 1.9 ml of dimethylformamide, 180 mg of 5-hydroxyindole and 112 mg of potassium carbonate to 190 mg of 6-(4-benzyloxyphenyl)-4-chloro-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine, the mixture was stirred at 135-140°C for 4 hours. After returning it to room temperature, water was added, and liquid separation and extraction were performed with an ethyl acetate:tetrahydrofuran (5:1) mixed solvent. The organic layer was concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 90 mg of the title compound.

MS Spectrum(ESI):563(M+1)

¹H-NMR Spectrum: (DMSO-d₆)-0.09(9H, s), 0.87(2H, t, J=8.4Hz), 3.62(2H, t, J=8.4Hz) 5.19(2H, s), 5.59(2H, s), 6.42-6.46(1H, m), 6.65(1H, s), 6.83(2H, d, J=8.4Hz), 6.97(1H, dd, J=2.6, 8.6Hz), 7.16(2H, d, J=8.6Hz), 7.32-7.50(8H, m), 7.70(2H, d, J=8.6Hz), 8.37(1H, d, J=1.7Hz), 11.21(1H, brs).

Production Example 179-2

5-[6-(4-Benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]indole-1-carboxylic ethylamide

[0532] After dissolving 6-(4-benzyloxyphenyl)-4-(1H-5-indolyloxy)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine (81 mg) in 1 ml of dimethylformamide, 7 mg of sodium hydride (60% dispersion) was added, the mixture was stirred at room temperature for 5 minutes, and then 31 mg of phenyl ethylcarbamate was added and the mixture was stirred for another 2 hours. Water was then added, and ethyl acetate was used for liquid separation and extraction. The organic layer was concentrated and subjected to silica gel column chromatography (hexane-ethyl acetate) to obtain 62 mg of the title compound.

MS Spectrum(ESI):634(M+1), 688(M+55); (M+Na+MeOH)

¹H-NMR Spectrum: (DMSO-d₆)-0.09(9H, s,), 0.87(3H, t, J=8.5Hz), 1.20(2H, t, J=6.7Hz), 3.10-3.70(4H, m, covered by H₂O peak), 5.20(2H, s), 5.60(2H, s), 6.67(1H, s,), 6.70(1H, d, J=3.8Hz), 7.12-7.20(3H, m), 7.30-7.52(6H, m), 7.72(2H, d, J=9.0Hz), 7.91(1H, d, J=3.8Hz), 8.23(1H, t, J=5.9Hz), 8.29(1H, d, J=9.0Hz), 8.38(1H, s)

Example 180

N-[4-(2-Cyclopropyl-3-methylimidazo[4,5-b]pyridin-4-yl)oxyphenyl]-N'-(4-fluorophenyl)urea

[0533] N-[4-(2-Cyclopropyl-3H-imidazo[4,5-b]pyridin-4-yl)oxyphenyl]-N'-(4-fluorophenyl)urea (25 mg), iodomethane (13 mg), potassium carbonate (26 mg) and dimethylformamide (5 ml) were stirred at 70°C for 20 minutes. Water was added, extraction was performed with ethyl acetate, and then silica gel was added to the extract and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel and purified by column chromatography (ethyl acetate, followed by ethyl acetate:methanol = 10:1) to obtain 3 mg of the target substance as a white powder.

¹H-NMR(CDCl₃) δ(ppm): 1.13-1.19 (2H, m), 1.28-1.35 (2H, m), 2.03-2.11 (1H, m), 3.95 (3H, s), 6.43 (1H, d, J= 5.6Hz), 6.95-7.04 (4H, m), 7.26-7.35 (4H, m), 8.19 (1H, d, J= 5.6Hz).

Example 181

N-[4-(2-Butylaminopyridin-4-yl)oxyphenyl]-N'-(4-fluorophenyl)urea

[0534] 4-(4-Aminophenoxy)-2-butylaminopyridine (54 mg), p-fluorophenyl isocyanate (34.5 mg) and tetrahydrofuran (5 ml) were stirred at room temperature for 2.5 hours. After adding NH type silica gel to the reaction solution, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 1:1, followed by ethyl acetate). The solvent was distilled off under reduced pressure and the residue was solidified with ethyl acetate-hexane to obtain 15 mg of the target substance as a light yellow powder.

¹H-NMR(DMSO-d₆) δ(ppm): 0.87 (3H, t, J= 7.2Hz), 1.30 (2H, tq, J= 7.2Hz, 7.2Hz), 1.44 (2H, tt, J= 7.2Hz, 7.2Hz), 3.16 (2H, q, J= 7.2Hz), 5.80 (1H, d, J= 2.0Hz), 6.09 (1H, ddd, J= 5.0Hz, 2.0Hz, 2.0Hz), 6.45 (1H, dd, J= 5.0Hz, 5.0Hz), 7.03-7.18 (4H, m), 7.43-7.55 (4H, m), 7.83 (1H, dd, J= 5.0Hz, 2.0Hz), 8.70 (1H, s), 8.74 (1H, s).

[0535] The intermediate was synthesized in the following manner.

Production Example 181-1

4-(4-Aminophenoxy)-2-butylaminopyridine

[0536] After dissolving 80 mg of 4-(4-aminophenoxy)-2-butylaminopyridine in 8 ml of tetrahydrofuran, 67 mg of lithium aluminum hydride was added while stirring at room temperature, and the mixture was stirred at 70°C for 10 minutes. Water was added, extraction was performed with ethyl acetate, and then silica gel was added to the extract and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel and purified by column chromatography (ethyl acetate) to obtain 54 mg of the target substance as a brown oil.

¹H-NMR(CDCl₃) δ(ppm): 0.93 (3H, t, J= 7.2Hz), 1.40 (2H, tq, J= 7.2Hz, 7.2Hz), 1.56 (2H, tt, J= 7.2Hz, 7.2Hz), 3.14 (2H, q, J= 7.2Hz), 5.82 (1H, d, J= 2.0Hz), 6.14 (1H, dd, J= 6.0Hz, 2.0Hz), 6.66-6.74 (2H, m), 6.86-6.94 (2H, m), 7.87 (1H, d, J= 6.0Hz).

Example 182

N-(4-Fluorophenyl)-N'-{4-[(7-oxo-5,6,7,8-tetrahydro[1,8] naphthyridin-4-yl)oxy]phenyl}urea

[0537] 4-[(7-Oxo-5,6,7,8-tetrahydro[1,8]naphthyridin-4-yl)oxy]aniline (43 mg), p-fluorophenyl isocyanate (28 mg), tetrahydrofuran (5 ml) and dimethylformamide (2 ml) were stirred at room temperature for 30 minutes. Water was added dropwise at room temperature until precipitation of crystals, and these were filtered out to obtain 48 mg of the target substance as white crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 2.50 (2H, t, J= 8.0Hz), 2.91 (2H, t, J= 8.0Hz), 6.24 (1H, d, J= 6.0Hz), 7.03-7.35 (4H, m), 7.40-7.55 (4H, m), 7.94 (1H, d, J= 6.0Hz), 8.70 (1H, s), 8.74 (1H, s), 10.48 (1H, s).

[0538] The intermediates were synthesized in the following manner.

Production Example 182-1

4-Chloro-3-iodo-2-pyridinamine

[0539] A solution of 10 g of the publicly known compound tert-butyl N-(4-chloro-2-pyridyl)carbamate, 16.6 ml of N, N, N', N'-tetramethylethylenediamine and 200 ml of tetrahydrofuran was cooled to -75°C, and then 42 ml of n-butyllithium (2.6M solution in hexane) was added dropwise over a period of 30 minutes while stirring. After stirring for 1 hour at -75°C, a solution of 28 g of iodine in 28 ml of tetrahydrofuran was added dropwise over a period of 30 minutes. After completion of the dropwise addition, stirring was continued for another 30 minutes at -75°C, and then the mixture was returned to room temperature, aqueous sodium bisulfate was added and extraction was performed with ethyl acetate. NH type silica gel was added to the extract, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 3:1). The solvent was distilled off under reduced pressure, 48% HBr water was added to the residue, and the mixture was stirred at 100°C for 5 minutes. After adding ice water and 5 N sodium hydroxide water to the reaction solution, the precipitated solid was filtered out to obtain 7.4 g of

a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 6.50 (2H, bs), 6.72 (1H, d, J= 5.6Hz), 7.82 (1H, d, J= 5.6Hz).

Production Example 182-2

3-Iodo-4-(4-nitrophenoxy)-2-pyridinamine

[0540] 4-Chloro-3-iodo-2-pyridinamine (1.0 g), p-nitrophenol (1.1 g), diisopropylethylamine (1.0 ml) and N-methyl-2-pyrrolidone (2 ml) were stirred at 170°C for 17 hours. After returning the reaction solution to room temperature, water was added and extraction was performed with ethyl acetate. NH type silica gel was added to the extract, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 3:1). The solvent was distilled off under reduced pressure, and then ethyl acetate and hexane were added to the residue for solidification to obtain 540 mg of light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 6.22 (1H, d, J= 5.2Hz), 6.37 (2H, brs), 7.19 (2H, d, J= 9.2Hz), 7.87 (1H, d, J= 5.2Hz), 8.26 (2H, d, J= 9.2Hz).

Production Example 182-3

Ethyl (E)-3-[2-amino-4-(4-nitrophenoxy)-3-pyridyl]-2-propenoate

[0541] 3-Iodo-4-(4-nitrophenoxy)-2-pyridinamine (500 mg), ethyl acrylate (0.3 ml), palladium (II) acetate (30 mg), tributylamine (0.66 ml) and dimethylformaldehyde (5 ml) were stirred at 130°C for 20 minutes. After returning the reaction solution to room temperature, water was added and extraction was performed with ethyl acetate. NH type silica gel was added to the extract, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 3:1). The solvent was distilled off under reduced pressure to obtain 330 mg of the target substance as a yellow oil.

¹H-NMR(CDCl₃) δ(ppm): 1.31 (3H, t, J= 7.2Hz), 4.25 (2H, q, J= 7.2Hz), 5.01 (2H, s), 6.18 (1H, d, J= 6.0Hz), 6.57 (1H, d, J= 16Hz), 7.12-7.19 (2H, m), 7.73 (1H, d, J= 16Hz), 7.99 (1H, d, J= 6.0Hz), 8.24-8.32 (2H, m).

Production Example 182-4

4-[(7-Oxo-5,6,7,8-tetrahydro[1,8]naphthyridin-4-yl)oxy]aniline

[0542] Ethyl (E)-3-[2-amino-4-(4-nitrophenoxy)-3-pyridyl]-2-propenoate (330 mg), palladium-carbon (10%, aqueous, 100 mg), methanol (5 ml) and tetrahydrofuran (5 ml) were stirred overnight at under a hydrogen atmosphere at 1 atmosphere. The palladium-carbon was filtered off, the filtrate was distilled off under reduced pressure, and then the residue was purified by silica gel column chromatography (ethyl acetate, followed by ethyl acetate:methanol = 5:1) to obtain 43 mg of a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 2.49 (2H, t, J= 8.0Hz), 2.89 (2H, t, J= 8.0Hz), 5.09 (2H, s), 6.15 (1H, dd J= 6.0Hz, 2.0Hz), 6.58 (2H, dd, J= 8.4Hz, 2.0Hz), 6.79 (2H, dd, J= 8.4Hz, 2.0Hz), 7.89 (1H, dd, J= 6.0Hz, 2.0Hz), 10.38(1H, s).

Example 183

N-(4-Fluorophenyl)-N'-{4-[(7-oxo-7,8-dihydro[1,8]naphthyridin-4-yl)oxy]phenyl}urea

[0543] N-(4-Fluorophenyl)-N'-{4-[(7-oxo-7,8-dihydro[1,8] naphthyridin-4-yl)oxy]aniline (30 mg), p-fluorophenyl isocyanate (0.016 ml) and dimethylformamide (6 ml) were stirred at 70°C until disappearance of the starting materials. After returning the reaction solution to room temperature, water was added dropwise and the precipitated solid was filtered out to obtain 22 mg of a light brown solid.

¹H-NMR(DMSO-d₆) δ(ppm) : 6.35 (1H, d, 5.6Hz), 6.54 (1H, d, J= 10Hz), 7.05-7.20 (4H, m), 7.40-7.60 (4H, m), 8.14 (1H, d, J= 10Hz), 8.29 (1H, d, J= 5.6Hz), 8.70 (1H, s), 8.78 (1H, s), 12.13 (1H, s).

[0544] The intermediates were synthesized in the following manner.

Production Example 183-14-(4-Nitrophenoxy)-7-oxo-7,8-dihydro[1,8]naphthyridine

5 **[0545]** Ethyl (E)-3-[2-amino-4-(4-nitrophenoxy)-3-pyridyl]-2-propenoate (350 mg), 2'-acetonaphthone (50 mg) and methanol (80 ml) were irradiated for 4 hours while stirring, and the precipitated solid was filtered out to obtain 156 mg of a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 6.57 (1H, d, J=9.6Hz), 6.70 (1H, d, J= 5.6Hz), 7.46 (2H, d, J= 8.0Hz), 8.05 (1H, d, J= 9.6Hz), 8.33 (2H, d, J= 8.0Hz), 8.42 (1H, d, J= 5.6Hz), 12.31(1H, s).

Production Example 183-24-[(7-Oxo-7,8-dihydro[1,8]naphthyridin-4-yl)oxy]aniline

15 **[0546]** 4-(4-Nitrophenoxy)-7-oxo-7,8-dihydro[1,8]naphthyridine (156 mg), iron powder (300 mg), ammonium chloride (600 mg), dimethylformamide (2 ml), ethanol (1 ml) and water (1 ml) were stirred at 100°C for 20 minutes. The mixture was filtered with celite, and then water and ethyl acetate were added for extraction. The organic layer was washed 4 times with aqueous ammonium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off and the solvent was distilled off under reduced pressure to obtain 30 mg of the target substance as a light yellow solid.

20 ¹H-NMR(DMSO-d₆) δ(ppm): 5.19 (2H, brs), 6.29 (1H, d, J= 5.6Hz), 6.51 (1H, d, J= 9.6Hz), 6.30 (2H, d, J= 8.0Hz), 6.87 (2H, d, J= 8.0Hz), 8.12 (1H, d, J= 9.6Hz), 8.25 (1H, d, J= 5.6Hz), 12.10 (1H, s).

Example 184Ethyl (E)-3-[2-[(cyclopropylcarbonyl)amino]-4-[(4-fluoroanilino)carbonyl]amino}phenoxy)-3-pyridyl]-2-propenoate

[0547] Ethyl (E)-3-[2-amino-4-[(4-[(4-fluoroanilino)carbonyl] amino}phenoxy)-3-pyridyl]-2-propenoate (200 mg), cyclopropanecarbonyl chloride (58 mg), triethylamine (0.1 m), tetrahydrofuran (4 ml) and dimethylformamide (1 ml) were stirred at room temperature for 20 minutes. A small amount of water was added dropwise and the precipitated solid was filtered out to obtain 130 mg of a faint yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.74 (4H, m), 1.21 (3H, t, J= 7.2Hz), 1.88-1.95 (1H, m), 4.14 (2H, q, J= 7.2Hz), 6.53 (1H, d, J= 5.6Hz), 6.90 (1H, d, J= 16Hz), 7.07-7.19 (4H, m), 7.40-7.48 (3H, m), 7.55 (2H, d, J= 8.0Hz), 8.21 (1H, d, J= 5.6Hz), 8.72 (1H, s), 8.81 (1H, s), 10.61 (1H, s).

[0548] The intermediates were obtained in the following manner.

Production Example 184-1Ethyl (E)-3-[2-amino-4-(4-aminophenoxy)-3-pyridyl]-2-propenoate

40 **[0549]** Ethyl (E)-3-[2-amino-4-(4-nitrophenoxy)-3-pyridyl]-2-propenoate (350 mg), iron powder (700 mg), ammonium chloride (1.4 g), dimethylformamide (7 ml), ethanol (2 ml) and water (2 ml) were stirred at 100°C for 20 minutes. The mixture was filtered with celite, and then water and ethyl acetate were added for extraction. The organic layer was washed 5 times with aqueous ammonium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off and the solvent was distilled off under reduced pressure to obtain 230 mg of the target substance as a light yellow solid.

45 ¹H-NMR(CDCl₃) δ(ppm): 1.33 (3H, t, J= 7.2Hz), 3.68 (2H, brs), 4.26 (2H, q, J= 7.2Hz), 4.87 (2H, bs), 6.02 (1H, d, J= 6.0Hz), 6.68 (1H, d, J= 16Hz), 6.70 (2H, d, J= 8.8Hz), 6.87 (2H, d, J= 8.8Hz), 7.82 (1H, d, J= 6.0Hz), 7.85 (1H, d, J= 16Hz).

Production Example 184-2Ethyl (E)-3-[2-amino-4-4-[(4-fluoroanilino)carbonyl]amino}phenoxy)-3-pyridyl]-2-propenoate

50 **[0550]** Ethyl(E)-3-[2-amino-4-(4-aminophenoxy)-3-pyridyl]-2-propenoate (230 mg), p-fluorophenyl isocyanate (0.11 ml) and tetrahydrofuran (6 ml) were stirred at room temperature for 30 minutes. After adding NH type silica gel to the reaction solution, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (ethyl acetate). The solvent was distilled off under reduced pressure to obtain 200 mg of a white solid.

¹H-NMR(DMSO-d₆) δ(ppm) : 1.22 (3H, t, J= 7.2Hz), 4.14 (2H, q, J= 7.2Hz), 5.83 (1H, d, J= 5.6Hz), 6.41 (2H, brs), 6.62 (1H, d, J= 16Hz), 7.04-7.14 (4H, m), 7.40-7.53 (4H, m), 7.72 (1H, d, J= 16Hz), 7.79 (1H, d, J= 5.6Hz), 8.69 (1H, s), 8.75 (1H, s).

Example 185

N-(4-Fluorophenyl)-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea

[0551] After dissolving 90 mg of 4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline in ethyl acetate at room temperature, 0.05 ml of parafluorophenyl isocyanate was added dropwise. The precipitated white crystals were filtered out to obtain 65 mg of the target substance.

¹H-NMR(DMSO-d₆) δ(ppm): 6.21 (1H, d, J= 3.6Hz), 6.38 (1H, d, J= 5.6Hz), 7.08-7.18 (4H, m), 7.34 (1H, d, J= 3.6Hz), 7.43-7.56 (4H, m), 8.06 (1H, d, J= 5.6Hz), 8.72 (1H, s), 8.76 (1H, s), 11.72 (1H, s).

[0552] The intermediates were obtained in the following manner.

Production Example 185-1

4-(4-Nitrophenoxy)-3-(2-(1,1,1-trimethylsilyl)-1-ethynyl)-2-pyridineamine

[0553] 4-(4-Nitrophenoxy)-3-iodo-pyridineamine (1.5 g), (trimethylsilyl)acetylene (1.5 ml), tetrakis(triphenylphosphine) palladium(0) (480 mg), copper (I) iodide (80 mg), dimethylformamide (3 ml) and triethylamine (3 ml) were stirred at 100°C for 35 minutes. After returning the mixture to room temperature, water was added and extraction was performed with ethyl acetate. NH type silica gel was added to the extract, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 4:1). The solvent was distilled off under reduced pressure, and ethyl acetate and hexane were added to the residue for solidification to obtain 560 mg of the target substance as a faint brown powder.

¹H-NMR(DMSO-d₆) δ(ppm): 0.30 (9H, s), 6.60 (1H, d, J= 5.6Hz), 6.67 (2H, brs), 7.47 (2H, d, J= 8.0Hz), 8.24 (1H, d, J= 5.6Hz), 8.52 (2H, d, J= 8.0Hz).

Production Example 185-2

4-(4-Nitrophenoxy)-1H-pyrrolo[2,3-b]pyridine

[0554] 4-(4-Nitrophenoxy)-3-[2-(1,1,1-trimethylsilyl)-1-ethynyl]-2-pyridineamine (560 mg), copper (I) iodide (680 mg) and dimethylformamide (5 ml) were stirred for 25 minutes under reflux. After filtering out the insoluble portion, NH type silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 2:1, followed by 1:1). The solvent was distilled off under reduced pressure to obtain 84 mg of a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 6.14 (1H, d, J= 3.6Hz), 6.78 (1H, d, J= 5.2Hz), 7.28 (2H, d, J= 9.2Hz), 7.43 (1H, d, J= 3.6Hz), 8.21 (1H, d, J= 5.2Hz), 8.27 (2H, d, J= 9.2Hz), 11.92 (1H, brs).

Production Example 185-3

4-(1H-Pyrrolo[2,3-b]pyridin-4-yloxy)aniline

[0555] 4-(4-Nitrophenoxy)-1H-pyrrolo[2,3-b]pyridine (84 mg), iron powder (160 mg), ammonium chloride (320 ml), dimethylformamide (4 ml), ethanol (2 ml) and water (2 ml) were stirred at 100°C for 15 minutes. The mixture was filtered with celite, and then water and ethyl acetate were added for extraction. The organic layer was washed 5 times with aqueous ammonium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off and the solvent was distilled off under reduced pressure to obtain 230 mg of the target substance as a brown oil.

¹H-NMR(CDCl₃) δ(ppm): 6.41 (1H, d, J= 3.6Hz), 6.42 (1H, d, J= 5.6Hz), 6.74 (2H, d, J= 8.8Hz), 7.00 (2H, d, J= 8.8Hz), 7.20 (1H, d, J=3.6Hz), 8.11 (1H, d, J= 5.6Hz), 10.00 (1H, brs).

Example 186

N1-Cyclopropylcarbonyl-N1-[3-(1-ethynyl)-4-(4-[[4-(4-fluoroanilino)carbonyl]amino]phenoxy)-2-pyridyl]-1-cyclopropanecarboxamide

[0556] After adding 57 mg of cyclopropanecarbonyl chloride to a solution of N-(4-[[2-amino-3-(1-ethynyl)-4-pyridyl]oxy]phenyl)-N'-(4-fluorophenyl)urea (100 mg), triethylamine (0.12 ml) and tetrahydrofuran (5 ml) while stirring at room temperature, stirring was continued for 1.5 hours. After adding NH type silica gel to the reaction solution, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (ethyl acetate). The organic solvent was distilled off under reduced pressure, and methanol and water were added to the residue for solidification to obtain 15 mg of the target substance as a white powder.

¹H-NMR(DMSO-d₆) δ(ppm) : 0.97-1.03 (8H, m), 1.93-2.02 (2H, m), 4.75 (1H, s), 6.74 (1H, d, J= 5.6Hz), 7.08-7.20 (4H, m), 7.42-7.49 (2H, m), 7.56 (2H, d, J= 8.8Hz), 8.35 (1H, d, J= 5.6Hz), 8.72 (1H, s), 8.81 (1H, s).

[0557] The intermediates were obtained in the following manner.

Production Example 186-13-(1-Ethynyl)-4-(4-nitrophenoxy)-2-pyridineamine

[0558] 4-(4-Nitrophenoxy)-3-[2-(1,1,1-trimethylsilyl)-1-ethynyl]-2-pyridineamine (560 mg), tetrabutylammonium fluoride (1.0 M solution in tetrahydrofuran, 1 ml) and tetrahydrofuran (2 ml) were stirred at room temperature for 10 minutes. Aqueous ammonium chloride solution and ethyl acetate were added for extraction, and the extract was passed through a glass filter coated with silica gel. The silica gel was thoroughly washed with ethyl acetate and the ethyl acetate was distilled off under reduced pressure to obtain 400 mg of the target substance as a brown powder.

¹H-NMR(DMSO-d₆) δ(ppm): 4.52 (1H, s), 6.23 (1H, d, J= 5.6Hz), 6.46 (2H, brs), 7.24 (2H, d, J= 7.2Hz), 7.94 (1H, d, J= 5.6Hz), 8.27 (2H, d, J= 7.2Hz).

Production Example 186-24-(4-Aminophenoxy)-3-(1-ethynyl)-2-pyridinamine

[0559] 3-(1-Ethynyl)-4-(4-nitrophenoxy)-2-pyridinamine (400 mg), iron powder (800 mg), ammonium chloride (1.6 g), dimethylformamide (3 ml), ethanol (1 ml) and water (1 ml) were stirred at 100°C for 30 minutes. The mixture was filtered with celite, and then water and ethyl acetate were added to the filtrate for extraction. The organic layer was washed 5 times with aqueous ammonium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off and the solvent was distilled off under reduced pressure to obtain 260 mg of the target substance as a brown solid.

¹H-NMR(CDCl₃) δ(ppm): 3.63 (1H, s), 3.64 (2H, brs), 5.12 (2H, brs), 5.95 (1H, d, J= 5.6Hz), 6.69 (2H, dd, J= 6.4Hz, 2.0Hz), 6.91 (2H, dd, J= 6.4Hz, 2.0Hz), 7.81 (1H, d, J= 5.6Hz).

Production Example 186-3N-(4-[[2-Amino-3-(1-ethynyl)-4-pyridyl]oxy]phenyl)-N'-(4-fluorophenyl)urea

[0560] 4-(4-Aminophenoxy)-3-(1-ethynyl)-2-pyridinamine (260 mg), para-fluorophenyl isocyanate (0.13 ml) and tetrahydrofuran (5 ml) were stirred at room temperature for 20 hours. Water was added to the reaction solution, the tetrahydrofuran was distilled off, and then a small amount of ethyl acetate was added and the precipitated solid was filtered off to obtain 20 mg of a light brown solid.

¹H-NMR(DMSO-d₆) δ(ppm): 4.53 (1H, s), 5.80 (1H, d, J= 5.6Hz), 6.22 (2H, brs), 7.00-7.15 (4H, m), 7.40-7.53 (4H, m), 7.76 (1H, d, J= 5.6Hz), 8.69 (1H, s), 8.73 (1H, s).

Example 187

N1-Cyclopropyl-5-[(2-[[4-(4-hydroxypiperidino)butanoyl]amino]-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0561] Phenyl N-cyclopropylcarbamate (120 mg) was added to a solution of 260 mg of 5-[(2-[[4-(4-hydroxypiperidino)butanoyl]amino]-4-pyridyl]oxy]indole, 53 mg of sodium hydride (60% in oil) and 5 ml of dimethylformamide while stirring

at room temperature. After stirring for 10 minutes, water was added and extraction was performed with ethyl acetate. NH type silica gel was added to the ethyl acetate layer, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and purification was performed by column chromatography (chloroform:methanol = 30:1). The solvent was distilled off under reduced pressure, and the residue was dissolved in ethyl acetate and washed twice with 1N aqueous sodium hydroxide. After drying over sodium sulfate, the solvent was distilled off under reduced pressure to obtain 20 mg of the target substance as a white powder.

¹H-NMR(DMSO-d₆) δ(ppm): 0.57-0.64 (2H, m), 0.68-0.75 (2H, m), 1.24-1.34 (2H, m), 1.55-1.67 (4H, m), 1.83-1.94 (2H, m), 2.17 (2H, t, J= 7.2Hz), 2.28 (2H, t, J= 7.2Hz), 2.55-2.66 (2H, m), 2.73-2.80 (1H, m), 3.30-3.40 (1H, m), 4.47 (1H, d, J= 3.6Hz), 6.62(1H, dd, J= 5.6Hz, 2.4Hz), 6.64 (1H, d, J= 3.6Hz), 7.04 (1H, dd, J= 8.8Hz, 2.4Hz), 7.36 (1H, d, J= 2.4Hz), 7.61 (1H, d, J= 2.4Hz), 7.87 (1H, d, J= 3.6Hz), 8.12 (1H, d, J= 5.6Hz), 8.25-8.30 (2H, m), 10.40 (1H, s).

Example 188

N1-(2-Fluoroethyl)-5-[(2-[(4-(4-hydroxypiperidino)butanoyl] amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0562] The target substance was obtained using phenyl N-(2-fluoroethyl)carbamate, in the same manner as Example 188.

¹H-NMR(DMSO-d₆) δ(ppm): 1.24-1.35 (2H, m), 1.57-1.67 (4H, m), 1.88 (2H, t, J= 10.4Hz), 2.17 (2H, t, J= 7.2Hz), 2.28 (2H, t, J= 7.2Hz), 2.56-2.55 (2H, m), 3.30-3.40 (1H, m), 3.55 (1H, q, J= 4.8Hz), 3.61 (1H, q, J= 4.8Hz), 4.48 (1H, d, J= 4.0Hz), 4.52 (1H, t, J= 4.8Hz), 4.64 (1H, t, J= 4.8Hz), 6.62 (1H, dd, J= 5.6Hz, 2.4Hz), 6.70 (1H, d, J= 3.6Hz), 7.05 (1H, dd, J= 8.8Hz, 2.4Hz), 7.38 (1H, d, J= 2.4Hz), 7.62 (1H, d, J= 2.4Hz), 7.95 (1H, d, J= 3.6Hz), 8.12 (1H, d, J= 5.6Hz), 8.28 (1H, d, J= 8.8Hz), 8.44-8.49 (1H, m), 10.41 (1H, s).

Example 189

N1-Phenyl-5-[(2-[(4-(4-hydroxypiperidino) butanoyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0563] The target substance was obtained using phenyl isocyanate, in the same manner as Example 187.

¹H-NMR(DMSO-d₆) δ(ppm): 1.24-1.35 (2H, m), 1.57-1.67 (4H, m), 1.84-1.96 (2H, m), 2.18 (2H, t, J= 6.8Hz), 2.29 (2H, t, J= 6.8Hz), 2.56-2.66 (2H, m), 3.30-3.40 (1H, m), 4.48 (1H, d, J= 4.4Hz), 6.65 (1H, dd, J= 5.6Hz, 2.4Hz), 6.77 (1H, d, J= 3.6Hz), 7.09 (1H, dd, J= 8.8Hz, 2.4Hz), 7.10-7.16 (1H, m), 7.35-7.41 (2H, m), 7.43 (1H, d, J= 2.4Hz), 7.62-7.67 (3H, m), 8.10-8.15 (2H, m), 8.27 (1H, d, J= 8.8Hz), 10.10 (1H, s), 10.42 (1H, s).

Example 190

N1-Cyclopropyl-5-[(2-[(2-(4-hydroxypiperidino)acetyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0564] The target substance was obtained using 5-[(2-[(2-(4-hydroxypiperidino) acetyl] amino)-4-pyridyl]oxy]indole, in the same manner as Example 188.

¹H-NMR(DMSO-d₆) δ(ppm): 0.58-0.63 (2H, m), 0.69-0.75 (2H, m), 1.35-1.45 (2H, m), 1.66-1.74 (2H, m), 2.17-2.25 (2H, m), 2.64-2.72 (2H, m), 2.72-2.80 (1H, m), 3.04 (2H, s), 3.38-3.49 (1H, m), 4.57 (1H, d, J= 4.4Hz), 6.65 (1H, d, J= 3.6Hz), 6.68 (1H, dd, J= 5.6Hz, 2.4Hz), 7.05 (1H, dd, J= 8.8Hz, 2.4Hz), 7.38 (1H, d, J= 2.8Hz), 7.59 (1H, d, J= 2.8Hz), 7.87 (1H, d, J= 3.6Hz), 8.15 (1H, d, J= 5.6Hz), 8.27-8.82 (2H, m), 9.85 (1H, s).

[0565] The intermediate was obtained in the following manner.

Production Example 190-1

5-[(2-[(2-(4-Hydroxypiperidino)acetyl]amino)-4-pyridyl]oxy]indole

[0566] Bromoacetyl chloride (2.14 g) was added to a solution of 2.0 g of N1-cyclopropyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide, 2.3 ml of triethylamine and 20 ml of tetrahydrofuran while stirring at room temperature. After stirring for 30 minutes, water was added and extraction was performed with ethyl acetate. The extract was passed through a glass filter coated with silica gel. The silica gel was thoroughly washed with ethyl acetate, and then the ethyl acetate layers were combined and subjected to distillation under reduced pressure to obtain 900 mg of a greenish-brown oil. The 900 mg of oil was stirred at 70°C for 35 minutes together with 640 mg of 4-hydroxypiperidine, 1.2 g of potassium carbonate and 20 ml of dimethylformamide. Water was added and extraction was performed with ethyl acetate. The extract was washed 3 times with water and once with brine, and then passed through a glass filter coated

with silica gel. The silica gel was washed thoroughly with ethyl acetate, and the solvent was distilled off under reduced pressure to obtain 530 mg of the target substance as a light yellow powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.35-1.47 (2H, m), 1.68-1.75 (2H, m), 2.21 (2H, t, J= 10.00Hz), 2.64-2.74 (2H, m), 3.03 (2H, s), 3.40-3.50 (1H, m), 4.57 (1H, d, J= 4.0Hz), 6.42 (1H, s), 6.63 (1H, dd, J= 5.6Hz, 2.4Hz), 6.86 (1H, dd, J= 8.8Hz, 2.4Hz), 7.30 (1H, s), 7.42 (1H, d, J= 2.4Hz), 7.45 (1H, d, J= 8.8Hz), 7.59 (1H, d, J= 2.4Hz), 8.12 (1H, d, J= 5.6Hz), 9.81 (1H, s), 11.25 (1H, s).

Example 191

N1-(2-Fluoroethyl)-5-[(2-[(2-(4-hydroxypiperidino)acetyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0567] The target substance was obtained using 5-[(2-[(2-(4-hydroxypiperidino)acetyl]amino)-4-pyridyl]oxy]indolephenyl and N-(2-fluoroethyl)carbamate, in the same manner as Example 187.

¹H-NMR(DMSO-d₆) δ(ppm): 1.35-1.45 (2H, m), 1.66-1.74 (2H, m), 2.21 (2H, t, J= 10.0Hz), 2.65-2.72 (2H, m), 3.04 (2H, s), 3.38-3.50 (1H, m), 3.55 (1H, q, J= 4.8Hz), 3.62 (1H, q, J= 4.8Hz), 4.52 (1H, t, J= 4.8Hz), 4.56 (1H, d, J= 4.4Hz), 4.64 (1H, t, J= 4.8Hz), 6.67 (1H, dd, J= 5.6Hz, 2.4Hz), 6.70 (1H, d, J= 3.6Hz), 7.06 (1H, dd, J= 8.8Hz, 2.4Hz), 7.40 (1H, d, J= 2.4Hz), 7.60 (1H, d, J= 2.4Hz), 7.95 (1H, d, J= 3.6Hz), 8.15 (1H, d, J= 5.6Hz), 8.30 (1H, d, J= 8.8Hz), 8.47 (1H, t, J= 4.8Hz), 9.85 (1H, s).

Example 192

N1-Cyclopropyl-5-[(2-[(3-(4-hydroxypiperidino)propionyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0568] The target substance was obtained using 5-[(2-[(3-(4-hydroxypiperidino)propionyl]amino)-4-pyridyl]oxy]indole, in the same manner as Example 187.

¹H-NMR(DMSO-d₆) δ(ppm): 0.58-0.64 (2H, m), 0.70-0.76 (2H, m), 1.29-1.91 (2H, m), 1.62-1.72 (2H, m), 1.95-2.06 (2H, m), 2.38-2.58 (4H, m), 2.63-2.73 (2H, m), 2.70-2.80 (1H, m), 3.35-3.46 (1H, m), 4.51 (1H, s), 6.61-6.66 (2H, m), 7.04 (1H, dd, J= 8.8Hz, 2.4Hz), 7.36 (1H, d, J= 2.4Hz), 7.59 (1H, d, J= 2.4Hz), 7.87 (1H, d, J= 3.6Hz), 8.13 (1H, d, J= 5.6Hz), 8.25-8.30 (2H, m), 10.77 (1H, s).

[0569] The intermediate was obtained in the following manner.

Production Example 192-1

5-[(2-[(3-(4-Hydroxypiperidino)propionyl]amino)-4-pyridyl]oxy]indole

[0570] 3-Bromopropionyl chloride (1.4 ml) was added to a solution of 2.0 g of N1-cyclopropyl-5-[(2-amino-4-pyridyl]oxy)-1H-1-indolecarboxamide, 2.3 ml of triethylamine and 80 ml of tetrahydrofuran, while stirring on ice. After stirring for 10 minutes, stirring was continued at room temperature for 10 minutes, water was added and extraction was performed with ethyl acetate. The extract was passed through a glass filter coated with silica gel. The silica gel was thoroughly washed with ethyl acetate, and then the ethyl acetate layers were combined and subjected to distillation under reduced pressure to obtain 1.7 g of a faint yellow oil. A 900 mg portion of the oil was stirred at 70°C for 30 minutes together with 470 mg of 4-hydroxypiperidine, 880 mg of potassium carbonate and 10 ml of dimethylformamide. Water was added and extraction was performed with ethyl acetate. NH type silica gel was added to the ethyl acetate layer, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and purification was performed by column chromatography (chloroform:methanol = 100:3). The solvent was distilled off under reduced pressure to obtain 170 mg of the target substance as a white powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.29-1.42 (2H, m), 1.62-1.72 (2H, m), 2.00 (2H, t, J= 7.2Hz), 2.37-2.55 (4H, m), 2.62-2.72 (2H, m), 3.35-3.46 (1H, m), 4.52 (1H, d, J= 4.0Hz), 6.42 (1H, s), 6.59 (1H, dd, J= 5.6Hz, 2.4Hz), 6.85 (1H, dd, J= 8.8Hz, 2.4Hz), 7.29 (1H, s), 7.41 (1H, d, J= 2.4Hz), 7.44 (1H, d, J= 8.8Hz), 7.59 (1H, d, J= 2.4Hz), 8.10 (1H, d, J= 5.6Hz), 10.74 (1H, s), 11.22 (1H, s).

Example 193

N1-(2-Fluoroethyl)-5-[(2-[(4-piperidylcarbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0571] After dissolving 160 mg of N1-(2-fluoroethyl)-5-[(2-[(1-tert-butyloxycarbonyl-4-piperidyl)carbonyl]amino)-4-pyridyl]oxy)-1H-1-indolecarboxamide in 10 ml of trifluoroacetic acid, the solution was stirred at room temperature for

10 minutes. Ethyl acetate and sodium bicarbonate water were added to alkalinity for liquid separation. The ethyl acetate layer was washed once with brine and dried over magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 86 mg of a colorless powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.60-1.73 (2H, m), 1.83-1.91 (2H, m), 2.65-2.73 (1H, m), 2.77-2.87 (2H, m), 3.22-3.32 (2H, m), 3.55 (1H, q, J = 5.2Hz), 3.62 (1H, q, J = 5.2Hz), 4.52 (1H, t, J = 5.2Hz), 4.64 (1H, t, J = 5.2Hz), 6.67 (1H, dd, J = 5.6Hz, 2.4Hz), 6.70 (1H, d, J = 3.6Hz), 7.05 (1H, dd, J = 8.8Hz, 2.4Hz), 7.38 (1H, d, J = 2.4Hz), 7.59 (1H, d, J = 2.4Hz), 7.96 (1H, d, J = 3.6Hz), 8.16 (1H, d, J = 5.6Hz), 8.29 (1H, d, J = 8.8Hz), 8.49 (1H, t, J = 5.2Hz), 10.59 (1H, s).

[0572] The intermediates were obtained in the following manner.

Production Example 193-1

N1-(2-Fluoroethyl)-5-[(2-[(1-tert-butyloxycarbonyl-4-piperidyl)carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0573] N1-(2-Fluoroethyl)-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide (500 mg), 1-tert-butyloxycarbonyl-piperidine-4-carboxylic acid (440 mg), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (Bop Reagent) (840 mg), triethylamine (0.44 ml) and dimethylformamide (10 ml) were stirred at room temperature for 17 hours. Water was added, extraction was performed with ethyl acetate, NH type silica gel was added to the extract, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane: ethyl acetate = 1:1). The solvent was distilled off under reduced pressure to obtain 160 mg of the target substance as a white powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.28-1.40 (2H, m), 1.36 (9H, s), 1.64-1.72 (2H, m), 2.54-2.80 (3H, m), 3.55 (1H, q, J = 5.2Hz), 3.61 (1H, q, J = 5.2Hz), 3.86-3.96 (2H, m), 4.52 (1H, t, J = 5.2Hz), 4.64 (1H, t, J = 5.2Hz), 6.66 (1H, dd, J = 5.6Hz, 2.4Hz), 6.70 (1H, d, J = 3.6Hz), 7.05 (1H, dd, J = 8.8Hz, 2.4Hz), 7.38 (1H, d, J = 2.4Hz), 7.59 (1H, d, J = 2.4Hz), 7.95 (1H, d, J = 3.6Hz), 8.14 (1H, d, J = 5.6Hz), 8.28 (1H, d, J = 8.8Hz), 8.48 (1H, t, J = 5.2Hz), 10.49 (1H, s).

Example 194

N1-(2-Fluoroethyl)-5-[(2-[(1-methyl-4-piperidyl) carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0574] N1-Cyclopropyl-5-[(2-[(4-piperidylcarbonyl)amino]-4-pyridyl)oxy]-1H-1-indolecarboxamide (70 mg), formaldehyde (37% in water, 0.1 ml), acetic acid (20 mg) and tetrahydrofuran (5 ml) were stirred at room temperature for 5 minutes, and then 70 mg of sodium triacetoxymethylborohydride was added prior to additional stirring for 10 minutes. Sodium bicarbonate water was added and extraction was performed with ethyl acetate. The extract was passed through a glass filter coated with NH type silica gel. The silica gel was thoroughly washed with ethyl acetate, and the ethyl acetate layers were combined and subjected to distillation under reduced pressure to obtain 40 mg of a colorless powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.45-1.56 (2H, m), 1.59-1.68 (2H, m), 1.73-1.83 (2H, m), 2.09 (3H, s), 2.30-2.40 (1H, m), 2.69-2.77 (2H, m), 3.56 (1H, q, J = 5.2Hz), 3.62 (1H, q, J = 5.2Hz), 4.52 (1H, t, J = 5.2Hz), 4.64 (1H, t, J = 5.2Hz), 6.65 (1H, dd, J = 5.6Hz, 2.4Hz), 6.70 (1H, d, J = 3.6Hz), 7.05 (1H, dd, J = 8.8Hz, 2.4Hz), 7.38 (1H, d, J = 2.4Hz), 7.60 (1H, d, J = 2.4Hz), 7.95 (1H, d, J = 3.6Hz), 8.13 (1H, d, J = 5.6Hz), 8.29 (1H, d, J = 8.8Hz), 8.48 (1H, t, J = 5.2Hz), 10.41 (1H, s).

Example 195

N1-Cyclopropyl-5-[(2-[(4-piperidylcarbonyl)amino]-4-pyridyl)oxy]-1H-1-indolecarboxamide

[0575] The target substance was obtained using N1-cyclopropyl-5-[(2-[(1-tert-butyloxycarbonyl-4-piperidyl)carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide, in the same manner as Example 193.

¹H-NMR(DMSO-d₆) δ(ppm): 0.59-0.66 (2H, m), 0.67-0.75 (2H, m), 1.30-1.43 (2H, m), 1.54-1.62 (2H, m), 2.36-2.45 (2H, m), 2.45-2.54 (1H, m), 2.73-2.80 (1H, m), 2.86-2.94 (2H, m), 6.60-6.67 (2H, m), 7.04 (1H, dd, J = 8.8Hz, 2.4Hz), 7.36 (1H, d, J = 2.4Hz), 7.60 (1H, d, J = 2.4Hz), 7.92 (1H, d, J = 2.4Hz), 8.13 (1H, d, J = 5.6Hz), 8.29 (1H, d, J = 8.8Hz), 8.34 (1H, s), 10.36 (1H, s).

[0576] The intermediates were obtained in the following manner.

Production Example 195-1N1-Cyclopropyl-5-[(2-[(1-tert-butyloxycarbonyl-4-piperidyl)carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0577] The target substance was obtained using N1-cyclopropyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide, in the same manner as Production Example 193-1.

¹H-NMR(DMSO-d₆) δ(ppm): 0.59-0.64 (2H, m), 0.70-0.75 (2H, m), 1.28-1.42 (11H, m), 1.64-1.71 (2H, m), 2.55-2.82 (4H, m), 3.87-3.97 (2H, m), 6.64-6.68 (2H, m), 7.03 (1H, dd, J= 8.8Hz, 2.4Hz), 7.36 (1H, d, J= 2.4Hz), 7.59 (1H, d, J= 2.4Hz), 7.87 (1H, d, J= 3.6Hz), 8.14 (1H, d, J= 5.6Hz), 8.27 (1H, s), 8.29 (1H, d, J= 8.8Hz), 10.48 (1H, s).

Example 196N1-Cyclopropyl-5-[(2-[(1-methyl-4-piperidyl) carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0578] The target substance was obtained using N1-cyclopropyl-5-[(2-[(4-piperidylcarbonyl)amino]-4-pyridyl)oxy]-1H-1-indolecarboxamide, in the same manner as Example 194.

¹H-NMR(DMSO-d₆) δ(ppm): 0.59-0.65 (2H, m), 0.70-0.76 (2H, m), 1.43-1.56 (2H, m), 1.59-1.68 (2H, m), 1.70-1.81 (2H, m), 2.09 (3H, s), 2.30-2.40 (1H, m), 2.69-2.80 (3H, m), 6.62-6.70 (2H, m), 7.04 (1H, dd, J= 8.8Hz, 2.4Hz), 7.36 (1H, d, J= 2.4Hz), 7.59 (1H, d, J= 2.4Hz), 7.87 (1H, d, J= 3.6Hz), 8.13 (1H, d, J= 5.6Hz), 8.27-8.83 (2H, m), 10.41 (1H, s).

Example 197N1-Phenyl-5-[(2-[(1-methyl-4-piperidyl)carbonyl] amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0579] The target substance was obtained using N1-phenyl-5-[(2-[(4-piperidylcarbonyl)amino]-4-pyridyl)oxy]-1H-1-indolecarboxamide, in the same manner Example 194.

¹H-NMR(DMSO-d₆) δ(ppm): 1.44-1.56 (2H, m), 1.59-1.67 (2H, m), 1.73-1.82 (2H, m), 2.09 (3H, s), 2.30-2.44 (1H, s), 2.69-2.76 (2H, s), 6.66-6.70 (1H, m), 6.77 (1H, d, J= 3.6Hz), 7.07-7.15 (2H, m), 7.35-7.45 (3H, m), 7.60-7.68 (3H, m), 8.10-8.18 (2H, m), 8.27 (1H, d, J= 8.8Hz), 10.10 (1H, s), 10.42 (1H, s).

[0580] The intermediates were obtained in the following manner.

Production Example 197-1N1-Phenyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide

[0581] After adding 28 mg of sodium hydride (60% in oil) to a solution of 3.0 g of 5-[(2-amino-4-pyridyl)oxy]-1H-indole in dimethylformamide at room temperature and stirring the mixture for 5 minutes, 1.6 g of phenyl isocyanate was added and the mixture was stirred for 20 minutes. Water was added, extraction was performed with ethyl acetate and the organic layer was washed with water, and then silica gel was added and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel and purified by column chromatography (ethyl acetate), to obtain 3.4 g of a colorless powder.

¹H-NMR(DMSO-d₆) δ(ppm): 5.77 (1H, d, J= 2.4Hz), 5.85 (2H, s), 6.14 (1H, dd, J= 5.6Hz, 2.4Hz), 6.75 (1H, d, J= 4.0Hz), 7.06 (1H, dd, J= 8.8Hz, 2.4Hz), 7.13 (1H, dd, J= 8.0Hz, 8.0Hz), 7.36-7.43 (3H, m), 7.64 (2H, d, J= 8.0Hz), 7.77 (1H, d, J= 5.6Hz), 8.10 (1H, d, J= 4.0Hz), 8.25 (1H, d, J= 8.8Hz), 10.08 (1H, s).

Production Example 197-2Tert-butyl 4-[(4-[(1-(anilino)carbonyl)-1H-5-indolyl] oxy)-2-pyridyl]amino]carbonyl]-1-piperidine carboxylate

[0582] The target substance was obtained using N1-phenyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide, in the same manner as Production Example 193-1.

¹H-NMR(DMSO-d₆) δ(ppm): 1.38-1.41 (11H, m), 1.64-1.72 (2H, m), 2.52-2.75 (3H, m), 3.87-3.97 (2H, m), 6.68 (1H, dd, J= 5.6Hz, 2.4Hz), 6.77 (1H, d, J= 3.6Hz), 7.09 (1H, dd, J= 8.8Hz, 2.4Hz), 7.13 (1H, dd, J= 7.2Hz, 7.2Hz), 7.38 (2H, dd, J= 7.2Hz, 7.2Hz), 7.43 (1H, d, J= 2.4Hz), 7.61 (1H, d, J= 2.4Hz), 7.65 (2H, d, J= 7.2Hz), 8.13 (1H, d, J= 3.6Hz), 8.15 (1H, d, J= 5.6Hz), 8.27 (1H, d, J= 8.8Hz), 10.10 (1H, s), 10.50 (1H, s).

Production Example 197-3N1-Phenyl-5-([2-[(4-piperidylcarbonyl)amino]-4-pyridyl]oxy)-1H-1-indolecarboxamide

[0583] The target substance was obtained using tert-butyl 4-[[[4-[(1-anilinocarbonyl)-1H-5-indolyl]oxy]-2-pyridyl]amino] carbonyl]-1-piperidine carboxylate, in the same manner as Example 193.

¹H-NMR(DMSO-d₆) δ(ppm): 1.32-1.43 (2H, m), 1.55-1.63 (2H, m), 2.37-2.53 (3H, m), 2.88-2.95 (2H, m), 6.67 (1H, dd, J= 5.6Hz, 2.4Hz), 6.77 (1H, d, J= 3.6Hz), 7.09 (1H, dd, J= 8.8Hz, 2.4Hz), 7.13 (1H, dd, J= 7.2Hz, 7.2Hz), 7.38 (2H, dd, J= 7.2Hz, 7.2Hz), 7.43 (1H, 2.4Hz), 7.62-7.67 (3H, m), 8.13 (1H, d, J= 3.6Hz), 8.15 (1H, d, J= 5.6Hz), 8.27 (1H, d, J= 8.8Hz), 10.10 (1H, bs), 10.40 (1H, s).

Example 198N1-Phenyl-5-([2-([(1-cyclopropylmethyl)-4-piperidyl]carbonyl)amino]-4-pyridyl]oxy)-1H-1-indolecarboxamide

[0584] The target substance was obtained using N1-phenyl-5-([2-[(4-piperidylcarbonyl)amino]-4-pyridyl]oxy)-1H-1-indolecarboxamide and cyclopropanecarboxyaldehyde, in the same manner as Example 194.

¹H-NMR(DMSO-d₆) δ(ppm): 0.00-0.06 (2H, m), 0.39-0.45 (2H, m), 0.72-0.82 (1H, m), 1.46-1.59 (2H, m), 1.60-1.70 (2H, m), 1.80-1.90 (2H, m), 2.10 (2H, d, J= 6.0Hz), 2.33-2.43 (1H, m), 2.90-3.00 (2H, m), 6.67 (1H, dd, J= 5.6Hz, 2.4Hz), 6.76 (1H, d, J= 3.6Hz), 7.06-7.16 (2H, m), 7.35-7.45 (3H, m), 7.60-7.68 (3H, m), 8.12 (1H, d, J=3.6Hz), 8.14 (1H, d, J= 5.6Hz), 8.27 (1H, d, J= 8.8Hz), 10.09 (1H, s), 10.40 (1H, s).

Example 199N4-(4-[4-[(Anilinocarbonyl)amino]-3-chlorophenoxy]-2-pyridyl)-1-methyl-4-piperidinecarboxamide

[0585] After dissolving 120 mg of t-butyl 4-[[[4-{4-[(anilinocarbonyl)amino]-3-chlorophenoxy}-2-pyridyl]amino]carbonyl]-1-piperidine carboxylate in 5 ml of trifluoroacetic acid, the solution was stirred at room temperature for 5 minutes. Sodium bicarbonate water and 5N aqueous sodium hydroxide were added and extraction was performed with ethyl acetate. The extract was washed with brine and dried over sodium sulfate. The drying agent was filtered off, and the solvent was distilled off under reduced pressure. After adding 5 ml of tetrahydrofuran, 26 mg of acetic acid, 92 mg of sodium triacetoxymethylborohydride and 0.5 ml of formaldehyde (37% in water) to the residue, the mixture was stirred at room temperature for 10 minutes. Sodium bicarbonate water and 5N aqueous sodium hydroxide were added to the reaction solution, and extraction was performed with ethyl acetate. The extract was washed with brine and then passed through a glass filter coated with NH type silica gel. The silica gel was washed thoroughly with ethyl acetate, the ethyl acetate layers were combined and subjected to distillation under reduced pressure, and the residue was solidified with ethyl acetate and hexane to obtain 80 mg of a colorless powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.48-1.62 (2H, m), 1.62-1.72 (2H, m), 1.76-1.86 (2H, m), 2.12 (3H, s), 2.34-2.44 (1H, m), 2.72-2.81 (2H, m), 6.68 (1H, dd, J= 5.6Hz, 2.4Hz), 6.98 (1H, dd, J= 7.2Hz, 7.2Hz), 7.15 (1H, dd, J= 8.8Hz, 2.4Hz), 7.29 (2H, dd, J= 7.2Hz, 7.2Hz), 7.38 (1H, d, J= 2.4Hz), 7.46 (2H, d, J= 7.2Hz), 7.66 (1H, d, J= 2.4Hz), 8.17 (1H, d, J= 5.6Hz), 8.22 (1H, d, J= 8.8Hz), 8.38 (1H, s), 9.42 (1H, s), 10.49 (1H, s).

Production Example 199-1t-Butyl 4-([(4-(4-amino-3-chlorophenoxy)-2-pyridyl]amino)carbonyl]-1-piperidinecarboxylate

[0586] 2-Amino-4-(4-amino-3-chlorophenoxy)pyridine (600 mg), 1-t-butyloxycarbonylpiperidine-4-carboxylic acid (700 mg), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (Bop Reagent) (1.4 g), triethylamine (0.71 ml) and dimethylformamide (10 ml) were stirred at 60°C for 3.5 hours and then at room temperature for 19 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate and the organic layer was washed with water, after which silica gel was added and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate) to obtain 660 mg of a reddish-brown powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.30-1.45 (11H, m), 1.65-1.74 (2H, m), 2.56-2.76 (3H, m), 3.88-4.03 (2H, m), 5.37 (2H, s), 6.59 (1H, dd, J= 5.6Hz, 2.4Hz), 6.82-6.88 (2H, m), 6.07 (1H, d, J= 2.4Hz), 7.57 (1H, d, J= 2.4Hz), 8.12 (1H, d, J= 5.6Hz), 10.48 (1H, s).

Production Example 199-2t-Butyl 4-(((4-{3-chloro-4-[(phenoxy-carbonyl) amino]phenoxy}-2-pyridyl)amino)carbonyl)-1-piperidinecarboxylate

[0587] After adding 0.21 ml of phenyl chloroformate to a solution of 660 mg of t-butyl 4-(((4-{4-amino-3-chlorophenoxy}-2-pyridyl)amino)carbonyl)-1-piperidine carboxylate, 0.14 ml of pyridine and 10 ml of tetrahydrofuran while stirring at room temperature, the mixture was further stirred for 13 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate and the organic layer was washed with water, after which silica gel was added and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate) to obtain 500 mg of a colorless oil.

¹H-NMR(DMSO-d₆) δ(ppm): 1.30-1.45 (11H, m), 1.67-1.77 (2H, m), 2.58-2.80 (3H, m), 3.88-4.00 (2H, m), 6.71 (1H, dd, J= 5.6Hz, 2.4Hz), 7.17-7.28 (4H, m), 7.37-7.46 (3H, m), 7.67 (1H, d, J= 2.4Hz), 7.79 (1H, d, J= 8.8Hz), 8.20 (1H, d, J= 5.6Hz), 9.78 (1H, bs), 10.58 (1H, s).

Production Example 199-3t-Butyl 4-(((4-{4-[(anilino-carbonyl)amino]-3-chlorophenoxy}-2-pyridyl)amino)carbonyl)-1-piperidinecarboxylate

[0588] t-Butyl 4-(((4-{3-chloro-4-[(phenoxy-carbonyl) amino]phenoxy}-2-pyridyl)amino)carbonyl)-1-piperidine carboxylate (250 mg), aniline (84 mg) and dimethylformamide (3 ml) were stirred at 130°C for 70 minutes. The mixture was returned to room temperature, water was added and extraction was performed with ethyl acetate. Silica gel was added to the extract, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with silica gel, and column purification was performed (hexane:ethyl acetate = 1:1, followed by ethyl acetate). The solvent was distilled off under reduced pressure to obtain 120 mg of a colorless oil.

¹H-NMR(DMSO-d₆) δ(ppm): 1.28-1.45 (11H, m), 1.67-1.75 (2H, m), 2.57-2.80 (3H, m), 3.87-4.03 (2H, m), 6.69 (1H, dd, J= 5.6Hz, 2.4Hz), 6.93 (1H, dd, J= 7.2Hz, 7.2Hz), 7.15 (1H, dd, J= 8.8Hz, 2.4Hz), 7.28 (2H, dd, J= 7.2Hz, 7.2Hz), 7.39 (1H, d, J= 2.4Hz), 7.45 (2H, d, J= 7.2Hz), 7.64 (1H, d, J= 2.4Hz), 8.18 (1H, d, J= 5.6Hz), 8.21 (1H, d, J= 8.8Hz), 8.36 (1H, s), 9.33 (1H, s), 10.55 (1H, s).

Example 200N4-[4-(3-Chloro-4-(((cyclopropylamino)carbonyl) amino)phenoxy)-2-pyridyl]-1-methyl-4-piperidinecarboxamide

[0589] The target substance was obtained using t-butyl 4-(((4-{3-chloro-4-[(cyclopropylamino) carbonyl]amino}phenoxy)-2-pyridyl)amino)carbonyl)-1-piperidine carboxylate, in the same manner as Example 199.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.48 (2H, brs), 0.60-0.70 (2H, m), 1.50-1.85 (6H, m), 2.11(3H, s), 2.33-2.45 (1H, m), 2.45-2.58 (1H, m), 2.70-2.80 (2H, m), 6.66 (1H, dd, J= 5.6Hz, 2.4Hz), 7.09 (1H, dd, J= 8.8Hz, 2.4Hz), 7.16 (1H, d, J=2.4Hz), 7.32 (1H, d, J= 2.4Hz), 7.62 (1H, s), 7.93 (1H, s), 8.16 (1H, d, J= 5.6Hz), 8.20 (1H, d, J= 8.8Hz), 10.46 (1H, s).

[0590] The intermediates were obtained in the following manner.

Production Example 200-1t-Butyl 4-(((4-{3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy}-2-pyridyl)amino)carbonyl)-1-piperidinecarboxylate

[0591] The target substance was obtained using cyclopropylamine with the starting material synthesized in Production Example 199-2, in the same manner as Production Example 199-3.

¹H-NMR(DMSO-d₆) δ(ppm) : 0.38-0.44 (2H, m), 0.60-0.68 (2H, m), 1.30-1.44 (11H, m), 1.67-1.74 (2H, m), 2.50-2.80 (4H, m), 3.88-4.00 (2H, m), 6.67 (1H, dd, J= 5.6Hz, 2.4Hz), 7.09 (1H, dd, J= 8.8Hz, 2.4Hz), 7.16 (1H, d, J= 2.4Hz), 7.32 (1H, d, J= 2.4Hz), 7.61 (1H, s), 7.93 (1H, s), 8.16 (1H, d, J= 5.6Hz), 8.20 (1H, d, J= 8.8Hz), 10.54 (1H, s).

Example 201N4-[4-(3-Chloro-4-(((4-fluoroanilino)carbonyl)amino)phenoxy)-2-pyridyl]-4-piperidinecarboxamide

[0592] After dissolving 320 mg of t-butyl 4-(((4-{3-chloro-4-(((4-fluoroanilino) carbonyl)amino)phenoxy)-2-pyridyl)amino)carbonyl)-1-piperidinecarboxylate

no)carbonyl)-1-piperidinecarboxylate in 10 ml of trifluoroacetic acid, the solution was stirred at room temperature for 5 minutes. Ethyl acetate and sodium bicarbonate water were added to alkalinity for liquid separation. The ethyl acetate layer was washed once with brine and then dried over magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 240 mg of a colorless powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.36-1.48 (2H, m), 1.58-1.66 (2H, m), 2.39-2.58 (3H, m), 2.89-2.98 (2H, m), 6.67 (1H, dd, J= 5.6Hz, 2.4Hz), 7.09-7.18 (3H, m), 7.38 (1H, d, J= 2.4Hz), 7.44-7.50 (2H, m), 7.66 (1H, d, J= 2.4Hz), 8.15 (2H, m), 8.38 (1H, s), 9.48 (1H, s), 10.44 (1H, s).

[0593] The intermediates were obtained in the following manner.

Production Example 201-1

t-Butyl 4-[[4-(3-chloro-4-[[4-(4-fluoroanilino)carbonyl]amino]phenoxy)-2-pyridyl]amino]carbonyl-1-piperidinecarboxylate

[0594] The target substance was obtained using parafluoroaniline with the starting material synthesized in Production Example 199-2, in the same manner as Production Example 199-3.

¹H-NMR(DMSO-d₆) δ(ppm): 1.32-1.46 (11H, m), 1.66-1.75 (2H, m), 2.56-2.78 (3H, m), 3.88-4.00 (2H, m), 6.69 (1H, dd, J= 5.6Hz, 2.4Hz), 7.10-7.18 (3H, m), 7.38 (1H, d, J= 2.4Hz), 7.43-7.50 (2H, m), 7.64 (1H, d, J= 2.4Hz), 8.17-8.23 (2H, m), 8.37 (1H, s), 9.45 (1H, s), 10.55 (1H, s).

Example 202

N4-[4-(3-Chloro-4-[[4-(4-fluoroanilino)carbonyl]amino]phenoxy)-2-pyridyl]-1-methyl-4-piperidinecarboxamide

[0595] The target substance was obtained using N4-[4-(3-chloro-4-[[4-(4-fluoroanilino)carbonyl]amino]phenoxy)-2-pyridyl]-4-piperidinecarboxamide, in the same manner as Example 199.

¹H-NMR(DMSO-d₆) δ(ppm): 1.48-1.60 (2H, m), 1.62-1.70 (2H, m), 1.74-1.83 (2H, m), 2.11 (3H, s), 2.33-2.43 (1H, m), 2.70-2.78 (2H, m), 6.68 (1H, dd, J= 5.6Hz, 2.4Hz), 7.10-7.20 (3H, m), 7.39 (1H, d, J= 2.4Hz), 7.44-7.50 (2H, m), 7.65 (1H, d, J= 2.4Hz), 8.16-8.23 (2H, m), 8.33 (1H, s), 9.41 (1H, s), 10.47 (1H, s).

Example 203

N1-[4-[4-[(Anilino)carbonyl]amino]-3-chlorophenoxy]-2-pyridyl]-2-(1-methyl-4-piperidyl)acetamide

[0596] The target substance was obtained using tert-butyl 4-[2-[(4-[4-[(anilino)carbonyl]amino]-3-chlorophenoxy)-2-pyridyl]amino]-2-oxoethyl]-1-piperidine carboxylate, in the same manner as Example 199.

¹H-NMR (DMSO-d₆) δ(ppm): 1.10-1.20 (2H, m), 1.50-1.70 (3H, m), 1.72-1.80 (2H, m), 2.08 (3H, s), 2.24 (2H, d, J= 6.8Hz), 2.63-2.72 (2H, m), 6.66 (1H, d, J= 5.6Hz, 2.4Hz), 6.97 (1H, dd, J= 7.2Hz, 7.2Hz), 7.14 (1H, dd, J= 8.8Hz, 2.4Hz), 7.28 (2H, dd, J= 7.2Hz, 7.2Hz), 7.39 (1H, d, J= 2.4Hz), 7.47 (2H, d, J= 7.2Hz), 7.68 (1H, d, J= 2.4Hz), 8.16 (1H, d, J= 5.6Hz), 8.20 (1H, d, J= 8.8Hz), 8.40 (1H, s), 9.42 (1H, s), 10.48 (1H, s).

[0597] The intermediates were obtained in the following manner.

Production Example 203-1

tert-Butyl 4-[2-[[4-(4-amino-3-chlorophenoxy)-2-pyridyl]amino]-2-oxoethyl]-1-piperidinecarboxylate

[0598] 2-Amino-4-(4-amino-3-chlorophenoxy)pyridine (1.0 g), Bop reagent (1.9 g), triethylamine (1.2 ml), 2-[1-(tert-butoxycarbonyl)-4-piperidyl]acetic acid (1.0 g) and dimethylformamide (10 ml) were stirred at 60°C for 2 hours and then at room temperature for 18 hours. Water was added to the reaction solution, and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1) to obtain 570 mg of a light brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 0.95-1.07 (2H, m), 1.36 (9H, s), 1.53-1.62 (2H, m), 1.30-1.43 (1H, m), 2.25 (2H, d, J= 7.2Hz), 2.55-2.75 (2H, m), 3.80-3.92 (2H, m), 5.37 (2H, s), 6.58 (1H, dd, J= 5.6Hz, 2.4Hz), 6.80-6.90 (2H, m), 7.07 (1H, d, J= 2.4Hz), 7.61 (1H, d, J= 2.4Hz), 8.11 (1H, d, J= 5.6Hz), 10.43 (1H, s).

Production Example 203-2

tert-Butyl 4-{2-[(4-{4-[(anilinocarbonyl)amino]-3-chlorophenoxy}-2-pyridyl)amino]-2-oxoethyl}-1-piperidine carboxylate

[0599] Phenyl chloroformate (210 mg) was added dropwise to a solution of 570 mg of tert-butyl 4-{2-[(4-{4-amino-3-chlorophenoxy}-2-pyridyl)amino]-2-oxoethyl}-1-piperidinecarboxylate, 110 mg of pyridine and 5 ml of dimethylformamide while stirring at room temperature, and the mixture was further stirred for 30 minutes. Water was added and extraction was performed with ethyl acetate. The organic layer was washed twice with water and once with brine, and then silica gel was added and the solvent was distilled off under reduced pressure. This was then charged into a dry column packed with silica gel and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate), to obtain 440 mg of tert-butyl 4-{2-[(4-{3-chloro-4-[(phenoxycarbonyl)amino]phenoxy}-2-pyridyl)amino]-2-oxoethyl}-1-piperidinecarboxylate as a light yellow oil. After adding 71 mg of aniline and 5 ml of dimethylformamide to the oil, it was stirred at 130°C for 15 minutes. The reaction solution was returned to room temperature, NH type silica gel was added, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 1:1). The solvent was distilled off under reduced pressure to obtain 180 mg of the target substance.

¹H-NMR(DMSO-d₆) δ(ppm): 0.94-1.06 (2H, m), 1.36 (9H, s), 1.53-1.61 (2H, m), 1.80-1.92 (1H, m), 2.27 (2H, d, J= 6.8Hz), 2.55-2.75 (2H, m), 3.80-3.90 (2H, m), 6.67 (1H, dd, J= 5.6Hz, 2.4Hz), 6.98 (1H, dd, J= 7.2Hz, 7.2Hz), 7.15 (1H, dd, J= 8.8Hz, 2.4Hz), 7.28 (2H, dd, J= 7.2Hz, 7.2Hz), 7.39 (1H, d, J= 2.4Hz), 7.45 (2H, d, J= 7.2Hz), 7.67 (1H, s), 8.17 (1H, d, J= 5.6Hz), 8.21 (1H, d, J= 8.8Hz), 8.36 (1H, s), 9.38 (1H, s), 10.50 (1H, s).

Example 204

N1-Phenyl-5-[(2-[(2-(1-methyl-4-piperidyl)acetyl)amino]-4-pyridyl)oxy]-1H-1-indolecarboxamide

[0600] The target substance was obtained using tert-butyl 4-{2-[(4-{[1-(anilinocarbonyl)-1H-5-indolyl]oxy}-2-pyridyl)amino]-2-oxoethyl}-1-piperidinecarboxylate, in the same manner as Example 199.

¹H-NMR(DMSO-d₆) δ(ppm): 1.08-1.20 (2H, m), 1.48-1.66 (3H, m), 1.71-1.80 (2H, m), 2.07 (3H, s), 2.22 (2H, d, J= 7.2Hz), 2.62-2.69 (2H, m), 6.65 (1H, dd, J= 5.6Hz, 2.4Hz), 6.77 (1H, d, J= 3.6Hz), 7.07-7.16 (2H, m), 7.38 (2H, dd, J= 7.2Hz, 7.2Hz), 7.43 (1H, d, J= 2.4Hz), 7.60-7.68 (3H, m), 8.10-8.17 (2H, m), 8.27 (1H, d, J= 8.8Hz), 10.09 (1H, s), 10.43 (1H, s).

[0601] The intermediates were obtained in the following manner.

Production Example 204-1

tert-Butyl 4-{2-[(4-{[1-(anilinocarbonyl)-1H-5-indolyl]oxy}-2-pyridyl)amino]-2-oxoethyl}-1-piperidinecarboxylate

[0602] N1-Phenyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide (500 mg), 2-[1-(tert-butoxycarbonyl)-4-piperidyl]acetic acid (350 mg), benzotriazol-1-yltris(dimethylamino)phosphonium hexafluorophosphate (640 mg), triethylamine (0.4 ml) and dimethylformamide (5 ml) were stirred at 60°C for 1 hour and then at room temperature for 19 hours. Water was added to the reaction solution and extraction was performed with ethyl acetate. The organic layer was washed twice with water and once with brine, and then silica gel was added and the solvent was distilled off under reduced pressure. The silica gel was then charged into a dry column packed with silica gel and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate), to obtain 220 mg of a colorless oil.

¹H-NMR(DMSO-d₆) δ(ppm): 0.92-1.08 (2H, m), 1.36 (9H, s), 1.50-1.62 (2H, m), 1.77-1.90 (1H, m), 2.24 (2H, d, J= 6.8Hz), 2.55-2.77 (2H, m), 3.78-3.93 (2H, m), 6.66 (1H, dd, J= 5.6Hz, 2.4Hz), 6.77 (1H, d, J= 3.6Hz), 7.08-7.16 (2H, m), 7.35-7.46 (3H, m), 7.60-7.68 (3H, m), 8.10-8.18 (2H, m), 8.27 (1H, d, J= 8.8Hz), 10.09 (1H, s), 10.44 (1H, s).

Example 205

N1-Phenyl-3-chloro-5-[(2-[(1-methyl-4-piperidyl)carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0603] After dissolving 260 mg of tert-butyl 4-{[(4-{[1-(anilinocarbonyl)-3-chloro-1H-5-indolyl]oxy}-2-pyridyl)amino]carbonyl}-1-piperidinecarboxylate in 5 ml of trifluoroacetic acid, the solution was stirred at room temperature for 5 minutes. Sodium bicarbonate water and 5N aqueous sodium hydroxide were added, and the mixture was extracted with ethyl acetate and dried over magnesium sulfate. The drying agent was filtered off and the solvent was distilled off

under reduced pressure to obtain 200 mg of N1-phenyl-3-chloro-5-[(2-[(4-piperidyl)carbonyl]amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide as a faint yellow solid. After adding 0.5 ml of formaldehyde (37% in water), 170 mg of sodium triacetoxyborohydride, 50 mg of acetic acid and 5 ml of tetrahydrofuran to the solid, the mixture was stirred at room temperature for 10 minutes. Sodium bicarbonate water and 5N aqueous sodium hydroxide were added, extraction was performed with ethyl acetate, and the extract was washed once with brine. The obtained ethyl acetate solution was passed through a glass filter coated with NH type silica gel. The silica gel was washed with ethyl acetate, and the solvent was distilled off under reduced pressure to obtain 210 mg of a faint yellow oil. The oil was solidified from a hexane and ethyl acetate mixed solvent to obtain 90 mg of a powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.44-1.56 (2H, m), 1.60-1.68 (2H, m), 1.73-1.82 (2H, m), 2.09 (3H, s), 2.30-2.45 (1H, m), 2.70-2.76 (2H, m), 6.69 (1H, dd, J= 5.6Hz, 2.4Hz), 7.14 (1H, dd, J= 7.2Hz, 7.2Hz), 7.22 (1H, dd, J= 8.8Hz, 2.4Hz), 7.34-7.42 (3H, m), 7.60-7.66 (3H, m), 8.17 (1H, d, J= 5.6Hz), 8.33 (1H, d, J= 8.8Hz), 8.38 (1H, s), 10.12 (1H, s), 10.45 (1H, s).

[0604] The intermediates were obtained in the following manner.

Production Example 205-1

5-[(2-Amino-4-pyridyl)oxy]-3-chloro-1H-1-indole

[0605] 5-[(2-Amino-4-pyridyl)oxy]-1H-1-indole (1.0 g), N-chlorosuccinimide (650 mg) and isopropanol (20 ml) were stirred at 80°C for 25 minutes. Water was added to the reaction solution and extraction was performed with ethyl acetate. The extract was passed through a glass filter coated with NH type silica gel. The silica gel was washed with ethyl acetate, and the solvent was distilled off under reduced pressure to obtain 1.3 g of a reddish-brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 5.73 (1H, d, J= 2.4Hz), 5.82 (2H, s), 6.13 (1H, dd, J= 5.6Hz, 2.4Hz), 6.93 (1H, dd, J= 8.8Hz, 2.4Hz), 7.15 (1H, d, J= 2.4Hz), 7.48 (1H, d, J= 8.8Hz), 7.58 (1H, d, J= 2.4Hz), 7.75 (1H, d, J= 5.6Hz), 11.48 (1H, s).

Production Example 205-2

N1-Phenyl-5-[(2-amino-4-pyridyl)oxy]-3-chloro-1H-1-indolecarboxamide

[0606] Phenyl isocyanate was added dropwise to a solution of 1.3 g of 5-[(2-amino-4-pyridyl)oxy]-3-chloro-1H-1-indole, 180 mg of sodium hydride and 15 ml of dimethylformamide, and the mixture was stirred for 20 minutes. Water was added to the reaction solution and extraction was performed with ethyl acetate. Silica gel was added to the extract and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate), to obtain 380 mg of a light red oil.

¹H-NMR(DMSO-d₆) δ(ppm) : 5.79 (1H, d, J= 2.4Hz), 5.89 (2H, s), 6.16 (1H, dd, J= 5.6Hz, 2.4Hz), 7.12-7.20 (2H, m), 7.28 (1H, d, J= 2.4Hz), 7.35-7.42 (2H, m), 7.64 (2H, d, J= 8.0Hz), 7.79 (1H, d, J= 5.6Hz), 8.31 (1H, d, J= 8.8Hz), 8.35 (1H, s), 10.09 (1H, s).

Production Example 205-3

tert-Butyl 4-[[[4-[(1-(anilino)carbonyl)-3-chloro-1H-5-indolyl]oxy]-2-pyridyl]amino]carbonyl]-1-piperidinecarboxylate

[0607] The target substance was obtained using N1-phenyl-5-[(2-amino-4-pyridyl)oxy]-3-chloro-1H-1-indolecarboxamide, in the same manner as Production Example 204-1.

¹H-NMR(DMSO-d₆) δ(ppm): 1.30-1.43 (11H, m), 1.65-1.73 (2H, m), 2.55-2.75 (3H, m), 3.87-4.00 (2H, m), 6.70 (1H, dd, J= 5.6Hz, 2.4Hz), 7.14 (1H, dd, J= 7.2Hz, 7.2Hz), 7.22 (1H, dd, J= 8.8Hz, 2.4Hz), 7.32-7.42 (3H, m), 7.60-7.67 (3H, m), 8.17 (1H, d, J= 5.6Hz), 8.32 (1H, d, J= 8.8Hz), 8.38 (1H, s), 10.12 (1H, s), 10.53 (1H, s).

Example 206

N-(4-Fluorophenyl)-N'-(4-{[2-(2-oxotetrahydro-1H-1-pyrrolyl)-4-pyridyl]oxy}phenyl)urea

[0608] N-(4-Fluorophenyl)-N'-(4-{[2-(4-chlorobutylamino)-4-pyridyl]oxy}phenyl)urea (56 mg), potassium carbonate (46 mg) and dimethylformamide (2 ml) were stirred at 150°C for 15 minutes. Water and ethyl acetate were added for extraction, and the extract was passed through a glass filter coated with silica gel. The silica gel was washed with ethyl acetate, and the organic layer was distilled off under reduced pressure. Ethyl acetate and hexane were added

to the residue, and the precipitated solid was filtered out to obtain 21 mg of a faint brown powder.

¹H-NMR(DMSO-d₆) δ(ppm): 1.98 (2H, tt, J= 7.6Hz, 7.6Hz), 2.50 (2H, t, J= 7.6Hz), 3.95 (2H, t, J= 7.6Hz), 6.70 (1H, d, J= 5.6Hz), 7.05-7.15 (4H, m), 7.45 (2H, dd, J= 8.4Hz, 5.2Hz), 7.52 (2H, d, J= 9.2Hz), 7.84 (1H, s), 8.22 (1H, d, J= 5.6Hz), 8.77 (1H, s), 8.83 (1H, s).

[0609] The intermediates were obtained in the following manner.

Production Example 206-1

4-{[2-(4-Chlorobutrylamino)-4-pyridyl]oxy}aniline

[0610] 2-Amino-4-(4-nitrophenoxy)pyridine (300 mg), 4-chlorobutryl chloride (0.18 ml), triethylamine (0.77 ml), dimethylformamide (1 ml) and tetrahydrofuran (1 ml) were stirred at room temperature for 10 minutes, and then silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with silica gel, for column purification (hexane:ethyl acetate = 3:1, followed by 2:1 and 1:1). The solvent was distilled off under reduced pressure, and then 300 mg of iron powder, 600 mg of ammonium chloride, 2 ml of DMF, 1 ml of ethanol and 1 ml of water were added to 150 mg of the resulting residue and the mixture was stirred at 100°C for 20 minutes. After filtration with celite, water and ethyl acetate were added for extraction. The organic layer was washed 5 times with aqueous ammonium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off and the solvent was distilled off under reduced pressure to obtain 110 mg of the target substance as an oil.

¹H-NMR(DMSO-d₆) δ(ppm): 1.95 (2H, tt, J= 6.8Hz, 6.8Hz), 2.48 (2H, t, J= 6.8Hz), 3.62 (2H, t, J= 6.8Hz), 5.10 (2H, brs), 6.55 (1H, dd, J= 5.6Hz, 1.2Hz), 6.59 (2H, d, J= 8.4Hz), 6.79 (2H, d, J= 8.4Hz), 7.57 (1H, d, J= 1.2Hz), 8.09 (1H, d, J= 5.6Hz).

Production Example 206-2

N-(4-Fluorophenyl)-N'-(4-{[2-(4-chlorobutrylamino)-4-pyridyl]oxy}phenyl)urea

[0611] 4-{[2-(4-Chlorobutrylamino)-4-pyridyl]oxy}aniline (100 mg), p-fluorophenyl isocyanate (0.037 ml) and tetrahydrofuran (3 ml) were stirred at room temperature for 25 minutes. Water and ethyl acetate were added to the reaction solution for extraction, NH type silica gel was added to the extract, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 1:1, followed by ethyl acetate and ethyl acetate:methanol = 10:1). The solvent was distilled off under reduced pressure to obtain 56 mg of the target substance as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 1.95 (2H, tt, J= 7.2Hz, 7.2Hz), 2.46 (2H, t, J= 7.2Hz), 3.62 (2H, t, J= 7.2Hz), 6.63 (1H, d, J= 5.6Hz), 7.04-7.16 (4H, m), 7.40-7.48 (2H, m), 7.51 (2H, d, J= 8.8Hz), 7.62 (1H, s), 8.15 (1H, d, J= 5.6Hz), 8.71 (1H, s), 8.76 (1H, s), 10.52 (1H, brs).

Example 207

N-[4-(2-Cyclobutanecarbonylamino)pyridin-4-yl]oxyphenyl]-N'-(2-thiazolyl)urea

[0612] 4-(2-Cyclobutanecarbonylamino)pyridin-4-yl)oxyaniline (130 mg), phenyl N-(2-thiazolyl)carbamate (110 mg) and dimethylsulfoxide (3 ml) were stirred at 80°C for 30 minutes. Water and ethyl acetate were added to the reaction solution for extraction, and the ethyl acetate layer was washed 5 times with aqueous ammonium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off, the solvent was distilled off under reduced pressure, ethyl acetate was added to the residue and the precipitated solid was filtered out to obtain 130 mg of the target substance as a light brown solid.

¹H-NMR(DMSO-d₆) δ(ppm): 1.68 (1H, m), 1.80-1.93 (1H, m), 1.95-2.10 (2H, m), 2.05-2.18 (2H, m), 3.25-3.35 (1H, m), 6.64 (1H, d, J= 5.6Hz), 7.06-7.17 (3H, m), 7.36 (1H, d, J= 1.6Hz), 7.56 (2H, d, J= 8.0Hz), 7.66 (1H, s), 8.14 (1H, d, J= 5.6Hz), 9.15 (1H, brs), 10.29 (1H, s).

[0613] The intermediates were obtained in the following manner.

Production Example 207-1N1-Cyclobutanecarbonyl-N1-[4-(4-nitrophenoxy)-2-pyridyl]-1-cyclobutanecarboxamide

[0614] 2-Amino-4-(4-nitrophenoxy)pyridine (1.0 g), cyclobutyl chloride (1.1 g), triethylamine (1.9 ml) and tetrahydrofuran (20 ml) were stirred at room temperature for 40 minutes. After adding water and ethyl acetate for extraction, the extract solution was distilled off under reduced pressure and the residue was purified with a column (hexane:ethyl acetate = 1:1) packed with NH type silica gel. The purified product was further purified by silica gel chromatography (hexane:ethyl acetate = 4:1, followed by 3:1). The initially eluted substance was the target substance, of which 720

mg was obtained as a colorless oil.

¹H-NMR(DMSO-d₆) δ(ppm): 1.62-1.96 (8H, m), 2.10-2.23 (4H, m), 3.35-3.45 (2H, m), 7.20 (1H, d, J= 5.6Hz), 7.23 (1H, s), 7.40 (2H, d, J= 9.2Hz), 8.33 (2H, d, J= 9.2Hz), 8.49 (1H, d, J= 5.6Hz).

[0615] The second eluted substance was 2-cyclobutanecarbonylamino (4-nitrophenoxy)pyridine, of which 560 mg was obtained as white crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 1.66-1.80 (1H, m), 1.80-1.94 (1H, m), 1.98-2.20 (4H, m), 3.26-3.36 (1H, m), 6.83 (1H, d, J= 5.6Hz), 7.38 (2H, d, J= 9.2Hz), 7.81 (1H, s), 8.27 (1H, d, J= 5.6Hz), 8.31 (2H, d, J= 9.2Hz).

Production Example 207-24-(4-Aminophenoxy)-2-cyclobutanecarbonylaminopyridine

[0616] N1-Cyclobutanecarbonyl-N1-[4-(4-nitrophenoxy)-2-pyridyl]-1-cyclobutanecarboxamide (720 mg), iron powder (1.4 g), ammonium chloride (2.4 g), dimethylformamide (52 ml), ethanol (2 ml) and water (2 ml) were stirred at 100°C for 15 minutes. The mixture was filtered with celite, and then water and ethyl acetate were added for extraction. The organic layer was washed 5 times with aqueous ammonium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off, the solvent was distilled off under reduced pressure, ethyl acetate and hexane were added to the residue and the precipitated solid was filtered out to obtain 130 mg of a solid.

¹H-NMR(DMSO-d₆) δ(ppm): 1.68-1.80 (1H, m), 1.80-1.93 (1H, m), 1.96-2.19 (4H, m), 3.23-3.34 (1H, m), 5.10 (2H, brs), 6.55 (1H, d, J= 5.6Hz), 6.59 (2H, d, J= 8.4Hz), 6.79 (2H, d, J= 8.4Hz), 7.61 (1H, s), 8.07 (1H, d, J= 5.6Hz), 10.22 (1H, brs).

Example 208N1-[4-[(Cyclopropylamino)carbonyl]amino]-3-chlorophenoxy]-2-pyridyl]-1-cyclopropanecarboxamide

[0617] 2-Amino-4-(4-amino-3-chlorophenoxy)pyridine (2.6 g), cyclopropanecarbonyl chloride (2.3 g), triethylamine (4.6 ml) and tetrahydrofuran (30 ml) were stirred at room temperature for 10 minutes. Water was added, extraction was performed with ethyl acetate, and the mixture was dried over magnesium sulfate. The drying agent was filtered off and the solvent was distilled off under reduced pressure to obtain 3.69 g of a brown oil. A 900 mg portion of the obtained oil was stirred together with 0.37 ml of triethylamine and 10 ml of tetrahydrofuran, while 0.3 ml of phenyl chloroformate was added dropwise at room temperature. After stirring for 15 minutes, 1 ml of cyclopropylamine was added and stirring was continued for 22 hours. Silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate) to obtain 38 mg of the target substance as a brown solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.40-0.52 (2H, m), 0.60-0.70 (2H, m), 0.70-0.85 (4H, m), 1.91-2.00 (1H, m), 2.50-2.70 (1H, m), 6.67 (1H, dd, J= 5.6Hz, 2.8Hz), 7.11 (1H, dd, J= 8.4Hz, 2.8Hz), 7.17 (1H, d, J= 2.8Hz), 7.33 (1H, d, J= 2.8Hz), 7.61 (1H, d, J= 2.8Hz), 7.94 (1H, s), 8.18 (1H, d, J= 5.6Hz), 8.20 (1H, d, J= 8.4Hz), 10.84 (1H, s).

[0618] The intermediates were obtained in the following manner.

Production Example 208-12-Amino-4-(4-amino-3-chlorophenoxy)pyridine

[0619] The publicly known compound 2-amino-4-chloropyridine (5.0 g), 4-amino-3-chlorophenol (11 g), sodium hydride (60% in oil) (3.1 g) and dimethylsulfoxide (80 ml) were stirred at 160°C for 9.5 hours. Water was added, extraction was performed with ethyl acetate, and the extract solution was washed 5 times with water. The extract solution was then passed through a glass filter coated with silica gel. The silica gel was washed with ethyl acetate, the ethyl acetate

layers were combined, and the solvent was distilled off under reduced pressure to obtain 5.1 g of a dark violet solid.
¹H-NMR(DMSO-d₆) δ(ppm): 5.32 (2H, s), 5.72 (1H, s), 5.86 (2H, bs), 6.07 (1H, d, J= 6.4Hz), 6.83 (2H, s), 7.01 (1H, s), 7.72 (1H, d, J= 6.4Hz).

Example 209

N1-[5-Bromo-4-(4-[(cyclopropylamino)carbonyl]amino)-3-chlorophenoxy]-2-pyridyl]-1-cyclopropanecarboxamide

[0620] A mixture of 67 mg of N1-[5-bromo-4-(4-amino-3-chlorophenoxy)-2-pyridyl]-N1-cyclopropylcarbonyl)-1-cyclopropanecarboxamide, 52 mg of pyridine and 5 ml of dimethylformamide was cooled to 0°C, and 54 mg of phenyl chloroformate was added. After 40 minutes, 80 mg of cyclopropanecarbonyl chloride was added and the mixture was stirred at 60°C for 20 minutes. The mixture was returned to room temperature, water was added, and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1). Methanol was added to the residue to obtain 11 mg of the target substance as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.40 (2H, brs), 0.65 (2H, m), 0.72 (4H, brs), 1.90 (1H, brs), 2.55 (1H, brs), 7.11 (1H, d, J= 9.2Hz), 7.19 (1H, s), 7.38 (1H, s), 7.56 (1H, s), 7.96 (1H, s), 8.22 (1H, d, J= 9.2Hz), 8.42 (1H, s), 10.94 (1H, s).

[0621] The intermediates were obtained in the following manner.

Production Example 209-1

2-Amino-3-bromo-4-(4-amino-3-chlorophenoxy)pyridine

[0622] 2-Amino-4-(4-amino-3-chlorophenoxy)pyridine (1.0 g), N-bromosuccinimide (0.78 g) and isopropanol (10 ml) were stirred for 15 minutes under reflux. The mixture was returned to room temperature, water was added, and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 2:1, followed by 1:1, ethyl acetate) to obtain 400 mg of the target substance as a brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 5.39 (2H, brs), 5.68 (1H, s), 6.06 (2H, brs), 6.85 (1H, s), 6.86 (1H, d, J= 2.4Hz), 7.09 (1H, d, J= 2.4Hz), 7.90 (1H, s).

Production Example 209-2

N1-[5-Bromo-4-(4-amino-3-chlorophenoxy)-2-pyridyl]-N1-cyclopropylcarbonyl)-1-cyclopropanecarboxamide

[0623] Cyclopropanecarbonyl chloride (260 mg) was added to a solution of 400 mg of 2-amino-3-bromo-4-(4-amino-3-chlorophenoxy)pyridine, 0.53 ml of triethylamine and 5 ml of tetrahydrofuran while stirring at room temperature. After 40 minutes, silica gel was added to the reaction solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 2:1, followed by 1:1, ethyl acetate) to obtain 67 mg of the target substance.

¹H-NMR(DMSO-d₆) δ(ppm): 0.66-1.00 (8H, m), 1.85-1.96 (2H, m), 5.45 (2H, brs), 6.77 (1H, s), 6.84 (1H, d, J= 8.8Hz), 6.92 (1H, dd, J= 8.8Hz, 2.8Hz), 7.17 (1H, d, J= 2.8Hz), 8.66 (1H, s).

Example 210

N1-[4-(3,5-Dichloro-4-[(cyclopropylamino)carbonyl]amino)phenoxy]-2-pyridyl]-1-cyclopropanecarboxamide

[0624] Phenylchloroformate (110 mg) was added to a solution of 96 mg of N1-[4-(4-amino-3,5-dichlorophenoxy)-2-pyridyl]-N1-cyclopropylcarbonyl)-1-cyclopropanecarboxamide, 0.076 ml of pyridine and 5 ml of dimethylformamide while stirring. After continuing stirring for 30 minutes, 0.5 ml of cyclopropylamine was added and the mixture was heated at 70°C for 10 minutes. The mixture was returned to room temperature, water was added, and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (ethyl acetate). Methanol was added to the residue for solidification to obtain 4.8 mg of the target substance as a light brown solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.42 (2H, s), 0.57-0.66 (2H, m), 0.70-0.83 (4H, m), 1.92-2.01 (1H, m), 2.43-2.53 (1H, m),

6.62 (1H, s), 6.71 (1H, d, J= 5.6Hz), 7.39 (2H, s), 7.69 (1H, s), 7.89 (1H, s), 8.22 (1H, d, J= 5.6Hz), 10.89 (1H, s).

[0625] The intermediates were obtained in the following manner.

Production Example 210-1

2-Amino-4-(4-amino-3,5-dichlorophenoxy)pyridine

[0626] 2-Amino-4-(4-amino-3-chlorophenoxy)pyridine (700 mg), N-chlorosuccinimide (0.44 g) and isopropanol (10 ml) were stirred at 80°C for 1 hour. The mixture was returned to room temperature, water was added, and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (ethyl acetate), to obtain 120 mg of a brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 5.47 (2H, brs), 5.73 (1H, d, J= 2.4Hz), 5.90 (2H, brs), 6.09 (1H, dd, J= 5.6Hz, 2.4Hz), 7.13 (2H, s), 7.75 (1H, d, J= 5.6Hz).

Production Example 210-2

N1-[4-(4-Amino-3,5-dichlorophenoxy)-2-pyridyl]-N1-cyclopropylcarbonyl)-1-cyclopropanecarboxamide

[0627] Cyclopropanecarbonyl chloride (93 mg) was added to a solution of 120 mg of 2-amino-4-(4-amino-3,5-dichlorophenoxy)pyridine, 0.19 ml of triethylamine and 5 ml of tetrahydrofuran while stirring at room temperature. After 20 minutes, silica gel was added to the reaction solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (ethyl acetate) to obtain 120 mg of a brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 0.82-0.98 (8H, m), 1.86-1.96 (2H, m), 5.55 (2H, brs), 6.95 (1H, dd, J= 5.6Hz, 2.4Hz), 7.03 (1H, d, J= 2.4Hz), 7.24 (2H, s), 8.38 (1H, d, J= 5.6Hz).

Example 211

N1-Cyclopropyl-5-([2-[di(cyclopropylcarbonyl)amino]-4-pyridyl]oxy)-1H-1-indolecarboxamide

[0628] Cyclopropanecarbonyl chloride (51 mg) was added to a solution of 100 mg of N1-cyclopropyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide and 49 mg of triethylamine in tetrahydrofuran at 0°C. After 20 minutes of stirring, silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure, and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate), after which water was added to the residue to obtain 19 mg of the target substance as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.57-0.63 (2H, m), 0.68-0.75 (2H, m), 0.83-0.96 (6H, m), 1.86-1.94 (2H, m), 2.73-2.80 (1H, m), 6.66 (1H, d, J= 3.6Hz), 6.91 (1H, d, J= 5.6Hz), 6.98 (1H, d, J= 2.4Hz), 7.08 (1H, dd, J= 9.2Hz, 2.4Hz), 7.41 (1H, d, J= 2.4Hz), 7.87 (1H, d, J= 3.6Hz), 8.26-8.32 (2H, m), 8.38 (1H, d, J= 5.6Hz).

[0629] The intermediates were obtained in the following manner.

Production Example 211-1

5-[(2-Amino-4-pyridyl)oxy]-1H-indole

[0630] 2-Amino-4-chloropyridine (2.0 g), 5-hydroxyindole (4.1 g), sodium hydride (60% in oil, 1.25 g) and dimethylsulfoxide (20 ml) were stirred at 160°C for 9.5 hours. Water was added, extraction was performed with ethyl acetate, and purification was performed by silica gel column chromatography (hexane:ethyl acetate = 1:1, ethyl acetate). The solvent was distilled off under reduced pressure, a small amount of ethyl acetate was added to the residue and the solid was filtered out to obtain 490 mg of a light brown solid.

¹H-NMR(DMSO-d₆) δ(ppm): 5.72 (1H, d, J= 2.0Hz), 5.78 (2H, brs), 6.10 (1H, d, J= 5.6Hz), 6.41 (1H, d, J= 2.0Hz), 6.82 (1H, d, J= 8.4Hz), 7.25 (1H, s), 7.36-7.74 (2H, m), 7.73 (1H, d, J= 5.6Hz), 11.15 (1H, s).

Production Example 211-2

N1-Cyclopropyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide

[0631] After adding 28 mg of sodium hydride (60% in oil) to a solution of 150 mg of 5-[(2-amino-4-pyridyl)oxy]-1H-indole in dimethylformamide at room temperature and stirring for 5 minutes, the mixture was cooled to 0°C, 124 mg of phenyl N-cyclopropylcarbamate was added and the mixture was further stirred for 30 minutes. Water was added, extraction was performed with ethyl acetate, the organic layer was washed 3 times with water and once with aqueous ammonium chloride solution, and then silica gel was added and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate), to obtain 2.4 g of a colorless powder.

¹H-NMR(DMSO-d₆) δ(ppm) : 0.57-0.64 (2H, m), 0.68-0.76 (2H, m), 2.72-2.79 (1H, m), 5.74 (1H, d, J= 2.4Hz), 5.83 (2H, brs), 6.12 (1H, dd, J= 5.6Hz, 2.4Hz), 6.64 (1H, d, J= 3.6Hz), 7.01 (1H, dd, J= 9.2Hz, 2.4Hz), 7.32 (1H, d, J= 2.4Hz), 7.75 (1H, d, J= 5.6Hz), 7.84 (1H, d, J= 3.6Hz), 8.24 (1H, s), 8.25 (1H, d, J= 9.2Hz).

Example 212N1-Cyclopropyl-5-[(2-[(cyclopropylcarbonyl)amino]-4-pyridyl)oxy]-1H-1-indolecarboxamide

[0632] N1-Cyclopropyl-5-[(2-[(di(cyclopropylcarbonyl)amino)-4-pyridyl]oxy)-1H-1-indolecarboxamide (190 mg), ammonium chloride (660 mg), dimethylformamide (5 ml), water (5 ml) and ethanol (5 ml) were stirred at 100°C for 1 hour. Water and ethyl acetate were added for extraction, and the extract was washed 6 times with water. After drying over magnesium sulfate, the drying agent was filtered off and the solvent was distilled off under reduced pressure. Ethyl acetate was added to the residue and the precipitated solid was filtered out to obtain 66 mg of a white powder.

¹H-NMR(DMSO-d₆) δ(ppm): 0.57-0.64 (2H, m), 0.66-0.78 (6H, m), 1.88-1.98 (1H, m), 2.72-2.80 (1H, m), 6.63-6.69 (2H, m), 7.04 (1H, d, J= 8.8Hz), 7.36 (1H, s), 7.56 (1H, s), 7.87 (1H, d, J= 3.6Hz), 8.14 (1H, d, J= 5.6Hz), 8.26 (1H, d, J= 8.8Hz), 8.28 (1H, s), 10.55 (1H, s).

Example 213N1-Cyclopropyl-5-[(2-(2,5-dioxotetrahydro-1H-1-pyrrolyl)-4-pyridyl)oxy]-1H-1-indolecarboxamide (Example 213-A)N1-Cyclopropyl-5-[(2-(diacetyl-amino)-4-pyridyl)oxy]-1H-1-indolecarboxamide (Example 213-B)N1-Cyclopropyl-5-[(2-(acetyl-amino)-4-pyridyl)oxy]-1H-1-indolecarboxamide (Example 213-C)

[0633] N1-Cyclopropyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide (830 mg), succinic anhydride (270 mg) and toluene (30 ml) were refluxed together for 30 minutes. After adding 50 ml of acetic anhydride and 82 mg of sodium acetate to the reaction solution, the mixture was stirred at 80°C for 15 minutes. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography (ethyl acetate). The second eluted substance was N1-cyclopropyl-5-[(2-(2,5-dioxotetrahydro-1H-1-pyrrolyl)-4-pyridyl)oxy]-1H-1-indolecarboxamide, of which 440 mg was obtained as a colorless powder.

(Example 213-A)

[0634] ¹H-NMR(DMSO-d₆) δ(ppm): 0.57-0.63 (2H, m), 0.70-0.75 (2H, m), 2.70-2.80 (1H, m), 2.71 (4H, s), 6.66 (1H, d, J= 3.6Hz), 6.76 (1H, d, J= 2.4Hz), 7.03 (1H, dd, J= 5.6Hz, 2.4Hz), 7.10 (1H, dd, J= 9.2Hz, 2.4Hz), 7.43 (1H, d, J= 2.4Hz), 7.87 (1H, d, J= 3.6Hz), 8.29 (1H, s), 8.30 (1H, d, J= 9.2Hz), 8.42 (1H, d, J= 5.6Hz).

[0635] The first eluted substance was a mixture of N1-cyclopropyl-5-[(2-(diacetyl-amino)-4-pyridyl)oxy]-1H-1-indolecarboxamide and N1-cyclopropyl-5-[(2-(acetyl-amino)-4-pyridyl)oxy]-1H-1-indolecarboxamide. The mixture was purified by silica gel chromatography (chloroform:methanol = 50:1). The first eluted substance was N1-cyclopropyl-5-[(2-(diacetyl-amino)-4-pyridyl)oxy]-1H-1-indolecarboxamide, of which 45 mg was obtained as a white powder.

(Example 213-B)

[0636] ¹H-NMR(DMSO-d₆) δ(ppm): 0.57-0.63 (2H, m), 0.70-0.75 (2H, m), 2.13 (6H, s), 2.74-2.80 (1H, m), 6.66 (1H, d, J= 3.6Hz), 6.96 (1H, dd, J= 5.6Hz, 2.4Hz), 6.99 (1H, d, J= 2.4Hz), 7.09 (1H, dd, J= 9.2Hz, 2.4Hz), 7.43 (1H, d, J= 2.4Hz), 7.87 (1H, d, J= 3.6Hz), 8.28 (1H, s), 8.30 (1H, d, J= 9.2Hz), 8.38 (1H, d, J= 5.6Hz).

[0637] The second eluted substance was N1-cyclopropyl-5-[[2-(acetylamino)-4-pyridyl]oxy]-1H-1-indolecarboxamide, which was solidified from ethyl acetate-hexane to obtain 28 mg.

(Example 213-C)

[0638] $^1\text{H-NMR}(\text{DMSO-}d_6)$ $\delta(\text{ppm})$: 0.57-0.63 (2H, m), 0.70-0.75 (2H, m), 2.00 (3H, s), 2.72-2.80 (1H, m), 6.62 (1H, d, $J = 5.6\text{Hz}$, 2.4Hz), 6.65 (1H, d, $J = 3.6\text{Hz}$), 7.04 (1H, dd, $J = 9.2\text{Hz}$, 2.4Hz), 7.36 (1H, d, $J = 2.4\text{Hz}$), 7.60 (1H, s), 7.87 (1H, d, $J = 3.6\text{Hz}$), 8.13 (1H, d, $J = 9.2\text{Hz}$), 8.25-8.30 (2H, m), 10.47 (1H, s).

Example 214

N1-Cyclopropyl-5-[[2-((2-chloroethylamino)carbonyl)amino]-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0639] N1-cyclopropyl-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide (400 mg), 2-chloroethyl isocyanate (150 mg) and tetrahydrofuran (5 ml) were stirred at 80°C for 1.5 hours. The mixture was returned to room temperature, silica gel was added, and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate) to obtain 280 mg of a colorless powder.

$^1\text{H-NMR}(\text{DMSO-}d_6)$ $\delta(\text{ppm})$: 0.57-0.63 (2H, m), 0.70-0.75 (2H, m), 2.73-2.80 (1H, m), 3.42 (2H, q, $J = 6.0\text{Hz}$), 3.61 (2H, t, $J = 6.0\text{Hz}$), 6.52 (1H, dd, $J = 5.6\text{Hz}$, 2.4Hz), 6.65 (1H, d, $J = 3.6\text{Hz}$), 6.85 (1H, d, $J = 2.4\text{Hz}$), 7.04 (1H, dd, $J = 8.8\text{Hz}$, 2.4Hz), 7.35 (1H, d, $J = 2.4\text{Hz}$), 7.86 (1H, d, $J = 3.6\text{Hz}$), 8.04 (1H, d, $J = 5.6\text{Hz}$), 8.27 (1H, s), 8.28 (1H, d, $J = 8.8\text{Hz}$), 8.34 (1H, brs), 9.19 (1H, s).

Example 215

N1-(2-Fluoroethyl)-5-[[2-((cyclopropylcarbonyl)amino)-4-pyridyl]oxy]-1H-1-indolecarboxamide

[0640] Cyclopropanecarbonyl chloride (330 mg) was added to a solution of 400 mg of N1-(2-fluoroethyl)-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide and 0.53 ml of triethylamine in tetrahydrofuran at room temperature. After stirring for 15 minutes, water and ethyl acetate were added for extraction. The extract was dried over magnesium sulfate and then passed through a glass filter coated with silica gel. The solvent was distilled off under reduced pressure to obtain 490 mg of an oil. After adding 1.5 g of ammonium chloride, 10 ml of dimethylformamide, 10 ml of water and 10 ml of ethanol to the residue, the mixture was stirred at 110°C for 1.5 hours. After returning it to room temperature, water was added and extraction was performed with ethyl acetate. Silica gel was added to the extract solution, and the solvent was distilled off under reduced pressure for adsorption onto the silica gel. The silica gel was charged into a dry column packed with silica gel and purification was performed by column chromatography (ethyl acetate). Ethyl acetate and hexane were added to the residue for solidification to obtain 180 mg of the target substance as a white solid.

$^1\text{H-NMR}(\text{DMSO-}d_6)$ $\delta(\text{ppm})$: 0.64-0.80 (4H, m), 1.88-1.97 (1H, m), 3.50-3.65 (2H, m), 4.52 (1H, t, $J = 4.8\text{Hz}$), 4.64 (1H, t, $J = 4.8\text{Hz}$), 6.65 (1H, dd, $J = 5.6\text{Hz}$, 2.4Hz), 6.69 (1H, d, $J = 3.6\text{Hz}$), 7.05 (1H, dd, $J = 8.8\text{Hz}$, 2.4Hz), 7.38 (1H, d, $J = 2.4\text{Hz}$), 7.57 (1H, d, $J = 2.4\text{Hz}$), 7.95 (1H, d, $J = 3.6\text{Hz}$), 8.14 (1H, d, $J = 5.6\text{Hz}$), 8.27 (1H, d, $J = 8.8\text{Hz}$), 8.47 (1H, t, $J = 5.6\text{Hz}$), 10.77 (1H, s).

[0641] The intermediates were obtained in the following manner.

Production Example 215-1

N1-(2-Fluoroethyl)-5-[(2-amino-4-pyridyl)oxy]-1H-1-indolecarboxamide

[0642] Sodium hydride (60% in oil) (360 mg) was added to a solution of 2.0 g of 5-[(2-amino-4-pyridyl)oxy]-1H-indole in 30 ml of dimethylformamide at room temperature. After stirring for 5 minutes, the mixture was placed in an ice bath and 1.8 g of phenyl N-(2-fluoroethyl)carbamate was added while cooling. The mixture was returned to room temperature and stirred for 30 minutes, after which water was added and extraction was performed with ethyl acetate. The extract was passed through a glass filter coated with silica gel. The ethyl acetate layer was washed once with sodium bicarbonate water and dried over magnesium sulfate. The drying agent was filtered off to obtain 1.93 g of a faint brown powder.

$^1\text{H-NMR}(\text{DMSO-}d_6)$ $\delta(\text{ppm})$: 3.52-3.64 (2H, m), 4.52 (1H, t, $J = 4.8\text{Hz}$), 4.64 (1H, t, $J = 4.8\text{Hz}$), 5.75 (1H, d, $J = 2.4\text{Hz}$), 5.82 (2H, brs), 6.12 (1H, dd, $J = 5.6\text{Hz}$, 2.4Hz), 6.68 (1H, d, $J = 3.6\text{Hz}$), 7.02 (1H, dd, $J = 8.8\text{Hz}$, 2.4Hz), 7.33 (1H, d, $J = 2.4\text{Hz}$), 7.76 (1H, d, $J = 5.6\text{Hz}$), 7.92 (1H, d, $J = 3.6\text{Hz}$), 8.26 (1H, d, $J = 8.8\text{Hz}$), 8.44 (1H, t, $J = 5.2\text{Hz}$).

Example 216

N1-Cyclopropyl-5-(4-([2-(2-oxotetrahydro-1H-1-pyrrolyl)-4-pyridyl]oxy)-1H-1-indolecarboxamide

[0643] Sodium hydride (60% in oil) (19 mg) was added to a solution of 130 mg of 5-(4-([2-(2-oxotetrahydro-1H-1-pyrrolyl)-4-pyridyl]oxy)-1H-1-indole in dimethylformamide at room temperature, and then 82 mg of phenyl N-cyclopropylcarbamate was added. After stirring for 10 minutes, water was added and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off for adsorption onto the silica gel. The silica gel was charged into a dry column packed with silica gel and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate). Ethyl acetate and hexane were added to the residue for solidification to obtain 25 mg of the target substance as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.58-0.63 (2H, m), 0.68-0.75 (2H, m), 1.97 (2H, tt, J= 6.4Hz, 6.4Hz), 2.47 (2H, t, J= 6.4Hz), 2.73-2.80 (1H, m), 3.94 (2H, t, J= 6.4Hz), 6.65 (1H, d, J= 3.6Hz), 6.71 (1H, dd, J= 5.6Hz, 2.4Hz), 7.04 (1H, dd, J= 8.8Hz, 2.4Hz), 7.36 (1H, d, J= 2.4Hz), 7.81 (1H, d, J= 2.4Hz), 7.86 (1H, d, J= 3.6Hz), 8.22 (1H, d, J= 5.6Hz), 8.27 (1H, brs), 8.28 (1H, d, J= 8.8Hz).

[0644] The intermediates were obtained in the following manner.

Production Example 216-15-(4-([2-(2-Oxotetrahydro-1H-1-pyrrolyl)-4-pyridyl]oxy)-1H-1-indole

[0645] 4-Bromobutyryl chloride (0.8 ml) was added to a solution of 1.0 g of N1-cyclopropyl-5-[(2-amino-4-pyridyl]oxy)-1H-1-indolecarboxamide, 1.1 ml of triethylamine and 20 ml of tetrahydrofuran at room temperature. After stirring for 20 minutes, water was added and extraction was performed with ethyl acetate. The extract was passed through a glass filter coated with silica gel. After adding 950 mg of 4-hydroxypiperidine, 1.7 g of potassium carbonate and 10 ml of dimethylformamide to the obtained oil, the mixture was stirred at 70°C for 20 minutes. Water was added, extraction was performed with ethyl acetate, silica gel was added to the extract solution, and the solvent was distilled off under reduced pressure for adsorption onto the silica gel. The silica gel was charged into a dry column packed with silica gel and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate). The first eluted substance was the target substance, of which 130 mg was obtained as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 1.97 (2H, tt, J= 6.4Hz, 6.4Hz), 2.46 (2H, t, J= 6.4Hz), 3.93 (2H, t, J= 6.4Hz), 6.42 (1H, s), 6.66 (1H, d, J= 5.6Hz), 6.85 (1H, d, J= 8.8Hz), 7.29 (1H, s), 7.42 (1H, s), 7.44 (1H, d, J= 8.8Hz), 7.80 (1H, s), 8.18 (1H, d, J= 5.6Hz), 11.05 (1H, s).

[0646] The second eluted substance was 5-[(2-([4-(4-hydroxypiperidino)butanoyl]amino)-4-pyridyl]oxy]indole, of which 520 mg was obtained as a light brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 1.25-1.35 (2H, m), 1.55-1.67 (4H, m), 1.85-1.95 (2H, m), 2.17 (2H, t, J= 6.8Hz), 2.28 (2H, t, J= 6.8Hz), 2.57-2.67 (2H, m), 3.15 (1, d, J= 3.6Hz), 3.30-3.42 (1H, m), 4.48 (1H, d, J= 3.6Hz), 6.42 (1H, s), 6.57 (1H, dd, J= 5.6Hz, 2.4Hz), 6.85 (1H, dd, J= 8.8Hz, 2.4Hz), 7.29 (1H, d, J= 2.4Hz), 7.40-7.43 (2H, m), 7.60 (1H, d, J= 2.4Hz), 8.09 (1H, d, J= 5.6Hz), 10.37 (1H, s), 11.23 (1H, s).

Example 217

1-(4-[6-Cyano-7-(3-diethylaminopropoxy)-4-quinolyloxy]2-fluorophenyl)-3-(4-fluorophenyl)urea

[0647] After dissolving 480 mg of 6-cyano-4-[4-[4-fluoroanilinocarbonyl]amino-3-fluorophenoxy]quinolin-7-ol sodium salt in 5 ml of dimethylformamide, 350 mg of potassium carbonate and 204 mg of 3-chloropropyl-diethylamine were added and the mixture was heated and stirred at 65°C for 7 hours. After standing to cool, water was added and extraction was performed with ethyl acetate and tetrahydrofuran, after which the solvent was distilled off under reduced pressure and the residue was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain 135 mg of the title compound.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.96(6H,t,J=7.0Hz) 1.93(2H,quint, J=7.0Hz) 2.45-2.53(4H,m),2.61 (2H, t, J=7.0Hz), 4.32(2H, t, J=7.0Hz), 6.62(1H, d, J=5.3Hz), 7.10-7.19(3H, m), 7.41(1H, dd, J=12.3Hz,J'=2.8 Hz), 7.46-7.52 (2H, m), 7.60 (1H, s) , 8.25(1H, t, J=9.0Hz),8.68(1H, d, J=2.0Hz), 8.76-8.78(2H, m),9.16 (1H, s)

[0648] The intermediates were synthesized in the following manner.

Production Example 217-11-(4-[7-Benzyloxy-6-cyano-4-quinolyloxy]-2-fluorophenyl)-3-(4-fluorophenyl)urea

[0649] After adding 210 mg of toluene and 20 ml of acetonitrile to 6.95 g of the 7-benzyloxy-6-cyano-4-(3-fluoro-4-aminophenoxy)quinoline obtained in Production Example 8, the mixture was heated to reflux. Next, 2.67 ml of 4-fluorophenyl isocyanate was added and the mixture was further heated to reflux for 1 hour. After cooling, the precipitated solid was filtered out and dried under reduced pressure to obtain 7.45 g of the title compound.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 5.49 (2H, s), 6.61 (1H, d, J=5.4Hz), 7.05-7.57(11H, m), 7.54(1H, s), 8.24 (1H, t, 9.5Hz), 8.63 (1H, s), 8.72(1H, d, J=5.4Hz), 8.77 (1H, s), 9.10 (1H, s)

Production Example 217-26-Cyano-4-(4-[4-fluoroanilincarbonyl]amino-3-fluorophenoxy)quinolin-7-ol sodium salt

[0650] A mixture of 1.7 g of 1-(4-[7-benzyloxy-6-cyanoquinolin-4-yloxy]-2-fluorophenyl)-3-(4-fluorophenyl)urea, 17 ml of trifluoroacetic acid and 1.7 ml of thioanisole was placed in an oil bath and heated and stirred for 20 hours at 70°C. After completion of the reaction, the reaction solution was concentrated, a saturated aqueous sodium bicarbonate solution and methanol were added, the mixture was stirred for 30 minutes, and the precipitated solid was filtered out. The obtained solid was dried under reduced pressure to obtain 1.15 g of the title compound.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 6.62 (1H, d, J=5.3Hz), 7.18-7.68(7H, m), 8.24 (1H, t, J=8.5 Hz), 8.70-8.86 (3H, m), 9.20 (1H, s)

Example 2181-(4-[6-Cyano-7-(3-morpholine-4-propoxy)-4-quinolyloxy]-2-fluorophenyl)-3-(4-fluorophenyl)urea

[0651] The title compound (205 mg) was obtained using 450 mg of 6-cyano-4-(4-[4-fluoroanilincarbonyl]amino-3-fluorophenoxy)quinolin-7-ol sodium salt, 5 ml of dimethylformamide, 328 mg of potassium carbonate and 194 mg of 4-(3-chloropropyl)morpholine, in the same manner as Example 217.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.01(2H, quint, J=6.9Hz), 2.36-2.44(4H, m), 2.48-2.54(2H, covered by DMSO peak), 3.58 (4H, t, J=4.0Hz), 4.35(2H, t, J=6.9Hz), 6.64(1H, d, J=5.3Hz), 7.10-7.19(3H, m), 7.41(1H, dd, J=2.9, 12.3Hz), 7.44-7.52(2H, m), 7.63 (1H, s), 8.25(1H, t, J=8.9Hz), 8.64(1H, d, J=2.0Hz), 8.74-8.78(2H, m), 9.20(1H, s)

Example 2191-(4-[6-Cyano-7-(3-diethylaminopropoxy)-4-quinolyloxy]-2-fluorophenyl)-3-phenylurea

[0652] After dissolving 179 mg of 6-cyano-4-(4-[4-anilincarbonylamino]-3-phenoxy)quinolin-7-ol sodium salt in 2 ml of dimethylformamide, 135 mg of potassium carbonate and 79 mg of 3-chloropropyl-diethylamine were added and the mixture was heated and stirred overnight at 65-75°C. After standing to cool, water was added, extraction was performed with ethyl acetate and tetrahydrofuran and the extract was dried over sodium sulfate, after which the solvent was distilled off under reduced pressure and the residue was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain 60 mg of the title compound.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.94(6H, t, J=7.2Hz), 1.92(2H, quint, J=7.2Hz), 2.43-2.55(4H, covered by DMSO peak), 2.60 (2H, t, J=7.2Hz), 4.42(2H, t, J=7.2Hz), 6.62(1H, d, J=5.0Hz), 6.98(1H, t, J=7.2 Hz), 7.12-7.18(1H, m), 7.29 (2H, t, J=7.2Hz), 7.40(1H, dd, J=11.9Hz, J'=2.8 Hz), 7.46(2H, d, J=7.2 Hz), 7.59(1H, s), 8.26(1H, t, J=9.0Hz), 8.67(1H, s), 8.72-8.78(2H, m), 9.16 (1H, s)

[0653] The intermediates were synthesized in the following manner.

Production Example 219-11-(4-[7-Benzyloxy-6-cyano-4-quinolyloxy]-2-fluorophenyl)-3-phenylurea

[0654] After adding 1.90 g of the 7-benzyloxy-6-cyano-4-(3-fluoro-4-aminophenoxy)quinoline obtained in Production Example 8 to 60 ml of toluene and 30 ml of acetonitrile, the mixture was heated to reflux. Next, 0.76 ml of phenyl isocyanate was added and the mixture was further heated to reflux for 1 hour. After cooling, the precipitated solid was filtered out and dried under reduced pressure to obtain 1.65 g of the title compound.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 5.45 (2H, s), 6.62 (1H, d, J=5.4Hz), 6.95-7.57(12H, m), 7.71(1H, s), 8.27 (1H, t, 9.2Hz), 8.66 (1H, s), 8.74(1H, d, J=5.4Hz), 8.78 (1H, s), 9.09(1H, s)

5 Production Example 219-2

6-Cyano-4-(4-[4-anilinocarbonylamino]-3-fluorophenoxy)quinolin-7-ol sodium salt

[0655] A mixture of 1.64 g of 1-(4-[7-benzyloxy-6-cyano-4-quinolyloxy]-2-fluorophenyl)-3-phenylurea, 16 ml of trifluoroacetic acid and 1.6 ml of thioanisole was placed in an oil bath and heated to reflux at 65-72°C for 14 hours. After completion of the reaction, the reaction solution was concentrated, a saturated aqueous sodium bicarbonate solution and methanol were added, the mixture was stirred for 30 minutes, and the precipitated solid was filtered out. The obtained solid was dried under reduced pressure to obtain 1.35 g of the title compound.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 6.41 (1H, d, J=5.1Hz), 6.98(1H,t,J=7.1 Hz), 7.11(1H,d,J=7.1Hz), 7.20-7.40(4H, m), 7.45(2H, d, J=7.1Hz), 8.24 (1H,t,J=8.0 Hz), 8.55(1H, s), 8.57(1H, d, J=5.1Hz), 8.66(1H, s), 9.10(1H, s),

Example 220

1-[4-[6-Cyano-7-(3-morpholino-4-propoxy)-4-quinolyloxy]-2-fluorophenyl]-3-phenylurea

[0656] The title compound (301 mg) was obtained using 505 mg of 6-cyano-4-(4-[4-anilinocarbonylamino]-3-phenoxy)-quinolin-7-ol sodium salt, 5 ml of dimethylformamide, 380 mg of potassium carbonate and 195 mg of 4-(3-chloropropyl)morpholine, in the same manner as Example 217.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.99(2H,quint, J=6.8Hz), 2.33-2.52(4H,m), 2.48-2.54(2H,covered by DMSO peak), 3.58 (4H, t, J=4.2Hz), 4.32(2H, t, J=6.8Hz), 6.62(1H, d, J=5.3Hz), 6.98(1H,t,J=7.2 Hz), 7.12-7.48(6H, m), 7.60 (1H, s), 8.26(1H, t, J=8.5Hz), 8.64(1H, d, J=1.5Hz), 8.72-8.78 (2H, m), 9.06 (1H, s)

Example 221

N-[4-(6-Cyano-7-[3-(dimethylamino)propoxy]-4-quinolyloxy) phenyl]-N'-(4-fluorophenyl)urea

[0657] The title compound (20 mg) was obtained from 100 mg of 6-cyano-4-(4-[(4-fluoroanilino)carbonyl]aminophenoxy)quinolin-7-ol sodium salt, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.97 (2H, quint, J=7.1Hz) 2.18 (6H, s), 2.42 (2H, t, J=7.1Hz), 4.32(2H, t, J=7.1Hz), 6.54(1H, d, J=5.6Hz), 7.05-7.65(9H, m), 8.63(1H, d, J=5.6Hz), 8.76 (1H, s) 8.80 (1H, s). 8.88 (1H, s)

Example 222

N-(5-(6,7-Dimethoxyquinolin-4-yloxy)pyridin-2-yl)-N'-phenylurea

[0658] 5-(6,7-Dimethoxyquinolin-4-yloxy)pyridin-2-ylamine (29.7 mg, 0.100 mmol) and phenyl isocyanate (13.1 mg, 0.110 mmol) were stirred in dimethylformamide (1 ml) at room temperature for 18 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 20:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (30.4 mg, 0.073 mmol, 73%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.95 (3H, s), 3.96 (3H, s), 6.53 (1H, d, J = 5.4 Hz), 7.00-7.06 (1H, m), 7.28-7.35 (2H, m), 7.41 (1H, s), 7.50-7.56 (3H, m), 7.76-7.82 (2H, m), 8.30-8.33 (1H, m), 8.49 (1H, d, J = 5.4 Hz), 9.56 (1H, s), 10.04 (1H, s).

[0659] The intermediates were synthesized in the following manner.

Production Example 222-1

55

2-Chloro-6-iodopyridin-3-ol

[0660] After dissolving 2-chloro-3-hydroxypyridine (5.00 g, 38.6 mmol) and sodium iodide (5.79 g, 38.6 mmol) in

dimethylformamide (70 ml), Chloramine T (10.9 g, 38.6 mmol) was added while cooling on ice, and then the mixture was stirred at room temperature for 1 hour. Upon adding 2N aqueous hydrochloric acid (19.3 ml, 38.6 mmol) after the reaction, the reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 1:2), and the fraction containing the target substance was concentrated to obtain the title compound (9.00 g, 35.2 mmol, 91%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 5.61 (1H, br s), 7.02 (1H, d, J = 8.2 Hz), 7.56 (1H, d, J = 8.2 Hz).

Production Example 222-2

4-(2-Chloro-6-iodopyridin-3-yloxy)-6,7-dimethoxyquinoline

[0661] 4-Chloro-6,7-dimethoxyquinoline (2.23 g, 10.0 mmol), 2-chloro-6-iodopyridin-3-ol (2.55 g, 22.0 mmol) and diisopropylethylamine (1.29 g, 10.0 mmol) were heated and stirred in dimethylformamide (5 ml) at 130°C for 3 hours. The reaction solution was distributed between an ethyl acetate-tetrahydrofuran mixed solvent and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (2.16 g, 4.88 mmol, 49%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.05 (3H, s), 4.06 (3H, s), 6.39 (1H, d, J = 5.2 Hz), 7.20 (1H, d, J = 8.2 Hz), 7.45 (1H, s), 7.48 (1H, s), 7.75 (1H, d, J = 8.2 Hz), 8.55 (1H, d, J = 5.2 Hz).

Production Example 222-3

6-Chloro-5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-ylamine

[0662] Benzophenoneimine (1.67 g, 9.21 mmol) and tert-butoxysodium (885 mg, 9.21 mmol) were heated and stirred in toluene (40 ml) for 1 hour at 80°C under a nitrogen atmosphere, and then 4-(2-chloro-6-iodopyridin-3-yloxy)-6,7-dimethoxyquinoline (3.72 g, 8.40 mmol), tris(dibenzylideneacetone)dipalladium(0) (86.9 mg, 0.084 mmol) and rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (157 mg, 0.252 mmol) were added and the mixture was heated and stirred at 90°C for 6 hours. After completion of the reaction, the reaction mixture was filtered with celite, the filtrate was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), and the fraction containing the target substance was concentrated to obtain a yellow oil (1.98 g). The yellow oil (1.98 g) was dissolved in ethanol (20 ml), 1N aqueous hydrochloric acid (5 ml) was added and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was neutralized with 5N aqueous sodium hydroxide (1 ml) and distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate), and the fraction containing the target substance was concentrated to obtain the title compound (506 mg, 1.53 mmol, 18%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.06 (3H, s), 4.07 (3H, s), 4.71 (2H, s), 6.34 (1H, d, J = 5.2 Hz), 6.53 (1H, d, J = 8.8 Hz), 7.37 (1H, d, J = 8.8 Hz), 7.43 (1H, s), 7.59 (1H, s), 8.50 (1H, d, J = 5.2 Hz).

Production Example 222-4

5-(6,7-Dimethoxyquinolin-4-yloxy)pyridin-2-ylamine

[0663] After suspending 6-chloro-5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-ylamine (500 mg, 1.51 mmol) in a mixed solvent of methanol (20 ml), tetrahydrofuran (10 ml) and triethylamine (3 ml), palladium carbon (300 mg) was added and the mixture was stirred for 15 hours at room temperature under a hydrogen atmosphere. The catalyst was filtered off by celite filtration, washing was performed with ethanol, and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (138 mg, 0.465 mmol, 31%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.05 (3H, s), 4.07 (3H, s), 4.52 (2H, s), 6.42 (1H, d, J = 5.2 Hz), 6.61 (1H, d, J =

8.8 Hz), 7.32 (1H, dd, J = 2.8, 8.8 Hz), 7.42 (1H, s), 7.57 (1H, s), 8.04 (1H, d, J = 2.8 Hz), 8.49 (1H, d, J = 5.2 Hz).

Example 223

5 N-(5-(6,7-Dimethoxyquinolin-4-yloxy)pyridin-2-yl)-N'-(4-fluorophenyl)urea

[0664] The title compound (50.9 mg, 117 mmol, 78%) was obtained as colorless crystals from the 5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-ylamine (44.5 mg, 0.150 mmol) obtained in Production Example 222-4 and 4-fluorophenyl isocyanate (22.6 mg, 0.165 mmol), in the same manner as Example 222.

10 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.95 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 7.13-7.20 (2H, m), 7.41 (1H, s), 7.51-7.57 (3H, m), 7.74-7.82 (2H, m), 8.30-8.33 (1H, m), 8.49 (1H, d, J = 5.2 Hz), 9.55 (1H, s), 10.09 (1H, s).

Example 224

15 N-(5-(6,7-Dimethoxyquinolin-4-yloxy)pyridin-2-yl)-N'-(thiazol-2-yl)urea

[0665] The 5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-ylamine (44.5 mg, 0.150 mmol) obtained in Production Example 222-4 and thiazol-2-ylcarbamic acid phenyl ester (39.6 mg, 0.180 mmol) were stirred in dimethylsulfoxide (1 ml) at 85°C for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 30:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (46.7 mg, 0.110 mmol, 74%) as colorless crystals.

25 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.95 (3H, s), 3.96 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 7.20 (1H, d, J = 3.4 Hz), 7.41 (1H, s), 7.43 (1H, d, J = 3.4 Hz), 7.54 (1H, s), 7.80-7.86 (2H, m), 8.36-8.39 (1H, m), 8.49 (1H, d, J = 5.2 Hz), 9.92 (1H, br s), 11.55 (1H, br s).

[0666] The intermediates were synthesized in the following manner.

30 Production Example 224-1

Thiazol-2-ylcarbamic acid phenyl ester

[0667] After dissolving 2-aminothiazole (5.01 g, 50.0 mmol) and pyridine (7.91 g, 100 mmol) in dimethylformamide (50 ml), phenyl chloroformate (8.22 g, 52.5 mmol) was added while cooling on ice, and the mixture was stirred at room temperature for 1 hour. The reaction solution was distributed between an ethyl acetate-tetrahydrofuran mixed solvent and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. After adding ethyl acetate and then hexane to the obtained crude product, the precipitated crystals were filtered out and blow-dried to obtain the title compound (10.6 g, 48.1 mmol, 96%) as colorless crystals.

40 ¹H-NMR Spectrum (CDCl₃)δ(ppm): 6.97 (1H, d, J = 3.4 Hz), 7.24-7.32 (3H, m), 7.40-7.46 (2H, m), 7.52 (1H, d, J = 3.4 Hz), 13.19 (1H, s).

Example 225

45 N-(6-Chloro-5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-N'-phenylurea

[0668] The 6-chloro-5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-ylamine (33.2 mg, 0.100 mmol) obtained in Production Example 222-3 and phenyl isocyanate (13.1 mg, 0.110 mmol) were heated and stirred in dimethylformamide (1 ml) at 60°C for 2 hours. the reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (17.5 mg, 0.039 mmol, 39%) as colorless crystals.

55 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.96 (6H, s), 6.50 (1H, d, J = 5.2 Hz), 7.01-7.07 (1H, m), 7.30-7.37 (2H, m), 7.43 (1H, s), 7.46-7.51 (2H, m), 7.54 (1H, s), 7.94-8.00 (2H, m), 8.49 (1H, d, J = 5.2 Hz), 9.29 (1H, br s), 9.75 (1H, br s).

Example 226

N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-phenylurea

[0669] 5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine (89.0 mg, 0.280 mmol) and phenyl isocyanate (36.6 mg, 0.307 mmol) were stirred in dimethylformamide (1 ml) at room temperature for 1 hour. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 50:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (60.0 mg, 0.137 mmol, 48%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.95 (3H, s), 3.98 (3H, s), 6.70 (1H, d, J = 3.6 Hz), 6.74 (1H, d, J = 4.8 Hz), 6.98-7.03 (1H, m), 7.26-7.36 (4H, m), 7.40 (1H, s), 7.43-7.50 (2H, m), 8.48 (1H, d, J = 4.8 Hz), 9.02 (1H, br s), 10.27 (1H, br s).

[0670] The intermediates were synthesized in the following manner.

Production Example 226-16,7-Dimethoxy-1H-quinolin-4-thione

[0671] After suspending the 6,7-dimethoxy-1H-quinolin-4-one (10.3 g, 50.0 mmol) described in WO9717329, phosphorus pentasulfide (26.7 g, 60.0 mmol) and sodium bicarbonate (26.7 g, 318 mmol) in diglyme (diethyleneglycol dimethyl ether) (100 ml), the suspension was heated and stirred at 80°C for 2 hours. The reaction solution was returned to room temperature and poured into ice water (1000 ml), and the precipitated crystals were filtered out, washed with water and blow-dried to obtain the title compound (8.19 g, 37.0 mmol, 74%) as yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.87 (3H, s), 3.91 (3H, s), 7.07 (1H, s), 7.19 (1H, d, J = 6.8 Hz), 7.74 (1H, d, J = 6.8 Hz), 8.11 (1H, s), 12.76 (1H, br s).

Production Example 226-26,7-Dimethoxy-4-(5-nitrothiophen-2-ylsulfanyl)quinoline

[0672] 6,7-Dimethoxy-1H-quinolin-4-thione (2.21 g, 10.0 mmol), 2-bromo-5-nitrothiophene (2.29 g, 11.0 mmol) and potassium carbonate (2.07 g, 15.0 mmol) were stirred in dimethylformamide (30 ml) at room temperature for 1 hour. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), and the fraction containing the target substance was concentrated to obtain the title compound (1.93 g, 5.54 mmol, 55%) as yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.04 (3H, s), 4.06 (3H, s), 7.10 (1H, d, J = 4.8 Hz), 7.22 (1H, d, J = 4.4 Hz), 7.37 (1H, s), 7.46 (1H, s), 7.89 (1H, d, J = 4.4 Hz), 8.60 (1H, d, J = 4.8 Hz).

Production Example 226-35-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine

[0673] After suspending 6,7-dimethoxy-4-(5-nitrothiophen-2-ylsulfanyl)quinoline (1.39 g, 4.00 mmol), iron (1.12 g, 20.0 mmol) and ammonium chloride (2.18 g, 40.0 mmol) in an ethanol (32 ml)-water (8 ml) mixed solvent, the suspension was heated and stirred at 80°C for 5 minutes. After completion of the reaction, the reaction mixture was filtered with celite and washed in ethyl acetate. The organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), and the fraction containing the target substance was concentrated to obtain the title compound (1.93 g, 5.54 mmol, 55%) as yellowish-brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.04 (3H, s), 4.06 (3H, s), 4.15 (2H, s), 6.21 (1H, d, J = 3.8 Hz), 6.87 (1H, d, J = 5.0 Hz), 7.04 (1H, d, J = 3.8 Hz), 7.31 (1H, s), 7.40 (1H, s), 8.47 (1H, d, J = 5.0 Hz).

Example 227N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-(4-fluorophenyl)urea

[0674] The title compound (29.3 mg, 64.3 mmol, 64%) was obtained as colorless crystals from 5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine (31.8 mg, 0.100 mmol) and 4-fluorophenyl isocyanate (15.1 mg, 0.110 mmol), by the same procedure as in Example 226.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.97 (3H, s), 6.70 (1H, d, J = 4.0 Hz), 6.74 (1H, d, J = 5.2 Hz), 7.10-7.18 (2H, m), 7.31 (1H, s), 7.33 (1H, d, J = 4.0 Hz), 7.39 (1H, s), 7.45-7.51 (2H, m), 8.48 (1H, d, J = 5.2 Hz), 9.05 (1H, br s), 10.29 (1H, br s).

Example 228N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-(3-fluorophenyl)urea

[0675] The title compound (62.0 mg, 0.136 mmol, 68%) was obtained as light brown crystals from 5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine (64.0 mg, 0.200 mmol) and 4-fluorophenyl isocyanate (15.1 mg, 0.110 mmol), by the same procedure as in Example 226.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.95 (3H, s), 3.97 (3H, s), 6.72 (1H, d, J = 3.6 Hz), 6.75 (1H, d, J = 4.6 Hz), 6.80-6.85 (1H, m), 7.17-7.21 (1H, m), 7.29-7.36 (3H, m), 7.40 (1H, s), 7.42-7.48 (1H, m), 8.48 (1H, d, J = 4.6 Hz), 9.18 (1H, br s), 10.27 (1H, br s).

Example 229N-(3-Cyanophenyl)-N'-(5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)urea

[0676] The title compound (60.0 mg, 0.130 mmol, 65%) was obtained as light brown crystals from 5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine (64 mg, 0.200 mmol) and 3-cyanophenyl isocyanate (31.7 mg, 0.220 mmol), by the same procedure as in Example 226.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.95 (3H, s), 3.97 (3H, s), 6.73-6.77 (2H, m), 7.31 (1H, s), 7.34 (1H, d, J = 4.0 Hz), 7.40 (1H, s), 7.44-7.48 (1H, m), 7.49-7.54 (1H, m), 7.71-7.75 (1H, m), 7.94-7.96 (1H, m), 8.48 (1H, d, J = 4.8 Hz), 9.30 (1H, br s), 10.40 (1H, br s).

Example 230N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-(thiazol-2-yl)urea

[0677] 5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine (31.8 mg, 0.100 mmol) and thiazol-2-ylcarbamic acid phenyl ester (33.0 mg, 0.150 mmol) were stirred in dimethylsulfoxide (1 ml) at 85°C for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 20:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (25.6 mg, 0.058 mmol, 58%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.95 (3H, s), 3.97 (3H, s), 6.74 (1H, d, J = 5.0 Hz), 6.75-6.80 (1H, m), 7.04-7.10 (1H, m), 7.32 (1H, s), 7.34 (1H, d, J = 4.0 Hz), 7.36-7.39 (1H, m), 7.40 (1H, s), 8.48 (1H, d, J = 5.0 Hz).

Example 231N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-(3-methanesulfonylphenyl)urea

[0678] The title compound (61.0 mg, 0.118 mmol, 59%) was obtained as light brown crystals from 5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine (64.0 mg, 0.200 mmol) and (3-methanesulfonylphenyl)carbamic acid phenyl ester (87.4 mg, 0.300 mmol), by the same procedure as in Example 230.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.20 (3H, s), 3.95 (3H, s), 3.97 (3H, s), 6.75 (1H, d, J = 4.8 Hz), 6.76 (1H, d, J = 4.0 Hz), 7.32 (1H, s), 7.35 (1H, d, J = 4.0 Hz), 7.40 (1H, s), 7.53-7.60 (2H, m), 7.70-7.74 (1H, m), 8.13-8.16 (1H, m), 8.48 (1H, d, J = 4.8 Hz), 9.40 (1H, br s), 10.35 (1H, br s).

Example 232N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-(2-hydroxymethylphenyl)urea

[0679] The title compound (27.0 mg, 0.058 mmol, 58%) was obtained as colorless crystals from (5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)carbamic acid phenyl ester (43.9 mg, 0.100 mmol) and 2-aminobenzyl alcohol (24.6 mg, 0.200 mmol), by the same procedure as in Example 230.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.94 (3H, s), 3.96 (3H, s), 4.54 (2H, d, J = 5.6 Hz), 5.51 (1H, t, J = 5.6 Hz), 6.65 (1H, d, J = 4.0 Hz), 6.74 (1H, d, J = 4.8 Hz), 7.02-7.07 (1H, m), 7.22-7.27 (1H, m), 7.28-7.34 (3H, m), 7.39 (1H, s), 7.80-7.84 (1H, m), 8.46-8.50 (2H, m), 10.89 (1H, br s).

[0680] The intermediates were synthesized in the following manner.

Production Example 232-1(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)carbamic acid phenyl ester

[0681] After dissolving 5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-ylamine (696 mg, 2.00 mmol) and pyridine (174 mg, 2.20 mmol) in a tetrahydrofuran (10 ml)-dimethylformamide (5 ml) mixed solvent, phenyl chloroformate (329 mg, 2.10 mmol) was added while cooling on ice, and the mixture was stirred at room temperature for 1 hour. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. After adding ethyl acetate and then hexane to the obtained crude product, the precipitated crystals were filtered out and blow-dried to obtain the title compound (720 mg, 1.64 mmol, 82%) as yellowish-brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.08 (3H, s), 4.09 (3H, s), 6.86-6.92 (2H, m), 7.10-7.16 (2H, m), 7.20-7.26 (2H, m), 7.34 (1H, s), 7.36-7.41 (2H, m), 7.80-7.85 (1H, m), 8.35 (1H, d, J = 5.6 Hz), 8.75 (1H, br s).

Example 233N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-(3-hydroxymethylphenyl)urea

[0682] The title compound (25.0 mg, 0.054 mmol, 54%) was obtained as light brown crystals from the (5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)carbamic acid phenyl ester (43.9 mg, 0.100 mmol) obtained in Production Example 232-1 and 3-aminobenzyl alcohol (24.6 mg, 0.200 mmol), by the same procedure as in Example 230.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.95 (3H, s), 3.97 (3H, s), 4.46 (2H, d, J = 5.6 Hz), 5.19 (1H, t, J = 5.6 Hz), 6.70 (1H, d, J = 4.0 Hz), 6.75 (1H, d, J = 4.8 Hz), 6.93-6.97 (1H, m), 7.21-7.26 (1H, m), 7.30-7.34 (3H, m), 7.40 (1H, s), 7.43-7.46 (1H, m), 8.48 (1H, d, J = 4.8 Hz), 8.97 (1H, s).

Example 234N-(5-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)-N'-(4-hydroxymethylphenyl)urea

[0683] The title compound (27.0 mg, 0.058 mmol, 58%) was obtained as light yellow crystals from (5-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiophen-2-yl)carbamic acid phenyl ester (43.9 mg, 0.100 mmol) and 4-aminobenzyl alcohol (224 mg, 1.82 mmol), by the same procedure as in Example 230.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.97 (3H, s), 4.42 (2H, d, J = 5.6 Hz), 5.07 (1H, t, J = 5.6 Hz), 6.69 (1H, d, J = 4.0 Hz), 6.75 (1H, d, J = 5.0 Hz), 7.21-7.26 (2H, m), 7.30-7.34 (2H, m), 7.38-7.43 (3H, m), 8.47 (1H, d, J = 5.0 Hz), 8.88 (1H, s), 10.13 (1H, s).

Example 235N-(2-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)-N'-phenylurea

[0684] 2-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (64.0 mg, 0.200 mmol) and phenyl isocyanate (26.2 mg, 0.220 mmol) were stirred in dimethylformamide (1 ml) at room temperature for 15 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:meth-

anol = 30:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (53.2 mg, 0.121 mmol, 60%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.94 (3H, s), 3.95 (3H, s), 6.98-7.05 (2H, m), 7.26-7.34 (2H, m), 7.39 (1H, s), 7.43-7.47 (3H, m), 7.64 (1H, s), 8.55 (1H, d, J = 4.8 Hz), 9.10 (1H, s), 10.29 (1H, br s).

[0685] The intermediates were synthesized in the following manner.

Production Example 235-1

6,7-Dimethoxy-4-(5-nitrothiazol-2-ylsulfanyl)quinoline

[0686] After suspending 6,7-dimethoxy-1H-quinoline-4-thione (2.21 g, 10.0 mmol) in dimethylformamide (30 ml), 2-bromo-5-nitrothiazole (2.30 g, 11.0 mmol) was added at 0°C, and then the mixture was stirred at room temperature for 1 hour. The reaction solution was distributed between ethyl acetate and 1N aqueous sodium hydroxide, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (1.70 g, 4.87 mmol, 49%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.00 (3H, s), 4.08 (3H, s), 7.50 (1H, s), 7.54 (1H, s), 7.70 (1H, d, J = 4.8 Hz), 8.37 (1H, s), 8.83 (1H, d, J = 4.8 Hz).

Production Example 235-2

2-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine

[0687] After suspending 6,7-dimethoxy-4-(5-nitrothiazol-2-ylsulfanyl)quinoline (699 mg, 2.00 mmol), iron (559 mg, 10.0 mmol) and ammonium chloride (1.07 g, 20.0 mmol) in an ethanol (20 ml)-water (5 ml) mixed solvent, the suspension was heated and stirred at 80°C for 20 minutes. After completion of the reaction, the reaction mixture was filtered with celite and washed in an ethyl acetate-tetrahydrofuran mixed solvent. The organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 30:1), and the fraction containing the target substance was concentrated to obtain the title compound (190 mg, 0.595 mmol, 30%) as yellowish-brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.99 (2H, br s), 4.04 (3H, s), 4.05 (3H, s), 7.10 (1H, d, J = 5.2 Hz), 7.17 (1H, s), 7.41 (1H, s), 7.42 (1H, s), 8.54 (1H, d, J = 5.2 Hz).

Example 236

N-(2-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)-N'-(4-fluorophenyl)urea

[0688] The title compound (62.3 mg, 0.136 mmol, 68%) was obtained as colorless crystals from 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (64.0 mg, 0.200 mmol) and 4-fluorophenyl isocyanate (30.1 mg, 0.220 mmol), by the same procedure as in Example 235.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.94 (3H, s), 3.95 (3H, s), 7.03 (1H, d, J = 4.8 Hz), 7.10-7.18 (2H, m), 7.39 (1H, s), 7.42-7.48 (3H, m), 7.64 (1H, s), 8.55 (1H, d, J = 4.8 Hz), 9.14 (1H, s), 10.32 (1H, br s).

Example 237

N-(2-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)-N'-(3-fluorophenyl)urea

[0689] The title compound (70.0 mg, 0.153 mmol, 51%) was obtained as colorless crystals from 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (95.8 mg, 0.300 mmol) and 3-fluorophenyl isocyanate (45.2 mg, 0.330 mmol), by the same procedure as in Example 235.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.94 (3H, s), 3.95 (3H, s), 6.80-6.86 (1H, m), 7.06 (1H, d, J = 4.8 Hz), 7.16-7.20 (1H, m), 7.28-7.35 (1H, m), 7.38-7.45 (3H, m), 7.66 (1H, s), 8.55 (1H, d, J = 4.8 Hz), 9.33 (1H, s), 10.37 (1H, br s).

Example 238N-(3-Cyanophenyl)-N'-(2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)urea

[0690] The title compound (94.0 mg, 0.203 mmol, 68%) was obtained as light yellow crystals from 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (95.8 mg, 0.300 mmol) and 3-cyanophenyl isocyanate (47.6 mg, 0.330 mmol), by the same procedure as in Example 235.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.95 (3H, s), 7.07 (1H, d, J = 4.8 Hz), 7.40 (1H, s), 7.43 (1H, s), 7.45-7.54 (2H, m), 7.67 (1H, s), 7.70-7.74 (1H, m), 7.91-7.94 (1H, m), 8.56 (1H, d, J = 4.8 Hz), 9.44 (1H, s), 10.49 (1H, br s).

Example 239N-(2,4-Difluorophenyl)-N'-(2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)urea

[0691] The title compound (123 mg, 0.259 mmol, 86%) was obtained as light orange crystals from 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (95.8 mg, 0.300 mmol) and 2,4-difluorophenyl isocyanate (51.2 mg, 0.330 mmol), by the same procedure as in Example 235.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.95 (3H, s), 7.04 (1H, d, J = 4.8 Hz), 7.05-7.09 (1H, m), 7.30-7.37 (1H, m), 7.39 (1H, s), 7.43 (1H, s), 7.65 (1H, s), 7.84-7.91 (1H, m), 8.54 (1H, d, J = 4.8 Hz), 8.84 (1H, s), 10.48 (1H, br s).

Example 240N-(2-Chlorophenyl)-N'-(2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)urea

[0692] The title compound (132 mg, 0.279 mmol, 93%) was obtained as light brown crystals from 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (95.8 mg, 0.300 mmol) and 2-chlorophenyl isocyanate (50.6 mg, 0.330 mmol), by the same procedure as in Example 235.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.95 (3H, s), 7.05 (1H, d, J = 5.0 Hz), 7.07-7.12 (1H, m), 7.28-7.34 (1H, m), 7.39 (1H, s), 7.43 (1H, s), 7.47-7.50 (1H, m), 7.67 (1H, s), 8.01-8.04 (1H, m), 8.55 (1H, d, J = 5.0 Hz), 8.62 (1H, s), 10.85 (1H, br s).

Example 241N-(3-Chlorophenyl)-N'-(2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)urea

[0693] The title compound (124 mg, 0.262 mmol, 87%) was obtained as light brown crystals from 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (95.8 mg, 0.300 mmol) and 3-chlorophenyl isocyanate (50.6 mg, 0.330 mmol), by the same procedure as in Example 235.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.95 (3H, s), 7.04-7.09 (2H, m), 7.30-7.34 (2H, m), 7.40 (1H, s), 7.43 (1H, s), 7.63-7.66 (2H, m), 8.55 (1H, d, J = 4.8 Hz), 9.30 (1H, s), 10.40 (1H, br s).

Example 242N-(4-Chlorophenyl)-N'-(2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)urea

[0694] The title compound (120 mg, 0.253 mmol, 85%) was obtained as colorless crystals from 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (95.8 mg, 0.300 mmol) and 4-chlorophenyl isocyanate (50.6 mg, 0.330 mmol), by the same procedure as in Example 235.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.95 (3H, s), 7.04 (1H, d, J = 4.8 Hz), 7.31-7.36 (2H, m), 7.39 (1H, s), 7.43 (1H, s), 7.45-7.50 (2H, m), 7.65 (1H, s), 8.55 (1H, d, J = 4.8 Hz), 9.24 (1H, s), 10.34 (1H, br s).

Example 243N-(2-(6,7-Dimethoxyquinolin-4-ylsulfanyl)thiazol-5-yl)-N'-(thiazol-2-yl)urea

[0695] After dissolving 2-(6,7-dimethoxyquinolin-4-ylsulfanyl)thiazol-5-ylamine (216 mg, 0.676 mmol) and pyridine (58.8 mg, 0.743 mmol) in tetrahydrofuran (3 ml), 4-nitrophenyl chloroformate (150 mg, 0.743 mmol) was added while

cooling on ice, the mixture was stirred at room temperature for 30 minutes, 2-aminothiazole (101 mg, 1.01 mmol) and triethylamine (1 ml) were added, and the mixture was heated and stirred at 60°C for 1 hour. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 30:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (57 mg, 0.128 mmol, 19%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.94 (3H, s), 3.95 (3H, s), 7.03-7.09 (2H, m), 7.34-7.38 (1H, m), 7.40 (1H, s), 7.43 (1H, s), 7.66 (1H, br s), 8.55 (1H, d, J = 4.8 Hz).

Example 244

7-Methoxy-4-(5-(3-phenylureido)thiophen-2-ylsulfanyl)quinoline-6-carboxamide

[0696] 4-(5-Aminothiophen-2-ylsulfanyl)-7-methoxyquinoline-6-carboxamide (49.0 mg, 0.150 mmol) and phenyl isocyanate (19.6 mg, 0.165 mmol) were stirred in dimethylformamide (1 ml) at room temperature for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate and diluted with hexane, and then the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (25.0 mg, 0.056 mmol, 37%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 4.02 (3H, s), 6.72 (1H, d, J = 3.4 Hz), 6.77 (1H, d, J = 4.8 Hz), 6.98-7.03 (1H, m), 7.27-7.34 (2H, m), 7.35 (1H, d, J = 3.4 Hz), 7.43-7.49 (2H, m), 7.53 (1H, s), 7.80 (1H, br s), 7.89 (1H, br s), 8.52 (1H, s), 8.65 (1H, d, J = 4.8 Hz), 8.95 (1H, br s), 10.21 (1H, br s).

[0697] The intermediates were synthesized in the following manner.

Production Example 244-1

7-Methoxy-4-(5-nitrothiophen-2-ylsulfanyl)quinoline-6-carboxamide

[0698] 4-Chloro-7-methoxyquinoline-6-carboxamide (1.18 g, 5.00 mmol) and sodium sulfide (1.20 g, 5.50 mmol) were heated and stirred in dimethylformamide (10 ml) at 60°C for 3 hours. After cooling the reaction solution to room temperature, 2-bromo-5-nitrothiophene (1.25 g, 6.00 mmol) was added and the mixture was further heated and stirred at 60°C for 1 hour. The reaction solution was returned to room temperature and then poured into ice water (50 ml), and the precipitated crystals were filtered out, washed with water and methanol and then blow-dried to obtain the title compound (700 mg, 1.94 mmol, 39%) as yellowish-brown crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 4.04 (3H, s), 7.17 (1H, d, J = 4.6 Hz), 7.59 (1H, s), 7.66 (1H, d, J = 4.0 Hz), 7.82 (1H, br s), 7.90 (1H, br s), 8.23 (1H, d, J = 4.0 Hz), 8.53 (1H, s), 8.76 (1H, d, J = 4.6 Hz).

Production Example 244-2

(4-(5-Aminothiophen-2-ylsulfanyl)-7-methoxyquinoline-6-carboxamide)

[0699] After suspending 7-methoxy-4-(5-nitrothiophen-2-ylsulfanyl)quinoline-6-carboxamide (320 mg, 0.885 mmol), iron (247 mg, 4.43 mmol) and ammonium chloride (481 mg, 8.85 mmol) in an ethanol (8 ml)-water (2 ml)-dimethylformamide (1 ml) mixed solvent, the suspension was heated and stirred at 80°C for 15 minutes. After completion of the reaction, the reaction mixture was filtered with celite and washed in a tetrahydrofuran-methanol mixed solvent. After adding ethyl acetate to the organic layer, it was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 20:1), and the fraction containing the target substance was concentrated to obtain the title compound (164 mg, 0.495 mmol, 56%) as yellowish-brown crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 4.02 (3H, s), 6.00 (1H, d, J = 4.0 Hz), 6.34 (2H, s), 6.83 (1H, d, J = 4.8 Hz), 7.08 (1H, d, J = 4.0 Hz), 7.51 (1H, s), 7.77 (1H, br s), 7.86 (1H, br s), 8.47 (1H, s), 8.66 (1H, d, J = 4.8 Hz).

Example 2454-(5-(3-(4-Fluorophenyl)ureido)thiophen-2-ylsulfanyl)-7-methoxyquinoline-6-carboxamide

[0700] The title compound (50.0 mg, 0.107 mmol, 71%) was obtained as colorless crystals from 4-(5-aminothiophen-2-ylsulfanyl)-7-methoxyquinoline-6-carboxamide (49.0 mg, 0.150 mmol) and 4-fluorophenyl isocyanate (22.6 mg, 0.165 mmol), by the same procedure as in Example 244.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 4.03 (3H, s), 6.72 (1H, d, J = 4.0 Hz), 6.76 (1H, d, J = 4.8 Hz), 7.10-7.18 (2H, m), 7.35 (1H, d, J = 4.0 Hz), 7.45-7.51 (2H, m), 7.53 (1H, s), 7.80 (1H, br s), 7.89 (1H, br s), 8.52 (1H, s), 8.65 (1H, d, J = 4.8 Hz), 8.99 (1H, br s), 10.24 (1H, br s).

Example 2467-Methoxy-4-(5-(3-thiazol-2-ylureido)thiophen-2-ylsulfanyl)quinoline-6-carboxamide

[0701] 4-(5-Aminothiophen-2-ylsulfanyl)-7-methoxyquinoline-6-carboxamide (66.0 mg, 0.200 mmol) and thiazol-2-ylcarbamic acid phenyl ester (66.0 mg, 0.300 mmol) were stirred in dimethylsulfoxide (1 ml) at 85°C for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 15:1), and the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, after which the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (35.0 mg, 0.077 mmol, 38%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 4.03 (3H, s), 6.77 (1H, d, J = 4.8 Hz), 6.77-6.83 (1H, m), 7.01-7.12 (1H, m), 7.34-7.39 (2H, m), 7.51 (1H, s), 7.80 (1H, br s), 7.89 (1H, br s), 8.52 (1H, s), 8.65 (1H, d, J = 4.8 Hz).

Example 247N1-[5-({7-[3-(Dimethylamino)propoxy]-6-methoxy-4-quinolyl}sulfanyl)-2-thienyl]-N'-(4-fluorophenyl)urea

[0702] 5-({7-[3-(Diethylamino)propoxy]-6-methoxy-4-quinolyl}sulfanyl)-2-thiophenylamine (190 mg), parafluorophenyl isocyanate (69 mg) and tetrahydrofuran (30 ml) were stirred together at room temperature for 30 minutes. The organic solvent was distilled off under reduced pressure, and the residue was purified by column chromatography (ethyl acetate, followed by ethyl acetate:methanol = 10:1) using NH type silica gel. The solvent was distilled off under reduced pressure, and ethyl acetate was added to the residue for solidification to obtain 16 mg of a yellowish-brown solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.93 (6H, t, J= 7.2Hz), 1.87 (2H, tt, J= 7.2Hz, 7.2Hz), 2.40-2.57 (6H, m), 3.94 (3H, s), 4.15 (2H, t, J= 7.2Hz), 6.68 (1H, d, J= 4.0Hz), 6.71 (1H, d, J= 4.8Hz), 7.11 (2H, dd, J= 8.8Hz, 8.8Hz), 7.28 (1H, s), 7.30 (1H, d, J= 4.0Hz), 7.34 (1H, s), 7.45 (2H, dd, J= 8.8Hz, 4.8Hz), 8.44 (1H, d, J= 4.8Hz), 8.94 (1H, bs), 10.15 (1H, bs).

[0703] The intermediates were obtained in the following manner.

Production Example 247-17-(Benzyloxy)-6-methoxy-1,4-dihydro-4-quinolinethione

[0704] 7-(Benzyloxy)-6-methoxy-1,4-dihydro-4-quinoline (28.1 g), diphosphorus pentasulfide (53.4 g), sodium bicarbonate (53.7 g) and diethyleneglycol dimethyl ether (200 ml) were stirred together at 80°C for 2 hours. After returning the mixture to room temperature, it was developed in ice water and stirred for 40 minutes, and then the solid was filtered out and blow-dried at 60°C to obtain 29.1 g of a yellow powder.

¹H-NMR(DMSO-d₆) δ(ppm) : 3.85 (3H, s), 5.22 (2H, s), 7.15 (1H, s), 7.17 (1H, d, J= 6.4Hz), 7.33-7.50 (5H, m), 7.71 (1H, d, J= 6.4Hz), 8.11 (1H, s).

Production Example 247-22-[[7-(Benzyloxy)-6-methoxy-4-quinolyl]sulfanyl]-5-nitrothiophene

[0705] 7-(Benzyloxy)-6-methoxy-1,4-dihydro-4-quinolinethione (14.3 g), 2-bromo-5-nitrothiophene (10 g), potassium carbonate (9.9 g) and dimethylformamide (150 ml) were stirred together at room temperature for 6 hours. Water was

added, and the precipitated solid was filtered out and washed with water and then ethyl acetate to obtain 15.7 g of a yellow powder.

¹H-NMR(DMSO-d₆) δ(ppm): 3.92 (3H, s), 5.29 (2H, s), 7.23 (1H, dd, J= 4.8Hz, 1.6Hz), 7.32-7.44 (4H, m), 7.49 (2H, d, J= 8.0Hz), 7.55 (1H, s), 7.57 (1H, dd, J= 4.4Hz, 1.6Hz), 8.16 (1H, dd, J= 4.4Hz, 2.0Hz), 8.58 (1H, dd, J= 4.8Hz, 1.6Hz).

Production Example 247-3

6-Methoxy-4-[(5-nitro-2-thienyl)sulfanyl]-7-quinolinol

[0706] 7-(Benzyloxy)-6-methoxy-4-[(5-nitro-2-thienyl)sulfanyl] quinoline (4.0 g), trifluoroacetic acid (40 ml) and thioanisole (4 ml) were stirred together at 65°C for 2 hours. The mixture was returned to room temperature, the solvent was distilled off under reduced pressure, 80 ml of methanol was added to the residue, and then sodium bicarbonate water was added until the foaming subsided. The precipitated solid was filtered out to obtain 2.7 g of a yellow powder.

¹H-NMR(DMSO-d₆) δ(ppm): 3.92 (3H, s), 7.16 (1H, d, J= 4.8Hz), 7.31 (1H, s), 7.33 (1H, s), 7.55 (1H, d, J= 4.0Hz), 8.15 (1H, d, J= 4.0Hz), 8.52 (1H, d, J= 4.8Hz).

Production Example 247-4

N,N-Diethyl-N-[3-{(6-methoxy-4-[(5-nitro-2-thienyl)sulfanyl]-7-quinolyl)oxy}propyl]amine

[0707] 6-Methoxy-4-[(5-nitro-2-thienyl)sulfanyl]-7-quinolinol (500 mg), 3-diethylaminopropanol (290 mg), diethyl azodicarboxylate (390 mg), triphenylphosphine (590 mg), tetrahydrofuran (30 ml), 1-methyl-2-pyrrolidinone (2 ml) and dimethylsulfoxide (10 ml) were stirred together at 0°C for 5 hours and then at room temperature for 10 hours. Water was added, extraction was performed with ethyl acetate, and the extract was back extracted with 2N aqueous hydrochloric acid. After adding 5N aqueous sodium hydroxide to the hydrochloric acid extract and performing extraction with ethyl acetate, the extract was washed with water and then with brine and dried over magnesium sulfate. NH type silica gel was coated onto a glass filter, the ethyl acetate layer was passed through the filter, and the solvent was distilled off under reduced pressure to obtain 500 mg of a reddish-brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 0.92 (6H, t, J= 7.2Hz), 1.87 (2H, tt, J= 7.2Hz, 7.2Hz), 2.40-2.58 (6H, m), 3.93 (3H, s), 4.20 (2H, t, J= 7.2Hz), 7.21 (1H, d, J= 4.8Hz), 7.37 (1H, s), 7.42 (1H, s), 7.58 (1H, d, J= 4.0Hz), 8.18 (1H, d, J= 4.0Hz), 8.60 (1H, d, J= 4.8Hz).

Production Example 247-5

5-({7-[3-(Diethylamino)propoxy]-6-methoxy-4-quinolyl}sulfanyl)-2-thiopheneamine

[0708] N,N-Diethyl-N-[3-({6-methoxy-4-[(5-nitro-2-thienyl)sulfanyl]-7-quinolyl}oxy)propyl]amine (525 mg), iron powder (330 mg), ammonium chloride (660 mg), ethanol (20 ml) and water (5 ml) were stirred together at 80°C for 80 minutes. After filtration with celite, NH type silica gel was added to the filtrate, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (ethyl acetate, followed by ethyl acetate:methanol = 3:1) to obtain 190 mg of a brown oil.

¹H-NMR(DMSO-d₆) δ(ppm) : 0.91 (6H, t, J= 7.2Hz), 1.88 (2H, tt, J= 7.2Hz, 7.2Hz), 2.47-2.57 (6H, m), 3.92 (3H, s), 4.16 (2H, t, J= 7.2Hz), 5.96 (1H, d, J= 4.0Hz), 6.76 (1H, d, J= 4.8Hz), 6.25-6.30(2H, m), 7.04 (1H, d, J= 4.0Hz), 7.22 (1H, s), 7.33 (1H, s), 8.45 (1H, d, J= 4.8Hz).

Example 248

N-[2-({7-[3-(Diethylamino)propoxy]-6-methoxy-4-quinolyl}sulfanyl)-1,3-thiazol-5-yl]-N'-(4-fluorophenyl)urea

[0709] N,N-Diethyl-N-[3-({6-methoxy-4-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-7-quinolyl}oxy)propyl]amine (770 mg), iron powder (480 mg), ethanol (17 ml) and acetic acid (3.4 ml) were stirred together at 80°C for 10 minutes. After adding 100 ml of water, 60 ml of ethyl acetate and 10 g of potassium carbonate to the reaction solution, the mixture was filtered through celite. The filtrate was subjected to liquid separation and ethyl acetate layer was passed through a glass filter coated with NH type silica gel. After adding 0.58 ml of p-fluorophenyl isocyanate to the obtained ethyl acetate solution, the mixture was stirred at room temperature for 17 hours. NH type silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (ethyl acetate:

methanol = 100:1, followed by 50:1, 10:1) to obtain 30 mg of the target substance as a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.93 (6H, t, J= 7.2Hz), 1.88 (2H, tt, J= 6.4Hz, 6.4Hz), 2.46 (4H, q, J= 7.2Hz), 2.55 (2H, t, J= 6.4Hz), 3.92 (3H, s), 4.17 (2H, t, J= 6.4Hz), 7.00 (1H, d, J= 5.2Hz), 7.10 (2H, dd, J= 8.8Hz, 8.8Hz), 7.36 (1H, s), 7.38 (1H, s), 7.43 (2H, dd, J= 8.8Hz, 4.8Hz), 7.60 (1H, s), 8.51 (1H, d, J= 5.2Hz), 9.10 (1H, bs).

[0710] The intermediates were obtained in the following manner.

Production Example 248-1

2-[[7-(Benzyloxy)-6-methoxy-4-quinolyl]sulfanyl]-5-nitro-1,3-thiazole

[0711] 7-(Benzyloxy)-6-methoxy-1,4-dihydro-4-quinolinethione (14.8 g), 2-bromo-5-nitro-1,3-thiazole (10.4 g), potassium carbonate (10.3 g) and dimethylformamide (150 ml) were stirred together at room temperature for 50 minutes. After adding 800 ml of water to the reaction solution, the precipitated solid was filtered out and washed with ethyl acetate to obtain 13.4 g of a light ochre powder.

¹H-NMR(DMSO-d₆) δ(ppm): 3.87 (3H, s), 5.32 (2H, s), 7.32-7.53 (6H, m), 7.64 (1H, s), 7.86 (1H, d, J= 4.8Hz), 8.70 (1H, s), 8.80 (1H, d, J= 4.8Hz).

Production Example 248-2

6-Methoxy-4-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-7-quinolinol

[0712] 2-[[7-(Benzyloxy)-6-methoxy-4-quinolyl]sulfanyl]-5-nitro-1,3-thiazole (2.0 g), trifluoroacetic acid (20 ml) and thioanisole (2 ml) were stirred together at 65°C for 90 minutes. The mixture was returned to room temperature, the solvent was distilled off under reduced pressure, 40 ml of methanol was added to the residue, and then sodium bicarbonate water was added until the foaming subsided. The precipitated solid was filtered out to obtain 1.4 g of a yellow powder.

¹H-NMR(DMSO-d₆) δ(ppm): 3.87(3H, s), 7.40 (1H, s), 7.43 (1H, s), 7.78 (1H, d, J= 4.8Hz), 8.71 (1H, d, J= 2.4Hz), 8.74 (1H, dd, J= 4.8Hz, 2.4Hz), 10.52 (1H, s).

Production Example 248-3

N,N-Diethyl-N-[3-[(6-methoxy-4-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-7-quinolyl)oxy]propyl]amine

[0713] The target substance was obtained using 6-methoxy-4-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-7-quinolinol, in the same manner as Production Example 247-2.

¹H-NMR(DMSO-d₆) δ(ppm): 0.95 (6H, t, J= 6.8Hz), 1.91 (2H, tt, J= 6.4Hz, 6.4Hz), 2.45-2.65 (6H, m), 3.86 (3H, s), 4.20 (2H, t, J= 6.4Hz), 7.42 (1H, s), 7.49 (1H, s), 7.83 (1H, d, J= 4.4Hz), 8.69 (1H, s), 8.79 (1H, d, J= 4.4Hz).

Example 249

N6-(2-Methoxyethyl)-4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino}phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0714] 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino}phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxylic acid (200 mg), 2-methoxyethylamine (38 mg), benzotriazol-1-yloxytris (dimethylamino)phosphonium hexafluorophosphate (Bop reagent) (230 mg), triethylamine (0.12 ml) and dimethylformamide (5 ml) were stirred together at room temperature for 14 hours. Water and ethyl acetate were added to the reaction solution for extraction, NH type silica gel was added to the extract, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (ethyl acetate). The solvent was distilled off under reduced pressure to obtain 120 mg of the target substance as a solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.45 (2H, m), 0.62-0.68 (2H, m), 2.48-2.60 (1H, m), 3.30 (3H, s), 3.37 (3H, s), 3.45-3.55 (4H, m), 3.79 (2H, t, J= 4.4Hz), 4.40 (2H, t, J= 4.4Hz), 6.52 (1H, d, J= 5.2Hz), 7.18 (1H, d, J= 2.8Hz), 7.23 (1H, dd, J= 9.2Hz, 2.8Hz), 7.49 (1H, d, J= 2.8Hz), 7.55 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J= 9.2Hz), 8.42-8.47 (1H, m), 8.66 (1H, d, J= 5.2Hz), 8.74 (1H, s).

[0715] The intermediates were obtained in the following manner.

Production Example 249-1

Methyl 4-chloro-7-(2-methoxyethoxy)-6-quinolinecarboxylate

[0716] 7-(2-Methoxyethoxy)-4-oxo-1,4-dihydro-6-quinolinecarboxylic acid (7.5 g), thionyl chloride (60 ml) and dimethylformamide (1 ml) were stirred together at 80°C for 3 hours. The reaction solution was distilled off under reduced pressure, toluene was added to the residue, and distillation under reduced pressure was repeated twice. After adding methanol to the residue, 10 ml of triethylamine was added. The resulting solution was distilled off under reduced pressure and then water and 5N aqueous sodium hydroxide were added to pH 4 and extraction was performed with ethyl acetate. The obtained ethyl acetate layer was passed through a glass filter coated with NH type silica gel, and then the solvent was distilled off under reduced pressure. Ether was added to the residue, and the solid was filtered out to obtain 3.6 g of the target substance as a light brown solid. The filtrate was purified by column chromatography (hexane: ethyl acetate = 3:1) using NH type silica gel to obtain 1.3 g of the target substance as a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 3.33 (3H, s), 3.71-3.75 (2H, m), 3.86 (3H, s), 4.32-4.35 (2H, m), 7.62 (1H, s), 7.66 (1H, d, J= 4.8Hz), 8.42 (1H, s), 8.83 (1H, d, J= 4.8Hz).

Production Example 249-2

Methyl 4-(4-amino-3-chlorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxylate

[0717] Methyl 4-chloro-7-(2-methoxyethoxy)-6-quinolinecarboxylate (4.9 g), 4-amino-3-chlorophenol (2.0 g), sodium hydride (550 mg) and dimethylformamide (20 ml) were stirred together at 100°C for 2 hours. The mixture was returned to room temperature, water was added, and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (hexane:ethyl acetate = 1:1, followed by ethyl acetate) to obtain 3.2 g of the target substance as a violet solid.

¹H-NMR(DMSO-d₆) δ(ppm): 3.34 (3H, s), 3.72 (2H, t, J= 4.4Hz), 3.83 (3H, s), 4.29 (2H, t, J= 4.4Hz), 5.44 (2H, s), 6.44 (1H, d, J= 5.6Hz), 6.88 (1H, d, J= 8.8Hz), 7.00 (1H, dd, J= 8.8Hz, 2.4Hz), 7.23 (1H, d, J= 2.4Hz), 7.49 (1H, s), 8.53 (1H, s), 8.63 (1H, d, J= 5.6Hz).

Production Example 249-3

Methyl 4-{3-chloro-4-[(phenoxyacarbonyl)amino]phenoxy}-7-(2-methoxyethoxy)-6-quinolinecarboxylate

[0718] Methyl 4-(4-amino-3-chlorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxylate (3.2 g), pyridine (0.71 ml) and tetrahydrofuran (50 ml) were stirred while cooling on ice, and then 1.1 ml of phenyl chloroformate was added dropwise. After 40 minutes, 0.8 ml of pyridine and 1.1 ml of phenyl chloroformate were added and the mixture was stirred for an additional 10 minutes. Water was added, extraction was performed with ethyl acetate, and the extract solution was passed through a glass filter coated with silica gel. The silica gel was washed with ethyl acetate, the solvent was distilled off under reduced pressure, hexane and ethyl acetate were added to the residue and the solid was filtered out to obtain 3.2 g of a faint red solid.

¹H-NMR(CDCl₃) δ(ppm): 3.50 (3H, s), 3.80 (2H, t, J= 4.4Hz), 3.98 (3H, s), 4.37 (2H, t, J= 4.4Hz), 6.49 (1H, d, J= 5.6Hz), 7.17-7.30 (6H, m), 7.40-7.52 (3H, m), 8.30-8.37 (1H, m), 8.66 (1H, d, J= 5.6Hz), 8.80 (1H, s).

Production Example 249-4

Methyl 4-(3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxylate

[0719] Methyl 4-{3-chloro-4-[(phenoxyacarbonyl)amino] phenoxy}-7-(2-methoxyethoxy)-6-quinolinecarboxylate (3.2 g), cyclopropylamine (1.3 ml) and dimethylformamide (20 ml) were stirred together at 60°C for 10 minutes. The mixture was returned to room temperature, water was added, and extraction was performed with ethyl acetate. Silica gel was added to the extract solution and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel, and purification was performed by column chromatography (ethyl acetate, followed by ethyl acetate:methanol = 50:1, 20:1) to obtain 2.26 g of the target substance as a white powder.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.45 (2H, m), 0.61-0.69 (2H, m), 2.50-2.58 (1H, m), 3.36 (3H, s), 3.73 (2H, t, J= 4.4Hz), 3.84 (3H, s), 4.31 (2H, t, J= 4.4Hz), 6.51 (1H, d, J= 5.2Hz), 7.18 (1H, s), 7.24 (1H, dd, J= 8.8Hz, 2.4Hz), 7.49 (1H, d, J= 2.4Hz), 7.52 (1H, s), 7.96 (1H, s), 8.26 (1H, d, J= 8.8Hz), 8.55 (1H, s), 8.67 (1H, d, J= 5.2Hz).

Production Example 249-54-(3-Chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxylic acid

[0720] Methyl 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxylate (2.26 g), 2N aqueous sodium hydroxide (20 ml), methanol (20 ml) and tetrahydrofuran (20 ml) were stirred together at room temperature for 1 hour. After adding 5N aqueous hydrochloric acid and distilling off 10 ml of the organic solvent, the precipitated solid was filtered out. The solid was washed with a methanol and water mixed solvent to obtain 2.0 g of the target substance as a faint red powder.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.45 (2H, m), 0.60-0.68 (2H, m), 2.50-2.59 (1H, m), 3.34 (3H, s), 3.73 (2H, t, J= 4.4Hz), 4.30 (2H, t, J= 4.4Hz), 6.51 (1H, d, J= 5.2Hz), 7.23 (1H, dd, J= 9.2Hz, 2.8Hz), 7.25 (1H, s), 7.49 (1H, d, J= 2.8Hz), 7.50 (1H, s), 8.00 (1H, s), 8.25 (1H, d, J= 9.2Hz), 8.50 (1H, s), 8.66 (1H, d, J= 5.2Hz).

Example 250N6-(2-Fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0721] The target substance was obtained using 2-fluoroethylamine hydrochloride, in the same manner as Example 249.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.45 (2H, m), 0.60-0.68 (2H, m), 2.48-2.58(1H, m), 3.35 (3H, s), 3.61 (1H, td, J= 4.8Hz, 4.8Hz), 3.68 (1H, td, J= 4.8Hz, 4.8Hz), 3.78 (2H, t, J= 4.8Hz), 4.41 (2H, t, J= 4.8Hz), 4.50 (1H, t, J= 4.8Hz), 4.62 (1H, t, J= 4.8Hz), 6.53 (1H, d, J= 5.2Hz), 7.20 (1H, s), 7.24 (1H, dd, J= 9.2Hz, 2.4Hz), 7.49 (1H, d, J= 2.4Hz), 7.56 (1H, s), 7.98 (1H, s), 8.26 (1H, d, J= 9.2Hz), 8.59 (1H, t, J= 4.8Hz), 8.67 (1H, d, J= 5.2Hz), 8.70 (1H, s).

Example 251N6-Methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0722] The target substance was obtained using O-methylhydroxylamine hydrochloride, in the same manner as Example 249.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.44 (2H, m), 0.62-0.98 (2H, m), 2.50-2.60 (1H, m), 3.35 (3H, s), 3.73 (3H, s), 3.77 (2H, t, J= 4.4Hz), 4.35 (2H, t, J= 4.4Hz), 6.52 (1H, d, J= 5.2Hz), 7.18 (1H, s), 7.22 (1H, dd, J= 9.2Hz, 2.4Hz), 7.47 (1H, d, J= 2.4Hz), 7.52 (1H, s), 7.96 (1H, s), 8.26 (1H, d, J= 9.2Hz), 8.41 (1H, s), 8.66 (1H, d, J= 5.2Hz), 11.30 (1H, s).

Example 2521-[5-[6-Cyano-7-(2-methoxyethoxy)-quinolin-4-ylsulfanyl]-thiophen-2-yl]-3-(thiazol-2-yl)urea

[0723] The title compound (45 mg) was obtained as a solid from 4-(5-aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)-quinoline-6-carbonitrile (118 mg) and thiazol-2-ylcarbamic acid phenyl ester(77 mg), in the same manner as Example 246.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.78 (2H, m), 4.40-4.42 (2H, m), 6.76-6.79 (1H, m), 6.80 (1H, d, J=5.2Hz), 7.02-7.08 (1H, m), 7.32-7.38(1H, m), 7.35 (1H, d, J=4.0Hz), 7.63 (1H, s), 8.62 (1H, s), 8.70 (1H, d, J=5.2Hz).

Production Example 252-17-(2-Methoxyethoxy)-4-thioxo-1,4-dihydroquinoline-6-carbonitrile

[0724] The title compound (9 g) was obtained as a solid from 6-cyano-7-methoxyethoxy-1H-quinolin-4-one (10 g), in the same manner as Production Example 226-1.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.35 (3H, s), 3.74-3.77 (2H, m), 4.31-4.34 (2H, m), 7.16-7.19 (2H, m), 7.82 (1H, d, J=6.8Hz), 8.86 (1H, s), 12.84 (1H, br s).

Production Example 252-27-(2-Methoxyethoxy)-4(5-nitrothiophen-2-ylsulfanyl)quinoline-6-carbonitrile

[0725] The title compound (2.2 g) was obtained as a solid from 7-(2-methoxyethoxy)-4-thioxo-1,4-dihydroquinoline-6-carbonitrile (7.1 g) and 2-bromo-5-nitrothiophene (6.3 g), by the same procedure as in Production Example 226-2. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.35 (3H, s), 3.75-3.78 (2H, m), 4.41-4.44 (2H, m), 7.18 (1H, d, J=4.4Hz), 7.68 (1H, d, J=4.8Hz), 7.69 (1H, s), 8.23 (1H, d, J=4.4Hz), 8.70 (1H, s), 8.79 (1H, d, J=4.8Hz).

Production Example 252-34-(5-Aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)quinoline-6-carbonitrile

[0726] The title compound (0.93 g) was obtained as a solid from 7-(2-methoxyethoxy)-4-(5-nitrothiophen-2-ylsulfanyl)quinoline-6-carbonitrile (2.2 g), in the same manner as Production Example 226-3. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.35 (3H, s), 3.74-3.78 (2H, m), 4.38-4.41 (2H, m), 5.98 (1H, d, J=3.6Hz), 6.37 (2H, t, br s), 6.86 (1H, d, J=4.8Hz), 7.07 (1H, d, J=3.6Hz), 7.61 (1H, s), 8.54 (1H, s), 8.71 (1H, d, J=4.8Hz).

Example 2531-[5-[6-Cyano-7-(2-methoxyethoxy)-quinolin-4-ylsulfanyl] thiophen-2-yl]-3-(4-fluorophenyl)urea

[0727] The title compound (24 mg) was obtained as a solid from 4-(5-amino-thiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)-quinoline-6-carbonitrile (30 mg) and 4-fluorophenyl isocyanate, in the same manner as Example 252. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.43 (2H, m), 6.71 (1H, d, J=3.6Hz), 6.80 (1H, d, J=4.8Hz), 7.12 (2H, t, J=9.2Hz), 7.34 (1H, d, J=4.0Hz), 7.43-7.47 (2H, m), 7.63 (1H, s), 8.62 (1H, s), 8.70 (1H, d, J=4.8Hz), 8.97(1H, br s), 10.23 (1H, br s).

Example 2541-[5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl]thiophen-2-yl]-3-(3-fluorophenyl)urea

[0728] The title compound (20 mg) was obtained as a solid from 4-(5-amino-thiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)-quinoline-6-carbonitrile (30 mg) and 3-fluorophenyl isocyanate, in the same manner as Example 252. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.43 (2H, m), 6.73(1H, d, J=4.0Hz), 6.81 (1H, d, J=4.8Hz), 6.78-6.85(1H, m), 7.15-7.19(1H, m), 7.27-7.32(1H, m), 7.35 (1H, d, J=4.0Hz), 7.40-7.45 (1H, m), 7.63 (1H, s), 8.62 (1H, s), 8.70 (1H, d, J=4.8Hz), 9.18 (1H, br s), 10.30 (1H, br s).

Example 2551-[5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl] thiophen-2-yl]-3-cyclopropylurea

[0729] The title compound (15 mg) was obtained as a solid from 4-(5-amino-thiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)-quinoline-6-carbonitrile (35 mg) and cyclopropylamine, by the same procedure as in Example 252. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.41-0.46 (2H, m), 0.61-0.68 (2H, m), 2.48-2.55 (1H, m), 3.36 (3H, s), 3.75-3.79 (2H, m), 4.39-4.43 (2H, m), 6.63 (1H, d, J=4.0Hz), 6.77 (1H, d, J=4.8Hz), 6.79-7.84 (1H, m), 7.28 (1H, d, J=4.0Hz), 7.62 (1H, s), 8.60 (1H, s), 8.69 (1H, d, J=4.8Hz), 9.93 (1H, br s).

Example 2561-[5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl] thiophen-2-yl]-3-(2-fluorophenyl)urea

[0730] The title compound (15 mg) was obtained as a solid from 4-(5-aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (38 mg) and 2-fluorophenyl isocyanate, in the same manner as Example 252. ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.43 (2H, m), 6.72 (1H, d, J=4.0Hz), 6.80 (1H, d, J=4.8Hz), 7.02-7.08 (1H, m), 7.12-7.16 (1H, m), 7.21-7.27 (1H, m), 7.36(1H, d, J=4.0Hz), 7.63 (1H, s), 7.99-8.04 (1H, m), 8.62 (1H, s), 8.70 (1H, d, J=4.8Hz), 8.74-8.78(1H, m), 10.45 (1H, brs).

Example 2571-{5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl] thiophen-2-yl}-3-phenylurea

[0731] The title compound (12 mg) was obtained as a solid from 4-(5-aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (38 mg) and phenyl isocyanate, in the same manner as Example 252.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.43 (2H, m), 6.71 (1H, d, J=4.0Hz), 6.81 (1H, d, J=4.8Hz), 6.97-7.01 (1H, m), 7.28 (2H, t, J=7.6Hz), 7.34 (1H, d, J=4.0Hz), 7.44 (2H, d, J=7.6Hz), 7.63 (1H, s), 8.62 (1H, s), 8.70 (1H, d, J=4.8Hz), 8.94 (1H, br s), 10.21 (1H, br s).

Example 2581-{5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl] thiophen-2-yl}-3-(2,4-difluorophenyl)urea

[0732] The title compound (18 mg) was obtained as a solid from 4-(5-aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (30 mg) and 2,4-difluorophenyl isocyanate, by the same procedure as in Example 252.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.35 (3H, s), 3.74-3.78 (2H, m), 4.39-4.43 (2H, m), 6.71 (1H, d, J=4.0Hz), 6.80 (1H, d, J=4.8Hz), 7.01-7.08 (1H, m), 7.29-7.34 (1H, m), 7.35 (1H, d, J=4.0Hz), 7.63 (1H, s), 7.89-7.97 (1H, m), 8.62 (1H, s), 8.70 (1H, d, J=4.8Hz), 8.73 (1H, br s), 10.44 (1H, br s).

Example 2591-{5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl] thiophen-2-yl}-3-(para-tolyl)urea

[0733] The title compound (28 mg) was obtained as a solid from 4-(5-aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (30 mg) and para-tolyl isocyanate, by the same procedure as in Example 252.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.23 (3H, s), 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.43 (2H, m), 6.69 (1H, d, J=4.0Hz), 6.80 (1H, d, J=4.8Hz), 7.08 (2H, d, J=8.0Hz), 7.32 (2H, d, J=8.0Hz), 7.33 (1H, d, J=4.0Hz), 7.63 (1H, s), 8.61 (1H, s), 8.70 (1H, d, J=4.8Hz), 8.81 (1H, br s), 10.15 (1H, br s).

Example 2601-{5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl]-thiophen-2-yl}-3-(3-cyanophenyl)-urea

[0734] The title compound (33 mg) was obtained as a solid from 4-(5-aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (30 mg) and 3-cyanophenyl isocyanate, by the same procedure as in Example 252.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.43 (2H, m), 6.75 (1H, d, J=4.0Hz), 6.80 (1H, d, J=4.8Hz), 7.36 (1H, d, J=4.0Hz), 7.43-7.52 (2H, m), 7.63 (1H, s), 7.70-7.73 (1H, m), 7.91-7.94 (1H, m), 8.62 (1H, s), 8.70 (1H, d, J=4.8Hz), 9.30 (1H, br s), 10.44 (1H, br s).

Example 2611-{5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-ylsulfanyl]thiophen-2-yl}-3-(4-cyanophenyl)urea

[0735] The title compound (28 mg) was obtained as a solid from 4-(5-aminothiophen-2-ylsulfanyl)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (30 mg) and 4-cyanophenyl isocyanate, by the same procedure as in Example 252.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.35 (3H, s), 3.74-3.78 (2H, m), 4.39-4.43 (2H, m), 6.76 (1H, d, J=4.0Hz), 6.80 (1H, d, J=4.8Hz), 7.36 (1H, d, J=4.0Hz), 7.61-7.66 (3H, m), 7.71-7.75 (2H, m), 8.62 (1H, s), 8.70 (1H, d, J=4.8Hz), 9.48 (1H, br s), 10.44 (1H, br s).

Example 262N-[4-(7-(2-Methoxyethoxy)-6-cyano-4-quinolyl)oxyphenyl-N'-(4-cyclopropyl)urea

[0736] The title compound (220 mg) was obtained as a solid from 7-(2-methoxyethoxy)-6-cyano-4-(4-amino-3-chlorophenoxy)quinoline (380 mg), by the same procedure as in Example 249-4.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.38-0.44 (2H, m), 0.63-0.69 (2H, m), 2.53-2.60 (1H, m), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.43 (2H, m), 6.58 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, J=8.8Hz), 7.50 (1H, d,

J=2.8Hz), 7.63 (1H, s), 7.98 (1H, s), 8.28 (1H, d, J=8.8Hz), 8.73 (1H, d, J=5.2Hz), 8.74 (1H, s).

Production Example 262-1

5 7-(2-Methoxyethoxy)-6-cyano-4-(4-amino-3-chlorophenoxy)quinoline

[0737] The title compound (380 mg) was obtained as a solid from 4-chloro-7-methoxyethoxy-6-cyanoquinoline (800 mg) obtained by a publicly known method, by the same procedure as in Production Example 395-1.

10 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.36 (3H, s), 3.75-3.78 (2H, m), 4.39-4.41 (2H, m), 5.46 (2H, br s), 6.51 (1H, d, J=5.2Hz), 6.89 (1H, d, J=8.8Hz), 7.01 (1H, dd, J= 2.8, 8.8Hz), 7.24 (1H, d, J=2.8Hz), 7.60 (1H, s), 8.70 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 263

15 (4-{4-[3-(4-Fluorophenyl)ureido]phenoxy}-7-methoxyquinolin-6-yl)carbamic acid benzyl ester

[0738] The title compound (380 mg) was obtained as a solid from [4-(4-aminophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester (330 mg) and 4-fluorophenyl isocyanate, in the same manner as Example 10.

20 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.97 (3H, s), 5.19 (2H, s), 6.42 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.19 (2H, d, J=8.8Hz), 7.29-7.49 (8H, m), 7.57 (2H, d, J=8.8Hz), 8.49 (1H, d, J=5.2Hz), 8.67 (1H, s), 8.80 (1H, br s), 8.87 (1H, br s), 8.98 (1H, s).

[0739] The intermediates were synthesized in the following manner.

Production Example 263-1

25 (7-Methoxy-4-oxo-1,4-dihydroquinolin-6-yl)carbamic acid benzyl ester

30 **[0740]** After dissolving 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid (2.58 g) in N,N-dimethylformamide (50 ml), there were added benzyl alcohol (3.29 ml), diphenylphosphoryl azide 2.51 ml and triethylamine (1.63 ml), and the mixture was heated and stirred at 95°C for 5 hours. The reaction solution was poured into saturated brine and extracted with ethyl acetate, and the organic layer was dried over magnesium sulfate and concentrated. The obtained residue was subjected to NH silica gel column chromatography and eluted with a solvent (ethyl acetate:methanol = 5:1) to obtain the title compound (2.03 g) as a solid.

35 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.85 (3H, s), 5.14 (2H, s), 5.93 (1H, d, J=7.2Hz), 7.07 (1H, s), 7.39-7.43 (5H, m), 7.74-7.81 (1H, m), 8.30 (1H, br s), 8.75 (1H, s), 11.97 (1H, br s).

Production Example 263-2

40 (4-Chloro-7-methoxyquinolin-6-yl)carbamic acid benzyl ester

[0741] (7-Methoxy-4-oxo-1,4-dihydroquinolin-6-yl) carbamic acid benzyl ester (2 g) was added to a mixture of thionyl chloride (20 ml) and N,N-dimethylformamide (0.5 ml), and the mixture was heated to reflux for 2 hours. After completion of the reaction, the thionyl chloride was distilled off, and a procedure of toluene addition and concentration was repeated 3 times to obtain the title compound (2.4 g) as a solid.

45 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.98 (3H, s), 5.22 (2H, s), 7.26-7.49 (6H, m), 7.55 (1H, d, J=5.2Hz), 8.63 (1H, d, J=5.2Hz), 8.65 (1H, s), 9.12 (1H, br s).

Production Example 263-3

50 [4-(4-Aminophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester

[0742] A 4-phenoxyquinoline compound (465 mg) was obtained from (4-chloro-7-methoxyquinolin-6-yl)carbamic acid benzyl ester (2.4 g) and 4-nitrophenol (2.07 g), in the same manner as Production Example 7. The 4-phenoxyquinoline compound (450 mg) was reduced in the same manner as Production Example 8 to obtain the title compound (330 mg) as a solid.

55 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.96 (3H, s), 5.15 (2H, br s), 5.18 (2H, s), 6.34 (1H, d, J=5.2Hz), 6.65 (2H, d, J=8.4Hz), 6.90 (2H, d, J=8.4Hz), 7.29-7.46 (6H, m), 8.45 (1H, d, J=5.2Hz), 8.65 (1H, s), 8.95 (1H, s).

Example 2641-[4-(6-Amino-7-methoxyquinolin-4-yloxy)phenoxy]-3-(4-fluorophenyl)urea

[0743] After dissolving 4-[4-[3-(4-fluorophenyl)ureido]phenoxy]-7-methoxyquinolin-6-yl)carbamic acid benzyl ester (100 mg) in a mixture of tetrahydrofuran (10 ml)-methanol (10 ml), 10% palladium carbon (10 mg) was added and the mixture was stirred for 7 hours at room temperature under hydrogen gas at 1 atmosphere. The reaction solution was filtered through celite and the filtrate was concentrated to obtain the title compound (60 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.94 (3H, s), 5.44 (2H, s), 6.34 (1H, d, J=5.2Hz), 7.07-7.15 (4H, m), 7.23 (1H, s), 7.23 (1H, s), 7.43-7.48 (2H, m), 7.53 (2H, d, J=8.8Hz), 8.25 (1H, d, J=5.2Hz), 8.83 (1H, br s), 8.87 (1H, br s).

Example 265N-(4-[4-[3-(4-Fluorophenyl)ureido]phenoxy]-7-methoxyquinolin-6-yl)acetamide

[0744] After dissolving 1-[4-(6-amino-7-methoxyquinolin-4-yloxy)phenoxy]-3-(4-fluorophenyl)urea (50 mg) in pyridine (5 ml), acetic anhydride (0.5 ml) was added and the mixture was allowed to stand at room temperature for 12 hours. The reaction solution was poured into saturated brine and extracted with ethyl acetate, and the organic layer was dried over magnesium sulfate and concentrated to obtain the title compound (50 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.17 (3H, s), 4.01 (3H, s), 6.41 (1H, d, J=5.6Hz), 7.11 (2H, t, J=8.8Hz), 7.18 (2H, d, J=8.8Hz), 7.42-7.49 (3H, m), 7.57 (2H, d, J=8.8Hz), 8.49 (1H, d, J=5.6Hz), 8.78 (1H, br s), 8.85 (1H, br s), 8.98 (1H, s), 9.45 (1H, s).

Example 266N-(4-[4-[3-(4-Fluorophenyl)ureido]phenoxy]-7-methoxyquinolin-6-yl)methanesulfonamide

[0745] After dissolving 1-[4-(6-amino-7-methoxyquinolin-4-yloxy)phenoxy]-3-(4-fluorophenyl)urea (50 mg) in tetrahydrofuran (3 ml), triethylamine (0.3 ml) and methanesulfonyl chloride (14 μl) were added and the mixture was stirred at room temperature for 1 hour. The reaction solution was poured into saturated aqueous ammonium chloride solution and extracted with ethyl acetate, and the organic layer was washed with saturated brine and dried over magnesium sulfate. The organic layer was concentrated and the obtained residue was subjected to silica gel column chromatography for elution with a solvent (ethyl acetate:methanol = 5:1) to obtain the title compound (13 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.05 (3H, s), 3.98 (3H, s), 6.43 (1H, d, J=5.2Hz), 7.11 (2H, t, J=8.8Hz), 7.19 (2H, d, J=8.8Hz), 7.43-7.48 (3H, m), 7.57 (2H, d, J=8.8Hz), 8.12 (1H, s), 8.53 (1H, d, J=5.2Hz), 8.76 (1H, br s), 8.84 (1H, br s), 9.31 (1H, br).

Example 267(4-[3-Fluoro-4-[3-(4-fluorophenyl)ureido]phenoxy]-7-methoxyquinolin-6-yl)carbamic acid benzyl ester

[0746] The title compound (180 mg) was obtained as a solid from [4-(4-amino-3-fluorophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester (166 mg) and 4-fluorophenyl isocyanate, in the same manner as Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.97 (3H, s), 5.18 (2H, s), 6.51 (1H, d, J=5.2Hz), 7.05-7.09 (1H, m), 7.12 (2H, t, J=8.8Hz), 7.29-7.41 (4H, m), 7.42-7.49 (5H, m), 8.20 (1H, t, J=8.8Hz), 8.52 (1H, d, J=5.2Hz), 8.62-8.64 (1H, m), 8.65 (1H, s), 8.99 (1H, s), 9.12 (1H, br s).

[0747] The intermediates were synthesized in the following manner.

Production Example 267-1[4-(3-Fluoro-4-nitrophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester

[0748] (4-Chloro-7-methoxyquinolin-6-yl)carbamic acid benzyl ester (1.58 g) was added to 1-methyl-2-pyrrolidone (5 ml), and then 3-fluoro-4-nitrophenol (0.87 g) and N,N-diisopropylethylamine (1.2 ml) were added and the mixture was heated and stirred at 130°C for 6 hours. The reaction solution was poured into saturated aqueous sodium bicarbonate and extracted with ethyl acetate, and the organic layer was washed with saturated brine and dried over magnesium sulfate. The organic layer was concentrated and the obtained residue was subjected to NH silica gel column chromatography for elution with a solvent (ethyl acetate) to obtain the title compound (188 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.98 (3H, s), 5.16 (2H, s), 6.96 (1H, d, J=5.2Hz), 7.16-7.21 (1H, m), 7.28-7.43 (5H, m), 7.50 (1H, s), 7.53-7.58 (1H, m), 8.26 (1H, t, J=8.8Hz), 8.51 (1H, s), 8.66 (1H, d, J=5.2Hz), 9.04 (1H, br s).

Production Example 267-2

[4-(4-Amino-3-fluorophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester

[0749] The title compound (170 mg) was obtained as a solid by reduction of [4-(3-fluoro-4-nitrophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester (188 mg) in an ethanol/water mixed solvent using iron and ammonium chloride, according to the same procedure as in Production Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.96 (3H, s), 5.18 (4H, br s), 6.40 (1H, d, J=5.2Hz), 6.79-6.86 (2H, m), 7.04 (1H, dd, J=2.4Hz, J=12Hz), 7.29-7.46 (6H, m), 8.47 (1H, d, J=5.2Hz), 8.63 (1H, s), 8.95 (1H, br s).

Example 268

1-[4-(6-Amino-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]-3-(4-fluorophenyl)urea

[0750] The title compound (125 mg) was obtained as a solid from (4-{3-fluoro-4-[3-(4-fluorophenyl)ureido]phenoxy}-7-methoxyquinolin-6-yl)carbamic acid benzyl ester (180 mg), in the same manner as Example 264.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.94 (3H, s), 5.45 (2H, br s), 6.45 (1H, d, J=5.2Hz), 6.96-7.01 (1H, m), 7.12 (2H, t, J=8.8Hz), 7.17-7.26 (3H, m), 7.42-7.48 (2H, m), 8.13 (1H, t, J=9.2Hz), 8.29 (1H, d, J=5.2Hz), 8.58 (1H, br's), 9.10 (1H, br s).

Example 269

N-(4-{3-Fluoro-4-[3-(4-fluorophenyl)ureido]phenoxy}-7-methoxyquinolin-6-yl)acetamide

[0751] The title compound (50 mg) was obtained as a solid from 1-[4-(6-amino-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]-3-(4-fluorophenyl)urea (60 mg), in the same manner as Example 265.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.16 (3H, s), 4.01 (3H, s), 6.50 (1H, d, J=5.2Hz), 7.05-7.09 (1H, m), 7.12 (2H, t, J=8.8Hz), 7.33 (1H, dd, J=2.8Hz, J=12Hz), 7.43-7.49 (3H, m), 8.16-8.23 (1H, m), 8.52 (1H, d, J=5.2Hz), 8.62 (1H, br s), 8.96 (1H, br s), 9.12 (1H, br s), 9.45 (1H, br s).

Example 270

[4-[3-Fluoro-4-(3-(thiazol-2-yl)ureido)phenoxy]-7-methoxyquinolin-6-yl]carbamic acid benzyl ester

[0752] [4-(4-Amino-3-fluorophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester (100 mg) and thiazolyl-2-yl-carbamic acid phenyl ester (79 mg) were heated in dimethylsulfoxide (1 ml) at 80°C, in the same manner as Example 224, to obtain the title compound (38 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.97 (3H, s), 5.19 (2H, s), 6.53 (1H, d, J=5.2Hz), 7.09-7.13 (1H, m), 7.14 (1H, d, J=3.6Hz), 7.29-7.41 (5H, m), 7.42-7.46 (3H, m), 8.20 (1H, t, J=9.2Hz), 8.53 (1H, d, J=5.2Hz), 8.65 (1H, s), 9.00 (1H, br s), 9.04 (1H, br), 10.83(1H, brs).

Example 271

1-[4-(6-Amino-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]-3-(thiazol-2-yl)urea

[0753] After adding [4-[3-fluoro-4-(3-(thiazol-2-yl)ureido)phenoxy]-7-methoxyquinolin-6-yl]carbamic acid benzyl ester (100 mg) to a mixture of trifluoroacetic acid (3 ml) and thioanisole (0.1 ml), the mixture was heated and stirred at 60°C for 2 hours. The solvent was distilled off and the residue was subjected to NH silica gel column chromatography for elution with a solvent (ethyl acetate:methanol = 10:1) to obtain the title compound (23 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.94 (3H, s), 5.47 (2H, br s), 6.48 (1H, d, J=5.2Hz), 6.99-7.03 (1H, m), 7.13 (1H, d, J=3.6Hz), 7.17 (1H, s), 7.23-7.31 (2H, m), 7.38 (1H, d, J=3.6Hz), 8.13 (1H, t, J=8.8Hz), 8.29 (1H, d, J=5.2Hz), 8.97 (1H, br), 10.80 (1H, br).

Example 272N-{4-[3-Fluoro-4-(3-(thiazol-2-yl)ureido)phenoxy]-7-methoxyquinolin-6-yl}acetamide

[0754] The title compound (4 mg) was obtained as a solid from 1-[4-(6-amino-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]-3-(thiazol-2-yl)urea (15 mg), in the same manner as Example 265.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.15 (3H, s), 4.02 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.07-7.12 (1H, m), 7.12 (1H, d, J=3.6Hz), 7.34-7.41 (2H, m), 7.45 (1H, s), 8.19 (1H, t, J=9.2Hz), 8.53 (1H, d, J=5.2Hz), 8.95-8.98 (1H, m), 9.07 (1H, br), 9.45 (1H, br s).

Example 273N-{4-[3-Fluoro-4-(3-(thiazol-2-yl)ureido)phenoxy]-7-methoxyquinolin-6-yl}methanesulfoneamide

[0755] The title compound (5 mg) was obtained as a solid from 1-[4-(6-amino-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]-3-(thiazol-2-yl)urea (50 mg), in the same manner as Example 266.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.06(3H, s), 4.00 (3H, s), 6.55 (1H, d, J=5.2Hz), 7.09-7.16 (2H, m), 7.25-7.35 (1H, m), 7.39 (1H, d, J=3.2Hz), 7.49 (1H, s), 8.10 (1H, s), 8.21 (1H, t, J=9.2Hz), 8.57 (1H, d, J=5.2Hz), 9.02 (1H, br s), 9.32 (1H, br s), 10.78 (1H, br s).

Example 274[4-[4-(Cyclopropylureido)-3-fluorophenoxy]-7-methoxyquinolin-6-yl]carbamic acid benzyl ester

[0756] [4-(4-Amino-3-fluorophenoxy)-7-methoxyquinolin-6-yl]carbamic acid benzyl ester (100 mg) and cyclopropylcarbamic acid phenyl ester (64 mg) were heated and stirred in dimethylsulfoxide (0.7 ml) at 85°C for 5 hours and 40 minutes, in the same manner as Example 224, to obtain the title compound (11 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.60-0.65 (2H, m), 2.50-2.56 (1H, m), 3.95 (3H, s), 5.16 (2H, s), 6.46 (1H, d, J=5.2Hz), 6.77-6.80 (1H, m), 6.99-7.03 (1H, m), 7.23-7.45 (7H, m), 8.16 (1H, t, J=9.2Hz), 8.19 (1H, s), 8.49 (1H, d, J=5.2Hz), 8.63 (1H, s), 8.97 (1H, s).

Example 275N-{4-[4-(Cyclopropylureido)3-fluorophenoxy]-7-methoxyquinolin-6-yl}acetamide

[0757] {4-[4-(cyclopropylureido)-3-fluorophenoxy]-7-methoxyquinolin-6-yl}carbamic acid benzyl ester (11 mg) was heated and stirred in a mixture of trifluoroacetic acid (3 ml) and thioanisole (0.5 ml) at 60°C, in the same manner as Example 264, for debenzilation. The resulting amino compound was acetylated in the same manner as Example 265 to obtain the title compound (2 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.36-0.40 (2H, m), 0.58-0.63 (2H, m), 2.14 (3H, s), 2.46-2.55 (1H, m), 3.99 (3H, s), 6.44 (1H, d, J=5.2Hz), 6.77 (1H, d, J=2.8Hz), 6.97-7.01 (1H, m), 7.23 (1H, dd, J=2.8Hz, J=11.6Hz), 7.41 (1H, s), 8.15 (1H, t, J=8.8Hz), 8.17 (1H, br s), 8.48 (1H, d, J=5.2Hz), 8.93 (1H, s), 9.42 (1H, s).

Example 2764-[4-(Cyclopropylureido)-2-methylphenoxy]-7-methoxyquinoline-6-carboxylic acid amide

[0758] The title compound (61 mg) was obtained as a solid from [4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-3-methylphenyl]carbamic acid phenyl ester (100 mg) and cyclopropylamine, in the same manner as Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.59-0.65 (2H, m), 2.04 (3H, s), 2.49-2.55 (1H, m), 4.01 (3H, s), 6.26 (1H, d, J=5.2Hz), 6.41-6.47 (1H, m), 7.05 (1H, d, J=8.8Hz), 7.35 (1H, dd, J=2.4Hz, J=8.8Hz), 7.42 (1H, d, J=2.4Hz), 7.48 (1H, s), 7.71 (1H, br s), 7.84 (1H, br s), 8.27-8.42 (1H, m), 8.59 (1H, d, J=5.2Hz), 8.69 (1H, s).

[0759] The intermediates were synthesized in the following manner.

Production Example 276-14-(4-Amino-2-methylphenoxy)-7-methoxyquinoline-6-carboxylic acid amide

[0760] The title compound (430 mg) was obtained as a solid from 4-chloro-7-methoxyquinoline-6-carboxylic acid amide (1 g) and 4-amino-2-methylphenol, in the same manner as Production Example 458-1.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.93 (3H, s), 4.01 (3H, s), 5.06-5.09 (2H, m), 6.27 (1H, d, J=5.2Hz), 6.49 (1H, dd, J=2.8Hz, J=8.4Hz), 6.54 (1H, d, J=2.8Hz), 6.84 (1H, d, J=8.4Hz), 7.47 (1H, s), 7.71 (1H, br s), 7.83 (1H, br's), 8.59 (1H, d, J=5.2Hz), 8.69 (1H, s).

Production Example 276-2[4-(6-Carbamoyl-7-methoxyquinolin-4-yloxy)-3-methylphenyl]carbamic acid phenyl ester

[0761] The title compound (112 mg) was obtained as a solid from 4-(4-amino-2-methylphenoxy)-7-methoxyquinoline-6-carboxylic acid amide (330 mg) and phenyl chlorocarbonate, in the same manner as Production Example 17.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.08 (3H, s), 4.02 (3H, s), 6.30 (1H, d, J=5.2Hz), 7.19-7.55 (9H, m), 7.73 (1H, br s), 7.85 (1H, br s), 8.62 (1H, d, J=5.2Hz), 8.71 (1H, s), 10.33 (1H, br s).

Example 2771-(3-Fluorophenyl)-3-[4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0762] The title compound (118 mg) was obtained as a solid from 4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine (90 mg) and 3-fluorophenyl isocyanate, in the same manner as Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 6.74-6.80 (1H, m), 7.11-7.15 (1H, m), 7.20 (2H, d, J=8.8Hz), 7.23 (1H, s), 7.29 (1H, t, J=7.6Hz), 7.34-7.38 (1H, m), 7.46-7.51 (1H, d, m), 7.52 (2H, d, J=8.8Hz), 7.87-7.92 (1H, m), 8.08 (1H, d, J=8.0Hz), 8.31 (1H, s), 8.63-8.66 (1H, m), 8.82 (1H, br s), 8.93 (1H, br s), 12.78 (1H, br s).

[0763] The intermediates were synthesized in the following manner.

Production Example 277-14-(4-Nitrophenoxy)-6-(pyridin-2-yl)-7-H-pyrrolo[2,3-d]pyrimidine

[0764] The title compound (1.0 g) was obtained as a solid from 4-chloro-6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (0.8 g) and nitrophenol (1.45 g), by the same procedure as in Production Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 7.33 (1H, s), 7.37 (1H, dd, J=4.8Hz, J=7.2Hz), 7.59 (2H, d, J=9.2Hz), 7.88-7.94 (1H, m), 8.12 (1H, d, J=7.2Hz), 8.33 (2H, d, J=9.2Hz), 8.38 (1H, s), 8.66 (1H, d, J=4.8Hz), 12.92 (1H, br s).

Production Example 277-24-(6-(Pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine

[0765] The title compound (0.4 g) was obtained as a solid from 4-(4-nitrophenoxy)-6-(pyridin-2-yl)-7-H-pyrrolo[2,3-d]pyrimidine (1.0 g), in the same manner as Production Example 8.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 5.06 (2H, br s), 6.60 (2H, d, J=8.8Hz), 6.90 (2H, d, J=8.8Hz), 7.07 (1H, s), 7.32-7.36 (1H, m), 7.86-7.91 (1H, m), 8.03 (1H, d, J= 8.0Hz), 8.29 (1H, s), 8.64 (1H, d, J=4Hz), 12.71 (1H, br s).

Example 2781-(4-Fluorophenyl)-3-[4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0766] The title compound (120 mg) was obtained as a solid from 4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine (100 mg) and 4-fluorophenyl isocyanate, in the same manner as Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 7.11 (2H, t, J=8.8Hz), 7.19 (2H, d, J=8.8Hz), 7.22 (1H, s), 7.35 (1H, dd, J=7.2Hz, J=7.6Hz), 7.43-7.48 (2H, m), 7.51 (2H, d, J=8.8Hz), 7.87-7.92 (1H, m), 8.08 (1H, d, J=8.0Hz), 8.32 (1H, s), 8.64-8.66 (1H, m), 8.73 (1H, br s), 8.75 (1H, br s), 12.78 (1H, br s).

Example 2791-[4-(6-(Pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-phenyl]-3-(thiazol-2-yl)urea

[0767] 4-(6-(Pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine (100 mg) and (thiazol-2-yl)carbamic acid phenyl ester (116 mg) were heated and stirred in dimethylsulfoxide (2.5 ml) at 80°C for 1 hour, in the same manner as Example 224, to obtain the title compound (110 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 7.10 (1H, d, J=3.6Hz), 7.23 (2H, d, J=8.8Hz), 7.24 (1H, s), 7.34-7.40 (2H, m), 7.55 (2H, d, J=8.8Hz), 7.87-7.93 (1H, m), 8.09 (1H, d, J=8.0Hz), 8.32 (1H, s), 8.63-8.67 (1H, m), 9.06 (1H, br s), 12.79 (1H, br s).

Example 2801-(4-Fluorophenyl)-3-[2-fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-phenyl]-urea

[0768] The title compound (110 mg) was obtained as a solid from 2-fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine (100 mg) and 4-fluorophenyl isocyanate, by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 7.07-7.16 (3H, m), 7.28 (1H, s), 7.33-7.38 (2H, m), 7.42-7.48 (2H, m), 7.87-7.93 (1H, m), 8.08-8.14 (2H, m), 8.33 (1H, s), 8.53-8.56 (1H, m), 8.64-8.66 (1H, m), 9.08 (1H, br s), 12.83 (1H, br s).

[0769] The intermediates were synthesized in the following manner.

Production Example 280-14-(3-Fluoro-4-nitrophenoxy)-6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine

[0770] The title compound (0.75 g) was obtained as a solid from the 4-chloro-6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (0.7 g) described in WO9702266 and PCT/EP96/02728 and fluoronitrophenol (0.95 g), in the same manner as Production Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 7.34-7.45 (3H, m), 7.74 (1H, dd, J=2.4Hz, J=12.4Hz), 7.89-7.94 (1H, m), 8.12 (1H, d, J=8.0Hz), 8.28 (1H, t, J=8.8Hz), 8.41 (1H, s), 8.65-8.68 (1H, m), 12.96 (1H, br s).

Production Example 280-22-Fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine

[0771] The title compound (450 mg) was obtained as a solid from 4-(3-fluoro-4-nitrophenoxy)-6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (750 mg), by the same procedure as in Production Example 8.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 5.10 (2H, br s), 6.79-6.83 (2H, m), 7.01-7.05 (1H, m), 7.16 (1H, s), 7.32-7.38 (1H, m), 7.86-7.92 (1H, m), 8.06 (1H, d, J=7.6Hz), 8.31 (1H, s), 8.64 (1H, d, J=4.4Hz), 12.75 (1H, br s).

Example 2811-(3-Fluorophenyl)-3-[2-fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0772] The title compound (30 mg) was obtained as a solid from 2-fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine (100 mg) and 3-fluorophenyl isocyanate, in the same manner as Example 10.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 6.76-6.83 (1H, m), 7.11 (2H, d, J=8.8Hz), 7.27-7.39 (4H, m), 7.48-7.53 (1H, m), 7.87-7.94 (1H, m), 8.11 (2H, d, J=8.8Hz), 8.34 (1H, s), 8.61-8.65 (1H, m), 8.66 (1H, br d, J=4.0Hz), 9.27 (1H, br s), 12.83 (1H, br s).

Example 2821-[2-Fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]-3-(thiazol-2-yl)urea

[0773] The title compound (100 mg) was obtained as a solid from 2-fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine (100 mg) and (thiazol-2-yl)carbamic acid phenyl ester (109 mg), by the same procedure as in Example 224.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 7.07-7.17 (2H, m), 7.29 (1H, s), 7.35-7.44 (3H, m), 7.87-7.95 (1H, m), 8.08-8.15

(2H, m), 8.34 (1H, s), 8.66 (1H, br d, J=4.0Hz), 8.99 (1H, br), 10.81(1H, brs), 12.83(1H, brs).

Example 283

1-Cyclopropyl-3-[2-fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea

[0774] The title compound (15 mg) was obtained as a solid from 2-fluoro-4-(6-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenylamine (75 mg) and cyclopropylcarbamic acid phenyl ester (66 mg), in the same manner as Example 224.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.42 (2H, m), 0.60-0.66 (2H, m), 2.49-2.57 (1H, m), 6.76 (1H, d, J=2.4Hz), 7.01-7.05 (1H, m), 7.24-7.29 (2H, m), 7.33-7.37 (1H, m), 7.86-7.92 (1H, m), 8.05-8.12 (2H, m), 8.13-8.16 (1H, m), 8.32 (1H, s), 8.62-8.66 (1H, m), 12.79 (1H, br s).

Example 284

7-((2R)-2-Hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile

[0775] The title compound (0.56 g) was obtained as a solid from 4-(1H-indol-5-yloxy)-(2R)-7-oxiranylmethoxyquinoline-6-carbonitrile (0.73 g), in the same manner as Example 454.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 2.61-2.72 (4H, m), 2.44-2.58 (6H, m), 2.68-2.73 (1H, m), 3.99-4.06 (1H, m), 4.20 (1H, dd, J=6.0Hz, J=10.4Hz), 4.29 (1H, dd, J=3.6Hz, J=10.4Hz), 5.02 (1H, br s), 6.42 (1H, d, J=5.2Hz), 6.44-6.48 (1H, m), 6.99 (1H, dd, J=1.6Hz, J=8.4Hz), 7.43-7.47 (2H, m), 7.51 (1H, d, J=8.4Hz), 7.59 (1H, s), 8.65 (1H, d, J=5.2Hz), 8.77 (1H, s).

[0776] The intermediates were synthesized in the following manner.

Production Example 284-1

4-(1H-Indol-5-yloxy)-(2R)-7-oxiranylmethoxyquinoline-6-carbonitrile

[0777] The title compound (0.73 g) was obtained as a solid from 4-(1H-indol-5-yloxy)-7-hydroxyquinoline-6-carbonitrile (1 g) using (2R)-oxiran-2-ylmethyl-4-methyl-1-benzene sulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.82 (1H, dd, J=2.4Hz, J=4.8Hz), 2.91 (1H, t, J=4.8Hz), 3.44-3.49 (1H, m), 4.17 (1H, dd, J=6.4Hz, J=11.6Hz), 4.71 (1H, dd, J=2.4Hz, J=11.6Hz), 6.44 (1H, d, J=5.2Hz), 6.46-6.48 (1H, m), 6.99 (1H, dd, J=2.4Hz, J=8.8Hz), 7.44-7.46 (2H, m), 7.52 (1H, d, J=8.8Hz), 7.62 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.82 (1H, s), 11.31 (1H, br s).

Example 285

5-[6-Cyano-7-((2R)-2-hydroxy-3-(pyrrolidin-1-yl)propoxy)quinolin-4-yloxy]indole-1-carboxylic acid cyclopropylamide

[0778] 7-((2R)-2-Hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile (0.56 g) was silyletherified using triethylsilyl chloride and imidazole to obtain 0.48 g of the target substance. Following the same procedure as in Example 310, an amide compound was obtained from the triethylsilyl ether compound (0.2 g), and this was deprotected at 50°C in a mixture of acetic acid, tetrahydrofuran and water to obtain the title compound (35 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 0.58-0.63 (2H, m), 0.71-0.76 (2H, m), 1.84-1.94 (2H, m), 1.98-2.06 (2H, m), 2.73-2.79 (1H, m), 3.07-3.16 (2H, m), 3.33-3.38 (2H, m), 3.57-3.64 (2H, m), 4.28-4.36 (3H, m), 6.55 (1H, d, J=5.6Hz), 6.70 (1H, d, J=3.6Hz), 7.19 (1H, dd, J=2.4Hz, J=8.8Hz), 7.53 (1H, d, J=2.4Hz), 7.66 (1H, s), 7.88 (1H, d, J=3.6Hz), 8.32 (1H, d, J=2.8Hz), 8.35 (1H, d, J=8.8Hz), 8.74 (1H, d, J=5.6Hz), 8.87 (1H, s).

Example 286

5-[6-Cyano-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yloxy]indole-1-carboxylic acid cyclopropylamide

[0779] The title compound (35 mg) was obtained as a solid from 4-(1H-indol-5-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinoline-6-carbonitrile (150 mg), in the same manner as Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.59-0.64 (2H, m), 0.71-0.76 (2H, m), 1.64-1.72 (4H, m), 1.95-2.03 (2H, m), 2.38-2.48 (4H, m), 2.59 (2H, d, J=6.8Hz), 2.74-2.81 (1H, m), 4.33 (2H, d, J=6.4Hz), 6.47 (1H, d, J=5.2Hz), 6.68 (1H,

d, J=3.6Hz), 7.19 (1H, dd, J=2.4Hz, 8.8Hz), 7.52 (1H, d, J=2.4Hz), 7.58 (1H, s), 7.90 (1H, d, J=3.6Hz), 8.23 (1H, d, J=2.8Hz), 8.35 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.2Hz), 8.79 (1H, s).

Example 287

5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-yloxy]indole-1-carboxylic acid cyclopropylamide

[0780] The title compound (210 mg) was obtained as a solid from 4-(1H-indol-5-yloxy)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (450 mg), in the same manner as Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.59-0.65 (2H, m), 0.71-0.77 (2H, m), 2.74-2.82 (1H, m), 3.76-3.80 (2H, m), 0.59-0.65 (2H, m), 4.39-4.43 (2H, m), 6.47 (1H, d, J=5.2Hz), 6.68 (1H, d, J=3.6Hz), 7.19 (1H, dd, J=2.4Hz, J=8.8Hz), 7.52 (1H, d, J=2.4Hz), 7.62 (1H, s), 7.90 (1H, d, J=3.6Hz), 8.30 (1H, d, J=2.8Hz), 8.35 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.2Hz), 8.79 (1H, s).

[0781] The intermediates were synthesized in the following manner.

Production Example 287-1

4-(1H-Indol-5-yloxy)-7-(2-methoxyethoxy)quinoline-6-carbonitrile

[0782] The title compound (0.8 g) was obtained as a solid from 4-chloro-7-methoxyethoxy-6-cyanoquinoline (1.0 g) and 5-hydroxyindole, in the same manner as Example 309.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.37(3H, s), 3.76-3.79 (2H, m), 4.39-4.43 (2H, m), 6.43 (1H, d, J=5.6Hz), 6.45-6.49 (1H, m), 6.99 (1H, dd, J=2.4Hz, J=8.8Hz), 7.43-7.47 (2H, m), 7.52 (1H, d, J=8.8Hz), 7.61 (1H, s), 8.66 (1H, d, J=5.6Hz), 8.79 (1H, s), 11.31 (1H, br s).

Example 288

4-(1H-Indol-5-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinoline-6-carbonitrile

[0783] The title compound (1.27 g) was obtained as a solid from 4-(1H-indol-5-yloxy)-7-hydroxyquinoline-6-carbonitrile (1.98 g) and 1-(3-chloropropyl)pyrrolidine hydrochloride, in the same manner as Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.64-1.72 (4H, m), 1.95-2.03 (2H, m), 2.42-2.48 (4H, m), 2.59 (2H, t, J=7.2Hz), 4.32 (2H, t, J=6.4Hz), 6.43 (1H, d, J=5.2Hz), 6.46-6.48 (1H, m), 6.99 (1H, dd, J=2.4Hz, J=8.8Hz), 7.43-7.47 (2H, m), 7.51 (1H, d, J=8.8Hz), 7.57 (1H, s), 8.66 (1H, d, J=5.2Hz), 8.78 (1H, s), 11.30 (1H, br s).

Example 289

5-[6-Cyano-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yloxy]indole-1-carboxylic acid (thiazol-2-yl)amide

[0784] The title compound (155 mg) was obtained as a solid from 4-(1H-indol-5-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinoline-6-carbonitrile (200 mg), in the same manner as Example 312.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.66-1.76 (4H, m), 1.98-2.07 (2H, m), 2.52-2.61 (4H, m), 2.70 (2H, t, J=7.2 Hz), 4.34 (2H, t, J=6.4Hz), 6.51 (1H, d, J=5.2Hz), 6.63 (1H, d, J=3.6Hz), 6.95 (1H, d, J=4.4Hz), 7.16 (1H, dd, J=2.4Hz, J=8.8Hz), 7.38 (1H, d, J=4.4Hz), 7.50 (1H, d, J=2.4Hz), 7.59 (1H, s), 8.09 (1H, d, J=3.6Hz), 8.68 (1H, d, J=5.2Hz), 8.72 (1H, d, J=8.8Hz), 8.81 (1H, s).

Example 290

5-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-yloxy]indole-1-carboxylic acid (thiazol-2-yl)amide

[0785] The title compound (31 mg) was obtained as a solid from 4-(1H-indol-5-yloxy)-7-(2-methoxyethoxy)quinoline-6-carbonitrile (100 mg), in the same manner as Example 312.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.37 (3H, s), 3.77-3.80 (2H, m), 4.41 (2H, m), 6.51 (1H, d, J=5.2Hz), 6.59-6.64 (1H, m), 6.88-6.95 (1H, m), 7.12-7.18 (1H, m), 7.32-7.39 (1H, m), 7.48-7.51 (1H, m), 7.62 (1H, s), 8.06-8.13 (1H, m), 8.69 (1H, d, J=5.2Hz), 8.69-8.77 (1H, m), 8.81 (1H, s).

Example 2915-(7-Benzyloxy-6-cyanoquinolin-4-yloxy)indole-1-carboxylic acid (2-fluoroethyl)-amide

[0786] The title compound (3.6 g) was obtained as a solid from 5-(7-benzyloxy-6-cyanoquinolin-4-yloxy)indole (4.5 g) and (2-fluoroethyl)carbamic acid phenyl ester, in the same manner as Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 3.54-3.61 (1H, m), 3.61-3.66 (1H, m), 4.53 (1H, t, J=4.8Hz), 4.65 (1H, t, J=4.8Hz), 5.45(2H, s), 6.48 (1H, d, J=5.2Hz), 6.73 (1H, d, J=3.6Hz), 7.20 (1H, dd, J=2.4Hz, J=8.8Hz), 7.34-7.39 (1H, m), 7.42-7.47 (2H, m), 7.53-7.57 (3H, m), 7.70 (1H, s), 7.98 (1H, d, J=3.6Hz), 8.36 (1H, d, J=8.8Hz), 8.50 (1H, t, J=5.2Hz), 8.68 (1H, d, J=5.2Hz), 8.82 (1H, s).

Example 2925-(6-Cyano-7-hydroxyquinolin-4-yloxy)indole-1-carboxylic acid (2-fluoroethyl)amide

[0787] The title compound (2.17 g) was obtained as a solid from 5-(7-benzyloxy-6-cyanoquinolin-4-yloxy)indole-1-carboxylic acid (2-fluoroethyl)amide (3 g) using trifluoroacetic acid, by the same procedure as in Production Example 21.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.54-3.59 (1H, m), 3.61-3.65 (1H, m), 4.53 (1H, t, J=5.2Hz), 4.65 (1H, t, J=5.2Hz), 6.39 (1H, d, J=5.2Hz), 6.73 (1H, d, J=3.6Hz), 7.19 (1H, dd, J=2.4Hz, J=8.8Hz), 7.41 (1H, s), 7.53 (1H, d, J=2.4Hz), 7.98 (1H, d, J=3.6Hz), 8.35 (1H, d, J=8.8Hz), 8.50 (1H, t, J=5.2Hz), 8.61 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 2935-[6-Cyano-7-(piperidin-4-yl)methoxy]quinolin-4-yloxy]indole-1-carboxylic acid (2-fluoroethyl)amide

[0788] In the same manner as Example 301, a tert-butoxycarbonyl compound (150 mg) was obtained from 5-(6-cyano-7-hydroxyquinolin-4-yloxy)indole-1-carboxylic acid (2-fluoroethyl)amide(1 g) and 4-bromoethylpiperidine-1-carboxylic acid tert-butyl ester, and then the tert-butoxycarbonyl group was deprotected with trifluoroacetic acid to obtain the title compound (97 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 1.48-1.61 (2H, m), 1.95-2.02 (2H, m), 2.16-2.26 (1H, m), 2.92-3.01 (2H, m), 3.28-3.38 (2H, m), 3.54-3.59 (1H, m), 3.61-3.66 (1H, m), 4.02-4.07 (1H, m), 4.22 (2H, d, J=6.4Hz), 4.53 (1H, t, J=5.2Hz), 4.65 (1H, t, J=5.2Hz), 6.49 (1H, d, J=5.2Hz), 6.74 (1H, d, J=4.0Hz), 7.19 (1H, dd, J=2.4Hz, J=8.8Hz), 7.54 (1H, d, J=2.4Hz), 7.64 (1H, s), 7.99 (1H, d, J=4.0Hz), 8.36 (1H, d, J=8.8Hz), 8.51(1H, t, J=5.6Hz), 8.82 (1H, s).

Example 2945-[6-Cyano-7-(1-(methylpiperidin-4-yl)methoxy)quinolin-4-yloxy]indole-1-carboxylic acid (2-fluoroethyl)amide

[0789] The title compound (35 mg) was obtained as a solid from 5-[6-cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy]indole-1-carboxylic acid (2-fluoroethyl)amide (97 mg), in the same manner as Example 302.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 1.52-1.61 (2H, m), 1.89-2.07 (5H, m), 2.31 (3H, s), 2.92-2.98 (2H, m), 3.69-3.74 (1H, m), 3.76-3.81 (1H, m), 4.30 (2H, d, J=6.0Hz), 4.68 (1H, t, J=5.2Hz), 4.80 (1H, t, J=5.2Hz), 6.63 (1H, d, J=5.2Hz), 6.88 (1H, d, J=4.0Hz), 7.35 (1H, dd, J=2.4Hz, J=8.8Hz), 7.69 (1H, d, J=2.4Hz), 7.73 (1H, s), 8.13 (1H, d, J=4.0Hz), 8.51 (1H, d, J=8.8Hz), 8.65 (1H, t, J=5.2Hz), 8.83 (1H, d, J=5.2Hz), 8.94 (1H, s).

Example 2955-[6-Cyano-7-(2-methoxyethoxy)quinolin-4-yloxy]indole-1-carboxylic acid ethylamide

[0790] The title compound (77 mg) was obtained as a solid from 7-(methoxyethoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile (100 mg), in the same manner as Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 1.18 (3H, t, J=7.2Hz), 3.28-3.33 (2H, m), 3.37(1H, s), 3.76-3.80 (2H, m), 4.40-4.44 (2H, m), 6.48 (1H, d, J=5.2Hz), 6.71 (1H, d, J=3.6Hz), 7.19 (1H, dd, J=2.4Hz, J=8.8Hz), 7.53 (1H, d, J=2.4Hz), 7.62 (1H, s), 7.93 (1H, d, J=3.6Hz), 8.24 (1H, d, J=5.2Hz), 8.35 (1H, d, J=8.8Hz), 8.69 (1H, d, J=5.2Hz), 8.80 (1H, s).

Example 2967-(3-Diethylaminopropoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile

[0791] The title compound (0.46 g) was obtained as a solid from 4-(1H-indol-5-yloxy)-7-hydroxyquinoline-6-carbonitrile (0.8 g) and 3-diethylaminopropyl chloride, in the same manner as Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.95 (6H, t, J=7.2Hz), 1.88-1.94 (2H, m), 2.43-2.49 (4H, m), 2.59 (2H, t, J=6.8Hz), 4.30 (2H, t, J=6.0Hz), 6.42 (1H, d, J=5.2Hz), 6.45-6.48 (1H, m), 6.98 (1H, dd, J=2.4Hz, J=8.8Hz), 7.43-7.47 (2H, m), 7.51 (1H, d, J=8.8Hz), 7.55 (1H, s), 8.65 (1H, d, J=5.2Hz), 8.77 (1H, s), 11.30 (1H, br s).

Example 2975-[6-Cyano-7-(3-diethylaminopropoxy)quinolin-4-yloxy]indole-1-carboxylic acid ethylamide

[0792] The title compound (35 mg) was obtained as a solid from 7-(3-diethylaminopropoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile (230 mg), in the same manner as Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.95 (6H, t, J=7.2Hz), 1.18 (3H, t, J=7.2Hz), 1.89-1.94 (2H, m), 2.43-2.49 (4H, m), 2.59 (2H, t, J=7.2Hz), 3.29-3.37 (2H, m), 4.31 (2H, t, J=6.0Hz), 6.47 (1H, d, J=5.2Hz), 6.70 (1H, d, J=3.6Hz), 7.18 (1H, dd, J=2.4Hz, J=8.8Hz), 7.52 (1H, d, J=2.4Hz), 7.57 (1H, s), 7.93 (1H, d, J=3.6Hz), 8.24 (1H, t, J=5.2Hz), 8.35 (1H, d, J=8.8Hz), 8.67 (1H, d, J=5.2Hz), 8.78 (1H, s).

Example 2985-[6-Cyano-7-(3-diethylaminopropoxy)quinolin-4-yloxy]indole-1-carboxylic acid cyclopropylamide

[0793] The title compound (0.21 g) was obtained as a solid from 7-(3-diethylaminopropoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile (0.5 g), in the same manner as Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.59-0.64 (2H, m), 0.71-0.76 (2H, m), 0.95 (6H, t, J=7.2Hz), 1.87-1.95 (2H, m), 2.43-2.49 (4H, m), 2.59 (2H, t, J=6.8Hz), 2.74-2.81 (1H, m), 4.31 (2H, t, J=6.0Hz), 6.46 (1H, d, J=5.2Hz), 6.68 (1H, d, J=3.6Hz), 7.19 (1H, dd, J=2.4Hz, J=8.8Hz), 7.52 (1H, d, J=2.4Hz), 7.56 (1H, s), 7.90 (1H, d, J=3.6Hz), 8.30 (1H, d, J=3.2Hz), 8.35 (1H, d, J=8.8Hz), 8.67 (1H, d, J=5.2Hz), 8.78 (1H, s).

Example 2995-[6-Cyano-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yloxy]indole-1-carboxylic acid ethylamide

[0794] The title compound (31 mg) was obtained as a solid from 7-(3-(pyrrolidin-1-yl)propoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile (100 mg), in the same manner as Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.18 (3H, t, J=7.2Hz), 1.85-1.99 (4H, m), 2.40-2.49 (2H, m), 3.01-3.48 (8H, m), 4.39 (2H, t, J=6.0Hz), 6.50 (1H, d, J=5.2Hz), 6.71 (1H, d, J=3.6Hz), 7.18 (1H, dd, J=2.4Hz, J=8.8Hz), 7.53 (1H, d, J=2.4Hz), 7.62 (1H, s), 7.96 (1H, d, J=3.6Hz), 8.28 (1H, t, J=5.2Hz), 8.36 (1H, d, J=8.8Hz), 8.70 (1H, d, J=5.2Hz), 8.82 (1H, s).

Example 3005-[6-Cyano-7-(3-diethylaminopropoxy)quinolin-4-yloxy]indole-1-carboxylic acid (thiazol-2-yl)amide

[0795] The title compound (5 mg) was obtained as a solid from 7-(3-diethylaminopropoxy)-4-(1H-indol-5-yloxy)quinoline-6-carbonitrile (80 mg), in the same manner as Example 312.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.00 (6H, t, J=7.2Hz), 1.93-2.01 (2H, m), 2.59 (4H, q, J=7.2Hz), 2.72 (2H, t, J=6.8Hz), 4.33 (2H, t, J=6.0Hz), 6.51 (1H, d, J=5.2Hz), 6.64 (1H, d, J=3.6Hz), 6.98 (1H, d, J=4.0Hz), 7.16 (1H, dd, J=2.4Hz, J=8.8Hz), 7.40 (1H, d, J=4.0Hz), 7.50 (1H, d, J=2.4Hz), 7.58 (1H, s), 8.09 (1H, d, J=3.6Hz), 8.68 (1H, d, J=5.2Hz), 8.70 (1H, d, J=8.8Hz), 8.81 (1H, s).

Example 301

6-Cyano-4-(1H-indol-5-yloxy)-7-(piperidin-4-yl)methoxyquinoline

[0796] 6-Cyano-4-(1H-indol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methoxy]quinoline (0.25 g, 0.5015 mmol) was dissolved in ethanol (2 ml) and tetrahydrofuran (2 ml), and then concentrated hydrochloric acid (0.2 ml) was added at room temperature and the mixture was stirred for 17 hours. The solvent was distilled off under reduced pressure, saturated sodium bicarbonate water was added, and then extraction was performed with a tetrahydrofuran and ethyl acetate mixed solvent, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto NH silica gel and purified by column chromatography (ethyl acetate-methanol system) with NH silica gel, and the obtained crystals were suspended in ethanol and diluted with diethyl ether and hexane. The crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (15 mg, 0.0376 mmol, 7.51%).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.23-1.29 (2H, m), 1.74-1.77 (2H, m), 1.95 (1H, brs), 2.48-2.55 (2H, m), 2.97-3.00 (2H, m), 4.12 (2H, d, J = 5.6 Hz), 6.43 (1H, d, J = 5.2 Hz), 6.47 (1H, s), 6.88 (1H, dd, J = 2.4, 9.2 Hz), 7.45 (1H, d, J = 2.4 Hz), 7.46 (1H, s), 7.52 (1H, d, J = 9.2 Hz), 7.57 (1H, s), 8.66 (1H, d, J = 5.2 Hz), 8.79 (1H, s), 11.31 (1H, s).

[0797] The starting materials were synthesized in the following manner.

Production Example 301-17-Benzoyloxy-6-cyano-4-(1H-indol-5-yloxy)quinoline

[0798] After suspending 7-benzoyloxy-6-cyano-4-chloroquinoline (23 g, 78.03 mmol) in N-methylpyrrolidone (15.8 ml), there were added 5-hydroxyindole (12.5 g, 83.64 mmol) and diisopropylethylamine (15.8 ml) and the mixture was heated and stirred at 150°C for 10 hours. After allowing it to cool to room temperature, water and tetrahydrofuran were added and the crystals were thoroughly dissolved. After extraction with tetrahydrofuran, washing with saturated brine, drying over anhydrous magnesium sulfate and distilling off of the solvent, the residue was adsorbed onto silica gel. Purification was performed by silica gel column chromatography (hexane/tetrahydrofuran system), and then concentrated hydrochloric acid (0.2 ml) was added at room temperature and the mixture was stirred for 17 hours. The solvent was distilled off under reduced pressure, saturated sodium bicarbonate water was added, and then extraction was performed with a tetrahydrofuran and ethyl acetate mixed solvent, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained crystals were suspended in ethyl acetate and diluted with diethyl ether and hexane. The crystals were filtered out, washed with diethyl ether/hexane and dried by aspiration to obtain the title compound (12.5 g, 31.93 mmol, 40.92%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 5.45 (2H, s), 6.44 (1H, d, J = 5.2 Hz), 6.47 (1H, m), 6.99 (1H, dd, J = 2.4, 8.8 Hz), 7.37 (1H, t, J = 7.4 Hz), 7.42-7.46 (4H, m), 7.51-7.56 (3H, m), 7.69 (1H, s), 8.66 (1H, d, J = 5.2 Hz), 8.82 (1H, s), 11.29 (1H, s).

Production Example 301-26-Cyano-4-(1H-indol-5-yloxy)-7-hydroxyquinoline

[0799] After dissolving 7-benzoyloxy-6-cyano-4-(1H-indol-5-yloxy)quinoline (3 g, 76.642 mmol) in tetrahydrofuran (250 ml), 10% palladium carbon powder (500 mg, wet) was added and the mixture was stirred for 11 hours at room temperature under a hydrogen atmosphere. After further adding 10% palladium carbon powder (300 mg, wet) and stirring the mixture for 9 hours at room temperature under a hydrogen atmosphere, additional 10% palladium carbon powder (200 mg, wet) was added and the mixture was stirred for 5 hours at room temperature under a hydrogen atmosphere. The solvent was distilled off, washing was performed with ethanol, and then the filtrate was distilled off under reduced pressure. The obtained crystals were suspended in ethanol and diluted with hexane, and the crystals were filtered out, washed with hexane:ethanol = 3:1 and dried by aspiration to obtain the title compound (1.82 g, 6.0402 mmol, 79.12%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 6.34 (1H, d, J = 5.4 Hz), 6.46 (1H, m), 6.98 (1H, dd, J = 2.4, 8.8 Hz), 7.40-7.46 (3H, m), 7.51 (1H, d, J = 8.8 Hz), 8.58 (1H, d, J = 5.4 Hz), 8.70 (1H, s), 11.29 (1H, s), 11.58 (1H, s).

Production Example 301-3

6-Cyano-4-(1H-indol-5-yloxy)-7-[(1-(tert-butoxycarbonyloxy) piperidin-4-yl)methyloxy]quinoline

[0800] After dissolving 6-cyano-4-(1H-indol-5-yloxy)-7-hydroxyquinoline (1.72 g, 5.7084 mmol) in N,N-dimethylformamide (20 ml), there were added potassium carbonate (0.87 g, 6.2792 mmol) and tert-butyl 4-bromomethylpiperidine-1-carboxylate (1.75 g, 6.2792 mmol), and the mixture was heated and stirred at 70°C for 7 hours. After allowing it to cool to room temperature, water was added, extraction was performed with ethyl acetate and tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure, after which the residue was adsorbed onto silica gel. Purification was performed by silica gel column chromatography (hexane/ethyl acetate system), and then ethyl acetate/ethanol/hexane was added to the obtained yellow oil to precipitate crystals. The crystals were filtered out, washed with hexane:ethanol = 10:1 and dried by aspiration to obtain the title compound (1.786 g, 3.3852 mmol, 59.30%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.20-1.33(2H, m), 1.39(9H, s), 1.78-1.82(2H, m), 2.06(1H, m), 2.78(2H, m), 3.98-4.02(2H, n), 4.17(2H, d, J = 6.4 Hz), 6.43(1H, d, J = 5.2 Hz), 6.49(1H, s), 6.98(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.44-7.46(2H, m), 7.51(1H, d, J = 8.8 Hz), 7.58(1H, s), 8.66(1H, d, J = 5.2 Hz), 8.79(1H, s), 11.30(1H, s).

Example 3026-Cyano-4-(1H-indol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methyloxy]quinoline

[0801] After dissolving 6-cyano-4-(1H-indol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methyloxy]quinoline (30 mg, 0.0753 mmol) in tetrahydrofuran (2.5 ml) and methanol (2.5 ml), there were added acetic acid (0.009 ml) and an aqueous formalin solution (0.047 ml, 0.5648 mmol, 12N). Sodium cyanoborohydride (10 mg) was added at room temperature, and the mixture was stirred at room temperature for 1 hour. Saturated sodium bicarbonate water was added, extraction was performed with ethyl acetate and tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure, after which the residue was adsorbed onto NH silica gel. Purification was then performed by NH silica gel column chromatography (ethyl acetate: methanol = 10:1), and the obtained crystals were suspended in diethyl ether. The crystals were filtered out and dried by aspiration to obtain the title compound (7 mg, 0.0170 mmol, 22.54%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.35-1.44 (2H, m), 1.76-1.91 (5H, m), 2.15 (3H, s), 2.78-2.82 (2H, m), 4.14 (2H, d, J = 6.0 Hz), 6.42 (1H, d, J = 5.2 Hz), 6.47 (1H, s), 6.98 (1H, dd, J = 2.4, 8.8 Hz), 7.44-7.46 (2H, m), 7.51 (1H, d, J = 8.8 Hz), 7.57 (1H, s), 8.66 (1H, d, J = 5.2 Hz), 8.78 (1H, s), 11.31 (1H, s).

Example 3036-Cyano-4-(1-ethylcarbamoylindol-5-yloxy)-7-[(piperidin-4-yl)methyloxy]quinoline

[0802] After dissolving 6-cyano-4-(1-ethylcarbamoylindol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline (180 mg, 0.0753 mmol) in trifluoroacetic acid (1 ml), the solution was stirred at room temperature for 0.5 hour. Saturated sodium bicarbonate water was added, extraction was performed with ethyl acetate and tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure, after which ethanol was added to the obtained amorphous substance for crystallization. After dilution with hexane, the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (132 mg, 0.2811 mmol, 88.96%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.18 (3H, t, J = 7.2 Hz), 1.50-1.59 (2H, m), 1.96-2.01 (2H, m), 2.21 (1H, brs), 2.93-2.99 (2H, m), 3.28-3.37 (4H, m), 4.22 (2H, d, J = 6.0 Hz), 6.49 (1H, d, J = 5.6 Hz), 6.71 (1H, d, J = 3.6 Hz), 7.17 (1H, dd, J = 2.4, 8.8 Hz), 7.53 (1H, d, J = 2.4 Hz), 7.64 (1H, s), 7.95 (1H, d, J = 8.8 Hz), 8.26 (1H, t, J = 5.4 Hz), 8.36 (1H, d, J = 8.8 Hz), 8.42 (1H, brs), 8.69 (1H, d, J = 5.6 Hz), 8.81 (1H, s).

[0803] The starting material was synthesized in the following manner.

Production Example 303-16-Cyano-4-(1-ethylcarbamoylindol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline

[0804] The title compound (180 mg, 0.3160 mmol, 44.74%) was obtained as colorless crystals by reaction in the same manner as Example 310, using 6-cyano-4-(1H-indol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline (350 mg, 0.7062 mmol) and phenyl N-ethylcarbamate (140 mg).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.18 (3H, t, J = 7.0 Hz), 1.18-1.35 (2H, m), 1.40 (9H, s), 1.78-1.82 (2H, m), 2.16 (1H, m), 2.79 (2H, m), 3.32 (2H, q, J = 7.0 Hz), 3.98-4.02 (2H, m), 4.18 (2H, d, J = 6.0 Hz), 6.48 (1H, d, J = 5.2 Hz), 6.70 (1H, d, J = 3.8 Hz), 7.18 (1H, dd, J = 2.4, 9.2 Hz), 7.52 (1H, d, J = 2.4 Hz), 7.59 (1H, s), 7.93 (1H, d, J = 3.8 Hz), 8.22 (1H, brs), 8.35 (1H, d, J = 9.2 Hz), 8.68 (1H, d, J = 5.2 Hz), 8.79 (1H, s).

Example 304

6-Cyano-4-(1-ethylcarbamoylindol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methyloxy]quinoline

[0805] After reaction in the same manner as Example 302 using 6-cyano-4-(1-ethylcarbamoylindol-5-yloxy)-7-[(piperidin-4-yl)methyloxy]quinoline (122 mg, 0.2598 mmol), the product was purified by NH silica gel column chromatography (ethyl acetate-methanol = 10:1). The obtained crystals were suspended in ethanol and diluted with hexane, and the crystals were filtered out and dried by aspiration to obtain the title compound (28 mg, 0.0579 mmol, 22.29%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.20 (3H, t, J = 7.2 Hz), 1.38-1.47 (2H, m), 1.78-1.93 (5H, m), 2.18 (3H, s), 2.80-2.84 (2H, m), 3.33-3.37 (2H, m), 4.17 (2H, d, J = 6.0 Hz), 6.49 (1H, d, J = 5.2 Hz), 6.72 (1H, d, J = 3.6 Hz), 7.20 (1H, dd, J = 2.4, 9.2 Hz), 7.54 (1H, d, J = 2.4 Hz), 7.60 (1H, s), 7.95 (1H, d, J = 3.6 Hz), 8.25 (1H, m), 8.37 (1H, d, J = 9.0 Hz), 8.70 (1H, d, J = 5.2 Hz), 8.80 (1H, s).

Example 305

6-Cyano-4-(1-cyclopropylcarbamoylindol-5-yloxy)-7-[(piperidin-4-yl)methyloxy]quinoline

[0806] The title compound (962 mg, quant.) was obtained using 6-cyano-4-(1-cyclopropylcarbamoylindol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline (965 mg, 1.6590 mmol), in the same manner as Example 301.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 0.60-0.64(2H, m), 0.71-0.74(2H, m), 1.50-1.60(2H, m), 1.96-2.00(2H, m), 2.21 (1H, m), 2.75-2.81(1H, m), 2.90-2.98(2H, m), 3.28-3.36(2H, m), 4.21(2H, d, J = 6.0 Hz), 6.49(1H, d, J = 5.2 Hz), 6.69 (1H, d, J = 3.8 Hz), 7.19(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.52(1H, d, J = 2.4 Hz), 7.64(1H, s), 7.92(1H, d, J = 3.8 Hz), 8.33 (1H, m), 8.36(1H, d, J = 8.8 Hz), 8.51(1H, brs), 8.69(1H, d, J = 5.2 Hz), 8.81(1H, s).

[0807] The starting material was synthesized in the following manner.

Production Example 305-1

6-Cyano-4-(1-cyclopropylcarbamoylindol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline

[0808] The title compound (965 mg, 1.6590 mmol, 82.72%) was obtained as light red crystals by reaction in the same manner as Example 310, using 6-cyano-4-(1H-indol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline (1.0 g, 2.0056 mmol) and phenyl N-cyclopropylcarbamate (426 mg).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.59-0.64(2H, m), 0.71-0.76(2H, m), 1.21-1.33(2H, m), 1.40(9H, s), 1.78-1.82 (2H, m), 2.07(1H, m), 2.40-2.70(3H, m), 3.95-4.15(2H, m), 4.18(2H, d, J = 6.0 Hz), 6.48(1H, d, J = 5.2 Hz), 6.80(1H, d, J = 3.6 Hz), 7.19(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.52(1H, d, J = 2.4 Hz), 7.59(1H, s), 7.90(1H, d, J = 3.6 Hz), 8.29(1H, brs), 8.35(1H, d, J = 8.8 Hz), 8.68(1H, d, J = 5.2 Hz), 8.79(1H, s).

Example 306

6-Cyano-4-(1-cyclopropylcarbamoylindol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methyloxy]quinoline

[0809] The title compound (335 mg, 0.6760 mmol, 37.76%) was obtained as colorless crystals using 6-cyano-4-(1-cyclopropylcarbamoylindol-5-yloxy)-7-[(piperidin-4-yl)methyloxy]quinoline (862 mg, 1.7900 mmol), by the same procedure as in Example 320.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.59-0.64(2H, m), 0.71-0.76(2H, m), 1.35-1.45(2H, m), 1.76-1.91(5H, m), 2.16 (3H, s), 2.74-2.82(3H, m), 4.15(2H, d, J = 6.0 Hz), 6.47(1H, d, J = 5.2 Hz), 6.68(1H, d, J = 3.8 Hz), 7.19(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.52(1H, d, J = 2.4 Hz), 7.58(1H, s), 7.90(1H, d, J = 3.8 Hz), 8.30(1H, d, J = 2.4 Hz), 8.35(1H, d, J = 8.8 Hz), 8.68(1H, d, J = 5.2 Hz), 8.78(1H, s).

Example 307

6-Cyano-7-[(piperidin-4-yl)methyloxy]-4-[1-(2-thiazolylcarbamoyl)indol-5-yloxy]quinoline

[0810] The title compound (114 mg, 0.2136 mmol) was obtained as colorless crystals using 6-cyano-4-[1-(2-thiazolylcarbamoyl)indol-5-yloxy]-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline (220 mg, 0.3522 mmol), in the same manner as Example 301.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.50-1.60 (2H, m), 1.97-2.01 (2H, m), 2.22 (1H, brs), 2.93-2.99 (2H, m), 3.31-3.37 (2H, m), 4.22 (2H, d, J = 5.6 Hz), 6.53 (1H, d, J = 5.2 Hz), 6.70 (1H, d, J = 3.0 Hz), 7.09 (1H, d, J = 4.2 Hz), 7.20 (1H, dd, J = 2.4 Hz, 8.8 Hz), 7.47 (1H, d, J = 4.2 Hz), 7.53 (1H, d, J = 2.4 Hz), 7.65 (1H, s), 8.09 (1H, d, J = 3.0 Hz), 8.10-8.67 (1H, brs), 8.67 (1H, d, J = 8.8 Hz), 8.70 (1H, d, J = 5.2 Hz), 8.83 (1H, s).

[0811] The starting material was synthesized in the following manner.

Production Example 307-16-Cyano-4-[1-(2-thiazolylcarbamoyl)indol-5-yloxy]-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline

[0812] The title compound (220 mg, 0.3522 mmol, 58.53%) was obtained as light yellow crystals by reaction in the same manner as Example 312, using 6-cyano-4-(1H-indol-5-yloxy)-7-[(1-(t-butoxycarbonyloxy)piperidin-4-yl)methyloxy]quinoline (300 mg, 0.6017 mmol), sodium hydride (51 mg, 1.2636 mmol, 60% in oil) and phenyl N-(2-thiazolyl)carbamate (146 mg, 0.6619 mmol).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.21-1.33 (2H, m), 1.39 (9H, s), 1.78-1.82 (2H, m), 2.06 (1H, m), 2.78 (2H, m), 3.98-4.02 (2H, m), 4.17 (2H, d, J = 6.4 Hz), 6.51 (1H, d, J = 5.2 Hz), 6.69 (1H, d, J = 3.4 Hz), 7.08 (1H, d, J = 4.6 Hz), 7.20 (1H, dd, J = 2.4 Hz, 9.2 Hz), 7.47 (1H, d, J = 4.6 Hz), 7.53 (1H, d, J = 2.4 Hz), 7.59 (1H, s), 8.08 (1H, d, J = 3.4 Hz), 8.67 (1H, d, J = 9.2 Hz), 8.69 (1H, d, J = 5.2 Hz), 8.80 (1H, s).

Example 308

6-Cyano-7-[(1-methylpiperidin-4-yl)methyloxy]-4-[1-(2-thiazolylcarbamoyl)indol-5-yloxy]quinoline

[0813] The same reaction was conducted as in Example 302 using 6-cyano-7-[(piperidin-4-yl)methyloxy]-4-[1-(2-thiazolylcarbamoyl)indol-5-yloxy]quinoline (104 mg, 0.1982 mmol), the product was purified by NH silica gel column chromatography (ethyl acetate:methanol = 10:1), the obtained crystals were suspended in ethanol and diluted with hexane, and the crystals were filtered out and dried by aspiration to obtain the title compound (38 mg, 0.0705 mmol, 35.60%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.45-1.48 (2H, m), 1.83-1.95 (3H, m), 2.08-2.15 (2H, m), 2.29 (3H, s), 2.93-2.96 (2H, m), 4.19 (2H, d, J = 5.6 Hz), 6.53 (1H, d, J = 5.2 Hz), 6.67 (1H, d, J = 3.4 Hz), 7.01 (1H, d, J = 4.4 Hz), 7.19 (1H, dd, J = 2.4 Hz, 9.2 Hz), 7.42 (1H, d, J = 4.4 Hz), 7.53 (1H, d, J = 2.4 Hz), 7.62 (1H, s), 7.81 (1H, d, J = 3.4 Hz), 8.71 (1H, d, J = 5.2 Hz), 8.73 (1H, d, J = 9.2 Hz), 8.83 (1H, s).

Example 309

6-Carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline

[0814] After mixing 6-carbamoyl-4-chloro-7-methoxyquinoline (2.0 g, 8.4509 mmol), 5-hydroxyindole (1.68 g), diisopropylethylamine (2.2 ml) and N-methylpyrrolidone (2.2 ml), the mixture was heated and stirred at 150°C for 5 hours. After cooling, the partly solidified reaction mixture was dissolved in dimethylsulfoxide and then adsorbed onto NH silica gel and purified by NH silica gel column chromatography (ethyl acetate-methanol system). The obtained crystals were suspended in ethanol, the suspension was diluted with diethyl ether and hexane, and the crystals were filtered out, washed with diethyl ether:hexane = 1:5 and dried by aspiration to obtain the title compound (1.291 g, 3.8698 mmol, 45.79%) as light yellow crystals. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.02 (3H, s), 6.37 (1H, d, J = 5.2 Hz), 6.46 (1H, brs), 6.98 (1H, dd, J = 2.4 Hz, 8.4 Hz), 7.43-7.45 (2H, m), 7.48 (1H, s), 7.51 (1H, d, J = 8.4 Hz), 7.71 (1H, brs), 7.84 (1H, brs), 8.58 (1H, d, J = 5.2 Hz), 8.74 (1H, s), 11.29 (1H, s).

Example 3106-Carbamoyl-4-[1-(2,4-difluorophenylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0815] After dissolving 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (100 mg, 0.3 mmol) in N,N-dimethylformamide (0.5 ml), there was added sodium hydride (12 mg, 0.3 mmol) while cooling on ice and the mixture was stirred at room temperature for 15 minutes. After adding phenyl N-(2,4-difluorophenyl)carbamate (79 mg, 0.3150 mmol), the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate and tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the filtrate was distilled off under reduced pressure. The obtained crystals were suspended in ethanol and diluted with hexane, and then the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (84 mg, 0.1718 mmol, 57.28%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 4.03(3H, s), 6.45(1H, J, J = 5.2 Hz), 6.81(1H, d, J = 3.8 Hz), 7.14-7.19(1H, m), 7.23(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.39-7.49(1H, m), 7.51(1H, s), 7.50-7.58(2H, m), 7.72(1H, brs), 7.85(1H, brs), 8.11(1H, d, J = 3.8 Hz), 8.32(1H, d, J = 8.8 Hz), 8.62(1H, d, J = 5.2 Hz), 8.73(1H, s), 10.03(1H, s).

[0816] The starting material was synthesized in the following manner.

Production Example 310-1Phenyl N-(2,4-difluorophenyl)carbamate

[0817] After dissolving 2,4-difluoroaniline (10 ml, 98.21 mmol) in tetrahydrofuran (200 ml), pyridine (8.7 ml, 108.33 mmol) was added at room temperature and the mixture was stirred. It was then cooled on ice, phenyl chloroformate (13.6 ml, 108.33 mmol) was added dropwise over 15 minutes, and the mixture was then stirred at room temperature for 24 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate and tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the filtrate was distilled off under reduced pressure. The obtained crystals were suspended in ethanol and diluted with hexane, and then the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (21.00 g, 84.26 mmol, 85.80%) as light violet crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 7.05-7.12(1H, m), 7.19(2H, d, J = 7.6 Hz), 7.24(1H, t, J = 7.6 Hz), 7.33(1H, m), 7.41(2H, t, J = 7.6 Hz), 7.59-7.68(1H, m), 9.91(1H, brs).

Example 3116-Carbamoyl-4-[1-(4-difluorophenylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0818] The title compound (60 mg, 0.1275 mmol, 42.51%) was obtained as colorless crystals by reaction in the same manner as Example 310, using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (100 mg, 0.3 mmol) and phenyl N-(4-fluorophenyl)carbamate (86 mg).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.03(3H, s), 6.45(1H, d, J = 5.2 Hz), 6.79(1H, d, J = 3.6 Hz), 7.21-7.26(3H, m), 7.51(1H, s), 7.57(1H, d, J = 2.0 Hz), 7.67(2H, dd, J = 5.2 Hz, 8.8 Hz), 7.73(1H, brs), 7.85(1H, brs), 8.13(1H, d, J = 3.6 Hz), 8.33(1H, d, J = 8.8 Hz), 8.62(1H, d, J = 5.2 Hz), 8.73(1H, s), 10.16(1H, s).

[0819] The starting material was synthesized in the following manner.

Production Example 311-1Phenyl N-(4-difluorophenyl)carbamate

[0820] The title compound (10.031 g, 43.38 mmol, 82.19%) was obtained as light violet crystals using 4-fluoroaniline (5 ml, 52.78 mmol), by the same procedure as in Production Example 310-1.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 7.13-7.27(5H, m), 7.39-7.44(2H, m), 7.48-7.52(2H, m), 10.26(1H, s).

Example 3126-Carbamoyl-4-[1-(2-thiazolylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0821] After suspending sodium hydride (50 mg, 1.2524 mmol) in N,N-dimethylformamide (0.5 ml), phenyl N-(2,4-difluorophenyl)carbamate (79 mg, 0.3150 mmol) and then 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (200

mg, 0.5964 mmol) were added thereto at room temperature, and the mixture was stirred at room temperature for 10 hours. Water and saturated brine were added to the reaction solution, extraction was performed with ethyl acetate and tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the filtrate was distilled off under reduced pressure. The residue was adsorbed onto silica gel and passed through a silica gel column (hexane-tetrahydrofuran system). The obtained crystals were wetted with one drop of dimethylsulfoxide and then suspended in ethanol, and the crystals were filtered out, washed with ethanol and dried by aspiration to obtain the title compound (138 mg, 0.3003 mmol, 50.36%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.03(3H, s), 6.46(1H, d, J = 5.2 Hz), 6.69(1H, d, J = 3.6 Hz), 7.09(1H, d, J = 4.4 Hz), 7.20(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.47(1H, d, J = 4.4 Hz), 7.51(1H, s), 7.52(1H, d, J = 2.4 Hz), 7.73(1H, brs), 7.86(1H, brs), 8.08(1H, d, J = 3.6 Hz), 8.62(1H, d, J = 5.2 Hz), 8.67(1H, d, J = 8.8 Hz), 8.74(1H, s), 13.16(1H, s).

Example 313

6-Carbamoyl-4-(1-cyclopropylcarbamoyl-1H-indol-5-yloxy)-7-methoxyquinoline

[0822] The title compound (35 mg, 0.0840 mmol, 28.02%) was obtained as colorless crystals by reaction in the same manner as Example 310, using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (100 g, 0.3 mmol) and phenyl N-(4-fluorophenyl)carbamate (56 mg).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.62(2H, m), 0.73(2H, m), 2.78(1H, m), 4.02(3H, s), 6.42(1H, d, J = 5.2 Hz), 6.68(1H, d, J = 3.2 Hz), 7.18(1H, d, J = 9.0 Hz), 7.50(2H, m), 7.73(1H, s), 7.85(1H, s), 7.89(1H, d, J = 3.2 Hz), 8.30(1H, s), 8.34(1H, d, J = 9.0 Hz), 8.61(1H, d, J = 5.2 Hz), 8.72(1H, s).

[0823] The starting material was synthesized in the following manner.

Production Example 313-1

Phenyl N-cyclopropylcarbamate

[0824] Cyclopropylamine (3 ml, 43.29 mmol) was used for reaction in the same manner as Production Example 310-1, the obtained crystals were suspended in diethyl ether:hexane = 1:2, and the crystals were then filtered out, washed with diethyl ether:hexane = 1:2 and dried by aspiration to obtain the title compound (5.832 g, 32.91 mmol, 76.03%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 0.60-0.65(2H, m), 0.76-0.80(2H, m), 2.69(1H, brs), 5.23(1H, brs), 7.13(2H, d, J = 7.6 Hz), 7.19(1H, t, J = 7.6 Hz), 7.35(2H, t, J = 7.6 Hz).

Example 314

6-Carbamoyl-4-[1-(2-fluoroethylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

Example 315

4-[1-(2-Fluoroethylcarbamoyl)1H-indol-5-yloxy]-6-(2-fluoroethylureidocarbamoyl)-7-methoxyquinoline

[0825] 6-Carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (800 mg, 2.3998 mmol), sodium hydride (104 mg, 2.5918 mmol) and phenyl N-(2-fluoroethyl)carbamate (483 mg, 2.6398 mmol) were used for reaction in the same manner as Example 310, extraction was performed with ethyl acetate and tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto silica gel and subjected to silica gel column chromatography (ethyl acetate-tetrahydrofuran-methanol system), and after removing off the starting materials, the product was adsorbed onto NH silica gel and subjected to NH silica gel column chromatography (ethyl acetate-tetrahydrofuran-methanol system) to obtain low polarity and high polarity compounds as crystals. These were each suspended in ethanol and diluted with hexane. The crystals were filtered out, washed with hexane and dried by aspiration, to obtain the low polarity compound 4-[1-(2-fluoroethylcarbamoyl)-1H-indol-5-yloxy]-6-(2-fluoroethylureidocarbamoyl)-7-methoxyquinoline (49 mg, 0.0958 mmol, 3.99%) as colorless crystals and the high polarity compound 6-carbamoyl-4-[1-(2-fluoroethylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline (632 mg, 1.4961 mmol, 62.34%) as light yellow crystals.

Low polarity compound (Example 315)

[0826] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.59(4H, m), 4.01(3H, s), 4.47(1H, m), 4.53(1H, m), 4.59(1H, m),

4.65(1H, m), 6.46(1H, d, J = 4.4 Hz), 6.73(1H, d, J = 2.0 Hz), 7.19(1H, d, J = 8.8 Hz), 7.53(2H, s), 7.97(1H, d, J = 2.0 Hz), 8.35(1H, d, J = 8.8 Hz), 8.50(1H, m), 8.51(1H, s), 8.63(1H, m), 8.64(1H, d, J = 4.4 Hz), 10.62(1H, s).

High polarity compound (Example 314)

[0827] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.56(1H, dt, J = 5.0 Hz, 5.0 Hz), 3.63(1H, dt, J = 5.0 Hz, 5.0 Hz), 4.02(3H, s), 4.53(1H, t, J = 5.0 Hz), 4.65(1H, t, J = 5.0 Hz), 6.43(1H, d, J = 5.2 Hz), 6.73(1H, d, J = 3.8 Hz), 7.19(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.52(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.85(1H, brs), 7.98(1H, d, J = 3.8 Hz), 8.35(1H, d, J = 8.8 Hz), 8.49(1H, t, J = 5.0 Hz), 8.61(1H, d, J = 5.2 Hz), 8.72(1H, s).

[0828] The starting material was synthesized in the following manner.

Production Example 314-1

Phenyl N-(2-fluoroethyl)carbamate

[0829] After dissolving 2-fluoroethylamine (0.5 g, 5.0321 mmol) in dimethylformamide (10 ml), pyridine (0.87 ml, 10.5674 mmol) was added at room temperature and the mixture was stirred. It was then cooled on ice, phenyl chloroformate (0.67 ml, 5.2837 mmol) was added dropwise, and after the dropwise addition the mixture was stirred at room temperature for 2.5 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain the title compound (0.797 g, 4.3509 mmol, 86.46%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 3.55(1H, q, J = 4.8 Hz), 3.62(1H, q, J = 4.8 Hz), 4.51(1H, t, J = 4.8 Hz), 4.62(1H, t, J = 4.8 Hz), 5.39(1H, brs), 7.13(2H, d, J = 7.6 Hz), 7.21(1H, t, J = 7.6 Hz), 7.37(2H, t, J = 7.6 Hz).

Example 316

6-Carbamoyl-4-(1-ethylcarbamoyl-1H-indol-5-yloxy)-7-methoxyquinoline

Example 317

4-(1-Ethylcarbamoyl-1H-indol-5-yloxy)-6-ethylureidocarbamoyl-7-methoxyquinoline

[0830] 6-Carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (1.2 g, 3.6141 mmol), phenyl N-4-ethylcarbamate (822 mg, 4.9761 mmol) and sodium hydride (195 mg, 4.8799 mmol) were used for reaction in the same manner as Example 310 to obtain the low polarity compound 4-(1-ethylcarbamoyl-1H-indol-5-yloxy)-6-ethylureidocarbamoyl-7-methoxyquinoline (105 mg, 0.2208 mmol, 6.11%) and the high polarity compound 6-carbamoyl-4-(1-ethylcarbamoyl-1H-indol-5-yloxy)-7-methoxyquinoline (506 mg, 1.2511 mmol, 34.62%), both as colorless crystals.

Low polarity compound (Example 317)

[0831] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.11(3H, t, J = 7.2 Hz), 1.77(3H, t, J = 7.2 Hz), 3.23(2H, q, J = 7.2 Hz), 3.29(2H, q, J = 7.2 Hz), 4.01(3H, s), 6.45(1H, d, J = 5.2 Hz), 6.70(1H, d, J = 3.6 Hz), 7.17(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.51(1H, d, J = 2.4 Hz), 7.52(1H, s), 7.93(1H, d, J = 3.6 Hz), 8.24(1H, t, J = 5.6 Hz), 8.35(1H, d, J = 8.8 Hz), 8.44(1H, m), 8.52(1H, s), 8.64(1H, d, J = 5.2 Hz), 10.46(1H, s).

High polarity compound (Example 316)

[0832] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.18(3H, t, J = 7.2 Hz), 3.32(2H, q, J = 7.2 Hz), 4.02(3H, s), 6.42(1H, d, J = 5.2 Hz), 6.70(1H, d, J = 3.6 Hz), 7.17(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.51(1H, d, J = 2.4 Hz), 7.71(1H, brs), 7.84(1H, brs), 7.93(1H, d, J = 3.6 Hz), 8.23(1H, t, J = 5.6 Hz), 8.34(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.2 Hz), 8.72(1H, s).

[0833] The starting material was synthesized in the following manner.

Production Example 316-1Phenyl N-ethyl carbamate

[0834] Ethylamine hydrochloride (20.3 g, 0.25 mol) was used for reaction in the same manner as Production Example 310-1, the obtained crystals were suspended in hexane, and then the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (33.33 g, 0.2018 mol, 80.71%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 1.21(3H, t, J = 7.2 Hz), 3.31(2H, m), 5.02(1H, brs), 7.12(2H, d, J = 7.6 Hz), 7.19(1H, t, J = 7.6 Hz), 7.35(2H, t, J = 7.6 Hz).

Example 3186-Carbamoyl-7-methoxy-4-(1-propylcarbamoyl-1H-indol-5-yloxy)quinolineExample 3197-Methoxy-4-(1-propylcarbamoyl-1H-indol-5-yloxy)-6-propylureidocarbamoylquinoline

[0835] 6-Carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (400 mg, 1.2 mmol), phenyl N-n-propyl carbamate (237 mg, 1.3199 mmol) and sodium hydride (55 mg, 1.3199 mmol) were used according to the same method as in Example 310 to obtain the low polarity compound 7-methoxy-4-(1-propylcarbamoyl-1H-indol-5-yloxy)-6-propylureido-carbamoylquinoline (49 mg, 0.0973 mmol, 8.11%) and the high polarity compound 6-carbamoyl-7-methoxy-4-(1-nor-malpropylcarbamoyl-1H-indol-5-yloxy)quinoline (218 mg, 0.5210 mmol, 43.41%), both as light yellow crystals.

Low polarity compound (Example 319)

[0836] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.89(3H, t, J = 7.2 Hz), 0.91(3H, t, J = 7.2 Hz), 1.51(2H, q, J = 7.2 Hz), 1.59(2H, q, J = 7.2 Hz), 3.18(2H, t, J = 7.2 Hz), 3.25(2H, t, J = 7.2 Hz), 4.02(3H, s), 6.45(1H, d, J = 5.2 Hz), 6.70(1H, d, J = 3.6 Hz), 7.27(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.51(1H, d, J = 2.4 Hz), 7.52(1H, s), 7.95(1H, d, J = 3.6 Hz), 8.22(1H, m), 8.34(1H, d, J = 8.8 Hz), 8.47(1H, brs), 8.54(1H, s), 8.64(1H, d, J = 5.2 Hz), 10.45(1H, s).

High polarity compound (Example 318)

[0837] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.92(3H, t, J = 7.2 Hz), 1.58(2H, q, J = 7.2 Hz), 3.24(2H, q, J = 7.2 Hz), 4.02(3H, s), 6.42(1H, d, J = 5.2 Hz), 6.70(1H, d, J = 3.6 Hz), 7.17(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.51(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.49(1H, brs), 7.95(1H, d, J = 3.6 Hz), 8.23(1H, t, J = 5.2 Hz), 8.34(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.2 Hz), 8.72(1H, s).

[0838] The starting material was synthesized in the following manner.

Production Example 318-1Phenyl N-(n-propyl)carbamate

[0839] n-Propylamine (4.1 ml, 50 mmol) was used for reaction in the same manner as Production Example 310-1, and the obtained crystals were suspended in hexane, filtered out, washed with hexane and dried by aspiration to obtain the title compound (4.502 g, 25.12 mmol, 50.24%) as colorless crystals

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.86(3H, t, J = 7.4 Hz), 1.41-1.50(2H, m), 3.00(2H, q, J = 6.8 Hz), 7.06(2H, d, J = 8.0 Hz), 7.17(1H, t, J = 8.0 Hz), 7.36(2H, t, J = 8.0 Hz), 7.72(1H, m).

Example 3206-Carbamoyl-7-methoxy-4-[1-(1-methyl)ethylcarbamoyl-1H-indol-5-yloxy]quinolineExample 3217-Methoxy-4-[1-(1-methyl)ethylcarbamoyl-1H-indol-5-yloxy]-6-(1-methyl)ethylureidocarbamoylquinoline

[0840] 6-Carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (400 mg, 1.2 mmol), phenyl N-(1-methyl)ethyl car-

bamate (237 mg) and sodium hydride (55 mg, 1.3199 mmol) were used by the same procedure as in Example 310 to obtain the low polarity compound 7-methoxy-4-[1-(1-methyl)ethylcarbamoyl-1H-indol-5-yloxy]-6-(1-methyl)ethylureidocarbamoylquinoline (62 mg, 0.1231 mmol, 10.26%) as light yellow crystals and the high polarity compound 6-carbamoyl-7-methoxy-4-[1-(1-methyl)ethylcarbamoyl-1H-indol-5-yloxy]quinoline (309 mg, 0.7384 mmol, 43.41%) as colorless crystals. The title compound (60 mg, 0.1275 mmol, 61.54%) was obtained as colorless crystals.

Low polarity compound (Example 321)

[0841] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.17(6H, d, J = 5.8 Hz), 1.22(6H, d, J = 5.8 Hz), 3.88(1H, m), 4.01(3H, s), 4.03(1H, m), 6.45(1H, d, J = 5.4 Hz), 6.69(1H, d, J = 3.4 Hz), 7.16(1H, dd, J = 2.4 Hz, 8.6 Hz), 7.50(1H, d, J = 2.4 Hz), 7.52(1H, s), 7.98(1H, s), 7.99(1H, d, J = 3.4 Hz), 8.33(2H, m), 8.52(1H, s), 8.64(1H, d, J = 5.4 Hz), 10.46(1H, s).

High polarity compound (Example 320)

[0842] ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.23(6H, d, J = 6.4 Hz), 4.00(1H, m), 4.33(3H, s), 6.42(1H, d, J = 5.4 Hz), 6.69(1H, d, J = 3.6 Hz), 7.17(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.51(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.85(1H, brs), 7.97(1H, s), 7.99(1H, d, J = 3.5 Hz), 8.33(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.4 Hz), 8.72(1H, s).

[0843] The starting material was synthesized in the following manner.

Production Example 320-1

Phenyl N-(iso-propyl)carbamate

[0844] i-Propylamine (4.3 ml, 50 mmol) was used for reaction in the same manner as Production Example 310-1, and the obtained crystals were suspended in hexane, filtered out, washed with hexane and dried by aspiration to obtain the title compound (5.105 g, 28.48 mmol, 56.97%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.01(6H, d, J = 6.4 Hz), 3.58-3.67(1H, m), 7.07(2H, d, J = 7.6 Hz), 7.17(1H, t, J = 7.6 Hz), 7.35(2H, t, J = 7.6 Hz), 7.65(1H, m).

Example 322

4-(1-Normalbutylcarbamoyl-1H-indol-5-yloxy)-6 carbamoyl-7-methoxyquinoline

[0845] The title compound (203 mg, 0.4694 mmol, 46.94%) was obtained as colorless crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (335 g, 1.0 mmol), phenyl N-n-butyl carbamate (213 mg, 1.1 mmol) and sodium hydride (44 mg, 1.1 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.92(3H, t, J = 7.2 Hz), 1.36(2H, m), 1.55(2H, m), 3.29(2H, m), 4.02(3H, s), 6.42(1H, d, J = 5.4 Hz), 6.70(1H, d, J = 3.6 Hz), 7.17(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50-7.52(2H, m), 7.73(1H, brs), 7.85(1H, brs), 7.94(1H, d, J = 3.6 Hz), 8.22(1H, t, J = 5.4 Hz), 8.34(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.4 Hz), 8.72(1H, s).

[0846] The starting material was synthesized in the following manner.

Production Example 322-1

Phenyl N-(n-butyl)carbamate

[0847] n-Butylamine (4.9 ml, 50 mmol) was used for the same reaction as in Production Example 310-1, and purification was performed by silica gel column chromatography (hexane:ethyl acetate = 4:1) to obtain the title compound (8.11 g, 41.97 mmol, 71.97%) as a colorless oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 0.95(3H, t, J = 7.2 Hz), 1.35-1.45(2H, m), 1.52-1.60(2H, m), 3.27(2H, q, J = 7.2 Hz), 5.01(1H, brs), 7.12(2H, d, J = 7.2 Hz), 7.19(1H, t, J = 7.2 Hz), 7.35(2H, t, J = 7.2 Hz).

Example 323

6-Carbamoyl-4-[1-(1,1-dimethylethylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0848] The title compound (225 mg, 0.5203 mmol, 52.03%) was obtained as colorless crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (335 mg, 1.0 mmol), phenyl N-(1,1-dimethylethyl)carbamate (213 mg, 1.1

mmol) and sodium hydride (44 mg, 1.1 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.42(9H, s), 4.02(3H, s), 6.41(1H, d, J = 5.0 Hz), 6.65(1H, d, J = 3.8 Hz), 7.15(1H, dd, J = 2.4 Hz, 9.2 Hz), 7.50(2H, s), 7.63(1H, s), 7.72(1H, brs), 7.85(1H, brs), 7.95(1H, d, J = 3.8 Hz), 8.26(1H, d, J = 9.2 Hz), 8.61(1H, d, J = 5.0 Hz), 8.73(1H, s).

[0849] The starting material was synthesized in the following manner.

Production Example 323-1

Phenyl N-(t-butyl)carbamate

[0850] The title compound (3.910 g, 20.23 mmol, 40.46%) was obtained as pink crystals using t-butylamine (5.3 ml, 50 mmol), by the same procedure as in Production Example 310-1.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.26(9H, s), 7.05(2H, d, J = 8.0 Hz), 7.16(1H, t, J = 8.0 Hz), 7.35(2H, t, J = 8.0 Hz), 7.53(1H, s).

Example 324

6-Carbamoyl-4-[1-(3-fluoropropylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0851] The title compound (105 mg, 0.2406 mmol, 28.82%) was obtained as colorless crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (280 mg, 0.8349 mmol), phenyl N-(3-fluoropropyl)carbamate (181 mg, 0.9184 mmol) and sodium hydride (37 mg, 0.9184 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.89-2.03(2H, m), 3.39(2H, m), 4.02(3H, s), 4.49(1H, t, J = 6.0 Hz), 4.61(1H, d, J = 6.0 Hz), 6.42(1H, d, J = 5.2 Hz), 6.71(1H, d, J = 3.6 Hz), 7.18(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.52(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.85(1H, brs), 7.94(1H, d, J = 3.6 Hz), 8.32(1H, t, J = 5.4 Hz), 8.34(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.2 Hz), 8.72(1H, s).

[0852] The starting material was synthesized in the following manner.

Production Example 324-1

Phenyl N-(3-fluoropropyl)carbamate

[0853] 3-Fluoropropylamine hydrochloride (0.92 g (wet), 8.10 mmol) was used for reaction in the same manner as Production Example 310-1, and purification was performed by silica gel column chromatography (hexane/ethyl acetate system) to obtain the title compound (0.470 g, 2.3832 mmol, 29.42%) as pink crystals.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 1.96(1H, m), 2.03(1H, m), 3.44(2H, q, J = 6.4 Hz), 4.54(1H, t, J = 5.6 Hz), 4.65(1H, t, J = 5.6 Hz), 5.22(1H, brs), 7.12(2H, d, J = 7.6 Hz), 7.20(1H, t, J = 7.6 Hz), 7.36(2H, t, J = 7.6 Hz).

Example 325

6-Carbamoyl-4-[1-(3-chloropropylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0854] The title compound (136 mg, 0.3003 mmol, 35.97%) was obtained as colorless crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (280 mg, 0.8349 mmol), phenyl N-(3-chloropropyl)carbamate (197 mg, 0.9184 mmol) and sodium hydride (37 mg, 0.9184 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.03(2H, q, J = 6.4 Hz), 3.42(2H, q, J = 6.4 Hz), 3.74(2H, t, J = 6.4 Hz), 4.02(3H, s), 6.42(1H, d, J = 5.2 Hz), 6.71(1H, d, J = 3.6 Hz), 7.18(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.52(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.85(1H, brs), 7.94(1H, d, J = 3.6 Hz), 8.30(1H, d, J = 5.4 Hz), 8.34(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.2 Hz), 8.72(1H, s).

[0855] The starting material was synthesized in the following manner.

Production Example 325-1

Phenyl N-(3-chloropropyl)carbamate

[0856] 3-Chloropropylamine hydrochloride (6.5 g, 50 mmol) was used for reaction in the same manner as Production Example 310-1, purification was performed by silica gel column chromatography (hexane/ethyl acetate system), the obtained crystals were suspended in diethyl ether and diluted with hexane, and the crystals were filtered out, washed

with hexane and dried by aspiration to obtain the title compound (4.316 g, 20.20 mmol, 40.40%) as colorless crystals. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.91(2H, quintet, J = 6.0 Hz), 3.18(2H, q, J = 6.0 Hz), 3.68(2H, t, J = 6.0 Hz), 7.08(2H, d, J = 8.0 Hz), 7.18(1H, t, J = 8.0 Hz), 7.35(2H, t, J = 8.0 Hz), 7.81(1H, t, J = 6.0 Hz).

5 Example 326

6-Carbamoyl-4-[1-(3-ethoxypropylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0857] The title compound (103 mg, 0.2227 mmol, 26.67%) was obtained as colorless crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (280 mg, 0.8349 mmol), phenyl N-(3-ethoxypropyl)carbamate (197 mg, 0.9184 mmol) and sodium hydride (37 mg, 0.9184 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.01(3H, t, J = 6.8 Hz), 1.80(2H, t, J = 6.8 Hz), 3.34(2H, q, J = 6.8 Hz), 3.39-3.46 (4H, m), 4.02(3H, s), 6.24(1H, d, J = 5.2 Hz), 6.70(1H, d, J = 3.6 Hz), 7.18(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.51(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.85(1H, brs), 7.93(1H, d, J = 3.6 Hz), 8.22(1H, t, J = 5.2 Hz), 8.34(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.2 Hz), 8.72(1H, s).

[0858] The starting material was synthesized in the following manner.

Production Example 326-1

20 Phenyl N-(3-ethoxypropyl)carbamate

[0859] 3-Ethoxypropylamine (6.0 ml, 50 mmol) was dissolved in dimethylformamide (100 ml), the reaction was subsequently conducted in the same manner as Production Example 310-1, and purification was performed by NH silica gel column chromatography (hexane/ethyl acetate system) to obtain the title compound (10.76 g, 48.19 mmol, 96.39%) as a light yellow oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 1.22 (3H, t, J = 7.0 Hz), 1.85(2H, quintet, J = 6.0 Hz), 3.40(2H, q, J = 6.0 Hz), 3.51(2H, q, J = 7.0 Hz), 3.56(2H, t, J = 6.0 Hz), 5.58(1H, brs), 7.12(2H, d, J = 7.6 Hz), 7.18(1H, t, J = 7.6 Hz), 7.35(2H, t, J = 7.6 Hz).

30 Example 327

6-Carbamoyl-4-[1-(3-diethylaminopropylcarbamoyl)1H-indol-5-yloxy]-7-methoxyquinoline

[0860] The title compound (65 mg, 0.1328 mmol, 18.55%) was obtained as colorless crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (240 mg, 0.7157 mmol), phenyl N-(3-diethylaminopropyl)carbamate (197 mg, 0.7872 mmol) and sodium hydride (31 mg, 0.7872 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.94(6H, t, J = 7.2 Hz), 1.69(2H, m), 2.42-2.48(6H, m), 3.27-3.30(2H, m), 4.02 (3H, s), 6.42(1H, d, J = 5.4 Hz), 6.70(1H, d, J = 3.6 Hz), 7.17(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.50(1H, s), 7.51(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.84(1H, brs), 7.91(1H, d, J = 3.6 Hz), 8.26(1H, t, J = 5.6 Hz), 8.33(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.4 Hz), 8.72(1H, s).

Production Example 327-1

Phenyl N-(3-diethylaminopropyl)carbamate

[0861] 3-Diethylaminopropylamine (7.9 ml, 50 mmol) was dissolved in dimethylformamide (100 ml), the reaction was subsequently conducted in the same manner as Production Example 310-1, and purification was performed by NH silica gel column chromatography (hexane/ethyl acetate system) to obtain the title compound (7.21 g, 28.80 mmol, 57.60%) as a light yellow oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 1.06 (6H, t, J = 7.0 Hz), 1.71(2H, quintet, J = 6.0 Hz), 2.49-2.57(6H, m), 3.36(2H, q, J = 6. Hz), 6.83(1H, brs), 7.12(2H, t, J = 7.6 Hz), 7.17(1H, t, J = 7.6 Hz), 7.34(2H, t, J = 7.6 Hz).

Example 328

6-Carbamoyl-7-methoxy-4-[1-(3-methylthiopropyl)1H-indol-5-yloxy]quinoline

[0862] The title compound (177 mg, 0.3810 mmol, 45.64%) was obtained as colorless crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (280 mg, 0.8349 mmol), phenyl N-(3-methylthiopropyl)carbamate (207 mg,

0.9184 mmol) and sodium hydride (37 mg, 0.9184 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.84(2H, tt, J = 6.8 Hz, 6.8 Hz), 2.48(3H, s), 2.55(2H, t, J = 6.8 Hz), 3.57(2H, m), 4.02(3H, s), 6.42(1H, d, J = 5.0 Hz), 6.70(1H, d, J = 3.4 Hz), 7.18(1H, d, J = 8.8 Hz), 7.50(1H, s), 7.51(1H, s), 7.72(1H, s), 7.85(1H, s), 7.94(1H, d, J = 3.4 Hz), 8.27(1H, brs), 8.34(1H, d, J = 8.8 Hz), 8.61(1H, d, J = 5.0 Hz), 8.72(1H, s).

Production Example 328-1

Phenyl N-(3-methylthiopropyl)carbamate

[0863] 3-Methylthiopropylamine (5.5 ml, 50 mmol) was used for reaction in the same manner as Production Example 310-1, and purification was performed by silica gel column chromatography (hexane/ethyl acetate system) to obtain the title compound (10.486 g, 46.54 mmol, 93.08%) as a yellow oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 1.89(2H, quintet, J = 6.8 Hz), 2.12(3H, s), 2.58(2H, t, J = 6.8 Hz), 3.38(2H, q, J = 6.8 Hz), 5.21(1H, brs), 7.12(2H, t, J = 7.6 Hz), 7.19(1H, t, J = 7.6 Hz), 7.35(2H, t, J = 7.6 Hz).

Example 329

6-Carbamoyl-4-[1-(2-chloroethylcarbamoyl)-1H-indol-5-yloxy]-7-methoxyquinoline

[0864] The title compound (36 mg, 0.0820 mmol, 9.82%) was obtained as light yellow crystals using 6-carbamoyl-4-(1H-indol-5-yloxy)-7-methoxyquinoline (280 mg, 0.8349 mmol), phenyl N-(2-chloroethyl)carbamate (184 mg, 0.9184 mmol) and sodium hydride (37 mg, 0.9184 mmol), by the same procedure as in Example 310.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.02 (3H, s), 4.03(2H, t, J = 9.2 Hz), 4.59(2H, t, J = 9.2 Hz), 6.44(1H, d, J = 5.6 Hz), 6.75(1H, d, J = 3.6 Hz), 7.24(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.51(1H, s), 7.57(1H, d, J = 2.4 Hz), 7.72(1H, brs), 7.76(1H, d, J = 3.6 Hz), 7.85(1H, brs), 8.38(1H, d, J = 8.8 Hz), 8.62(1H, d, J = 5.6 Hz), 8.72(1H, s).

Production Example 329-1

Phenyl N-(2-chloroethyl)carbamate

[0865] 2-Chloroethylamine hydrochloride (5.8 g, 50 mmol) was used for reaction in the same manner as Production Example 310-1, purification was performed by silica gel column chromatography (hexane/ethyl acetate system), the obtained crystals were suspended in diethyl ether/hexane, and the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (6.088 g, 30.49 mmol, 60.99%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.38(2H, q, J = 6.0 Hz), 3.66(2H, t, J = 6.0 Hz), 7.09(2H, t, J = 7.6 Hz), 7.19(1H, t, J = 7.6 Hz), 7.36(2H, t, J = 7.6 Hz), 8.01(1H, t, J = 6.0 Hz).

Example 330

4-[1-(2,4-Difluorophenylcarbamoyl)-1H-indol-5-yloxy]-6,7-dimethoxyquinoline

[0866] After dissolving 4-(1H-indol-5-yloxy)-6,7-dimethoxyquinoline (40 mg, 0.1249 mmol, described in WO9717329) in N,N-dimethylformamide (0.7 ml), sodium hydride (10 mg.) was added and the mixture was stirred at room temperature for 15 minutes. 2,4-Difluorophenyl isocyanate (0.018 ml, 0.1561 mmol) was further added, and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the filtrate was distilled off under reduced pressure. The obtained crystals were suspended in diethyl ether:ethanol = 10:1 and diluted with hexane, and then the crystals were filtered out, washed with diethyl ether:ethanol = 10:1 and dried by aspiration to obtain the title compound (35 mg, 0.0736 mmol, 58.94%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 4.06(3H, s), 4.07(3H, s), 6.44(1H, J, J = 5.2 Hz), 6.75(1H, d, J = 4.0 Hz), 6.94-7.20 (2H, m), 7.23(1H, dd, J = 2.4, 8.8 Hz), 7.42-7.48(3H, m), 7.63(1H, s), 8.14-8.22(1H, m), 8.29(1H, d, J = 8.8 Hz), 8.47(1H, d, J = 5.2 Hz).

Example 331-1

4-[1-(Phenylcarbamoyl)-1H-indol-5-yloxy]-6,7-dimethoxyquinoline

[0867] 4-(1H-Indol-5-yloxy)-6,7-dimethoxyquinoline (25 mg, 0.0780 mmol) and phenyl isocyanate (0.013 ml, 0.117

mmol) were used for reaction in the same manner as Example 330, the obtained crystals were suspended in diethyl ether:ethanol = 10:1, and then the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (11 mg, 0.0250 mmol, 32.09%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 4.03(3H, s), 4.12(3H, s), 6.45(1H, m), 6.73(1H, m), 7.16-7.27(2H, m), 7.38-7.43(3H, m), 7.65-7.69(3H, m), 7.97(2H, m), 8.08(1H, m), 8.43(1H, brs), 8.38(1H, d, J = 8.8 Hz).

Example 331-2

4-[1-(2-Thiazolylcarbamoyl)-1H-indol-5-yloxy]-6,7-dimethoxyquinoline

[0868] After dissolving 4-(1H-indol-5-yloxy)-6,7-dimethoxyquinoline (25 mg, 0.0780 mmol) in N,N-dimethylformamide (0.4 ml), sodium hydride (6 mg) was added and the mixture was stirred at room temperature for 15 minutes. Phenyl N-(2-thiazolyl)carbamate (30 mg, 0.1362 mmol) was further added and the mixture was stirred at 80°C for 2 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the filtrate was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography (hexane/ethyl acetate/ethanol system), the obtained crystals were suspended in ethanol and diluted with hexane, and then the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (23 mg, 0.0515 mmol, 66.04%) as light yellow crystals. ¹H-NMR Spectrum (CDCl₃) δ (ppm): 3.94(6H, s), 6.42(1H, d, J = 5.2 Hz), 6.68(1H, d, J = 3.4 Hz), 7.08(1H, d, J = 4.0 Hz), 7.17(1H, d, J = 8.8 Hz), 7.38(1H, s), 7.46-7.48(2H, m), 7.56(1H, s), 8.07(1H, d, J = 3.4 Hz), 8.43(1H, d, J = 5.2 Hz), 8.65(1H, d, J = 8.8 Hz), 13.13(1H, brs).

Example 332

4-(1-Cyclopropylcarbamoyl)-1H-indol-5-yloxy)-6,7-dimethoxyquinoline

[0869] The title compound (30 mg, 0.0744 mmol, 47.64%) was obtained as light red crystals by reaction in the same manner as Example 310, using 4-(1H-indol-5-yloxy)-6,7-dimethoxyquinoline (50 mg, 0.1560 mmol), sodium hydride (8 mg, 0.1873 mmol) and phenyl N-cyclopropylcarbamate (30 mg, 0.1716 mmol).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.71 (2H, m), 0.94 (2H, m), 2.91(1H, m), 4.06(3H, s), 4.07(3H, s), 5.79(1H, brs), 6.41(1H, d, J = 5.2 Hz), 6.63(1H, d, J = 3.2 Hz), 7.16(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.26(1H, s), 7.39-7.43(2H, m), 7.63(1H, s), 8.26(1H, d, J = 8.8 Hz), 8.45(1H, d, J = 5.2 Hz).

Example 333

4-[1-(2-Fluoroethylcarbamoyl)-1H-indol-5-yloxy]-6,7-dimethoxyquinoline

[0870] 4-(1H-Indol-5-yloxy)-6,7-dimethoxyquinoline (75 mg, 0.3122 mmol), sodium hydride (13 mg, 0.3278 mmol) and phenyl N-(2-fluoroethyl)carbamate (45 mg, 0.3278 mmol) were used for reaction in the same manner as Example 310, followed by extraction with ethyl acetate/tetrahydrofuran, washing with saturated brine and drying over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was adsorbed onto silica gel and subjected to silica gel column chromatography (hexane/ethyl acetate system) to obtain the title compound (24 mg, 0.0586 mmol, 18.78%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.56(1H, q, J = 5.0 Hz), 3.63(1H, q, J = 5.0 Hz), 3.92(3H, s), 3.96(3H, s), 4.53(1H, t, J = 5.0 Hz), 4.65(1H, t, J = 5.0 Hz), 6.39(1H, d, J = 5.0 Hz), 6.71(1H, d, J = 3.8 Hz), 7.17(1H, dd, J = 2.0 Hz, 8.8 Hz), 7.40(1H, s), 7.49(1H, d, J = 2.0 Hz), 7.55(1H, s), 7.96(1H, d, J = 3.8 Hz), 8.34(1H, d, J = 8.8 Hz), 8.42(1H, d, J = 5.0 Hz), 8.48(1H, t, J = 5.0 Hz).

Example 334

6,7-Dimethoxy-4-(5-(1-(4-fluorophenylcarbonyl)-indolyl)oxy)quinoline

[0871] After dissolving 6,7-dimethoxy-4-(5-indolyl)oxy)quinoline (25 mg, 0.0780 mmol, described in WO9717329, p. 52) in toluene (1.6 ml), 4-fluorophenyl isocyanate (22 ml, 0.1951 mmol, 2.5 eqM) was added and the mixture was heated to reflux for 5 hours and 30 minutes under a nitrogen atmosphere. After cooling, the reaction solution was diluted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate system). The obtained crystals were suspended in ethanol and diluted with hexane, and then the crystals were

filtered out, washed with hexane and dried by aspiration to obtain the title compound (18 mg, 0.0393 mmol, 50.44%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 4.05 (3H, s), 4.07 (3H, s), 6.43 (1H, d, J = 5.6 Hz), 6.72 (1H, d, J = 3.4 Hz), 7.12 (2H, t, J = 8.8 Hz), 7.22 (1H, dd, J = 2.0, 8.8 Hz), 7.43 (3H, m), 7.53 (2H, m), 7.62 (1H, d, J = 3.6 Hz), 7.63 (1H, s), 8.29 (1H, d, J = 8.8 Hz), 8.46 (1H, d, J = 5.6 Hz).

Example 335

6,7-Dimethoxy-4-(5-(1-(4-fluorophenylcarbamoyl)-indolinyloxy)quinoline

[0872] 6,7-Dimethoxy-4-(5-indolinyloxy)quinoline (20 mg, 0.0620 mmol) was used for reaction in the same manner as Example 334 to obtain the title compound (18 mg, 0.0392 mmol, 63.19%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 3.30 (2H, t, J = 8.4 Hz), 4.05 (3H, s), 4.06 (3H, s), 4.12 (2H, t, J = 8.4 Hz), 6.45 (1H, d, J = 5.2 Hz), 6.47 (1H, brs), 7.01-7.07 (4H, m), 7.42 (2H, dd, J = 9.2, 13.2 Hz), 7.43 (1H, s), 7.57 (1H, s), 8.04 (1H, d, J = 8.8 Hz), 8.48 (1H, d, J = 5.2 Hz).

[0873] The intermediate was synthesized in the following manner.

Production Example 335-1

6,7-Dimethoxy-4-(5-indolinyloxy)quinoline

[0874] After dissolving 6,7-dimethoxy-4-(5-indolinyloxy)quinoline (30 mg, 0.0780 mmol, described in WO9717329, p. 52) in trifluoroacetic acid (0.9 ml), triethylsilane (45 ml, 0.2808 mmol, 3.0 eqM) was added while cooling on ice, and the mixture was stirred for 4 hours and 30 minutes at room temperature under a nitrogen atmosphere. After cooling, the reaction solution was diluted with ethyl acetate, neutralized with saturated sodium bicarbonate water, extracted with ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/ethanol system) to obtain the title compound (20 mg, 0.0620 mmol, 66.28%) as light yellow crystals. ¹H-NMR Spectrum (CDCl₃) δ (ppm) : 3.08 (2H, t, J = 8.4 Hz), 3.65 (2H, t, J = 8.4 Hz), 4.06 (6H, s), 6.48 (1H, d, J = 5.4 Hz), 6.69 (1H, d, J = 8.4 Hz), 6.84 (1H, dd, J = 1.6, 8.4 Hz), 6.95 (1H, d, J = 1.6 Hz), 7.49 (1H, s), 7.60 (1H, s), 8.48 (1H, d, J = 5.4 Hz).

Example 336

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-methylthiopropyl)urea

[0875] The title compound (35.7 mg, 0.077 mmol, 87.1%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (40 mg, 0.088 mmol) and 3-(methylthio)propylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 1.68 (2H, m), 2.04 (3H, s), 3.16 (2H, m), 3.18-3.35 (2H, m), 3.36 (3H, s), 3.76-3.79 (2H, m), 4.40-4.42 (2H, m), 6.23 (1H, t, J=5.6Hz), 6.48 (1H, d, J=5.2Hz), 7.16 (2H, d, J=9.2Hz), 7.52 (2H, d, J=9.2Hz), 7.61 (1H, s), 8.59 (1H, s), 8.70 (1H, d, J=4.0Hz), 8.75 (1H, s).

Example 337

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-methylsulfonylpropyl)urea

[0876] The title compound (32.4 mg, 0.065 mmol, 59.2%) was obtained as white crystals from phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (50 mg, 0.11 mmol) and 3-(methanesulfonyl)propylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.85 (2H, m), 2.97 (3H, s), 3.11 (2H, m), 3.21 (2H, m), 3.36 (3H, s), 3.77 (2H, m), 4.41 (2H, m), 6.30 (1H, m), 6.48 (1H, d, J=5.6Hz), 7.16 (2H, d, J=8.8Hz), 7.53 (2H, d, J=8.8Hz), 7.61 (1H, s), 8.67 (1H, s), 8.70 (1H, d, J=5.2Hz), 8.75 (1H, s).

Example 338

N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(methylsulfonyl)urea

[0877] After suspending sodium hydride (11 mg, 0.275 mmol) in tetrahydrofuran (8 ml) under a nitrogen atmosphere,

methanesulfonylamide (31.4 mg, 0.330 mmol) was added while cooling in an ice water bath, and the mixture was stirred at room temperature for 10 minutes. Phenyl N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (50 mg, 0.110 mmol) was added and the mixture was stirred at 60°C for 1 hour. The insoluble portion was filtered off, and after concentration under reduced pressure, tetrahydrofuranhexane (1:2) was added for crystallization to obtain the title compound (37.6 mg, 0.082 mmol, 75.0%) as gray crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.75 (3H, s), 3.36 (3H, s), 3.77 (2H, m), 4.41 (2H, m), 6.47 (1H, d, J=5.2Hz), 7.05 (1H, d, J=8.8Hz), 7.61 (2H, d, J=8.8Hz), 7.64 (1H, s), 8.44 (1H, s), 8.69 (2H, d, J=5.2Hz), 8.75 (1H, s).

Example 339

Methyl 4-(4-(((4-fluoroanilino)carbonyl)amino)phenoxy)-7-methoxy-6-quinoline carboxylate

[0878] The title compound (600 mg, 1.3 mmol, 86.8%) was obtained as light brown crystals from 4-(4-aminophenoxy)-7-methoxy-6-methoxycarbonylquinoline (486 mg, 1.5 mmol) and 4-fluorophenyl isocyanate, by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.85 (3H, s), 3.96 (3H, s), 6.46 (1H, d, J=5.2Hz), 7.12 (2H, m), 7.23 (2H, d, J=8.8Hz), 7.46 (2H, m), 7.51 (1H, s), 7.58 (2H, d, J=8.8Hz), 8.59 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.73 (1H, s), 8.82 (1H, s).

[0879] The starting material was synthesized in the following manner.

Production Example 339-1

7-Methoxy-6-methoxycarbonyl-4-(4-nitrophenoxy)quinoline

[0880] The title compound (1.743 g, 4.91 mmol, 27.2%) was obtained as light brown crystals from the 4-chloro-7-methoxy-6-methoxycarbonylquinoline hydrochloride (5.19 g, 18.0 mmol) described in WO0050405, by the same procedure as in Production Example 11.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.97 (3H, s), 4.07 (3H, s), 6.62 (1H, d, J=5.2Hz), 7.32 (2H, d, J=9.2Hz), 7.55 (1H, s), 8.36 (2H, d, J=9.2Hz), 8.69 (1H, s), 8.76 (1H, d, J=5.2Hz).

Production Example 339-2

4-(4-Aminophenoxy)-7-methoxy-6-methoxycarbonylquinoline

[0881] The title compound (1.053 g, 3.25 mmol, 66.5%) was obtained as light brown crystals from 7-methoxy-6-methoxycarbonyl-4-(4-nitrophenoxy)quinoline (1.73 g, 4.88 mmol), in the same manner as Production Example 10.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.97 (3H, s), 4.04 (3H, s), 6.42 (1H, d, J=5.2Hz), 6.76 (2H, m), 6.98 (2H, m), 7.48 (1H, s), 8.61 (1H, d, J=5.2Hz), 8.83 (1H, s).

Example 340

Methyl 7-methoxy-4-(4-(((1,3-thiazol-2-ylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylate

[0882] The title compound (306 mg, 0.68 mmol, 45.3%) was obtained as light brown crystals from 4-(4-aminophenoxy)-7-methoxy-6-methoxycarbonylquinoline (486 mg, 1.5 mmol) and phenyl N-(1,3-thiazol-2-yl)carbamate, by the same procedure as in Example 131.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.85 (3H, s), 3.97 (3H, s), 6.47 (1H, d, J=5.2Hz), 7.11 (1H, br), 7.27 (2H, d, J=9.2Hz), 7.37 (1H, br), 7.52 (1H, s), 7.61 (2H, d, J=9.2Hz), 8.59 (1H, s), 8.67 (1H, d, J=5.2Hz), 9.11 (1H, br), 10.53 (1H, br).

Example 341

4-(4-(((4-Fluoroanilino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid

[0883] After adding methanol (9 ml) and 2N aqueous sodium hydroxide (3 ml) to methyl-4-(4-(((4-fluoroanilino)carbonyl)amino)phenoxy)-7-methoxy-6-quinoline carboxylate (300 mg, 0.65 mmol), the mixture was stirred at room temperature for 2 hours and then at 60°C for 20 minutes. The reaction solution was cooled to room temperature and 1N hydrochloric acid was added for neutralization, after which methanol (6 ml) and water (6 ml) were added, the mixture was stirred overnight, and the precipitated light brown crystals were filtered out and dried under reduced pressure to

obtain the title compound (227 mg, 0.51 mmol, 78.0%).

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.97 (3H, s), 6.49 (1H, d, J=5.2Hz), 7.11 (2H, m), 7.23 (2H, d, J=8.8Hz), 7.46 (2H, m), 7.49 (1H, s), 7.58 (2H, d, J=8.8Hz), 8.57 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.75 (1H, s), 8.84 (1H, s).

5 Example 342

7-Methoxy-4-(4-(((1,3-thiazol-2-ylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylic acid

10 **[0884]** The title compound (243 mg, 0.56 mmol, 95.4%) was obtained as light brown crystals from methyl 7-methoxy-4-(4-(((1,3-thiazol-2-ylamino)carbonyl)amino)phenoxy)-6-quinoline carboxylate (263 mg, 0.58 mmol), by the same procedure as in Example 341.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 4.00 (3H, s), 6.63 (1H, d, J=5.2Hz), 7.10 (1H, d, J=3.6Hz), 7.31 (2H, d, J=8.8Hz), 7.36 (1H, d, J=3.6Hz), 7.57 (1H, s), 7.65 (2H, d, J=8.8Hz), 8.62 (1H, s), 8.78 (1H, d, J=5.2Hz), 9.64 (1H, s).

15 Example 343

2-Propyl 4-(4-(((4-fluoroanilino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxylate

20 **[0885]** After dissolving 4-(4-(((4-fluoroanilino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxylic acid (84 mg, 0.19 mmol) in dimethylformamide (1 ml), there were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (54 mg, 0.28 mmol), 1-hydroxy-1H-benzotriazole monohydrate (38 mg, 0.28 mmol), triethylamine (0.079 ml, 0.56 mmol) and 2-propanol (0.15 ml) while stirring on ice, and the mixture was stirred overnight at room temperature. The reaction solution was directly subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals

25 were filtered out and blow-dried to obtain the title compound (15.0 mg, 0.03 mmol, 16%) as white crystals.
¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.32 (6H, d, J=6.4Hz), 3.95 (3H, s), 5.15 (1H, m), 6.45 (1H, d, J=5.2Hz), 7.11 (2H, m), 7.23 (2H, d, J=9.2Hz), 7.46 (2H, m), 7.50 (1H, s), 7.58 (2H, d, J=9.2Hz), 8.48 (1H, s), 8.66 (1H, d, J=5.2Hz), 8.73 (1H, s), 8.82 (1H, s).

30 Example 344

2-Methoxyethyl 4-(4-(((4-fluoroanilino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylate

35 **[0886]** After dissolving 4-(4-(((4-fluoroanilino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxylic acid (84 mg, 0.19 mmol) in dimethylformamide (1 ml), there were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (54 mg, 0.28 mmol), 1-hydroxy-1H-benzotriazole monohydrate (38 mg, 0.28 mmol), triethylamine (0.079 ml, 0.56 mmol) and 2-methoxyethanol (0.15 ml) while stirring on ice, and the mixture was stirred overnight at room temperature. The reaction solution was directly subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and

40 the crystals were filtered out and blow-dried to obtain the title compound (47.1 mg, 0.093 mmol, 49.6%) as white crystals.
¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.29 (3H, s), 3.65 (2H, m), 3.96 (3H, s), 4.40 (2H, m), 6.46 (1H, d, J=5.2Hz), 7.11 (2H, m), 7.24 (2H, d, J=8.8Hz), 7.46 (2H, m), 7.51 (1H, s), 7.58 (2H, d, J=8.8Hz), 8.56 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.73 (1H, s), 8.81 (1H, s).

45 Example 345

2-Methoxyethyl 7-methoxy-4-(4-(((1,3-thiazol-2-ylamino)carbonyl) amino)phenoxy)-6-quinolinecarboxylate

50 **[0887]** After dissolving 7-methoxy-4-(4-(((1,3-thiazol-2-ylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylic acid (87.3 mg, 0.20 mmol) in dimethylformamide (1 ml), there were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (58 mg, 0.30 mmol), 1-hydroxy-1H-benzotriazole monohydrate (41 mg, 0.30 mmol), triethylamine (0.084 ml, 0.60 mmol) and 2-methoxyethylamine (0.052 ml, 0.60 mmol) while stirring on ice, and the mixture was stirred at room temperature for 5 hours. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and dried over anhydrous magnesium sulfate. After distilling off the solvent, ethyl acetate

55 and then hexane was added to precipitate crystals, which were filtered out and dried under reduced pressure to obtain the title compound (24.4 mg, 0.049 mmol, 24.7%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.29 (3H, s), 3.48 (4H, s), 4.02 (3H, s), 6.47 (1H, d, J=5.2Hz), 7.11 (1H, br), 7.26 (2H, d, J=8.8Hz), 7.37 (1H, br), 7.51 (1H, s), 7.61 (2H, d, J=8.8Hz), 8.44 (1H, s), 8.62 (1H, s), 8.65 (1H, d, J=5.2Hz),

9.11 (1H, s), 10.54 (1H, s).

Example 346

N6-Methoxy-7-methoxy-4-(4-(((1,3-thiazol-2-ylamino)carbonyl) amino)phenoxy)-6-quinolinecarboxamide

[0888] The title compound (36.1 mg, 0.078 mmol, 61.5%) was obtained as light yellow crystals from 7-methoxy-4-(4-(((1,3-thiazol-2-ylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylic acid (55 mg, 0.13 mmol) and methoxylamine hydrochloride, by the same procedure as in Example 345.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.73 (3H, s), 3.97 (3H, s), 6.47 (1H, d, J=5.2Hz), 7.11 (1H, br), 7.25 (2H, d, J=8.8Hz), 7.37 (1H, br), 7.48 (1H, s), 7.62 (2H, d, J=8.8Hz), 8.44 (1H, s), 8.65 (1H, d, J=5.2Hz), 9.11 (1H, s), 11.44 (1H, s).

Example 347

4-(4-(2,4-Difluoroanilino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0889] The title compound (59.9 mg, 0.13 mmol, 79.8%) was obtained as light yellow crystals from 4-(4-aminophenoxy)-7-methoxy-6-quinolinecarboxamide (50 mg, 0.16 mmol) and 2,4-difluorophenyl isocyanate, by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 4.00 (3H, s), 6.46 (1H, d, J=5.2Hz), 7.03 (1H, m), 7.23 (2H, d, J=8.8Hz), 7.33 (1H, m), 7.50 (1H, s), 7.58 (2H, d, J=8.8Hz), 7.72 (1H, s), 7.84 (1H, s), 8.07 (1H, m), 8.52 (1H, s), 8.64 (1H, d, J=5.2Hz), 8.67 (1H, s), 9.16 (1H, s).

[0890] The starting material was synthesized in the following manner.

Production Example 347-1

4-(4-Aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0891] The title compound (1.56 g, 5.0 mmol, 43.4%) was obtained as light yellow crystals from the 4-(4-aminophenoxy)-6-cyano-7-methoxyquinoline (4.76 g, 11.6 mmol) described in Production Example 14, by the same procedure as in Example 112.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 4.00 (3H, s), 5.15 (2H, m), 6.39 (1H, d, J=5.2Hz), 6.65 (2H, d, J=8.8Hz), 6.92 (2H, d, J=8.8Hz), 7.46 (1H, s), 7.70 (1H, s), 7.83 (1H, s), 8.60 (1H, d, J=5.2Hz), 8.66 (1H, s).

Example 348

4-(4-(4-Fluoroanilino)carbonyl)-4-methylaminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0892] The title compound (265 mg, 0.58 mmol, 64.6%) was obtained as white crystals from 7-methoxy-4-(4-methylaminophenoxy)-6-quinolinecarboxamide (288 mg, 0.89 mmol) and 4-fluorophenyl isocyanate, by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.29 (3H, s), 4.00 (3H, s), 6.65 (1H, d, J=5.2Hz), 7.06 (2H, m), 7.32 (2H, d, J=8.8Hz), 7.41-7.48 (4H, m), 7.51 (1H, s), 7.73 (1H, s), 7.85 (1H, s), 8.23 (1H, s), 8.67 (1H, s), 8.69 (1H, d, J=5.2Hz).

[0893] The starting material was synthesized in the following manner.

Production Example 348-1

7-Methoxy-4-(4-methylaminophenoxy)-6-quinolinecarboxamide

[0894] After dissolving 4-methylaminophenol (1.04 g, 8.45 mmol) in dimethylsulfoxide (10 ml), sodium hydride (290 mg, 8.45 mmol) was gradually added at room temperature and the mixture was stirred for 20 minutes. The 7-methoxy-4-chloro-6-quinolinecarboxamide (1.00 g, 4.23 mmol) obtained in Production Example 152-3 was added, and the mixture was heated at 100°C for 3 hours while stirring. Upon cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off and subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (815 mg, 2.52 mmol,

59.6%) as white crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.88 (3H, s), 4.09-4.16 (4H, m), 5.88 (1H, br), 6.45 (1H, d, J=5.6Hz), 6.68 (2H, m), 7.01 (2H, m), 7.51 (1H, s), 7.80 (1H, br), 8.61 (1H, d, J=5.6Hz), 9.31 (1H, s).

Example 349

7-Methoxy-4-(4-((2-thiazolylamino)carbonyl)-4-methylaminophenoxy)-6-quinolinecarboxamide

[0895] The title compound (33.0 mg, 0.073 mmol, 47.5%) was obtained as white crystals from 6-carbamoyl-7-methoxy-4-(4-methylaminophenoxy)quinoline (50 mg, 0.16 mmol) and phenyl N-(1,3-thiazol-2-yl)carbamate, by the same procedure as in Example 131.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.37 (3H, s), 4.02 (3H, s), 6.64 (1H, br), 7.02 (1H, br), 7.30-7.33 (3H, m), 7.47 (2H, d, J=8.8Hz), 7.51 (1H, s), 7.72 (1H, s), 7.85 (1H, s), 8.67 (1H, s), 8.69 (1H, d, J=5.2Hz).

Example 350

4-(4-(Cyclopropylaminocarbonyl)-4-methylaminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0896] The title compound (30.0 mg, 0.073 mmol, 49.4%) was obtained as white crystals from 4-nitrophenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxyphenyl)-N-methylcarbamate (73 mg, 0.15 mmol) and cyclopropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.54 (2H, m), 2.50 (1H, m), 3.16 (3H, s), 4.03 (3H, s), 6.27 (1H, d, J=2.8Hz), 6.60 (1H, d, J=5.6Hz), 7.27 (2H, m), 7.36 (2H, m), 7.52 (1H, s), 7.73 (1H, s), 7.85 (1H, s), 8.66 (1H, s), 8.69 (1H, d, J=5.6Hz).

[0897] The starting material was synthesized in the following manner.

Production Example 350-1

4-Nitrophenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxyphenyl)-N-methyl carbamate

[0898] The title compound (373 mg, 0.076 mmol, 76.4%) was obtained as light yellow crystals from 6-carbamoyl-7-methoxy-4-(4-methylaminophenoxy)quinoline (323 mg, 1.00 mmol) and 4-nitrophenyl chloroformate, by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.47 (3H, s), 4.15 (3H, s), 5.89 (1H, br), 6.56 (1H, d, J=5.6Hz), 7.23-7.45 (6H, m), 7.56 (1H, s), 7.82 (1H, s), 8.27 (2H, d, J=8.8Hz), 8.69 (1H, d, J=5.6Hz), 9.29 (1H, s).

Example 351

7-Methoxy-4-(4-((3-methylthiopropylamino)carbonyl)-4-methylaminophenoxy)-6-quinolinecarboxamide

[0899] The title compound (44.8 mg, 0.099 mmol, 65.9%) was obtained as white crystals from 4-nitrophenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxyphenyl)-N-methylcarbamate (73 mg, 0.15 mmol) and 3-(methylthio)propylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.64 (2H, m), 2.01 (3H, s), 2.42 (2H, m), 3.09 (2H, m), 3.16 (3H, s), 4.01 (3H, s), 6.17 (1H, t, J=5.6Hz), 6.59 (1H, d, J=5.2Hz), 7.28 (2H, d, J=8.8Hz), 7.37 (2H, d, J=8.8Hz), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.65 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 352

4-(4-((3-Methylsulfonyl)propylamino)carbonyl)-4-methylaminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0900] The title compound (42.7 mg, 0.088 mmol, 58.7%) was obtained as white crystals from 4-nitrophenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxyphenyl)-N-methylcarbamate (73 mg, 0.15 mmol) and 3-(methylsulfonyl)propylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.81 (2H, m), 2.94 (3H, s), 3.06 (2H, m), 3.12 (2H, m), 3.17 (3H, s), 4.01 (3H, s), 6.26 (1H, t, J=5.6Hz), 6.60 (1H, d, J=5.2Hz), 7.28 (2H, d, J=8.8Hz), 7.39 (2H, d, J=8.8Hz), 7.51 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.65 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 3534-(3-Fluoro-4-((3-methylthiopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0901] The title compound (71.1 mg, 0.155 mmol, 77.5%) was obtained as light brown crystals from 4-phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (89.5 mg, 0.20 mmol) and 3-(methylthio)propylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.69 (2H, m), 2.04 (3H, s), 2.04-2.05 (2H, m), 3.17 (2H, m), 4.01 (3H, s), 6.51 (1H, d, J=5.2Hz), 6.65 (1H, t, J=6.0Hz), 7.05 (1H, d, J=9.6Hz), 7.30 (1H, dd, J=2.8, 11.6Hz), 7.49 (1H, s), 7.71 (1H, s), 7.83 (1H, s), 8.21 (1H, m), 8.33 (1H, s), 8.64-8.65 (2H, m).

[0902] The starting material was synthesized in the following manner.

Production Example 353-1Phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate

[0903] The title compound (391.5 mg, 0.875 mmol, 38.1%) was obtained as light yellow crystals from 6-carbamoyl-7-methoxy-4-(3-fluoro-4-aminophenoxy)quinoline (752 mg, 2.30 mmol), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.14 (3H, s), 5.92 (1H, s), 6.52 (1H, d, J=5.6Hz), 7.02 (2H, m), 7.21-7.31 (4H, m), 7.43 (2H, m), 7.55 (1H, s), 7.81 (1H, s), 8.23 (1H, br), 8.68 (1H, d, J=5.6Hz), 9.27 (1H, s).

Example 3544-(3-Fluoro-4-((3-methylsulfonylpropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0904] The title compound (41.3 mg, 0.084 mmol, 42.1%) was obtained as white crystals from 4-phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (89.5 mg, 0.20 mmol) and 3-(methylsulfonyl)propylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.85 (2H, m), 2.97 (3H, s), 3.12 (2H, m), 3.21 (2H, m), 4.01 (3H, s), 6.51 (1H, d, J=5.2Hz), 6.73 (1H, t, J=5.6Hz), 7.05 (1H, d, J=9.6Hz), 7.31 (1H, dd, J=2.8, 11.6Hz), 7.50 (1H, s), 7.72 (1H, s), 7.83 (1H, s), 8.20 (1H, m), 8.40 (1H, s), 8.64-8.66 (2H, m).

Example 3554-(3-Fluoro-4-((2,2,2-trifluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0905] The title compound (47.4 mg, 0.105 mmol, 69.9%) was obtained as light yellow crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (67 mg, 0.15 mmol) and 2,2,2-trifluoroethylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.96 (2H, m), 4.02 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.09 (1H, d, J=8.8Hz), 7.17 (1H, t, J=6.4Hz), 7.35 (1H, dd, J=2.8, 11.6Hz), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.16 (1H, m), 8.51 (1H, s), 8.64-8.67 (2H, m).

Example 3564-(4-((3-Ethoxypropylamino)carbonyl)amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide

[0906] The title compound (45.2 mg, 0.099 mmol, 66.0%) was obtained as light brown crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (67 mg, 0.15 mmol) and 3-ethoxypropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.10 (3H, t, J=7.2Hz), 1.65 (2H, m), 3.14 (2H, q, J=7.2Hz), 3.35-3.44 (4H, m), 4.01 (3H, s), 6.52 (1H, d, J=5.2Hz), 6.61 (1H, m), 7.05 (1H, d, J=8.8Hz), 7.31 (1H, dd, J=2.8, 11.6Hz), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.22 (1H, m), 8.35 (1H, s), 8.64-8.67 (2H, m).

Example 3574-(3-Fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0907] The title compound (23.9 mg, 0.057 mmol, 77.8%) was obtained as light brown crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (33 mg, 0.074 mmol) and 2-fluoroethylamine hydrochloride, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.08 (2H, m), 4.02 (3H, s), 4.40 (1H, t, J=5.2Hz), 4.52 (1H, t, J=5.2Hz), 6.55 (1H, d, J=5.2Hz), 6.88 (1H, m), 7.08 (1H, d, J=9.2Hz), 7.33 (1H, dd, J=2.8, 11.6Hz), 7.51 (1H, s), 7.74 (1H, s), 7.85 (1H, s), 8.21 (1H, m), 8.51 (1H, s), 8.65 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 3584-(4-((3-Chloropropylamino)carbonyl)amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide

[0908] The title compound (22.0 mg, 0.049 mmol, 66.8%) was obtained as light yellow crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (33 mg, 0.074 mmol) and 3-chloropropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.89 (2H, m), 3.22 (2H, m), 3.68 (2H, m), 4.01 (3H, s), 6.52 (1H, d, J=5.2Hz), 6.71 (1H, m), 7.06 (1H, d, J=8.8Hz), 7.31 (1H, dd, J=2.8, 11.6Hz), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.20 (1H, m), 8.37 (1H, s), 8.64-8.66 (2H, m).

Example 3594-(3-Fluoro-4-((3-fluoropropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0909] The title compound (7.9 mg, 0.018 mmol, 12.2%) was obtained as light yellow crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (67 mg, 0.15 mmol) and 3-fluoropropylamine hydrochloride, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.82 (2H, m), 3.20 (2H, m), 4.01 (3H, s), 4.44 (1H, t, J=6.0Hz), 4.55 (1H, t, J=6.0Hz), 6.52 (1H, d, J=5.2Hz), 6.69 (1H, m), 7.06 (1H, d, J=8.8Hz), 7.31 (1H, dd, J=2.8, 11.6Hz), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.21 (1H, m), 8.38 (1H, s), 8.64-8.66 (2H, m).

Example 3607-(2-Methoxyethoxy)-4-(4-((3-methoxypropylamino)carbonyl)aminophenoxy)-6-quinolinecarboxamide

[0910] The title compound (35.2 mg, 0.075 mmol, 71.1%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (50 mg, 0.106 mmol) and 3-methoxypropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.66 (2H, m), 3.13 (2H, m), 3.23 (3H, s), 3.28-3.34 (2H, m), 3.36 (3H, s), 3.79 (2H, m), 4.40 (2H, m), 6.16 (1H, m), 6.43 (1H, d, J=5.6Hz), 7.15 (2H, d, J=8.8Hz), 7.51 (2H, d, J=8.8Hz), 7.54 (1H, s), 7.79 (1H, s), 7.81 (1H, s), 8.60 (1H, s), 8.63 (1H, d, J=5.6Hz), 8.77 (1H, s).

[0911] The starting material was synthesized in the following manner.

Production Example 360-14-(4-Aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0912] The title compound (1.303 g) was obtained as brown crystals from the 4-(4-aminophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (3.448 g, 9.67 mmol) described in Production Example 10, by the same procedure as in Example 112. This was used directly for the following reaction.

Production Example 360-24-Phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate

[0913] The title compound (1.462 g, 3.09 mmol, 83.7%) was obtained as light yellow crystals from 4-(4-aminophe-

noxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide (1.303 g, 3.69 mmol), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.48 (3H, s), 3.89 (2H, m), 4.44 (2H, m), 5.87 (1H, s), 6.50 (1H, d, J=5.6Hz), 7.16-7.29 (7H, m), 7.42 (2H, m), 7.58 (1H, s), 7.60 (1H, s), 8.10 (1H, s), 8.64 (1H, d, J=5.6Hz), 9.31 (1H, s).

Example 361

4-(4-((2-Fluoroethylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0914] The title compound (33.1 mg, 0.075 mmol, 74.8%) was obtained as light brown crystals from phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (47.3 mg, 0.10 mmol) and 2-fluoroethylamine hydrochloride, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.26-3.38 (5H, m), 3.79 (2H, m), 4.38-4.41 (3H, m), 4.51 (1H, t, J=5.2Hz), 6.39 (1H, m), 6.43 (1H, d, J=5.2Hz), 7.17 (2H, d, J=8.8Hz), 7.50-7.54 (3H, m), 7.79 (1H, s), 7.81 (1H, s), 8.63 (1H, d, J=5.2Hz), 8.71 (1H, s), 8.77 (1H, s).

Example 362

4-(4-((3-Fluoropropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0915] The title compound (8.0 mg, 0.018 mmol, 17.5%) was obtained as light yellow crystals from phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)carbamate (47.3 mg, 0.10 mmol) and 3-fluoropropylamine hydrochloride, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.76-1.87 (2H, m), 3.17 (2H, m), 3.36 (3H, s), 3.79 (2H, m), 4.38-4.45 (3H, m), 4.55 (1H, m), 6.24 (1H, m), 6.43 (1H, d, J=5.2Hz), 7.16 (2H, d, J=8.8Hz), 7.51 (2H, d, J=8.8Hz), 7.53 (1H, s), 7.79 (1H, s), 7.81 (1H, s), 8.62-8.64 (2H, m), 8.77 (1H, s).

Example 363

4-(3-Fluoro-4-((3-methoxypropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0916] The title compound (37.2 mg, 0.076 mmol, 75.2%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (50 mg, 0.102 mmol) and 3-methoxypropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.66 (2H, m), 3.16 (2H, m), 3.23 (3H, s), 3.28-3.34 (2H, m), 3.36 (3H, s), 3.79 (2H, m), 4.40 (2H, m), 6.52 (1H, d, J=5.6Hz), 6.62 (1H, m), 7.06 (1H, d, J=11.2Hz), 7.31 (1H, dd, J=2.8, 11.6Hz), 7.55 (1H, s), 7.80 (1H, s), 7.81 (1H, s), 8.22 (1H, m), 8.36 (1H, s), 8.65 (1H, d, J=5.6Hz), 8.75 (1H, s).

[0917] The starting material was synthesized in the following manner.

Production Example 363-1

4-(4-Amino-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0918] The title compound (991 mg) was obtained as light yellow crystals from the 4-(4-amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (6.368 g, 18.0 mmol) described in Production Example 12, by the same procedure as in Example 112. This was used directly for the following reaction.

Production Example 363-2

Phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate

[0919] The title compound (1.074 g, 2.19 mmol, 81.9%) was obtained as light brown crystals from 4-(4-amino-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide (991 mg, 2.67 mmol), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.48 (3H, s), 3.90 (2H, m), 4.46 (2H, m), 5.88 (1H, s), 6.58 (1H, d, J=5.2Hz), 7.02-7.06 (2H, m), 7.21-7.30 (4H, m), 7.43 (2H, m), 7.71 (1H, s), 8.08 (1H, s), 8.27 (1H, br), 8.68 (1H, d, J=5.2Hz), 9.29 (1H, s).

Example 3644-(4-(3-Fluoro(2-fluoroethylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0920] The title compound (35.4 mg, 0.077 mmol, 76.9%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (49.1 mg, 0.10 mmol) and 2-fluoroethylamine hydrochloride, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.36 (3H, s), 3.45 (2H, m), 3.79 (2H, m), 4.38-4.41 (3H, m), 4.52 (1H, t, J=4.8Hz), 6.52 (1H, d, J=5.2Hz), 6.87 (1H, m), 7.07 (1H, d, J=6.8Hz), 7.33 (1H, dd, J=2.8, 11.6Hz), 7.55 (1H, s), 7.79 (1H, s), 7.81 (1H, s), 8.20 (1H, m), 8.49 (1H, s), 8.65 (1H, d, J=5.2Hz), 8.75 (1H, s).

Example 3654-(4-(3-Fluoro(2-fluoropropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0921] The title compound (6.8 mg, 0.014 mmol, 14.3%) was obtained as light yellow crystals from phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate (49.1 mg, 0.10 mmol) and 3-fluoropropylamine hydrochloride, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.76-1.87 (2H, m), 3.18 (2H, m), 3.34 (3H, s), 3.79 (2H, m), 4.38-4.45 (3H, m), 4.55 (1H, m), 6.52 (1H, d, J=5.2Hz), 6.69 (1H, m), 7.07 (1H, d, J=8.8Hz), 7.32 (1H, dd, J=2.8, 11.6Hz), 7.55 (1H, s), 7.80 (1H, s), 7.81 (1H, s), 8.21 (1H, m), 8.39 (1H, s), 8.65 (1H, d, J=5.2Hz), 8.75 (1H, s).

Example 3664-(3-Chloro-4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0922] The title compound (53.6 mg, 0.111 mmol, 76.9%) was obtained as light brown crystals from 4-(4-amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (50 mg, 0.145 mmol) and 4-fluorophenyl isocyanate, by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 4.01 (3H, s), 6.55 (1H, d, J=5.2Hz), 7.14 (2H, m), 7.28 (1H, dd, J=2.4, 9.2Hz), 7.47 (2H, m), 7.51 (1H, s), 7.55 (1H, d, J=2.4Hz), 7.73 (1H, s), 7.85 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.38 (1H, s), 8.65 (1H, s), 8.67 (1H, d, J=5.2Hz), 9.43 (1H, s).

[0923] The starting material was synthesized in the following manner.

Production Example 366-14-(4-Amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide

[0924] After dissolving 4-amino-3-chlorophenol (1.213 g, 8.45 mmol) in dimethylsulfoxide (10 ml), sodium hydride (290 mg, 8.45 mmol) was gradually added at room temperature and the mixture was stirred for 30 minutes. The 7-methoxy-4-chloro-6-quinolinecarboxamide (1.00 g, 4.23 mmol) obtained in Production Example 152-3 was added, and the mixture was heated at 100°C for 2 hours while stirring. Upon cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off and subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 9:1), the fraction containing the target substance was concentrated, suspended in tetrahydrofuran and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (1.216 g, 3.54 mmol, 83.7%) as light brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 4.10 (2H, s), 4.13 (3H, s), 5.90 (1H, br), 6.46 (1H, d, J=5.6Hz), 6.86 (1H, m), 6.93 (1H, dd, J=2.4, 8.4Hz), 7.13 (1H, d, J=2.4Hz), 7.53 (1H, s), 7.80 (1H, br), 8.64 (1H, d, J=5.6Hz), 9.27 (1H, s).

Example 3674-(3-Chloro-4-((2-thiazolylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0925] The title compound (38.3 mg, 0.082 mmol, 56.2%) was obtained as light brown crystals from 4-(4-amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (50 mg, 0.145 mmol) and phenyl N-(1,3-thiazol-2-yl)carbamate, by the same procedure as in Example 131.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 4.02 (3H, s), 6.56 (1H, d, J=5.2Hz), 7.15 (1H, s), 7.31 (1H, d, J=8.0Hz), 7.40

(1H, s), 7.51 (1H, s), 7.59 (1H, s), 7.73 (1H, s), 7.85 (1H, s), 8.27 (1H, d, J=8.0Hz), 8.65 (1H, s), 8.67 (1H, d, J=5.2Hz), 11.19 (1H, s).

Example 368

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0926] The title compound (22.4 mg, 0.052 mmol, 34.8%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (70 mg, 0.15 mmol) and cyclopropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.66 (2H, m), 2.56 (1H, m), 4.01 (3H, s), 6.51 (1H, d, J=5.6Hz), 7.18 (1H, d, J=2.8Hz), 7.23 (1H, dd, J=2.8, 8.8Hz), 7.48 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 7.97 (1H, s), 8.25 (1H, d, J=8.8Hz), 8.64 (1H, s), 8.65 (1H, d, J=5.6Hz).

[0927] The starting material was synthesized in the following manner.

Production Example 368-1

Phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate

[0928] The title compound (708 mg, 1.526 mmol, 87.4%) was obtained as light brown crystals from 4-(4-amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (600 mg, 1.745 mmol), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.14 (3H, s), 5.89 (1H, br), 6.50 (1H, d, J=5.6Hz), 7.16 (2H, dd, J=2.4, 8.8Hz), 7.22-7.30 (4H, m), 7.44 (2H, m), 7.55 (1H, s), 7.81 (1H, br), 8.31 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.6Hz), 9.27 (1H, s).

Example 369

4-(3-Chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[0929] The title compound (95.8 mg, 0.221 mmol, 51.3%) was obtained as light brown crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (200 mg, 0.431 mmol) and 2-fluoroethylamine hydrochloride, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.98 (1H, m), 3.46 (1H, m), 4.02 (3H, s), 4.42 (1H, t, J=4.8Hz), 4.53 (1H, dd, J=4.8, 5.6Hz), 6.52 (1H, d, J=5.2Hz), 7.23 (1H, d, J=2.4, 8.8Hz), 7.29 (1H, m), 7.48 (1H, d, J=2.4Hz), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.22-8.25 (2H, m), 8.64-8.66 (2H, m).

Example 370

7-Benzyloxy-4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-6-quinolinecarboxamide

[0930] The title compound (663 mg, 1.363 mmol, 93.9%) was obtained as light yellow crystals from phenyl N-(4-(7-benzyloxy-6-carbamoyl-4-quinolyl)oxy-2-fluorophenyl)carbamate (760 mg, 1.452 mmol) and cyclopropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 5.44 (2H, s), 6.54 (1H, d, J=5.6Hz), 6.82 (1H, d, J=2.8Hz), 7.08 (1H, m), 7.33 (1H, dd, J=2.8, 12.0Hz), 7.38 (1H, d, J=7.2Hz), 7.44 (2H, m), 7.58 (2H, d, J=7.2Hz), 7.61 (1H, s), 7.75 (1H, s), 7.84 (1H, s), 8.20-8.24 (2H, m), 8.63 (1H, s), 8.66 (1H, d, J=5.6Hz).

[0931] The starting material was synthesized in the following manner.

Production Example 370-1

4-(4-Amino-3-fluorophenoxy)-7-(benzyloxy)-6-quinolinecarboxamide

[0932] The title compound (752 mg, 1.86 mmol, 31.6%) was obtained as light brown crystals from the 4-(4-amino-3-fluorophenoxy)-7-benzyloxy-6-cyanoquinoline (2.27 g, 5.89 mmol) described in Production Example 8, by the same procedure as in Example 112.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 3.77 (2H, s), 5.34 (2H, s), 5.78 (1H, br), 6.47 (1H, d, J=5.2Hz), 6.79-6.91 (3H, m), 7.41-7.54 (5H, m), 7.62 (1H, s), 7.81 (1H, br), 8.65 (1H, d, J=5.2Hz), 9.31 (1H, s).

Production Example 370-2Phenyl N-(4-(7-benzyloxy-6-carbamoyl-4-quinolyl)oxy-2-fluorophenyl)carbamate

[0933] The title compound (760 mg, 1.452 mmol, 77.9%) was obtained as light yellow crystals from 4-(4-amino-3-fluorophenoxy)-7-(benzyloxy)-6-quinolinecarboxamide (752 mg, 1.864 mmol), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 5.35 (2H, s), 5.80 (1H, br), 6.52 (1H, d, J=5.2Hz), 7.03 (2H, m), 7.22-7.30 (4H, m), 7.41-7.49 (5H, m), 7.53 (2H, d, J=6.8Hz), 7.64 (1H, s), 7.82 (1H, br), 8.24 (1H, br), 8.69 (1H, d, J=5.2Hz), 9.30 (1H, s).

Example 3714-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide

[0934] The title compound (498 mg, 1.256 mmol, 95.5%) was obtained as light yellow crystals from 7-benzyloxy-4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-6-quinolinecarboxamide (640 mg, 1.316 mmol), by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.66 (2H, m), 2.57 (1H, m), 6.42 (1H, d, J=5.2Hz), 6.83 (1H, s), 7.31 (1H, d, J=9.2Hz), 7.30 (1H, s), 7.34 (1H, dd, J=2.8, 11.6Hz), 8.08 (1H, s), 8.21-8.26 (2H, m), 8.61 (1H, d, J=5.2Hz), 8.91 (1H, br), 8.96 (1H, s).

Example 3724-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-(3-(N,N-diethylamino)propoxy)-6-quinolinecarboxamide

[0935] The title compound (34.2 mg, 0.067 mmol, 53.2%) was obtained as light yellow crystals from 4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.126 mmol) and N-(3-chloropropyl)-N,N-diethylamine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 0.95 (6H, t, J=7.2Hz), 1.96 (2H, m), 2.44-2.49 (4H, m), 2.57-2.59 (3H, m), 4.30 (2H, m), 6.52 (1H, d, J=5.2Hz), 6.70 (1H, s), 7.09 (1H, d, J=10.8Hz), 7.32 (1H, m), 7.50 (1H, s), 7.79 (1H, s), 7.91 (1H, s), 8.19-8.22 (2H, m), 8.66 (1H, d, J=5.2Hz), 8.69 (1H, s).

Example 3734-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-(2-(N,N-diethylamino)ethoxy)-6-quinolinecarboxamide

[0936] The title compound (20.6 mg, 0.042 mmol, 33.0%) was obtained as light yellow crystals from 4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.126 mmol) and N-(2-bromoethyl)-N,N-diethylamine hydrobromide, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 0.97 (6H, t, J=7.2Hz), 2.50-2.58 (5H, m), 2.85 (2H, m), 4.36 (2H, m), 6.52 (1H, d, J=5.2Hz), 6.81 (1H, s), 7.09 (1H, d, J=6.8Hz), 7.34 (1H, d, J=11.6Hz), 7.57 (1H, s), 7.81 (1H, s), 8.19-8.22 (2H, m), 8.31 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.80 (1H, s).

Example 3744-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-(3-(4-morpholino)propoxy)-6-quinolinecarboxamide

[0937] The title compound (35.0 mg, 0.067 mmol, 53.0%) was obtained as yellow crystals from 4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.126 mmol) and N-(3-chloropropyl)morpholine, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.01 (2H, m), 2.39 (4H, br), 2.46-2.50 (2H, m), 2.56 (1H, m), 3.59 (4H, m), 4.31 (2H, m), 6.52 (1H, d, J=5.2Hz), 6.82 (1H, s), 7.08 (1H, d, J=8.4Hz), 7.31 (1H, m), 7.52 (1H, s), 7.78 (2H, s), 8.19-8.24 (2H, m), 8.65-8.67 (2H, m).

Example 3754-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide

[0938] The title compound (35.1 mg, 0.069 mmol, 54.6%) was obtained as yellow crystals from 4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.126 mmol) and N-(2-chloroethyl) morpholine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.50-2.56 (5H, m), 2.79 (2H, m), 3.60 (4H, br), 4.41 (2H, m), 6.53 (1H, d, J=5.2Hz), 6.81 (1H, s), 7.08 (1H, d, J=9.6Hz), 7.33 (1H, d, J=12.8Hz), 7.58 (1H, s), 7.87 (1H, s), 8.19-8.23 (2H, m), 8.39 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.82 (1H, s).

Example 3764-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-((2-pyridyl)methoxy)-6-quinolinecarboxamide

[0939] The title compound (20.2 mg, 0.041 mmol, 32.8%) was obtained as light brown crystals from 4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.126 mmol) and 2-chloromethylpyridine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 5.53 (2H, s), 6.54 (1H, d, J=5.2Hz), 6.80 (1H, s), 7.08 (1H, d, J=10.4Hz), 7.30-7.40 (2H, m), 7.59 (1H, s), 7.62 (1H, d, J=8.0Hz), 7.79 (1H, s), 7.86 (1H, dd, J=2.0, 7.6Hz), 8.19-8.23 (3H, m), 8.61-8.68 (3H, m).

Example 3774-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-((3-pyridyl)methoxy)-6-quinolinecarboxamide

[0940] The title compound (20.2 mg, 0.041 mmol, 32.8%) was obtained as light yellow crystals from 4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.126 mmol) and 3-chloromethylpyridine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 5.47 (2H, s), 6.55 (1H, d, J=5.2Hz), 6.81 (1H, s), 7.08 (1H, d, J=10.0Hz), 7.32 (1H, d, J=12.4Hz), 7.45 (1H, m), 7.64 (1H, s), 7.73 (1H, s), 7.83 (1H, s), 7.98 (1H, m), 8.23 (2H, br), 8.57 (2H, br), 8.66 (1H, d, J=5.2Hz), 8.80 (1H, s).

Example 3784-(4-(Cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-((4-pyridyl)methoxy)-6-quinolinecarboxamide

[0941] The title compound (29.8 mg, 0.061 mmol, 48.5%) was obtained as light yellow crystals from 4-(4-(cyclopropylaminocarbonyl)amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.126 mmol) and 4-chloromethylpyridine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 5.50 (2H, s), 6.54 (1H, d, J=5.2Hz), 6.80 (1H, s), 7.07 (1H, d, J=8.0Hz), 7.32 (1H, d, J=11.6Hz), 7.53-7.55 (3H, m), 7.76 (1H, s), 7.92 (1H, s), 8.19-8.22 (2H, m), 8.55 (1H, s), 8.60-8.66 (3H, m).

Example 3797-Benzoyloxy-4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-6-quinolinecarboxamide

[0942] The title compound (2.433 g, 4.84 mmol, 87.9%) was obtained as light yellow crystals from phenyl N-(4-(7-benzoyloxy-6-carbamoyl-4-quinolyl)oxy-2-chlorophenyl)carbamate (2.97 g, 5.50 mmol) and cyclopropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 5.41 (2H, s), 6.51 (1H, d, J=5.6Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, m), 7.35 (1H, d, J=7.2Hz), 7.42 (2H, m), 7.48 (1H, s), 7.55 (2H, d, J=7.2Hz), 7.59 (1H, s), 7.73 (1H, s), 7.82 (1H, s), 7.97 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.60 (1H, s), 8.64 (1H, d, J=5.6Hz).

[0943] The starting material was synthesized in the following manner.

Production Example 379-14-(4-Amino-3-chlorophenoxy)-7-benzyloxy-6-cyanoquinoline

[0944] After dissolving 4-amino-3-chlorophenol (10.77 g, 75.0 mmol) in dimethylsulfoxide (150 ml), sodium hydride (3.00 g, 75.0 mmol) was gradually added at room temperature and the mixture was stirred for 30 minutes. 7-Benzyloxy-4-chloro-6-cyanoquinoline (14.737 g, 50.0 mmol) obtained by a publicly known method was added, and the mixture was heated at 100°C for 2 hours while stirring. Upon cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off and subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (11.777 g, 29.3 mmol, 58.6%) as light brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 4.13 (2H, s), 5.35 (2H, s), 6.47 (1H, d, J=5.2Hz), 6.85 (1H, d, J=8.8Hz), 6.92 (1H, dd, J=2.4, 9.2Hz), 7.13 (1H, d, J=2.4Hz), 7.36 (1H, d, J=7.6Hz), 7.42 (2H, m), 7.51-7.55 (3H, m), 8.65 (1H, d, J=5.2Hz), 8.69 (1H, s).

Production Example 379-24-(4-Amino-3-chlorophenoxy)-7-(benzyloxy)-6-quinolinecarboxamide

[0945] The title compound (5.74 g, 13.7 mmol, 37.8%) was obtained as light brown crystals from 4-(4-amino-3-chlorophenoxy)-7-benzyloxy-6-cyanoquinoline (14.55 g, 36.2 mmol), by the same procedure as in Example 112.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 4.10 (2H, s), 5.34 (2H, s), 5.78 (1H, br), 6.47 (1H, d, J=5.2Hz), 6.85 (1H, d, J=8.4Hz), 6.92 (1H, dd, J=2.4, 8.4Hz), 7.13 (1H, d, J=2.4Hz), 7.38-7.53 (4H, m), 7.62 (1H, s), 7.82 (1H, br), 8.62 (1H, s), 8.64 (1H, d, J=5.2Hz), 9.30 (1H, s).

Production Example 379-3Phenyl N-(4-(7-benzyloxy-6-carbamoyl-4-quinolyl)oxy-2-chlorophenyl)carbamate

[0946] The title compound (2.97 g, 5.50 mmol, 55.0%) was obtained as light brown crystals from 4-(4-amino-3-chlorophenoxy)-7-(benzyloxy)-6-quinolinecarboxamide (4.20 g, 10.0 mmol), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 5.35 (2H, s), 5.81 (1H, br), 6.51 (1H, d, J=5.2Hz), 7.16 (1H, dd, J=2.8, 8.8Hz), 7.22-7.30 (4H, m), 7.41-7.54 (8H, m), 7.64 (1H, s), 7.81 (1H, br), 8.32 (1H, d, J=9.2Hz), 8.69 (1H, d, J=5.2Hz), 9.30 (1H, s).

Example 3804-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide

[0947] The title compound (697 mg, 1.69 mmol, 83.6%) was obtained as yellow crystals from 7-benzyloxy-4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-6-quinolinecarboxamide (1.016 g, 2.02 mmol) by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.43 (2H, m), 0.68 (2H, m), 2.58 (1H, m), 6.56 (1H, d, J=5.6Hz), 7.23 (1H, s), 7.30 (1H, m), 7.36 (1H, s), 7.55 (1H, d, J=2.4Hz), 8.01 (1H, s), 8.19 (1H, s), 8.33 (1H, d, J=9.2Hz), 8.72 (1H, d, J=5.6Hz), 8.82 (1H, s), 9.01 (1H, s).

Example 3814-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[0948] The title compound (29.9 mg, 0.063 mmol, 52.4%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.121 mmol) and 2-methoxyethylbromide, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.57 (1H, m), 3.36 (3H, s), 3.81 (2H, m), 4.41 (2H, m), 6.53 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.41 (1H, d, J=2.8Hz), 7.57 (1H, s), 7.82

(1H, s), 7.83 (1H, s), 7.99 (1H, s), 8.28 (1H, d, J=9.2Hz), 8.68 (1H, d, J=5.2Hz), 8.77 (1H, s).

Example 382

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(3-(4-morpholino)propoxy)-6-quinolinecarboxamide

[0949] The title compound (30.5 mg, 0.056 mmol, 46.6%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.121 mmol) and N-(3-chloropropyl)morpholine, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.02 (2H, m), 2.39 (4H, br), 2.46-2.59 (3H, m), 3.59 (4H, m), 4.31 (2H, m), 6.53 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.78 (2H, s), 7.98 (1H, s), 8.28 (1H, d, J=9.2Hz), 8.65 (1H, s), 8.66 (1H, d, J=5.2Hz).

Example 383

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide

[0950] The title compound (29.8 mg, 0.057 mmol, 46.8%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.121 mmol) and N-(2-chloroethyl)morpholine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.50-2.56 (5H, m), 2.80 (2H, m), 3.60 (4H, br), 4.41 (2H, m), 6.53 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 8.8Hz), 7.50 (1H, d, J=2.8Hz), 7.58 (1H, s), 7.87 (1H, s), 7.99 (1H, s), 8.27 (1H, d, J=8.8Hz), 8.38 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.82 (1H, s).

Example 384

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(3-(1-piperidino)propoxy)-6-quinolinecarboxamide

[0951] The title compound (27.3 mg, 0.051 mmol, 41.9%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.121 mmol) and 1-(chloropropyl)piperidine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 1.36 (2H, m), 1.47 (4H, m), 1.99 (2H, m), 2.33 (4H, br), 2.42 (2H, m), 2.56 (1H, m), 4.27 (2H, m), 6.50 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.76 (2H, br), 7.96 (1H, s), 8.25 (1H, d, J=8.8Hz), 8.64 (1H, d, J=5.2Hz), 8.65 (1H, s).

Example 385

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(1-pyrrolidino)ethoxy)-6-quinolinecarboxamide

[0952] The title compound (24.6 mg, 0.048 mmol, 39.8%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (50 mg, 0.121 mmol) and 1-(chloroethyl)pyrrolidine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 1.67 (4H, br), 2.49-2.58 (5H, m), 2.89 (2H, m), 4.38 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.23 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.56 (1H, s), 7.72 (1H, s), 7.96 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.33 (1H, s), 8.65 (1H, d, J=5.2Hz), 8.76 (1H, s).

Example 386

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide

[0953] The title compound (63.7 mg, 0.139 mmol, 27.9%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (206 mg, 0.499 mmol) and 2-bromoethanol, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.84 (2H, m), 4.30 (2H, m), 5.12 (1H, t, J=5.2Hz), 6.51 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 8.8Hz), 7.49 (1H, d, J=2.8Hz), 7.54 (1H, s), 7.82 (1H, s), 7.94 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.66 (1H, d, J=5.2Hz), 8.80 (1H, s).

Example 3874-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(3-hydroxypropoxy)-6-quinolinecarboxamide

[0954] The title compound (67.0 mg, 0.142 mmol, 28.5%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (206 mg, 0.499 mmol) and 3-bromopropanol, by the same procedure as in Example 7. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 1.98 (2H, m), 2.56 (1H, m), 3.62 (2H, m), 4.32 (2H, m), 4.69 (1H, m), 6.50 (1H, d, J=5.2Hz), 7.18-7.24 (2H, m), 7.48-7.50 (2H, m), 7.73 (1H, s), 7.86 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=8.4Hz), 8.64 (1H, d, J=5.2Hz), 8.67 (1H, s).

Example 3884-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-quinolinecarboxamide

[0955] The title compound (234.4 mg, 0.445 mmol, 44.5%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (413 mg, 1.00 mmol) and ((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-toluenesulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 1.33 (3H, s), 1.40 (3H, s), 2.56 (1H, m), 3.99 (1H, m), 4.14 (1H, m), 4.27 (1H, m), 4.41 (1H, m), 4.58 (1H, m), 6.51 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 8.8Hz), 7.49 (1H, d, J=2.8Hz), 7.57 (1H, s), 7.84 (2H, br), 7.99 (1H, s), 8.28 (1H, d, J=8.8Hz), 8.67 (1H, d, J=5.2Hz), 8.80 (1H, s).

Example 3894-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-quinolinecarboxamide

[0956] The title compound (253 mg, 0.480 mmol, 48.0%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (413 mg, 1.00 mmol) and ((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-toluenesulfonate, by the same procedure as in Example 7.

Example 3904-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2R)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide

[0957] After dissolving 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-quinolinecarboxamide (219 mg, 0.416 mmol) in trifluoroacetic acid (2 ml)-tetrahydrofuran (2 ml)-water (1 ml) at room temperature, the solution was stirred for 1 hour. The reaction solution was diluted with water (30 ml), and then sodium bicarbonate (3 g) was gradually added thereto for neutralization, after which extraction was performed with ethyl acetate, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and suspended in tetrahydrofuran, and the precipitated crystals were filtered out, washed with a small amount of ethyl acetate and blow-dried to obtain the title compound (121.4 mg, 0.249 mmol, 60.0%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.53 (2H, m), 3.94 (1H, m), 4.24 (1H, m), 4.33 (1H, m), 4.83 (1H, t, J=5.6Hz), 5.26 (1H, d, J=5.6Hz), 6.53 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.26 (1H, dd, J=2.8, 9.2Hz), 7.51 (1H, d, J=2.8Hz), 7.54 (1H, s), 7.84 (1H, s), 7.99 (2H, br), 8.28 (1H, d, J=9.2Hz), 8.67 (1H, d, J=5.2Hz), 8.81 (1H, s).

Example 391-14-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide

[0958] After dissolving 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-quinolinecarboxamide (236 mg, 0.448 mmol) in trifluoroacetic acid (2 ml)-tetrahydrofuran (2 ml)-water (1 ml) at room temperature, the solution was stirred for 1 hour. The reaction solution was diluted with water (30 ml), and then sodium bicarbonate (3 g) was gradually added thereto for neutralization, after which extraction was performed with ethyl acetate, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate.

The solvent was distilled off under reduced pressure and suspended in tetrahydrofuran, and the precipitated crystals were filtered out, washed with a small amount of ethyl acetate and blow-dried to obtain the title compound (115.6 mg, 0.237 mmol, 53.0%) as white crystals.

Example 391-2

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(1,3-dioxolan-2-yl)methoxy)-6-quinolinecarboxamide

[0959] The title compound (71.2 mg, 0.143 mmol, 19.0%) was obtained as white crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (310 mg, 0.75 mmol) and 2-(bromomethyl)-1,3-dioxolane, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.92-4.02 (4H, m), 4.36 (2H, m), 5.36 (1H, m), 6.53 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.26 (1H, dd, J=2.8, 8.8Hz), 7.51 (1H, d, J=2.8Hz), 7.58 (1H, s), 7.81 (1H, s), 7.83 (1H, s), 7.99 (1H, s), 8.28 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.2Hz), 8.75 (1H, s).

Example 392

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(3-(N,N-diethylamino)propyl)oxy)-6-quinolinecarboxamide

[0960] The title compound (119.6 mg, 0.227 mmol, 37.5%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (250 mg, 0.606 mmol) and N-(3-chloropropyl)-N,N-diethylamine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 0.95 (6H, t, J=7.2Hz), 1.96 (2H, m), 2.45-2.59 (7H, m), 4.30 (2H, m), 6.52 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.79 (1H, s), 7.86 (1H, s), 7.99 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.66 (1H, d, J=5.2Hz), 8.69 (1H, s).

Example 393

tert-Butyl 4-(((6-(aminocarbonyl)-4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[0961] The title compound (460 mg, 0.754 mmol, 44.5%) was obtained as white crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (700 mg, 1.696 mmol) and tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 1.17-1.25 (3H, m), 1.39 (9H, s), 1.79 (2H, m), 2.10 (1H, m), 2.56 (1H, m), 2.74 (1H, m), 4.01 (2H, m), 4.12 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.70 (1H, br), 7.71 (1H, br), 7.97 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.55 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 394

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide

[0962] After dissolving tert-butyl 4-(((6-(aminocarbonyl)-4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (460 mg, 0.754 mmol) in trifluoroacetic acid (2.3 ml) at room temperature, the solution was stirred for 2 hours. The reaction solution was concentrated under reduced pressure, saturated aqueous sodium bicarbonate was gradually added for neutralization, and the mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((4-piperidyl)methoxy)-6-quinolinecarboxamide as a crude product. This was dissolved in tetrahydrofuran (10 ml)-water (10 ml), and then a 37% aqueous formaldehyde solution (1 ml), acetic acid (0.086 ml, 1.51 mmol) and sodium cyanoborohydride (95 mg, 1.51 mmol) were added at room temperature and the mixture was stirred for 20 minutes. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated and suspended in ethyl acetate, and the suspension was diluted with hexane and the crystals filtered out and blow-dried to obtain the title compound (226.1 mg, 0.431 mmol, two stages, 57.2%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 1.37 (2H, m), 1.74-1.89 (5H, m), 2.15 (3H, s), 2.56 (1H, m), 2.79 (2H, m), 4.11 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.70 (1H, s), 7.74 (1H, s), 7.96 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.59 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 395

Methyl 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylate

[0963] The title compound (2.894 g, 6.55 mmol, 98.5%) was obtained as light brown crystals from phenyl N-(2-chloro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate (3.184 g, 6.65 mmol) and cyclopropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.85 (3H, s), 3.96 (3H, s), 6.52 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.50 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.56 (1H, s), 8.68 (1H, d, J=5.2Hz).

[0964] The starting material was synthesized in the following manner.

Production Example 395-1

Methyl 4-(4-amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxylate

[0965] After dissolving 4-amino-3-chlorophenol (3.17 g, 22.05 mmol) in dimethylsulfoxide (50 ml), sodium hydride (882 mg, 22.05 mmol) was gradually added at room temperature and the mixture was stirred for 30 minutes. The 4-chloro-7-methoxy-6-methoxycarbonylquinoline (3.70 g, 14.7 mmol) described in WO0050405 was added, and the mixture was heated at 100°C for 3 hours. After standing to cool to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, silica gel column chromatography (eluent - ethyl acetate) was performed, the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (3.092 g, 8.62 mmol, 57.4%) as light brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.98 (3H, s), 4.06 (3H, s), 4.12 (2H, s), 6.44 (1H, d, J=5.2Hz), 6.86 (1H, d, J=8.8Hz), 6.95 (1H, dd, J=2.8, 8.8Hz), 7.16 (1H, d, J=2.8Hz), 7.49 (1H, s), 8.64 (1H, d, J=5.2Hz), 8.80 (1H, s).

Production Example 395-2

Phenyl N-(2-chloro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate

[0966] The title compound (3.184 g, 6.65 mmol, 77.2%) was obtained as light brown crystals from methyl 4-(4-amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxylate (3.09 g, 8.61 mmol) in the same manner as Production Example 17.

¹H-NMR Spectrum (CDCl₃) δ(ppm) : 3.98 (3H, s), 4.06 (3H, s), 6.48 (1H, d, J=5.2Hz), 7.17 (1H, dd, J=2.8, 9.2Hz), 7.21-7.31 (4H, m), 7.41-7.46 (2H, m), 7.50 (2H, br), 8.32 (1H, d, J=8.8Hz), 8.67 (1H, d, J=5.2Hz), 8.77 (1H, s).

Example 396

4-(3-Chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid

[0967] After adding methanol (48 ml) and 2N aqueous sodium hydroxide (16 ml) to methyl 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylate (2.87 g, 6.50 mmol), the mixture was stirred at room temperature for 1.5 hours and at 60°C for 15 minutes. The reaction solution was allowed to cool to room temperature, and after neutralization by addition of 1N hydrochloric acid, the methanol was distilled off and the precipitated light brown crystals were filtered out, thoroughly washed with water and dried at 70°C to obtain the title compound (2.628 g, 6.14 mmol, 94.6%).

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.96 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.17-7.26 (2H, m), 7.49 (2H, s), 7.96 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.52 (1H, s), 8.66 (1H, d, J=5.2Hz), 13.08 (1H, br).

Example 397N6-Cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0968] After dissolving 4-(3-chloro-4-(((cyclopropylamino) carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) in dimethylformamide (2 ml), there were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (77 mg, 0.40 mmol), 1-hydroxy-1H-benzotriazole monohydrate (61 mg, 0.40 mmol), triethylamine (0.112 ml, 0.80 mmol) and cyclopropylamine (0.055 ml) while stirring on ice, and the mixture was stirred overnight at room temperature. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and then dried over anhydrous sodium sulfate. After distilling off the solvent, the residue was suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (40.0 mg, 0.086 mmol, 42.6%) as white crystals. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.57 (2H, m), 0.65 (2H, m), 0.69 (2H, m), 2.57 (1H, m), 2.86 (1H, m), 3.97 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.21 (1H, dd, J=2.8, 9.2Hz), 7.46 (1H, d, J=2.8Hz), 7.47 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.33 (1H, m), 8.40 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 398N6-(2-Methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0969] The title compound (17.8 mg, 0.037 mmol, 18.3%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-methoxyethylamine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.57 (1H, m), 3.29 (3H, s), 3.47 (4H, s), 4.01 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.51 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.43 (1H, s), 8.59 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 399N6-(2-(4-Morpholino)ethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0970] The title compound (62.9 mg, 0.116 mmol, 57.9%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and N-(2-aminoethyl)morpholine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.43 (4H, br), 2.47-2.51 (2H, m), 2.56 (1H, m), 3.43 (2H, m), 3.60 (4H, m), 4.04 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.48 (1H, m), 8.66 (1H, d, J=5.2Hz), 8.67 (1H, s).

Example 400N6-(3-(4-Morpholino)propyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0971] The title compound (84.7 mg, 0.153 mmol, 76.1%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and N-(3-aminopropyl)morpholine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.69 (2H, m), 2.33-2.37 (6H, m), 2.56 (1H, m), 3.30-3.37 (2H, m), 3.56 (4H, m), 4.02 (3H, s), 6.51 (1H, d, J=5.6Hz), 7.20 (1H, d, J=2.8Hz), 7.23 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.98 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.40 (1H, m), 8.52 (1H, s), 8.66 (1H, d, J=5.6Hz).

Example 401N6-(2-(Diethylamino)ethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0972] The title compound (67.7 mg, 0.129 mmol, 64.0%) was obtained as light brown crystals from 4-(3-chloro-

4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and N-(2-aminoethyl)-N,N-diethylamine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 0.98 (6H, t, J=7.2Hz), 2.47-2.59 (7H, m), 3.37 (2H, m), 4.03 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.25 (1H, d, J=8.8Hz), 8.48 (1H, m), 8.65 (1H, d, J=5.2Hz), 8.69 (1H, s).

Example 402

N6-(3-(1-Pyrrolidino)propyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0973] The title compound (87.0 mg, 0.162 mmol, 80.4%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 1-(3-aminopropyl)pyrrolidine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.65-1.72 (6H, m), 2.41-2.49 (6H, m), 2.56 (1H, m), 3.28-3.36 (2H, m), 4.01 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, m), 7.22 (1H, m), 7.47 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.96 (1H, s), 8.25 (1H, dd, J=1.2, 9.2Hz), 8.41 (1H, m), 8.51 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 403

N6-(2-(2-Pyridyl)ethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0974] The title compound (78.4 mg, 0.147 mmol, 73.7%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-(2-aminoethyl)pyridine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.02 (2H, m), 3.68 (2H, m), 3.97 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.21-7.24 (2H, m), 7.32 (1H, d, J=7.6Hz), 7.47-7.49 (2H, m), 7.72 (1H, m), 7.97 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.53-8.59 (3H, m), 8.65 (1H, d, J=5.2Hz).

Example 404

N6-(2-(Methylsulfonyl)ethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0975] The title compound (58.8 mg, 0.110 mmol, 55.2%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-(methylsulfonyl)ethylamine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.06 (3H, s), 3.41 (2H, m), 3.75 (2H, m), 4.01 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.66 (1H, d, J=5.2Hz), 8.67 (1H, s), 8.75 (1H, m).

Example 405

N6-(1H-2-Imidazolyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0976] The title compound (27.0 mg, 0.055 mmol, 27.3%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-aminoimidazole, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 4.03 (3H, s), 6.55 (1H, d, J=5.2Hz), 6.72 (1H, m), 6.85 (1H, m), 7.18 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 8.8Hz), 7.48 (1H, d, J=2.8Hz), 7.55 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.52 (1H, s), 8.68 (1H, d, J=5.2Hz), 11.21 (1H, br), 11.80 (1H, m).

Example 406

N6-(1,3-Thiazol-2-yl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0977] The title compound (83.7 mg, 0.164 mmol, 81.7%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-aminothiazole, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 4.03 (3H, s), 6.56 (1H, dd, J=1.6, 5.2Hz), 7.18 (1H, s), 7.23 (1H, m), 7.30 (1H, s), 7.47-7.57 (3H, m), 7.97 (1H, s), 8.26 (1H, dd, J=1.6, 8.8Hz), 8.53 (1H, s), 8.69 (1H, dd, J=1.6, 5.2Hz), 12.28 (1H, s).

Example 407

N6-(2-Pyridyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0978] The title compound (17.0 mg, 0.034 mmol, 33.6%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 2-aminopyridine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 4.09 (3H, s), 6.55 (1H, d, J=5.2Hz), 7.15-7.26 (3H, m), 7.50 (1H, s), 7.59 (1H, s), 7.86 (1H, m), 7.98 (1H, s), 8.26 (2H, d, J=9.2Hz), 8.36 (1H, m), 8.68-8.70 (2H, m), 10.70 (1H, s).

Example 408

N6-(3-Pyridyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0979] The title compound (46.4 mg, 0.092 mmol, 92.1%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 3-aminopyridine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 4.09 (3H, s), 6.56 (1H, d, J=5.2Hz), 7.23-7.41 (3H, m), 7.46 (1H, s), 7.57 (1H, s), 8.03 (1H, s), 8.18-8.31 (3H, m), 8.48 (1H, s), 8.68 (1H, d, J=5.2Hz), 8.80 (1H, s), 10.58 (1H, s).

Example 409

N6-(4-Pyridyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0980] The title compound (31.1 mg, 0.062 mmol, 61.7%) was obtained as light brown crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 4-aminopyridine, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 4.01 (3H, s), 6.56 (1H, d, J=5.2Hz), 7.21-7.24 (2H, m), 7.47 (1H, d, J=2.8Hz), 7.57 (1H, s), 7.71 (2H, d, J=5.6Hz), 7.99 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.44-8.48 (3H, m), 8.69 (1H, d, J=5.2Hz), 10.73 (1H, s).

Example 410

N6-(2-Hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0981] The title compound (34.4 mg, 0.073 mmol, 36.3) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-aminoethanol, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.40 (2H, m), 3.55 (2H, m), 4.03 (3H, s), 4.80 (1H, t, J=5.6Hz), 6.56 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.50 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.99 (1H, s), 8.28 (1H, d, J=9.2Hz), 8.42 (1H, m), 8.65 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 411

N6-(3-Hydroxypropyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0982] The title compound (51.2 mg, 0.106 mmol, 52.5%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 3-aminopropanol, by the same procedure as in Example 397.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.67 (2H, m), 2.56 (1H, m), 3.36 (2H, m), 3.50 (2H, m), 4.02 (3H, s), 4.56 (1H, t, J=5.2Hz), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.48 (1H, m), 8.57 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 412

N6-((2-Hydroxy-1-(hydroxymethyl)ethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0983] After dissolving 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) in dimethylformamide (4 ml) under a nitrogen atmosphere, serinol (37 mg, 0.40 mmol), triethylamine (0.2 ml) and (1H-1,2,3-benzotriazol-1-yloxy)(tri(dimethylamino))phosphonium hexafluorophosphate (177 mg, 0.40 mmol) were added in that order at room temperature, and the mixture was stirred for 8 hours. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, and purification was performed by silica gel column chromatography (eluent - ethyl acetate:methanol = 9:1). The fraction containing the target substance was concentrated under reduced pressure and suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (75.8 mg, 0.151 mmol, 75.3%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.50 (2H, m), 3.56 (2H, m), 3.96 (1H, m), 4.03 (3H, s), 4.80 (2H, t, J=5.2Hz), 6.51 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.23 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.29 (1H, m), 8.66 (1H, d, J=5.2Hz), 8.72 (1H, s).

Example 413

N6-(1,3-Dioxolan-2-ylmethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0984] The title compound (190.3 mg, 0.371 mmol, 79.4%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (200 mg, 0.467 mmol) and 2-aminomethyl-1,3-dioxolane, by the same procedure as in Example 412.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.51 (2H, m), 3.85 (2H, m), 3.96 (2H, m), 4.04 (3H, s), 5.04 (1H, m), 6.51 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.54 (1H, s), 7.99 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.48 (1H, m), 8.64 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 414

N6-(tert-Butoxy)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0985] The title compound (360 mg, 0.722 mmol, 72.2%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (428 mg, 1.00 mmol) and tert-butoxylamine hydrochloride, by the same procedure as in Example 412.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.25 (9H, s), 2.56 (1H, m), 3.97 (3H, s), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.97 (1H, s), 8.24 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.65 (1H, d, J=5.2Hz), 10.75 (1H, s).

Example 415

N6-(2-Fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0986] The title compound (130.7 mg, 0.276 mmol, 69.1%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (160 mg, 0.40 mmol) and 2-fluoroethanamine, by the same procedure as in Example 412.

clopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (171 mg, 0.40 mmol) and 2-fluoroethylamine hydrochloride, by the same procedure as in Example 412.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.59 (1H, m), 3.67 (1H, m), 4.03 (3H, s), 4.50 (1H, m), 4.62 (1H, m), 6.52 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.99 (1H, s), 8.28 (1H, d, J=9.2Hz), 8.58-8.62 (2H, m), 8.67 (1H, d, J=5.2Hz).

Example 416

N6-(2-(Methylthio)ethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0987] The title compound (146.2 mg, 0.292 mmol, 73.0%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (171 mg, 0.40 mmol) and 2-(methylthio)ethylamine, by the same procedure as in Example 412.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.10 (3H, s), 2.56 (1H, m), 2.67 (2H, m), 3.50 (2H, m), 4.02 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.51 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.56 (1H, m), 8.61 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 417

N6-Methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[0988] The title compound (109.3 mg, 0.239 mmol, 59.9%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (171 mg, 0.40 mmol) and methoxyethylamine hydrochloride, by the same procedure as in Example 412.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.74 (3H, s), 3.99 (3H, s), 6.54 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.99 (1H, s), 8.28 (1H, d, J=9.2Hz), 8.43 (1H, s), 8.67 (1H, d, J=5.2Hz), 11.46 (1H, s).

Example 418

N-(4-((7-(Benzoyloxy)-6-cyano-4-quinolyl))oxy-2-chlorophenyl)-N'-cyclopropylurea

[0989] After dissolving 4-(4-amino-3-chlorophenoxy)-7-benzoyloxy-6-cyanoquinoline (8.037 g, 20.0 mmol) in dimethylformamide (40 ml) under a nitrogen atmosphere, pyridine (1.94 ml, 24.0 mmol) and phenyl chloroformate (3.01 ml, 24.0 mmol) were added dropwise at room temperature and the mixture was stirred for 1 hour. Cyclopropylamine (3.46 ml, 50 mmol) was added dropwise, and the mixture was further stirred for 3 hours. Water (400 ml) and diethyl ether (400 ml) were added to the reaction solution, and after stirring overnight, the precipitated crystals were filtered out, washed with water and diethyl ether and dried at 70°C to obtain the title compound (8.570 g, 17.7 mmol, 88.4%) as light brown crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 5.45 (2H, s), 6.58 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.36 (1H, m), 7.44 (2H, t, J=7.2Hz), 7.50 (1H, d, J=2.8Hz), 7.54 (2H, d, J=7.2Hz) , 7.71 (1H, s) , 7.98 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.73 (1H, d, J=5.2Hz), 8.77 (1H, s).

Example 419

N-(2-Chloro-4-((6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[0990] An N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxy-2-chlorophenyl)-N'-cyclopropylurea crude product (5.67 g) was obtained as light brown crystals from N-(4-((7-(benzyloxy)-6-cyano-4-quinolyl))oxy-2-chlorophenyl)-N'-cyclopropylurea (8.53 g, 17.6 mmol) by the same procedure as in Example 83. The title compound (200 mg, 0.394 mmol, 24.6%) was obtained as light yellow crystals from the crude product (500 mg, 1.60 mmol) and N-(3-chloropropyl)-N,N-diethylamine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 0.79 (2H, m), 0.96 (2H, m), 1.05 (6H, t, J=7.2Hz), 2.06 (2H, m), 2.52-2.60 (5H, m), 2.67-2.73 (3H, m), 4.29 (2H, t, J=6.0Hz), 5.00 (1H, s), 6.49 (1H, d, J=5.2Hz), 7.12 (1H, dd, J=2.8, 8.8Hz), 7.48 (1H, s), 7.72 (1H, s), 8.44 (1H, d, J=8.8Hz), 8.66 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 420

tert-Butyl 4-(((4-(3-chloro-4-((cyclopropylamino)carbonyl)aminophenoxy)-6-cyano-7-quinolyl)oxy)methyl)-1-piperidine
carboxylate

[0991] The title compound (275.8 mg, 0.466 mmol, 14.6%) was obtained as white crystals from an N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxy-2-chlorophenyl)-N'-cyclopropylurea crude product (1.00 g, 3.20 mmol) and tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 0.79 (2H, m), 0.96 (2H, m), 1.33 (3H, m), 1.48 (9H, s), 1.93 (2H, m), 2.16 (1H, m), 2.68 (1H, m), 2.79 (2H, m), 4.06 (2H, d, J=6.8Hz), 4.20 (2H, m), 4.99 (1H, s), 6.50 (1H, d, J=5.2Hz), 7.12 (1H, dd, J=2.8, 9.2Hz), 7.43 (1H, d, J=2.8Hz), 7.72 (1H, s), 8.44 (1H, d, J=9.2Hz), 8.66 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 421

N-(2-Chloro-4-((6-cyano-7-(4-piperidylmethoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[0992] After adding trifluoroacetic acid (2.5 ml) to tert-butyl 4-(((4-(3-chloro-4-((cyclopropylamino)carbonyl)aminophenoxy)-6-cyano-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (501 mg, 0.846 mmol) at room temperature, the mixture was stirred for 1 hour. The reaction solution was diluted with water (35 ml) while cooling in an ice water bath, and then sodium bicarbonate (3.5 g) was gradually added for neutralization and extraction was performed with ethyl acetate. The organic layer was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate and diluted with hexane, and the precipitated crystals were filtered out and blow-dried to obtain the title compound (414.4 mg, 0.842 mmol, 99.6%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 1.49 (2H, m), 1.92-1.97 (3H, m), 2.48 (1H, m), 2.56 (1H, m), 2.86-2.93 (3H, m), 4.19 (2H, d, J=6.0Hz), 6.58 (1H, dd, J=1.2, 5.2Hz), 7.20 (1H, s), 7.24 (1H, d, J=9.2Hz), 7.48 (1H, d, J=1.2Hz), 7.63 (1H, s), 7.99 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.72-8.75 (2H, m).

Example 422

N-(2-Chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[0993] After dissolving N-(2-chloro-4-((6-cyano-7-(4-piperidylmethoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea (540 mg, 0.846 mmol) in tetrahydrofuran (20 ml)-methanol (20 ml), there were added 37% aqueous formaldehyde (1 ml), acetic acid (0.10 ml, 1.69 mmol) and sodium cyanoborohydride (106 mg, 1.69 mmol) at room temperature, and the mixture was stirred for 1 hour. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (282 mg, 0.557 mmol, 65.9%) as white crystals. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.66 (2H, m), 1.39 (2H, m), 1.75-1.90 (5H, m), 2.15 (3H, s), 2.56 (1H, m), 2.79 (2H, d, J=7.2Hz), 4.14 (2H, d, J=5.6Hz), 6.57 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.58 (1H, s), 7.98 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.71-8.75 (2H, m).

Example 423

N-(4-((7-(3-Bromopropoxy)-6-cyano-4-quinolyl)oxy)-2-chlorophenyl)-N'-cyclopropylurea

[0994] The title compound (129 mg, 0.250 mmol, 15.6%) was obtained as light brown crystals from an N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxy-2-chlorophenyl)-N'-cyclopropylurea crude product (500 mg, 1.60 mmol) and 1,3-dibromopropane, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.43 (2H, m), 0.65 (2H, m), 2.37 (2H, m), 2.56 (1H, m), 3.65 (2H, m), 4.41 (2H, m), 6.60 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.26 (1H, dd, J=2.8, 8.8Hz), 7.51 (1H, d, J=2.8Hz), 7.65 (1H, s), 7.99 (1H, s), 8.28 (1H, d, J=8.8Hz), 8.73-8.78 (2H, m).

Example 424

N-(2-Chloro-4-(6-cyano-7-(3-(1-pyrrolidino)propoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[0995] After dissolving N-(4-((7-(3-bromopropoxy)-6-cyano-4-quinolyl)oxy)-2-chlorophenyl)-N'-cyclopropylurea (116

mg, 0.225 mmol) in dimethylformamide (1.2 ml), pyrrolidine (0.20 ml) was added and the mixture was stirred at room temperature for 4 hours. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (57.3 mg, 0.113 mmol, 50.3%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 1.68 (4H, br), 1.99 (2H, m), 2.45-2.61 (7H, m), 4.33 (2H, m), 6.56 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.59 (1H, s), 7.98 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.72 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 425

N-(2-Chloro-4-((6-cyano-7-((1-methyl-3-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[0996] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-((1-methyl-3-piperidyl)methoxy)quinoline (246 mg, 0.582 mmol) in dimethylformamide (6 ml) under a nitrogen atmosphere, pyridine (0.19 ml, 2.33 mmol) and phenyl chloroformate (0.15 ml, 1.16 mmol) were added dropwise at room temperature, and the mixture was stirred for 1 hour. Cyclopropylamine (0.20 ml, 2.91 mmol) was added dropwise, and the mixture was further stirred for 3 hours. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in methanol and diluted with water, and the crystals were filtered out and dried at 70°C to obtain the title compound (198.7 mg, 0.393 mmol, 67.5%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 1.18 (1H, m), 1.54 (1H, m), 1.68 (1H, m), 1.79 (1H, m), 1.90 (2H, m), 2.11 (1H, m), 2.17 (3H, s), 2.56 (1H, m), 2.65 (1H, m), 2.85 (1H, m), 4.18 (2H, d, J=6.4Hz), 6.59 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.26 (1H, dd, J=2.8, 9.2Hz), 7.51 (1H, s), 7.60 (1H, s), 8.00 (1H, s), 8.29 (1H, d, J=9.2Hz), 8.74-8.76 (2H, m).

[0997] The starting material was synthesized in the following manner.

Production Example 425-1

4-(4-Amino-3-chlorophenoxy)-6-cyano-7-((1-methyl-3-piperidyl)methoxy)quinoline

[0998] A 4-(4-amino-3-chlorophenoxy)-6-cyano-7-hydroxyquinoline crude product (3.306 g) was obtained as light brown crystals from 4-(4-amino-3-chlorophenoxy)-7-benzyloxy-6-cyanoquinoline (3.728 g, 9.28 mmol), by the same procedure as in Example 83. The title compound (246 mg, 0.581 mmol, 36.4%) was obtained as light brown crystals from the crude product (500 mg, 1.60 mmol) and 3-chloromethyl-1-methylpiperidine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 1.25 (1H, m), 1.62-2.01 (5H, m), 2.27 (1H, m), 2.33 (3H, s), 2.33 (1H, m), 2.76 (1H, m), 4.05-4.15 (4H, m), 6.46 (1H, d, J=5.2Hz), 6.86 (1H, d, J=8.8Hz), 6.93 (1H, dd, J=2.8, 8.8Hz), 7.14 (1H, d, J=2.8Hz), 7.43 (1H, s), 8.65-8.67 (2H, m).

Example 426

tert-Butyl 4-(2-((4-(3-chloro-4-((cyclopropylamino)carbonyl)aminophenoxy)-6-cyano-7-quinolyl)oxy)ethyl)-1-piperidinecarboxylate

[0999] After dissolving tert-butyl 4-(((4-(4-amino-3-chlorophenoxy)-6-cyano-7-quinolyl)oxy)ethyl)-1-piperidine carboxylate (486.5 mg, 0.930 mmol) in dimethylformamide (5 ml) under a nitrogen atmosphere, pyridine (0.170 ml, 2.09 mmol) and phenyl chloroformate (0.175 ml, 1.34 mmol) were added dropwise at room temperature, and the mixture was stirred for 1 hour. Cyclopropylamine (0.322 ml, 4.65 mmol) was added dropwise, and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (343 mg, 0.566 mmol, 60.8%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 0.80 (2H, m), 0.95 (2H, m), 1.21-1.28 (3H, m), 1.47 (9H, s), 1.77 (2H, m), 1.89 (2H, m), 2.67 (1H, m), 2.75 (2H, m), 4.12 (2H, m), 4.28 (2H, m), 4.97 (1H, s), 6.50 (1H, d, J=5.2Hz), 7.12 (1H, dd,

J=2.8, 8.8Hz), 7.25 (1H, d, J=2.8Hz), 7.45 (1H, s), 7.72 (1H, s), 8.44 (1H, d, J=8.8Hz), 8.66 (1H, s), 8.68 (1H, d, J=5.2Hz).

[1000] The starting material was synthesized in the following manner.

5 Production Example 426-1

tert-Butyl 4-((4-amino-3-chlorophenoxy)-6-cyano-7-quinolyl)oxyethyl)-1-piperidinecarboxylate

[1001] The title compound (492.6 mg, 0.942 mmol, 39.6%) was obtained as light brown crystals from an 4-(4-amino-3-chlorophenoxy)-6-cyano-7-hydroxyquinoline crude product (742 mg, 2.38 mmol) and tert-butyl 4-(bromoethyl)-1-piperidine carboxylate, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 1.11-1.31 (4H, m), 1.46 (9H, s), 1.77 (2H, m), 1.90 (2H, m), 2.52-2.56 (3H, m), 4.11 (2H, m), 4.27 (2H, m), 6.48 (1H, d, J=5.2Hz), 6.86 (1H, d, J=9.2Hz), 6.93 (1H, dd, J=2.8, 9.2Hz), 7.14 (1H, d, J=2.8Hz), 7.44 (1H, s), 8.66-8.68 (2H, m).

15 Example 427

N-(2-Chloro-4-((6-cyano-7-(2-(4-piperidyl)ethoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1002] After adding trifluoroacetic acid (3.0 ml) to tert-butyl 4-(((4-(3-chloro-4-((cyclopropylamino)carbonyl)aminophenoxy)-6-cyano-7-quinolyl)oxy)ethyl)-1-piperidinecarboxylate (343 mg, 0.566 mmol) at room temperature, the mixture was stirred for 1 hour. The reaction solution was diluted with water (40 ml) while cooling in an ice water bath, and then sodium bicarbonate (4.0 g) was gradually added for neutralization and extraction was performed with ethyl acetate. The organic layer was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate and diluted with hexane, and the precipitated crystals were filtered out and blow-dried to obtain the title compound (286 mg, 0.566 mmol, quantitative) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 0.78 (2H, m), 0.95 (2H, m), 1.63 (2H, m), 1.96-2.05 (5H, m), 2.66 (1H, m), 2.90 (2H, m), 3.41 (2H, m), 4.27-4.30 (3H, m), 5.10 (1H, s), 6.50 (1H, d, J=5.2Hz), 7.12 (1H, dd, J=2.8, 8.8Hz), 7.27 (1H, d, J=2.8Hz), 7.46 (1H, s), 7.73 (1H, s), 8.44 (1H, d, J=8.8Hz), 8.66 (1H, s), 8.68 (1H, d, J=5.2Hz).

30 Example 428

N-(2-Chloro-4-((6-cyano-7-(2-(1-methyl-4-piperidyl)ethoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1003] After dissolving N-(2-chloro-4-((6-cyano-7-(2-(4-piperidyl)ethoxy))-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea (286 mg, 0.566 mmol) in tetrahydrofuran (5 ml)-methanol (5 ml), there were added 37% aqueous formaldehyde (0.5 ml), acetic acid (0.065 ml, 1.13 mmol) and sodium cyanoborohydride (71 mg, 1.13 mmol) at room temperature, and the mixture was stirred for 1 hour. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (218.2 mg, 0.420 mmol, 74.1%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41 (2H, m), 0.65 (2H, m), 1.23 (2H, m), 1.50 (1H, m), 1.71-1.88 (6H, m), 2.15 (3H, s), 2.56 (1H, m), 2.75 (2H, m), 4.33 (2H, t, J=6.4Hz), 6.58 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.26 (1H, dd, J=2.8, 9.2Hz), 7.50 (1H, d, J=2.8Hz), 7.62 (1H, s), 8.00 (1H, s), 8.28 (1H, d, J=9.2Hz), 8.73-8.75 (2H, m).

45 Example 429

N-(2-Chloro-4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1004] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)quinoline (96.9 mg, 0.22 mmol) in dimethylformamide (1 ml) under a nitrogen atmosphere, pyridine (0.027 ml, 0.33 mmol) and phenyl chloroformate (0.035 ml, 0.28 mmol) were added dropwise at room temperature, and the mixture was stirred for 1 hour. Cyclopropylamine (0.10 ml) was added dropwise, and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered

out and blow-dried to obtain the title compound (61.6 mg, 0.118 mmol, 53.5%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 0.96 (6H, t, J=7.2Hz), 2.42-2.67 (7H, m), 3.95 (1H, m), 4.21 (1H, m), 4.30 (1H, m), 4.91 (1H, m), 6.57 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.50 (1H, d, J=2.8Hz), 7.61 (1H, s), 7.98 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.70 (1H, s), 8.72 (1H, d, J=5.2Hz).

[1005] The starting materials were synthesized in the following manner.

Production Example 429-1

4-(4-Amino-3-chlorophenoxy)-6-cyano-7-((2R)-oxiran-2-yl)methoxyquinoline

[1006] The title compound (198 mg, 0.538 mmol, 16.8%) was obtained as light brown crystals from an 4-(4-amino-3-chlorophenoxy)-6-cyano-7-hydroxyquinoline crude product (1.00 g, 3.21 mmol) and (2R)-oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 2.93 (1H, m), 2.98 (1H, m), 3.50 (1H, m), 4.12 (2H, m), 4.24 (1H, dd, J=5.2, 11.2Hz), 4.49 (1H, dd, J=2.8, 11.2Hz), 6.49 (1H, d, J=5.2Hz), 6.86 (1H, d, J=8.8Hz), 6.93 (1H, dd, J=2.8, 8.8Hz), 7.14 (1H, d, J=2.8Hz), 7.48 (1H, s), 8.66-8.68 (2H, m).

Production Example 429-2

4-(4-Amino-3-chlorophenoxy)-6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)quinoline

[1007] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-((2R)-oxiran-2-yl)methoxyquinoline (96 mg, 0.261 mmol) in tetrahydrofuran (2.6 ml) under a nitrogen atmosphere, diethylamine (0.5 ml) was added and the mixture was stirred at 50°C for 5 days. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (96.9 mg, 0.220 mmol, 84.2%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 1.09 (6H, t, J=7.2Hz), 2.57-2.74 (8H, m), 4.12 (2H, m), 4.25 (2H, d, J=4.8Hz), 6.48 (1H, d, J=5.2Hz), 6.85 (1H, d, J=8.8Hz), 6.93 (1H, dd, J=2.8, 8.8Hz), 7.14 (1H, d, J=2.8Hz), 7.49 (1H, s), 8.66-8.68 (2H, m).

Example 430

N-(2-Chloro-4-((6-cyano-7-(((2S)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1008] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-(((2S)-3-(diethylamino)-2-hydroxypropyl)oxy)quinoline (78.6 mg, 0.18 mmol) in dimethylformamide (1 ml) under a nitrogen atmosphere, pyridine (0.022 ml, 0.27 mmol) and phenyl chloroformate (0.028 ml, 0.22 mmol) were added dropwise at room temperature, and the mixture was stirred for 1 hour. Cyclopropylamine (0.10 ml) was added dropwise, and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (37.8 mg, 0.072 mmol, 40.5%) as light yellow crystals.

[1009] The starting materials were synthesized in the following manner.

Production Example 430-1

4-(4-Amino-3-chlorophenoxy)-6-cyano-7-((2S)-oxiran-2-yl)methoxyquinoline

[1010] The title compound (147 mg, 0.400 mmol, 12.5%) was obtained as light brown crystals from a 4-(4-amino-3-chlorophenoxy)-6-cyano-7-hydroxyquinoline crude product (1.00 g, 3.21 mmol) and (2S)-oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate, by the same procedure as in Example 7.

Production Example 430-24-(4-Amino-3-chlorophenoxy)-6-cyano-7-(((2S)-3-(diethylamino)-2-hydroxypropyl)oxy)quinoline

[1011] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-((2S)-oxiran-2-yl)methoxyquinoline (72 mg, 0.196 mmol) in tetrahydrofuran (2.0 ml) under a nitrogen atmosphere, diethylamine (0.4 ml) was added and the mixture was stirred at 50°C for 5 days. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (78.6 mg, 0.178 mmol, 91.1%) as light yellow crystals.

Example 431N-(2-Chloro-4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1012] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)quinoline (95.1 mg, 0.217 mmol) in dimethylformamide (1 ml) under a nitrogen atmosphere, pyridine (0.026 ml, 0.33 mmol) and phenyl chloroformate (0.034 ml, 0.27 mmol) were added dropwise at room temperature, and the mixture was stirred for 1 hour. Cyclopropylamine (0.10 ml) was added dropwise, and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (40.3 mg, 0.077 mmol, 35.6%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.44 (2H, m), 0.68 (2H, m), 1.69 (4H, br), 2.50-2.75 (7H, m), 4.02 (1H, m), 4.22 (1H, dd, J=5.6, 10.4Hz), 4.31 (1H, dd, J=3.6, 10.4Hz), 5.04 (1H, m), 6.59 (1H, d, J=5.2Hz), 7.21 (1H, d, J=2.8Hz), 7.27 (1H, dd, J=2.8, 9.2Hz), 7.52 (1H, d, J=2.8Hz), 7.63 (1H, s), 7.99 (1H, s), 8.29 (1H, d, J=9.2Hz), 8.72-8.74 (2H, m).

Production Example 431-14-(4-Amino-3-chlorophenoxy)-6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)quinoline

[1013] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-((2R)-oxiran-2-yl)methoxyquinoline (96 mg, 0.261 mmol) in tetrahydrofuran (2.0 ml) under a nitrogen atmosphere, pyrrolidine (0.2 ml) was added and the mixture was stirred at room temperature for 5 days. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (95.5 mg, 0.218 mmol, 83.4%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 1.26 (2H, m), 1.82 (4H, br), 2.58-2.76 (5H, m), 2.94 (1H, m), 4.11 (2H, m), 4.20-4.45 (2H, m), 6.48 (1H, d, J=5.2Hz), 6.85 (1H, d, J=8.8Hz), 6.93 (1H, dd, J=2.8, 8.8Hz), 7.14 (1H, d, J=2.8Hz), 7.49 (1H, s), 8.66-8.68 (2H, m).

Example 432N-(2-Chloro-4-((6-cyano-7-(((2S)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1014] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)quinoline (82.0 mg, 0.187 mmol) in dimethylformamide (1 ml) under a nitrogen atmosphere, pyridine (0.023 ml, 0.28 mmol) and phenyl chloroformate (0.029 ml, 0.23 mmol) were added dropwise at room temperature and the mixture was stirred for 1 hour. Cyclopropylamine (0.10 ml) was added dropwise, and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (25.0 mg, 0.048 mmol, 25.6%) as light yellow crystals.

Production Example 432-14-(4-Amino-3-chlorophenoxy)-6-cyano-7-(((2S)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)quinoline

[1015] After dissolving 4-(4-amino-3-chlorophenoxy)-6-cyano-7-((2S)-oxiran-2-yl)methoxyquinoline (72 mg, 0.196 mmol) in tetrahydrofuran (1.5 ml) under a nitrogen atmosphere, pyrrolidine (0.15 ml) was added and the mixture was stirred at room temperature for 5 days. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (82.0 mg, 0.187 mmol, 95.4%) as light yellow crystals.

Example 433Methyl 4-(4-(((4-fluoroanilino)carbonyl)(methyl) amino)phenoxy)-7-methoxy-6-quinoline carboxylate

[1016] The title compound (1.078 g, 2.27 mmol, 92.6%) was obtained as white crystals from methyl 7-methoxy-4-(4-(methylamino)phenoxy)quinolinecarboxylate (828 mg, 2.45 mmol) and 4-fluorophenyl isocyanate, by the same procedure as in Example 10.

¹H-NMR Spectrum (DMSO-d₆)δ (ppm): 3.39 (3H, s), 3.98 (3H, s), 4.06 (3H, s), 6.20 (1H, s), 6.57 (1H, d, J=5.2Hz), 6.97 (2H, m), 7.24-7.34 (4H, m), 7.46 (2H, m), 7.52 (1H, s), 8.71 (1H, d, J=5.2Hz), 8.78 (1H, s).

[1017] The starting material was synthesized in the following manner.

Production Example 433-1Methyl 7-methoxy-4-(4-(methylamino)phenoxy)-6-quinolinecarboxylate

[1018] After dissolving 4-methylaminophenol (1.11 g, 9.00 mmol) in dimethylsulfoxide (15 ml), sodium hydride (360 mg, 9.00 mmol) was gradually added at room temperature and the mixture was stirred for 20 minutes. 4-Chloro-7-methoxy-6-methoxycarbonylquinoline (1.51 g, 6.00 mmol) obtained by a publicly known method was added, and the mixture was heated at 100°C for 2 hours while stirring. Upon cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off and subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (830 mg, 2.45 mmol, 40.9%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.88 (3H, s), 3.83 (1H, br), 3.97 (3H, s), 4.04 (3H, s), 6.42 (1H, d, J=5.2Hz), 6.68 (2H, d, J=8.8Hz), 7.01 (2H, d, J=8.8Hz), 7.45 (1H, s), 8.60 (1H, d, J=5.2Hz), 8.84 (1H, s).

Example 4344-(4-(((4-Fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid

[1019] After adding methanol (20 ml) and 2N aqueous sodium hydroxide (5 ml) to methyl 4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylate (1.042 g, 2.19 mmol), the mixture was stirred at room temperature for 3 hours. 2N Hydrochloric acid was added to the reaction solution for neutralization, and then the methanol was distilled off under reduced pressure and the precipitated white crystals were filtered out and dried at 70°C to obtain the title compound (1.01 g, 2.19 mmol, quantitative).

¹H-NMR Spectrum (DMSO-d₆)δ (ppm): 3.29 (3H, s), 3.96 (3H, s), 6.64 (1H, d, J=5.2Hz), 7.06 (2H, t, J=8.8Hz), 7.33 (2H, d, J=8.8Hz), 7.42-7.50 (5H, m), 8.23 (1H, s), 8.54 (1H, s), 8.70 (1H, d, J=5.2Hz), 13.09 (1H, br).

Example 435N6-Cyclopropyl-4-(4-(((4-fluoroanilino)carbonyl)(methyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1020] After dissolving 4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (115 mg, 0.25 mmol) in dimethylformamide (2 ml) under a nitrogen atmosphere, triethylamine (0.2ml), (1H-1,2,3-benzotriazol-1-yloxy) (tri (dimethylamino))phosphonium hexafluorophosphate (221 mg, 0.50 mmol) and cyclopropylamine (0.10 ml) were added in that order at room temperature, and the mixture was stirred overnight. The reaction

solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, and purification was performed by silica gel column chromatography (eluent - ethyl acetate). The fraction containing the target substance was concentrated under reduced pressure and suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (78.7 mg, 0.157 mmol, 63.1%) as white crystals. ¹H-NMR Spectrum (DMSO-d₆)δ (ppm): 0.57 (2H, m), 0.70 (2H, m), 2.86 (1H, m), 3.29 (3H, s), 3.98 (3H, s), 6.64 (1H, d, J=5.2Hz), 7.06 (2H, t, J=8.8Hz), 7.31 (2H, d, J=8.8Hz), 7.42-7.49 (5H, m), 8.23 (1H, s), 8.34 (1H, d, J=4.0Hz), 8.43 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 436

N6-(2-Methoxyethyl)-4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1021] The title compound (97.0 mg, 0.187 mmol, 75.1%) was obtained as white crystals from 4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (115 mg, 0.25 mmol) and 2-methoxyethylamine, by the same procedure as in Example 435.

¹H-NMR Spectrum (DMSO-d₆)δ (ppm): 3.29 (3H, s), 3.30 (3H, s), 3.48 (4H, br), 4.02 (3H, s), 6.65 (1H, d, J=5.2Hz), 7.06 (2H, t, J=8.8Hz), 7.32 (2H, d, J=8.8Hz), 7.43-7.48 (4H, m), 7.52 (1H, s), 8.23 (1H, s), 8.45 (1H, br), 8.62 (1H, s), 8.69 (1H, d, J=5.2Hz).

Example 437

N6-Methoxy-4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1022] The title compound (79.2 mg, 0.161 mmol, 64.8%) was obtained as white crystals from 4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (115 mg, 0.25 mmol) and methoxylamine hydrochloride, by the same procedure as in Example 435.

¹H-NMR Spectrum (DMSO-d₆)δ (ppm): 3.29 (3H, s), 3.73 (3H, s), 3.98 (3H, s), 6.65 (1H, d, J=5.2Hz), 7.06 (2H, t, J=8.8Hz), 7.32 (2H, d, J=8.8Hz), 7.42-7.50 (5H, m), 8.23 (1H, s), 8.44 (1H, s), 8.69 (1H, d, J=5.2Hz), 11.45 (1H, s).

Example 438

N6-(2-Ethoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1023] After dissolving 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) in dimethylformamide (2 ml) under a nitrogen atmosphere, 2-ethoxyethylamine (0.042 ml, 0.40 mmol), triethylamine (0.2 ml) and ((1H-1,2,3-benzotriazol-1-yloxy)(tri(dimethylamino)) phosphonium hexafluorophosphate) (133 mg, 0.20 mmol) were added in that order at room temperature, and the mixture was stirred overnight. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off and suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (87.7 mg, 0.176 mmol, 87.9%) as white crystals. ¹H-NMR Spectrum (DMSO-d₆)δ (ppm): 0.42 (2H, m), 0.64 (2H, m), 1.13 (3H, t, J=6.8Hz), 2.56 (1H, m), 3.44-3.53 (6H, m), 4.02 (3H, s), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.25 (1H, s), 8.26 (1H, dd, J=2.8, 9.2Hz), 8.46 (1H, m), 8.62 (1H, s), 8.66 (1H, d, J=5.2Hz).

Example 439

N6-(2-(2-Propoxy)ethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1024] The title compound (90.0 mg, 0.175 mmol, 87.7%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-(2-propoxy)ethylamine, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ (ppm): 0.42 (2H, m), 0.65 (2H, m), 1.11 (6H, d, J=6.4Hz), 2.56 (1H, m), 3.43-3.53 (4H, m), 3.60 (1H, m), 4.02 (3H, s), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.43 (1H, m), 8.46 (1H, s), 8.66 (1H, d, J=5.2Hz).

Example 440N6-(2-Cyanoethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1025] The title compound (73.8 mg, 0.154 mmol, 76.5%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 3-aminopropionitrile, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 2.81 (2H, m), 3.56 (2H, m), 4.02 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 8.8Hz), 7.49 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.99 (1H, s), 8.27 (1H, d, J=8.8Hz), 8.61 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.74 (1H, m).

Example 441N6-Cyanomethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1026] The title compound (82.7 mg, 0.178 mmol, 88.8%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (86 mg, 0.20 mmol) and 2-aminoacetone nitrile hydrochloride, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 4.05 (3H, s), 4.35 (2H, d, J=5.6Hz), 6.54 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 9.2Hz), 7.50 (1H, d, J=2.8Hz), 7.56 (1H, s), 7.99 (1H, s), 8.28 (1H, d, J=9.2Hz), 8.69 (1H, d, J=5.2Hz), 8.71 (1H, s), 9.05 (1H, m).

Example 442N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1027] The title compound (31.6 mg, 0.072 mmol, 71.7%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 40% methylamine (methanol solution), by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 2.82 (3H, d, J=4.8Hz), 4.00 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.96 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.34 (1H, m), 8.57 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 443N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1028] The title compound (29.6 mg, 0.065 mmol, 65.1%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 2.0 M ethylamine (tetrahydrofuran solution), by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.13 (3H, t, J=7.2Hz), 2.56 (1H, m), 3.25-3.35 (2H, m), 4.00 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.21 (1H, dd, J=2.8, 9.2Hz), 7.46 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.96 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.37 (1H, m), 8.52 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 444N6-Propyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1029] The title compound (21.6 mg, 0.046 mmol, 46.1%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and propylamine, by the same procedure as in Example 438. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 0.90 (3H, t, J=7.2Hz), 1.54 (2H, m), 2.56 (1H, m), 3.22-3.28 (2H, m), 4.00 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.21 (1H, dd, J=2.8, 9.2Hz), 7.46 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.97 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.35 (1H, m), 8.49 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 445

N6-Propargyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1030] The title compound (25.4 mg, 0.055 mmol, 54.6%) was obtained as a white powder from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and propargylamine, by the same procedure as in Example 438. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.13 (1H, m), 4.00 (3H, s), 4.10 (2H, m), 6.53 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.99 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.59 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.79 (1H, m).

Example 446

N6-Cyclopropylmethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1031] The title compound (25.6 mg, 0.053 mmol, 53.2%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and (aminomethyl) cyclopropane hydrochloride, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.26 (2H, m), 0.41-0.47 (4H, m), 0.65 (2H, m), 1.06 (1H, m), 2.56 (1H, m), 3.22 (2H, m), 4.03 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.98 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.45 (1H, m), 8.56 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 447

N6-(Cis-2-fluorocyclopropyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1032] The title compound (38.4 mg, 0.079 mmol, 79.2%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and cis-2-fluorocyclopropylamine tosylate, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.03-1.17 (2H, m), 2.56 (1H, m), 2.91 (1H, m), 4.00 (3H, s), 4.79 (1H, m), 6.51 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.51 (1H, s), 7.98 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.45 (1H, m), 8.50 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 448

N6-(3-Methoxypropyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1033] The title compound (30.3 mg, 0.061 mmol, 60.7%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 3-methoxypropylamine, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.77 (2H, m), 2.56 (1H, m), 3.24 (3H, s), 3.34-3.42 (4H, m), 4.00 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.96 (1H, s), 8.27 (1H, dd, J=2.8, 9.2Hz), 8.41 (1H, m), 8.54 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 449

N6-(2-Amino-2-oxoethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1034] The title compound (37.4 mg, 0.077 mmol, 77.3%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and glycineamide hydrochloride, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.94 (2H, d, J=5.6Hz), 4.07 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.14 (1H, s), 7.20 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.44 (1H, s), 7.50 (1H, d, J=2.8Hz), 7.56 (1H, s), 7.99 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.67-8.71 (2H, m), 8.77 (1H, s).

Example 450

N6-((2R)Tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1035] The title compound (31.8 mg, 0.062 mmol, 62.2%) was obtained as a white powder from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and R-tetrahydrofurfurylamine, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.62 (1H, m), 1.78-1.93 (3H, m), 2.57 (1H, m), 3.38 (2H, m), 3.64 (1H, dd, J=3.6, 14.0Hz), 3.79 (1H, dd, J=4.0, 14.0Hz), 3.99 (1H, m), 4.02 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, s), 7.23 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.41 (1H, m), 8.59 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 451

N6-((2S)Tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1036] The title compound (36.4 mg, 0.071 mmol, 71.2%) was obtained as a white powder from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and S-tetrahydrofurfurylamine, by the same procedure as in Example 438.

Example 452

N-(4-(6-Cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[1037] After dissolving N-(4-(7-(benzyloxy)-6-cyano-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (6.20 g, 12.3 mmol) in trifluoroacetic acid (60 ml) and thioanisole (3.6 ml, 30.7 mmol) under a nitrogen atmosphere, the solution was stirred at 60°C overnight. The reaction solution was concentrated under reduced pressure, and after adding water (100 ml) to the obtained residue, sodium bicarbonate was added to neutralization, diethyl ether (200 ml) was added, the mixture was stirred, and the precipitated crystals were filtered out, washed with water and diethyl ether and dried at 70°C to obtain the title compound (4.816 g, 11.6 mmol, 94.8%) as yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.42 (1H, d, J=5.2Hz), 7.11 (2H, m), 7.22 (2H, m), 7.41 (1H, s), 7.46 (2H, m), 7.58 (2H, m), 8.64 (1H, d, J=5.2Hz), 8.67 (1H, s), 8.73 (1H, s), 8.82 (1H, s).

Example 453

N-(4-(6-Cyano-7-((2R)-oxiran-2-yl)methoxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea

[1038] The title compound (713 mg, 1.52 mmol, 50.5%) was obtained as light yellow crystals from N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (1.24 g, 3.0 mmol) and (2R)-oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.81 (1H, m), 2.92 (1H, m), 3.46 (1H, m), 4.17 (1H, dd, J=6.8, 11.6Hz), 4.71 (1H, dd, J=2.4, 11.6Hz), 6.53 (1H, d, J=5.2Hz), 7.12 (2H, m), 7.24 (2H, m), 7.46 (2H, m), 7.58 (2H, m), 7.63 (1H, s), 8.71-8.73 (2H, m), 8.78 (1H, s), 8.83 (1H, s).

Example 454

N-(4-(6-Cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(4-fluorophenyl)urea

[1039] After dissolving N-(4-(6-cyano-7-((2R)-oxiran-2-yl)methoxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (200 mg, 0.425 mmol) in tetrahydrofuran (5.0 ml) under a nitrogen atmosphere, pyrrolidine (0.5 ml) was added and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 9:1), the fraction containing the target substance was concentrated, methanol (5 ml) was added for crystallization, and the crystals were filtered out and blow-dried to obtain the title compound (157.7 mg, 0.291 mmol, 68.5%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.67 (4H, br), 2.47-2.52 (5H, m), 2.69 (1H, m), 4.01 (1H, m), 4.20 (1H, dd, J=5.6, 10.8Hz), 4.30 (1H, dd, J=3.6, 10.8Hz), 5.02 (1H, d, J=4.4Hz), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, m), 7.23 (2H, m), 7.46

(2H, m), 7.57-7.61 (3H, m), 8.70-8.75 (3H, m), 8.83 (1H, s).

Example 455

N-(4-((6-Cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(4-fluorophenyl)urea

[1040] After dissolving N-(4-(6-cyano-7-((2R)-oxiran-2-yl)methoxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (200 mg, 0.425 mmol) in tetrahydrofuran (5.0 ml) under a nitrogen atmosphere, diethylamine (1.0 ml) was added and the mixture was stirred overnight at 60°C. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 9:1), the fraction containing the target substance was concentrated, methanol (5 ml) was added for crystallization, and the crystals were filtered out and blow-dried to obtain the title compound (126.4 mg, 0.233 mmol, 54.7%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.96 (6H, t, J=7.2Hz), 2.42-2.57 (5H, m), 2.64 (1H, m), 3.95 (1H, m), 4.21 (1H, dd, J=5.6, 10.4Hz), 4.30 (1H, dd, J=3.6, 10.4Hz), 4.91 (1H, d, J=4.4Hz), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, m), 7.23 (2H, m), 7.46 (2H, m), 7.56-7.60 (3H, m), 8.70-8.75 (3H, m), 8.82 (1H, s).

Example 456

N-(4-((6-Cyano-7-(((2R)-2-hydroxy-3-(1-piperidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(4-fluorophenyl)urea

[1041] After dissolving N-(4-(6-cyano-7-((2R)-oxiran-2-yl)methoxy-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea (200 mg, 0.425 mmol) in tetrahydrofuran (5.0 ml) under a nitrogen atmosphere, piperidine (0.5 ml) was added and the mixture was stirred overnight at 60°C. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 9:1), the fraction containing the target substance was concentrated, methanol (5 ml) was added for crystallization, and the crystals were filtered out and blow-dried to obtain the title compound (169.8 mg, 0.306 mmol, 71.9%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.36 (2H, m), 1.47 (4H, m), 2.34-2.51 (6H, m), 4.02 (1H, m), 4.20 (1H, dd, J=5.6, 10.4Hz), 4.30 (1H, dd, J=3.2, 10.4Hz), 4.93 (1H, d, J=4.4Hz), 6.51 (1H, d, J=5.2Hz), 7.11 (2H, m), 7.23 (2H, m), 7.46 (2H, m), 7.57-7.62 (3H, m), 8.70-8.75 (3H, m), 8.83 (1H, s).

Example 457

Methyl 7-(benzyloxy)-4-(3-chloro-4-((cyclopropylamino) carbonyl)amino)phenoxy)-6-quinoline carboxylate

[1042] After dissolving methyl 4-(4-amino-3-chlorophenoxy)-7-(benzyloxy) -6-quinolinecarboxylate (3.938 g, 9.06 mmol) in dimethylformamide (40 ml) under a nitrogen atmosphere, pyridine (1.10 ml, 13.6 mmol) and phenyl chloroformate (1.70 ml, 13.6 mmol) were added dropwise at room temperature and the mixture was stirred for 1 hour. Cyclopropylamine (1.88 ml, 27.2 mmol) was added dropwise, and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate (400 ml) and water (200 ml), and then the organic layer was washed with water and concentrated under reduced pressure, ethyl acetate (40 ml) was added and the precipitated crystals were filtered out and blow-dried to obtain the title compound (2.225 g, 4.30 mmol, 47.4%) as light brown crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 3.87 (3H, s), 5.39 (2H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.32 (1H, m), 7.41 (2H, m), 7.49 (1H, d, J=2.8Hz), 7.54 (2H, m), 7.61 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.60 (1H, s), 8.67 (1H, d, J=5.2Hz).

[1043] The starting materials were synthesized in the following manner.

Production Example 457-1

Methyl 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene) methyl)amino)-2-hydroxybenzoate

[1044] After adding Meldrum acid (7.2 g, 50 mmol), triethyl orthoformate (50 ml) and 2-propanol (50 ml) to the publicly known compound methyl 4-amino-2-hydroxybenzoate (7.59 g, 45.4 mmol), the mixture was stirred at 100°C for 1 hour. Upon cooling to room temperature, the precipitated crystals were filtered out, washed with diethyl ether and blow-dried to obtain the title compound (13.98 g, 43.5 mmol, 95.8%) as white crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 1.76 (6H, s), 3.97 (3H, s), 6.75 (1H, dd, J=2.4, 8.8Hz), 6.83 (1H, d, J=2.4Hz), 7.90 (1H, d, J=8.8Hz), 8.65 (1H, m), 11.0 (1H, s), 11.20 (1H, m).

Production Example 457-2Methyl 2-(benzyloxy)-4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)benzoate

[1045] After suspending methyl 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-hydroxybenzoate (13.975 g, 43.5 mmol) in dimethylformamide (140 ml) at room temperature under a nitrogen atmosphere, sodium hydride (1.87 g, 46.8 mmol) was gradually added. After 1.5 hours, benzyl bromide 5.7 ml, 47.9 mmol) was added dropwise and the mixture was stirred for 2 days. The reaction solution was diluted with water (700 ml) and stirred overnight, and the precipitated crystals were filtered, washed with diethyl ether and dried at 70°C to obtain the title compound (15.477 g, 37.6 mmol, 86.5%) as white crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 1.76 (6H, s), 3.91 (3H, s), 5.23 (2H, s), 6.83 (1H, s), 6.88 (1H, m), 7.26-7.54 (5H, m), 7.95 (1H, m), 8.62 (1H, m), 11.24 (1H, m).

Production Example 457-3Methyl 7-(benzyloxy)-4-oxo-1,4-dihydro-6-quinoline carboxylate

[1046] After adding Dowtherm A (160 ml) to methyl 2-(benzyloxy)-4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino) benzoate (15.477 g, 37.6 mmol), the mixture was stirred at 200°C for 1 hour. Upon cooling to room temperature, the precipitated crystals were filtered, washed with diethyl ether and blow-dried to obtain the title compound (7.19 g, 23.2 mmol, 61.8%). ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.81 (3H, s), 5.26 (2H, s), 5.97 (1H, d, J=7.6Hz), 7.09 (1H, s), 7.30-7.53 (5H, m), 7.84 (1H, m), 8.46 (1H, s), 11.69 (1H, m).

Production Example 457-4Methyl 7-(benzyloxy)-4-chloro-6-quinoline carboxylate

[1047] After adding thionyl chloride (70 ml) and a catalytic amount of dimethylformamide to methyl 7-(benzyloxy)-4-oxo-1,4-dihydro-6-quinolinecarboxylate (7.19 g, 23.2 mmol), the mixture was heated to reflux for 3 hours while stirring. The reaction solution was concentrated under reduced pressure, a 2N sodium hydroxide solution was gradually added for neutralization, extraction was performed with ethyl acetate, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, diethyl ether was added for crystallization, and the crystals were filtered out and blow-dried to obtain the title compound (4.067 g, 12.4 mmol) as light brown crystals. ¹H-NMR Spectrum (CDCl₃)δ(ppm) : 4.00 (3H, s), 5.33 (2H, s), 7.31-7.58 (7H, m), 8.66 (1H, s), 8.75 (1H, d, J=5.2Hz).

Production Example 457-5Methyl 4-(4-amino-3-chlorophenoxy)-7-(benzyloxy)-6-quinolinecarboxylate

[1048] After dissolving 4-amino-3-chlorophenol (2.22 g, 15.45 mmol) in dimethylsulfoxide (40 ml), sodium hydride (618 mg, 15.45 mmol) was gradually added at room temperature and the mixture was stirred for 30 minutes. Methyl 7-(benzyloxy)-4-chloro-6-quinolinecarboxylate (4.05 g, 12.36 mmol) was added, and the mixture was heated at 100°C for 2 hours while stirring. Upon cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off and subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (3.938 g, 9.06 mmol, 73.3%) as light brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 3.98 (3H, s), 4.11 (2H, m), 5.34 (2H, s), 6.43 (1H, d, J=5.2Hz), 6.85 (1H, d, J=8.8Hz), 6.93 (1H, dd, J=2.8, 8.8Hz), 7.14 (1H, d, J=2.8Hz), 7.30-7.57 (6H, m), 8.62 (1H, d, J=5.2Hz), 8.82 (1H, s).

Example 458N6-(2-Fluoroethyl)-4-(4-((cyclopropylamino)carbonyl)amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxamide

[1049] After dissolving methyl 4-(4-amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxylate (30 mg, 0.0736 mmol) in N,N-dimethylformamide (1.4 ml), there were added triethylamine (0.071 ml) and benzotriazol-1-yltris(dimethylamino)phosphonium hexafluorophosphate (63 mg) and the mixture was stirred at room temperature for 5 hours.

Water was added to the reaction solution, extraction was performed with ethyl acetate/tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the filtrate was distilled off under reduced pressure. The obtained crystals were suspended in ethanol, and after diluting the suspension with diethyl ether, the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (22 mg, 0.0486 mmol, 66.03%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.41-0.45(2H, m), 0.63-0.69(2H, m), 2.22(3H, s), 2.52-2.60(1H, m), 3.61(1H, q, J = 5.2 Hz), 3.67(1H, q, J = 5.2 Hz), 4.03(3H, s), 4.52(1H, t, J = 5.2 Hz), 4.64(1H, t, J = 5.2 Hz), 6.47(1H, d, J = 5.0 Hz), 6.78(1H, m), 7.05(1H, dd, J = 2.8 Hz, 8.8 Hz), 7.11(1H, d, J = 2.8 Hz), 7.52(1H, s), 7.63(1H, s), 7.94(1H, d, J = 8.8 Hz), 8.59-8.62(2H, m), 8.66(1H, d, J = 5.0 Hz).

[1050] The starting materials were synthesized in the following manner.

Production Example 458-1

Methyl 4-(4-amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxylate

[1051] The title compound (158 mg, 0.4669 mmol, 7.90%) was obtained as brown crystals by the same procedure as in Production Example 395-1 using the methyl 4-chloro-7-methoxy-6-quinolinecarboxylate (1.5 g, 5.9127 mmol) described in WO/0050405 and 4-amino-3-cresol (1.46 g, 11.8254 mmol).

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.06(3H, s), 3.84(3H, s), 3.95(3H, s), 4.93(2H, s), 6.40(1H, d, J = 5.0 Hz), 6.69(1H, d, J = 8.4 Hz), 6.82(1H, d, J = 8.4 Hz), 6.86(1H, s), 7.47(1H, s), 8.56(1H, s), 8.62(1H, d, J = 5.0 Hz).

Production Example 458-2

Methyl 4-(4-((cyclopropylamino)carbonyl)amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxylate

[1052] 4-(4-Amino-3-methylphenoxy)-7-methoxy-6-methoxycarbonylquinoline (158 mg, 0.4669 mmol) was used for phenyl carbamating reaction by the same procedure as in Production Example 17, and the product was used directly without purification for reaction with cyclopropylamine by the same procedure as in Example 11 to obtain the title compound (173 mg, 0.4105 mmol, 87.92%) as light brown crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.40-0.43(2H, m), 0.61-0.66(2H, m), 2.20(3H, s), 2.52-2.57(1H, m), 3.85(3H, s), 3.96(3H, s), 6.45(1H, d, J = 5.4 Hz), 6.75(1H, s), 7.04(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.10(1H, d, J = 2.4 Hz), 7.51(1H, s), 7.60(1H, s), 7.92(1H, d, J = 8.8 Hz), 8.57(1H, s), 8.66(1H, d, J = 5.4 Hz).

Production Example 458-3

4-(4-((Cyclopropylamino)carbonyl)amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxylic acid

[1053] After dissolving N-cyclopropyl-N'-[2-methyl-4-(6-carboxyl-7-methoxy-4-quinolyl)oxyphenyl]urea (173 mg, 0.3972 mmol) in methanol (3 ml), 2N aqueous sodium hydroxide (1 ml) was added and the mixture was heated and stirred at 60°C for 45 minutes. The solvent was distilled off under reduced pressure, the precipitated crystals were redissolved in methanol, and then 1N hydrochloric acid was added to pH 4 and saturated brine was further added. After extraction with ethyl acetate/tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the obtained crystals were suspended in acetone/diethyl ether and then filtered out and dried by aspiration to obtain the title compound (95 mg, 0.2332 mmol, 56.80%) as brown crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.42(2H, m), 0.66(2H, m), 2.25(3H, s), 2.57(1H, m), 3.51(1H, brs), 4.05(3H, s), 6.84(1H, d, J = 6.8 Hz), 7.12(1H, brs), 7.16(1H, dd, J = 2.4 Hz, 8.8 Hz), 7.21(1H, brs), 7.74(1H, s), 7.92(1H, s), 8.06(1H, d, J = 8.8 Hz), 8.70(1H, s), 8.95(1H, d, J = 6.8 Hz).

Example 459

N6-(2-Methoxyethyl)-4-(4-((cyclopropylamino)carbonyl)amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxamide

[1054] 4-(4-((Cyclopropylamino)carbonyl)amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxylic acid (30 mg, 0.0736 mmol) and 2-methoxyethylamine (0.0123 ml) were used for reaction in the same manner as Example 458, and after purification by NH silica gel column chromatography (ethyl acetate:methanol = 10:1), the obtained crystals were suspended in acetone:diethyl ether = 1:5, filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (17 mg, 0.0366 mmol, 49.73%) as light yellow crystals. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.41-0.45

(2H, m), 0.63-0.69(2H, m), 2.22(3H, s), 2.54-2.60(1H, s), 3.30(3H, s), 3.50(4H, m), 4.04(3H, s), 6.47(1H, d, J = 5.0 Hz), 6.78(1H, m), 7.05(1H, dd, J = 2.4 Hz, 8.4 Hz), 7.12(1H, d, J = 2.4 Hz), 7.52(1H, s), 7.63(1H, s), 7.94(1H, d, J = 8.4 Hz), 8.45(1H, brs), 8.63(1H, s), 8.66(1H, d, J = 5.0 Hz).

5 Example 460

N6-Methoxy-4-(4-((cyclopropylamino)carbonyl)amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxamide

10 **[1055]** 4-(4-((Cyclopropylamino)carbonyl)amino-3-methylphenoxy)-7-methoxy-6-quinolinecarboxylic acid (30 mg, 0.0736 mmol) and methoxyamine hydrochloride (0.0123 ml) were used for reaction in the same manner as Example 458, and after purification by NH silica gel column chromatography (ethyl acetate:methanol = 10:1), the obtained crystals were suspended in ethanol, diluted with hexane, filtered out, washed with hexane and dried by aspiration to obtain the title compound (7 mg, 0.0160 mmol, 21.74%) as light yellow crystals.

15 ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.40-0.45(2H, m), 0.63-0.68(2H, m), 2.21(3H, s), 2.51(3H, s), 2.53-2.59(1H, m), 3.94(3H, s), 6.46(1H, d, J = 5.0 Hz), 6.79(1H, s), 7.04(1H, d, J = 8.4 Hz), 7.09(1H, s), 7.43(1H, s), 7.63(1H, s), 7.92(1H, d, J = 8.4 Hz), 8.04(1H, s), 8.62(1H, d, J = 5.0 Hz), 9.86(1H, s).

Example 461

20 N-[4-(2-Cyclopropyl-3H-imidazo[4,5-b]pyridin-4-yl)oxyphenyl]-N'-(4-fluorophenyl)urea

[1056] A mixture of 2-cyclopropyl-7-(4-aminophenoxy)-3H-imidazo[4,5-b]pyridine (130 mg), p-fluorophenyl isocyanate (0.06 ml), tetrahydrofuran (5 ml) and dimethylformamide (0.5 ml) was stirred at room temperature for 35 minutes. NH type silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (ethyl acetate, followed by ethyl acetate:methanol = 10:1). The obtained residue was solidified from ethyl acetate-methanol-hexane to obtain 38 mg of the target substance as a gray solid.

30 ¹H-NMR(DMSO-d₆) δ(ppm): 1.02-1.12 (4H, m), 2.04-2.14 (1H, m), 6.34 (0.75H, d, J = 5.6Hz), 6.35 (0.25H, d, J = 5.6 Hz), 7.05-7.18 (4H, m), 7.40-7.55 (4H, m), 7.98 (0.75H, d, J = 5.6Hz), 8.07 (0.25H, d, J = 5.6Hz) 8.69 (0.75H, s), 8.70 (0.25H, s), 8.73 (0.75H, s), 8.76 (0.25H, s).

[1057] The starting material was obtained in the following manner.

Production Example 461-1

35 2-Cyclopropyl-7-(4-aminophenoxy)-3H-imidazo[4,5-b]pyridine

[1058] 4-Chloro-2-nitroaminopyridine (9.3 g) was added in small portions at a time to 60 ml of ice-cooled concentrated sulfuric acid. When the addition was complete, the ice bath was immediately removed and the mixture was stirred at room temperature for 2.5 hours. The reaction solution was developed in ice and concentrated ammonia water was added to pH 5. The precipitated solid was filtered out and blow-dried at 60°C to obtain 11.2 g of a yellow solid. The 11.2 g of the solid was added to a mixture of 10.8 g of p-nitrophenol, 17 ml of Hunig's base and 34 ml of 1-methyl-2-pyrrolidinone, and the mixture was heated and stirred at 120°C for 3 hours. After returning the mixture to room temperature, 50 ml of water was added and the precipitated solid was filtered out. It was then blow-dried at 60°C to obtain 4.77 g of a solid. The 4.77 g of solid was dissolved in 100 ml of tetrahydrofuran, 2.0 g of palladium carbon (Pd-C (10%, wet)) was added and the mixture was refluxed under normal pressure for 24 hours. After filtering off the Pd-C, the solvent was distilled off under reduced pressure to obtain 5.2 g of a reddish-brown oil. The 5.2 g of oil was added to a mixture of 4.6 g of cyclopropanecarboxylic acid and 50 ml of phosphoric acid, and the mixture was heated and stirred at 160°C for 5 hours. The reaction solution was developed in ice, neutralized with 5N aqueous sodium hydroxide and extracted with ethyl acetate. The extract was dried over magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by NH type silica gel (chloroform:methanol = 10:1). The residue obtained by distilling off the solvent under reduced pressure was dissolved in a small amount of ethyl acetate, the solution was allowed to stand, and the precipitated solid was filtered out to obtain 130 mg of the target substance as a blackish-violet solid.

55 ¹H-NMR(DMSO-d₆) δ(ppm): 1.00-1.12 (4H, m), 2.05-2.14 (1H, m), 5.08 (2H, bs), 6.23 (1H, d, J = 5.6Hz), 6.61 (2H, d, J = 8.8 Hz), 6.83 (1.5H, d, J = 8.8 Hz), 6.90 (0.5H, d, J = 8.8Hz), 7.92 (0.75H, d, J = 5.6Hz), 8.01 (0.25H, d, J = 5.6Hz), 12.75(0.75H, s), 12.85(0.25H, s).

Example 462N-[4-(2-Cyclobutanecarbonylamino)pyridin-4-yl]oxyphenyl]-N'-(4-fluorophenyl)urea

[1059] After adding 70 mg of cyclobutanecarbonyl chloride to a solution of 100 mg of N-[4-(2-aminopyridin-4-yl)oxyphenyl]-N'-(4-fluorophenyl)urea, 0.12 ml of triethylamine and 10 ml of tetrahydrofuran stirred at room temperature, the mixture was further stirred for 15 minutes. NH type silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (chloroform:methanol = 40:1). The obtained residue was solidified from ethyl acetate-methanol-hexane to obtain 64 mg of the target substance as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 1.68-1.78 (1H, m), 1.80-1.92 (1H, m), 1.95-2.18 (4H, m), 3.24-3.34 (1H, m), 6.63 (1H, dd, J= 5.6 Hz, J= 2.4Hz), 7.05-7.15 (4H, m), 7.42-7.49 (2H, m), 7.52 (2H, d, J= 8.8Hz), 7.66 (1H, d, J= 2.4Hz), 8.13 (1H, d, J= 5.6Hz), 8.71 (1H, s), 8.77 (1H, s), 10.29(1H, s).

[1060] The starting materials were obtained in the following manner.

Production Example 462-12-Amino-4-(4-nitrophenoxy)pyridine

[1061] A mixture of 15.88 g of 2-amino-4-chloropyridine 34.5 g of p-nitrophenol, 52 ml of Hunig's base and 100 ml of 1-methyl-2-pyrrolidinone was stirred at 160°C for 15 hours. Water was added, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by column chromatography (hexane:ethyl acetate = 1:1) using NH type silica gel to obtain 3.24 g of the target substance as a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 6.04 (1H, d, J= 2.4Hz), 6.12 (2H, brs), 6.26 (1H, dd, J= 6.0Hz, J= 2.4Hz), 7.32 (2H, d, J= 8.8Hz), 7.92 (2H, d, J= 6.0Hz), 8.31 (2H, d, J= 8.8Hz).

Production Example 462-22-Amino-4-(4-aminophenoxy)pyridine

[1062] After adding 1 g of 2-amino-4-(4-nitrophenoxy)pyridine to a mixture of 2.0 g of iron powder, 4.0 g of ammonium chloride, 30 ml of ethanol, 30 ml of dimethylformamide and 15 ml of water, the mixture was vigorously stirred at 100°C for 10 minutes. The reaction solution was filtered with celite and the solvent was distilled off under reduced pressure to obtain 0.53 g of the target substance as a solid. ¹H-NMR(DMSO-d₆) δ(ppm): 5.04 (2H, bs), 5.72 (1H, d, J= 1.6Hz), 5.81 (2H, brs), 6.05 (1H, dd, J= 5.6Hz, J= 1.6Hz), 6.57 (2H, d, J= 8.8Hz), 6.75 (2H, d, J= 8.8Hz), 7.70 (1H, d, J= 5.6Hz).

Production Example 462-3N-[4-(2-Aminopyridin-4-yl)oxyphenyl]-N'-(4-fluorophenyl)urea

[1063] After dissolving 0.53 g of 2-amino-4-(4-aminophenoxy)pyridine in a mixture of 20 ml of tetrahydrofuran and 10 ml of dimethylformamide, 0.36 ml of p-fluorophenyl isocyanate was added and the mixture was stirred for 1 hour. NH type silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (chloroform:methanol = 20:1, followed by 10:1). The solvent was distilled off under reduced pressure to obtain 610 mg of the target substance as a white powder.

¹H-NMR(DMSO-d₆) δ(ppm): 5.78 (1H, s), 5.87(1H, s), 5.89 (1H, s), 6.09-6.13 (1H, m), 7.00-7.15 (4H, m), 7.42-7.52 (4H, m), 7.77 (1H, dd, J= 6.0Hz, J= 1.6Hz), 8.69 (1H, s), 8.73 (1H, s).

[1064] The following samples were synthesized by the same procedure as in Example 462.

Example 463N-[4-(2-Butanoylamino)pyridin-4-yl]oxyphenyl]-N'-(4-fluorophenyl)urea

[1065] ¹H-NMR(DMSO-d₆) δ(ppm) : 0.85 (3H, t, J= 7.2Hz), 1.52 (2H, tq, J= 7.2Hz, J= 7.2Hz), 2.30 (2H, t, J= 7.2Hz), 6.63 (1H, dd, J= 5.6Hz, J= 2.0Hz), 7.06-7.16 (4H, m), 7.42-7.50 (2H, m), 7.52 (2H, d, J= 8.8Hz), 7.65 (1H, d, J= 2.0Hz), 8.14 (1H, d, J= 5.6Hz), 8.72 (1H, s), 8.77 (1H, s), 10.45(1H, s).

Example 464N-{4-[2-(4-Ethoxycarbonylbutanoyl)aminopyridin-4-yl]oxyphenyl}-N'-(4-fluorophenyl)urea

[1066] ¹H-NMR(DMSO-d₆) δ(ppm): 1.14 (3H, t, J= 7.2Hz), 1.74 (2H, tt, J= 7.2Hz, J= 7.2Hz), 2.26 (2H, t, J= 7.2Hz), 2.35 (2H, t, J= 7.2Hz), 4.01 (2H, q, J= 7.2Hz), 6.62 (1H, dd, J= 6.0Hz, J= 2.4Hz), 7.05-7.15 (4H, m), 7.41-7.49 (2H, m), 7.51 (2H, d, J= 8.8Hz), 7.62 (1H, d, J= 2.4Hz), 8.14 (1H, d, J= 6.0Hz), 8.70 (1H, s), 8.76 (1H, s).

Example 465N-[4-(2-Nicotinoylaminopyridin-4-yl)oxyphenyl]-N'-(4-fluorophenyl)urea

[1067] ¹H-NMR(DMSO-d₆) δ(ppm): 6.75 (1H, dd, J= 5.6Hz, J= 2.4Hz), 7.06-7.18 (4H, m), 7.42-7.58 (5H, m), 7.75 (1H, 2.4Hz), 8.22 (2H, m), 8.72 (2H, brs), 8.78 (1H, s), 9.06 (1H, s).

Example 466N-{4-[2-(4-Carboxybutanoyl)aminopyridin-4-yl]oxyphenyl}-N'-(4-fluorophenyl)urea

[1068] N-{4-[2-(4-Ethoxycarbonylbutyryl)aminopyridin-4-yl]oxyphenyl}-N'-(4-fluorophenyl)urea (22 mg), 2N aqueous sodium hydroxide (1 ml), methanol (2 ml) and dimethylformamide (1 ml) were stirred together at 80°C for 20 minutes. After returning the mixture to room temperature, 0.4 ml of 5N aqueous hydrochloric acid was added and the precipitated solid was filtered out to obtain 16 mg of the target substance as a white solid. ¹H-NMR(DMSO-d₆) δ(ppm): 1.72 (2H, tt, J= 7.2Hz, J= 7.2Hz), 2.20 (2H, t, J= 7.2Hz), 2.36 (2H, t, J= 7.2Hz), 6.62 (1H, dd, J= 6.0Hz, J= 2.0Hz), 7.05-7.15 (4H, m), 7.41-7.49 (2H, m), 7.52 (2H, d, J= 8.8Hz), 7.63 (1H, d, J= 2.0Hz), 8.14 (1H, d, J= 6.0Hz), 8.71 (1H, s), 8.76 (1H, s), 10.46(1H, s), 12.03(1H, s).

Example 467N-(4-{2-[(Cyclopropylmethyl)aminocarbonyl]pyridin-4-yl}oxyphenyl)-N'-(4-fluorophenyl)urea

[1069] After adding 100 mg of 4-(4-Aminophenoxy)-2-[(cyclopropylmethyl)aminocarbonyl]pyridine to 5 ml of tetrahydrofuran, 0.075 ml of p-fluorophenyl isocyanate was added at room temperature and the mixture was stirred for 1 hour. NH type silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (hexane:ethyl acetate = 1:1, followed by ethyl acetate and ethyl acetate:methanol = 10:1). The solvent was distilled off under reduced pressure, ethyl acetate and hexane were added to the residue, and the precipitated solid was filtered out to obtain 25 mg of the target substance as a light yellow powder. ¹H-NMR(DMSO-d₆) δ(ppm): 0.21 (2H, bs), 0.38 (2H, bs), 1.02 (1H, bs), 3.12 (2H, dd, J= 6.0Hz, 6.0Hz), 7.07-7.21 (5H, m), 7.37 (1H, s), 7.43-7.51 (2H, m), 7.56 (2H, d, J= 8.0Hz), 8.49 (1H, d, J= 5.2Hz), 8.74 (1H, s), 8.81 (1H, s), 8.83 (1H, t, J= 6.0Hz).

[1070] The starting materials were obtained in the following manner.

Production Example 467-14-Chloro-2-[(cyclopropylmethyl)aminocarbonyl]pyridine

[1071] 4-Chloro-2-carboxypyridine (2.0 g), (aminomethyl)cyclopropane hydrochloride (1.7 g), 1-ethyl-3-(3-diethylaminopropyl)carbodiimide hydrochloride (WSC) (2.9 g), 1-hydroxybenzotriazole (HOBt) (2.3 g), triethylamine (2.1 ml) and tetrahydrofuran (30 ml) were stirred together at room temperature for 2 hours. Water was added, extraction was performed with ethyl acetate, and then silica gel was added to the extract and the solvent was distilled off under reduced pressure. The silica gel was charged into a dry column packed with silica gel and purified by column chromatography (hexane:ethyl acetate = 4:1, followed by 2:1) to obtain 1.5 mg of the target substance as a yellow oil.

¹H-NMR(DMSO-d₆) δ(ppm): 0.19-0.30 (2H, m), 0.36-0.43 (2H, m), 0.99-1.09 (1H, m), 3.15 (2H, dd, J= 6.4Hz, J= 6.4Hz), 7.75 (1H, d, J= 5.6Hz), 8.01 (1H, s), 8.62 (1H, d, J= 5.6Hz), 8.90 (1H, t, J= 6.4Hz).

Production Example 467-22-[(Cyclopropylmethyl)aminocarbonyl]-4-(4-nitrophenoxy)pyridine

[1072] 4-Chloro-2-[(cyclopropylmethyl)aminocarbonyl]pyridine (1.5 g), p-nitrophenol (2.0 g), Hunig's base (3.1 ml) and 1-methyl-2-pyrrolidinone (6.2 ml) were stirred together at 160°C for 3 hours. Water was added, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by column chromatography (hexane:ethyl acetate = 4:1, followed by 2:1) using NH type silica gel to obtain 0.35 g of the target substance as a colorless oil.

¹H-NMR(DMSO-d₆) δ(ppm): 0.19-0.24 (2H, m), 0.36-0.41 (2H, m), 1.02 (1H, bs), 3.13 (2H, dd, J= 6.4Hz, J= 6.4Hz), 7.34 (1H, dd, J= 5.6Hz, J= 1.6Hz), 7.44 (2H, d, J= 8.8Hz), 7.55 (1H, d, J= 1.6Hz), 8.33 (2H, d, J= 8.8Hz), 8.61 (1H, d, J= 5.6Hz), 8.90 (1H, t, J= 6.4Hz).

Production Example 467-34-(4-Aminophenoxy)-2-[(cyclopropylmethyl)aminocarbonyl] pyridine

[1073] After adding 0.35 g of 2-[(cyclopropylmethyl) aminocarbonyl]-4-(4-nitrophenoxy)pyridine to a mixture of 0.7 g of iron powder, 1.4 g of ammonium chloride, 10 ml of ethanol, 10 ml of dimethylformamide and 5 ml of water, the mixture was vigorously stirred at 100°C for 20 minutes. The reaction solution was filtered with celite and the solvent was distilled off under reduced pressure to obtain 0.37 g of the target substance as a light brown oil.

¹H-NMR(DMSO-d₆) δ(ppm): 0.20-0.30 (2H, m), 0.38-0.44 (2H, m), 0.99-1.10 (1H, m), 3.13 (2H, dd, J= 6.4Hz, J= 6.4Hz), 5.14-5.19 (2H, m), 6.65 (2H, d, J= 8.8Hz), 6.87 (2H, d, J= 8.8Hz), 7.10 (1H, dd, J= 5.6Hz, J= 2.8Hz), 7.35 (1H, d, J= 2.8Hz), 8.47 (1H, d, J= 5.6Hz), 8.81 (1H, t, J= 6.4Hz).

Example 468N-{4-[2-(Butyroylamino)pyridin-4-yl]oxyphenyl}-N'-cyclopropylurea

[1074] Phenyl N-{4-[2-(butyroylamino)pyridin-4-yl]oxyphenyl}carbamate (0.116 g), cyclopropylamine (0.034 g), triethylamine (0.041 ml) and tetrahydrofuran (10 ml) were heated together in a sealed tube at 100°C for 1 hour. NH type silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with NH type silica gel, and column purification was performed (ethyl acetate). The solvent was distilled off under reduced pressure, ethyl acetate and hexane were added to the residue, and the precipitated solid was filtered out to obtain 20 mg of the target substance as a white solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.45 (2H, m), 0.61-0.67 (2H, m), 0.86 (3H, t, J= 7.2Hz), 1.54 (2H, tq, J= 7.2Hz, J= 7.2Hz), 2.31 (2H, t, J= 7.2Hz), 2.48-2.58 (1H, m), 6.42 (1H, s), 6.62 (1H, dd, J= 5.6Hz, J= 2.0Hz), 7.05 (2H, d, J= 8.8Hz), 7.49 (2H, d, J= 8.8Hz), 7.64 (1H, d, J= 2.0Hz), 8.15 (1H, d, J= 5.6Hz), 8.41 (1H, s), 10.82 (1H, s).

[1075] The starting materials were obtained in the following manner.

Production Example 468-12-Butyroylamino-4-(4-nitrophenoxy)pyridine

[1076] Butyroyl chloride (0.93 ml) was added dropwise to a stirred solution of 2-amino-4-(4-nitrophenoxy)pyridine (1.0 g), triethylamine (1.8 ml) and tetrahydrofuran (20 ml) at room temperature. After stirring for 1 hour, water was added, extraction was performed with ethyl acetate, the extract was dried over magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography (hexane:ethyl acetate = 2:1) to obtain 0.6 g of the target substance as a colorless oil.

¹H-NMR(CDCl₃) δ(ppm): 0.99 (3H, t, J= 7.2Hz), 1.73 (2H, tq, J= 7.2Hz, J= 7.2Hz), 2.36 (2H, t, J= 7.2Hz), 6.72 (1H, dd, J= 5.6Hz, 2.4Hz), 7.21 (2H, d, J= 8.8Hz), 7.95 (1H, d, J= 2.4Hz), 8.22 (1H, d, J= 5.6Hz), 8.25 (1H, brs), 8.30 (2H, d, J= 8.8Hz).

Production Example 468-24-(4-Aminophenoxy)-2-(butyrylamino)pyridine

[1077] A mixture of 0.6 g of 2-butyrylamino-4-(4-nitrophenoxy)pyridine, 1.2 g of iron powder, 2.8 g of ammonium chloride, 10 ml of ethanol, 10 ml of dimethylformamide and 5 ml of water was vigorously stirred at 100°C for 10 minutes. The reaction was filtered with celite, the solvent was distilled off under reduced pressure, and then water was added to the filtrate and extraction was performed with ethyl acetate. The extract was dried over magnesium sulfate and the solvent distilled off under reduced pressure to obtain 0.6 g of the target substance as a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.86 (3H, t, J= 7.2Hz), 1.54 (2H, tq, J= 7.2Hz, J= 7.2Hz), 2.30 (2H, t, J= 7.2Hz), 5.06-5.15 (2H, m), 6.56 (1H, dd, J= 5.6Hz, J= 2.4Hz), 6.61 (2H, d, J= 8.8Hz), 6.81 (2H, d, J= 8.8Hz), 7.61 (1H, d, J= 2.4Hz), 8.10 (1H, d, J= 5.6Hz), 10.38(1H, s).

Production Example 468-3Phenyl N-{4-[2-(butyrylamino)pyridin-4-yl]oxyphenyl}carbamate

[1078] Phenyl chloroformate (0.14 ml) was added dropwise to an ice-cooled stirred solution of 4-(4-aminophenoxy)-2-(butyrylamino)pyridine (0.3 g), triethylamine (0.14 ml) and tetrahydrofuran (10 ml). The cooling bath was removed and the mixture was stirred at room temperature overnight. Silica gel was added to the reaction solution, the solvent was distilled off under reduced pressure and the reaction product was adsorbed onto the silica gel. The silica gel was charged into a dry column packed with silica gel, and column purification was performed (hexane:ethyl acetate = 2:1, followed by 1:1). The solvent was distilled off under reduced pressure to obtain the target substance as a colorless solid. ¹H-NMR(DMSO-d₆) δ(ppm): 0.86 (3H, t, J= 7.2Hz), 1.54 (2H, tq, J= 7.2Hz, J= 7.2Hz), 2.31 (2H, t, J= 7.2Hz), 6.64-6.80 (1H, m), 7.16 (2H, d, J= 8.8Hz), 7.22-7.31 (3H, m), 7.41-7.48 (2H, m), 7.60 (2H, d, J= 8.8Hz), 7.66 (1H, d, J= 2.0Hz), 8.17 (1H, dd, J= 5.6Hz, J= 2.0Hz) 10.72 (1H, s), 10.90 (1H, s).

Example 4691-[4-(5-Dimethylaminomethyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]-(3-fluorophenyl)urea

[1079] N,N-Dimethylmethyleammonium iodide (Eschenmoser's salt) (29.5 mg) and dimethylformamide (1.5 ml) were added to 1-(3-fluorophenyl)-3-[4-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea (50 mg), and the mixture was stirred overnight at 100°C, after which water was added and liquid separation and extraction were performed with ethyl acetate. The organic layer was concentrated, dried under reduced pressure and subjected to NH silica gel column chromatography (ethyl acetate/methanol) to obtain 20 mg of the title compound.

MS Spectrum(ESI):497(M+1)

¹H-NMR Spectrum: (DMSO-d₆) 2.26 (6H, s), 3.64(2H, s), 6.73-6.80 (1H, m), 6.85(1H, s), 7.08-7.58(10H, m), 8.00 (1H, d, J=7.7Hz), 8.26(1H, d, J=0.9Hz), 8.82(1H, s), 8.92(1H, s), 12.54(1H,brs)

Example 4701-[4-[6-(4-Benzyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-3-cyclopropylurea

[1080] After dissolving 38 mg of 1-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylanyloxy)methyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-3-cyclopropylurea in 0.8 ml of tetrahydrofuran, 0.2 ml of tetrabutylammonium fluoride (1 M tetrahydrofuran solution) was added dropwise and the mixture was refluxed for 2 hours. It was then returned to room temperature, water was added, and liquid separation and extraction were performed with ethyl acetate and tetrahydrofuran. The organic layer was washed with water and saturated brine, concentrated and dried under reduced pressure to obtain 26 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 0.39-0.44(2H,m), 0.60-0.70(2H,m), 2.50-2.60(1H,m), 5.18(2H, s), 6.93(1H, s), 7.09-7.50 (10H,m), 7.89(2H, d, J=8.1Hz), 7.92(1H, s), 8.13(1H, d, J=8.1Hz), 8.28(1H, d, J=1.0Hz), 12.60(1H, brs)

Example 4711-[2-Chloro-4-[6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-phenyl]-3-cyclopropylurea

[1081] After adding 2 ml of trifluoroacetic acid and 0.1 ml of thioanisole to 24 mg of 1-[4-[6-(4-benzyloxyphenyl)-7H-

pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl)-3-cyclopropylurea, the mixture was stirred at 45°C for 30 minutes. The reaction mixture was concentrated under reduced pressure, saturated sodium bicarbonate water was added to alkalinity, and then liquid separation and extraction were performed with ethyl acetate and tetrahydrofuran. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated and dried under reduced pressure to obtain 15 mg of the title compound. ¹H-NMR Spectrum: (DMSO-d₆) 0.39-0.44(2H,m), 0.60-0.67(2H,m), 2.52-2.60(1H,m), 6.80-6.88(3H,m), 7.12(1H, d, J=2.0Hz), 7.27(1H, dd, J=9.0Hz, J'=2.0Hz), 7.40(1H, d, J=2.0Hz), 7.76(2H, d, J=9.0Hz), 7.91(1H, s), 8.13(1H, d, J=9.0Hz), 8.25(1H, d, J=1.0Hz), 9.77(1H, brs), 12.50(1H, brs)

Example 472

1-{4-[6-(4-Benzoyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl}-3-(3-fluorophenyl)urea

[1082] After adding 600 mg of iron powder, 1.1 g of ammonium chloride, 10 ml of ethanol, 20 ml of tetrahydrofuran and 10 ml of water to 550 mg of 6-(4-benzoyloxyphenyl)-4-(4-nitrophenoxy)-7H-pyrrolo[2,3-d]pyrimidine, the mixture was stirred at 80-85°C for 1.5 hours. Upon returning the mixture to room temperature, it was filtered with celite, and ethyl acetate and water were added to the filtrate for liquid separation and extraction. The organic layer was dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 493 mg of an amino compound-containing crude product. After dissolving 490 mg of the crude product in 10 ml of toluene and 10 ml of acetonitrile at 90°C, 0.3 ml of 3-fluorophenyl isocyanate was added and the mixture was stirred for 1 hour. After cooling to room temperature, the precipitated crystals were filtered out and dried to obtain 450 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 5.17(2H, s), 6.77(1H, dt, J=2.9, 7.8Hz), 6.88 (1H, d, J=1.2Hz), 7.08-7.53 (14H, m), 7.88 (2H, d, J=9.1Hz), 8.25(1H, s), 8.75(1H, s), 8.98(1H, s), 12.56(1H, brs)

Example 473

1-(3-Fluorophenyl)-3-{4-[6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl}urea

[1083] After dissolving 377 mg of 1-{4-[6-(4-benzoyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl}-3-(3-fluorophenyl)urea in 4 ml of trifluoroacetic acid and 0.4 ml of thioanisole, the solution was stirred at 45°C for 40 minutes. It was then returned to room temperature, potassium carbonate was added to alkalinity, and liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran (5:1) mixed solvent. The organic layer was concentrated to dryness to obtain 310 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 6.70-6.80 (2H, m), 6.82 (2H, d, J=8.3Hz), 7.10-7.52(7H, m), 7.75(2H, d, J=8.3Hz), 8.23 (1H, s), 8.85(1H, s), 8.98(1H, s), 8.98(1H, s), 12.48(1H, brs)

Example 474

1-(4-[6-[4-(2-Diethylaminoethoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl)-3-(3-fluorophenyl)urea

[1084] After dissolving 114 mg of 1-(3-fluorophenyl)-3-{4-[6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl}urea in 2 ml of dimethylformamide, there were added 44 mg (ca. 1 equivalent) of 2-chloroethyldiethylamine hydrochloride and 63 mg (2.5 equivalents) of potassium bicarbonate, and the mixture was stirred at 50-60°C for 16 hours. There were then added 17 mg of 2-chloroethyldiethylamine hydrochloride, 20 mg of potassium bicarbonate and 1 ml of dimethylformamide, and the mixture was stirred overnight at the same temperature. It was then returned to room temperature, water was added, and liquid separation and extraction were performed with ethyl acetate-tetrahydrofuran. The organic layer was washed with water and saturated brine, concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 33 mg of a crude solid containing the title compound. This was washed with ethyl acetate to obtain 5 mg of the title compound.

MS Spectrum(ESI):555(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.96(6H,t, J=7.4Hz) 2.53(4H,q, J=7.4Hz), 2.78(2H,t, J=6.2Hz), 4.06(2H,t, J=6.2Hz), 6.74-6.88(2H, m), 7.02(2H,d, J=9.0Hz), 7.09-7.54(7H, m), 7.86(2H, d, J=9.0Hz), 8.25(1H, s), 8.83(1H, brs), 8.96(1H, brs), 12.50(1H, brs)

[1085] The intermediate was synthesized in the following manner.

Production Example 474-16-(4-Benzyloxyphenyl)-4-(4-nitrophenoxy)-7H-pyrrolo[2,3-d]pyrimidine

[1086] After adding 2.97 of potassium carbonate and 30 ml of dimethylformamide to 3.09 g of 4-nitrophenol and stirring the mixture at 130°C for 10 minutes, 2.49 g of 6-(4-benzyloxyphenyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine was added and the mixture was further stirred at 130°C for 5 hours and at 135°C overnight. After returning the mixture to room temperature, water was added, the precipitated solid was filtered out and subjected to NH silica gel column chromatography (ethyl acetate) and silica gel column chromatography (ethyl acetate), and then ether and ethyl acetate were added prior to sonication. The solid was filtered out to obtain 1.2 g of the title compound.
¹H-NMR Spectrum: (DMSO-d₆) 5.18(2H, s), 6.99 (1H, d, J=1.7 Hz), 7.08-7.13(2H, m), 7.28-7.48(5H, m), 7.53-7.60 (2H, m), 7.88-7.93(2H, m), 8.30-8.35 (3H, m) , 12.71 (1H, brs)

Example 4751-(3-Fluorophenyl)-3-{4-[6-(4-pyrrolidin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl}urea

[1087] After adding 646 mg of 4-nitrophenol, 817 mg of potassium carbonate and 6.3 ml of dimethylformamide to 630 mg of 4-chloro-6-(4-pyrrolidin-1-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidine, the mixture was stirred overnight at 130°C. Water was added, liquid separation and extraction were performed with ethyl acetate, and the organic layer was washed with water and saturated brine and concentrated to dryness to obtain 510 mg of a solid. After adding to the solid 500 mg of iron powder, 1 g of ammonium chloride, 20 ml of ethanol, 10 ml of tetrahydrofuran 10 ml and 3 ml of water, the mixture was stirred at 80°C for 2 hours. Upon returning the mixture to room temperature, it was filtered with celite, and ethyl acetate, tetrahydrofuran and water were added to the filtrate for liquid separation and extraction, after which the organic layer was dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 380 mg of a crude product. After adding thereto 5 ml of toluene, 5 ml of acetonitrile and 5 ml of tetrahydrofuran for dissolution at 100°C, the solution was stirred for 1 hour. It was then allowed to cool to room temperature and the precipitated crystals were filtered out, washed with ether and dried under reduced pressure to obtain 40 mg of the title compound.

MS Spectrum(ESI:nega):509(M+1)

¹H-NMR Spectrum: (DMSO-d₆) 1.85-2.02(4H, m), 3.10-3.32(4H, m), 6.42(1H,d, J=8.2Hz), 6.60(1H,d, J=8.2Hz), 6.70-6.80(2H, m), 7.02-7.53(9H, m), 8.00(1H, s), 8.99(1H, s), 9.17(1H, s), 11.81(1H,brs)

[1088] The intermediates were synthesized in the following manner.

Production Example 475-12-Amino-5-(4-pyrrolidine-1-phenyl)-1H-pyrrole-3-carboxylic acid ethyl ester

[1089] After adding 150 ml of ethanol to 13.8 g of 2-amidino-ethyl acetate ester hydrochloride (publicly known compound described in Liebigs Ann. Chem., 1895(1977)), there was further added 5.94 g of sodium ethoxide (0.97 equivalent with respect to the 2-amidino-ethyl acetate ester hydrochloride) at 0°C and the mixture was stirred for 10 minutes under a nitrogen atmosphere. There was further added 12 g of 2-bromo-1-(4-pyrrolidine-1-phenyl)ethanone (Lancaster), and the mixture was stirred at room temperature for 48 hours. Ethyl acetate was added prior to sonication, the solid was filtered out, and the filtrate was concentrated and subjected to silica gel column chromatography (ethyl acetate) to obtain 4.82 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 1.22(3H,d,J=7.3Hz), 1.88-1.98(4H,m), 3.16-3.24(4H,m), 4.06-4.14(2H, m), 5.52(2H, s), 6.13(1H, d, J=2.8Hz), 6.48(2H, d, J=8.8Hz), 7.28(2H, d, J=8.8Hz), 10.48(1H, s)

Production Example 475-26-(4-Pyrrolidin-1-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol

[1090] After adding 8 ml of formic acid, 31.8 ml of formamide and 15.9 ml of dimethylformamide to 4.80 g of 2-amino-5-(4-pyrrolidine-1-phenyl)-1H-pyrrole-3-carboxylic acid ethyl ester and stirring the mixture at 140°C for 48 hours, it was allowed to stand at room temperature for 24 hours. The precipitated solid was filtered out and dried under reduced pressure to obtain 3.0 g of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 1.86-2.00(4H, m), 3.08-3.13(4H, m), 6.54(2H,d, J=8.8Hz), 6.62(1H, s), 7.61(2H,d, J=8.8Hz), 7.78(1H, s), 12.40(1H,brs)

Production Example 475-34-Chloro-6-(4-pyrrolidin-1-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidine

[1091] After adding 20 ml of phosphorous oxychloride to 1.9 g of 6-(4-pyrrolidin-1-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol and stirring the mixture at 140°C for 3 hours, the reaction system was returned to room temperature and concentrated. Ice water was added to the residue, sodium bicarbonate was used for neutralization, and liquid separation and extraction were performed with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to dryness to obtain 12 g of a crude product containing the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 1.86-2.02(4H, m), 3.10-3.32(4H, m), 6.60(2H, d, J=8.9Hz), 6.77(1H, d, J=2.0Hz), 7.81(2H, d, J=8.9Hz), 8.46(1H, s), 12.70(1H, brs)

Example 476N-{4-[6-(Methylamino)carbonyl-7-methoxy-4-quinolyloxyphenyl]-N'-(4-fluorophenyl)urea

[1092] The title compound (85 mg) was obtained as light yellow crystals from 4-(4-amino-phenoxy)-7-methoxyquinoline-6-carboxylic acid methylamide (65 mg) and 4-fluorophenyl isocyanate (0.05 ml), by the same procedure as in Example 10.

¹H-NMR(DMSO-d₆) δ(ppm) 2.81-2.84(3H, m), 4.00(3H, s), 6.46 (1H, s), 7.07-7.24(4H, m), 7.43-7.61(5H, m), 8.32-8.38 (1H, m), 8.59-8.65(2H, m), 8.80(1H, brs), 8.89(1H, brs)

[1093] The starting materials were synthesized by the following 3 steps.

Production Example 476-14-Chloro-7-methoxyquinoline-6-carboxylic acid methylamide

[1094] After dissolving 7-methoxy-4-chloro-quinoline-6-carbonyl chloride synthesized by the method of Production Example 152-2 from 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid (947 mg) in tetrahydrofuran (70 ml), the solution was cooled to 0°C. A 40% aqueous methylamine solution (0.4 ml) was added, and the mixture was stirred at room temperature for 30 minutes. Water was added, extraction was performed 3 times with ethyl acetate, and the organic layers were combined, washed with water and saturated brine, dried over sodium sulfate and then dried under reduced pressure to obtain the title compound (710 mg). ¹H-NMR(DMSO-d₆) δ(ppm) 3.07-3.10(3H, m), 4.12(3H, s), 7.40-7.43(1H, m), 7.56(1H, s), 7.83(1H, brs), 8.73-8.77(1H, m), 9.13(1H, s)

Production Example 476-27-Methoxy-4-(4-nitrophenoxy)quinoline-6-carboxylic acid methylamide

[1095] The title compound (736 mg) was obtained as light yellow crystals from 4-chloro-7-methoxyquinoline-6-carboxylic acid methylamide (492 mg) and 4-nitrophenol (492 mg), by the same procedure as in Production Example 7. ¹H-NMR(DMSO-d₆) δ(ppm) 2.76-2.82(3H, m), 4.02(3H, s), 6.86(1H, d, J=5.2Hz), 7.45-7.51(2H, m), 7.56(1H, s), 8.32-8.38(2H, m), 8.45(1H, s), 8.76-8.79(1H, m)

Production Example 476-34-(4-Aminophenoxy)-7-methoxyquinoline-6-carboxylic acid methylamide

[1096] The title compound (250 mg) was obtained from 7-methoxy-4-(4-nitrophenoxy)-quinoline-6-carboxylic acid methylamide (736 mg), by the same procedure as in Production Example 10.

¹H-NMR(DMSO-d₆) δ(ppm) 2.81-2.84(3H, m), 3.99(3H, s), 5.14-5.19(2H, m), 6.39(1H, d, J=5.2Hz), 6.45(2H, d, J=8.4Hz), 6.92(2H, d, J=8.4Hz), 7.46(1H, s), 8.30-8.38(1H, m), 8.57-8.61(2H, m)

Example 477N-{4-[6-(Methylamino)carbonyl-7-methoxy-4-quinolyloxyphenyl]-N'-(2-thiazolyl)urea

[1097] The title compound (32 mg) was obtained as light yellow crystals from 4-(4-amino-phenoxy)-7-methoxyquin-

oline-6-carboxylic acid methylamide (65 mg) and phenyl N-(2-thiazolyl)carbamate (49 mg), by the method described in Example 11.

¹H-NMR(DMSO-d₆) δ(ppm) 2.80-2.85(3H, m), 4.00(3H, s), 6.47(1H, d, J=5.2Hz), 7.05-7.15(1H, m), 7.25(2H, d, J=8.8Hz), 7.35-7.40(1H, m), 7.50(1H, s), 7.62(2H, d, J=8.8Hz), 8.58-8.66(2H, m)

Example 478

N-{4-[6-(Dimethylamino)carbonyl-7-methoxy-4-quinolyl]oxyphenyl}-N'-(2-thiazolyl)urea

[1098] The title compound (60 mg) was obtained as light yellow crystals from 4-(4-aminophenoxy)-7-methoxyquinoline-6-carboxylic acid dimethylamide (100 mg) and phenyl N-(2-thiazolyl)carbamate (60 mg), by the method described in Example 11.

¹H-NMR(DMSO-d₆) δ(ppm) 2.78(3H, s), 3.00(3H, s), 3.97(3H, s), 6.47(1H, d, J=5.2Hz), 7.05-7.15(1H, m), 7.24(2H, d, J=8.8Hz), 7.35-7.39(1H, m), 7.48(1H, s), 7.60(2H, d, J=8.8Hz), 8.04(1H, s), 8.62(1H, d, J=5.2Hz)

[1099] The starting materials were synthesized by the following 3 steps.

Production Example 478-1

4-Chloro-7-methoxy-quinoline-6-carboxylic acid dimethylamide

[1100] After dissolving 7-methoxy-4-chloro-quinoline-6-carbonyl chloride synthesized by the method of Production Example 152-2 from 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid (1.0 g) in tetrahydrofuran (60 ml), the solution was cooled to 0°C. Diisopropylethylamine (1.6 ml) and a 2.0 M dimethylamine tetrahydrofuran solution (3 ml) were added and the mixture was stirred overnight at room temperature. Water was added, extraction was performed 3 times with ethyl acetate, and the organic layers were combined, washed with water and saturated brine, dried over sodium sulfate and then dried under reduced pressure to obtain the title compound (933 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 2.75(3H, s), 3.01(3H, s), 3.97(3H, s), 7.57(1H, s), 7.63(1H, d, J=4.8Hz), 7.93(1H, s), 8.78(1H, d, J=4.8Hz)

Production Example 478-2

7-Methoxy-4-(4-nitrophenoxy)-quinoline-6-carboxylic acid dimethylamide

[1101] The title compound (904 mg) was obtained as light yellow crystals from 4-chloro-7-methoxyquinoline-6-carboxylic acid dimethylamide (933 mg) and 4-nitrophenol (737 mg), by the same procedure as in Production Example 10.

¹H-NMR(DMSO-d₆) δ(ppm) 2.75(3H, s), 2.99(3H, s), 3.95(3H, s), 6.87(1H, d, J=5.2Hz), 7.46(2H, d, J=7.2Hz), 7.55(1H, s), 7.94(1H, s), 8.33(2H, d, J=7.2Hz), 8.76(1H, d, J=5.2Hz)

Production Example 478-3

4-(4-Aminophenoxy)-7-methoxyquinoline-6-carboxylic acid dimethylamide

[1102] The title compound (511 mg) was obtained from 7-methoxy-4-(4-nitrophenoxy)quinoline-6-carboxylic acid dimethylamide (904 mg), by the same procedure as in Production Example 10.

¹H-NMR(CDCl₃) δ(ppm) 2.90(3H, s), 3.18(3H, s), 3.98(3H, s), 6.43(1H, d, J=5.6Hz), 6.75(2H, d, J=8.8Hz), 6.95(2H, d, J=8.8Hz), 7.45(1H, s), 8.27(1H, s), 8.57(1H, d, J=5.6Hz)

Example 479

N-{4-[6-(Cyclopropylamino)carbonyl-7-methoxy-4-quinolyl]oxyphenyl}-N'-(4-fluorophenyl)urea

[1103] After dissolving the N-[4-(6-carboxy-7-methoxy-4-quinolyl)oxyphenyl]-N'-(4-fluorophenyl)urea (60 mg) synthesized in Example 341 in dimethylformamide (1.5 ml), there were added 1-ethyl-3-(3-diethylaminopropyl)-carbodiimide hydrochloride (39 mg), 1-hydroxy-1H-benzotriazole monohydrate (31 mg), triethylamine (30 μl) and cyclopropylamine (0.05 ml) and the mixture was stirred overnight at room temperature. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and then dried over anhydrous sodium sulfate. After distilling off the solvent, crystals were precipitated with ethyl acetate, filtered out and dried under reduced pressure to obtain the title compound (29 mg) as white crystals.

¹H-NMR(CDCl₃) δ(ppm) 0.45-0.59(2H, m), 0.67-0.73(2H, m), 2.82-2.89 (1H, m), 3.97(3H, s), 6.45(1H, d, J=5.2Hz), 7.08-7.23(4H, m), 7.43-7.50(3H, m), 7.55-7.60(2H, m), 8.32-8.35(1H, m), 8.42(1H, s), 8.62(1H, d, J=5.2Hz), 8.75(1H, brs), 8.84(1H, brs)

5 Example 480

N-[4-(6-Aminomethyl-7-methoxyquinolin-4-yloxy)-phenyl]-N'-phenylurea trifluoroacetate

10 **[1104]** After dissolving the N-[4-(6-cyano-7-methoxyquinolin-4-yloxy)phenyl]-N'-phenylurea (100 mg) synthesized in Example 37 in an ethanol (5 ml) and tetrahydrofuran (5 ml) mixed solvent, there were added trifluoroacetic acid (0.5 ml) and 50% palladium-carbon (50 mg), and the mixture was stirred overnight under a hydrogen atmosphere. After filtering off the palladium carbon, the filtrate was concentrated. The obtained residue was washed with tetrahydrofuran to obtain the title compound (70 mg).

15 ¹H-NMR(DMSO-d₆) δ(ppm) 4.02(3H, s), 4.24(2H, s), 6.64(1H, d, J=5.6Hz), 6.94-6.99(1H, m), 7.21-7.31(4H, m), 7.44-7.49(2H, m), 7.53(1H, s), 7.62-7.66(2H, m), 8.25(2H, brs), 8.48(1H, s), 8.76(1H, d, J=5.6Hz), 8.87(1H, brs), 9.04(1H, brs)

Example 481

20 N-[4-(6-Acetylaminomethyl-7-methoxyquinolin-4-yloxy)phenyl]-N'-phenylurea

[1105] After dissolving N-[4-(6-aminomethyl-7-methoxyquinolin-4-yloxy)phenyl]-N'-phenylurea trifluoroacetate (40 mg) in pyridine (1.0 ml) and acetic anhydride (1.0 ml), the solution was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure and the obtained crude product was crystallized with ethyl acetate to obtain the title compound (13 mg).

25 ¹H-NMR(DMSO-d₆) δ(ppm) 1.90(3H, s), 3.98(3H, s), 4.37-4.40(2H, m), 6.46(1H, d, J=5.2Hz), 6.93-6.99(1H, m), 7.18-7.30(4H, m), 7.40(1H, s), 7.45(2H, d, J=7.6Hz), 7.59(2H, d, J=8.8Hz), 8.06(1H, s), 8.38-8.44(1H, m), 8.59(1H, d, J=5.2Hz) 8.70(1H, s), 8.83(1H, s)

30 Example 482

N-(2-Fluoro-4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]phenyl)-N'-cyclopropylurea

[1106] Cyclopropylamine (0.10 ml) was added to dimethylsulfoxide (0.8 ml), and then [4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]carbamic acid phenyl ester (80 mg) was dissolved therein and the mixture was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution and the precipitated crystals were filtered out to obtain the title compound (33 mg).

35 ¹H-NMR(DMSO-d₆) δ(ppm) 0.38-0.41(2H, m), 0.62-0.66(2H, m), 2.51-2.59(1H, m), 4.01(3H, s), 6.52(1H, d, J=5.2Hz), 6.78-6.81(1H, m), 7.04-7.09(1H, m), 7.28-7.34(1H, m), 7.50(1H, s), 7.72(1H, brs), 7.84(1H, brs), 8.16-8.23(2H, m), 8.63-8.67(2H, m)

[1107] The starting material was synthesized in the following manner.

Production Example 482-1

45 [4-(6-Carbamoyl-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]carbamic acid phenyl ester

[1108] The title compound was obtained from the 6-carbamoyl-4-(4-amino-3-fluorophenoxy)-7-methoxyquinoline synthesized in Production Example 152-5, by the method described in Production Example 17. ¹H-NMR(CDCl₃) δ(ppm) 4.13(3H, s), 5.90(1H, brs), 6.53(1H, d, J=5.6Hz), 6.99-7.06(2H, m), 7.20-7.30(4H, m), 7.40-7.45(2H, m), 7.59(1H, s), 7.80(1H, brs), 8.24(1H, brs), 8.68(1H, d, J=5.6Hz), 9.27(1H, s)

Example 483

N-(2-Fluoro-4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]phenyl)-N'-(2-thiazolyl)urea

55 **[1109]** The title compound (24 mg) was obtained as light yellow crystals from the 6-carbamoyl-4-(4-amino-3-fluorophenoxy)-7-methoxyquinoline (60 mg) and phenyl N-(2-thiazolyl)carbamate (60 mg) synthesized in Example 152-5, by the method described in Example 224.

¹H-NMR(DMSO-d₆) δ(ppm) 4.02(3H, s), 6.57(1H, d, J=5.2Hz), 7.12-7.18(2H, m), 7.37-7.45(2H, m), 7.51(1H, s), 7.73(1H, brs), 7.85(1H, brs), 8.18-8.26(1H, m), 8.64-8.69(2H, m)

Example 484

N-[4-[6-(Methylamino)carbonyl-7-methoxy-4-quinolyl]oxyphenyl]-N'-cyclopropylurea

[1110] The title compound (33 mg) was obtained as light yellow crystals from N-[4-(7-methoxy-6-methylcarbamoylquinolin-4-yloxy)phenyl]carbamic acid phenyl ester (80 mg) and cyclopropylamine (20 mg), by the method described in Example 11.

¹H-NMR(DMSO-d₆) δ(ppm) 0.39-0.43(2H, m), 0.62-0.68(2H, m), 2.50-2.58(1H, m), 2.84(3H, d, J=4.8Hz), 4.02(3H, s), 6.43-6.46(2H, m), 7.14-7.20(2H, m), 7.50(1H, s), 7.53-7.57(2H, m), 8.35-8.38(1H, m), 8.47(1H, brs), 8.61(1H, s), 8.64(1H, d, J=5.2Hz)

[1111] The starting material was synthesized in the following manner.

Production Example 484-1

N-[4-(7-Methoxy-6-methylcarbamoylquinolin-4-yloxy)phenyl]carbamic acid phenyl ester

[1112] The title compound (60 mg) was obtained from 4-(4-aminophenoxy)-7-methoxyquinoline-6-carboxylic acid methylamide (53 mg), by the method described in Production Example 17.

¹H-NMR(CDCl₃) δ(ppm) 3.08(3H, d, J=4.8Hz), 4.12(3H, s), 6.48(1H, d, J=5.2Hz), 7.14-7.29(6H, m), 7.37-7.45(2H, m), 7.55-7.63(3H, m), 7.89(1H, brs), 8.63(1H, d, J=5.2Hz), 9.28(1H, s)

Example 485

N-(2-Fluoro-4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]phenyl)-N'-cyclobutylurea

[1113] The title compound (28 mg) was obtained from [4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]carbamic acid phenyl ester (73 mg) and cyclobutylamine (28 mg), by the method described in Example 11.

¹H-NMR(DMSO-d₆) δ(ppm) 2.52-2.67(2H, m), 2.72-2.87(2H, m), 2.14-2.26(2H, m), 4.01(3H, s), 4.04-4.18(1H, m), 6.51(1H, d, J=5.2Hz), 6.88(1H, d, J=8.0Hz), 7.02-7.08(1H, m), 7.27-7.34(1H, m), 7.50(1H, s), 7.72(1H, brs), 7.84(1H, brs), 8.15-8.26(2H, m), 8.63-8.67(2H, m)

Example 486

N-(2-Fluoro-4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]phenyl)-N'-cyclopentylurea

[1114] The title compound (68 mg) was obtained from [4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]carbamic acid phenyl ester (80 mg) and cyclopentylamine (38 mg), by the method described in Example 11.

¹H-NMR(DMSO-d₆) δ(ppm) 1.30-1.40(2H, m), 1.49-1.59(4H, m), 1.78-1.88(2H, m), 3.88-3.98(1H, m), 4.01(3H, s), 6.51(1H, d, J=5.2Hz), 6.67(1H, d, J=7.2Hz), 7.02-7.07(1H, m), 7.27-7.33(1H, m), 7.50(1H, s), 7.72(1H, brs), 7.84(1H, brs), 8.20-8.28(2H, m), 8.63-8.67(2H, m)

Example 487

N-(2-Fluoro-4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]phenyl)-N'-(2-propyl)urea

[1115] The title compound (39 mg) was obtained from [4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-fluorophenyl]carbamic acid phenyl ester (60 mg) and isopropylamine (25 mg), by the method described in Example 11.

¹H-NMR(DMSO-d₆) δ(ppm) 1.09(6H, d, J=6.4Hz), 3.70-3.80(1H, m), 4.01(3H, s), 6.50-6.55(2H, m), 7.03-7.07(1H, m), 7.27-7.34(1H, m), 7.50(1H, s), 7.72(1H, brs), 7.84(1H, brs), 8.20-8.27(2H, m), 8.63-8.66(2H, m)

Example 488

N-[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-methylphenyl]-N'-cyclopropylurea

[1116] Cyclopropylamine (0.10 ml) was added to dimethylsulfoxide (0.8 ml), and then [4-(6-carbamoyl-7-methoxy-

4-quinolyl)oxy)-2-methylphenyl]carbamic acid phenyl ester (136 mg) was dissolved therein and the mixture was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution and the precipitated crystals were filtered out to obtain the title compound (90 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 0.38-0.44(2H, m), 0.62-0.69(2H, m), 2.22(3H, s), 2.53-2.60(1H, m), 4.03(3H, s), 6.46(1H, d, J=5.2Hz), 6.75-6.79(1H, m), 7.01-7.12(2H, m), 7.50(1H, s), 7.62(1H, s), 7.73(1H, brs), 7.85(1H, brs), 7.90-7.96(1H, m), 8.62-8.69(2H, m)

[1117] The starting materials were synthesized by the following 3 steps.

Production Example 488-1

6-Carbamoyl-4-(3-methyl-4-nitrophenoxy)-7-methoxyquinoline

[1118] The title compound (1.2 g) was obtained from 7-methoxy-4-chloroquinoline-6-carboxamide (1.0 g) and 4-nitro-3-methylphenol (810 mg), in the same manner as Production Example 7.

¹H-NMR(DMSO-d₆) δ(ppm) 2.54(3H, s), 4.00(3H, s), 6.80(1H, d, J=5.2Hz), 7.28-7.32(1H, m), 7.41-7.43(1H, m), 7.54(1H, s), 7.72(1H, brs), 7.83(1H, brs), 8.13-8.16(1H, m), 8.55(1H, s), 8.72-8.76(1H, m)

Production Example 488-2

4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-methylphenylamine

[1119] The title compound (0.22 g) was obtained from 6-carbamoyl-4-(3-methyl-4-nitrophenoxy)-7-methoxyquinoline (1.2 g), in the same manner as Production Example 8.

¹H-NMR(DMSO-d₆) δ(ppm) 2.07(3H, s), 4.00(3H, s), 4.88-4.94(2H, m), 6.39(1H, d, J=5.2Hz), 6.70-6.71(1H, m), 6.77-6.88(2H, m), 7.46(1H, s), 7.70(1H, brs), 7.83(1H, brs), 8.59(1H, d, J=5.2Hz), 8.66(1H, s)

Production Example 488-3

[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-methylphenyl]carbamic acid phenyl ester

[1120] The title compound was obtained from 4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-methylphenylamine, by the method described in Production Example 141-1.

¹H-NMR(CDCl₃) δ(ppm) 2.38(3H, s), 4.12(3H, s), 5.88(1H, brs), 6.49(1H, d, J=5.6Hz), 6.76(1H, brs), 7.04-7.09(2H, m), 7.20-7.29(3H, m), 7.38-7.45(2H, m), 7.54(1H, s), 7.80(1H, brs), 7.94(1H, brs), 8.64(1H, d, J=5.6Hz), 9.29(1H, s)

Example 489

N-[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy)-2-trifluoromethyl-phenyl]-N'-cyclopropylurea

[1121] Cyclopropylamine (0.10 ml) was added to dimethylsulfoxide (0.8 ml), and then [4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy)-2-trifluoromethylphenyl]carbamic acid phenyl ester (140 mg) was dissolved therein and the mixture was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution and the precipitated crystals were filtered out to obtain the title compound (103 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 0.38-0.44(2H, m), 0.62-0.68(2H, m), 2.51-2.59(1H, m), 4.02(3H, s), 6.52(1H, d, J=5.2Hz), 7.18-7.24(1H, m), 7.50-7.62(3H, m), 7.70-7.77(2H, m), 7.84(1H, brs), 8.07-8.14(1H, m), 8.64-8.69(2H, m)

[1122] The starting material was synthesized by the following 3 steps.

Production Example 489-1

6-Carbamoyl-4-(3-trifluoromethyl-4-nitrophenoxy)-7-methoxyquinoline

[1123] The title compound (1.2 g) was obtained from 7-methoxy-4-chloroquinoline-6-carboxamide (900 mg) and 4-nitro-3-(trifluoromethyl)phenol, in the same manner as Production Example 7.

¹H-NMR(DMSO-d₆) δ(ppm) 4.03(3H, s), 6.91(1H, d, J=5.2Hz), 7.57(1H, s), 7.72-7.87(3H, m), 8.01-8.05(1H, m), 8.27-8.32(1H, m), 8.58(1H, s), 8.75-8.79(1H, m)

Production Example 489-24-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-trifluoromethylphenylamine

[1124] After dissolving 6-carbamoyl-4-(3-trifluoromethyl-4-nitrophenoxy)-7-methoxyquinoline (0.60 g) in tetrahydrofuran (10 ml) and methanol (10 ml), the solution was subjected to catalytic reduction with palladium-carbon (600 mg) for 10 hours under a hydrogen atmosphere to obtain the title compound (0.60 g).

¹H-NMR(DMSO-d₆) δ(ppm) 4.00(3H, s), 5.71(2H, brs), 6.42(1H, d, J=5.2Hz), 6.93-6.98(1H, m), 7.23-7.30(2H, m), 7.46-7.52(1H, m), 7.71(1H, brs), 7.83(1H, brs), 8.60-8.69(2H, m)

Production Example 489-3[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-trifluoromethylphenyl]carbamic acid phenyl ester

[1125] The title compound was obtained from 4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-trifluoromethylphenylamine, by the method described in Production Example 141-1.

¹H-NMR(CDCl₃) δ(ppm) 4.12(3H, s), 5.90(1H, brs), 6.48(1H, d, J=5.6Hz), 7.20-7.30(4H, m), 7.38-7.51(3H, m), 7.56(1H, s), 7.80(1H, brs), 8.27-8.31(1H, m), 8.70(1H, d, J=5.2Hz), 9.26(1H, s)

Example 490N-[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2,3-dimethylphenyl]-N'-cyclopropylurea

[1126] Cyclopropylamine (0.10 ml) was added to dimethylsulfoxide (3.0 ml), and then [4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2,3-dimethylphenyl]carbamic acid phenyl ester (120 mg) was dissolved therein and the mixture was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution and the precipitated crystals were filtered out to obtain the title compound (60 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 0.37-0.44(2H, m), 0.60-0.65(2H, m), 2.01(3H, s), 2.14(3H, s), 4.01(3H, s), 6.23(1H, d, J=5.2Hz), 6.64-6.69(1H, m), 6.98(1H, d, J=8.8Hz), 7.50(1H, s), 7.60-7.69(2H, m), 7.73(1H, brs), 7.85(1H, brs), 8.60(1H, d, 5.2Hz), 8.71(1H, s)

[1127] The starting material was synthesized by the following 2 steps.

Production Example 490-14-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2,3-dimethylphenylamine

[1128] The title compound (840 mg) was obtained from 7-methoxy-4-chloroquinoline-6-carboxamide (890 mg) and 4-nitro-2,3-dimethylphenol (940 mg), in the same manner as Production Example 7. Next, 6-carbamoyl-4-(2,3-dimethyl-4-nitrophenoxy)-7-methoxyquinoline (840 mg) was dissolved in tetrahydrofuran (25 ml) and methanol (25 ml), and the solution was subjected to catalytic reduction with palladium-carbon (840 mg) for 10 hours under a hydrogen atmosphere to obtain the title compound (639 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 1.92(3H, s), 2.02(3H, s), 4.00(3H, s), 4.82-4.88(2H, m), 6.22(1H, d, J=5.2Hz), 6.60(1H, d, J=8.4Hz), 6.75(1H, d, J=8.4Hz), 7.47(1H, s), 7.71(1H, brs), 7.84(1H, brs), 8.57(1H, d, J=5.2Hz), 8.70(1H, s)

Production Example 490-2[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2,3-dimethylphenyl] carbamic acid phenyl ester

[1129] The title compound was obtained from 4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2,3-dimethylphenylamine, by the method described in Production Example 141-1.

¹H-NMR(CDCl₃-d₆) δ(ppm) 2.13(3H, s), 2.33(3H, s), 4.13(3H, s), 5.88(1H, brs), 6.29(1H, d, J=5.6Hz), 6.98-7.01(1H, m), 7.20-7.25(4H, m), 7.38-7.42(2H, m), 7.54(1H, s), 7.70(1H, brs), 7.80(1H, brs), 8.60(1H, d, J=5.6Hz), 9.36(1H, s)

Example 491N-[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2,5-dimethylphenyl]-N'-cyclopropylurea

[1130] Cyclopropylamine (0.06 ml) was added to dimethylsulfoxide (2.0 ml), and then [4-(6-carbamoyl-7-methoxy-

4-quinolyl)oxy)-2,5-dimethylphenyl]carbamic acid phenyl ester (100 mg) was dissolved therein and the mixture was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution and the precipitated crystals were filtered out to obtain the title compound (60 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 0.40-0.44(2H, m), 0.63-0.67(2H, m), 2.04(3H, s), 2.17(3H, s), 2.53-2.60(1H, m), 4.03(3H, s), 6.29(1H, d, J=5.2Hz), 6.75-6.78(1H, m), 7.02(1H, s), 7.51(1H, s), 7.58(1H, s), 7.74(1H, brs), 7.83-7.88(2H, m), 8.62(1H, d, 5.2Hz), 8.72(1H, s)

[1131] The starting material was synthesized by the following 2 steps.

Production Example 491-1

4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2,5-dimethylphenylamine

[1132] 4-Amino-2,5-dimethylphenol (1.0 g) was dissolved in dimethylsulfoxide (5 ml), and then 60% sodium hydride (1.0 g) was added and the mixture was stirred for a while. After adding 7-methoxy-4-chloroquinoline-6-carboxamide (900 mg), the mixture was heated at 100°C for 6 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, and then the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was washed with ethyl acetate to obtain the title compound (135 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 1.91(3H, s), 2.03(3H, s), 4.01(3H, s), 6.26(1H, d, J=5.2Hz), 6.57(1H, s), 6.77(1H, s), 7.46(1H, s), 7.70(1H, brs), 7.83(1H, brs), 8.57(1H, d, J=5.2Hz), 8.69(1H, s)

Production Example 491-2

[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2,5-dimethylphenyl]carbamic acid phenyl ester

[1133] The title compound was obtained from 4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2,5-dimethylphenylamine, by the method described in Production Example 141-1.

¹H-NMR(CDCl₃) δ(ppm) 2.13(3H, s), 2.33(3H, s), 4.13(3H, s), 5.88(1H, brs), 6.30(1H, d, J=5.6Hz), 6.75(1H, brs), 6.94(1H, s), 7.18-7.32(3H, m), 7.38-7.45(2H, m), 7.54(1H, s), 7.82(2H, brs), 8.62(1H, d, J=5.6Hz), 9.32(1H, s)

Example 492

N-{4-[6-Cyano-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy) quinolin-4-yloxy]-2-fluorophenyl}-N'-(4-fluorophenyl)urea

[1134] After adding tetrahydrofuran (1 ml) and pyrrolidine (0.1 ml) to N-[4-(6-cyano-7-oxiranylmethoxyquinolin-4-yloxy)-2-fluorophenyl]-N'-(4-fluorophenyl)urea (100 mg), the mixture was heated at 50°C for 30 minutes. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (45 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 1.60-1.70(4H, m), 2.40-2.75(6H, m), 3.95-4.05(1H, m), 4.20(1H, dd, J=10, 6.0Hz), 4.30(1H, dd, J=10, 4Hz), 5.02(1H, d, J=4.4Hz), 6.61(1H, d, J=5.2), 7.10-7.17(3H, m), 7.35-7.50(3H, m), 7.62(1H, s), 8.21-8.27(1H, m), 8.62-8.64(1H, m), 8.72-8.75(2H, m), 9.09(1H, brs)

[1135] The starting material was synthesized by the following 2 steps.

Production Example 492-1

4-(4-Amino-3-fluorophenoxy)-7-oxiranylmethoxyquinoline-6-carbonitrile

[1136] After adding dimethylformamide (6 ml), epibromohydrin (1.3 ml) and potassium carbonate (380 mg) to 4-(4-amino-3-fluorophenoxy)-6-cyano-7-hydroxyquinoline (400 mg), the mixture was stirred overnight at room temperature. Water was added to the reaction solution, extraction was performed with ethyl acetate, and then the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (400 mg).

¹H-NMR(DMSO-d₆) δ(ppm): 2.79-2.93(2H, m), 3.42-3.49(1H, m), 4.15(1H, dd, J=12, 7.2Hz), 4.69(1H, dd, J=12, 2.4Hz), 5.25(2H, brs), 6.53(1H, d, J=5.2), 6.83-6.89(2H, m), 7.07-7.15(1H, m), 7.61(1H, s), 8.69-8.74(2H, m)

Production Example 492-2N-[4-(6-Cyano-7-oxiranylmethoxyquinolin-4-yloxy)-2-fluorophenyl]-N'-(4-fluorophenyl)urea

[1137] After adding dimethylformamide (2 ml) and 4-fluorophenyl isocyanate (0.15 ml) to 4-(4-amino-3-fluorophenoxy)-7-oxiranylmethoxyquinoline-6-carbonitrile (400 mg), the mixture was stirred overnight at room temperature. Water was added to the reaction solution and the precipitated crystals were filtered off to obtain the title compound (480 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 2.79-2.95(2H, m), 3.40-3.50(1H, m), 4.10-4.20(1H, m), 4.65-4.76(1H, m), 6.62(1H, d, J=6.0Hz), 7.05-7.18(3H, m), 7.36-7.50(3H, m), 7.62(1H, s), 8.20-8.28(1H, m), 8.60-8.68(1H, m), 8.73-8.80(2H, m), 9.10(1H, brs)

Example 493N-[4-[6-Cyano-7-(3-diethylamino-2-hydroxypropoxy)quinolin-4-yloxy]-2-fluorophenyl]-N'-(4-fluorophenyl)urea

[1138] After adding tetrahydrofuran (1 ml) and diethylamine (0.1 ml) to N-[4-(6-cyano-7-oxiranylmethoxyquinolin-4-yloxy)-2-fluorophenyl]-N'-(4-fluorophenyl)urea (100 mg), the mixture was heated at 50°C for 30 minutes. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (32 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 0.958(6H, t, J=7Hz), 2.40-2.68(6H, m), 3.91-3.99(1H, m), 4.20(1H, dd, J=10, 5.2Hz), 4.31(1H, dd, J=10, 3.6Hz), 4.91(1H, d, J=4.4Hz), 6.61(1H, d, J=5.2Hz), 7.10-7.17(3H, m), 7.37-7.49(3H, m), 7.62(1H, s), 8.21-8.27(1H, m), 8.63(1H, brs), 8.72-8.75(2H, m), 9.10(1H, brs)

Example 494N-[4-[6-Cyano-7-(2-hydroxy-(3-morpholin-4-yl)propoxy)quinolin-4-yloxy]-2-fluorophenyl]-N'-(4-fluorophenyl)urea

[1139] After adding tetrahydrofuran (1 ml) and morpholine (0.1 ml) to N-[4-(6-cyano-7-oxiranylmethoxyquinolin-4-yloxy)-2-fluorophenyl]-N'-(4-fluorophenyl)urea (100 mg), the mixture was heated at 50°C for 30 minutes. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (32 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 2.38-2.58(6H, m), 3.53-3.59(4H, m), 4.03-4.09(1H, m), 4.22(1H, dd, J=10, 6.0Hz), 4.31(1H, dd, J=10, 4.0Hz), 5.03(1H, d, J=4.8), 6.61(1H, d, J=5.2Hz), 7.10-7.17(3H, m), 7.36-7.49(3H, m), 7.64(1H, s), 8.20-8.27(1H, m), 8.60-8.64(1H, m), 8.73-8.75(2H, m), 9.10(1H, brs)

Example 495N-[4-[6-Cyano-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)quinolin-4-yloxy]-2-fluorophenyl]-N'-(thiazol-2-yl)urea

[1140] After adding tetrahydrofuran (1 ml) and pyrrolidine (0.1 ml) to N-[4-(6-cyano-7-oxiranylmethoxyquinolin-4-yloxy)-2-fluorophenyl]-N'-(thiazol-2-yl)urea (120 mg), the mixture was heated at 50°C for 40 minutes. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (70 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 1.60-1.70(4H, m), 2.40-2.75(6H, m), 3.95-4.05(1H, m), 4.20(1H, dd, J=10, 6.0Hz), 4.31(1H, dd, J=10, 4Hz), 5.02(1H, brs), 6.62(1H, d, J=5.2Hz), 6.85(1H, s), 7.10-7.20(2H, m), 7.37-7.47(2H, m), 7.62(1H, s), 8.20-8.26(1H, m), 8.71-8.76(2H, m), 9.05(1H, brs)

[1141] The starting material was synthesized in the following manner.

Production Example 495-1N-[4-(6-Cyano-7-oxiranylmethoxyquinolin-4-yloxy)-2-fluorophenyl]-N'-(thiazol-2-yl)urea

[1142] After adding dimethylsulfoxide (1 ml) and phenyl N-(2-thiazolyl)carbamate (94 mg) to 4-(4-amino-3-fluorophenoxy)-7-oxiranylmethoxyquinoline-6-carbonitrile (100 mg), the mixture was heated at 80°C for 90 minutes. Water was added and the precipitated crystals were filtered out to obtain the title compound (16 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 2.78-2.94(2H, m), 3.41-3.49(1H, m), 4.17(1H, dd, J=12, 6.4Hz), 4.71(1H, dd, J=12, 2.0), 6.64(1H, d, J=5.2Hz), 7.08-7.20(3H, m), 7.36-7.48(2H, m), 7.65(1H, s), 8.20-8.27(1H, m), 8.73-8.79(2H, m), 9.07(1H,

brs)

Example 496

N-[4-[6-Cyano-7-(2-hydroxy-3-(piperidin-1-yl)propoxy)quinolin-4-yloxy]-2-fluorophenyl]-N'-(4-fluorophenyl)urea

[1143] After adding tetrahydrofuran (1.5 ml) and piperidine (0.08 ml) to N-[4-(6-cyano-7-oxiranylmethoxyquinolin-4-yloxy)-2-fluorophenyl]-N'-(4-fluorophenyl)urea (78 mg), the mixture was heated at 50°C for 30 minutes. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (32 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 1.30-1.55 (6H, m), 2.35-2.55 (6H, m), 4.00-4.08(1H, m), 4.20(1H, dd, J=10, 6.0Hz), 4.30(1H, dd, J=10, 4.0Hz), 4.94(1H, d, J=4.8Hz), 6.61(1H, d, J=5.6Hz), 7.10-7.17(3H, m), 7.36-7.50(3H, m), 7.63(1H, m), 8.20-8.23(1H, m), 8.62-8.64(1H, m), 8.72-8.75(2H, m), 9.10(1H, m)

Example 497

N-(4-{6-Cyano-7-[(2R)-2-hydroxy-3-(piperidin-1-yl)propoxy] quinolin-4-yloxy}-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[1144] The title compound (115 mg) was obtained as light yellow crystals from N-(4-{6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-fluorophenyl)-N'-(4-fluorophenyl)urea (345 mg), by the same procedure as in Example 496.

¹H-NMR(DMSO-d₆) δ(ppm): 1.30-1.55 (6H, m), 2.35-2.55 (6H, m), 4.00-4.08(1H, m), 4.20(1H, dd, J=10, 6.0Hz), 4.30(1H, dd, J=10, 4.0Hz), 4.94(1H, d, J=4.8Hz), 6.61(1H, d, J=5.6Hz), 7.10-7.17(3H, m), 7.36-7.50(3H, m), 7.63(1H, m), 8.20-8.23(1H, m), 8.62-8.64(1H, m), 8.72-8.75(2H, m), 9.10(1H, m)

[1145] The starting material was synthesized by the following 2 steps.

Production Example 497-1

4-(4-Amino-3-fluoro-phenoxy)-7-[(2R)-oxiran-2-yl]methoxyquinoline-6-carbonitrile

[1146] After adding dimethylformamide (8 ml), p-toluenesulfonic acid (2R)-glycidyl ester (100.0 mg) and potassium carbonate (940 mg) to 4-(4-amino-3-fluorophenoxy)-6-cyano-7-hydroxyquinoline (1000 mg), the mixture was heated at 50°C for 4 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, and then the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was purified by silica gel column chromatography (ethyl acetate) to obtain the title compound (659 mg) as light yellow crystals. ¹H-NMR(DMSO-d₆) δ (ppm): 2.79-2.93(2H, m), 3.42-3.49(1H, m), 4.15(1H, dd, J=12, 7.2Hz), 4.69(1H, dd, J=12, 2.4Hz), 5.25(2H, brs), 6.53(1H, d, J=5.2Hz), 6.83-6.89(2H, m), 7.07-7.15(1H, m), 7.61(1H, s), 8.69-8.74(2H, m)

Production Example 497-2

N-(4-{6-Cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[1147] The title compound (200 mg) was obtained from 4-(4-amino-3-fluorophenoxy)-7-[(2R)-oxiran-2-yl]methoxyquinoline-6-carbonitrile (150 mg), by the method described in Production Example 492-1.

¹H-NMR(DMSO-d₆) δ(ppm): 2.79-2.95(2H, m), 3.40-3.50(1H, m), 4.10-4.20(1H, m), 4.65-4.76(1H, m), 6.62(1H, d, J=6.0Hz), 7.05-7.18(3H, m), 7.36-7.50(3H, m), 7.62(1H, s), 8.20-8.28(1H, m), 8.60-8.68(1H, m), 8.73-8.80(2H, m), 9.10(1H, brs)

Example 498

N-(4-{6-Cyano-7-[3-diethylamino-(2R)-2-hydroxypropoxy] quinolin-4-yloxy}-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[1148] The title compound (120 mg) was obtained as light yellow crystals from N-(4-{6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-fluorophenyl)-N'-(4-fluorophenyl)urea (200 mg), by the same procedure as in Example 493.

¹H-NMR(DMSO-d₆) δ(ppm): 0.96(6H, t, J=7Hz), 2.40-2.68(6H, m), 3.91-3.99(1H, m), 4.20(1H, dd, J=10, 5.2Hz), 4.31(1H, dd, J=10, 3.6Hz), 4.91(1H, d, J=4.4Hz), 6.61(1H, d, J=5.2Hz), 7.10-7.17(3H, m), 7.37-7.49(3H, m), 7.62(1H, s), 8.21-8.27(1H, m), 8.63(1H, brs), 8.72-8.75(2H, m), 9.10(1H, brs)

Example 499

N-(4-{6-Cyano-7-[3-dimethylamino-(2R)-2-hydroxypropoxy]-quinolin-4-yloxy}-2-fluorophenyl)-N'-(4-fluorophenyl)urea

[1149] After adding tetrahydrofuran (0.5 ml) and a dimethylamine-2N tetrahydrofuran solution (Aldrich, 0.2 ml) to N-(4-{6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-fluorophenyl)-N'-(4-fluorophenyl)urea (40 mg), the mixture was stirred overnight at room temperature. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (45 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 2.20(6H, m), 2.30-2.58(2H, m), 3.95-4.95(1H, m), 4.19(1H, dd, J=10, 5.6Hz), 4.29(1H, dd, J=10, 4.0Hz), 4.99(1H, d, J=4.4Hz), 6.61(1H, d, J=5.6Hz), 7.10-7.17(3H, m), 7.37-7.50(3H, m), 7.62(1H, s), 8.20-8.30(1H, m), 8.64(1H, brs), 8.70-8.76(2H, m), 9.11(1H, brs)

Example 500

N-(4-{6-Cyano-7-[3-diethylamino-(2R)-2-hydroxypropoxy]-quinolin-4-yloxy}-2-fluorophenyl)-N'-(thiazol-2-yl)urea

[1150] After adding tetrahydrofuran (4 ml) and diethylamine (0.2 ml) to N-(4-{6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-fluorophenyl)-N'-(thiazol-2-yl)urea (200 mg), the mixture was stirred at 50°C for 2 hours. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (60 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 0.96(6H, t, J=7.0Hz), 2.40-2.70(6H, m), 3.90-3.98(1H, m), 4.21(1H, dd, J=10, 5.2Hz), 4.31(1H, dd, J=10, 3.2Hz), 4.90-4.95(1H, m), 6.62(1H, d, J=5.2Hz), 7.11-7.20(2H, m), 7.36-7.47(2H, m), 7.62(1H, s), 8.20-8.27(1H, m), 8.72-8.76(2H, m)

[1151] The starting material was synthesized in the following manner.

Production Example 500-1

N-(4-{6-Cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-fluorophenyl)-N'-(thiazol-2-yl)urea

[1152] The title compound (370 mg) was obtained as light yellow crystals from 4-(4-amino-3-fluorophenoxy)-7-[(2R)-oxiran-2-yl]methoxyquinoline-6-carbonitrile (300 mg), by the method described in Example 495.

¹H-NMR(DMSO-d₆) δ(ppm): 2.78-2.94(2H, m), 3.41-3.49(1H, s), 4.17(1H, dd, J=12, 6.4Hz), 4.71(1H, dd, J=12, 2.0Hz), 6.64(1H, d, J=5.2Hz), 7.08-7.20(2H, m), 7.36-7.48(2H, m), 7.65(1H, s), 8.20-8.27(1H, m), 8.73-8.79(2H, m), 9.07(1H, brs)

Example 501

N-(2-Fluoro-4-[[6-cyano-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl)-N'-(4-fluorophenyl)urea

[1153] After dissolving 4-(6-cyano-4-{3-fluoro-4-[3-(4-fluorophenyl)ureido]phenoxy}quinolin-7-yloxymethyl)piperidine-1-carboxylic acid tert-butyl ester (395 mg) in trifluoroacetic acid (2 ml), the solution was stirred for 10 minutes at room temperature. Water (20 ml) was added, the mixture was neutralized with sodium bicarbonate, and the precipitated crystals were filtered out to obtain the title compound (260 mg).

¹H-NMR(DMSO-d₆) δ(ppm): 1.15-1.30(2H, m), 1.69-1.76(2H, m), 1.85-2.00(1H, m), 2.44-2.70(2H, m), 2.90-2.99(2H, m), 4.09-4.25(3H, m), 6.61(1H, d, J=5.2Hz), 7.05-7.14(3H, m), 7.34-7.40(1H, m), 7.48-7.55(2H, m), 7.59(1H, s), 8.10-8.17(1H, m), 8.70-8.76(2H, m)

[1154] The starting material was synthesized by the following 3 steps.

Production Example 501-1

9-[4-(4-Amino-3-fluorophenoxy)-6-cyanoquinolin-7-yloxymethyl]-piperidine-1-carboxylic acid tert-butyl ester

[1155] After adding dimethylformamide (4 ml), tert-butyl 4-(bromomethyl)-1-piperidine carboxylate (708 mg) and potassium carbonate (467 mg) to 4-(4-amino-3-fluorophenoxy)-6-cyano-7-hydroxyquinoline (500 mg), the mixture was heated at 50°C for 4 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate and the organic layer was washed with water and saturated brine in that order and then dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was purified by silica gel column chromatography (n-hexane:ethyl acetate) to obtain the title compound (398 mg).

¹H-NMR(DMSO-d₆) δ(ppm): 1.16-1.31(2H, m), 1.39(9H, s), 1.72-1.82(2H, m), 2.00-2.08(1H, m), 2.65-2.83(2H, m), 3.93-4.03(2H, m), 4.11-4.18(2H, m), 5.20-5.26(2H, m), 6.50(1H, d, J=5.2Hz), 6.82-6.85(2H, m), 7.02-7.10(1H, m), 7.56(1H, s), 8.65-8.72(2H, m)

5 Production Example 501-2

4-(6-Cyano-4-[3-fluoro-4-[3-(4-fluorophenyl)ureido]phenoxy]quinolin-7-yloxymethyl)piperidine-1-carboxylic acid tert-butyl ester

10 **[1156]** The title compound (500 mg) was obtained as light yellow crystals from 4-[4-(4-amino-3-fluorophenoxy)-6-cyanoquinolin-7-yloxymethyl]piperidine-1-carboxylic acid tert-butyl ester (619 mg) and 4-fluorophenyl isocyanate (0.22 ml), by the same procedure as in Example 492.

¹H-NMR(DMSO-d₆) δ(ppm): 1.20-1.35(2H, m), 1.39(9H, s), 1.73-1.85(2H, m), 2.00-2.10(1H, m), 2.63-2.86(2H, m), 3.92-4.06(2H, m), 4.13-4.20(2H, m), 6.61(1H, d, J=5.6Hz), 7.10-7.16(3H, m) 7.36-7.50(3H, m), 7.60(1H, s), 8.20-8.28(1H, m), 8.68-8.76(2H, m), 9.27(1H, brs)

Example 502

N-{4-[6-Cyano-7-(1-methylpiperidin-4-yl)methoxyquinolin-4-yloxy]-2-fluorophenyl}-N'-(4-fluorophenyl)urea

20 **[1157]** After dissolving N-(2-fluoro-4-[[6-cyano-7-(4-piperidinomethoxy)-4-quinolyl]oxy]phenyl)-N'-(4-fluorophenyl)urea (180 mg) in tetrahydrofuran (10 ml)-methanol (10 ml), there were added 37% aqueous formaldehyde (0.5 ml), acetic acid (0.04 ml) and sodium cyanoborohydride (43 mg) at room temperature, and the mixture was stirred for 1 hour. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the
25 organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, and after suspension in ethyl acetate and dilution with hexane, the crystals were filtered out and blow-dried to obtain the title compound (130 mg) as white crystals.

¹H-NMR(DMSO-d₆) δ(ppm): 1.13-1.47(2H, m), 1.73-1.92(5H, m), 2.15(3H, s), 2.77-2.85(2H, m), 4.13-4.16(2H, m), 6.61(1H, d, J=5.6Hz), 7.10-7.16(3H, m), 7.36-7.49(3H, m), 7.59(1H, s), 8.20-8.26(1H, m), 8.62-8.68(1H, m), 8.72-8.76(2H, m), 9.08-9.15(1H, m)

Example 503

N-{4-[6-Cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy]-2-fluorophenyl}-N'-(2-thiazolyl)urea

35 **[1158]** The title compound (240 mg) was obtained from 4-{6-cyano-4-[3-fluoro-4-(3-(thiazol-2-yl)ureido)phenoxy]quinolin-7-yloxymethyl}piperidine-1-carboxylic acid tert-butyl ester (370 mg), by the same procedure as in Example 501.
¹H-NMR(DMSO-d₆) δ(ppm): 1.45-1.56 (2H, m), 1.92-2.00(2H, m), 2.13-2.23(1H, m), 2.45-2.50(2H, m), 2.85-2.98(2H, m), 4.18-4.23(2H, m), 6.64(1H, d, J=5.2Hz), 7.14-7.19(2H, m), 7.37-7.47(2H, m), 7.65(1H, s), 8.21-8.28(1H, m), 8.74-8.79(2H, m), 9.06(1H, brs)

[1159] The starting material was synthesized in the following manner.

Production Example 503-1

45 4-[6-Cyano-4-[3-fluoro-4-(3-(thiazol-2-yl)ureido)phenoxy]quinolin-7-yloxymethyl]piperidine-1-carboxylic acid tert-butyl ester

[1160] This was synthesized from 4-[4-(4-amino-3-fluorophenoxy)-6-cyanoquinolin-7-yloxymethyl]piperidine-1-carboxylic acid tert-butyl ester, by the method described for the intermediate synthesis in Example 495.

¹H-NMR(DMSO-d₆) δ(ppm): 1.18-1.32(2H, m), 1.39(9H, s), 1.73-1.83(2H, m), 2.00-2.10(1H, m), 2.63-2.86(2H, m), 3.95-4.05(2H, m), 4.13-4.20(2H, m), 6.62(1H, d, J=5.2Hz), 7.10-7.20(2H, m), 7.36-7.47(2H, m), 7.61(1H, s), 8.20-8.27(1H, m), 8.72-8.77(2H, m)

Example 504

N-{4-[6-Cyano-7-(1-methylpiperidin-4-ylmethoxy)quinolin-4-yloxy]-2-fluorophenyl}-N'-(2-thiazolyl) urea

[1161] The title compound was obtained from N-{4-[6-cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy]-2-fluoroph-

enyl)-N'-(2-thiazolyl)urea, by the method described in Example 502.

¹H-NMR(DMSO-d₆) δ(ppm): 1.30-1.46(2H, m), 1.70-1.93(5H, m), 2.15(3H, s), 2.77-2.85(2H, m), 4.13-4.17(2H, m), 6.62(1H, d, J=5.2Hz), 7.12-7.19(2H, m), 7.37-7.47(2H, m), 7.60(1H, s), 8.20-8.30(1H, m), 8.73-8.76(2H, m)

Example 505

N-{4-[6-Cyano-7-(1-methylpiperidin-3-ylmethoxy)quinolin-4-yloxy]-2-fluorophenyl}-N'-(2-thiazolyl)urea

[1162] The title compound was obtained from 4-(4-amino-3-fluorophenoxy)-7-(1-methylpiperidin-3-ylmethoxy)quinoline-6-carbonitrile by the method described for the intermediate synthesis in Example 495.

¹H-NMR(DMSO-d₆) δ(ppm): 1.10-1.20(1H, m), 1.43-1.96(5H, m), 2.05-2.15(1H, m), 2.16(3H, s), 2.61-2.67(1H, m), 2.80-2.87(1H, m), 4.15-4.19(2H, m), 6.62(1H, d, J=5.6Hz), 7.12-7.20(2H, m), 7.37-7.47(2H, m), 7.60(1H, s), 8.20-8.26(1H, m), 8.72-8.77(2H, m)

[1163] The starting material was synthesized in the following manner.

Production Example 505-1

4-(4-Amino-3-fluorophenoxy)-7-(1-methylpiperidin-3-ylmethoxy)quinoline-6-carbonitrile

[1164] After adding dimethylformamide (4 ml), 3-chloromethyl-1-methylpiperidine hydrochloride (621 mg) and potassium carbonate (840 mg) to 4-(4-amino-3-fluorophenoxy)-6-cyano-7-hydroxyquinoline (400 mg), the mixture was stirred at 20°C for 3 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was purified by NH silica gel column chromatography (ethyl acetate) to obtain the title compound (60 mg).

¹H-NMR(DMSO-d₆) δ(ppm): 1.10-1.20(1H, m), 1.45-1.95(5H, m), 2.03-2.14(1H, m), 2.14(3H, s), 2.56-2.68(1H, m), 2.78-2.88(1H, m), 4.12-4.18(2H, m), 5.23-5.28(2H, m), 6.51(1H, d, J=5.2Hz), 6.83-6.89(2H, m), 7.03-7.10(1H, m), 7.56(1H, s), 8.65-8.72(2H, m)

Example 506

N-(4-[(7-Cyano-6-methoxy-4-quinolyl)oxy]phenyl)-N'-(4-fluoro-phenyl)urea

[1165] After adding toluene (5 ml), acetonitrile (1.5 ml) and 4-fluorophenyl isocyanate (0.105 ml) to 4-(4-aminophenoxy)-6-methoxyquinoline-7-carbonitrile (180 mg), the mixture was heated to reflux for 30 minutes. The mixture was cooled, and the precipitated crystals were filtered out and washed with toluene to obtain the title compound (230 mg) as light yellow crystals. ¹H-NMR(DMSO-d₆) δ(ppm) 4.05(3H, m), 6.66(1H, d, J=5.2Hz), 7.08-7.14(2H, m), 7.24(2H, d, J=8.8Hz), 7.43-7.48(2H, m), 7.59(2H, d, J=8.8Hz), 7.76(1H, s), 8.54(1H, s), 8.64(1H, d, J=5.2Hz), 8.74(1H, brs), 8.84(1H, brs)

[1166] The starting material was synthesized by the following 4 steps.

Production Example 506-1

6-Methoxy-4-(4-nitrophenoxy)quinolin-7-ol

[1167] After adding trifluoroacetic acid (30 ml) and thioanisole (3 ml) to 7-benzyloxy-6-methoxy-4-(4-nitrophenoxy)quinoline (4.0 g), the mixture was heated and stirred at 70°C for 2 hours. After cooling the reaction solution, it was concentrated under reduced pressure, sodium bicarbonate water and methanol were added and the precipitated crystals were filtered out. They were then washed with diethyl ether to obtain 4.0 g of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm) 3.94(3H, s), 6.93(1H, d, J=5.6Hz), 7.42(1H, s), 7.55-7.60(3H, m), 8.40(2H, d, J=10Hz), 8.71(1H, d, J=6Hz)

Production Example 506-2

Trifluoromethanesulfonic acid 6-methoxy-4-(4-nitrophenoxy)quinolin-7-yl ester

[1168] After dissolving 6-methoxy-4-(4-nitrophenoxy)quinolin-7-ol (1.0 g) in dimethylformamide (10 ml), there were added trifluoromethanesulfonic acid 4-nitrophenyl ester (640 mg) and potassium carbonate (1.3 g), and the mixture

was stirred at room temperature for 5 hours. Water was added, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Ethyl acetate was used for recrystallization to obtain the title compound (1.0 g).
¹H-NMR(DMSO-d₆) δ(ppm) 4.04(3H, s), 7.01(1H, d, J=4.8Hz), 7.52-7.57(2H, m), 7.80(1H, s), 8.18(1H, s), 8.34-8.39
 5 (2H, m), 8.72-8.76(1H, m)

Production Example 506-3

6-Methoxy-4-(4-nitrophenoxy)quinoline-7-carbonitrile

[1169] After dissolving trifluoromethanesulfonic acid 6-methoxy-4-(4-nitrophenoxy)quinolin-7-yl ester (500 mg) in dimethylformamide (5 ml), there were added zinc cyanide (260 mg) and tetrakis(triphenyl)phosphine palladium (0) (130 mg) and the mixture was heated and stirred at 110°C for 2 hours under a nitrogen atmosphere. Water was added, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order
 15 and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Ethyl acetate was used for recrystallization to obtain the title compound (300 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 4.03(3H, s), 7.05(1H, d, J=5.2Hz), 7.51-7.56(2H, m), 7.68(1H, s), 8.34-8.39(2H, m), 8.62
 (1H, s), 8.76(1H, d, J=5.2Hz)

Production Example 506-4

4-(4-Aminophenoxy)-6-methoxyquinoline-7-carbonitrile

[1170] 6-Methoxy-4-(4-nitrophenoxy)quinoline-7-carbonitrile (290 mg) was subjected to iron reduction by the same
 25 method as in Production Example 10 to obtain the title compound (180 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 4.05(3H, s), 5.19(2H, s), 6.59(1H, d, J=5.2Hz), 6.66(2H, d, J=8.8Hz), 6.94(2H, d, J=8.8Hz),
 7.73(1H, s), 8.51(1H, s), 8.61(1H, d, J=5.2Hz)

Example 507

N-(4-[(7-Carbamoyl-6-methoxy-4-quinolyl)oxy]phenyl)-N'-(4-fluorophenyl)urea

[1171] After dissolving N-(4-[(7-cyano-6-methoxy-4-quinolyl)oxy]phenyl)-N'-(4-fluorophenyl)urea (43 mg) in 1.5 ml
 35 of dimethylsulfoxide at 80°C, a 5N aqueous NaOH solution was added thereto and the mixture was heated and stirred for 2 hours. The reaction solution was neutralized with 1N HCl and the precipitated crystals were filtered out and washed with ethanol to obtain 17 mg of the title compound.

¹H-NMR(DMSO-d₆) δ(ppm) 4.00(3H, s), 6.58(1H, d, J=5.2Hz), 7.06-7.14(2H, m), 7.17-7.24(2H, m), 7.45-7.53(2H, m),
 7.55-7.67(3H, m), 7.70(1H, brs), 7.86(1H, brs), 8.22(1H, s), 8.56(1H, d, J=5.2Hz)

Example 508

N-(4-[(7-Aminomethyl-6-methoxy-4-quinolyl)oxy]phenyl)-N'-(4-fluorophenyl)urea trifluoroacetate

[1172] The title compound (52 mg) was obtained from N-(4-[(7-cyano-6-methoxy-4-quinolyl)oxy]phenyl)-N'-(4-fluorophenyl)urea (50 mg), by the same procedure as in Example 480.
 45

¹H-NMR(DMSO-d₆) δ(ppm) 4.01(3H, s), 4.21-4.26(2H, m), 6.66(1H, d, J=5.2Hz), 7.08-7.15(2H, m), 7.23(2H, d, J=8.8Hz),
 7.43-7.50(2H, m), 7.61(2H, d, J=8.8Hz), 7.67(1H, s), 8.08(1H, s), 8.63(1H, d, J=5.2Hz), 8.85(1H, brs), 8.95
 (1H, brs)

Example 509

N-(4-[(7-Acetylaminoethyl-6-methoxy-4-quinolyl)oxy]phenyl)-N'-(4-fluorophenyl)urea

[1173] The title compound (5 mg) was obtained from N-(4-[(7-aminomethyl-6-methoxy-4-quinolyl)oxy]phenyl)-
 55 -N'-(4-fluorophenyl)urea trifluoroacetate (30 mg), by the method described in Example 481.

¹H-NMR(DMSO-d₆) δ(ppm) 1.94(3H, s), 3.96 (3H, s), 4.37-4.40(2H, m), 6.51(1H, d, J=5.2Hz), 7.08-7.14(2H, m), 7.20
 (2H, d, J=8.8Hz), 7.43-7.50(2H, m), 7.50-7.60(3H, m), 7.74(1H, s), 8.39-8.45(1H, m), 8.50(1H, d, J=5.2Hz), 8.80(1H,
 brs), 8.88(1H, brs)

Example 5104-{4-[3-(4-Fluorophenyl)ureido]phenoxy}furo[2,3-b]pyridine-2-carboxylic acid methyl ester

[1174] After adding toluene (1 ml), acetonitrile (0.5 ml) and 4-fluorophenyl isocyanate (0.02 ml) to 4-(4-aminophenoxy) furo[2.3-b]pyridine-2-carboxylic acid methyl ester (28 mg), the mixture was heated to reflux for 30 minutes. After cooling, the precipitated crystals were filtered off and washed with toluene to obtain the title compound (24 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 3.87(3H, s), 6.75(1H, d, J=5.6Hz), 7.08-7.14(2H, m), 7.21-7.25(2H, m), 7.40(1H, s), 7.43-7.48(2H, m), 7.55-7.60(2H, m), 8.35(1H, d, J=5.6Hz), 8.79(1H, brs), 8.89(1H, brs)

[1175] The starting material was synthesized by the following 5 steps.

Production Example 510-15-[(2,2-Dimethyl-4,6-dioxo-[1.3]dioxan-5-ylidenemethyl)amino] furan-2-carboxylic acid methyl ester

[1176] Methyl 5-amino-2-furoate (4 g) by Lancaster was added to a mixed solution of triethyl orthoformate (20 ml) and isopropyl alcohol (20 ml), and then Meldrum acid (4.5 g) was added and the mixture was heated and stirred at 100°C for 1 hour. After cooling, the precipitated crystals were filtered out and washed with isopropyl alcohol to obtain the title compound (7.8 g). ¹H-NMR(CDCl₃) δ(ppm) 1.75(6H, s), 3.89(3H, s), 6.04-6.09(1H, m), 7.08-7.12(1H, m), 8.56-8.64(1H, m), 11.4-11.6(1H, m)

Production Example 510-24-Oxo-4,7-dihydrofuro[2.3-b]pyridine-2-carboxylic acid methyl ester

[1177] After adding 5-[(2,2-dimethyl-4,6-dioxo-[1.3]dioxan-5-ylidenemethyl)amino]furan-2-carboxylic acid methyl ester (4.0 g) to Dowtherm A (30 ml), the mixture was heated and stirred at 200°C for 1 hour. After cooling, the precipitated crystals were filtered out and washed with diethyl ether to obtain the title compound (2.0 g).

¹H-NMR(DMSO-d₆) δ(ppm) 3.86(3H, s), 6.77(1H, d, J=5.6Hz), 7.71(1H, s), 8.18(1H, d, J=5.6Hz), 11.85(1H, brs)

Production Example 510-224-Chloro-furo[2.3-b]pyridine-2-carboxylic acid methyl ester

[1178] After adding thionyl chloride (8.0 ml) and dimethylformamide (0.08 ml) to 4-oxo-4,7-dihydrofuro[2.3-b]pyridine-2-carboxylic acid methyl ester (2.0 g), the mixture was heated to reflux for 1 hour. After cooling, the mixture was concentrated under reduced pressure and the precipitated crystals were filtered out and washed with tetrahydrofuran and ethyl acetate to obtain the title compound (2.1 g).

¹H-NMR(DMSO-d₆) δ(ppm) 3.92(3H, s), 7.66(1H, d, J=5.2Hz), 7.86(1H, s), 8.49(1H, d, J=5.2Hz)

Production Example 510-34-(4-Nitrophenoxy)furo[2.3-b]pyridine-2-carboxylic acid methyl ester

[1179] After adding N-methylpyrrolidone (4.0 ml), diisopropylethylamine (1.3 ml) and para-nitrophenol (822 mg) to 4-chlorofuro[2.3-b]pyridine-2-carboxylic acid methyl ester (1.0 g), the mixture was heated and stirred at 140°C for 5 hours. After cooling, water was added, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Tetrahydrofuran was used for recrystallization to obtain the title compound (70 mg). ¹H-NMR(DMSO-d₆) δ(ppm) 3.87(3H, s), 7.04(1H, d, J=5.6Hz), 7.48-7.53(2H, m), 7.59(1H, s), 8.32-8.37(2H, m), 8.47(1H, d, J=5.6Hz)

Production Example 510-4Synthesis of 4-(4-Aminophenoxy)furo[2.3-b]pyridine-2-carboxylic acid methyl ester

[1180] 4-(4-Nitrophenoxy)-furo[2.3-b]pyridine-2-carboxylic acid methyl ester (70 mg) was subjected to iron reduction by the same method as in Production Example 10 to obtain the title compound (55 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 3.86(3H, s), 5.23(2H, brs), 6.64(2H, d, J=8.4Hz), 6.72(1H, d, J=6.0Hz), 6.93(2H, d, J=8.4Hz), 7.23(1H, s), 8.31(1H, d, J=6.0Hz)

Example 511

N-(4-Fluorophenoxy)-N'-[4-(2-hydroxymethylfuro[2.3-b]pyridin-4-yloxy)phenyl]urea

[1181] After dissolving 4-{4-[3-(4-fluorophenyl)ureido]phenoxy}-furo[2.3-b]pyridine-2-carboxylic acid methyl ester (13 mg) in tetrahydrofuran (3 ml), lithium borohydride (10 mg) was added and the mixture was stirred overnight at room temperature. After adding a small amount of acetone, water was added, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (10 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 4.52(2H, d, J=6.0Hz), 5.52(1H, t, J=6.0Hz), 6.38(1H, s), 6.69(1H, d, J=5.6Hz), 7.07-7.19 (4H, m), 7.43-7.49(2H, m), 7.51-7.57(2H, m), 8.11(1H, d, J=5.4Hz), 8.11(1H, brs), 8.81(1H, brs)

Example 512

N-(4-Fluorophenyl)-N'-[4-(6-phenylfuro[2.3-d]pyrimidin-4-yloxy)phenyl]urea

[1182] After adding toluene (1 ml), acetonitrile (0.5 ml) and 4-fluorophenyl isocyanate (0.03 ml) to 4-(6-phenylfuro[2.3-d]pyrimidin-4-yloxy)phenylamine (40 mg), the mixture was heated to reflux for 30 minutes. After cooling, the precipitated crystals were filtered out and washed with toluene to obtain the title compound (42 mg) as light yellow crystals. ¹H-NMR(DMSO-d₆) δ(ppm) 7.08-7.15(2H, m), 7.23(2H, d, J=8.4Hz), 7.43-7.57(7H, m), 7.65(1H, s), 7.97(2H, d, J=8.4Hz), 8.50(1H, s), 8.74-8.81(2H, m)

[1183] The starting material was synthesized by the following 4 steps.

Production Example 512-1

6-Phenylfuro[2.3-d]pyrimidin-4-ylamine

[1184] After adding formamide (10 ml) and 2 drops of acetic anhydride to 2-amino-5-phenyl-3-furonitrile (1.8 g) synthesized according to the method described in J. Heterocyclic Chem., 35, 1313 (1998), the mixture was heated and stirred at 200°C for 2 hours. After cooling, the precipitated crystals were filtered out and washed with diethyl ether to obtain the title compound (1.3 g).

¹H-NMR(DMSO-d₆) δ(ppm) 7.30(1H, s), 7.35-7.41(1H, m), 7.46-7.53(2H, m), 7.74-7.79(2H, m), 8.16(1H, m)

Production Example 512-2

4-(4-Nitrophenoxy-6-phenyl-furo[2.3-d]pyrimidine

[1185] After adding dibromomethane (1.2 ml) and isoamyl nitrite (1.2 ml) to 6-phenylfuro[2.3-d]pyrimidin-4-ylamine (211 mg), the mixture was heated and stirred at 80°C for 30 minutes. The reaction solution was concentrated under reduced pressure, water was added, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. After adding dimethylformamide (10 ml), para-nitrobenzene (222 mg) and potassium carbonate (414 mg), the mixture was heated and stirred at 80°C for 1 hour. Water was added to the reaction solution, extraction was performed with ethyl acetate, and then the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Ethyl acetate was used for recrystallization to obtain the title compound (150 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 7.43-7.67(5H, m), 7.76(1H, s), 7.98-8.03(2H, m), 8.34-8.39 (2H, m), 8.56(1H, s)

Production Example 512-3

4-(6-Phenylfuro[2.3-d]pyrimidin-4-yloxy)phenylamine

[1186] 4-(4-Nitrophenoxy-6-phenylfuro[2.3-d]pyrimidine (150 mg) was subjected to iron reduction by the same method as in Production Example 6 to obtain the title compound (50 mg).

¹H-NMR(DMSO-d₆) 5.10 (2H, brs), 6.59-6.63(2H, m), 6.91-6.96(2H, m), 7.42-7.56(4H, m), 7.91-7.95(2H, m), 8.47(1H,

s)

Example 5136-Carboxy-7-methoxy-4-(indol-5-yloxy)quinoline

[1187] After dissolving 6-methoxycarbonyl-7-methoxy-4-(indol-5-yloxy)quinoline (400 mg) in tetrahydrofuran (5 ml), a 1.5N aqueous lithium hydroxide solution (2.5 ml) was added and the mixture was stirred at room temperature for 3 hours. The reaction solution was adjusted to pH 4 with 1N aqueous hydrochloric acid, and the precipitated crystals

were filtered out and washed with ethyl acetate to obtain the title compound (280 mg).
¹H-NMR(DMSO-d₆) δ(ppm) 3.94(3H, s), 6.37(1H, d, J=5.2Hz), 6.43-6.47(1H, m), 6.95-7.01(1H, m), 7.40-7.55(4H, m), 8.55-8.61(2H, m), 11.3(1H, brs)

[1188] The intermediate was synthesized in the following manner.

Production Example 513-16-Methoxycarbonyl-7-methoxy-4-(indol-5-yloxy)quinoline

[1189] After mixing methyl 4-chloro-7-methoxyquinoline-6-carboxylate (WO0050405, P.34, 8.5 g, 33.77 mmol), 5-hydroxyindole (7 g), diisopropylethylamine (8.9 ml) and N-methylpyrrolidone (8.9 ml), the mixture was heated and stirred at 130°C for 5 hours and then at 150°C for 8 hours. After cooling, the solution was adsorbed onto silica gel and purified with a silica gel column (hexane-ethyl acetate system). Ethanol, diethyl ether and hexane were added to the obtained yellow oil, and crystals precipitated upon standing. These were filtered out, washed with diethyl ether and hexane and dried by aspiration to obtain light yellow crystals (3.506 g, 10.06 mmol, 29.80%).

¹H-NMR Spectrum(DMSO-d₆)δ(ppm) : 3.86(3H,s), 3.97(3H,s), 6.38(1H,d,J=5.2Hz), 6.46(1H,s), 6.98(1H,d,J=8.8Hz), 7.44-7.52(4H,m), 8.60-8.65(2H,m), 11.29(1H,s)

Example 5146-(2-Methoxyethylcarbamoyl)-7-methoxy-4-(indol-5-yloxy)quinoline

[1190] After dissolving 6-carboxy-7-methoxy-4-(indol-5-yloxy)quinoline (100 mg) in dimethylformamide (4.0 ml), there were added methoxyethylamine (0.04 ml), triethylamine (0.08 ml) and benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate (198 mg), and the mixture was stirred at room temperature for 5 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, and then the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Ethyl acetate was used for recrystallization to obtain the title compound (86 mg). ¹H-NMR (DMSO-d₆) δ(ppm) 3.29(3H, s), 3.46-3.49(4H, m), 4.02(3H, s), 6.37(1H, d, J=5.2Hz), 6.45-6.47(1H, m), 6.95-7.00(1H, m), 7.41-7.54(4H, m), 8.42-8.45(1H, m), 8.59(1H, d, J=5.2Hz), 8.68(1H, s), 11.3(1H, brs).

Example 5156-(2-Methoxyethylcarbonyl)-7-methoxy-4-(1-ethylcarbamoyl-indol-5-yloxy)quinoline

[1191] After adding 60% sodium hydride (10 mg) to dimethylformamide (1 ml), the mixture was stirred at room temperature, 6-(2-methoxyethylcarbamoyl)-7-methoxy-4-(indol-5-yloxy)quinoline (10 mg) was added, and the mixture was stirred for another 15 minutes. Ethylcarbamic acid phenyl ester (43 mg) was then added and the mixture was stirred for 1 hour. Water was added to the reaction solution, extraction was performed with ethyl acetate, and then the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Ethyl acetate was used for recrystallization to obtain the title compound (27 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 1.18(3H, t, J=7.2Hz), 3.27-3.29(5H, m), 3.47-3.49(4H, m), 4.02(3H, s), 6.42(1H, d, J=5.2Hz), 6.70(1H, d, J=3.6Hz), 7.15-7.20(1H, m), 7.50-7.52(2H, m), 7.93(1H, d, J=3.6Hz), 8.20-8.50(3H, m), 8.61(1H, d, J=5.2Hz), 8.67(1H, s)

Example 516

6-(2-Methoxyethylcarbonyl)-7-methoxy-4-[1-(2-fluoroethylcarbamoyl)indol-5-yloxy]quinoline

[1192] The title compound was obtained from 6-(2-methoxyethylcarbamoyl)-7-methoxy-4-(indol-5-yloxy)quinoline using 2-fluoroethylcarbamic acid phenyl ester, by the same procedure as in Example 515.

¹H-NMR(DMSO-d₆) δ(ppm) 3.24 (3H, s), 3.45-3.67(6H, m), 4.02(3H, s), 4.50-4.68(2H, m), 6.43(1H, d, J=5.2Hz), 6.72 (1H, d, J=3.6Hz), 7.16-7.21(1H, m), 7.50-7.54(2H, m), 7.98(1H, d, J=3.6Hz), 8.35(1H, d, J=9.2Hz), 8.42-8.53(2H, m), 8.61(1H, d, J=5.2Hz), 8.76(1H, s)

Example 517

6-(2-Fluoroethylcarbamoyl)-7-methoxy-4-(indol-5-yloxy)quinoline

[1193] The title compound was obtained from 6-carboxy-7-methoxy-4-(indol-5-yloxy)quinoline using 2-fluoroethylamine hydrochloride, by the same procedure as in Example 514.

¹H-NMR(DMSO-d₆) δ(ppm) 3.53-3.71(2H, m), 4.02(3H, s), 4.48-4.63(2H, m), 6.37(1H, d, J=5.2Hz), 6.45-6.47(1H, m), 6.95-7.00(1H, m), 7.42-7.46(2H, m), 7.48-7.53(2H, m), 8.57-8.63(2H, m), 8.66(1H, s), 11.6(1H, brs)

Example 518

6-(2-Fluoroethylcarbonyl)-7-methoxy-4-((1-ethylcarbamoyl) indol-5-yloxy)quinoline

[1194] The title compound was obtained from 6-(2-fluoroethylcarbamoyl)-7-methoxy-4-(indol-5-yloxy)quinoline, by the same procedure as in Example 515.

¹H-NMR(DMSO-d₆) δ(ppm) 1.18 (3H, t, J=7.2Hz), 3.27-3.32(2H, m), 3.56-3.68(2H, m), 4.02(3H, s), 4.47-4.65(2H, m), 6.42(1H, d, J=5.2Hz), 6.70(1H, d, J=4.0Hz), 7.15-7.20(1H, m), 7.50-7.52(2H, m), 7.93(1H, d, J=4.0Hz), 8.22-8.27(1H, m), 8.34(1H, d, J=8.9Hz), 8.57-8.66(3H, m).

Example 519

6-Methoxycarbamoyl-7-methoxy-4-(indol-5-yloxy)quinoline

[1195] The title compound was obtained from 6-carboxy-7-methoxy-4-(indol-5-yloxy)quinoline using methylhydroxylamine hydrochloride, by the same procedure as in Example 514.

¹H-NMR(DMSO-d₆) δ(ppm) 3.73(3H, s), 3.98(3H, s), 6.38(1H, d, J=5.2Hz), 6.44-6.48(1H, m), 6.95-7.00(1H, m), 7.40-7.54(4H, m), 8.49(1H, s), 8.59(1H, d, J=5.2Hz), 11.29(1H, brs), 11.45(1H, brs)

Example 520

6-Methoxycarbamoyl-7-methoxy-4-((1-ethylcarbamoyl)indol-5-yloxy)quinoline

[1196] The title compound was obtained from 6-methoxycarbamoyl-7-methoxy-4-(indol-5-yloxy)quinoline, by the same procedure as in Example 515.

¹H-NMR(DMSO-d₆) δ(ppm) 1.16(3H, t, J=7.2Hz), 3.27-3.30(2H, m), 3.73(3H, s), 3.98(3H, s), 6.43(1H, d, J=5.2Hz), 6.70(1H, d, J=3.2Hz), 7.15-7.20(1H, m), 7.45-7.53(2H, m), 7.93(1H, d, J=3.6Hz), 8.21-8.26(1H, m), 8.35(1H, d, J=8.8Hz), 8.48(1H, s), 8.61(1H, d, J=5.2Hz), 11.45(1H, brs)

Example 521

6-Methoxycarbamoyl-7-methoxy-4-((1-cyclopropylcarbamoyl)indol-5-yloxy)quinoline

[1197] The title compound was obtained from 6-methoxycarbamoyl-7-methoxy-4-(indol-5-yloxy)quinoline using cyclopropylcarbamic acid phenyl ester, by the same procedure as in Example 515.

¹H-NMR(DMSO-d₆) δ(ppm) 0.58-0.65(2H, m), 0.70-0.77(2H, m), 2.73-2.82(1H, m), 3.73(3H, s), 3.98(3H, s), 6.42(1H, d, J=5.2Hz), 6.68(1H, d, J=3.6Hz), 7.15-7.20(1H, m), 7.47-7.52(2H, m), 7.89(1H, d, J=3.6Hz), 8.28-8.36(2H, m), 8.48 (1H, s), 8.61(1H, d, J=5.2Hz), 11.44(1H, brs)

Example 5226-(Pyridin-2-ylcarbamoyl)-7-methoxy-4-(indol-5-yloxy)quinoline

5 **[1198]** The title compound was obtained from 6-carboxy-7-methoxy-4-(indol-5-yloxy)quinoline using 2-aminopyridine, by the same procedure as in Example 514. ¹H-NMR(DMSO-d₆) δ(ppm) 4.08(3H, s), 6.39-6.48(2H, m), 6.97-7.02(1H, m), 7.15-7.20(1H, m), 7.43-7.60(4H, m), 7.83-7.89(1H, m), 8.25-8.38(2H, m), 8.60-8.80(2H, m), 10.70(1H, brs), 11.30(1H, brs)

10 Example 5236-(Pyridin-2-ylcarbamoyl)-7-methoxy-4-((1-ethylcarbamoyl) indol-5-yloxy)quinoline

15 **[1199]** The title compound was obtained from 6-(pyridin-2-ylcarbamoyl)-7-methoxy-4-(indol-5-yloxy)quinoline, by the same procedure as in Example 515.

¹H-NMR(DMSO-d₆) δ(ppm) 1.18(3H, t, J=7.6Hz), 3.27-3.30(2H, m), 4.10(3H, s), 6.46(1H, d, J=5.2Hz), 6.71(1H, d, J=3.6Hz), 7.15-7.21(2H, m), 7.53(1H, d, J=2.8Hz), 7.60(1H, s), 7.83-7.89(1H, m), 7.93(1H, d, J=3.6Hz), 8.22-8.38(4H, m), 8.65(1H, d, J=5.2Hz), 8.76(1H, d, J=5.2Hz), 10.70(1H, brs)

20 Example 5246-Methoxycarbonyl-7-methoxy-4-[1-(2-fluoroethylcarbamoyl) indol-5-yloxy]quinoline

25 **[1200]** The title compound was obtained from 6-methoxycarbonyl-7-methoxy-4-(indol-5-yloxy)quinoline using 2-fluoroethylcarbamic acid phenyl ester, in the same manner as Example 515.

¹H-NMR(DMSO-d₆) δ(ppm) 3.50-3.68(2H, m), 3.84(3H, s), 3.97(3H, s), 4.48-4.70(2H, m), 6.42(1H, d, J=5.6Hz), 6.72(1H, d, J=3.6Hz), 7.17-7.22(1H, m), 7.45-7.56(2H, m), 7.98(1H, d, J=3.6Hz), 8.35(1H, d, J=9.2Hz), 8.46-8.53(1H, m), 8.58-8.64(2H, m)

30 Example 5256-Carboxy-7-methoxy-4-[1-(2-fluoroethylcarbamoyl)indol-5-yloxy]quinoline

35 **[1201]** The title compound was obtained from 6-methoxycarbonyl-7-methoxy-4-[1-(2-fluoroethylcarbamoyl)indol-5-yloxy]quinoline using 2-phenylcarbamic acid phenyl ester, by the same procedure as in Example 513.

¹H-NMR(DMSO-d₆) δ(ppm) 3.50-3.70(2H, m), 3.94(3H, s), 4.48-4.70(2H, m), 6.42(1H, d, J=5.2Hz), 6.72(1H, d, J=3.6Hz), 7.18-7.22(1H, m), 7.42-7.55(2H, m), 7.98(1H, d, J=3.6Hz), 8.35(1H, d, J=9.2Hz), 8.46-8.52(1H, m), 8.54-8.64(2H, m)

40 Example 5266-Methoxycarbamoyl-7-methoxy-4-[1-(2-fluoroethylcarbamoyl) indol-5-yloxy]quinoline

45 **[1202]** The title compound was obtained from 6-carboxy-7-methoxy-4-[1-(2-fluoroethylcarbamoyl)indol-5-yloxy]quinoline using methylhydroxylamine hydrochloride, by the same procedure as in Example 514.

¹H-NMR(DMSO-d₆) δ(ppm) 3.53-3.66(2H, m), 3.73(3H, s), 3.98(3H, s), 4.50-4.68(2H, m), 6.43(1H, d, J=5.2Hz), 6.73(1H, d, J=3.6Hz), 7.15-7.21(1H, m), 7.47-7.54(2H, m), 7.98(1H, d, J=3.6Hz), 8.35(1H, d, J=8.4Hz), 8.46-8.53(2H, m), 8.61(1H, d, J=5.2Hz), 11.5(1H, brs)

50 Example 5276-Isobutoxycarbamoyl-7-methoxy-4-[1-(2-fluoroethylcarbamoyl) indol-5-yloxy]quinoline

55 **[1203]** The title compound was obtained from 6-carboxy-7-methoxy-4-[1-(2-fluoroethylcarbamoyl)indol-5-yloxy]quinoline using o-isobutylhydroxylamine hydrochloride, by the same procedure as in Example 514.

¹H-NMR(DMSO-d₆) δ(ppm) 0.93(6H, d), 1.90-2.00(1H, m), 3.52-3.67(2H, m), 3.70(2H, d, J=6.8Hz), 3.97(3H, s), 4.50-4.69(2H, m), 6.43(1H, d, J=5.6Hz), 6.73(1H, d, J=4.0Hz), 7.15-7.21(1H, m), 7.47-7.54(2H, m), 7.98(1H, d, J=4.0Hz), 8.35(1H, d, J=9.2Hz), 8.41(1H, s), 8.45-8.55(1H, m), 8.61(1H, d, J=5.6Hz), 11.84(1H, brs)

Example 528

N-[2-Fluoro-4-([6-cyano-7-([(2R)-2-hydroxy-3-(1-pyrrolidino) propyl]oxy)-4-quinolyl]oxy)phenyl]-N'-(2-thiazolyl)urea

[1204] The title compound was obtained from N-(4-[6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy]-2-fluorophenyl)-N'-(thiazol-2-yl)urea, by the method described in Example 495.

¹H-NMR (DMSO-d₆) δ(ppm) 1.60-1.70(4H, m), 2.40-2.75 (6H, m), 3.95-4.05(1H, m), 4.20(1H, dd, J=10, 6.0Hz), 4.31(1H, dd, J=10, 4Hz), 5.02(1H, brs), 6.62(1H, d, J=5.2Hz), 7.10-7.20(2H, m), 7.37-7.47(2H, m), 7.62(1H, s), 8.20-8.26(1H, m), 8.71-8.76(2H, m), 9.05 (1H, brs)

Example 529

N-[2-Fluoro-4-([6-cyano-7-([(2R)-2-hydroxy-3-(1-piperidino) propyl]oxy)-4-quinolyl]oxy)phenyl]-N'-(2-thiazolyl)urea

[1205] The title compound was obtained from N-(4-[6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy]-2-fluorophenyl)-N'-thiazol-2-yl-urea, by the method described in Example 496.

¹H-NMR(DMSO-d₆) δ(ppm) 1.30-1.55(6H, m), 2.32-2.55(6H, m), 3.97-4.16(1H, m), 4.20(1H, dd, J=10, 6Hz), 4.30(1H, dd, J=10, 4.0Hz), 4.44(1H, brs), 6.62(1H, d, J=5.2Hz), 7.11-7.21(2H, m), 7.37-7.47(2H, m), 7.64(1H, s), 8.20-8.27(1H, m), 8.72-8.76(2H, m)

Example 530

N-[2-Fluoro-4-([6-cyano-7-([(2R)-2-hydroxy-3-(1-pyrrolidino) propyl]oxy)-4-quinolyl]oxy)phenyl]-N'-cyclopropylurea

[1206] The title compound was obtained from N-(2-fluoro-4-[(6-cyano-7-[(2R)-(oxiran-2-yl)methoxy]-4-quinolyl]oxy)phenyl)-N'-cyclopropylurea, by the method described in Example 492.

¹H-NMR(DMSO-d₆) δ(ppm) 0.37-0.44(2H, m), 0.62-0.69(2H, m), 1.63-1.75(4H, m), 2.45-2.60(6H, m), 2.65-2.77(1H, m), 3.98-4.08(1H, m), 4.22(1H, dd, J=10, 5.2Hz), 4.31(1H, dd, J=10, 3.6Hz), 5.04(1H, brs), 6.59(1H, d, J=5.6Hz), 6.82-6.85(1H, m), 7.08-7.13(1H, m), 7.32-7.38(1H, m), 7.63(1H, s), 8.20-8.28(2H, m), 8.72-8.76(2H, m)

[1207] The starting material was synthesized by the following 2 steps.

Production Example 530-1

[2-Fluoro-4-([6-cyano-7-([(2R)-(oxiran-2-yl)methoxy]-4-quinolyl]oxy)phenyl]carbamic acid phenyl ester

[1208] This was synthesized from 4-(4-amino-3-fluorophenoxy)-7-[(2R)-oxiran-2-yl]methoxyquinoline-6-carbonitrile, by the method described in Production Example 141-1.

¹H-NMR(CDCl₃) δ(ppm) 2.90-3.01(2H, m), 3.44-3.55(1H, m), 4.21-4.28(1H, m), 4.47-4.54(1H, m), 6.53(1H, d, J=5.2Hz), 7.00-7.06(2H, m), 7.19-7.30(4H, m), 7.40-7.46(2H, m), 7.48-7.53(1H, m), 8.27(1H, brs), 8.65-8.73(2H, m)

Production Example 530-2

N-(2-Fluoro-4-[(6-cyano-7-[(2R)-(oxiran-2-yl)methoxy]-4-quinolyl]oxy)phenyl)-N'-cyclopropylurea

[1209] Cyclopropylamine (0.04 ml) was added to dimethylsulfoxide (3 ml), and then [2-fluoro-4-([6-cyano-7-[(2R)-oxiran-2-yl]methoxy]-4-quinolyl]oxy)phenyl]carbamic acid phenyl ester (212 mg) was dissolved therein and the solution was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution, and the precipitated crystals were filtered out to obtain the title compound (150 mg). ¹H-NMR(DMSO-d₆) δ(ppm) 0.37-0.44(2H, m), 0.61-0.69(2H, m), 2.50-2.60(1H, m), 2.78-2.79(2H, m), 3.45-3.50(1H, m), 4.20(1H, dd, J=12, 6.0Hz), 4.73(1H, dd, J=12, 2.4Hz), 6.59(1H, d, J=5.6Hz), 6.82-6.85(1H, m), 7.08-7.13(1H, m), 7.32-7.38(1H, m), 7.63(1H, s), 8.20-8.28(2H, m), 8.72-8.78(2H, m)

Example 531

N-[2-Fluoro-4-([6-cyano-7-([(2R)-2-hydroxy-3-(1-piperidino) propyl]oxy)-4-quinolyl]oxy)phenyl]-N'-cyclopropylurea

[1210] The title compound was obtained from N-(2-fluoro-4-[(6-cyano-7-[(2R)-(oxiran-2-yl)methoxy]-4-quinolyl]oxy)phenyl)-N'-cyclopropylurea, by the method described in Example 496.

¹H-NMR(DMSO-d₆) δ(ppm) 0.38-0.44(2H, m), 0.62-0.69(2H, m), 1.33-1.54(6H, m), 2.30-2.70(7H, m), 4.00-4.09(1H, m), 4.21(1H, dd, J=10.4, 5.6Hz), 4.32(1H, dd, J=10.4, 3.2Hz), 4.95(1H, d, J=4.4Hz), 6.59(1H, d, J=5.6Hz), 6.83-6.85(1H, m), 7.08-7.13(1H, m), 7.32-7.38(1H, m), 7.64(1H, s), 8.20-8.28(2H, m), 8.72-8.78(2H, m)

5 Example 532

N-[2-Fluoro-4-([6-cyano-7-([3-(1-piperidino)propyl]oxy)-4-quinolyl]oxy)phenyl]-N'-(2-thiazolyl) urea

[1211] The title compound was obtained from 2-fluoro-4-([6-cyano-7-([3-(1-piperidino)propyl]oxy)-4-quinolyl]oxy) phenylamine, by the method described in Example 495.

¹H-NMR(DMSO-d₆) δ(ppm) 1.30-1.53(6H, m), 1.92-2.00(2H, m), 2.30-2.50(6H, m), 4.28-4.35(2H, m), 6.62(1H, d, J=5.6Hz), 7.12-7.20(2H, m), 7.36-7.47(2H, m), 7.60(1H, s), 8.20-8.28(1H, m), 8.72-8.77(2H, m).

[1212] The starting material was synthesized in the following manner.

15 Production Example 532-1

2-Fluoro-4-([6-cyano-7-([3-(1-piperidino)propyl]oxy)-4-quinolyl]oxy)phenylamine

[1213] After adding dimethylformamide (4 ml), 1-(3-chloropropyl)piperidine hydrochloride (268 mg) and potassium carbonate (374 mg) to 4-(4-amino-3-fluorophenoxy)-6-cyano-7-hydroxyquinoline (200 mg), the mixture was heated at 60°C for 8 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate and the organic layer was washed with water and saturated brine in that order and then dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was purified by silica gel column chromatography (ethyl acetate) to obtain the title compound (80 mg) as light yellow crystals.

¹H-NMR(CDCl₃) δ(ppm) 1.38-1.64(6H, m), 2.07-2.18(2H, m), 2.37-2.48(6H, m), 3.79(2H, brs), 4.24-4.34(2H, m), 6.47(1H, d, J=5.6Hz), 6.77-6.92(3H, m), 7.46(1H, s), 8.63-8.67(2H, m)

Example 533

N-[2-Fluoro-4-([6-cyano-7-([3-(1-pyrrolidino)propyl]oxy)-4-quinolyl]oxy)phenyl]-N'-(2-thiazolyl)urea

[1214] The title compound was obtained from 2-fluoro-4-([6-cyano-7-([3-(1-pyrrolidino)propyl]oxy)-4-quinolyl]oxy) phenylamine, by the method described in Example 495.

¹H-NMR(DMSO-d₆) δ(ppm) 1.65-1.72(4H, m), 1.94-2.02(2H, m), 2.40-2.50(4H, m), 2.56-2.62(2H, m), 4.30-4.36(2H, m), 6.63(1H, d, J=5.6Hz), 7.13-7.20(2H, m), 7.37-7.47(2H, m), 7.60(1H, s), 8.20-8.27(1H, m), 8.72-8.76(2H, m)

[1215] The starting material was synthesized in the following manner.

Production Example 533-1

2-Fluoro-4-([6-cyano-7-([3-(1-pyrrolidino)propyl]oxy)-4-quinolyl]oxy)phenylamine

[1216] After adding dimethylformamide (4 ml), 1-(3-chloropropylpyrrolidine) hydrochloride (376 mg) and potassium carbonate (553 mg) to 4-(4-amino-3-fluorophenoxy)-6-cyano-7-hydroxyquinoline (300 mg), the mixture was heated at 60°C for 8 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate and the organic layer was washed with water and saturated brine in that order and then dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was purified by silica gel column chromatography (ethyl acetate) to obtain the title compound (200 mg) as light yellow crystals. ¹H-NMR(DMSO-d₆) δ(ppm) 1.62-1.72(4H, m), 1.93-2.03(2H, m), 2.40-2.49(4H, m), 2.55-2.61(2H, m), 4.28-4.35(2H, m), 5.22-5.25(2H, m), 6.51(1H, d, J=4.8Hz), 6.82-6.90(2H, m), 7.06-7.12(1H, m) 7.56(1H, s), 8.68-8.72(2H, m)

Example 534

N-(2-Chloro-5-((6-cyano-7-(2-(1-pyrrolidino)ethoxy)-4-quinolyl]oxy)phenyl)-N'-phenylurea

[1217] The title compound (19.8 mg, 0.038 mmol, 34.5%) was obtained as white crystals from 4-(3-amino-4-chlorophenoxy)-6-cyano-7-(2-(1-pyrrolidino)ethoxy)quinoline (44.5 mg, 0.109 mmol) and phenyl isocyanate, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.69 (4H, m), 2.59 (4H, m), 2.91 (2H, t, J=5.6Hz), 4.38 (2H, t, J=5.6Hz), 6.66

(1H, d, J=5.2Hz), 6.97-7.01 (2H, m), 7.24-7.28 (2H, m), 7.41 (2H, d, J=7.2Hz), 7.60-7.63 (2H, m), 8.20 (1H, m), 8.51 (1H, s), 8.74-8.76 (2H, m), 9.53 (1H, d, J=4.4Hz).

[1218] The starting materials were synthesized in the following manner.

5 Production Example 534-1

7-(Benzyloxy)-4-(4-chloro-3-nitrophenoxy)-6-cyanoquinoline

[1219] The title compound (4.794 g, 11.10 mmol, 59.9%) was obtained as light brown crystals from 7-(benzyloxy)-4-chloro-6-cyanoquinoline (5.462 g, 18.53 mmol) and 4-chloro-3-nitrophenol, by the same procedure as in Production Example 11.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 5.74 (2H, s), 6.57 (1H, d, J=5.2Hz), 7.34-7.55 (6H, m), 7.58 (1H, s), 7.70 (1H, d, J=8.8Hz), 7.76 (1H, d, J=2.8Hz), 8.64 (1H, s), 8.76 (1H, d, J=5.2Hz).

15 Production Example 534-2

4-(4-Chloro-3-nitrophenoxy)-6-cyano-7-hydroxyquinoline

[1220] The title compound (743 mg, 2.17 mmol, 93.9%) was obtained as light yellow crystals from 7-(benzyloxy)-4-(4-chloro-3-nitrophenoxy)-6-cyanoquinoline (1.00 g, 2.32 mmol), by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.73 (1H, d, J=5.2Hz), 7.45 (1H, s), 7.69 (1H, dd, J=2.8, 8.8Hz), 7.91 (1H, d, J=8.8Hz), 8.14 (1H, d, J=2.8Hz), 8.67 (1H, s), 8.71 (1H, d, J=5.2Hz), 11.71 (1H, br).

Production Example 534-3

25

4-(3-Amino-4-chlorophenoxy)-6-cyano-7-hydroxyquinoline

[1221] The title compound (464 mg, 1.49 mmol, 68.5%) was obtained as light yellow crystals from 4-(4-chloro-3-nitrophenoxy)-6-cyano-7-hydroxyquinoline (743 mg, 2.17 mmol), by the same procedure as in Production Example 6.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 5.62-5.65 (2H, m), 6.43 (1H, dd, J=2.8, 8.8Hz), 6.54 (1H, d, J=5.2Hz), 6.63 (1H, d, J=2.8Hz), 7.30 (1H, d, J=8.8Hz), 7.41 (1H, s), 8.62 (1H, s), 8.65 (1H, d, J=5.2Hz).

Production Example 534-4

35

4-(3-Amino-4-chlorophenoxy)-6-cyano-7-(2-(1-pyrrolidino)ethoxy)quinoline

[1222] The title compound (143 mg, 0.350 mmol, 54.5%) was obtained as white crystals from 4-(3-amino-4-chlorophenoxy)-6-cyano-7-hydroxyquinoline (200 mg, 0.642 mmol) and 1-(2-chloroethyl)pyrrolidine hydrochloride, by the same procedure as in Example 7. ¹H-NMR Spectrum (CDCl₃)δ(ppm): 1.84 (4H, m), 2.74 (4H, m), 3.08 (2H, t, J=5.6Hz), 4.20-4.24 (2H, m), 4.37 (2H, t, J=5.6Hz), 6.50 (1H, dd, J=2.8, 8.8Hz), 6.54 (1H, d, J=5.2Hz), 6.59 (1H, d, J=2.8Hz), 7.33 (1H, d, J=8.8Hz), 7.46 (1H, s), 8.64 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 535

45

N-(2-Chloro-5-((6-cyano-7-(2-(1-pyrrolidino)ethoxy)-4-quinolyl)oxy)phenyl)-N'-(1,3-thiazol-2-yl)urea

[1223] The title compound (5.7 mg, 0.011 mmol, 9.35%) was obtained as white crystals from 4-(3-amino-4-chlorophenoxy)-6-cyano-7-(2-(1-pyrrolidino)ethoxy)quinoline (46.6 mg, 0.114 mmol) and phenyl N-(1,3-thiazol-2-yl)carbamate, by the same procedure as in Example 131.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.69 (4H, m), 2.61 (4H, m), 2.93 (2H, m), 4.39 (2H, m), 6.65 (1H, d, J=5.2Hz), 7.06 (1H, dd, J=2.8, 8.8Hz), 7.13-7.14 (2H, m), 7.38-7.40 (2H, m), 7.63 (1H, s), 7.66 (1H, d, J=8.8Hz), 8.19 (1H, d, J=3.2Hz), 8.75 (1H, d, J=5.2Hz), 8.77 (1H, s).

Example 536

55

N-(2-Chloro-5-((6-cyano-7-(2-(1-pyrrolidino)ethoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1224] After dissolving 4-(3-amino-4-chlorophenoxy)-6-cyano-7-(2-(1-pyrrolidino)ethoxy)quinoline (47.9 mg, 0.117

mmol) in dimethylformamide (1 ml) in a nitrogen atmosphere, pyridine (0.019 ml, 0.234 mmol) and phenyl chloroformate (0.030 ml, 0.234 mmol) were added dropwise at room temperature and the mixture was stirred for 1 hour. Cyclopropylamine (0.1 ml) was added dropwise, and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate and water, washed with saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent, the crystals precipitated from ethyl acetate were filtered out and blow-dried to obtain the title compound (12.6 mg, 0.026 mmol, 21.9%) as light brown crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.39 (2H, m), 0.63 (2H, m), 1.70 (4H, m), 2.49-2.53 (1H, m), 2.60 (4H, m), 2.91 (2H, m), 4.40 (2H, m), 6.64 (1H, d, J=5.2Hz), 6.93 (1H, dd, J=2.8, 8.8Hz), 7.33 (1H, d, J=2.8Hz), 7.57 (1H, d, J=8.8Hz), 7.64 (1H, s), 8.09 (1H, s), 8.19 (1H, d, J=2.8Hz), 8.75-8.77 (2H, m).

Example 537

N-(2-Chloro-S-((6-cyano-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1225] The title compound (20.7 mg, 0.040 mmol, 20.7%) was obtained as a white powder from phenyl N-(2-chloro-5-((6-cyano-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-4-quinolyl)oxy)phenyl)carbamate (107 mg, 0.191 mmol) and cyclopropylamine, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.40 (2H, m), 0.65 (2H, m), 1.69 (4H, m), 2.49-2.68 (6H, m), 2.72 (1H, m), 4.03 (1H, m), 4.23 (1H, dd, J=5.6, 10.4Hz), 4.33 (1H, dd, J=4.4, 10.4Hz), 5.03 (1H, m), 6.64 (1H, d, J=5.2Hz), 6.94 (1H, dd, J=2.8, 8.4Hz), 7.33 (1H, m), 7.56-7.93 (2H, m), 8.10 (1H, s), 8.20 (1H, d, J=2.8Hz), 8.71-8.77 (2H, m).

[1226] The starting materials were synthesized in the following manner.

Production Example 537-1

4-(3-Amino-4-chlorophenoxy)-6-cyano-7-((2R)oxiran-2-yl)methoxyquinoline

[1227] The title compound (201 mg, 0.547 mmol, 64.6%) was obtained as light yellow crystals from 4-(3-amino-4-chlorophenoxy)-6-cyano-7-hydroxyquinoline (264 mg, 0.847 mmol) and (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.93 (1H, dd, J=2.4, 4.8Hz), 2.98 (1H, dd, J=4.0, 4.8Hz), 3.50 (1H, m), 4.21-4.24 (3H, m), 4.50 (1H, dd, J=3.2, 11.2Hz), 6.50 (1H, dd, J=2.8, 8.8Hz), 6.56 (1H, d, J=5.2Hz), 6.59 (1H, d, J=2.8Hz), 7.33 (1H, d, J=8.8Hz), 7.48 (1H, s), 8.67 (1H, s), 8.69 (1H, d, J=5.2Hz).

Production Example 537-2

4-(3-Amino-4-chlorophenoxy)-6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)quinoline

[1228] After dissolving 4-(3-amino-4-chlorophenoxy)-6-cyano-7-((2R)oxiran-2-yl)methoxyquinoline (201 mg, 0.547 mmol) in tetrahydrofuran (5.0 ml) under a nitrogen atmosphere, pyrrolidine (0.456 ml) was added and the mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (235 mg, 0.535 mmol, 98.0%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 1.82 (4H, m), 2.59 (2H, m), 2.65 (1H, dd, J=4.0, 12.0Hz), 2.74 (2H, m), 2.94 (1H, dd, J=5.2, 12.0Hz), 4.19-4.27 (5H, m), 6.50 (1H, dd, J=2.8, 8.8Hz), 6.55 (1H, d, J=5.2Hz), 6.59 (1H, d, J=2.8Hz), 7.33 (1H, d, J=8.8Hz), 7.50 (1H, s), 8.65 (1H, s), 8.68 (1H, d, J=5.2Hz).

Production Example 537-3

Phenyl N-(2-chloro-5-((6-cyano-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-4-quinolyl)oxy)phenyl)carbamate

[1229] The title compound (107 mg, 0.191 mmol, 35.7%) was obtained as white crystals from 4-(3-amino-4-chlorophenoxy)-6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)quinoline (235 mg, 0.535 mmol), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.20 (4H, m), 3.39-3.48 (5H, m), 4.11 (1H, m), 4.25 (1H, m), 4.44 (1H, dd, J=4.8, 9.2Hz), 4.67 (1H, m), 6.50 (1H, m), 6.57-6.60 (2H, m), 6.91 (1H, m), 7.17-7.49 (6H, m), 8.17 (1H, s), 8.66 (1H, d, J=5.2Hz), 8.71 (1H, d, J=5.6Hz).

Example 538N6-Methyl-4-(4-chloro-3-(((4-fluoroanilino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxamide

[1230] The title compound (77.6 mg, 0.157 mmol, 77.9%) was obtained as white crystals from N6-methyl-4-(3-amino-4-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (72 mg, 0.2 mmol) and 4-fluorophenyl isocyanate, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.82 (3H, d, J=4.4Hz), 4.01 (3H, s), 6.62 (1H, d, J=5.2Hz), 6.96 (1H, dd, J=2.8, 8.8Hz), 7.10 (2H, m), 7.40 (2H, m), 7.51 (1H, s), 7.60 (1H, d, J=8.8Hz), 8.15 (1H, d, J=2.8Hz), 8.35 (1H, d, J=4.4Hz), 8.47 (1H, s), 8.54 (1H, s), 8.68 (1H, d, J=5.2Hz), 9.56 (1H, s).

[1231] The starting materials were synthesized in the following manner.

Production Example 538-1Methyl 4-(4-chloro-3-nitrophenoxy)-7-methoxy-6-quinoline carboxylate

[1232] The title compound (2.114 g, 5.44 mmol, 54.4%) was obtained as light yellow crystals from methyl 4-chloro-7-methoxy-6-quinoline carboxylate (2.517 g, 10.0 mmol) and 4-chloro-3-nitrophenol, by the same procedure as in Production Example 11.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.97 (3H, s), 4.06 (3H, s), 6.54 (1H, d, J=5.2Hz), 7.38 (1H, dd, J=2.8, 8.8Hz), 7.53 (1H, s), 7.66 (1H, d, J=8.8Hz), 7.75 (1H, d, J=2.8Hz), 8.70 (1H, s), 8.73 (1H, d, J=8.8Hz).

Production Example 538-24-(4-Chloro-3-nitrophenoxy)-7-methoxy-6-quinolinecarboxylic acid

[1233] After adding methanol (30 ml) and 2N aqueous sodium hydroxide (10 ml) to methyl 4-(4-chloro-3-nitrophenoxy)-7-methoxy-6-quinolinecarboxylate (1.00 g, 2.57 mmol), the mixture was stirred at 60°C for 1 hour. The reaction solution was allowed to cool to room temperature, 2N hydrochloric acid was added for neutralization, the methanol was distilled off, and the precipitated light brown crystals were filtered out, thoroughly washed with water and dried at 70°C to obtain the title compound (897 mg, 2.39 mmol, 93.1%).

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.97 (3H, s), 6.76 (1H, d, J=5.2Hz), 7.53 (1H, s), 7.70 (1H, dd, J=2.8, 8.8Hz), 7.91 (1H, d, J=8.8Hz), 8.16 (1H, d, J=2.8Hz), 8.49 (1H, s), 8.73 (1H, d, J=5.2Hz), 13.13 (1H, br).

Production Example 538-3N6-Methyl-4-(4-chloro-3-nitrophenoxy)-7-methoxy-6-quinolinecarboxamide

[1234] After dissolving 4-(4-chloro-3-nitrophenoxy)-7-methoxy-6-quinolinecarboxylic acid (897 mg, 2.39 mmol) in dimethylformamide (10 ml) under a nitrogen atmosphere, a 40% methylamine-methanol solution (2.0 ml), triethylamine (1.0 ml) and (1H-1,2,3-benzotriazol-1-yloxy)(tri(dimethylamino)) phosphonium hexafluorophosphate (1.27 g, 2.87 mmol) were added in that order at room temperature and the mixture was stirred for 4 hours. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (928 mg, quantitative) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.82 (3H, d, J=4.4Hz), 4.01 (3H, s), 6.77 (1H, d, J=5.2Hz), 7.54 (1H, s), 7.68 (1H, dd, J=2.8, 8.8Hz), 7.90 (1H, d, J=8.8Hz), 8.13 (1H, d, J=2.8Hz), 8.35 (1H, d, J=4.4Hz), 8.53 (1H, s), 8.72 (1H, d, J=5.2Hz).

Production Example 538-4N6-Methyl-4-(3-amino-4-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide

[1235] The title compound (614 mg, 1.72 mmol, 71.7%), was obtained as light gray crystals from N6-methyl-4-(4-chloro-3-nitrophenoxy)-7-methoxy-6-quinolinecarboxamide (928 mg, 2.39 mmol), by the same procedure as in Production Example 6.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.08 (3H, d, J=5.2Hz), 4.12 (3H, s), 4.17-4.21 (2H, m), 6.49-6.54 (2H, m), 6.59

(1H, d, J=2.8Hz), 7.30 (1H, d, J=8.8Hz), 7.51 (1H, s), 7.86 (1H, br), 8.64 (1H, d, J=5.2Hz), 9.23 (1H, s).

Example 539

5 N6-Methyl-4-(4-chloro-3-(((1,3-thiazol-2-ylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1236] The title compound (170.4 mg, 0.352 mmol, 88.0%) was obtained as white crystals from N6-methyl-4-(3-amino-4-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (143 mg, 0.4 mmol) and phenyl N-(1,3-thiazol-2-yl)carbamate, by the same procedure as in Example 131. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.82 (3H, d, J=4.8Hz), 4.01 (3H, s), 6.62 (1H, d, J=5.2Hz), 7.03 (1H, dd, J=2.8, 8.8Hz), 7.13 (1H, d, J=3.6Hz), 7.39 (1H, d, J=3.6Hz), 7.52 (1H, s), 7.64 (1H, d, J=8.8Hz), 8.16 (1H, d, J=2.8Hz), 8.35 (1H, d, J=4.8Hz), 8.55 (1H, s), 8.68 (1H, d, J=5.2Hz), 11.30 (1H, br).

Example 540

15 N6-Methyl-4-(4-chloro-3-(((cyclopropylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1237] After dissolving N6-methyl-4-(3-amino-4-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (179 mg, 0.50 mmol) in dimethylformamide (2 ml) under a nitrogen atmosphere, pyridine (0.061 ml, 0.75 mmol) and phenyl chloroformate (0.094 ml, 0.75 mmol) were added dropwise at room temperature and the mixture was stirred for 1 hour. Cyclopropylamine (0.2 ml) was added dropwise and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate and water, washed with saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent, the crystals precipitated from ethyl acetate were filtered out and blow-dried to obtain the title compound (163.9 mg, 0.372 mmol, 74.3%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.39 (2H, m), 0.62 (2H, m), 2.49-2.53 (1H, m), 2.83 (3H, d, J=4.8Hz), 4.02 (3H, s), 6.60 (1H, d, J=5.2Hz), 6.90 (1H, dd, J=3.2, 8.8Hz), 7.32 (1H, d, J=2.8Hz), 7.52-7.56 (2H, m), 8.07 (1H, s), 8.16 (1H, d, J=3.2Hz), 8.37 (1H, d, J=4.8Hz), 8.54 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 541

30 N6-Methyl-4-(4-chloro-3-(((methylamino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxamide

[1238] The title compound (71.9 mg, 0.173 mmol, 57.4%) was obtained as white crystals from N6-methyl-4-(3-amino-4-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (108 mg, 0.30 mmol), by the same procedure as in Example 540. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.60 (3H, d, J=4.4Hz), 2.81 (3H, t, J=4.8Hz), 4.00 (3H, s), 6.59 (1H, d, J=5.2Hz), 6.87 (1H, dd, J=2.8, 8.4Hz), 7.14 (1H, t, J=7.6Hz), 7.50-7.54 (2H, m), 8.13 (1H, d, J=2.8Hz), 8.19 (1H, s), 8.35 (1H, d, J=4.4Hz), 8.53 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 542

40 N6-Methyl-4-(4-chloro-3-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1239] The title compound (90.6 mg, 0.211 mmol, 70.6%) was obtained as white crystals from N6-methyl-4-(3-amino-4-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide (107 mg, 0.30 mmol), by the same procedure as in Example 540. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.02 (3H, t, J=7.2Hz), 2.81 (3H, t, J=4.4Hz), 3.06 (2H, m), 4.00 (3H, s), 6.58 (1H, d, J=5.2Hz), 6.87 (1H, dd, J=3.2, 8.8Hz), 7.13 (1H, m), 7.50-7.54 (2H, m), 8.14-8.15 (2H, m), 8.35 (1H, d, J=4.4Hz), 8.53 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 543

50 N-(2-Chloro-4-(6-cyano-7-(((2R)oxiran-2-ylmethoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1240] The title compound (663 mg, 1.47 mmol, 66.5%) was obtained as light yellow crystals from N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxy-2-chlorophenyl)-N'-cyclopropylurea (873 mg, 2.21 mmol) and (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 2.83 (1H, m), 2.93 (1H, m), 3.48 (1H, m), 4.18 (1H, dd, J=6.4, 12.0Hz), 4.72 (1H, m), 6.61 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.27 (1H, dd, J=2.4, 9.2Hz), 7.51 (1H, d, J=2.8Hz), 7.65 (1H, s), 8.00 (1H, s), 8.29 (1H, dd, J=4.0, 9.2Hz), 8.75 (1H, d, J=5.2Hz), 8.78 (1H, s).

Example 544

N-(2-Chloro-4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-piperidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea

[1241] After adding tetrahydrofuran (2.5 ml) and piperidine (0.25 ml) to N-(2-chloro-4-(6-cyano-7-(((2R)oxiran-2-yl-methoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea (113 mg, 0.25 mmol), the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (57.7 mg, 0.108 mmol, 43.1%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.35 (2H, m), 1.48 (4H, m), 2.34-2.51 (6H, m), 2.56 (1H, m), 4.02 (1H, m), 4.19 (1H, dd, J=6.0, 10.4Hz), 4.29 (1H, dd, J=3.6, 10.4Hz), 4.93 (1H, d, J=4.0Hz), 6.57 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 8.8Hz), 7.50 (1H, d, J=2.8Hz), 7.62 (1H, s), 7.98 (1H, s), 8.27 (1H, d, J=8.8Hz), 8.71-8.73 (2H, m).

Example 545

N6-Methyl-4-(4-(((4-fluoroanilino)carbonyl)(methyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1242] The title compound (89.4 mg, 0.188 mmol, 75.6%) was obtained as white crystals from 4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (115 mg, 0.25 mmol) and a 40% methylamine-methanol solution, by the same procedure as in Example 435.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.83 (3H, d, J=4.8Hz), 3.28 (3H, s), 4.01 (3H, s), 6.65 (1H, d, J=5.2Hz), 7.08 (2H, m), 7.32 (2H, m), 7.42-7.48 (4H, m), 7.51 (1H, s), 8.23 (1H, s), 8.35 (1H, d, J=4.8Hz), 8.60 (1H, s), 8.69 (1H, d, J=5.2Hz).

Example 546

N6-Ethyl-4-(4-(((4-fluoroanilino)carbonyl)(methyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1243] The title compound (87.0 mg, 0.178 mmol, 71.5%) was obtained as white crystals from 4-(4-(((4-fluoroanilino)carbonyl)(methyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (115 mg, 0.25 mmol) and a 2.0 M ethylamine-tetrahydrofuran solution, by the same procedure as in Example 435.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.13 (3H, t, J=7.2Hz), 3.28 (3H, s), 3.28-3.36 (2H, m), 4.01 (3H, s), 6.64 (1H, d, J=5.2Hz), 7.06 (2H, m), 7.31 (2H, m), 7.42-7.48 (4H, m), 7.51 (1H, s), 8.23 (1H, s), 8.39 (1H, t, J=5.2Hz), 8.55 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 547

N6-(2-(1-Pyrrolidino)ethyl)-4-(3-chloro-4-(((cyclopropylamino) carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1244] The title compound (42.9 mg, 0.082 mmol, 81.9%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 1-(2-aminoethyl)pyrrolidine, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.70 (4H, m), 2.48-2.61 (7H, m), 3.43 (2H, m), 4.01 (3H, s), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, s), 7.22 (1H, dd, J=2.4, 8.8Hz), 7.47 (1H, d, J=2.4Hz), 7.51 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.50 (1H, m), 8.64 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 548

N6-(2-(1-Piperidino)ethyl)-4-(3-chloro-4-(((cyclopropylamino) carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1245] The title compound (44.6 mg, 0.083 mmol, 82.9%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 1-(2-aminoethyl)piperidine, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.39 (2H, m), 1.51 (4H, m), 2.39 (4H, m), 2.43-2.49

(2H, m), 2.56 (1H, m), 3.39 (2H, m), 4.05 (3H, s), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, s), 7.23 (1H, dd, J=2.8, 8.8Hz), 7.48 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.96 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.48 (1H, m), 8.66 (1H, d, J=5.2Hz), 8.70 (1H, s).

Example 549

N6-(2-Propyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1246] The title compound (15.2 mg, 0.032 mmol, 32.4%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and 2-propylamine, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.17 (6H, d, J=6.8Hz), 2.56 (1H, m), 3.99 (3H, s), 4.08 (1H, m), 6.51 (1H, d, J=5.2Hz), 7.19 (1H, s), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.46 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.97 (1H, s), 8.15 (1H, d, J=8.0Hz), 8.26 (1H, d, J=8.8Hz), 8.43 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 550

N6-Cyclopentyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1247] The title compound (34.3 mg, 0.069 mmol, 69.3%) was obtained as white crystals from 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (43 mg, 0.10 mmol) and cyclopentylamine, by the same procedure as in Example 438.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.53 (4H, m), 1.67 (2H, m), 1.89 (2H, m), 2.56 (1H, m), 4.00 (3H, s), 4.23 (1H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, s), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.46 (1H, d, J=2.8Hz), 7.48 (1H, s), 7.97 (1H, s), 8.23-8.27 (2H, m), 8.41 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 551

N-(4-(6-Aminopyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1248] 6-(4-Aminophenoxy)pyrimidin-4-ylamine (88.9 mg, 0.440 mmol) and phenyl isocyanate (52.4 mg, 0.440 mmol) were stirred together for 3 hours in dimethylformamide (2 ml) at room temperature. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (98.0 mg, 0.305 mmol, 69%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 5.66 (1H, s), 6.81 (2H, br s), 6.94-6.99 (1H, m), 7.03-7.08 (2H, m), 7.25-7.32 (2H, m), 7.43-7.52 (4H, m), 8.07 (1H, s), 8.74 (1H, s), 8.80 (1H, s).

[1249] The intermediates were synthesized in the following manner.

Production Example 551-1

4-Chloro-6-(4-nitrophenoxy)pyrimidine

[1250] 2,4-Dichloropyrimidine (2.98 g, 20.0 mmol), 4-nitrophenol (2.78 g, 20.0 mmol) and potassium carbonate (4.15 g, 30.0 mmol) were stirred together in dimethylformamide (20 ml) at room temperature for 15 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 1:4), and the fraction containing the target substance was concentrated to obtain the title compound (3.89 g, 15.5 mmol, 77%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 7.08 (1H, d, J = 0.6 Hz), 7.32-7.37 (2H, m), 8.32-8.37 (2H, m), 8.60 (1H, d, J = 0.6 Hz).

Production Example 551-26-(4-Nitrophenoxy)pyrimidin-4-ylamine

[1251] 4-Chloro-6-(4-nitrophenoxy)pyrimidine (1.04 g, 4.00 mmol) was heated and stirred in an ammonia-ethanol solution (14%, 10 ml) at 110°C for 15 minutes using an autoclave. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 1:1), and the fraction containing the target substance was concentrated to obtain the title compound (306 mg, 1.32 mmol, 33%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 5.00 (2H, br s), 6.03 (1H, s), 7.25-7.32 (2H, m), 8.26-8.33 (3H, m).

Production Example 551-36-(4-Aminophenoxy)pyrimidin-4-ylamine

[1252] After suspending 6-(4-nitrophenoxy)pyrimidin-4-ylamine (306 mg, 1.32 mmol), iron powder (369 mg, 6.60 mmol) and ammonium chloride (706 mg, 13.2 mmol) in an ethanol (20 ml)-water (5 ml) mixed solvent, the suspension was heated and stirred at 80°C for 20 minutes. After completion of the reaction, the reaction mixture was filtered with celite and washed in ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was concentrated to obtain the title compound (266 mg, 1.32 mmol, 100%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 5.05 (2H, br s), 5.55 (1H, s), 6.57-6.62 (2H, m), 6.73 (2H, br s), 6.77-6.82 (2H, m), 8.04 (1H, s).

Example 552N-(6-(4-(3-Phenylureido)phenoxy)pyrimidin-4-yl)acetamide

[1253] N-(4-(6-Aminopyrimidin-4-yloxy)phenyl)-N'-phenylurea (60.0 mg, 0.187 mmol) was heated and stirred in an acetic anhydride (1 ml)-pyridine (1 ml) mixed solvent at 60°C for 18 hours. After returning the reaction solution to room temperature, it was poured into water and the precipitated crystals were filtered out, washed with water and methanol and blow-dried to obtain the title compound (35.0 mg, 0.096 mmol, 52%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.11 (3H, s), 6.94-7.00 (1H, m), 7.10-7.15 (2H, m), 7.25-7.31 (2H, m), 7.44-7.54 (5H, m), 8.49 (1H, d, J = 0.4 Hz), 8.72 (1H, s), 8.80 (1H, s), 10.94 (1H, s).

Example 553N-(4-(6-Aminopyrimidin-4-yloxy)phenyl)-N'-(4-fluorophenyl)urea

[1254] The title compound (100 mg, 0.295 mmol, 65%) was obtained as colorless crystals from 6-(4-aminophenoxy)pyrimidin-4-ylamine (88.9 mg, 0.440 mmol) and 4-fluorophenyl isocyanate (60.3 mg, 0.440 mmol), by the same procedure as in Example 551.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 5.66 (1H, d, J = 0.6 Hz), 6.81 (2H, br s), 7.04-7.15 (4H, m), 7.44-7.52 (4H, m), 8.07 (1H, d, J = 0.6 Hz), 8.84 (1H, s), 8.85 (1H, s).

Example 554N-(6-(4-(3-(4-Fluorophenyl)ureido)phenoxy)pyrimidin-4-yl)acetamide

[1255] The title compound (56 mg, 0.147 mmol, 79%) was obtained as colorless crystals from N-(4-(6-aminopyrimidin-4-yloxy)phenyl)-N'-(4-fluorophenyl)urea (60.0 mg, 0.176 mmol), by the same procedure as in Example 552.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.11 (3H, s), 7.09-7.16 (4H, m), 7.44-7.54 (5H, m), 8.49 (1H, s), 8.80 (1H, s), 8.83 (1H, s), 10.94 (1H, s).

Example 555N-(4-(6-Aminopyrimidin-4-yloxy)phenyl)-N'-(3-methanesulfonylphenyl)urea

[1256] 6-(4-Aminophenoxy)pyrimidin-4-ylamine (88.9 mg, 0.440 mmol) and (3-methylsulfonylphenyl)carbamic acid phenyl ester (128 mg, 0.440 mmol) were stirred in dimethylsulfoxide (2 ml) at 85°C for 18 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 30:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (75.0 mg, 0.188 mmol, 43%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.20 (3H, s), 5.67 (1H, s), 6.82 (2H, br s), 7.04-7.12 (2H, m), 7.44-7.59 (4H, m), 7.65-7.70 (1H, m), 8.07 (1H, s), 8.16-8.19 (1H, m), 8.92 (1H, br s), 9.19 (1H, br s).

Example 556N-(6-(4-(3-(3-Methylsulfonylphenyl)ureido)phenoxy)pyrimidin-4-yl)acetamide

[1257] The title compound (13 mg, 0.029 mmol, 24%) was obtained as colorless crystals from N-(4-(6-aminopyrimidin-4-yloxy)phenyl)-N'-(3-methylsulfonylphenyl)urea (50.0 mg, 0.125 mmol), by the same procedure as in Example 552.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.11 (3H, s), 3.20 (3H, s), 7.11-7.17 (2H, m), 7.50-7.59 (5H, m), 7.66-7.70 (1H, m), 8.16-8.19 (1H, m), 8.50 (1H, s), 9.01 (1H, br s), 9.28 (1H, br s), 10.95 (1H, s).

Example 557N-(4-(2-Aminopyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1258] The title compound (105 mg, 0.327 mmol, 65%) was obtained as colorless crystals from 4-(4-aminophenoxy)pyrimidin-2-ylamine (101 mg, 0.500 mmol) and phenyl isocyanate (59.6 mg, 0.500 mmol), by the same procedure as in Example 551.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.07 (1H, d, J = 5.8 Hz), 6.61 (2H, br s), 6.94-6.99 (1H, m), 7.05-7.10 (2H, m), 7.25-7.31 (2H, m), 7.43-7.51 (4H, m), 8.0 (1H, d, J = 5.8 Hz), 8.74 (1H, br s), 8.79 (1H, br s).

[1259] The intermediates were synthesized in the following manner.

Production Example 557-14-Chloro-6-(4-nitrophenoxy)pyrimidin-2-ylamine

[1260] 2-Amino-4,6-dichloropyrimidine (3.28 g, 20.0 mmol), 4-nitrophenol (2.78 g, 20.0 mmol), and potassium carbonate (4.15 g, 30.0 mmol) were heated and stirred in dimethylformamide (20 ml) at 100°C for 3 hours. After returning the reaction solution to room temperature, it was poured into ice water (100 ml) and the precipitated crystals were filtered out, washed with water and blow-dried to obtain the title compound (4.93 g, 18.5 mmol, 92%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.43 (1H, s), 7.25 (2H, br s), 7.46-7.52 (2H, m), 8.28-8.34 (2H, m).

Production Example 557-24-(4-Aminophenoxy)pyrimidin-2-ylamine

[1261] After suspending 4-chloro-6-(4-nitrophenoxy)pyrimidin-2-ylamine (1.60 g, 1.32 mmol) in a methanol (30 ml)-tetrahydrofuran (30 ml) mixed solvent, palladium hydroxide-carbon (300 mg) was added and the mixture was stirred at room temperature for 18 hours under a hydrogen atmosphere. The catalyst was filtered off by celite filtration, and after washing with ethanol, the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), and the fraction containing the target substance was concentrated to obtain the title compound (910 mg, 4.50 mmol, 75%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 5.01 (2H, br s), 5.93 (1H, d, J = 5.4 Hz), 6.50-6.60 (4H, m), 6.76-6.82 (2H, m),

8.03 (1H, d, J = 5.4 Hz).

Example 558

5 N-(4-(2-Aminopyrimidin-4-yloxy)phenyl)-N'-(4-fluorophenyl)urea

[1262] The title compound (105 mg, 0.309 mmol, 62%) was obtained as colorless crystals from 4-(4-aminophenoxy) pyrimidin-2-ylamine (101 mg, 0.500 mmol) and 4-fluorophenyl isocyanate (68.6 mg, 0.500 mmol), by the same procedure as in Example 551.

10 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 6.06 (1H, d, J = 5.6 Hz), 6.61 (2H, br s), 7.05-7.15 (4H, m), 7.44-7.52 (4H, m), 8.08 (1H, d, J = 5.6 Hz), 8.75-8.79 (2H, m).

Example 559

15 N-(4-(2-Aminopyrimidin-4-yloxy)phenyl)-N'-(3-methylsulfonylphenyl)urea

[1263] The title compound (96 mg, 0.240 mmol, 48%) was obtained as colorless crystals from 4-(4-aminophenoxy) pyrimidin-2-ylamine (101 mg, 0.500 mmol) and (3-methylsulfonylphenyl)carbamic acid phenyl ester (146 mg, 0.500 mmol), by the same procedure as in Example 555.

20 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.20 (3H, s), 6.07 (1H, d, J = 5.8 Hz), 6.61 (2H, br s), 7.06-7.12 (2H, m), 7.46-7.59 (4H, m), 7.65-7.70 (1H, m), 8.09 (1H, d, J = 5.8 Hz), 8.16-8.19 (1H, m), 8.89 (1H, br s), 9.18 (1H, br s).

Example 560

25 4-(3-Fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[1264] The title compound (22 mg) was obtained as light yellow crystals from phenyl N-(4-(6-carbamoyl-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)carbamate, which was obtained from 4-(4-amino-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide (100 mg) by the same procedure as in Example 11, and cyclopropylamine.

30 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.39 (2H, m), 0.63 (2H, m), 2.49 (1H, m), 3.30 (3H, s), 3.79 (2H, m), 4.39 (2H, m), 6.51 (1H, d, J=5.2Hz), 6.79 (1H, s), 7.06 (1H, m), 7.31 (1H, m), 7.54 (1H, s), 7.79 (1H, s), 7.83 (1H, s), 8.18-8.22 (2H, m), 8.65 (1H, d, J=5.2Hz), 8.74 (1H, s).

35 Example 561

1-[4-(7-Benzyloxy-6-cyanoquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropylurea

[1265] A carbamate (1.73 g) was obtained as a solid from 4-(4-amino-2-methylphenoxy)-7-methoxyquinoline-6-carboxylic acid amide (2 g) and phenyl chlorocarbonate, in the same manner as Production Example 17. The carbamate (1.7 g) was then treated with cyclopropylamine in dimethylsulfoxide at room temperature in the same manner as Example 11, to obtain the title compound (1.4 g) as a solid.

40 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.59-0.64 (2H, m), 2.23 (3H, s), 2.50-2.56 (1H, m), 5.42 (2H, s), 6.49 (1H, d, J=5.2Hz), 6.73-6.75 (1H, m), 7.02 (1H, dd, J=2.8Hz, J=8.8Hz), 7.08 (1H, d, J=2.8Hz), 7.32-7.53 (5H, m), 7.60 (1H, s), 7.66 (1H, s), 7.89 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.2Hz), 8.73 (1H, s).

[1266] The intermediate was synthesized in the following manner.

Production Example 561-1

50 4-(4-Amino-3-methylphenoxy)-7-benzyloxyquinoline-6-carbonitrile

[1267] The title compound (3.6 g) was obtained as a solid from 7-benzyloxy-4-chloroquinoline-6-carbonitrile (5 g) and 4-amino-3-methylphenol, in the same manner as Production Example 395-1.

55 ¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 2.07 (3H, s), 4.94 (2H, s), 5.43 (2H, s), 6.46 (1H, d, J=5.2Hz), 6.69 (1H, d, J=8.8Hz), 6.82 (1H, dd, J=2.8Hz, J=8.8Hz), 6.87 (1H, d, J=2.8Hz), 7.36 (1H, t, J=7.2Hz), 7.44 (2H, t, J=7.2Hz), 7.53 (2H, d, J=7.2Hz), 7.66 (1H, s), 8.67 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 5621-[4-(6-Cyano-7-hydroxyquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropylurea

[1268] In the same manner as Production Example 301-2, 1-[4-(7-benzyloxy-6-cyano-quinolin-4-yloxy)-2-methylphenyl]-3-cyclopropyl-urea (0.8 g) was debenzylated in tetrahydrofuran using palladium-carbon, to obtain the title compound (0.5 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.36-0.41 (2H, m), 0.59-0.65 (2H, m), 2.17 (3H, s), 2.49-2.56 (1H, m), 6.32 (1H, d, J=5.2Hz), 6.74 (1H, d, J=2.8Hz), 7.01 (1H, dd, J=2.4Hz, J=8.8Hz), 7.07 (1H, d, J=2.4Hz), 7.30 (1H, s), 7.59 (1H, s), 7.90 (1H, d, J=8.8Hz), 8.56 (1H, d, J=5.2Hz), 8.57 (1H, s).

Example 5631-[4-(6-Cyano-(2R)-7-oxiranylmethoxyquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropylurea

[1269] The title compound (312 mg) was obtained as a solid from 1-[4-(6-cyano-7-hydroxyquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropylurea (500 mg), in the same manner as Production Example 284-1.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.42 (2H, m), 0.59-0.65 (2H, m), 2.18 (3H, s), 2.49-2.56 (1H, m), 2.78-2.81 (1H, m), 2.89 (1H, t, J=4.8Hz), 3.42-3.47 (1H, m), 4.14 (1H, dd, J=6.4Hz, J=11.6Hz), 4.68 (1H, dd, J=2.4Hz, J=11.6Hz), 6.49 (1H, d, J=5.2Hz), 6.74 (1H, d, J=2.4Hz), 7.03 (1H, dd, J=2.4Hz, J=8.4Hz), 7.09 (1H, d, J=2.4Hz), 7.59 (1H, s), 7.61 (1H, s), 7.92 (1H, d, J=8.4Hz), 8.70 (1H, d, J=5.2Hz), 8.74 (1H, s).

Example 5641-[4-[6-Cyano-7-((2R)-2-hydroxy-3-pyrrolidin-1-yl-propoxy) quinolin-4-yloxy]-2-methyl-phenyl]-3-cyclopropyl-urea

[1270] The title compound (11 mg) was obtained as a solid from 1-[4-(6-cyano-7-(2R)-oxiranylmethoxyquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropyl-urea (55 mg) and pyrrolidine, in the same manner as Example 284.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.58-0.65 (2H, m), 2.26 (3H, s), 1.62-1.69 (4H, m), 2.44-2.56 (6H, m), 2.68 (1H, dd, J=6.4Hz, J=12Hz), 3.96-4.03 (1H, m), 4.18 (1H, dd, J=5.6Hz, J=10.4Hz), 4.28 (1H, dd, J=3.6Hz, J=10.4Hz), 5.00 (1H, d, J=5.2Hz), 6.48 (1H, d, J=5.2Hz), 6.75 (1H, d, J=2.4Hz), 7.03 (1H, dd, J=2.4Hz, J=8.8Hz), 7.09 (1H, d, J=2.4Hz), 7.58 (1H, s), 7.60 (1H, s), 7.91 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 5651-[4-[6-Cyano-7-((2R)-2-hydroxy-3-piperidin-1-ylpropoxy) quinolin-4-yloxy]-2-methylphenyl]-3-cyclopropyl-urea

[1271] The title compound (8 mg) was obtained as a solid from [1-[4-(6-cyano-(2R)-7-oxiranylmethoxyquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropylurea (100 mg) and piperidine, in the same manner as Example 284.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.59-0.66 (2H, m), 1.31-1.38 (2H, m), 1.43-1.53 (4H, m), 2.20 (3H, s), 2.33-2.58 (7H, m), 3.99-4.06 (1H, m), 4.19 (1H, dd, J=5.6Hz, J=10.4Hz), 4.29 (1H, dd, J=3.2Hz, J=10.4Hz), 4.94 (1H, br), 6.49 (1H, d, J=5.2Hz), 6.75-6.79 (1H, m), 7.02-7.08 (1H, m), 7.09-7.13 (1H, m), 7.60 (1H, s), 7.62 (1H, s), 7.93 (1H, d, J=9.2Hz), 8.70 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 5661-[4-[6-Cyano-7-(3-diethylamino-(2R)-2-hydroxypropoxy)quinolin-4-yloxy]-2-methyl-phenyl]-3-cyclopropyl-urea

[1272] The title compound (21 mg) was obtained as a solid from [1-[4-(6-cyano-(2R)-7-oxiranylmethoxyquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropylurea (55 mg) and diethylamine, in the same manner as Example 284.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.59-0.65 (2H, m), 0.91-1.00 (6H, m), 2.18 (3H, s), 2.43-2.69 (7H, m), 3.91-4.00 (1H, m), 4.17-4.22 (1H, m), 4.26-4.31 (1H, m), 6.48 (1 d, J=5.2Hz), 6.76 (1H, d, J=2.8Hz), 7.03 (1H, dd, J=2.8Hz, J=8.8Hz), 7.09 (1H, d, J=2.4Hz), 7.58 (1H, s), 7.60 (1H, s), 7.91 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 5671-[4-[6-Cyano-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-yloxy]-2-methylphenyl]-3-cyclopropylurea

[1273] The title compound (23 mg) was obtained as a solid from 1-[4-(6-cyano-7-hydroxyquinolin-4-yloxy)-2-methylphenyl]-3-cyclopropylurea (60 mg) and 1-(3-chloropropyl)pyrrolidine, in the same manner as Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.59-0.65 (2H, m), 1.62-1.69 (4H, m), 1.93-2.01 (2H, m), 2.18 (3H, s), 2.39-2.45 (4H, m), 2.49-2.55 (1H, m), 2.57 (2H, t, J=7.2Hz), 4.30 (2H, t, J=6.4Hz), 6.48 (1H, d, J=5.2Hz), 6.75 (1H, d, J=2.8Hz), 7.03 (1H, dd, J=2.8Hz, J=8.8Hz), 7.08 (1H, d, J=2.8Hz), 7.55 (1H, s), 7.60 (1H, s), 7.91 (1H, d, J=8.8Hz), 8.68 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 568N-Phenyl-N'-(4-(6-phenylaminopyrimidin-4-yloxy)phenyl)urea

[1274] N-(6-(4-Aminophenoxy)pyrimidin-4-yl)phenylamine (55.6 mg, 0.200 mmol) and phenyl isocyanate (26.1 mg, 0.220 mmol) were stirred together in dimethylformamide (1 ml) at room temperature for 12 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (69.0 mg, 0.174 mmol, 87%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 6.06 (1H, d, J = 1.6 Hz), 6.95-7.02 (2H, m), 7.11-7.16 (2H, m), 7.25-7.34 (4H, m), 7.44-7.50 (2H, m), 7.50-7.56 (2H, m), 7.58-7.63 (2H, m), 8.35 (1H, d, J = 1.6 Hz), 8.71 (1H, s), 8.79 (1H, s), 9.54 (1H, s).

[1275] The intermediates were synthesized in the following manner.

Production Example 568-1N-(6-(4-Nitrophenoxy)pyrimidin-4-yl)phenylamine

[1276] 4-Chloro-6-(4-nitrophenoxy)pyrimidine (508 mg, 2.00 mmol) and aniline (559 mg, 6.00 mmol) were heated and stirred in 1-methylpyrrolidone (5 ml) at 90°C for 3 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 1:3), and the fraction containing the target substance was concentrated to obtain the title compound (508 mg, 1.65 mmol, 82%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 6.34 (1H, s), 7.03 (1H, br s), 7.21-7.35 (5H, m), 7.40-7.46 (2H, m), 8.26-8.32 (2H, m), 8.35 (1H, s).

Production Example 568-2N-(6-(4-Aminophenoxy)pyrimidin-4-yl)phenylamine

[1277] After suspending N-(6-(4-nitrophenoxy)pyrimidin-4-yl)phenylamine (508 mg, 1.65 mmol), iron powder (461 mg, 8.25 mmol) and ammonium chloride (882 mg, 16.5 mmol) in an ethanol (16 ml)-water (4 ml) mixed solvent, the suspension was heated and stirred at 80°C for 20 minutes. Upon completion of the reaction, the reaction mixture was filtered with celite and washed in ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (387 mg, 1.39 mmol, 84%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 3.64 (2H, br s), 6.17 (1H, d, J = 0.8 Hz), 6.67-6.73 (2H, m), 6.77 (1H, br s), 6.89-6.95 (2H, m), 7.14-7.20 (1H, m), 7.26-7.32 (2H, m), 7.35-7.41 (2H, m), 8.37 (1H, d, J = 0.8 Hz).

Example 569

N-(3-Methylsulfonylphenyl)-N'-(4-(6-phenylaminopyrimidin-4-yloxy)phenyl)urea

[1278] N-(6-(4-Aminophenoxy)pyrimidin-4-yl)phenylamine (55.6 mg, 0.200 mmol) and (3-methylsulfonylphenyl)carbamic acid phenyl ester (63.8 mg, 0.220 mmol) were heated and stirred in dimethylsulfoxide (1 ml) at 85°C for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (77.0 mg, 0.162 mmol, 81%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.20 (3H, s), 6.07 (1H, s), 6.98-7.03 (1H, m), 7.12-7.17 (2H, m), 7.28-7.34 (2H, m), 7.50-7.63 (6H, m), 7.66-7.72 (1H, m), 8.17-8.20 (1H, m), 8.34 (1H, s), 8.93 (1H, br s), 9.19 (1H, br s), 9.54 (1H, s).

Example 570

N-(4-(6-(4-Methylsulfonylphenylamino)pyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1279] N-(6-(4-Aminophenoxy)pyrimidin-4-yl)-4-methylsulfonylphenylamine (194 mg, 0.600 mmol) and phenyl isocyanate (78.6 mg, 0.660 mmol) were stirred in dimethylformamide (2 ml) at room temperature for 18 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (250 mg, 0.564 mmol, 94%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.44 (3H, s), 6.03 (1H, d, J = 1.6 Hz), 6.95-7.00 (1H, m), 7.10-7.15 (2H, m), 7.22-7.32 (4H, m), 7.44-7.50 (2H, m), 7.50-7.60 (4H, m), 8.34 (1H, d, J = 1.6 Hz), 8.73 (1H, br s), 8.81 (1H, br s), 9.56 (1H, s).

[1280] The intermediates were synthesized in the following manner.

Production Example 570-1N-(6-(4-Nitrophenoxy)pyrimidin-4-yl)-4-methylsulfonylphenylamine

[1281] 4-Chloro-6-(4-nitrophenoxy)pyrimidine (2.33 g, 9.25 mmol), 4-(methylthio) aniline (1.29 g, 9.25 mmol) and diisopropylethylamine (1.79 g, 13.9 mmol) were heated and stirred in 1-methylpyrrolidone (10 ml) at 80°C for 18 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 1:3), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (620 mg, 1.75 mmol, 19%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.51 (3H, s), 6.28 (1H, d, J = 1.0 Hz), 6.99 (1H, br s), 7.23-7.34 (6H, m), 8.26-8.32 (2H, m), 8.34 (1H, d, J = 1.0 Hz).

Production Example 570-2N-(6-(4-Aminophenoxy)pyrimidin-4-yl)-4-methylsulfonylphenylamine

[1282] N-(6-(4-Nitrophenoxy)pyrimidin-4-yl)-4-methylsulfonylphenylamine (620 mg, 1.75 mmol), iron powder (489 mg, 8.75 mmol) and ammonium chloride (936 mg, 17.5 mmol) were suspended in an ethanol (16 ml)-water (4 ml) mixed solvent and the suspension was heated and stirred at 80°C for 1 hour. Upon completion of the reaction, the reaction mixture was filtered with celite and washed in an ethyl acetate-tetrahydrofuran mixed solvent. The organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (392 mg, 1.21 mmol, 69%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.49 (3H, s), 3.65 (2H, br s), 6.10 (1H, d, J = 1.0 Hz), 6.66-6.72 (2H, m), 6.76 (1H,

br s), 6.88-6.94 (2H, m), 7.21-7.30 (4H, m), 8.35 (1H, d, J = 1.0 Hz).

Example 571

N-(3-Methylsulfonylphenyl)-N'-(4-(6-(4-methylsulfonylphenylamino)pyrimidin-4-yloxy)phenyl)urea

[1283] N-(6-(4-Aminophenoxy)pyrimidin-4-yl)-4-methylsulfonylphenylamine (194 mg, 0.600 mmol) and (3-methylsulfonylphenyl)carbamic acid phenyl ester (192 mg, 0.660 mmol) were heated and stirred in dimethylsulfoxide (2 ml) at 85°C for 18 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (297 mg, 0.569 mmol, 95%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.44 (3H, s), 3.20 (3H, s), 6.04 (1H, d, J = 0.8 Hz), 7.12-7.17 (2H, m), 7.22-7.27 (2H, m), 7.50-7.63 (6H, m), 7.67-7.71 (1H, m), 8.17-8.20 (1H, m), 8.34 (1H, d, J = 0.8 Hz), 8.92 (1H, s), 9.17 (1H, s), 9.56 (1H, s).

Example 572

N-(4-(6-(4-Methylsulfonylphenylamino)pyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1284] N-(4-(6-(4-Methylsulfonylphenylamino)pyrimidin-4-yloxy)phenyl)-N'-phenylurea (180 mg, 0.406 mmol) and 3-chloroperbenzoic acid (200 mg, 0.812 mmol) were stirred in dichloromethane (6 ml) at room temperature for 12 hours. A saturated aqueous sodium thiosulfate solution was added to suspend the reaction, and then the reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (137 mg, 0.288 mmol, 71%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.16 (3H, s), 6.18 (1H, s), 6.97-7.02 (1H, m), 7.13-7.19 (2H, m), 7.27-7.33 (2H, m), 7.46-7.51 (2H, m), 7.53-7.59 (2H, m), 7.81-7.87 (2H, m), 7.89-7.94 (2H, m), 8.47 (1H, s), 8.72 (1H, s), 8.81 (1H, s), 10.06 (1H, s).

Example 573

N-(3-Methylsulfonylphenyl)-N'-(4-(6-(4-methylsulfonylphenylamino)pyrimidin-4-yloxy)phenyl)urea

[1285] The title compound (157 mg, 0.284 mmol, 64%) was obtained as colorless crystals from N-(3-methylsulfonylphenyl)-N'-(4-(6-(4-methylsulfonylphenylamino)pyrimidin-4-yloxy)phenyl)urea (230 mg, 0.441 mmol), by the same procedure as in Example 572.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.16 (3H, s), 3.20 (3H, s), 6.19 (1H, d, J = 1.0 Hz), 7.04-7.10 (2H, m), 7.50-7.60 (4H, m), 7.66-7.70 (1H, m), 7.82-7.88 (2H, m), 7.88-7.94 (2H, m), 8.17-8.20 (1H, m), 8.47 (1H, d, J = 1.0 Hz), 8.95 (1H, s), 9.19 (1H, s), 10.06 (1H, s).

Example 574

N-(4-(6-(4-Fluorophenylamino)pyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1286] N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea (68.0 mg, 0.200 mmol) and 4-fluoroaniline (111 mg, 1.00 mmol) were heated and stirred in 1-methylpyrrolidone (1 ml) at 130°C for 3 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with saturated aqueous sodium bicarbonate, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (33.0 mg, 0.079 mmol, 40%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.00 (1H, d, J = 0.8 Hz), 6.95-7.00 (1H, m), 7.10-7.19 (4H, m), 7.26-7.32 (2H,

m), 7.44-7.50 (2H, m), 7.50-7.56 (2H, m), 7.57-7.63 (2H, m), 8.33 (1H, d, J = 0.8 Hz), 8.68 (1H, s), 8.76 (1H, s), 9.56 (1H, s).

[1287] The intermediates were synthesized in the following manner.

5 Production Example 574-1

4-(6-Chloropyrimidin-4-yloxy)phenylamine

[1288] 4-Chloro-6-(4-nitrophenoxy)pyrimidine (2.52 g, 10.0 mmol), iron powder (2.79 g, 50.0 mmol) and ammonium chloride (5.35 g, 100 mmol) were suspended in an ethanol (100 ml)-water (25 ml) mixed solvent and the suspension was heated and stirred at 80°C for 1 hour. Upon completion of the reaction, the reaction mixture was filtered with celite and washed in an ethanol-ethyl acetate mixed solvent. The organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 2:3), and the fraction containing the target substance was concentrated to obtain the title compound (1.74 g, 7.85 mmol, 79%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 3.71 (2H, br s), 6.70-6.75 (2H, m), 6.84 (1H, s), 6.90-6.95 (2H, m), 8.60 (1H, s).

20 Production Example 574-2

N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1289] 4-(6-Chloropyrimidin-4-yloxy)phenylamine (663 mg, 3.00 mmol) and phenyl isocyanate (393 mg, 3.30 mmol) were stirred in dimethylformamide (5 ml) at room temperature for 18 hours. The reaction solution was poured into water and the precipitated crystals were filtered out, washed with water and ethanol and blow-dried to obtain the title compound (988 mg, 2.91 mmol, 97%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.94-7.00 (1H, m), 7.14-7.20 (2H, m), 7.25-7.32 (2H, m), 7.33 (1H, d, J = 0.8 Hz), 7.43-7.49 (2H, m), 7.50-7.56 (2H, m), 8.65 (1H, d, J = 0.8 Hz), 8.70 (1H, s), 8.78 (1H, s).

30 Example 575

N-(4-(6-(3-Fluorophenylamino)pyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1290] N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea (68.0 mg, 0.200 mmol) and 3-fluoroaniline (111 mg, 1.00 mmol) were heated and stirred in 1-methylpyrrolidone (1 ml) at 150°C for 90 minutes. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with saturated aqueous sodium bicarbonate, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and then blow-dried to obtain the title compound (43.0 mg, 0.104 mmol, 52%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.09 (1H, s), 6.77-6.83 (1H, m), 6.95-7.00 (1H, m), 7.11-7.17 (2H, m), 7.26-7.36 (4H, m), 7.45-7.50 (2H, m), 7.50-7.55 (2H, m), 7.71-7.77 (1H, m), 8.42 (1H, s), 8.69 (1H, s), 8.77 (1H, s), 9.76 (1H, s).

45 Example 576

N-(4-(6-(2-Fluorophenylamino)pyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1291] N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea (68.0 mg, 0.200 mmol) and 2-fluoroaniline (111 mg, 1.00 mmol) were heated and stirred in 1-methylpyrrolidone (1 ml) at 170°C for 3 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with saturated aqueous sodium bicarbonate, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:2), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (26.0 mg, 0.062 mmol, 31%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.17 (1H, d, J = 0.8 Hz), 6.95-7.00 (1H, m), 7.10-7.19 (4H, m), 7.22-7.32 (3H, m), 7.45-7.50 (2H, m), 7.50-7.55 (2H, m), 7.86-7.93 (1H, m), 8.29 (1H, d, J = 0.8 Hz), 8.69 (1H, s), 8.76 (1H, s), 9.32 (1H, s).

Example 577N-(4-(6-(3,5-Difluorophenylamino)pyrimidin-4-yloxy)phenyl)-N'-phenylurea

[1292] N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea (68.0 mg, 0.200 mmol) and 3,5-difluoroaniline (129 mg, 1.00 mmol) were heated and stirred in 1-methylpyrrolidone (1 ml) at 170°C for 3 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with saturated aqueous sodium bicarbonate, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 1:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (17.5 mg, 0.040 mmol, 20%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 6.09 (1H, s), 6.77-6.85 (1H, m), 6.95-7.00 (1H, m), 7.13-7.19 (2H, m), 7.27-7.33 (2H, m), 7.38-7.50 (4H, m), 7.50-7.58 (2H, m), 8.46 (1H, s), 8.69 (1H, s), 8.78 (1H, s), 9.94 (1H, s).

Example 578N-Phenyl-N'-(4-(6-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yloxy)phenyl)urea hydrochloride

[1293] N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea (68.0 mg, 0.200 mmol) and 3,4,5-trimethoxyaniline (183 mg, 1.00 mmol) were heated and stirred in 1-methylpyrrolidone (1 ml) at 150°C for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with saturated aqueous sodium bicarbonate, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), the fraction containing the target substance was concentrated, converted to a hydrochloride with 1N hydrochloric acid and suspended in methanol, the suspension was diluted with ethyl acetate and the crystals were filtered out, washed with ethyl acetate and blow-dried to obtain the title compound (50.0 mg, 0.095 mmol, 48%) as light green crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.61 (3H, s), 3.74 (6H, s), 6.03 (1H, s), 6.90 (2H, s), 6.95-7.00 (1H, m), 7.10-7.16 (2H, m), 7.27-7.33 (2H, m), 7.45-7.50 (2H, m), 7.50-7.55 (2H, m), 8.36 (1H, s), 8.91 (1H, s), 9.02 (1H, s), 9.55 (1H, s).

Example 5791-(4-(6-(N-Methyl-N-phenylamino)pyrimidin-4-yloxy)phenyl)-3-phenylurea

[1294] N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea (68.0 mg, 0.200 mmol) and N-methylaniline (107 mg, 1.00 mmol) were heated and stirred in 1-methylpyrrolidone (1 ml) at 130°C for 36 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 1:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (38 mg, 0.092 mmol, 46%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.42 (3H, s), 5.75 (1H, s), 6.95-7.03 (3H, m), 7.25-7.38 (5H, m), 7.41-7.50 (6H, m), 8.27 (1H, s), 8.64 (1H, s), 8.68 (1H, s).

Example 580N-(5-Chloro-2-thiazolyl)-N'-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)urea

[1295] The title compound (66.0 mg, 0.128 mmol, 64%) was obtained as white crystals from 4-(4-amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (71.0 mg, 0.200 mmol) and phenyl 5-chloro-2-thiazolylcarbamate prepared from 2-amino-5-chlorothiazole and phenyl chloroformate, by the same procedure as in Example 145.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 3.38 (3H, s), 3.80 (2H, m), 4.43 (2H, m), 6.65 (1H, d, J=5.2Hz), 7.20 (1H, m), 7.44 (1H, s), 7.47 (1H, m), 7.66 (1H, s), 8.20 (1H, m), 8.76 (1H, d, J=5.2Hz), 8.77 (1H, s), 9.02 (1H, s), 11.01 (1H, s).

Example 581N-(4-(6-Cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-cyclopropyl-2-thiazolyl)urea

[1296] The title compound (88.0 mg, 0.169 mmol, 85%) was obtained as white crystals from 4-(4-amino-3-fluorophenoxy)-6-cyano-7-(2-methoxyethoxy)quinoline (71.0 mg, 0.200 mmol) and phenyl 4-cyclopropyl-2-thiazolylcarbamate prepared from 2-amino-4-cyclopropylthiazole and phenyl chloroformate, by the same procedure as in Example 145. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.75 (2H, m), 0.84 (2H, m), 1.95 (1H, m), 3.38 (3H, s), 3.80 (2H, m), 4.44 (2H, m), 6.64 (1H, d, J=5.2Hz), 6.72 (1H, s), 7.19 (1H, m), 7.46 (1H, m), 7.66 (1H, s), 8.25 (1H, m), 8.76 (1H, d, J=5.2Hz), 8.77 (1H, s), 10.84 (1H, br s).

Example 5824-(3-Chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1297] The title compound (65.0 mg, 0.162 mmol, 50%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (150 mg, 0.324 mmol) and 40% methylamine (methanol solution), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 2.68 (3H, d, J=4.4Hz), 4.03 (3H, s), 6.53 (1H, d, J=5.0Hz), 6.88 (1H, q, J=4.4Hz), 7.23 (1H, dd, J=2.8, 8.2Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.74 (1H, s), 7.86 (1H, s), 8.12 (1H, s), 8.25 (1H, d, J=8.2Hz), 8.67 (1H, s), 8.68 (1H, d, J=5.0Hz).

Example 5834-(3-Chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1298] The title compound (92.0 mg, 0.221 mmol, 68%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (150 mg, 0.324 mmol) and 2 M ethylamine (tetrahydrofuran solution), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.08 (3H, t, J=7.2Hz), 3.14 (2H, m), 4.03 (3H, s), 6.53 (1H, d, J=5.2Hz), 6.99 (1H, t, J=5.6Hz), 7.23 (1H, dd, J=2.8, 8.8Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.73 (1H, s), 7.85 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J=8.8Hz), 8.66 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 5844-(3-Chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1299] The title compound (111 mg, 0.258 mmol, 80%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (150 mg, 0.324 mmol) and propylamine, by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.91 (3H, t, J=7.4Hz), 1.47 (2H, m), 3.08 (2H, m), 4.03 (3H, s), 6.53 (1H, d, J=5.2Hz), 7.03 (1H, t, J=5.6Hz), 7.23 (1H, dd, J=2.8, 8.8Hz), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.74 (1H, s), 7.85 (1H, s), 8.09 (1H, s), 8.28 (1H, d, J=8.8Hz), 8.66 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 5854-(3-Chloro-4-(cyanomethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1300] The title compound (107 mg, 0.251 mmol, 77%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (150 mg, 0.324 mmol) and 2-aminoacetonitrile hydrochloride, by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 4.03 (3H, s), 4.22 (2H, t, J=6.0Hz), 6.56 (1H, d, J=5.2Hz), 7.28 (1H, dd, J=2.8, 8.8Hz), 7.50 (1H, t, J=6.0Hz), 7.53 (1H, s), 7.54 (1H, d, J=2.8Hz), 7.74 (1H, s), 7.86 (1H, s), 8.17 (1H, d, J=8.8Hz), 8.51 (1H, s), 8.66 (1H, s), 8.68 (1H, d, J=5.2Hz).

Example 5864-(3-Chloro-4-(2-cyanoethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1301] The title compound (109 mg, 0.248 mmol, 76%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (150 mg, 0.324 mmol) and 3-aminopropionitrile, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 2.72 (2H, t, J=6.4Hz), 3.41 (2H, m), 4.03 (3H, s), 6.54 (1H, d, J=5.2Hz), 7.25 (1H, dd, J=2.8, 8.8Hz), 7.37 (1H, t, J=6.0Hz), 7.50 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.74 (1H, s), 7.86 (1H, s), 8.24 (1H, d, J=8.8Hz), 8.31 (1H, s), 8.66 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 5894-(3-Chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1302] The title compound (39.0 mg, 0.088 mmol, 27%) was obtained as white crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (150 mg, 0.324 mmol) and cis-2-fluorocyclopropylamine tosylate, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.82 (1H, m), 1.11 (1H, m), 2.68 (1H, m), 4.04 (3H, s), 4.78 (1H, m), 6.54 (1H, d, J=5.2Hz), 7.25 (1H, dd, J=2.8, 8.8Hz), 7.32 (1H, d, J=3.6Hz), 7.50 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.74 (1H, s), 7.86 (1H, s), 8.25 (1H, s), 8.29 (1H, d, J=8.8Hz), 8.66 (1H, s), 8.67 (1H, d, J=5.2Hz).

Example 5904-(3-Chloro-4-(aminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1303] The title compound (61.0 mg, 79%) was obtained as light red crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate (100 mg, 0.22 mmol) and ammonia water (2 ml), by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 4.01 (3H, s), 6.41 (2H, s), 6.51 (1H, d, J=5.2Hz), 7.21 (1H, d, J=9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.50 (1H, s), 7.73 (1H, s), 7.84 (1H, s), 8.15 (1H, s), 8.25 (1H, d, J=8.8Hz), 8.65 (1H, d, J=5.2Hz), 8.66 (1H, s).

Example 591N-(4-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-N'-thiazol-2-ylurea

[1304] 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester (208 mg, 0.500 mmol) and 2-aminothiazole (100 mg, 1.00 mmol) were heated and stirred in dimethylsulfoxide (1 ml) at 85°C for 1 hour. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 20:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (150 mg, 0.355 mmol, 71%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.02-4.05 (6H, m), 6.46 (1H, d, J = 5.2 Hz), 6.92 (2H, d, J = 3.6 Hz), 7.16-7.22 (2H, m), 7.40-7.44 (2H, m), 7.56 (1H, s), 7.61-7.67 (2H, m), 8.48 (1H, d, J = 5.2 Hz).

[1305] The intermediate was synthesized in the following manner.

Production Example 591-14-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester

[1306] The 4-(6,7-dimethoxyquinolin-4-yloxy)phenylamine (2.96 g, 10.0 mmol) obtained by the method described in WO97/17329 and triethylamine (1.21 g, 12.0 mmol) were dissolved in dimethylformamide (30 ml), and after adding phenyl chloroformate (1.72 g, 11.0 mmol) while cooling on ice, the mixture was stirred at room temperature for 1 hour. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was

distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 3:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (2.50 g, 6.00 mmol, 60%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.05 (3H, s), 4.06 (3H, s), 6.46 (1H, d, J = 5.2 Hz), 7.12 (1H, br s), 7.16-7.28 (5H, m), 7.38-7.44 (3H, m), 7.53-7.60 (3H, m), 8.49 (1H, d, J = 5.2 Hz).

Example 592

N-Cyclopropyl-N'-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)urea

[1307] 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester (104 mg, 0.250 mmol) and cyclopropylamine (28.5 mg, 0.500 mmol) were stirred in dimethylsulfoxide (1 ml) at room temperature for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 15:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (76 mg, 0.200 mmol, 80%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 0.70-0.75 (2H, m), 0.87-0.92 (2H, m), 2.60-2.66 (1H, m), 4.04-4.07 (6H, m), 4.93 (1H, s), 6.45 (1H, d, J = 5.2 Hz), 6.99 (1H, s), 7.12-7.18 (2H, m), 7.42 (1H, s), 7.50-7.56 (2H, m), 7.57 (1H, s), 8.48 (1H, d, J = 5.2 Hz).

Example 593

N-(4-(6,7-Dimethoxyquinolin-4-yloxy)-2-fluorophenyl)-N'-thiazol-2-ylurea

[1308] 4-(6,7-Dimethoxyquinolin-4-yloxy)-2-fluorophenylcarbamic acid phenyl ester (109 mg, 0.250 mmol) and 2-aminothiazole (50.0 mg, 0.500 mmol) were heated and stirred in dimethylsulfoxide (1 ml) at 85°C for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 30:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (95.0 mg, 0.216 mmol, 86%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.05 (3H, s), 4.06 (3H, s), 6.52 (1H, d, J = 5.2 Hz), 6.92 (1H, d, J = 3.6 Hz), 6.96-7.04 (2H, m), 7.36 (1H, d, J = 3.6 Hz), 7.40 (1H, s), 7.53 (1H, s), 8.30-8.36 (1H, m), 8.47 (1H, d, J = 5.2 Hz).

[1309] The intermediate was synthesized in the following manner.

Production Example 593-1

4-(6,7-Dimethoxyquinolin-4-yloxy)-2-fluorophenylcarbamic acid phenyl ester

[1310] 4-(6,7-Dimethoxyquinolin-4-yloxy)-2-fluorophenylamine (3.55 g, 9.17 mmol) obtained by the method described in Japanese Unexamined Patent Publication HEI No. 11-158149 and pyridine (3.63 g, 45.8 mmol) were dissolved in dimethylformamide (30 ml), and after adding phenyl chloroformate (1.51 g, 9.64 mmol) while cooling on ice, the mixture was stirred at room temperature for 1 hour. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:hexane = 2:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (2.30 g, 5.29 mmol, 58%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 4.05 (3H, s), 4.06 (3H, s), 6.52 (1H, d, J = 5.2 Hz), 7.00-7.05 (2H, m), 7.18-7.30 (4H, m), 7.40-7.46 (3H, m), 7.50 (1H, s), 8.21 (1H, br s), 8.53 (1H, d, J = 5.2 Hz).

Example 594N-Cyclopropyl-N'-(4-(6,7-dimethoxyquinolin-4-yloxy)-2-fluorophenyl)urea

[1311] 4-(6,7-Dimethoxyquinolin-4-yloxy)-2-fluorophenylcarbamic acid phenyl ester (109 mg, 0.250 mmol) and cyclopropylamine (28.5 mg, 0.500 mmol) were stirred in dimethylsulfoxide (1 ml) at room temperature for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 50:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (73 mg, 0.183 mmol, 73%) as colorless crystals. ¹H-NMR Spectrum (CDCl₃)δ(ppm): 0.71-0.76 (2H, m), 0.90-0.95 (2H, m), 2.60-2.66 (1H, m), 4.05 (3H, s), 4.06 (3H, s), 5.00 (1H, s), 6.50 (1H, d, J = 5.2 Hz), 6.95-7.02 (2H, m), 7.23 (1H, s), 7.43 (1H, s), 7.52 (1H, s), 8.25-8.32 (1H, m), 8.51 (1H, d, J = 5.2 Hz).

Example 5954-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide

[1312] The title compound (96.0 mg, 0.198 mmol, 39.7%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (206 mg, 0.499 mmol) and 2-ethoxyethylbromide, by the same procedure as in Example 7. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 1.16 (3H, t, J=7.2Hz), 2.56 (1H, m), 3.53 (2H, q, J=7.2Hz), 3.83 (2H, m), 4.40 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.56 (1H, s), 7.85 (1H, s), 7.87 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.66 (1H, d, J=5.2Hz), 8.78 (1H, s).

Example 5964-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-cyclopropylmethoxy-6-quinolinecarboxamide

[1313] The title compound (61.4 mg, 0.132 mmol, 26.4%) was obtained as light yellow crystals from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-hydroxy-6-quinolinecarboxamide (206 mg, 0.499 mmol) and bromomethylcyclopropane, by the same procedure as in Example 7. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.41-0.47 (4H, m), 0.60-0.69 (4H, m), 1.39 (1H, m), 2.56 (1H, m), 4.14 (2H, d, J=6.8Hz), 6.52 (1H, d, J=5.2Hz), 7.20 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 8.8Hz), 7.49-7.50 (2H, m), 7.83 (1H, s), 7.85 (1H, s), 7.98 (1H, s), 8.28 (1H, d, J=8.8Hz), 8.66 (1H, d, J=5.2Hz), 8.72 (1H, s).

Example 5974-(3-Fluoro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1314] The title compound (37 mg) was obtained as yellow crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (73 mg) and methylamine (2M tetrahydrofuran solution), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 2.65 (3H, d, J=4.4Hz), 4.01 (3H, s), 6.45-6.46 (1H, m), 6.51-6.52 (1H, m), 7.04-7.06 (1H, m), 7.28-7.31 (1H, m), 7.50 (1H, s), 7.72 (1H, s), 7.84 (1H, s), 8.17-8.22 (1H, m), 8.40 (1H, s), 8.64-8.65 (2H, m).

Example 5984-(3-Fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1315] The title compound (38 mg) was obtained as yellow crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)carbamate (69 mg) and ethylamine (2M tetrahydrofuran solution), by the same procedure as in Example 11. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.05 (3H, t, J=7Hz), 3.11 (2H, q, J=7Hz), 4.01 (3H, s), 6.50-6.52 (1H, m),

6.57-6.58 (1H, m), 7.04-7.06 (1H, m), 7.28-7.32 (1H, m), 7.50 (1H, s), 7.73 (1H, s), 7.84 (1H, s), 8.19-8.24 (1H, m), 8.33 (1H, s), 8.64-8.65 (2H, m).

Example 599

tert-Butyl 4-((((4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolyl)carbonyl)amino)methyl)-1-piperidinecarboxylate

[1316] 4-(3-Chloro-4-(((cyclopropylamino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxylic acid (171 mg, 0.40 mmol) was dissolved in dimethylformamide (4 ml) under a nitrogen atmosphere, and then tert-butyl 4-aminomethyl-1-piperidinecarboxylate (171 mg, 0.80 mmol), triethylamine (0.2 ml) and 1H-1,2,3-benzotriazol-1-yloxy(tri(dimethylamino)) phosphonium hexafluorophosphate (265 mg, 0.60 mmol) were added in that order at room temperature, and the mixture was stirred overnight. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (249 mg, quantitative) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.05 (2H, m), 1.22 (1H, m), 1.37 (9H, s), 1.66 (2H, m), 2.56 (1H, m), 2.67 (2H, m), 3.20 (2H, m), 3.93 (2H, m), 3.99 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.17-7.24 (2H, m), 7.46 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.97 (1H, s), 8.26 (1H, dd, J=2.8, 8.8Hz), 8.39 (1H, m), 8.46 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 600

N6-(1-Methyl-4-piperidylmethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1317] After adding trifluoroacetic acid (1 ml) to tert-butyl 4-((((4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolyl)carbonyl)amino)methyl)-1-piperidinecarboxylate (249 mg, 0.40 mmol) at room temperature, the mixture was stirred for 2 hours. The reaction solution was poured into saturated aqueous sodium bicarbonate for neutralization and extracted 3 times with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate. After distilling off the solvent, the residue was dissolved in tetrahydrofuran (5 ml)-methanol (5 ml), and then 37% aqueous formaldehyde (0.5 ml), acetic acid (0.05 ml) and sodium cyanoborohydride (50 mg, 0.8 mmol) were added in that order at room temperature and the mixture was stirred for 1 hour. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with saturated aqueous sodium bicarbonate and saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent, ethyl acetate was used for crystallization and the crystals were filtered out and blow-dried to obtain the title compound (125.6 mg, 0.233 mmol, 58.4%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.18 (2H, m), 1.49 (1H, m), 1.64 (2H, m), 1.78 (2H, m), 2.11 (3H, s), 2.56 (1H, m), 2.73 (2H, m), 3.18 (2H, m), 3.99 (3H, s), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.4Hz), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.46 (1H, d, J=2.4Hz), 7.49 (1H, s), 7.97 (1H, s), 8.26 (1H, dd, J=2.8, 8.8Hz), 8.35 (1H, m), 8.47 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 601

tert-Butyl 4-((((4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-6-(methylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[1318] The title compound (188.4 mg, 0.302 mmol, 57.1%) was obtained as white crystals from N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (225.5 mg, 0.528 mmol) and tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.13-1.26 (3H, m), 1.39 (9H, s), 1.75 (2H, m), 2.06 (1H, m), 2.56 (1H, m), 2.75 (1H, m), 2.81 (3H, d, J=4.8Hz), 3.99 (2H, m), 4.10 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.21 (1H, dd, J=2.8, 9.2Hz), 7.45 (1H, d, J=2.8Hz), 7.48 (1H, s), 7.96 (1H, s), 8.18 (1H, d, J=4.8Hz), 8.25 (1H, d, J=9.2Hz), 8.43 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 602

tert-Butyl 4-(((4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-6-(ethylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[1319] The title compound (155.4 mg, 0.244 mmol, 63.0%) was obtained as light yellow crystals from N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (170.5 mg, 0.387 mmol) and tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.10-1.16 (4H, m), 1.27 (2H, m), 1.39 (9H, s), 1.76 (2H, m), 2.05 (1H, m), 2.56 (1H, m), 2.75 (1H, m), 3.20-3.40 (2H, m), 4.01 (2H, m), 4.11 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.17-7.23 (2H, m), 7.45 (1H, d, J=2.8Hz), 7.48 (1H, s), 7.96 (1H, s), 8.20-8.27 (2H, m), 8.44 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 603

N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide

[1320] After adding trifluoroacetic acid (1 ml) to tert-butyl 4-(((4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-6-(methylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (179.0 mg, 0.287 mmol) at room temperature, the mixture was stirred for 2 hours. The reaction solution was poured into saturated aqueous sodium bicarbonate for neutralization and extracted 5 times with ethyl acetate-tetrahydrofuran (1:1), and the organic layer was dried over anhydrous sodium sulfate. After distilling off the solvent, the residue was dissolved in tetrahydrofuran (5 ml)-methanol (5 ml), and then 37% aqueous formaldehyde (0.3 ml), acetic acid (0.05 ml) and sodium cyanoborohydride (36 mg, 0.57 mmol) were added in that order at room temperature and the mixture was stirred for 1 hour. The reaction solution was distributed between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was washed with saturated aqueous sodium bicarbonate and saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent, ethyl acetate was used for crystallization and the crystals were filtered out and blow-dried to obtain the title compound (101.0 mg, 0.188 mmol, 65.4%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.41 (2H, m), 0.65 (2H, m), 1.34 (2H, m), 1.72-1.89 (5H, m), 2.14 (3H, s), 2.56 (1H, m), 2.78 (2H, m), 2.82 (3H, d, J=4.4Hz), 4.08 (2H, d, J=6.4Hz), 6.51 (1H, d, J=5.2Hz), 7.19-7.23 (2H, m), 7.45 (1H, d, J=2.8Hz), 7.48 (1H, s), 7.97 (1H, s), 8.20 (1H, d, J=4.4Hz), 8.25 (1H, d, J=9.2Hz), 8.45 (1H, s), 8.63 (1H, d, J=5.2Hz).

Example 604

N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide

[1321] The title compound (82.6 mg, 0.150 mmol, 64.8%) was obtained as light yellow crystals from tert-butyl 4-(((4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-6-(ethylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (147.2 mg, 0.231 mmol), by the same procedure as in Example 603.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.14 (3H, t, J=7.2Hz), 1.36 (2H, m), 1.75-1.89 (5H, m), 2.15 (3H, s), 2.56 (1H, m), 2.79 (2H, m), 3.20-3.40 (2H, m), 4.08 (2H, d, J=6.4Hz), 6.51 (1H, d, J=5.2Hz), 7.20-7.23 (2H, m), 7.46 (1H, d, J=2.8Hz), 7.48 (1H, s), 7.98 (1H, s), 8.22-8.27 (2H, m), 8.47 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 605

1-[4-(7-Benzyloxy-6-cyanoquinolin-4-yloxy)-2-chloro-phenyl]-3-ethyl-urea

[1322] A carbamate (1.51 g) was obtained as a solid from 4-(4-amino-3-chlorophenoxy)-7-benzyloxy-quinoline-6-carbonitrile (1.78 g) and phenyl chlorocarbonate, by the same procedure as in Production Example 17. The carbamate (1.5 g) was then treated with ethylamine in dimethylsulfoxide at room temperature in the same manner as Example 11, to obtain the title compound (1.4 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.06 (3H, t, J=7.6Hz), 3.08-3.16 (2H, m), 5.45 (2H, s), 6.58 (1H, d, J=5.2Hz), 6.99 (1H, t, J=5.2Hz), 7.23 (1H, dd, J=2.8Hz, J=9.2Hz), 7.36 (1H, t, J=7.2Hz), 7.44 (2H, t, J=7.2Hz), 7.48 (1H, d, J=2.8Hz), 7.54 (2H, d, J=7.2Hz), 7.70 (1H, s), 8.06 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.72 (1H, d, J=5.2Hz), 8.76 (1H, s).

Example 6061-(2-Chloro-4-(6-cyano-(2R)-7-oxiranylmethoxyquinolin-4-yloxy)-phenyl)-3-ethylurea

[1323] 1-(4-(7-Benzoyloxy-6-cyanoquinolin-4-yloxy)-2-chloro-phenyl)-3-ethylurea (1 g) was treated with trifluoroacetic acid and thioanisole for deprotection in the same manner as Production Example 21, and the obtained hydroxy compound (0.48 g) was treated in the same manner as Example 543 to obtain the title compound (0.31 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.06 (3H, t, J=7.2Hz), 2.81 (1H, dd, J=2.8Hz, J=5.2Hz), 2.91 (1H, t, J=4.8Hz), 3.80-3.16 (2H, m), 3.44-3.48 (1H, m), 4.17 (1H, dd, J=6.4Hz, J=11.6Hz), 4.71 (1H, dd, J=2Hz, J=11.6Hz), 6.59 (1H, d, J=5.2Hz), 6.99 (1H, t, J=5.2Hz), 7.24 (1H, dd, J=2.8Hz, J=9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.64 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.73 (1H, d, J=5.2Hz), 8.76 (1H, s).

Example 6071-(2-Chloro-4-(6-cyano-7-((2R)-2-hydroxy-3-pyrrolidin-1-ylpropoxy)quinolin-4-yloxy)phenyl)-3-ethylurea

[1324] The title compound (38 mg) was obtained as a solid from 1-(2-chloro-4-(6-cyano-(2R)-7-oxiranylmethoxyquinolin-4-yloxy)-phenyl)-3-ethylurea (110 mg) and pyrrolidine, in the same manner as Example 544.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.07 (3H, t, J=7.2Hz), 1.62-1.72 (4H, m), 2.44-2.56 (5H, m), 2.67-2.73 (1H, m), 3.08-3.16 (2H, m), 3.97-4.04 (1H, m), 4.17-4.23 (1H, m), 4.25-4.32 (1H, m), 5.02 (1H, d, J=4.4Hz), 6.57 (1H, d, J=5.2Hz), 6.97-7.03 (1H, m), 7.23 (1H, dd, J=2.4Hz, J=9.2Hz), 7.49 (1H, d, J=2.4Hz), 7.61 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.72 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 6081-(2-Chloro-4-(6-cyano-7-((2R)-3-diethylamino-2-hydroxypropoxy)quinolin-4-yloxy)phenyl)-3-ethylurea

[1325] The title compound (12 mg) was obtained as a solid from 1-(2-chloro-4-(6-cyano-(2R)-7-oxiranylmethoxyquinolin-4-yloxy)phenyl)-3-ethylurea (100 mg) and diethylamine, in the same manner as Example 544.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.96 (6H, t, J=7.2Hz), 1.06 (3H, t, J=7.2Hz), 2.42-2.57 (5H, m), 2.64 (1H, dd, J=7.6Hz, J=13.2Hz), 3.08-3.16 (2H, m), 3.91-4.00 (1H, m), 4.21 (1H, dd, J=5.2Hz, J=10Hz), 4.30 (1H, dd, J=3.6Hz, J=10Hz), 4.88-4.93 (1H, m), 6.57 (1H, d, J=5.2Hz), 6.99 (1H, t, J=4.8Hz), 7.23 (1H, dd, J=2.8Hz, J=9.2Hz), 7.49 (1H, d, J=2.8Hz), 7.61 (1H, s), 8.06 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.72 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 6091-(2-Chloro-4-(6-cyano-7-((2R)-2-hydroxy-3-piperidin-1-ylpropoxy)quinolin-4-yloxy)phenyl)-3-ethylurea

[1326] The title compound (46 mg) was obtained as a solid from 1-(2-chloro-4-(6-cyano-(2R)-7-oxiranylmethoxyquinolin-4-yloxy)phenyl)-3-ethylurea (100 mg) and piperidine, in the same manner as Example 544.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.06 (3H, t, J=7.2Hz), 1.32-1.39 (2H, m), 1.44-1.53 (4H, m), 2.34-2.51 (6H, m), 3.08-3.16 (2H, m), 3.99-4.07 (1H, m), 4.19 (1H, dd, J=5.6Hz, J=10.4Hz), 4.30 (1H, dd, J=3.2Hz, J=10.4Hz), 4.93 (1H, d, J=4.4Hz), 6.57 (1H, d, J=5.2Hz), 6.99 (1H, t, J=5.2Hz), 7.23 (1H, dd, J=2.8Hz, J=9.2Hz), 7.48 (1H, d, J=2.8Hz), 7.62 (1H, s), 8.06 (1H, s), 8.27 (1H, d, J=9.2Hz), 8.72 (1H, d, J=5.2Hz), 8.72 (1H, s).

Example 6101-(2-Chloro-4-(6-(4-(piperidin-4-ylmethoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)-3-cyclopropylurea

[1327] After dissolving 37 mg of 4-(4-(4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenoxy)methyl)piperidine-1-carboxylic acid tert-butyl ester in 1 ml of trifluoroacetic acid, the mixture was stirred at room temperature for 2 hours. The reaction system was concentrated under reduced pressure, saturated sodium bicarbonate water was added to alkalinity and liquid separation and extraction were performed with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to dryness to obtain the

25 mg of the title compound.
MS Spectrum(ESI):533(M+1),

Example 611

1-(2-Chloro-4-{6-(4-(1-methylpiperidin-4-ylmethoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl)-3-cyclopropylurea

[1328] After adding 2 ml of methanol, 2 ml of methylene chloride, 0.05 ml of 37% aqueous formaldehyde and 4.4 μ l of acetic acid to 24 mg of 1-(2-chloro-4-{6-[4-(piperidin-4-ylmethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-2-phenyl)-3-cyclopropylurea, 30 mg of triacetoxyborohydride was added while stirring, which was continued at room temperature for 40 minutes. Water was added, extraction was performed with an ethyl acetate-tetrahydrofuran (5:1) mixed solvent, and the extract was concentrated and subjected to NH silica gel column chromatography to obtain 12 mg of the title compound.
MS Spectrum(ESI):547(M+1),

Example 612

4-{4-[4-{3-Chloro-4-(3-cyclopropylureido)phenoxy]-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl}phenoxy}methyl}piperidine-1-carboxylic acid tert-butyl ester

[1329] After adding 38 mg of 4-bromomethylpiperidine-1-carboxylic acid tert-butyl ester, 59 mg of potassium carbonate and 1 ml of dimethylformamide to 60 mg of 1-{2-chloro-4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-phenyl}-3-cyclopropylurea, the mixture was stirred at 70-75°C for 6 hours. It was then returned to room temperature, water was added, and liquid separation and extraction were performed with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to dryness to obtain 63 mg of the title compound.
MS Spectrum(ESI):786(M+23),

Example 613

4-(2,3-Dimethyl-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1330] The title compound (30 mg) was obtained as colorless crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2,3-dimethylphenyl)carbamate (56 mg) and methylamine (2M tetrahydrofuran solution), by the same procedure as in Example 11.
¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 2.01 (3H, s), 2.14 (3H, s), 2.64 (3H, d, J=3.2Hz), 4.01 (3H, s), 6.24 (1H, d, J=5.2Hz), 6.28 (1H, d, J=4.4Hz), 6.97 (1H, d, J=8.8Hz), 7.49 (1H, s), 7.60 (1H, d, J=8.4Hz), 7.73-7.85 (3H, m), 8.59 (1H, d, J=4.8Hz), 8.71 (1H, s).

Example 614

4-(2,3-Dimethyl-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

[1331] The title compound (33 mg) was obtained as colorless crystals from phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2,3-dimethylphenyl)carbamate (55 mg) and ethylamine (2M tetrahydrofuran solution), by the same procedure as in Example 11.
¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 1.54 (3H, t, J=7Hz), 2.01 (3H, s), 2.14 (3H, s), 3.07-3.12 (2H, m), 4.01 (3H, s), 6.24 (1H, d, J=4.8Hz), 6.41 (1H, m), 6.97 (1H, d, J=8.4Hz), 7.49 (1H, s), 7.64 (1H, d, J=8.8Hz), 7.73 (2H, brs), 7.85 (1H, s), 8.59 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 615

4-(3-Chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1332] After adding (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate (308 mg, 1.35 mmol), potassium carbonate (149 mg, 1.08 mmol) and dimethylformamide (9 ml) to 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (372.0 mg, 0.90 mmol), the mixture was stirred at 60°C for 7 hours. The reaction solution was allowed to stand to return to room temperature, and then pyrrolidine (1 ml) was added and the mixture was stirred overnight. The reaction solution was distributed between ethyl acetate and water, and the organic layer

was washed with water and saturated brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 95:5), the fraction containing the target substance was concentrated, and crystals were precipitated from ethyl acetate, filtered out and blow-dried to obtain the title compound (133.3 mg, 0.247 mmol, 27.4%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 1.67 (4H, m), 2.45-2.59 (6H, m), 2.69 (1H, m), 4.05 (1H, m), 4.19 (1H, dd, J=6.0, 10.0Hz), 4.32 (1H, dd, J=3.6, 10.0Hz), 5.19 (1H, d, J=4.8Hz), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 8.8Hz), 7.49 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.82 (1H, s), 7.97 (1H, s), 7.99 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.66 (1H, d, J=5.2Hz), 8.80 (1H, s).

Example 616

N-[[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy]-2-methylphenyl]-N'-(4-fluorophenyl)-N-methylurea

[1333] After dissolving 6-carbamoyl-4-chloro-7-methoxyquinoline (100 mg, 0.2982 mmol), N-(4-fluorophenyl)-N'-(4-hydroxy-2-methylphenyl)-N'-methylurea (100 mg, 0.2917 mmol) and diisopropylethylamine (0.1 ml, 0.4375 mmol) in N-methylpyrrolidone (0.1 ml), the mixture was heated and stirred at 150°C for 3 hours. After cooling to room temperature, water was added to the reaction solution, the mixture was extracted with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate-ethanol) and then by NH silica gel column chromatography (hexane-ethyl acetate-ethanol), after which diethyl ether was added to the obtained amorphous substance to make a suspension, the suspension was diluted with hexane, and the precipitate was filtered out, washed with diethyl ether:hexane = 1:1 and dried by aspiration to obtain the title compound (11 mg, 0.023 mmol, 7.95%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 2.21 (3H, s), 3.16 (3H, s), 4.02(3H, s), 6.71(1H, d, J = 5.2 Hz), 7.05(2H, t, J = 8.8 Hz), 7.18(1H, dd, J = 2.8 Hz, 8.4 Hz), 7.28(1H, d, J = 2.8 Hz), 7.39-7.44(3H, m), 7.51(1H, s), 7.72(1H, brs), 7.84 (1H, brs), 7.89(1H, brs), 8.66(1H, s), 8.70(1H, d, J = 5.2 Hz).

[1334] The starting materials were synthesized in the following manner.

Production Example 616-1

4-Benzoyloxy-2-methylaniline

[1335] After dissolving 4-amino-3-cresol (10 g, 81.20 mmol) in dimethylsulfoxide (80 ml), sodium hydride (3.25 g, 81.20 mmol, 60% in oil) was added and the mixture was stirred for 15 minutes at room temperature under a nitrogen atmosphere. Benzyl bromide (4.83 ml, 40.60 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Water was added to the reaction solution, extraction was performed with diethyl ether/tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto silica gel, purified by silica gel column chromatography (hexane-ethyl acetate-ethanol) and then by NH silica gel column chromatography (hexane-ethyl acetate) to obtain the title compound (6.55 g, 30.72 mmol, 75.64%) as a violet oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 2.16(3H, s), 3.36(2H, brs), 4.99(2H, s), 6.61(1H, d, J = 8.4 Hz), 6.69(1H, dd, J = 2.8 Hz, 8.4 Hz), 6.75(1H, d, J = 2.8 Hz), 7.30(1H, t, J = 6.8 Hz), 7.37(2H, t, J = 6.8 Hz), 7.42(2H, d, J = 6.8 Hz).

Production Example 616-2

N-Methyl-4-benzyloxy-2-methylaniline

[1336] After dissolving 4-benzyloxy-2-methylaniline (6.55 g, 30.72 mmol) in N,N-dimethylformamide (10 ml) and methanol (60 ml), 1H-benzotriazole-1-methanol (4.58 g, 30.72 mmol) was added and the mixture was stirred for 30 minutes at room temperature. N,N-Dimethylformamide (20 ml) was added for complete dissolution of the precipitated crystals, sodium borohydride (2.32 g, 61.44 mmol) was added in small portions at a time at room temperature (internal temperature increase), and the mixture was stirred for 30 minutes. Water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto silica gel and purified by silica gel column chromatography (hexane-ethyl acetate) to obtain the title compound (4.364 g, 19.20 mmol, 62.49%) as a brown oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm) : 2.13(3H, s), 2.86(3H, s), 4.99(2H, s), 6.24(1H, d, J = 9.6 Hz), 6.79-6.81(2H, m), 7.30(1H, t, J = 6.8 Hz), 7.37(2H, t, J = 6.8 Hz), 7.43(2H, d, J = 6.8 Hz).

Production Example 616-3

N-(4-Fluorophenyl)-N'-(4-hydroxy-2-methylphenyl)-N'-methylurea

[1337] After dissolving N-methyl-4-benzyloxy-2-methylaniline (2.64 g, 11.61 mmol) in N,N-dimethylformamide (20 ml), sodium hydride (1.16 g, 29.00 mmol, 60% in oil) was added and the mixture was stirred at 85°C for 45 minutes under a nitrogen atmosphere. Phenyl N-(4-fluorophenyl)carbamate (3.50 g, 12.76 mmol) was added and the mixture was further stirred at 85°C for 1 hour under a nitrogen atmosphere. After cooling to room temperature, water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto NH silica gel and subjected to crude purification by NH silica gel column chromatography (hexane-ethyl acetate-ethanol) to obtain N'-(4-benzyloxy-2-methylphenyl)-N-(4-fluorophenyl)-N'-methylurea (2.66 g) as a yellow oil. This was dissolved in methanol (50 ml), and then 10% palladium carbon (0.2 g) was added and the mixture was stirred for 2 hours at room temperature under a hydrogen atmosphere. The catalyst was filtered off, and then filtrate was washed with ethanol, and the solvent was distilled off under reduced pressure. The precipitated crystals were suspended in ethanol, the suspension was diluted with diethyl ether and hexane, and the crystals were filtered out, washed with hexane and dried by aspiration to obtain the title compound (0.83 g, 3.0258 mmol, 41.86%) as brown crystals. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.07(3H, s), 3.04 (3H, s), 6.63(1H, d, J = 8.0 Hz), 6.67(1H, s), 6.97-7.03(3H, m), 7.34-7.39(2H, m), 7.54(1H, brs), 9.46(1H, s).

Example 617N-[[4-(7-Benzyloxy-6-cyano-4-quinolyl)oxy]-2-methylphenyl]]-N'-(4-fluorophenyl)-N-methylurea

[1338] 6-Cyano-4-chloro-7-methoxyquinoline (90 mg, 0.3038 mmol) and N-(4-fluorophenyl)-N'-(4-hydroxy-2-methylphenyl)-N'-methylurea (100 mg, 0.3646 mmol) were dissolved in dimethylsulfoxide (3 ml), and then sodium hydride (15 mg, 0.3646 mmol) was added and the mixture was heated and stirred at 85°C for 1 hour. After cooling to room temperature, water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate), and the obtained crystals were suspended in diethyl ether and filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (80 mg, 0.1502 mmol, 49.44%) as pink crystals. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.21(3H, s), 3.16(3H, s), 5.46(2H, s), 6.76(1H, d, J = 5.4 Hz), 7.05(2H, t, J = 8.8 Hz), 7.20(1H, dd, J = 2.4 Hz, 8.4 Hz), 7.29(1H, d, J = 2.4 Hz), 7.34-7.46(6H, m), 7.54 (2H, d, J = 6.8 Hz), 7.72(1H, s), 7.91(1H, brs), 8.75(1H, s), 8.77(1H, d, J = 5.4 Hz).

Example 618N-[[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl]]-N'-(4-fluorophenyl)-N-methylurea

[1339] 6-Carbamoyl-4-chloro-7-methoxyquinoline (41 mg, 0.1744 mmol) and N-(2-fluoro-4-hydroxyphenyl)-N'-(4-fluorophenyl)-N-methylurea (57 mg, 0.2048 mmol) were dissolved in dimethylsulfoxide (1.0 ml), and then sodium hydride (8.4 mg, 0.2093 mmol) was added and the mixture was heated and stirred at 85°C for 30 minutes. After cooling the reaction solution to room temperature, water was added and the precipitated crystals were filtered out. The crystals were then suspended in acetone:diethyl ether = 1:2 and refiltered out, washed with diethyl ether and dried by aspiration to obtain the title compound (46 mg, 0.0961 mmol, 55.13%) as yellow crystals. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 3.44(3H, s), 4.01(3H, s), 6.44(1H, d, J = 5.4 Hz), 6.99(1H, brs), 7.10(1H, dd, J = 2.4 Hz, 8.4 Hz), 7.34(2H, t, J = 8.8 Hz), 7.38(1H, d, J = 8.4 Hz), 7.47(1H, s), 7.59(2H, dd, J = 5.0 Hz, 8.8 Hz), 7.69 (1H, brs), 7.81(1H, brs), 8.59(1H, d, J = 5.4 Hz), 8.69(1H, s).

[1340] The starting materials were synthesized in the following manner.

Production Example 618-14-Benzyloxy-2-fluoronitrobenzene

[1341] 3-Fluoro-4-nitrophenol (10 g, 63.65 mmol) was dissolved in N,N-dimethylformamide (120 ml), and then sodium hydride (2.68 g, 67.00 mmol, 60% in oil) was added and the mixture was stirred for 15 minutes at room temperature under a nitrogen atmosphere. After adding benzyl bromide (7.6 ml, 63.65 mmol), the mixture was stirred overnight at

room temperature under a nitrogen atmosphere. Water was added to the reaction solution, and the precipitated crystals were filtered out, washed with water and dried by aspiration to obtain the title compound (16.06 g, quant.) as crude light yellow crystals. These were used without further purification for the following reaction.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 5.25(2H, s), 7.04(1H, dd, J = 1.6 Hz, 9.2 Hz), 7.27(1H, dd, J = 2.8 Hz, 14.0 Hz), 7.32-7.42(3H, m), 7.46(2H, d, J = 6.8 Hz), 8.15(1H, t, J = 9.2 Hz).

Production Example 618-2

4-Benzyloxy-2-fluoroaniline

[1342] After dissolving the 4-benzyloxy-2-fluoronitrobenzene crude crystals (16.06 g, 63.65 mmol) in ethanol (1000 ml) and water (200 ml), electrolytic iron powder (14.0 g, 254.60 mmol) and ammonium chloride (27.2 g, 509.20 mmol) were added and the mixture was heated to reflux for 4.5 hours. The reaction solution was cooled to near room temperature, the insoluble portion was filtered off, washing was performed with ethanol and the solvent of the filtrate was distilled off under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto silica gel and purified by silica gel column chromatography (hexane-ethyl acetate system) to obtain the title compound (11.25 g, 51.78 mmol, 81.35%) as a brown oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 3.44(2H, brs), 4.98(2H, s), 6.10(1H, dd, J = 2.8 Hz, 8.8 Hz), 6.68-6.74(2H, m), 7.30-7.43(5H, m).

Production Example 618-3

N-{1-(1H-Benzotriazolyl)methyl}-4-benzyloxy-2-fluoroaniline

[1343] After dissolving 4-benzyloxy-2-fluoroaniline (11.25 g, 51.78 mmol) in methanol (300 ml), 1H-benzotriazole-1-methanol (8.11 g, 54.37 mmol) was added and the mixture was stirred for 10 hours at room temperature. The precipitated crystals were filtered out, washed with ethanol and dried by aspiration to obtain the title compound (12.01 g, 34.47 mmol, 66.57%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 4.92(2H, s), 6.07(2H, d, J = 6.8 Hz), 6.64(1H, dd, J = 2.8 Hz, 9.2 Hz), 6.78(1H, dd, J = 2.8 Hz, 9.2 Hz), 6.82(1H, m), 6.99(1H, t, J = 9.2 Hz), 7.24-7.38(6H, m), 7.53(1H, t, J = 8.4 Hz), 7.99(1H, d, J = 8.4 Hz), 8.10(1H, d, J = 8.4 Hz).

Production Example 618-4

N-Methyl-4-benzyloxy-2-fluoroaniline

[1344] After dissolving N-{1-(1H-benzotriazolyl)methyl}-4-benzyloxy-2-fluoroaniline (14.13 g, 40.56 mmol) in N,N-dimethylformamide (200 ml), methanol (150 ml) and ethanol (50 ml), there was added sodium borohydride (3.06 g, 81.12 mmol) and the mixture was stirred for 2.5 hours at room temperature. There was further added sodium borohydride (0.78 g, 20.28 mmol), and the mixture was stirred for 13.5 hours at room temperature. Water was added to the reaction solution, extraction was performed with ethyl acetate-tetrahydrofuran, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto silica gel and purified by silica gel column chromatography (hexane-ethyl acetate system) to obtain the title compound (5.98 g, 26.31 mmol, 64.87%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.64 (3H, d, J = 4.8 Hz), 4.97(2H, s), 5.02(1H, d, J = 4.8 Hz), 6.55(1H, t, J = 9.2 Hz), 6.68(1H, d, J = 9.2 Hz), 6.79(1H, J = 13.2 Hz), 7.25-7.50 (5H, m).

Production Example 618-5

N-(4-Benzyloxy-2-fluorophenyl)-N'-(4-fluorophenyl)-N-methylurea

[1345] N-Methyl-4-benzyloxy-2-fluoroaniline (250 mg, 1.0805 mmol) was dissolved in N,N-dimethylformamide (5.0 ml), and then sodium hydride (65 mg, 1.6207 mmol, 60% in oil) was added and the mixture was stirred at 95°C for 45 minutes under a nitrogen atmosphere. After adding 4-fluorophenyl isocyanate (0.14 ml, 1.1836 mmol), the mixture was stirred at 85°C for 45 minutes under a nitrogen atmosphere. There was further added 4-fluorophenyl isocyanate (0.14 ml, 0.5094 mmol), and the mixture was stirred at 85°C for 30 minutes under a nitrogen atmosphere. After cooling to room temperature, water was added to the reaction solution, extraction was performed with ethyl acetate, the extract

was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto NH silica gel and purified by NH silica gel column chromatography (hexane-ethyl acetate system) to obtain the title compound (0.105 g, 0.2881 mmol, 21.67%) as a light yellow oil.

¹H-NMR Spectrum (CDCl₃) δ (ppm): 2.16(3H, s), 3.44(3H, s), 5.01(2H, s), 6.90(1H, d, J = 2.0 Hz), 6.78(1H, dd, J = 2.0 Hz, 8.4 Hz), 6.91(1H, d, J = 8.4 Hz), 7.19(2H, t, J = 8.4 Hz), 7.30-7.46(5H, m).

Production Example 618-6

N-(2-Fluoro-4-hydroxyphenyl)-N'-(4-fluorophenyl)-N-methylurea

[1346] After dissolving N-(4-benzyloxy-2-fluorophenyl)-N'-(4-fluorophenyl)-N-methylurea (105 mg, 0.2881 mmol) in methanol (10 ml), 10% palladium carbon (20 mg) was added and the mixture was stirred for 45 minutes at room temperature under a hydrogen atmosphere. The catalyst was filtered off, and then was washed with ethanol, and the solvent of the filtrate was distilled off under reduced pressure. The precipitated crystals were suspended in diethyl ether, and then filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (57 mg, 0.2048 mmol, 71.10%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.07(3H, s), 6.41(1H, d, J = 1.6 Hz), 6.54(1H, dd, J = 1.6 Hz, 8.4 Hz), 7.00(1H, d, J = 8.4 Hz), 7.38(2H, t, J = 8.8 Hz), 7.53(2H, dd, J = 4.8 Hz, 8.8 Hz).

Example 619

N-Cyclopropyl-N'-{[4-(6-(methoxy)carbamoyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl}urea

[1347] N-{[4-(6-carboxyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl}-N'-cyclopropylurea (40 mg, 0.0972 mmol) and O-methylhydroxylamine hydrochloride (16 mg, 0.1945 mmol) were used for reaction in the same manner as Example 412. After completion of the reaction, water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained crystals were suspended in acetone and diluted with diethyl ether, and the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (20 mg, 0.0454 mmol, 46.71%) as light yellow crystals. ¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.41(2H, m), 0.66(2H, m), 2.56(1H, m), 3.75(3H, s), 3.99(3H, s), 6.54(1H, d, J = 5.0 Hz), 6.82(1H, s), 7.08(1H, d, J = 8.4 Hz), 7.32(1H, d, J = 8.4 Hz), 7.50(1H, s), 8.19-8.24(2H, m), 8.43(1H, s), 8.67(1H, d, J = 5.0 Hz), 11.46(1H, s).

Example 620

N-Cyclopropyl-N'-{[4-(6-(2-ethoxyethyl)carbamoyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl}urea

[1348] N-{[4-(6-carboxyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl}-N'-cyclopropylurea (40 mg, 0.0972 mmol) and 2-ethoxyethylamine (17 mg, 0.1945 mmol) were used for reaction in the same manner as Example 412. After completion of the reaction, water was added to the reaction solution, and the precipitated crystals were filtered out. These were suspended in acetone and diluted with diethyl ether, and then the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (33 mg, 0.0684 mmol, 70.93%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 0.39-0.44(2H, m), 0.63-0.68(2H, m), 1.14(3H, t, J = 6.6 Hz), 2.57(1H, m), 3.46-3.55(6H, m), 4.04(3H, s), 6.54(1H, d, J = 5.2 Hz), 6.81(1H, m), 7.08(1H, m), 7.33(1H, dd, J = 2.4 Hz, 11.6 Hz), 7.53(1H, s), 8.19-8.24(2H, m), 8.46(1H, t, J = 5.2 Hz), 8.63(1H, s), 8.68(1H, d, J = 5.2 Hz).

Example 621

N-Cyclopropyl-N'-{[4-(6-(2-fluorocyclopropyl)carbamoyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl}urea

[1349] N-{[4-(6-carboxyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl}-N'-cyclopropylurea (40 mg, 0.0972 mmol) and 2-fluorocyclopropylamine tosylate (39 mg, 0.1945 mmol) were used for reaction in the same manner as Example 412. After completion of the reaction, water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was adsorbed onto silica gel and purified by silica gel column chromatography (ethyl acetate-ethanol system), and the obtained crystals were suspended in acetone:diethyl ether = 1:3 and filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (12 mg, 0.0256 mmol, 26.35%) as colorless crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 0.42 (2H, m), 0.65(2H, m), 1.05-1.18(2H, m), 2.56(1H, m), 2.93(1H, m), 4.01 (3H, m), 4.54-4.93(1H, m), 6.54(1H, d, J = 5.2 Hz), 6.80(1H, m), 7.08(1H, m), 7.32(1H, dd, J = 2.0 Hz, 11.6 Hz), 7.53 (1H, s), 8.22(2H, m), 8.45(1H, m), 8.52(1H, s), 8.67(1H, d, J = 5.2 Hz).

Example 622

N-[[4-(6-(2-Cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl]-N'-cyclopropylurea

[1350] N-[[4-(6-carboxyl-7-methoxy-4-quinolyl)oxy]-2-fluorophenyl]-N'-cyclopropylurea (40 mg, 0.0972 mmol) and 2-cyanoethylamine (14 mg, 0.1945 mmol) were used for reaction in the same manner as Example 412. After completion of the reaction, water was added to the reaction solution, extraction was performed with ethyl acetate, the extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained crystals were suspended in acetone and diluted with diethyl ether, and then the crystals were filtered out, washed with diethyl ether and dried by aspiration to obtain the title compound (18 mg, 0.0684 mmol, 39.96%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 0.41(2H, m), 0.63-0.66(2H, m), 2.56(1H, m), 2.82(2H, t, J = 6.4 Hz), 3.57 (2H, q, J = 6.4 Hz), 4.03(3H, s), 6.54(1H, d, J = 5.2 Hz), 6.81(1H, m), 7.08(1H, m), 7.32(1H, dd, J = 2.4 Hz, 11.6 Hz), 7.54(1H, s), 8.18-8.26 (2H, m), 8.61(1H, s), 8.68(1H, d, J = 5.2 Hz), 8.73(1H, m).

Example 623

N-[[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy]-2-methylphenyl]-N'-methylurea

[1351] [4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-methylphenyl]carbamic acid phenyl ester (70 mg) was added to dimethylsulfoxide (0.8 ml), and then a methylamine-containing 2N tetrahydrofuran solution (0.4 ml) was added and the mixture was stirred for 5 minutes. Water and ethyl acetate were added to the reaction solution, and the precipitated crystals were filtered out to obtain the title compound (48 mg). ¹H-NMR(DMSO-d₆) δ(ppm) 2.20(3H, s), 2.65(3H, d, J=4.8Hz), 4.01(3H, s), 6.38-6.47(2H, m), 7.00-7.05(1H, m), 7.09(1H, d, J=2.8Hz), 7.49(1H, s), 7.71(1H, brs), 7.74(1H, s), 7.84(1H, brs), 7.86-7.92(1H, m), 8.63(1H, d, J=5.2Hz), 8.66(1H, s)

Example 624

N-[[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy]-2-methylphenyl]-N'-ethylurea

[1352] [4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-methylphenyl]-carbamic acid phenyl ester (65 mg) was added to dimethylsulfoxide (1.0 ml), and then an ethylamine-containing 2N tetrahydrofuran solution (0.37 ml) was added and the mixture was stirred for 5 minutes. Water and ethyl acetate were added to the reaction solution, and the precipitated crystals were filtered out to obtain the title compound (38 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 1.06(3H, t, J=7.2Hz), 2.20(3H, s), 3.06-3.16 (2H, m), 4.01(3H, s), 6.44(1H, d, J=5.6Hz), 6.49-6.45(1H, m), 7.00-7.04(1H, m), 7.09(1H, d, J=2.8Hz), 7.49(1H, s), 7.68(1H, s), 7.71(1H, brs), 7.84(1H, brs), 7.88-7.95(1H, m), 8.63(1H, d, J=5.6Hz), 8.66(1H, s)

Example 625

N-[2-Fluoro-4-([6-cyano-7-([3-(1-piperidino)propyl)oxy]-4-quinolyl)oxy]phenyl]-N'-cyclopropylurea

[1353] Cyclopropylamine (0.05 ml) was added to dimethylsulfoxide (0.5 ml), and then [2-fluoro-4-([6-cyano-7-([3-(1-piperidino)propyl)oxy]-4-quinolyl)oxy]phenyl]carbamic acid phenyl ester (66 mg) was dissolved therein and the solution was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution, and the precipitated crystals were filtered out to obtain the title compound (33 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 0.38-0.45(2H, m), 0.61-0.69(2H, m), 1.30-1.55(6H, m), 1.92-2.02(2H, m), 2.30-2.50(6H, m), 2.53-2.59(1H, m), 4.33(2H, t, J=6.0Hz), 6.59(1H, d, J=5.6Hz), 6.82-6.86(1H, m), 7.07-7.13(1H, m), 7.31-7.37(1H, m), 7.61(1H, s), 8.20-8.29(2H, m), 8.72-8.77(2H, m)

[1354] The starting material was synthesized in the following manner.

Production Example 625-1[2-Fluoro-4-([6-cyano-7-([3-(1-piperidino)propyl]oxy)-4-quinolyl]oxy)phenyl]carbamic acid phenyl ester

[1355] The title compound (33 mg) was obtained from 2-fluoro-4-([6-cyano-7-([3-(1-piperidino)propyl]oxy)-4-quinolyl]oxy)phenylamine (66 mg), by the method described in Production Example 141-1.

¹H-NMR(DMSO-d₆) δ(ppm) 1.40-1.75(6H, m), 1.90-2.15(4H, m), 2.50-2.67(2H, m), 3.13-3.27(2H, m), 4.30-4.38(2H, m), 6.54(1H, d, J=5.2Hz), 6.97-7.06(2H, m), 7.20-7.30(6H, m), 8.01(1H, s), 8.27(1H, brs), 8.66(1H, s), 8.72(1H, d, J=5.2Hz)

Example 626N-[4-(7-Benzoyloxy-6-cyanoquinolin-4-yloxy)-2-chlorophenyl]-N'-methylurea

[1356] [4-(7-Benzoyloxy-6-cyanoquinolin-4-yloxy)-2-chlorophenyl]carbamic acid phenyl ester (1.17 g) was added to dimethylformamide (6 ml), and then a methylamine-containing 2N tetrahydrofuran solution (0.4 ml) was added and the mixture was stirred for 10 minutes. Water (15 ml) was added, and the precipitated crystals were filtered out and washed with diethyl ether to obtain the title compound (968 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 2.66(3H, d, J=4.0Hz), 5.45(2H, s), 6.59(1H, d, J=5.2Hz), 6.86-6.92(1H, m), 7.24(1H, dd, J=8.8, 4.8Hz), 7.32-7.57(6H, m), 7.71(1H, s), 8.12(1H, s), 8.21-8.28(1H, m), 8.73(1H, d, J=5.2Hz), 8.76(1H, s)

[1357] The starting material was synthesized in the following manner.

Production Example 626-1[4-(7-Benzoyloxy-6-cyanoquinolin-4-yloxy)-2-chlorophenyl]-carbamic acid phenyl ester

[1358] The title compound (1.69 mg) was obtained from 4-(4-amino-3-chlorophenyl)-7-benzoyloxy-6-cyanoquinoline (1.68 g), by the method described in Production Example 141-1.

¹H-NMR(DMSO-d₆) δ(ppm) 5.28(2H, s), 6.44(1H, d, J=5.2Hz), 7.09(1H, dd, J=2.8, 9.2Hz), 7.13-7.50(13H, m), 8.24-8.30(1H, m), 8.60-8.65(2H, m)

Example 627N-[2-Chloro-4-(6-cyano-7-hydroxyquinolin-4-yloxy)-phenyl]-N'-methylurea

[1359] After adding N-[4-(7-benzoyloxy-6-cyanoquinolin-4-yloxy)-2-chlorophenyl]-N'-methylurea (968 mg) and thioanisole (3.7 ml) to trifluoroacetic acid (10 ml), the mixture was stirred overnight at 50°C. It was then concentrated under reduced pressure, ethyl acetate and aqueous sodium bicarbonate were added and the precipitated crystals were filtered out and washed with ethyl acetate to obtain the title compound (849 mg). ¹H-NMR(DMSO-d₆) δ(ppm) 2.66(3H, d, J=4.0Hz), 5.30(1H, d, d=5.2Hz), 6.37(1H, s), 6.83-6.90(1H, m), 7.12-7.16(1H, m), 7.33-7.35(1H, m), 8.00(1H, s), 8.08(1H, brs), 8.14-8.19(2H, m)

Example 628N-(4-{6-Cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-chlorophenyl)-N'-methylurea

[1360] N-[2-Chloro-4-(6-cyano-7-hydroxyquinolin-4-yloxy)phenyl]-N'-methylurea (600 mg) was added to dimethylformamide (4 ml), and then p-toluenesulfonic acid (2R)-glycidyl ester (484 mg) and potassium carbonate (450 mg) were added thereto and the mixture was heated at 50°C for 4 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was recrystallized with ethyl acetate to obtain the title compound (650 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 2.68(3H, d, J=4.8Hz), 2.80-2.96(2H, m), 3.45-3.51(1H, m), 4.18(1H, dd, J=11.6, 6.4Hz), 4.73(1H, dd, J=11.6, 2.0Hz), 6.61(1H, d, J=5.2Hz), 6.86-6.93(1H, m), 7.26(1H, dd, J=9.2, 2.8Hz), 7.51(1H, d, J=2.8Hz), 7.66(1H, s), 8.14(1H, s), 8.27(1H, d, J=9.2Hz), 8.75(1H, d, J=5.2Hz), 8.78(1H, s)

Example 629

N-(4-{6-Cyano-7-[(2R)-2-hydroxy-3-pyrrolidin-1-ylpropoxy]quinolin-4-yloxy}-2-chlorophenyl)-N'-methylurea

[1361] After adding tetrahydrofuran (1.0 ml) and pyrrolidine (0.10 ml) to N-(4-{6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-chlorophenyl)-N'-methylurea (110 mg), the mixture was heated at 60°C for 2 hours. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (65 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 1.55-1.73(4H, m), 2.45-2.58(5H, m), 2.68-2.77(4H, m), 4.00-4.06(1H, m), 4.22(1H, dd, J=10.4, 5.6Hz), 4.32(1H, dd, J=10.4, 3.2Hz), 5.00-5.05 (1H, m), 6.59(1H, d, J=5.2Hz), 6.86-6.93(1H, m), 7.26(1H, dd, J=9.2, 2.8Hz), 7.51(1H, d, J=2.8Hz), 7.63(1H, s), 8.14(1H, brs), 8.27(1H, dd, J=9.2, 2.8Hz), 8.72-8.76(2H, m).

Example 630

N-(4-{6-Cyano-7-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]quinolin-4-yloxy}-2-chlorophenyl)-N'-methylurea

[1362] After adding tetrahydrofuran (2.0 ml) and piperidine (0.20 ml) to N-(4-{6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-chlorophenyl)-N'-methylurea (110 mg), the mixture was heated at 60°C for 3 hours. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol system) to obtain the title compound (80 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 1.30-1.42(2H, m), 1.45-1.57(4H, m), 2.35-2.50(6H, m), 2.68(3H, d, J=4.4Hz), 4.00-4.08 (1H, m), 4.22(1H, dd, J=10.4, 6.0Hz), 4.32(1H, dd, J=10.4, 3.2Hz), 4.93-4.97(1H, m), 6.59(1H, d, J=5.6Hz), 6.86-6.93 (1H, m), 7.26(1H, dd, J=9.2, 2.8Hz), 7.51(1H, d, J=2.8Hz), 7.64(1H, s), 8.14(1H, brs), 8.27(1H, dd, J=9.2, 2.8Hz), 8.72-8.76(2H, m).

Example 631

N-(4-{6-Cyano-7-[3-diethylamino-(2R)-2-hydroxypropoxy]quinolin-4-yloxy}-2-chlorophenyl)-N'-methylurea

[1363] After adding tetrahydrofuran (3.0 ml) and diethylamine (1.50 ml) to N-(4-{6-cyano-7-[(2R)-oxiran-2-yl]methoxyquinolin-4-yloxy}-2-chlorophenyl)-N'-methylurea (100 mg), the mixture was heated at 60°C for 5 hours. The reaction solution was purified by NH silica gel column chromatography (ethyl acetate-methanol) to obtain the title compound (75 mg) as light yellow crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 0.98(6H, t, J=7.2Hz), 2.40-2.70(9H, m), 3.93-4.00(1H, m), 4.23(1H, dd, J=10.4, 5.6Hz), 4.32(1H, dd, J=10.4, 3.6Hz), 4.93(1H, brs), 6.59(1H, d, J=5.6Hz), 6.86-6.93(1H, m), 7.26(1H, dd, J=9.2, 2.8Hz), 7.51 (1H, d, J=2.8Hz), 7.63(1H, s), 8.14(1H, brs), 8.27(1H, dd, J=9.2, 2.8Hz), 8.72-8.76(2H, m).

Example 632

Methyl 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylate

[1364] Phenyl N-(2-chloro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate (1.92 g, 4.00 mmol) and 40% methylamine (methanol solution) (2 ml) were stirred in dimethylformamide (8 ml) at room temperature for 30 minutes. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, and the drying agent was filtered out and the filtrate distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (1.41 g, 3.39 mmol, 85%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.68 (3H, d, J = 4.4 Hz), 3.87 (3H, s), 3.99 (3H, s), 6.54 (1H, d, J=5.2Hz), 6.89 (1H, q, J = 4.4 Hz), 7.25 (1H, dd, J = 2.8, 9.0 Hz), 7.50 (1H, d, J = 2.8 Hz), 7.54 (1H, s), 8.13 (1H, s), 8.26 (1H, d, J = 9.0 Hz), 8.58 (1H, s), 8.69 (1H, d, J = 5.2 Hz).

Example 633

4-(3-Chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid

[1365] After adding methanol (14 ml) and a 2N sodium hydroxide aqueous solution (7 ml) to methyl 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylate (1.31 g, 3.15 mmol), the mixture was

stirred at 60°C for 30 minutes. The reaction solution was cooled to room temperature, 2N hydrochloric acid was added for neutralization, the methanol was distilled off, and the precipitated white crystals were filtered out, thoroughly washed with water and dried at 60°C to obtain the title compound (1.26 g, 3.15 mmol, 100%).

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.68 (3H, d, J = 4.4 Hz), 3.98 (3H, s), 6.54 (1H, d, J = 5.0 Hz), 6.89 (1H, q, J = 4.4 Hz), 7.25 (1H, dd, J = 2.8, 9.0 Hz), 7.48-7.53 (2H, m), 8.13 (1H, s), 8.25 (1H, d, J = 9.0 Hz), 8.54 (1H, s), 8.69 (1H, d, J = 5.0 Hz), 13.12 (1H, brs).

Example 634

N6-Methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1366] After dissolving 4-(3-chloro-4-(((methylamino) carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) in dimethylformamide (3 ml), there were added a 40% methylamine-methanol solution (0.100 ml), triethylamine (0.250 ml) and 1H-1,2,3-benzotriazol-1-yloxy (tri(dimethylamino))phosphonium hexafluorophosphate (221 mg, 0.500 mmol) in that order at room temperature, and the mixture was stirred for 15 hours. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (85.0 mg, 0.204 mmol, 82%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.68 (3H, d, J = 4.2 Hz), 2.84 (3H, d, J = 4.2 Hz), 4.02 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 6.88 (1H, q, J = 4.2 Hz), 7.22 (1H, dd, J = 2.8, 9.2 Hz), 7.45 (1H, d, J = 2.8 Hz), 7.52 (1H, s), 8.12 (1H, s), 8.24 (1H, d, J = 9.2 Hz), 8.36 (1H, q, J = 4.2 Hz), 8.59 (1H, s), 8.67 (1H, d, J = 5.2 Hz).

Example 635

N6-Ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1367] The title compound (93.0 mg, 0.217 mmol, 87%) was obtained as white crystals from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and 2.0M ethylamine (tetrahydrofuran solution), by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.15 (3H, t, J = 7.2 Hz), 2.68 (3H, d, J = 4.4 Hz), 3.28-3.38 (2H, m), 4.02 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 6.87 (1H, q, J = 4.4 Hz), 7.21 (1H, dd, J = 2.8, 9.2 Hz), 7.47 (1H, d, J = 2.8 Hz), 7.51 (1H, s), 8.11 (1H, s), 8.25 (1H, d, J = 9.2 Hz), 8.38 (1H, m), 8.54 (1H, s), 8.66 (1H, d, J = 5.2 Hz).

Example 636

N6-Cyclopropyl-4-(3-chloro-4-(((methylamino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxamide

[1368] The title compound (66.0 mg, 0.150 mmol, 60%) was obtained as white crystals from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and cyclopropylamine, by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.59 (2H, m), 0.69 (2H, m), 2.68 (3H, d, J = 4.8 Hz), 2.87 (1H, m), 3.99 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 6.88 (1H, q, J = 4.8 Hz), 7.22 (1H, dd, J = 2.8, 9.2 Hz), 7.47 (1H, d, J = 2.8 Hz), 7.49 (1H, s), 8.12 (1H, s), 8.25 (1H, d, J = 9.2 Hz), 8.34 (1H, d, J = 4.0 Hz), 8.41 (1H, s), 8.66 (1H, d, J = 5.2 Hz).

Example 637

N6-Methoxy-4-(3-chloro-4-(((methylamino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxamide

[1369] The title compound (51.0 mg, 0.118 mmol, 47%) was obtained as white crystals from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and methoxylamine hydrochloride, by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.56 (3H, d, J = 4.4 Hz), 3.74 (3H, s), 3.99 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 6.88 (1H, q, J = 4.4 Hz), 7.24 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.50 (1H, s), 8.12 (1H, s), 8.25 (1H, d, J = 9.2 Hz), 8.43 (1H, s), 8.67 (1H, d, J = 5.2 Hz), 11.46 (1H, s).

Example 638N6-(2-Methoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1370] The title compound (71.0 mg, 0.154 mmol, 62%) was obtained as white crystals from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and 2-methoxyethylamine, by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.68 (3H, d, J = 4.4 Hz), 3.30 (3H, s), 3.46-3.52 (4H, m), 4.03 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 6.88 (1H, q, J = 4.4 Hz), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.53 (1H, s), 8.12 (1H, s), 8.25 (1H, d, J = 9.2 Hz), 8.46 (1H, m), 8.61 (1H, s), 8.67 (1H, d, J = 5.2 Hz).

Example 639N6-(2-Fluoroethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1371] The title compound (86.0 mg, 0.192 mmol, 77%) was obtained as white crystals from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and 2-fluoroethylamine hydrochloride, by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 2.68 (3H, d, J = 4.4 Hz), 3.59 (1H, m), 3.67 (1H, m), 4.03 (3H, s), 4.50 (1H, m), 4.62 (1H, m), 6.54 (1H, d, J = 5.2 Hz), 6.88 (1H, q, J = 4.4 Hz), 7.24 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.53 (1H, s), 8.12 (1H, s), 8.24 (1H, d, J = 9.2 Hz), 8.58-8.62 (2H, m), 8.67 (1H, d, J = 5.2 Hz).

Example 640N6-((2R)Tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1372] The title compound (81.0 mg, 0.167 mmol, 67%) was obtained as a white powder from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and R-tetrahydrofurylamine, by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.62 (1H, m), 1.80-2.00 (3H, m), 2.68 (3H, d, J = 4.4 Hz), 3.40 (2H, m), 3.66 (1H, dd, J = 3.6, 14.0 Hz), 3.81 (1H, dd, J = 4.0, 14.0 Hz), 3.99 (1H, m), 4.02 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 6.88 (1H, q, J = 4.4 Hz), 7.23 (1H, dd, J = 2.8, 8.8 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.54 (1H, s), 8.12 (1H, s), 8.24 (1H, d, J = 8.8 Hz), 8.43 (1H, m), 8.61 (1H, s), 8.67 (1H, d, J = 5.2 Hz).

Example 641N6-((2S)Tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1373] The title compound (85.0 mg, 0.175 mmol, 70%) was obtained as a white powder from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and S-tetrahydrofurylamine, by the same procedure as in Example 634.

Example 642N6-(2-Ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1374] The title compound (94.0 mg, 0.199 mmol, 80%) was obtained as a white powder from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and 2-ethoxyethylamine, by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.15 (3H, t, J = 6.8 Hz), 2.68 (3H, d, J = 4.4 Hz), 3.45-3.56 (6H, m), 4.04 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 6.89 (1H, q, J = 4.4 Hz), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.54 (1H, s), 8.13 (1H, s), 8.25 (1H, dd, J = 2.8, 9.2 Hz), 8.46 (1H, m), 8.64 (1H, s), 8.67 (1H, d, J = 5.2 Hz).

Example 643N6-Isobutoxy-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1375] The title compound (72.0 mg, 0.152 mmol, 61%) was obtained as a white powder from 4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (100 mg, 0.250 mmol) and isobutoxylamine hydrochloride, by the same procedure as in Example 634.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.95 (6H, d, J = 6.8 Hz), 1.97 (1H, m), 2.68 (3H, d, J = 4.4 Hz), 3.71 (2H, d, J = 6.8 Hz), 3.99 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 6.89 (1H, q, J = 4.4 Hz), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.50 (1H, s), 8.13 (1H, s), 8.25 (1H, dd, J = 2.8, 9.2 Hz), 8.36 (1H, s), 8.67 (1H, d, J = 5.2 Hz), 11.35 (1H, br s).

Example 6444-(3-Chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide

[1376] After adding (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate (308 mg, 1.35 mmol), potassium carbonate (149 mg, 1.08 mmol) and dimethylformamide (9 ml) to 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (372.0 mg, 0.90 mmol), the mixture was stirred at 60°C for 6 hours. Next, diethylamine (2 ml) was added and the mixture was further stirred overnight at 50°C. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 95:5), the fraction containing the target substance was concentrated, and crystals were precipitated from diethyl ether, filtered out and blow-dried to obtain the title compound (177.5 mg, 0.327 mmol, 36.3%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 0.94 (6H, t, J=7.2Hz), 2.44-2.60 (7H, m), 3.98 (1H, m), 4.21 (1H, dd, J=5.6, 10.0Hz), 4.31 (1H, dd, J=3.2, 10.0Hz), 5.09 (1H, d, J=4.4Hz), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.24 (1H, dd, J=2.8, 8.8Hz), 7.49 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.84 (1H, s), 7.97 (1H, s), 8.00 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.65 (1H, d, J=5.2Hz), 8.81 (1H, s).

Example 645N6-Methyl-7-(benzyloxy)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide

[1377] The title compound (466 mg, 0.950 mmol, 81.6%) was obtained as light brown crystals from phenyl N-(4-(7-(benzyloxy)-6-(methylamino)carbonyl-4-quinolyl)oxy-2-chlorophenyl) carbamate (645 mg, 1.16 mmol) and 2M methylamine-tetrahydrofuran solution, by the same procedure as in Example 11.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.66 (3H, d, J=4.4Hz), 2.81 (3H, d, J=4.4Hz), 5.42 (2H, s), 6.51 (1H, d, J=5.2Hz), 6.86 (1H, q, J=4.4Hz), 7.21 (1H, dd, J=2.8, 9.2Hz), 7.30-7.45 (4H, m), 7.52-7.55 (3H, m), 8.10 (1H, s), 8.22 (1H, d, J=9.2Hz), 8.38 (1H, q, J=4.4Hz), 8.49 (1H, s), 8.62 (1H, d, J=5.2Hz).

[1378] The starting materials were synthesized in the following manner.

Production Example 645-1Phenyl 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-hydroxy benzoate

[1379] After adding Meldrum acid (29.2 g, 202 mmol), triethyl orthoformate (200 ml) and isopropanol (200 ml) to phenyl 4-aminosalicylate (42.2 g, 184 mmol), the mixture was heated and stirred at 100°C for 1 hour. After allowing the reaction solution to cool to room temperature, it was further stirred overnight. The precipitated crystals were filtered out, washed with isopropanol and diethyl ether and blow-dried to obtain the title compound (69.5 g, 181 mmol, 99%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.69 (6H, s), 7.21-7.28 (2H, m), 7.29-7.36 (3H, m), 7.44-7.52 (2H, m), 8.04 (1H, d, J = 8.4 Hz), 8.64 (1H, s), 10.52 (1H, br s), 11.24 (1H, br s).

Production Example 645-2Phenyl 7-(benzyloxy)-4-oxo-1,4-dihydro-6-quinolinecarboxylate

[1380] Phenyl 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-hydroxybenzoate (11.5 g, 0.030 mmol), benzyl bromide (5.64 g, 0.033 mmol) and potassium carbonate (4.56 g, 0.033 mmol) were stirred in dimethylformamide (45 ml) at 80°C for 3 hours. The reaction solution was distributed between a diethyl ether-tetrahydrofuran mixed solvent and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, and the drying agent was filtered out and the filtrate distilled off under reduced pressure. The obtained crude product was suspended in ethanol, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain white crystals. The crystals were then heated and stirred for 1 hour in Dowtherm A (50 ml) at 200°C. After allowing the reaction solution to cool to room temperature, diethyl ether (25 ml) was added and the mixture was further stirred overnight. The precipitated crystals were filtered out, washed with diethyl ether and blow-dried to obtain the title compound (1.20 g, 3.23 mmol, 11%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 5.33 (2H, s), 6.03 (1H, d, J = 7.4 Hz), 7.19 (1H, s), 7.21-7.27 (2H, m), 7.28-7.36 (2H, m), 7.36-7.43 (2H, m), 7.43-7.50 (2H, m), 7.52-7.58 (2H, m), 7.90 (1H, d, J = 7.4 Hz), 8.71 (1H, s), 11.79 (1H, br s).

Production Example 645-3N6-Methyl-7-(benzyloxy)-4-chloro-6-quinolinecarboxamide

[1381] After adding thionyl chloride (12 ml) and a catalytic amount of dimethylformamide to phenyl 7-(benzyloxy)-4-oxo-1,4-dihydro-6-quinolinecarboxylate (1.20 g, 3.23 mmol), the mixture was heated to reflux for 2 hours while stirring. The reaction solution was concentrated under reduced pressure and azeotropically distilled twice with toluene, the residue was suspended in dimethylformamide (20 ml), a 40% methylamine-methanol solution (5 ml) was gradually added while cooling in an ice water bath, and the mixture was stirred for 1 hour. The reaction solution was distributed between ethyl acetate-tetrahydrofuran (1:1) and water, and the organic layer was washed with saturated aqueous ammonium chloride solution, water and saturated brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, diethyl ether and then hexane were added for crystallization, and the crystals were filtered out and blow-dried to obtain the title compound (947 mg, 2.90 mmol, 89.7%) as light yellow crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.97 (3H, d, J=4.8Hz), 5.35 (2H, s), 7.40-7.52 (6H, m), 7.64 (1H, s), 7.91 (1H, m), 8.75 (1H, q, J=4.8Hz), 9.16 (1H, s).

Production Example 645-4N6-Methyl-4-(4-amino-3-chlorophenoxy)-7-(benzyloxy)-6-quinolinecarboxamide

[1382] After dissolving 4-amino-3-chlorophenol (624 mg, 4.35 mmol) in dimethylsulfoxide (15 ml), sodium hydride (174 mg, 4.35 mmol) was gradually added at room temperature and the mixture was stirred for 30 minutes. N6-Methyl-7-(benzyloxy)-4-chloro-6-quinolinecarboxamide (947 mg, 2.90 mmol) was added, and the mixture was heated at 100°C while stirring for 2 hours. After cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out and blow-dried to obtain the title compound (1.098 g, 2.53 mmol, 87.3%) as light brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.96 (3H, d, J=4.8Hz), 4.10 (2H, m), 5.35 (2H, s), 6.46 (1H, d, J=5.2Hz), 6.84 (1H, d, J=8.8Hz), 6.93 (1H, dd, J=2.8, 8.8Hz), 7.14 (1H, d, J=2.8Hz), 7.39-7.54 (5H, m), 7.58 (1H, s), 7.95 (1H, br), 8.62 (1H, d, J=5.2Hz), 9.28 (1H, s).

Production Example 645-5Phenyl N-(4-(7-(benzyloxy)-6-(methylamino)carbonyl-4-quinolyl)oxy-2-chlorophenyl)carbamate

[1383] The title compound (1.291 g, 2.33 mmol, 92.1%) was obtained as light brown crystals from N6-methyl-4-(4-amino-3-chlorophenoxy)-7-(benzyloxy)-6-quinolinecarboxamide (1.098 g, 2.53 mmol), in the same manner as Production Example 17.

¹H-NMR Spectrum (CDCl₃)δ(ppm): 2.96 (3H, d, J=4.8Hz), 5.35 (2H, s), 6.50 (1H, d, J=5.2Hz), 7.15 (1H, dd, J=2.8, 8.8Hz), 7.19-7.30 (6H, m), 7.40-7.52 (6H, m), 7.61 (1H, s), 7.95 (1H, m), 8.30 (1H, q, J=4.8Hz), 8.67 (1H, d, J=5.2Hz),

9.27 (1H, s).

Example 646

5 N6-Methyl-7-(benzyloxy)-4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide

[1384] The title compound (579 mg, 1.15 mmol, 98.4%) was obtained as light brown crystals from phenyl N-(4-(7-(benzyloxy)-6-(methylamino)carbonyl-4-quinolyl)oxy-2-chlorophenyl)carbamate (645 mg, 1.16 mmol) and a 2 M ethylamine-tetrahydrofuran solution, by the same procedure as in Example 11.

10 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.06 (3H, t, J=7.2Hz), 2.81 (3H, d, J=4.8Hz), 3.11 (2H, m), 5.42 (2H, s), 6.51 (1H, d, J=5.2Hz), 6.99 (1H, m), 7.19 (1H, dd, J=2.8, 9.2Hz), 7.30-7.45 (4H, m), 7.52-7.55 (3H, m), 8.06 (1H, s), 8.24 (1H, d, J=9.2Hz), 8.38 (1H, q, J=4.8Hz), 8.49 (1H, s), 8.62 (1H, d, J=5.2Hz).

Example 647

15 N6-Methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

[1385] The title compound (365.7 mg, 0.91 mmol, 96.1%) was obtained as yellow crystals from N6-methyl-7-(benzyloxy)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide (466.3 mg, 0.95 mmol), by the same procedure as in Example 83.

20 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 2.66 (3H, brs), 2.85 (3H, brs), 6.37 (1H, m), 6.86 (1H, m), 7.10-7.30 (2H, m), 7.45 (1H, m), 8.09 (1H, brs), 8.22 (1H, m), 8.56 (1H, m), 8.84 (1H, brs).

Example 648

25 N6-Methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

[1386] The title compound (431.4 mg, 1.04 mmol, 90.8%) was obtained as light yellow crystals from N6-methyl-7-(benzyloxy)-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide (578.5 mg, 1.15 mmol), by the same procedure as in Example 83.

30 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.06 (3H, t, J=7.2Hz), 2.85 (3H, brs), 3.12 (2H, m), 6.36 (1H, m), 6.98 (1H, m), 7.20-7.24 (2H, m), 7.45 (1H, d, J=2.8Hz), 8.05 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.55 (1H, m), 8.84 (1H, s).

Example 649

35 tert-Butyl 4-(((4-(3-chloro-4-((methylamino)carbonyl)amino)phenoxy)-6-(methylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[1387] The title compound (98.4 mg, 0.165 mmol, 55.0%) was obtained as light brown crystals from N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (120 mg, 0.299 mmol) and tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate, by the same procedure as in Example 7.

40 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.17-1.33 (3H, m), 1.39 (9H, s), 1.75 (2H, m), 2.06 (1H, m), 2.66 (3H, d, J=4.4Hz), 2.77 (1H, m), 2.81 (3H, d, J=4.8Hz), 3.97 (2H, m), 4.10 (2H, d, J=6.0Hz), 6.51 (1H, d, J=5.2Hz), 6.85 (1H, q, J=4.4Hz), 7.20 (1H, dd, J=2.8, 8.8Hz), 7.44 (1H, d, J=2.8Hz), 7.48 (1H, s), 8.10 (1H, s), 8.18 (1H, q, J=4.8Hz), 8.22 (1H, d, J=8.8Hz), 8.43 (1H, s), 8.63 (1H, d, J=5.2Hz).

Example 650

50 tert-Butyl 4-(((4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-6-(methylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[1388] The title compound (119.5 mg, 0.195 mmol, 56.6%) was obtained as light brown crystals from N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (143 mg, 0.345 mmol) and tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate, by the same procedure as in Example 7.

55 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.06 (3H, t, J=7.2Hz), 1.18-1.26 (3H, m), 1.39 (9H, s), 1.76 (2H, m), 2.06 (1H, m), 2.77 (1H, m), 2.81 (3H, d, J=4.8Hz), 3.12 (2H, m), 3.98 (2H, m), 4.10 (2H, d, J=6.0Hz), 6.51 (1H, d, J=5.2Hz), 6.97 (1H, m), 7.19 (1H, dd, J=2.8, 8.8Hz), 7.44 (1H, d, J=2.8Hz), 7.48 (1H, s), 8.04 (1H, s), 8.18 (1H, q, J=4.8Hz), 8.24 (1H, d, J=8.8Hz), 8.43 (1H, s), 8.63 (1H, d, J=5.2Hz).

Example 651

N6-Methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide

[1389] After adding trifluoroacetic acid (1 ml) to tert-butyl 4-(((4-(3-chloro-4-((methylamino)carbonyl)amino)phenoxy)-6-(methylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (98.4 mg, 0.165 mmol) at room temperature, the mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and then the residue was dissolved in methanol, and triethylamine was added dropwise for neutralization. After distilling off the solvent, the residue was dissolved in tetrahydrofuran (2 ml)-methanol (2 ml), and then 37% aqueous formaldehyde (0.3 ml), acetic acid (0.05 ml) and sodium cyanoborohydride (21 mg, 0.33 mmol) were added in that order at room temperature and the mixture was stirred for 30 minutes. The reaction solution was distributed between ethyl acetate-tetrahydrofuran (1:1) and saturated aqueous sodium bicarbonate, and the organic layer was washed with saturated aqueous sodium bicarbonate and saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent, the residue was subjected to silica gel column chromatography, and the target fraction was concentrated under reduced pressure and crystallized with ethyl acetate-hexane (1:5), after which the crystals were filtered out and blow-dried to obtain the title compound (64.2 mg, 0.125 mmol, 76.2%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.34 (2H, m), 1.72-1.89 (5H, m), 2.15 (3H, s), 2.66 (3H, d, J=4.4Hz), 2.77-2.83 (5H, m), 4.08 (2H, d, J=6.4Hz), 6.51 (1H, d, J=5.2Hz), 6.85 (1H, q, J=4.8Hz), 7.20 (1H, dd, J=2.8, 8.8Hz), 7.44 (1H, d, J=2.8Hz), 7.48 (1H, s), 8.10 (1H, s), 8.20 (1H, q, J=4.4Hz), 8.22 (1H, d, J=8.8Hz), 8.45 (1H, s), 8.63 (1H, d, J=5.2Hz).

Example 652

N6-Methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide

[1390] After adding trifluoroacetic acid (1 ml) to tert-butyl 4-(((4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-6-(methylaminocarbonyl)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (119.5 mg, 0.195 mmol) at room temperature, the mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and then the residue was dissolved in methanol and triethylamine was added dropwise for neutralization. After distilling off the solvent, the residue was dissolved in tetrahydrofuran (2 ml)-methanol (2 ml), and then 37% aqueous formaldehyde (0.3 ml), acetic acid (0.05 ml) and sodium cyanoborohydride (25 mg, 0.39 mmol) were added in that order at room temperature and the mixture was stirred for 30 minutes. The reaction solution was distributed between ethyl acetate-tetrahydrofuran (1:1) and saturated aqueous sodium bicarbonate, and the organic layer was washed with saturated aqueous sodium bicarbonate and saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent, the residue was subjected to silica gel column chromatography, and the target fraction was concentrated under reduced pressure and crystallized with ethyl acetate-hexane (1:5), after which the crystals were filtered out and blow-dried to obtain the title compound (78.3 mg, 0.149 mmol, 76.2%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.06 (3H, t, J=7.2Hz), 1.34 (2H, m), 1.72-1.89 (5H, m), 2.15 (3H, s), 2.76-2.82 (5H, m), 3.12 (2H, m), 4.08 (2H, d, J=6.4Hz), 6.51 (1H, d, J=5.2Hz), 6.97 (1H, m), 7.19 (1H, dd, J=2.8, 8.8Hz), 7.44 (1H, d, J=2.8Hz), 7.48 (1H, s), 8.04 (1H, s), 8.19 (1H, q, J=4.4Hz), 8.24 (1H, d, J=8.8Hz), 8.45 (1H, s), 8.63 (1H, d, J=5.2Hz).

Example 653

N6-Methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide

[1391] After adding (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate (103 mg, 0.499 mmol), potassium carbonate (50 mg, 0.359 mmol) and dimethylformamide (3 ml) to N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (120 mg, 0.299 mmol), the mixture was stirred at 60°C for 7 hours. Next, diethylamine (1.5 ml) was added and the mixture was further stirred overnight at 60°C. The reaction solution was distributed between ethyl acetate-tetrahydrofuran (1:1) and water, and the organic layer was washed with water and saturated brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 95:5), the fraction containing the target substance was concentrated, and crystals were precipitated from ethyl acetate-hexane (1:1), filtered out and blow-dried to obtain the title compound (71.8 mg, 0.135 mmol, 45.2%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.95 (6H, t, J=7.2Hz), 2.40-2.60 (6H, m), 2.66 (3H, d, J=4.8Hz), 2.85 (3H, d,

J=4.8Hz), 4.00 (1H, m), 4.18 (1H, dd, J=6.0, 10.0Hz), 4.32 (1H, dd, J=3.2, 10.0Hz), 5.12 (1H, d, J=4.0Hz), 6.52 (1H, d, J=5.2Hz), 6.86 (1H, q, J=4.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.53 (1H, s), 8.10 (1H, s), 8.23 (1H, d, J=9.2Hz), 8.50 (1H, q, J=4.8Hz), 8.65 (1H, d, J=5.2Hz), 8.71 (1H, s).

5 Example 654

N6-Methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide

10 **[1392]** The title compound (92.4 mg, 0.170 mmol, 49.3%) was obtained as white crystals from N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (143 mg, 0.345 mmol), by the same procedure as in Example 653.

15 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.95 (6H, t, J=7.2Hz), 1.06 (3H, t, J=7.2Hz), 2.40-2.60 (6H, m), 2.85 (3H, d, J=4.8Hz), 3.12 (2H, m), 4.00 (1H, m), 4.18 (1H, dd, J=6.0, 9.6Hz), 4.32 (1H, dd, J=3.2, 9.6Hz), 5.12 (1H, d, J=4.4Hz), 6.51 (1H, d, J=5.2Hz), 6.98 (1H, m), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.53 (1H, s), 8.05 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.50 (1H, q, J=4.8Hz), 8.65 (1H, d, J=5.2Hz), 8.72 (1H, s).

Example 655

20 N6-Methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1393] After adding (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate (103 mg, 0.499 mmol), potassium carbonate (50 mg, 0.359 mmol) and dimethylformamide (3 ml) to N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (120 mg, 0.299 mmol), the mixture was stirred at 60°C for 7 hours. After allowing the reaction solution to cool to room temperature, pyrrolidine (0.5 ml) was added and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate-tetrahydrofuran (1:1) and water, and the organic layer was washed with water and saturated brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 95:5), the fraction containing the target substance was concentrated, and crystals were precipitated from ethyl acetate-hexane (1:1), filtered out and blow-dried to obtain the title compound (79.3 mg, 0.150 mmol, 50.2%) as white crystals. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.67 (4H, m), 2.40-2.60 (5H, m), 2.64-2.69 (4H, m), 2.85 (3H, d, J=4.8Hz), 4.06 (1H, m), 4.17 (1H, m), 4.33 (1H, dd, J=3.6, 10.4Hz), 5.23 (1H, d, J=4.8Hz), 6.52 (1H, d, J=5.2Hz), 6.86 (1H, q, J=4.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.54 (1H, s), 8.10 (1H, s), 3.23 (1H, d, J=9.2Hz), 8.50 (1H, q, J=4.8Hz), 8.65 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 656

40 N6-Methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1394] The title compound (94.8 mg, 0.175 mmol, 50.7%) was obtained as white crystals from N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (143 mg, 0.345 mmol), by the same procedure as in Example 655.

45 ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.06 (3H, t, J=7.2Hz), 1.67 (4H, m), 2.40-2.60 (5H, m), 2.66 (1H, dd, J=6.4, 12.4Hz), 2.85 (3H, d, J=4.8Hz), 3.12 (2H, m), 4.06 (1H, m), 4.16 (1H, dd, J=6.0, 10.0Hz), 4.33 (1H, dd, J=3.2, 10.0Hz), 5.23 (1H, d, J=5.2Hz), 6.51 (1H, d, J=5.2Hz), 6.98 (1H, m), 7.21 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.53 (1H, s), 8.05 (1H, s), 8.25 (1H, d, J=8.8Hz), 8.50 (1H, q, J=4.8Hz), 8.65 (1H, d, J=5.2Hz), 8.71 (1H, s).

50 Example 657

N-Cyclopropyl-N'-(4-(6-(4-(2-diethylaminoethoxy)-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenyl)urea

55 **[1395]** After dissolving 65 mg of N-cyclopropyl-N'-(4-(6-(4-(2-diethylaminoethoxy)-phenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenyl)urea in 2 ml of tetrahydrofuran, there was added dropwise 0.5 ml of tetrabutylammonium fluoride (1M tetrahydrofuran solution) and the mixture was refluxed for 3 hours. After returning it to room temperature, water was added, the mixture was stirred, and the precipitated crystals were filtered out, washed with water and ether-hexane (1:1) and dried under reduced pressure to obtain 25 mg of the title

compound.

MS Spectrum(ESI):519(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.38-0.43(2H,m), 0.62-0.68(2H,m), 0.99(6H,t, J=7.3Hz) 2.53-2.61(5H,m), 2.80(2H,t, J=6.9Hz), 4.08(2H,t, J=6.9Hz), 6.79-6.84(1H,m), 6.91(1H, s), 7.01-7.07(3H,m), 7.26(1H, dd, J=2.9, 11.2Hz), 7.88(2H, d, J=9.0Hz), 8.05-8.16(1H,m), 8.18(1H, brs), 8.28(1H,s), 12.68(1H, brs)

[1396] The intermediates were synthesized in the following manner.

Production Example 657-1

6-(4-Benzyloxyphenyl)-4-(3-fluoro-4-nitrophenoxy)-7-(trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine

[1397] After adding 248 mg of 3-fluoro-4-nitrophenol, 0.208 ml of 2,6-lutidine and 1 ml of N-methylpyrrolidine to 490 mg of 6-(4-benzyloxyphenyl)-4-chloro-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine, the mixture was stirred at 130°C for 24 hours. After returning it to room temperature, water was added, liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran mixed solvent, and the organic layer was washed with saturated brine, dried over sodium sulfate, concentrated and subjected to NH silica gel column chromatography (ethyl acetate) to obtain 472 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) -0.08(9H,s), 0.87(2H, t, J=7.4Hz), 3.63(2H, t, J=7.4Hz), 5.20(2H, s), 5.61(2H, s), 6.83(1H, s), 7.00-7.80(11H,m), 8.30(1H, t, J=8.6Hz), 8.40(1H,s).

Production Example 657-2

4-(6-(4-Benzyloxyphenyl)-7-(trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenylamine

[1398] After adding 400 mg of iron powder, 1 g of ammonium chloride, 20 ml of ethanol, 10 ml of tetrahydrofuran and 10 ml of water to 470 mg of 6-(4-benzyloxyphenyl)-4-(3-fluoro-4-nitrophenoxy)-7-(trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine, the mixture was stirred at 85°C for 3 hours. After returning it to room temperature, it was filtered with celite, and ethyl acetate and water were added to the filtrate for liquid separation and extraction. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with plug cotton, concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 263 mg of the title compound.

MS Spectrum(ESI):557(M+1).

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H,s), 0.85(2H, t, J=8.9Hz), 3.61(2H, t, J=8.9Hz), 5.09-5.13(2H,m), 5.19(2H, s), 5.59(2H, s), 6.60(1H, s), 6.79-6.73(2H,m), 7.03(1H, d, J=11.5Hz), 7.16(2H, d, J=9.6Hz), 7.32-7.50(5H,m), 7.70(2H, d, J=9.6Hz), 8.40(1H,s).

Production Example 657-3

N-(4-(6-(4-Benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenyl)-N'-cyclopropylurea

[1399] After dissolving 261 mg of 4-[6-(4-benzyloxyphenyl)-7-(trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-fluorophenylamine in 3 ml of dimethylformamide, 0.053 ml of pyridine and 0.082 ml of phenyl chloro-carbonate were added, the mixture was stirred at room temperature for 2 hours, 0.081 ml of cyclopropylamine was added and the mixture was further stirred overnight. Water was added, liquid separation and extraction were performed with ethyl acetate, and the organic layer was washed with saturated brine, dried over sodium sulfate, concentrated and subjected to silica gel column chromatography (hexane-ethyl acetate) to obtain 265 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) -0.09(9H,s), 0.38-0.43(2H,m), 0.60-0.70(2H,m), 0.87(2H, t, J=7.5Hz), 2.50-2.60(1H, m), 3.61(2H, t, J=7.5Hz), 5.20(2H, s), 5.60(2H, s), 6.61(1H, s), 6.68-6.72(1H,m), 7.04(1H, d, J=8.3Hz), 7.18(2H, d, J=9.0Hz), 7.28(1H, dd, J=3.4, 11.7Hz), 7.32-7.53(5H,m), 7.72(2H, d, J=9.0Hz), 8.10(1H, t, J=8.2Hz), 8.18(1H, brs), 8.40(1H,s).

Production Example 657-4

N-Cyclopropyl-N'-(2-fluoro-4-(6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)urea

[1400] After dissolving 263 mg of 1-(4-(6-(4-benzyloxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]

pyrimidin-4-yloxy)-2-fluorophenyl)-3-cyclopropylurea in 7 ml of ethanol and 3 ml of tetrahydrofuran, 30 mg of platinum oxide was added and the mixture was stirred overnight at room temperature and ordinary pressure under a hydrogen atmosphere, after which it was filtered with celite and concentrated under reduced pressure. The residue was subjected

to silica gel column chromatography (hexane-ethyl acetate) to obtain 160 mg of the title compound.
¹H-NMR Spectrum: (DMSO-d₆) -0.08(9H,s), 0.39-0.43(2H,m), 0.61-0.68(2H,m), 0.86(2H, t, J=7.5Hz), 2.50-2.60(1H, m), 3.61(2H, t, J=7.5Hz), 5.58(2H, s), 6.63(1H, s), 6.78-6.82(1H,m), 6.90(2H, d, J=8.6Hz), 7.01-7.07(1H, m,), 7.28(1H, dd, J=3.3, 11.9Hz), 7.60(2H, d, J=8.6Hz), 8.06-8.13(1H, m,), 8.19(1H,brs),8.40(1H,s).

Production Example 657-5

N-Cyclopropyl-N'-(4-(6-(4-(2-diethylaminoethoxy)-phenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenyl)urea

[1401] After dissolving 100 mg of N-cyclopropyl-N'-(2-fluoro-4-(6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-phenyl)urea in 1 ml of dimethylformamide, 110 mg of 2-chloroethyldiethylamine hydrochloride and 126 mg of potassium carbonate were added and the mixture was stirred at 80°C for 15 hours. The mixture was then returned to room temperature, water was added, and liquid separation and extraction were performed with an ethyl acetate-tetrahydrofuran mixed solvent. The organic layer was washed with saturated brine, dried over sodium sulfate, concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 67 mg of the title compound.

MS Spectrum(ESI):649(M+1).

Example 658

N-Cyclopropyl-N'-(2-fluoro-4-(6-(4-((2R)-2-hydroxy-3-pyrrolidin-1-ylpropoxy)-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-phenyl)urea

[1402] The title compound (30 mg) was obtained from 63 mg of N-cyclopropyl-N'-(2-fluoro-4-(6-(4-((2R)-2-hydroxy-3-pyrrolidinopropoxy)phenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-phenyl)urea, by the same procedure as in Example 657.

MS Spectrum(ESI):597(M+1),

¹H-NMR Spectrum: (DMSO-d₆) 0.38-0.43(2H,m), 0.60-0.69(2H,m), 1.65-1.72(4H,m), 2.45-2.70(7H,m, covered by DMSO peak), 3.90-4.10(3H,m), 4.96(1H, brs) 6.91(1H, s), 6.76-6.80(1H,m), 7.01-7.07(3H,m), 7.26(1H, dd, J=10.9, 2.4Hz), 7.88(2H, d, J=9.1Hz), 8.06-8.14(1H, m,), 8.15(1H, brs,), 8.28(1H, s,) 12.60(1H, brs)

[1403] The intermediate was synthesized in the following manner.

Production Example 658-1

N-Cyclopropyl-N'-(2-fluoro-4-(6-(4-((2R)-2-hydroxy-3-pyrrolidinopropoxy)phenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)urea

[1404] After dissolving N-cyclopropyl-N'-(2-fluoro-4-(6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)urea (89 mg) in dimethylformamide (2 ml), there were added p-toluenesulfonic acid (2R)-(-)-glycidyl ester (111 mg, 3 equivalents) and potassium carbonate (112 mg, 5 equivalents), and the mixture was stirred overnight at 65°C. It was then returned to room temperature and stationed, and the supernatant was decanted (1.8 ml portion of dimethylformamide). After adding 0.1 ml of pyrrolidine thereto, the mixture was stirred at 65°C for 3 hours. Water was then added and liquid separation and extraction were performed with ethyl acetate-tetrahydrofuran. The organic layer was concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 63 mg of the title compound.

MS Spectrum(ESI) :677(M+1).

Example 659

N-Cyclopropyl-N'-(4-(6-(4-(3-diethylamino-(2R)-2-hydroxypropoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenyl)urea

[1405] The title compound (1 mg) was obtained from 5 mg of N-cyclopropyl-N'-(4-(6-(4-(3-diethylamino-(2R)-2-hydroxypropoxy)-phenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenyl)urea,

by the same procedure as in Example 657.

MS Spectrum (ESI) :549(M+1).

[1406] The intermediate was synthesized in the following manner.

5 Production Example 659-1

N-Cyclopropyl-N'-(4-(6-(4-(3-diethylamino-(2R)-2-hydroxypropoxy)-phenyl))-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-fluorophenyl)urea

10 **[1407]** After dissolving N-cyclopropyl-N'-(2-fluoro-4-(6-(4-hydroxyphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-2-phenyl)urea (89 mg) in dimethylformamide (2 ml), there were added p-toluenesulfonic acid (2R)-(-)-glycidyl ester (111 mg, 3 equivalents) and potassium carbonate (112 mg, 5 equivalents), and the mixture was stirred overnight at 65°C. It was then returned to room temperature and stationed, and the supernatant was decanted (0.2 ml portion of dimethylformamide). After adding 1 ml of tetrahydrofuran and 0.4 ml of diethylamine
15 thereto, the mixture was stirred at 65°C for 30 minutes. Water was then added and liquid separation and extraction were performed with ethyl acetate-tetrahydrofuran. The organic layer was concentrated and subjected to NH silica gel column chromatography (hexane-ethyl acetate) to obtain 5 mg of the title compound.
MS Spectrum(ESI):679(M+1).

20 Example 660

7-(Benzyloxy)-4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylic acid

[1408] After adding methanol (30 ml) and a 2N sodium hydroxide aqueous solution (10 ml) to methyl 7-(benzyloxy)-4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylate (2.218 g, 4.28 mmol), the mixture was stirred at 60°C for 1 hour. The reaction solution was allowed to cool to room temperature, and after neutralization by addition of 1N hydrochloric acid, the methanol was distilled off and the precipitated light brown crystals were filtered out, thoroughly washed with water and dried at 70°C to obtain the title compound (2.121 g, 4.21 mmol, 98.3%).
1H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.43 (2H, m), 0.67 (2H, m), 2.57 (1H, m), 5.40 (2H, s), 6.56 (1H, d, J=5.2Hz),
30 7.21 (1H, d, J=2.8Hz), 7.26 (1H, dd, J=2.8, 8.8Hz), 7.32-7.44 (3H, m), 7.51 (1H, d, J=2.8Hz), 7.56 (2H, d, J=6.8Hz), 7.60 (1H, s), 8.00 (1H, s), 8.28 (1H, dd, J=2.8, 8.8Hz), 8.57 (1H, s), 8.69 (1H, d, J=5.2Hz).

Example 661

35 N6-Methyl-7-(benzyloxy)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide

[1409] After dissolving 7-(benzyloxy)-4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylic acid (1.056 g, 2.10 mmol) in dimethylformamide (10 ml) under a nitrogen atmosphere, there were added a 40% methylamine-methanol solution (2 ml), triethylamine (1 ml) and (1H-1,2,3-benzotriazol-1-yloxy)(tri(dimethylamino)) phosphonium hexafluorophosphate (1.11 g, 2.52 mmol) in that order at room temperature, and the mixture was stirred for 6 hours. Water was added to the reaction solution to precipitate crystals, and these were filtered out, washed thoroughly with water and dried at 70°C to obtain the title compound (988 mg, 1.91 mmol, 91.2%) as white crystals.
1H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 2.82 (3H, d, J=4.4Hz), 5.42 (2H, s),
40 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.21 (1H, dd, J=2.8, 8.8Hz), 7.30-7.55 (7H, m), 7.96 (1H, s), 8.25 (1H, d, J=8.8Hz), 8.38 (1H, q, J=4.4Hz), 8.49 (1H, s), 8.62 (1H, d, J=5.2Hz).

Example 662

N6-Ethyl-7-(benzyloxy)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide

50 **[1410]** The title compound (1.022 g, 1.92 mmol, 91.8%) was obtained as white crystals from 7-(benzyloxy)-4-(3-chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxylic acid (1.056 g, 2.10 mmol) and 2M ethylamine-tetrahydrofuran solution, by the same procedure as in Example 661.
1H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.04 (3H, t, J=7.2Hz), 2.56 (1H, m), 3.25-3.31 (2H, m), 5.39 (2H, s), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, d, J=2.8, 8.8Hz), 7.32-7.44 (3H, m), 7.47 (1H, d, J=2.8Hz), 7.56 (2H, d, J=7.2Hz), 7.59 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=8.8Hz), 8.34 (1H, t, J=7.2Hz), 8.49 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 663N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

[1411] The title compound (811 mg, 1.90 mmol, quantitative) was obtained as light yellow crystals from N6-methyl-7-(benzyloxy)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide (983 mg, 1.90 mmol), by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 2.85 (3H, s), 6.32 (1H, br), 7.18-7.24 (4H, m), 7.45 (1H, s), 7.96 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.51 (1H, m), 8.81 (1H, s).

Example 664N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

[1412] The title compound (845 mg, 1.91 mmol, quantitative) was obtained as light yellow crystals from N6-ethyl-7-(benzyloxy)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide (1.016 g, 1.91 mmol), by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.16 (3H, t, J=7.2Hz), 2.56 (1H, m), 3.36 (2H, m), 6.41 (1H, d, J=5.2Hz), 7.15-7.35 (4H, m), 7.49 (1H, d, J=2.4Hz), 7.97 (1H, s), 8.27 (1H, dd, J=4.0, 9.2Hz), 8.60 (1H, d, J=5.2Hz), 8.88 (1H, s), 12.68 (1H, br).

Example 665N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1413] The title compound (78.4 mg, 0.146 mmol, 29.1%) was obtained as light yellow crystals from N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (213.4 mg, 0.50 mmol) and 1-(3-chloropropyl)pyrrolidine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.68 (4H, m), 1.99 (2H, m), 2.44 (4H, m), 2.54-2.59 (3H, m), 2.83 (3H, d, J=4.8Hz), 4.28 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.49 (1H, s), 7.96 (1H, s), 8.24-8.27 (2H, m), 8.53 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 666N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1414] The title compound (85.0 mg, 0.154 mmol, 30.8%) was obtained as light yellow crystals from N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (213.4 mg, 0.50 mmol) and 1-(3-chloropropyl)pyrrolidine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.16 (3H, t, J=7.2Hz), 1.68 (4H, m), 2.00 (2H, m), 2.44 (4H, m), 2.53-2.60 (3H, m), 3.32-3.36 (2H, m), 4.27 (2H, m), 6.51 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.48 (1H, s), 7.96 (1H, s), 8.24-8.27 (2H, m), 8.51 (1H, s), 8.64 (1H, d, J=5.2Hz).

Example 667N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)oxiran-2-yl)methoxy-6-quinolinecarboxamide

[1415] The title compound (230.0 mg, 0.476 mmol, 47.6%) was obtained as light yellow crystals from N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (426.9 mg, 1.00 mmol) and (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 2.56 (1H, m), 2.79-2.90 (2H, m), 2.84 (3H, d, J=4.4Hz), 3.47 (1H, m), 4.16 (1H, dd, J=6.0, 11.6Hz), 4.63 (1H, dd, J=2.4, 11.6Hz), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 8.8Hz), 7.47 (1H, d, J=2.8Hz), 7.54 (1H, s), 7.97 (1H, s), 8.24-8.28 (2H, m), 8.53 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 668

N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)oxiran-2-yl)methoxy-6-quinolinecarboxamide

[1416] The title compound (235.4 mg, 0.474 mmol, 47.4%) was obtained as light yellow crystals from N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (440.9 mg, 1.00 mmol) and (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.15 (3H, t, J=7.2Hz), 2.56 (1H, m), 2.82 (1H, m), 2.89 (1H, m), 3.28-3.36 (2H, m), 3.48 (1H, m), 4.17 (1H, dd, J=2.0, 11.2Hz), 4.62 (1H, dd, J=2.4, 11.2Hz), 6.52 (1H, d, J=5.2Hz), 7.18 (1H, d, J=2.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.53 (1H, s), 7.97 (1H, s), 8.24-8.30 (2H, m), 8.52 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 669

N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1417] After dissolving N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)oxiran-2-yl)methoxy-6-quinolinecarboxamide (225 mg, 0.466 mmol) in tetrahydrofuran (5.0 ml) under a nitrogen atmosphere, pyrrolidine (1.0 ml) was added and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 95:5), the fraction containing the target substance was concentrated, and crystals precipitated from ethyl acetate were filtered out and blow-dried to obtain the title compound (164.5 mg, 0.297 mmol, 63.7%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.67 (4H, m), 2.48-2.59 (6H, m), 2.66 (1H, dd, J=6.4, 12.0Hz), 2.85 (3H, d, J=4.8Hz), 4.05 (1H, m), 4.16 (1H, dd, J=6.0, 10.0Hz), 4.34 (1H, dd, J=3.2, 10.0Hz), 5.24 (1H, d, J=4.8Hz), 6.51 (1H, d, J=5.2Hz), 7.18-7.25 (2H, m), 7.48 (1H, d, J=2.8Hz), 7.54 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.50 (1H, q, J=4.8Hz), 8.65 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 670

N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1418] The title compound (146.0 mg, 0.257 mmol, 55.5%) was obtained as light yellow crystals from N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)oxiran-2-yl)methoxy-6-quinolinecarboxamide (230 mg, 0.463 mmol), by the same procedure as in Example 669.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.42 (2H, m), 0.65 (2H, m), 1.16 (3H, t, J=7.2Hz), 1.67 (4H, m), 2.47-2.58 (6H, m), 2.68 (1H, dd, J=6.8, 12.0Hz), 3.30-3.40 (2H, m), 4.04 (1H, m), 4.19 (1H, dd, J=5.6, 9.6Hz), 4.33 (1H, dd, J=3.2, 9.6Hz), 5.18 (1H, d, J=4.8Hz), 6.51 (1H, d, J=5.2Hz), 7.18-7.25 (2H, m), 7.48 (1H, d, J=2.8Hz), 7.52 (1H, s), 7.97 (1H, s), 8.26 (1H, d, J=9.2Hz), 8.53 (1H, m), 8.65 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 670-1

N-(4-((6-Cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)-2-fluorophenyl)-N'-cyclopropylurea

[1419] After suspending 320 mg of N-(4-((6-cyano-7-(4-piperidylmethoxy)-4-quinolyl)oxy)-2-fluorophenyl)-N'-cyclopropylurea in 20 ml of tetrahydrofuran, there were added 1 ml of formaldehyde (37% aqueous solution), 80 mg of acetic acid and 280 mg of sodium triacetoxymethylborohydride while stirring at room temperature. After stirring for 20 minutes, a 2N aqueous sodium hydroxide solution and ethyl acetate were added for extraction. The extract was passed through a glass filter coated with NH type silica gel, and the silica gel was thoroughly washed with an ethyl acetate:methanol = 20:1 mixed solvent. The organic solvents were combined and distilled off under reduced pressure. Ethyl acetate was added to the residue, and the mixture was filtered to obtain 130 mg of a light yellow solid.

¹H-NMR(DMSO-d₆) δ(ppm): 0.35-0.45 (2H, m), 0.59-0.69 (2H, m), 1.32-1.46 (2H, m), 1.71-1.89 (5H, m), 2.14 (3H, s), 2.49-2.59 (1H, m), 2.74-2.84 (2H, m), 4.12 (2H, d, J= 5.2Hz), 6.56 (1H, d, J= 5.2Hz), 6.80 (1H, s), 7.07 (1H, d, J= 9.2Hz), 7.31 (1H, d, J= 11.2Hz), 7.55 (1H, s), 8.16-8.27 (2H, m), 8.69 (1H, s), 8.70 (1H, d, J= 5.2Hz).

[1420] The intermediates were obtained in the following manner.

Production Example 670-1-1

tert-Butyl 4-(((4-(4-amino-3-fluorophenoxy)-6-cyano-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[1421] 4-(4-Amino-3-fluorophenoxy)-7-hydroxy-6-quinolinecarbonitrile (500 mg), tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate (550 mg), potassium carbonate (700 mg) and dimethylformamide (5 ml) were stirred together at 60°C for 2 hours. Water and ethyl acetate were added for extraction, and the extract was dried over magnesium sulfate. The drying agent was filtered out, and silica gel was added to the filtrate which was then distilled off under reduced pressure for adsorption. The reaction solution-adsorbed silica gel was subjected to column chromatography (hexane:ethyl acetate = 1:1, followed by 1:2, 1:3, ethyl acetate) in a dry column packed with silica gel, to obtain 423 mg of a brown oil. ¹H-NMR(DMSO-d₆) δ(ppm): 1.20-1.32 (2H, m), 1.39 (9H, s), 1.75-1.83 (2H, m), 1.98-2.10 (1H, m), 2.67-2.88 (2H, m), 3.94-4.05 (2H, m), 4.15 (2H, d, J= 6.4Hz), 5.25 (2H, bs), 6.51 (1H, d, J= 5.2Hz), 6.83-6.88 (2H, m), 7.06-7.7.11 (1H, m), 7.55 (1H, s), 8.69 (1H, s), 8.70 (1H, d, J= 5.2Hz).

Production Example 670-1-2

tert-Butyl 4-(((6-cyano-4-(3-fluoro-4-((phenoxycarbonyl)amino)phenoxy)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[1422] tert-Butyl 4-(((4-(4-amino-3-fluorophenoxy)-6-cyano-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (523 mg), pyridine (0.17 ml) and tetrahydrofuran (10 ml) were stirred while cooling on ice, and then phenyl chloroformate was added dropwise. Immediately after completion of the dropwise addition, the cooling bath was removed and the mixture was returned to room temperature. After 15 minutes of stirring, water and ethyl acetate were added for extraction. Silica gel was added to the extract and the solvent was distilled off under reduced pressure for adsorption. The reaction solution-adsorbed silica gel was purified by column chromatography (hexane:ethyl acetate = 1:1, followed by 1:2, ethyl acetate) in a dry column packed with silica gel, to obtain 490 mg of a yellow powder. ¹H-NMR(DMSO-d₆) δ(ppm): 1.20-1.32 (2H, m), 1.39 (9H, s), 1.75-1.83 (2H, m), 1.98-2.10 (1H, m), 2.70-2.85 (2H, m), 3.95-4.04 (2H, m), 4.16 (2H, d, J= 6.0Hz), 6.64 (1H, d, J= 5.2Hz), 7.16-7.28 (4H, m), 7.38-7.46 (3H, m), 7.59 (1H, s), 7.80 (1H, dd, J= 8.8Hz, 8.8Hz), 8.72 (1H, s), 8.75 (1H, d, J= 5.2Hz), 10.02 (1H, brs).

Production Example 670-1-3

tert-Butyl 4-(((6-cyano-4-(4-(((cyclopropylamino)carbonyl)amino)-3-fluorophenoxy)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate

[1423] tert-Butyl 4-(((6-cyano-4-(3-fluoro-4-((phenoxycarbonyl)amino)phenoxy)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (490 mg), cyclopropylamine (0.72 ml) and tetrahydrofuran (5 ml) were stirred together at 60°C for 35 minutes. Silica gel was added to the reaction solution and the solvent was distilled off under reduced pressure for adsorption. The reaction solution-adsorbed silica gel was purified by column chromatography (ethyl acetate, followed by ethyl acetate:methanol = 20:1) in a dry column packed with silica gel, to obtain 340 mg of a light yellow solid. ¹H-NMR(DMSO-d₆) δ(ppm): 0.37-0.44 (2H, m), 0.59-0.69 (2H, m), 1.29-1.32 (2H, m), 1.39 (9H, s), 1.77-1.84 (2H, m), 1.99-2.11 (1H, m), 2.39-2.59 (1H, m), 2.59-2.87 (2H, m), 3.96-4.04 (2H, m), 4.16 (2H, d, J= 6.4Hz), 6.57 (1H, d, J= 5.2Hz), 6.80 (1H, d, J= 2.8Hz), 7.05-7.11 (1H, m), 7.31 (1H, dd, J= 12.0Hz, 2.8Hz), 7.58 (1H, s), 8.19-8.27 (2H, m), 8.71 (1H, s), 8.73 (1H, d, J= 5.2Hz)

Production Example 670-1-4

N-(4-((6-Cyano-7-(4-piperidylmethoxy)-4-quinolyl)oxy)-2-fluorophenyl)-N'-cyclopropylurea

[1424] After adding 5 ml of trifluoroacetic acid to 340 mg of tert-butyl 4-(((6-cyano-4-(4-(((cyclopropylamino)carbonyl)amino)-3-fluorophenoxy)-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate, the mixture was stirred at room temperature for 7 minutes. Saturated sodium bicarbonate water and ethyl acetate were added to the reaction solution for extraction. The ethyl acetate layer was washed with brine and dried over sodium sulfate. The drying agent was filtered off and the solvent was distilled off under reduced pressure to obtain 320 mg of a light yellow solid. ¹H-NMR(DMSO-d₆) δ(ppm): 0.37-0.44 (2H, m), 0.59-0.69 (2H, m), 1.47-1.59 (2H, m), 1.92-2.02 (2H, m), 2.14-2.25 (1H, m), 2.47-2.57 (3H, m), 2.87-2.98 (2H, m), 4.19 (2H, d, J= 6.4Hz), 6.59 (1H, d, J= 5.2Hz), 6.88 (1H, d, J= 2.8Hz), 7.05-7.10 (1H, m), 7.31 (1H, dd, J= 12.0Hz, 2.8Hz), 7.63 (1H, s), 8.11 (1H, dd, J= 9.2Hz, 9.2Hz), 8.28 (1H, s), 8.73 (1H, d, J= 5.2Hz), 8.74 (1H, s).

Example 6714-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid methyl ester

[1425] Phenyl N-(2-fluoro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate (0.9 g) was treated with ethylamine in dimethylsulfoxide at room temperature in the same manner as Example 11, to obtain the title compound (0.6 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.05 (3H, t, J=7.2Hz), 3.07-3.15 (2H, m), 3.85 (3H, s), 3.96 (3H, s), 6.52 (1H, d, J=5.2Hz), 6.58 (1H, t, J=5.2Hz), 7.04-7.08 (1H, m), 7.31 (1H, dd, J=2.8Hz, J=12Hz), 7.51 (1H, s), 8.21 (1H, t, J=9.2Hz), 8.33 (1H, br s), 8.55 (1H, s), 8.67 (1H, d, J=5.2Hz).

[1426] The intermediates were synthesized in the following manner.

Production Example 671-1Methyl 4-(4-nitro-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxylate

[1427] Methyl 4-(4-nitro-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxylate (2.44 g) was obtained from 4-chloro-7-methoxy-6-methoxycarbonylquinoline (2.51 g), by the same procedure as in Production Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.83 (3H, s), 3.99 (3H, s), 6.93 (1H, d, J=5.1Hz), 7.30-7.33 (1H, m), 7.58 (1H, m), 7.65-7.69 (1H, m), 8.27-8.31 (1H, m), 8.44 (1H, s), 8.81 (1H, d, J=5.1Hz).

Production Example 671-2Methyl 4-(4-amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxylate

[1428] Methyl 4-(4-amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxylate (1.54 g) was obtained from methyl 4-(4-nitro-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxylate (2.40 g), by the same procedure as in Production Example 8.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 3.84 (3H, s), 3.95 (3H, s), 5.21 (2H, brd), 6.46 (1H, d, J=5.1Hz), 6.85-6.86 (2H, m), 7.09 (1H, d, J=11.9Hz), 7.49 (1H, s), 8.55 (1H, s), 8.65 (1H, d, J=5.1Hz).

Production Example 671-3Phenyl N-(2-fluoro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate

[1429] Phenyl N-(2-fluoro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate (1.87 g) was obtained from methyl 4-(4-amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxylate (1.50 g), by the same procedure as in Production Example 17.

¹H-NMR Spectrum (CDCl₃) δ(ppm): 3.98 (3H, s), 4.05 (3H, s), 6.49 (1H, d, J=5.3Hz), 7.03-7.05 (2H, m), 7.22-7.28 (4H, m), 7.50 (1H, s), 8.25 (1H, brs), 8.67 (1H, d, J=5.1Hz), 8.77 (1H, s).

Example 6724-(4-(3-Cyclopropylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid methyl ester

[1430] Phenyl N-(2-fluoro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate (0.9 g) was treated with cyclopropylamine in dimethylsulfoxide at room temperature in the same manner as Example 11, to obtain the title compound (0.5 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.41 (2H, m), 0.60-0.66 (2H, m), 2.51-2.57 (1H, m), 3.47 (3H, s), 3.59 (3H, s), 6.52 (1H, d, J=5.6Hz), 6.79-6.82 (1H, m), 7.05-7.10 (1H, m), 7.32 (1H, dd, J=2.8Hz, J=11.6Hz), 7.51 (1H, s), 8.17-8.24 (2H, m), 8.55 (1H, s), 8.30 (1H, d, J=5.6Hz).

Example 6734-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid

[1431] 4-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid methyl ester (600 mg) was hydrolyzed in the same manner as Example 633, to obtain the title compound (210 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.05 (3H, t, J=7.2Hz), 3.07-3.15 (2H, m), 3.96 (3H, s), 6.54 (1H, d, J=5.2Hz), 6.77 (1H, t, J=5.6Hz), 7.03-7.09 (1H, m), 7.31 (1H, dd, J=2.4Hz, J=11.6Hz), 7.50 (1H, s), 8.21 (1H, t, J=9.2 Hz), 8.45 (1H, br s), 8.56 (1H, s), 8.67 (1H, d, J=5.2Hz).

5 Example 674

4-(4-(3-Cyclopropylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid

[1432] 4-(4-(3-Cyclopropylureido)-3-fluorophenoxy)-7-methoxy-quinoline-6-carboxylic acid methyl ester (500 mg) was hydrolyzed in the same manner as Example 633, to obtain the title compound (220 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.38-0.43 (2H, m), 0.61-0.67 (2H, m), 2.51-2.58 (1H, m), 3.95 (3H, s), 6.52 (1H, d, J=5.2Hz), 6.83 (1H, d, J=2.8Hz), 7.05-7.09 (1H, m), 7.31 (1H, dd, J=2.4Hz, J=11.6Hz), 7.47 (1H, s), 8.20 (1H, t, J=9.2 Hz), 8.22-8.26 (1H, m), 8.46 (1H, s), 8.65 (1H, d, J=5.2Hz).

15 Example 675

4-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid methoxyamide

[1433] 4-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid (65 mg) was treated with methoxylamine, triethylamine and benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate in the same manner as Example 634, to obtain the title compound (21 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.05 (3H, t, J=7.2Hz), 3.08-3.15 (2H, m), 3.73 (3H, s), 3.97 (3H, s), 6.52 (1H, d, J=5.2Hz), 6.56-6.61 (1H, m), 7.02-7.07 (1H, m), 7.30 (1H, dd, J=2.4Hz, J=11.6Hz), 7.48 (1H, s), 8.22 (1H, t, J=9.2 Hz), 8.33 (1H, br s), 8.41 (1H, s), 8.65 (1H, d, J=5.2Hz), 11.44 (1H, br s).

25 Example 676

4-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid cis-(2-fluorocyclopropyl)amide

[1434] 4-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid (20 mg) was treated with cis-2-fluorocyclopropylamine, triethylamine and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate in the same manner as Example 634, to obtain the title compound (9 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.05 (3H, t, J=7.2Hz), 1.04-1.18 (2H, m), 2.87-2.95 (1H, m), 3.08-3.15 (2H, m), 3.99 (3H, s), 4.69-4.74 (0.5H, m), 4.86-4.90 (0.5H, m), 6.52 (1H, d, J=5.2Hz), 6.58 (1H, t, J=5.2Hz), 7.02-7.07 (1H, m), 7.30 (1H, dd, J=2.4Hz, J=11.6Hz), 7.51 (1H, s), 8.21 (1H, t, J=9.2 Hz), 8.31-8.35 (1H, m), 8.45 (1H, d, J=4Hz), 8.50 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 677

40 4-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid (2-ethoxyethyl)-amide

[1435] 4-(4-(3-Ethylureido)-3-fluorophenoxy)-7-methoxyquinoline-6-carboxylic acid (50 mg) was treated with ethoxyethylamine, triethylamine and benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate in the same manner as Example 634, to obtain the title compound (18 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.05 (3H, t, J=7.2Hz), 1.13 (3H, t, J=7.2Hz), 3.07-3.15 (2H, m), 3.46-3.57 (6H, m), 4.02 (3H, s), 6.52 (1H, d, J=5.2Hz), 6.58 (1H, t, J=5.2Hz), 7.02-7.07 (1H, m), 7.30 (1H, dd, J=2.4Hz, J=11.6Hz), 7.51 (1H, s), 8.21 (1H, t, J=9.2 Hz), 8.31-8.35 (1H, m), 8.44 (1H, t, J=5.2Hz), 8.61 (1H, s), 8.65 (1H, d, J=5.2Hz).

Example 678

50 4-(4-(3-Ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic acid (2-cyanoethyl)amide

[1436] 4-(4-(3-Ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic acid (40 mg) was treated with cyanoethylamine, triethylamine and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate in the same manner as Example 634, to obtain the title compound (29 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.05 (3H, t, J=7.2Hz), 2.78 (2H, t, J=6.4Hz), 3.07-3.15 (2H, m), 3.52-3.58 (2H, m), 4.01 (3H, s), 6.52 (1H, d, J=5.2Hz), 6.56-6.61 (1H, m), 7.02-7.07 (1H, m), 7.30 (1H, dd, J=2.4Hz, J=11.6Hz), 7.52 (1H, s), 8.21 (1H, t, J=9.2 Hz), 8.33 (1H, br s), 8.59 (1H, s), 8.65 (1H, d, J=5.2Hz), 8.72 (1H, t, J=6Hz).

Example 6791-(4-(7-Benzyloxy-6-cyanoquinolin-4-yloxy)-2-methylphenyl)-3-ethylurea

[1437] A carbamate (2.1 g) was obtained as a solid from 4-(4-amino-3-methylphenoxy)-7-benzyloxyquinoline-6-carbonitrile (2 g) and phenyl chlorocarbonate, in the same manner as Production Example 17. The carbamate (1 g) was then treated with ethylamine in dimethylsulfoxide at room temperature in the same manner as Example 11, to obtain the title compound (0.87 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.57 (3H, t, J=7.2Hz), 2.20 (3H, s), 3.07-3.15 (2H, m), 5.43 (2H, s), 6.48-6.55 (2H, m), 7.02 (1H, dd, J=2.8Hz, J=8.8Hz), 7.08 (1H, d, J=2.8Hz), 7.34-7.55 (5H, m), 7.68 (2H, s), 7.92 (1H, d, J=8.8Hz), 8.70 (1H, d, J=5.6Hz), 8.74 (1H, s).

Example 680N-(4-(6-Cyano-7-hydroxyquinolin-4-yloxy)-2-methylphenyl)-N'-ethylurea

[1438] In the same manner as Production Example 301-2, N-(4-(7-benzyloxy-6-cyanoquinolin-4-yloxy)-2-methylphenyl)-N'-ethylurea (0.8 g) was debenzylated in tetrahydrofuran using palladium-carbon, to obtain the title compound (0.42 g) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.06 (3H, t, J=7.2Hz), 2.20 (3H, s), 3.07-3.15 (2H, m), 6.37 (1H, d, J=5.2Hz), 6.52 (1H, t, J=5.6Hz), 7.01 (1H, dd, J=2.8Hz, J=8.8Hz), 7.08 (1H, d, J=2.8Hz), 7.35 (1H, s), 7.68 (1H, s), 7.93 (1H, d, J=8.8Hz), 8.59 (1H, d, J=5.2Hz), 8.61 (1H, s).

Example 681N-(4-(6-Cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy)-2-methylphenyl)-N'-cyclopropylurea

[1439] The target substance was obtained from N-(4-(6-cyano-7-hydroxyquinolin-4-yloxy)-2-methylphenyl)-N'-cyclopropylurea (410 mg) and 4-bromoethyl-piperidine-1-carboxylic acid tert-butyl ester, in the same manner as Example 7, and was deprotected to obtain the title compound (15 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.37-0.43 (2H, m), 0.63-0.66 (2H, m), 1.44-1.56 (2H, m), 1.92-1.98 (2H, m), 2.11-2.20 (1H, m), 2.20 (3H, s), 2.51-2.58 (1H, m), 2.85-2.94 (2H, m), 3.15-3.45 (2H, m), 4.19 (2H, d, J=6.4Hz), 6.51 (1H, d, J=5.2Hz), 6.79 (1H, d, J=2.8Hz), 7.04 (1H, dd, J=2.8Hz, J=8.8Hz), 7.10 (1H, d, J=2.8Hz), 7.62 (1H, s), 7.64 (1H, s), 7.93 (1H, d, J=8.8Hz), 8.71 (1H, d, J=5.2Hz), 8.75 (1H, s).

Example 682N-(4-(6-Cyano-7-(1-methyl-piperidin-4-ylmethoxy)quinolin-4-yloxy)-2-methylphenyl)-N'-cyclopropylurea

[1440] The title compound (3 mg) was obtained as a solid from N-(4-(6-cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy)-2-methylphenyl)-N'-cyclopropylurea (10 mg), in the same manner as Example 670.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 0.38-0.44 (2H, m), 0.61-0.67 (2H, m), 1.38-1.50 (2H, m), 1.78-1.85 (2H, m), 2.04-2.13 (1H, m), 2.20 (3H, s), 2.26 (3H, br s), 2.48-2.58 (1H, m), 2.84-2.99 (2H, m), 3.04-3.54 (2H, m), 4.15 (2H, d, J=6Hz), 6.50 (1H, d, J=5.2Hz), 6.82 (1H, d, J=2.8Hz), 7.04 (1H, dd, J=2.4Hz, J=8.8Hz), 7.10 (1H, d, J=2.4Hz), 7.58 (1H, s), 7.66 (1H, s), 7.93 (1H, d, J=8.8Hz), 8.71 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 683N-(4-(6-Cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy)-2-methylphenyl)-N'-ethylurea

[1441] The target substance was obtained from N-(4-(6-cyano-7-hydroxyquinolin-4-yloxy)-2-methylphenyl)-N'-ethylurea (410 mg) and 4-bromoethyl-piperidine-1-carboxylic acid tert-butyl ester, in the same manner as Example 7, and was deprotected to obtain the title compound (15 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.06 (3H, t, J=7.2Hz), 1.44-1.57 (2H, m), 1.93-1.99 (2H, m), 2.11-2.20 (1H, m), 2.20 (3H, s), 2.88-2.98 (2H, m), 3.07-3.14 (2H, m), 3.15-3.45 (2H, m), 4.19 (2H, d, J=6Hz), 6.51 (1H, d, J=5.2Hz), 6.57 (1H, t, J=5.6Hz), 7.02 (1H, dd, J=2.4Hz, J=8.8Hz), 7.09 (1H, d, J=2.4Hz), 7.62 (1H, s), 7.73 (1H, s), 7.94 (1H, d, J=8.8Hz), 8.71 (1H, d, J=5.2Hz), 8.74 (1H, s).

Example 684

N-(4-(6-Cyano-7-(1-methyl-piperidin-4-ylmethoxy)quinolin-4-yloxy)-2-methylphenyl)-N'-ethylurea

[1442] The title compound (5 mg) was obtained as a solid from N-(4-(6-cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy)-2-methylphenyl)-N'-ethylurea (15 mg), in the same manner as Example 670.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.06 (3H, t, J=7.2Hz), 1.38-1.51 (2H, m), 1.78-1.86 (2H, m), 2.07-2.18 (1H, m), 2.20 (3H, s), 2.28 (3H, br s), 2.89-2.97 (2H, m), 3.07-3.15 (2H, m), 3.15-3.41 (2H, m), 4.15 (2H, d, J=6Hz), 6.50 (1H, d, J=5.2Hz), 6.58 (1H, t, J=5.6Hz), 7.03 (1H, dd, J=2.8Hz, J=8.8Hz), 7.09 (1H, d, J=2.4Hz), 7.58 (1H, s), 7.73 (1H, s), 7.94 (1H, d, J=8.8Hz), 8.79 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 697

Methyl 4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylate

[1443] Phenyl N-(2-chloro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate (1.92 g, 4.00 mmol) and 2 M ethylamine (tetrahydrofuran solution) (4 ml) were stirred in dimethylformamide (8 ml) at room temperature for 30 minutes. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, and the drying agent was filtered out and the filtrate distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (1.60 g, 3.72 mmol, 93%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.09 (3H, t, J = 7.4 Hz), 3.15 (2H, m), 3.87 (3H, s), 3.99 (3H, s), 6.54 (1H, d, J=5.2Hz), 7.01 (1H, t, J = 5.4 Hz), 7.25 (1H, dd, J = 2.8, 9.0 Hz), 7.50 (1H, d, J = 2.8 Hz), 7.54 (1H, s), 8.08 (1H, s), 8.28 (1H, d, J = 9.0 Hz), 8.58 (1H, s), 8.69 (1H, d, J = 5.2 Hz).

Example 698

4-(3-Chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid

[1444] After adding methanol (14 ml) and 2N sodium hydroxide aqueous solution (7 ml) to methyl 4-(3-chloro-4-(((ethylamino)carbonyl)amino) phenoxy)-7-methoxy-6-quinolinecarboxylate (1.50 g, 3.49 mmol), the mixture was stirred at 60°C for 90 minutes. The reaction solution was allowed to cool to room temperature, and after neutralization by addition of 2N hydrochloric acid, the methanol was distilled off and the precipitated white crystals were filtered out, thoroughly washed with water and dried at 60°C to obtain the title compound (1.36 g, 3.27 mmol, 94%).

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.09 (3H, t, J = 7.4 Hz), 3.15 (2H, m), 3.98 (3H, s), 6.53 (1H, d, J = 5.0 Hz), 7.00 (1H, t, J = 5.4 Hz), 7.25 (1H, dd, J = 2.8, 9.0 Hz), 7.48-7.53 (2H, m), 8.08 (1H, s), 8.27 (1H, d, J = 9.0 Hz), 8.54 (1H, s), 8.68 (1H, d, J = 5.0 Hz), 13.12 (1H, brs).

Example 699

N6-Methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1445] After dissolving 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) in dimethylformamide (3 ml), there were added a 40% methylamine-methanol solution (0.100 ml), triethylamine (0.250 ml) and 1H-1,2,3-benzotriazol-1-yloxy(tri(dimethylamino)) phosphonium hexafluorophosphate (221 mg, 0.500 mmol) in that order at room temperature, and the mixture was stirred for 15 hours. The reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate. After distilling off the solvent, the residue was suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out and blow-dried to obtain the title compound (79.0 mg, 0.184 mmol, 74%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.08 (3H, t, J = 7.4 Hz), 2.85 (3H, d, J = 4.2 Hz), 3.15 (2H, m), 4.02 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.2 Hz), 7.22 (1H, dd, J = 2.8, 9.2 Hz), 7.47 (1H, d, J = 2.8 Hz), 7.52 (1H, s), 8.07 (1H, s), 8.26 (1H, d, J = 9.2 Hz), 8.36 (1H, q, J = 4.2 Hz), 8.59 (1H, s), 8.67 (1H, d, J = 5.2 Hz).

Example 700N6-Ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1446] The title compound (90.0 mg, 0.203 mmol, 81%) was obtained as white crystals from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and 2.0 M ethylamine (tetrahydrofuran solution), by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.09 (3H, t, J = 7.4 Hz), 1.15 (3H, t, J = 7.2 Hz), 3.15 (2H, m), 3.28-3.38 (2H, m), 4.02 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.4 Hz), 7.22 (1H, dd, J = 2.8, 9.2 Hz), 7.47 (1H, d, J = 2.8 Hz), 7.51 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J = 9.2 Hz), 8.40 (1H, t, J = 5.4 Hz), 8.54 (1H, s), 8.66 (1H, d, J = 5.2 Hz).

Example 701N6-Cyclopropyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1447] The title compound (83.0 mg, 0.182 mmol, 73%) was obtained as white crystals from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and cyclopropylamine, by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.58 (2H, m), 0.71 (2H, m), 1.08 (3H, t, J = 7.4 Hz), 2.87 (1H, m), 3.14 (2H, m), 3.99 (3H, s), 6.53 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 4.8 Hz), 7.21 (1H, dd, J = 2.8, 9.2 Hz), 7.47 (1H, d, J = 2.8 Hz), 7.49 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J = 9.2 Hz), 8.34 (1H, d, J = 4.0 Hz), 8.42 (1H, s), 8.66 (1H, d, J = 5.2 Hz).

Example 702N6-Methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1448] The title compound (52.0 mg, 0.117 mmol, 47%) was obtained as white crystals from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and methoxylamine hydrochloride, by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.09 (3H, t, J = 7.4 Hz), 3.15 (2H, m), 3.75 (3H, s), 4.00 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.4 Hz), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.50 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J = 9.2 Hz), 8.43 (1H, s), 8.67 (1H, d, J = 5.2 Hz), 11.45 (1H, s).

Example 703N6-(2-Methoxyethyl)-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1449] The title compound (71.0 mg, 0.150 mmol, 60%) was obtained as white crystals from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and 2-methoxyethylamine, by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.08 (3H, t, J = 7.4 Hz), 3.15 (2H, m), 3.30 (3H, s), 3.47-3.52 (4H, m), 4.03 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.4 Hz), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.53 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J = 9.2 Hz), 8.44 (1H, m), 8.62 (1H, s), 8.67 (1H, d, J = 5.2 Hz).

Example 704N6-(2-Fluoroethyl)-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1450] The title compound (80.0 mg, 0.174 mmol, 69%) was obtained as white crystals from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and 2-fluoroethylamine hydrochloride, by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.08 (3H, t, J = 7.4 Hz), 3.15 (2H, m), 3.59 (1H, m), 3.67 (1H, m), 4.03 (3H, s), 4.51 (1H, m), 4.63 (1H, m), 6.54 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.4 Hz), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.53 (1H, s), 8.07 (1H, s), 8.27 (1H, d, J = 9.2 Hz), 8.58-8.62 (2H, m), 8.67 (1H, d, J = 5.2 Hz).

Example 705

N6-((2R)Tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1451] The title compound (99.0 mg, 0.198 mmol, 79%) was obtained as a white powder from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and R-tetrahydrofurfurylamine, by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.08 (3H, t, J = 7.4 Hz), 1.62 (1H, m), 1.80-2.00 (3H, m), 3.15 (2H, m), 3.40 (2H, m), 3.66 (1H, dd, J = 3.6, 14.0 Hz), 3.81 (1H, dd, J = 4.0, 14.0 Hz), 3.99 (1H, m), 4.04 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.4 Hz), 7.23 (1H, dd, J = 2.8, 8.8 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.54 (1H, s), 8.07 (1H, s), 8.26 (1H, d, J = 8.8 Hz), 8.43 (1H, t, J = 5.6 Hz), 8.61 (1H, s), 8.67 (1H, d, J = 5.2 Hz).

Example 706

N6-((2S)Tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1452] The title compound (87.0 mg, 0.174 mmol, 70%) was obtained as a white powder from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and S-tetrahydrofurfurylamine, by the same procedure as in Example 699.

Example 707

N6-(2-Ethoxyethyl)-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1453] The title compound (112 mg, 0.239 mmol, 95%) was obtained as a white powder from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and 2-ethoxyethylamine, by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.08 (3H, t, J = 7.4 Hz), 1.16 (3H, t, J = 6.8 Hz), 3.15 (2H, m), 3.45-3.56 (6H, m), 4.03 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 7.01 (1H, m), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.48 (1H, d, J = 2.8 Hz), 7.54 (1H, s), 8.08 (1H, s), 8.27 (1H, dd, J = 2.8, 9.2 Hz), 8.46 (1H, m), 8.64 (1H, d, J = 2.0 Hz), 8.68 (1H, d, J = 5.2 Hz).

Example 708

N6-Isobutoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

[1454] The title compound (64.0 mg, 0.131 mmol, 53%) was obtained as a white powder from 4-(3-chloro-4-(((ethylamino)carbonyl) amino)phenoxy)-7-methoxy-6-quinolinecarboxylic acid (104 mg, 0.250 mmol) and isobutoxylamine hydrochloride, by the same procedure as in Example 699.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.95 (6H, d, J = 6.8 Hz), 1.08 (3H, t, J = 7.4 Hz), 1.97 (1H, m), 3.15 (2H, m), 3.71 (2H, d, J = 6.8 Hz), 3.99 (3H, s), 6.54 (1H, d, J = 5.2 Hz), 7.00 (1H, m), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.47 (1H, d, J = 2.8 Hz), 7.50 (1H, s), 8.08 (1H, s), 8.27 (1H, dd, J = 2.8, 9.2 Hz), 8.36 (1H, s), 8.67 (1H, d, J = 5.2 Hz), 11.36 (1H, br s).

Example 709

N6-Ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide

[1455] After adding (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate (66 mg, 0.290 mmol), potassium carbonate (32 mg, 0.231 mmol) and dimethylformamide (2 ml) to N6-ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (80.0 mg, 0.193 mmol), the mixture was stirred at 60°C for 7 hours. Diethylamine (1 ml) was then added, and the mixture was stirred at 60°C overnight. The reaction solution was distributed between ethyl acetate-tetrahydrofuran (1:1) and water, and the organic layer was washed with water and saturated brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 95:5), the fraction containing the target substance was concentrated, and crystals were precipitated from ethyl acetate-hexane (1:1), filtered out and blow-dried to obtain the

title compound (51.7 mg, 0.095 mmol, 49.3%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.94 (6H, t, J=7.2Hz), 1.16 (3H, t, J=7.2Hz), 2.40-2.60 (6H, m), 2.66 (3H, d, J=4.8Hz), 3.20-3.40 (2H, m), 3.98 (1H, m), 4.19 (1H, dd, J=5.2, 10.0Hz), 4.31 (1H, dd, J=3.2, 10.0Hz), 5.09 (1H, d, J=4.8Hz), 6.51 (1H, d, J=5.2Hz), 6.86 (1H, q, J=4.8Hz), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.52 (1H, s), 8.10 (1H, s), 8.23 (1H, d, J=9.2Hz), 8.54 (1H, m), 8.65 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 710

N6-Ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide

[1456] The title compound (44.5 mg, 0.080 mmol, 43.8%) was obtained as white crystals from N6-ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (78.0 mg, 0.182 mmol), by the same procedure as in Example 709.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 0.94 (6H, t, J=7.2Hz), 1.06 (3H, t, J=7.2Hz), 1.16 (3H, t, J=7.2Hz), 2.40-2.60 (6H, m), 3.12 (2H, m), 3.20-3.40 (2H, m), 3.98 (1H, m), 4.22 (1H, dd, J=5.6, 9.6Hz), 4.31 (1H, dd, J=3.2, 9.6Hz), 5.08 (1H, d, J=4.4Hz), 6.51 (1H, d, J=5.2Hz), 6.98 (1H, m), 7.22 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.52 (1H, s), 8.05 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.54 (1H, m), 8.65 (1H, d, J=5.2Hz), 8.73 (1H, s).

Example 711

N6-Ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1457] After adding (2R)oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate (66 mg, 0.290 mmol), potassium carbonate (32 mg, 0.231 mmol) and dimethylformamide (2 ml) to N6-ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (80.0 mg, 0.193 mmol), the mixture was stirred at 60°C for 7 hours. After allowing the reaction solution to cool to room temperature, pyrrolidine (0.5 ml) was added and the mixture was further stirred overnight. The reaction solution was distributed between ethyl acetate-tetrahydrofuran (1:1) and water, and the organic layer was washed with water and saturated brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 95:5), the fraction containing the target substance was concentrated, and crystals were precipitated from ethyl acetate-hexane (1:1), filtered out and blow-dried to obtain the title compound (54.8 mg, 0.101 mmol, 52.4%) as white crystals. ¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.16 (3H, t, J=7.2Hz), 1.67 (4H, m), 2.40-2.60 (5H, m), 2.65-2.71 (4H, m), 3.20-3.40 (2H, m), 4.05 (1H, m), 4.19 (1H, dd, J=6.0, 10.0Hz), 4.32 (1H, dd, J=3.6, 10.0Hz), 5.18 (1H, d, J=4.4Hz), 6.52 (1H, d, J=4.0Hz), 6.86 (1H, q, J=4.8Hz), 7.22 (1H, d, J=9.2Hz), 7.47 (1H, s), 7.52 (1H, s), 8.10 (1H, s), 8.23 (1H, d, J=9.2Hz), 8.53 (1H, m), 8.65 (1H, d, J=4.0Hz), 8.71 (1H, s).

Example 712

N6-Ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide

[1458] The title compound (47.3 mg, 0.085 mmol, 46.8%) was obtained as white crystals from N6-ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (78.0 mg, 0.182 mmol), by the same procedure as in Example 711.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.06 (3H, t, J=7.2Hz), 1.16 (3H, t, J=7.2Hz), 1.67 (4H, m), 2.40-2.60 (5H, m), 2.68 (1H, dd, J=6.4, 12.0Hz), 3.12 (2H, m), 3.35 (2H, m), 4.05 (1H, m), 4.19 (1H, dd, J=6.4, 10.0Hz), 4.32 (1H, dd, J=3.6, 10.0Hz), 5.18 (1H, d, J=4.8Hz), 6.51 (1H, d, J=5.2Hz), 6.98 (1H, m), 7.21 (1H, dd, J=2.8, 9.2Hz), 7.47 (1H, d, J=2.8Hz), 7.52 (1H, s), 8.05 (1H, s), 8.25 (1H, d, J=9.2Hz), 8.53 (1H, m), 8.65 (1H, d, J=5.2Hz), 8.71 (1H, s).

Example 713

N-(4-((6-Cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(thiazol-2-yl)urea

[1459] After dissolving 4-(4-aminophenoxy)-6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)quinoline (105 mg, 0.2583 mmol) in dimethylsulfoxide (1 ml), there was added phenyl (thiazol-2-yl)carbamate (60 mg, 0.2712 mmol), and the mixture was heated and stirred at 85°C for 40 minutes. After cooling to room temperature, water was added

to the reaction solution, extraction was performed with ethyl acetate-tetrahydrofuran, and the extract was washed with saturated brine and dried over anhydrous sodium sulfate. Upon distilling off the solvent, the residue was dissolved in acetone and diluted with diethyl ether, and the precipitate was washed with diethyl ether and blow-dried to obtain the title compound (75 mg, 0.1408 mmol, 54.51%) as a light yellow powder.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 0.96(6H, t, J=7.0 Hz), 2.41-2.68(6H, m), 3.96(1H, m), 4.21(1H, dd, J=5.2, 10.0 Hz), 4.31(1H, dd, J=3.2, 10.0 Hz), 4.92(1H, brs), 6.52(1H, d, J=5.2 Hz), 7.10(1H, d, J=3.6 Hz), 7.27(2H, d, J=9.0 Hz), 7.37(1H, d, J=3.6 Hz), 7.61(1H, s), 7.63(2H, d, J=9.0 Hz), 8.72(1H, d, J=5.2 Hz), 8.76(1H, s), 9.15(1H, brs).

[1460] The starting materials were synthesized in the following manner.

Production Example 713-1

4-(4-Aminophenoxy)-6-cyano-7-hydroxyquinoline

[1461] 6-cyano-7-hydroxy-4-(4-nitrophenoxy)quinoline (1.23 g, 4.00 mmol), obtained by deprotecting the benzyl group of the 7-benzyloxy-6-cyano-4-(4-nitrophenoxy)quinoline obtained in Production Example 5 according to the method of Production Example 21, was used in a reaction for reduction of the nitro group in the same manner as Production Example 21, to obtain the title compound (0.864 g, 3.1160 mmol, 77.90%) as yellowish-brown crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 5.18(2H, brs), 6.36 (1H, d, J=5.2 Hz), 6.65(2H, d, J=8.4 Hz), 6.92(2H, d, J=8.4 Hz), 7.38(1H, s), 8.60(1H, d, J=5.2 Hz), 8.62(1H, s).

Production Example 713-2

4-(4-Aminophenoxy)-6-cyano-7-((2R)-oxiran-2-yl)methoxyquinoline

[1462] After dissolving 4-(4-aminophenoxy)-6-cyano-7-hydroxyquinoline (277 mg, 1.00 mmol) in dimethylformamide (3.0 ml), sodium hydride (40 mg, 1.00 mmol, 60% in oil) was added at room temperature and the mixture was stirred. There was then added (2R)-oxiran-2-ylmethyl 4-methyl-1-benzenesulfonate (228 mg, 1.00 mmol), and the mixture was heated and stirred at 60°C for 5 hours. After cooling to room temperature, the reaction solution was distributed between ethyl acetate and water. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate, and the solvent was distilled off to obtain the title compound (322 mg, 0.97 mmol, 97%) as a yellow solid.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 2.82(1H, dd, J=2.8, 4.8 Hz), 2.93(1H, dd, J=4.8, 4.8 Hz), 3.48(1H, m), 4.17 (1H, dd, J=6.6, 12.0 Hz), 4.71(1H, dd, J=2.0, 12.0 Hz), 5.20(2H, m), 6.49(1H, d, J=5.2 Hz), 6.68(2H, d, J=8.8 Hz), 6.96 (2H, d, J=8.8 Hz), 7.62(1H, s), 8.71(1H, d, J=5.2 Hz), 8.76(1H, s).

Production Example 713-3

4-(4-Aminophenoxy)-6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)quinoline

[1463] The title compound (105 mg, 0.2583 mmol, 29.02%) was obtained as a light yellow oil using 4-(4-aminophenoxy)-6-cyano-7-((2R)-oxiran-2-yl)methoxyquinoline (297 mg, 0.8900 mmol), by the same procedure as in Production Example 429-2.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 1.08(6H, t, J=7.0 Hz), 1.50-2.50(1H, brs), 2.55-2.76(6H, m), 3.79(2H, brs), 4.15 (1H, m), 4.24(2H, d, J=4.8 Hz), 6.46(1H, d, J=5.4 Hz), 6.77 (2H, d, J=8.8 Hz), 6.96(2H, d, J=8.8 Hz), 7.48(1H, s), 8.64 (1H, d, J=5.4 Hz), 8.69(1H, s).

Example 714

N-(4-((6-Cyano-7-(((2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(thiazol-2-yl)urea

[1464] 4-(4-Aminophenoxy)-6-cyano-7-((2R)-oxiran-2-yl)methoxyquinoline (322 mg, 0.966 mmol) and thiazol-2-yl-carbamic acid phenyl ester (255 mg, 1.26 mmol) were heated and stirred in dimethylsulfoxide (2 ml) at 85°C for 4 hours. The reaction solution was distributed between an ethyl acetate-tetrahydrofuran mixed solvent and water, the organic layer was washed with water and saturated brine and then dried over anhydrous magnesium sulfate, and the drying agent was filtered off and the filtrate distilled off under reduced pressure. The obtained product and pyrrolidine (343 mg, 4.83 mmol) were stirred in dimethylformamide (3 ml) at room temperature for 15 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off, and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:meth-

anol = 15:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (45 mg, 0.085 mmol, 9%) as light yellow crystals.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.67 (4H, m), 2.40-2.60 (5H, m), 2.73 (1H, dd, J = 6.4, 12.4 Hz), 4.03 (1H, m), 4.22 (1H, dd, J = 6.0, 10.0 Hz), 4.33 (1H, dd, J = 3.2, 10.0 Hz), 5.04 (1H, d, J = 5.2 Hz), 6.54 (1H, d, J = 5.2 Hz), 7.12 (1H, d, J = 3.6 Hz), 7.27-7.32 (2H, m), 7.38 (1H, d, J = 3.6 Hz), 7.62-7.69 (3H, m), 8.74 (1H, d, J = 5.2 Hz), 8.77 (1H, s), 9.25 (1H, br s), 10.73 (1H, br s).

Example 715

4-{6-Cyano-4-[4-(3-thiazol-2-ylureido)phenoxy]quinolin-7-yloxymethyl}piperidine-1-carboxylic acid tert-butyl ester

[1465] 4-(4-(4-Aminophenoxy)-6-cyanoquinolin-7-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester (225 mg) was heated in dimethylsulfoxide together with thiazol-2-yl-carbamic acid phenyl ester at 80°C in the same manner as Example 713 to obtain the title compound (240 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.19-1.32 (2H, m), 1.39 (9H, s), 1.75-1.84 (2H, m), 2.01-2.11 (1H, m), 2.66-2.87 (2H, m), 3.94-4.04 (2H, m), 4.17 (2H, d, J=5.6Hz), 6.52 (1H, d, J=5.2Hz), 7.11 (1H, d, J=3.2Hz), 7.27 (2H, d, J=8.8Hz), 7.37 (1H, d, J=3.2Hz), 7.58 (1H, s), 7.62 (2H, d, J=8.8Hz), 8.71 (1H, d, J=5.2Hz), 8.75 (1H, s), 9.14 (1H, brs).

[1466] The intermediate was synthesized in the following manner.

Production Example 715-1

4-(4-(4-Aminophenoxy)-6-cyanoquinolin-7-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester

[1467] After treating 4-(4-aminophenoxy)-7-hydroxyquinoline-6-carbonitrile (0.32 g) with sodium hydride in dimethylformamide in the same manner as Production Example 713-2, it was reacted with 4-bromoethylpiperidine-1-carboxylic acid tert-butyl ester to obtain the title compound (225 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.18-1.32 (2H, m), 1.39 (9H, s), 1.75-1.82 (2H, m), 1.98-2.10 (1H, m), 2.62-2.92 (2H, m), 3.94-4.03 (2H, m), 4.15 (2H, d, J=6Hz), 5.16-5.21 (2H, m), 6.45 (1H, d, J=5.2Hz), 6.65 (2H, d, J=8.8Hz), 6.93 (2H, d, J=8.8Hz), 7.55 (1H, s), 8.68 (1H, d, J=5.2Hz), 8.70 (1H, s).

Example 716

1-(4-(6-Cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy)phenyl)-3-(thiazol-2-yl)urea

[1468] 4-(6-Cyano-4-(4-(3-thiazol-2-yl-ureido)-phenoxy)-quinolin-7-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl-ester (240 mg) was deprotected with trifluoroacetic acid in the same manner as Production Example 670-4 to obtain the title compound (220 mg) as a solid.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.46-1.59 (2H, m), 1.87-1.96 (2H, m), 2.06-2.18 (1H, m), 2.78-2.89 (2H, m), 3.08-3.38 (2H, m), 4.13 (2H, d, J=6Hz), 6.43 (1H, d, J=5.2Hz), 7.07 (1H, d, J=3.2Hz), 7.20 (2H, d, J=9.2Hz), 7.36 (1H, d, J=3.2Hz), 7.57 (1H, s), 7.68 (2H, d, J=9.2Hz), 8.63 (1H, d, J=5.2Hz), 8.71 (1H, s), 9.82 (1H, br).

Example 717

1-(4-(6-Cyano-7-(1-methylpiperidin-4-ylmethoxy)quinolin-4-yloxy)phenyl)-3-(thiazol-2-yl)urea

[1469] The title compound (51 mg) was obtained as a solid from 1-(4-(6-cyano-7-(piperidin-4-ylmethoxy)quinolin-4-yloxy)phenyl)-3-(thiazol-2-yl)urea (220 mg), in the same manner as Example 670.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm): 1.35-1.48 (2H, m), 1.75-1.85 (2H, m), 1.89-1.96 (1H, m), 2.18 (3H, brs), 2.79-2.86 (2H, m), 3.18-3.38 (2H, m), 4.15 (2H, d, J=5.6Hz), 6.52 (1H, d, J=5.2Hz), 7.10 (1H, d, J=3.2Hz), 7.27 (2H, d, J=9.2Hz), 7.37 (1H, d, J=3.2Hz), 7.58 (1H, s), 7.63 (2H, d, J=9.2Hz), 8.72 (1H, d, J=5.2Hz), 8.76 (1H, s), 9.20 (1H, br).

Example 718

N-(4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-trifluoromethylphenyl)-N'-ethylurea

[1470] Ethylamine 2N tetrahydrofuran solution (0.10 ml) was added to dimethylsulfoxide (0.5 ml), and then (4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-trifluoromethylphenyl) carbamic acid phenyl ester (25 mg) was dissolved therein

and the mixture was stirred for 10 minutes. Water and ethyl acetate were added to the reaction solution, and the precipitated crystals were filtered out to obtain the title compound (5.0 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 1.08(3H, t, J=7.2Hz), 3.10-3.18(2H, m), 4.04(3H, s), 6.54(1H, d, J=5.2Hz), 7.00-7.07(1H, m), 7.51-7.63(3H, m), 7.74(1H, brs), 7.82-7.88(2H, m), 8.06-8.13(1H, m), 8.66-8.70(2H, m)

Example 719

N-[4-(6-Carbamoyl-7-methoxy-4-quinolyl)oxy-2-trifluoromethylphenyl]-N'-methylurea

[1471] After adding [4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-trifluoromethylphenyl]carbamic acid phenyl ester (25 mg) to methylamine 2N tetrahydrofuran solution (1.00 ml), the mixture was stirred for 10 minutes. The precipitated crystals were filtered out and washed with tetrahydrofuran to obtain the title compound (10 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 2.68(3H, d, J=4.0Hz), 4.04(3H, s), 6.54(1H, d, J=5.6Hz), 6.87-6.94(1H, m), 7.51-7.63(3H, m), 7.75(1H, brs), 7.86(1H, brs), 7.90(1H, brs), 8.03-8.09(1H, m), 8.66-8.70(2H, m)

Example 720

N-(4-(7-Benzyloxy-6-cyano-quinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea

[1472] Cyclopropylamine (1 ml) was added to dimethylformamide (10 ml), and then (4-(7-benzyloxy-6-cyano-quinolin-4-yloxy)-2,3-dimethylphenyl)carbamic acid phenyl ester (1.99 g) was added thereto and the mixture was stirred at room temperature for 10 minutes. Water (30 ml) and ethyl acetate (30 ml) were added, and the precipitated crystals were filtered out and washed with ethyl acetate to obtain the title compound (1660 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 0.40-0.45(2H, m), 0.62-0.67(2H, m), 2.03(3H, s), 2.16(3H, s), 2.52-2.59(1H, m), 5.47(2H, s), 6.33(1H, d, J=5.2Hz), 6.68-6.74(1H, m), 7.00(1H, d, J=8.8Hz), 7.35-7.49 (3H, m), 7.52-7.73(5H, m), 8.69(1H, d, J=5.2Hz), 8.76(1H, s)

[1473] The starting material was synthesized by the following 2 steps.

Production Example 720-1

4-(4-Amino-2,3-dimethylphenoxy)-7-benzyloxy-6-cyanoquinoline

[1474] 4-Amino-2,3-xyleneol (2.80 g) purchased from Tokyo Chemical Industries was dissolved in dimethylsulfoxide (15 ml), and after gradually adding sodium hydride (816 mg) at room temperature, the mixture was stirred for 20 minutes. 7-Benzyloxy-4-chloro-6-cyanoquinoline (3.0 g) was added, and the mixture was heated at 100°C for 4 hours while stirring. After cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water, 1N aqueous sodium hydroxide and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained crude product was washed with ethyl acetate to obtain the title compound (1.72 g) as light brown crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 1.91(3H, s), 2.01(3H, s), 4.83-4.90 (2H, m), 5.44(2H, s), 6.30(1H, d, J=5.2Hz), 6.60(1H, d, J=8.4Hz), 6.73-6.79(1H, m), 7.33-7.47(3H, m), 7.51-7.58(2H, m), 7.67(1H, s), 8.65(1H, d, J=5.2Hz), 8.80(1H, s)

Production Example 720-2

[4-(7-Benzyloxy-6-cyanoquinolin-4-yloxy)-2,3-dimethylphenyl]carbamic acid phenyl ester

[1475] The title compound (1.99 g) was obtained as light brown crystals from 4-(4-amino-2,3-dimethylphenoxy)-7-benzyloxy-6-cyanoquinoline (1.72 g), by the method described in Production Example 141-1.

¹H-NMR(CDCl₃) δ(ppm) 2.02(3H, s), 2.13(3H, s), 5.36(2H, s), 6.32(1H, d, J=5.2Hz), 6.78(1H, brs), 7.00(1H, d, J=8.8Hz), 7.20-7.80(12H, m), 8.62(1H, d, J=5.2Hz), 8.78(1H, s)

Example 721

N-[2,3-Dimethyl-4-(6-cyano-7-hydroxyquinolin-4-yloxy)phenyl]-N'-cyclopropylurea

[1476] After adding N-[4-(7-benzyloxy-6-cyanoquinolin-4-yloxy)-2,3-dimethylphenyl]-N'-cyclopropylurea (1600 mg) to tetrahydrofuran (400 ml), palladium-carbon (2000 mg) was further added and the mixture was stirred overnight at room temperature under a hydrogen atmosphere. The palladium-carbon was removed by filtration, washing was per-

formed with dimethylformamide, and the filtrate was concentrated under reduced pressure to obtain the title compound (827 mg).

¹H-NMR(DMSO-d₆) δ(ppm) 0.40-0.46(2H, m), 0.62-0.67(2H, m), 2.03(3H, s), 2.16(3H, s), 2.54-2.60(1H, m), 6.20(1H, d, J=5.2Hz), 6.68(1H, d, J=3.2Hz), 7.00(1H, d, J=8.8Hz), 7.39(1H, brs), 7.65(1H, d, J=8.8Hz) 7.69(1H, s), 8.59(1H, d, J=5.2Hz), 8.71(1H, s)

Example 722

N-(4-(6-Cyano-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea

[1477] After adding the N-[2,3-dimethyl-4-(6-cyano-7-hydroxyquinolin-4-yloxy)phenyl]-N'-cyclopropylurea (100 mg) synthesized in Example 721, 1-(3-chloropropyl)pyrrolidine hydrochloride (95 mg) and potassium carbonate (150 mg) to dimethylformamide (2 ml), the mixture was heated at 60°C for 7 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, and then the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was washed with ethyl acetate to obtain the title compound (49 mg) as light yellow crystals.

¹H-NMR(CDCl₃) δ(ppm) 0.38-0.44(2H, m), 0.59-0.66(2H, m), 1.64-1.71(4H, m), 1.94-2.00(2H, m), 2.01(3H, s), 2.14(3H, s), 2.40-2.60(7H, m), 4.33(2H, t, J=6.4Hz), 6.30(1H, d, J=5.6Hz), 6.82(1H, brs), 6.99(1H, d, J=8.8Hz), 7.58(1H, s), 7.64(1H, d, J=8.8Hz) 7.69(1H, brs), 8.67(1H, d, J=5.6Hz), 8.80(1H, s).

Example 723

N-(4-(6-Cyano-7-((2R)-2-hydroxy-3-pyrrolidin-1-ylpropoxy) quinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea

[1478] After adding tetrahydrofuran (2.0 ml) and pyrrolidine (0.20 ml) to N-(4-(6-cyano-7-((2R)-oxiran-2-yl)methoxyquinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea (110 mg), the mixture was heated at 60°C for 2 hours. After allowing the reaction solution to cool, the precipitated crystals were filtered out to obtain the title compound (18 mg) as light brown crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 0.40-0.46(2H, m), 0.62-0.68(2H, m), 1.65-1.73(4H, m), 2.03(3H, s), 2.16(3H, s), 2.45-2.70(7H, m), 4.00-4.08(1H, m), 4.22(1H, dd, J=10.4, 5.6Hz), 4.32(1H, dd, J=10.4, 3.6Hz), 5.04(1H, d, J=4.4Hz), 6.32(1H, d, J=5.6Hz), 6.67-6.72(1H, m), 7.02(1H, d, J=8.8Hz), 7.61-7.72(3H, m), 8.69(1H, d, J=5.6Hz), 8.82(1H, s).

[1479] The starting material was synthesized in the following manner.

Production Example 723-1

N-(4-(6-Cyano-7-((2R)-oxiran-2-yl)methoxyquinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea

[1480] Dimethylformamide (4 ml) was added to N-(2,3-dimethyl-4-(6-cyano-7-hydroxyquinolin-4-yloxy)-phenyl)-N'-cyclopropylurea (476 mg), and then p-toluenesulfonic acid (2R)-glycidyl ester (365 mg) and potassium carbonate (340 mg) were further added and the mixture was heated at 50°C for 4 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was washed with ethyl acetate to obtain the title compound (270 mg) as light yellow crystals.

¹H-NMR (DMSO-d₆) δ(ppm) 0.40-0.46(2H, m), 0.62-0.68(2H, m), 2.03(3H, s), 2.16(3H, s), 2.52-2.60(1H, m), 2.80-2.96(2H, m), 3.45-3.52(1H, m), 4.18(1H, dd, J=11.6, 6.4Hz), 4.73(1H, dd, J=11.6, 2.0Hz), 6.34(1H, d, J=5.6Hz), 6.69-6.74(1H, m), 7.01(1H, d, J=8.8Hz), 7.61-7.75(2H, m), 7.95(1H, brs), 8.70(1H, d, J=5.6Hz), 8.85(1H, s).

Example 724

N-(4-(6-Cyano-7-((2R)-2-hydroxy-3-piperidin-1-ylpropoxy)quinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea

[1481] After adding tetrahydrofuran (2.0 ml) and piperidine (0.20 ml) to N-(4-(6-cyano-7-((2R)-oxiran-2-yl)methoxyquinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea (80 mg), the mixture was heated at 60°C for 4 hours. After allowing the reaction solution to cool, the precipitated crystals were filtered out to obtain the title compound (50 mg) as light brown crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 0.40-0.46(2H, m), 0.62-0.68(2H, m), 1.30-1.55(6H, m), 2.03(3H, s), 2.16(3H, s), 2.30-2.70(7H, m), 4.00-4.09(1H, m), 4.22(1H, dd, J=10.4, 5.6Hz), 4.32(1H, dd, J=10.4, 3.6Hz), 4.95(1H, d, J=4.0Hz), 6.32(1H, d, J=5.6Hz), 6.71-6.74(1H, m), 7.02(1H, d, J=8.8Hz), 7.62-7.70(2H, m), 7.73(1H, brs), 8.69(1H, d, J=5.6Hz), 8.82(1H, s).

s).

Example 725

N-(4-(6-Cyano-7-(3-diethylamino-(2R)-2-hydroxypropoxy)quinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea

[1482] After adding tetrahydrofuran (2.0 ml) and diethylamine (0.50 ml) to N-(4-(6-cyano-7-((2R)-oxiran-2-yl)methoxyquinolin-4-yloxy)-2,3-dimethylphenyl)-N'-cyclopropylurea (80 mg), the mixture was heated at 60°C for 6 hours. The reaction solution was allowed to cool, and the precipitated crystals were filtered out to obtain the title compound (32 mg) as light brown crystals.

¹H-NMR(DMSO-d₆) δ(ppm) 0.40-0.46(2H, m), 0.62-0.69(2H, m), 0.98(6H, t, J=7.2Hz), 2.03(3H, s), 2.16(3H, s), 2.40-2.70(7H, m), 3.90-4.02(1H, m), 4.22(1H, dd, J=10.4, 5.6Hz), 4.32(1H, dd, J=10.4, 3.6Hz), 4.93(1H, d, J=4.0Hz), 6.32(1H, d, J=5.6Hz), 6.71-6.74(1H, m), 7.02(1H, d, J=8.8Hz), 7.61-7.70(2H, m), 7.72(1H, brs), 8.69(1H, d, J=5.6Hz), 8.82(1H, s).

Example 726

N6-Ethyl-7-benzyloxy-4-(3-chloro-4-((methylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide

[1483] N6-Ethyl-4-(4-amino-3-chlorophenoxy)-7-benzyloxy-6-quinolinecarboxamide(870 mg, 1.94 mmol) and pyridine (460 mg, 5.82 mmol) were dissolved in dimethylformamide (10 ml), and after adding phenyl chloroformate (456 mg, 2.91 mmol) while cooling on ice, the mixture was stirred at room temperature for 18 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off, and the filtrate was distilled off under reduced pressure. A portion of the obtained product (460 mg, 0.810 mmol) and a 40% methylamine-methanol solution (0.810 ml) were stirred together in dimethylformamide (5 ml) at room temperature for 30 minutes. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off, and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate and diluted with hexane, and then the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (359 mg, 0.711 mmol, 74%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.07 (3H, t, J = 7.4 Hz), 2.68 (3H, d, J = 4.0 Hz), 3.30 (2H, m), 5.41 (2H, s), 6.54 (1H, d, J = 5.2 Hz), 6.89 (1H, m), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.34-7.40 (1H, m), 7.40-7.49 (3H, m), 7.55-7.60 (2H, m), 7.61 (1H, s), 8.13 (1H, s), 8.25 (1H, dd, J = 3.2, 9.2 Hz), 8.36 (1H, t, J = 5.2 Hz), 8.51 (1H, s), 8.66 (1H, d, J = 5.2 Hz).

[1484] The starting materials were synthesized in the following manner.

Production Example 726-1

N6-Ethyl-7-benzyloxy-4-chloro-6-quinolinecarboxamide

[1485] After adding thionyl chloride (10 ml) and a catalytic amount of dimethylformamide to phenyl 7-benzyloxy-4-oxo-1,4-dihydro-6-quinolinecarboxylate (2.32 g, 6.25 mmol), the mixture was heated to reflux for 2 hours while stirring. The reaction solution was concentrated under reduced pressure and azeotropically distilled twice with toluene, the residue was dissolved in a dimethylformamide (10 ml) and triethylamine (5 ml) mixed solvent, 2M ethylamine (tetrahydrofuran solution) (6.25 ml, 12.5 mmol) was gradually added thereto while cooling in an ice water bath, and the mixture was stirred at room temperature for 3 hours. The reaction solution was distributed between ethyl acetate and water, and then the organic layer was washed with ammonia water, water and saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off, after which ethyl acetate and then diethyl ether were added for crystallization and the crystals were filtered out and blow-dried to obtain the title compound (723 mg, 2.12 mmol, 34%) as yellow crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.08 (3H, t, J = 7.2 Hz), 3.30 (2H, m), 5.41 (2H, s), 7.34-7.39 (1H, m), 7.40-7.46 (2H, m), 7.54-7.59 (2H, m), 7.66 (1H, d, J = 4.8 Hz), 7.70 (1H, s), 8.36 (1H, s), 8.42 (1H, m), 8.81 (1H, d, J = 4.8 Hz).

Production Example 726-2

N6-Ethyl-4-(4-amino-3-chlorophenoxy)-7-benzyloxy-6-quinolinecarboxamide

[1486] After dissolving 4-amino-3-chlorophenol (379 mg, 2.64 mmol) in dimethylsulfoxide (10 ml), sodium hydride (106 mg, 2.64 mmol) was gradually added at room temperature and the mixture was stirred for 30 minutes. N6-Ethyl-7-benzyloxy-4-chloro-6-quinolinecarboxamide (720 mg, 2.11 mmol) was added, and the mixture was heated at 100°C for 2 hours while stirring. Upon cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with ammonia water, water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, suspended in ethyl acetate and diluted with hexane, and the crystals were filtered out and blow-dried to obtain the title compound (870 mg, 1.94 mmol, 92%) as brown crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 1.07 (3H, t, J = 7.2 Hz), 3.30 (2H, m), 5.40 (2H, s), 5.43-5.49 (2H, m), 6.47 (1H, d, J = 5.2 Hz), 6.91 (1H, d, J = 8.8 Hz), 7.01 (1H, dd, J = 2.8, 8.8 Hz), 7.24 (1H, d, J = 2.8 Hz), 7.34-7.39 (1H, m), 7.41-7.46 (2H, m), 7.55-7.60 (3H, m), 8.36 (1H, t, J = 5.2 Hz), 8.52 (1H, s), 8.62 (1H, d, J = 5.2 Hz).

Example 727N6-Ethyl-7-benzyloxy-4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide

[1487] After dissolving N6-ethyl-4-(4-amino-3-chlorophenoxy)-7-benzyloxy-6-quinolinecarboxamide (870 mg, 1.94 mmol) and pyridine (460 mg, 5.82 mmol) in dimethylformamide (10 ml), phenyl chloroformate (456 mg, 2.91 mmol) was added while cooling on ice, and the mixture was stirred at room temperature for 18 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. A portion of the obtained product (460 mg, 0.810 mmol) and a 2 M ethylamine-tetrahydrofuran solution (4.05 ml) were stirred together in dimethylformamide (5 ml) at room temperature for 30 minutes. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in ethyl acetate and diluted with hexane, and then the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (347 mg, 0.669 mmol, 83%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm) : 1.03-1.11 (6H, m), 3.14 (2H, m), 3.30 (2H, m), 5.41 (2H, s), 6.54 (1H, d, J = 5.2 Hz), 7.01 (1H, m), 7.23 (1H, dd, J = 2.8, 9.2 Hz), 7.34-7.40 (1H, m), 7.41-7.49 (3H, m), 7.55-7.60 (2H, m), 7.61 (1H, s), 8.07 (1H, s), 8.27 (1H, dd, J = 3.2, 9.2 Hz), 8.36 (1H, t, J = 5.2 Hz), 8.51 (1H, s), 8.66 (1H, d, J = 5.2 Hz).

Example 728N6-Ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

[1488] The title compound (253 mg, 0.609 mmol, 90%) was obtained as yellow crystals from N6-ethyl-7-benzyloxy-4-(3-chloro-4-((methylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide (344 mg, 0.681 mmol), by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.18 (3H, t, J = 7.2 Hz), 2.68 (3H, d, J = 4.4 Hz), 3.38 (2H, m), 6.42 (1H, d, J = 5.2 Hz), 6.88 (1H, q, J = 4.4 Hz), 7.25 (1H, dd, J = 2.8, 9.2 Hz), 7.31 (1H, s), 7.49 (1H, d, J = 2.8 Hz), 8.13 (1H, s), 8.27 (1H, d, J = 9.2 Hz), 8.61 (1H, d, J = 5.2 Hz), 8.89 (1H, s).

Example 729N6-Ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

[1489] The title compound (247 mg, 0.576 mmol, 90%) was obtained as yellow crystals from N6-ethyl-7-benzyloxy-4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide (332 mg, 0.640 mmol), by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆) δ (ppm): 1.08 (3H, t, J = 7.2 Hz), 1.18 (3H, t, J = 7.2 Hz), 3.14 (2H, m), 3.39 (2H, m), 6.42 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.2 Hz), 7.25 (1H, dd, J = 2.8, 9.2 Hz), 7.30 (1H, s), 7.49 (1H, d, J = 2.8 Hz), 8.08 (1H, s), 8.29 (1H, d, J = 9.2 Hz), 8.61 (1H, d, J = 5.2 Hz), 8.90 (1H, s).

Example 730

N6-Ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide

[1490] N6-Ethyl-4-(3-chloro-4-(((methylamino)carbonyl)amino) phenoxy)-7-hydroxy-6-quinolinecarboxamide (80.0 mg, 0.193 mmol), tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate (80.5 mg, 0.289 mmol) and potassium carbonate (33.3 mg, 0.241 mmol) were heated and stirred in dimethylformamide (1 ml) at 60°C for 15 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained product was stirred in trifluoroacetic acid (1 ml) at room temperature for 1 hour, and then the reaction solution was concentrated under reduced pressure, the residue was dissolved in methanol and triethylamine was added dropwise for neutralization. After distilling off the solvent, the residue was dissolved in a tetrahydrofuran (2 ml)-methanol (2 ml) mixed solvent, and then a 37% formaldehyde aqueous solution (0.360 ml), acetic acid (0.070 ml) and sodium cyanoborohydride (36.3 mg, 0.579 mmol) were added in that order at room temperature and the mixture was stirred for 15 minutes. After adding basic silica gel to the reaction solution and concentrating it, it was subjected to silica gel column chromatography, the target fraction was concentrated under reduced pressure, the obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (57.5 mg, 0.109 mmol, 57%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.16 (3H, t, J = 7.2 Hz), 1.38 (2H, m), 1.72-1.92 (5H, m), 2.17 (3H, s), 2.68 (3H, d, J = 4.4 Hz), 2.81 (2H, m), 3.36 (2H, m), 4.11 (2H, d, J = 6.0 Hz), 6.53 (1H, d, J = 5.2 Hz), 6.87 (1H, m), 7.22 (1H, dd, J = 2.8, 8.8 Hz), 7.46 (1H, d, J = 2.8 Hz), 7.49 (1H, s), 8.12 (1H, s), 8.20-8.28 (2H, m), 8.50 (1H, s), 8.65 (1H, d, J = 5.2 Hz).

Example 731

N6-Ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide

[1491] N6-Ethyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino) phenoxy)-7-hydroxy-6-quinolinecarboxamide (78.0 mg, 0.182 mmol), tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate (75.9 mg, 0.273 mmol) and potassium carbonate (31.4 mg, 0.228 mmol) were heated and stirred in dimethylformamide (1 ml) at 60°C for 15 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained product was stirred in trifluoroacetic acid (1 ml) at room temperature for 1 hour, and then the reaction solution was concentrated under reduced pressure, the residue was dissolved in methanol and triethylamine was added dropwise for neutralization. After distilling off the solvent, the residue was dissolved in a tetrahydrofuran (2 ml)-methanol (2 ml) mixed solvent, and then a 37% formaldehyde aqueous solution (0.340 ml), acetic acid (0.070 ml) and sodium cyanoborohydride (34.3 mg, 0.546 mmol) were added in that order at room temperature and the mixture was stirred for 15 minutes. After adding basic silica gel to the reaction solution and concentrating it, it was subjected to silica gel column chromatography, the target fraction was concentrated under reduced pressure, the obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (58.1 mg, 0.108 mmol, 59%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm): 1.08 (3H, t, J = 7.2 Hz), 1.16 (3H, t, J = 7.2 Hz), 1.38 (2H, m), 1.72-1.92 (5H, m), 2.17 (3H, s), 2.81 (2H, m), 3.14 (2H, m), 3.35 (2H, m), 4.10 (2H, d, J = 6.0 Hz), 6.53 (1H, d, J = 5.2 Hz), 7.00 (1H, m), 7.22 (1H, dd, J = 2.8, 8.8 Hz), 7.47 (1H, d, J = 2.8 Hz), 7.49 (1H, s), 8.07 (1H, s), 8.22-8.29 (2H, m), 8.50 (1H, s), 8.66 (1H, d, J = 5.2 Hz).

Example 732

N6-Methoxy-7-benzyloxy-4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide

[1492] N6-Methoxy-4-(4-amino-3-chlorophenoxy)-7-benzyloxy-6-quinolinecarboxamide (81.0 mg, 0.180 mmol) and pyridine (32.0 mg, 0.404 mmol) were dissolved in dimethylformamide (2 ml), and after adding phenyl chloroformate (42.3 mg, 0.270 mmol) while cooling on ice, the mixture was stirred at room temperature for 30 minutes. A 2 M ethylamine-tetrahydrofuran solution (0.270 ml) was added to the reaction solution, and the mixture was further stirred at room temperature for 30 minutes. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was

filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was suspended in diethyl ether and diluted with hexane, and then the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (68.5 mg, 0.131 mmol, 73%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.08 (3H, t, J = 7.2 Hz), 3.15 (2H, m), 3.72 (3H, s), 5.40 (2H, s), 6.54 (1H, d, J = 5.2 Hz), 7.01 (1H, m), 7.22 (1H, dd, J = 2.8, 9.2 Hz), 7.32-7.37 (1H, m), 7.40-7.46 (2H, m), 7.47 (1H, d, J = 2.8 Hz), 7.53-7.60 (3H, m), 8.07 (1H, s), 8.27 (1H, dd, J = 3.2, 9.2 Hz), 8.34 (1H, s), 8.65 (1H, d, J = 5.2 Hz), 11.53 (1H, br s).

[1493] The starting materials were synthesized in the following manner.

Production Example 732-1

N6-Methoxy-7-benzyloxy-4-chloro-6-quinolinecarboxamide

[1494] After adding thionyl chloride (10 ml) and a catalytic amount of dimethylformamide to phenyl 7-benzyloxy-4-oxo-1,4-dihydro-6-quinolinecarboxylate (2.32 g, 6.25 mmol), the mixture was heated to reflux for 2 hours while stirring. The reaction solution was concentrated under reduced pressure and azeotropically distilled twice with toluene, the residue was dissolved in a dimethylformamide (20 ml) and triethylamine (20 ml) mixed solvent, methoxylamine hydrochloride (10.4 g, 125 mmol) was added thereto while cooling in an ice water bath, and the mixture was stirred at room temperature for 18 hours. The reaction solution was distributed between ethyl acetate and water, and then the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate. After distilling off the solvent, it was subjected to silica gel column chromatography, the target fraction was concentrated under reduced pressure, the obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (392 mg, 1.14 mmol, 18%) as white crystals.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 3.72 (3H, s), 5.41 (2H, s), 7.32-7.38 (1H, m), 7.40-7.46 (2H, m), 7.52-7.56 (2H, m), 7.64-7.70 (2H, m), 8.22 (1H, s), 8.82 (1H, d, J = 4.8 Hz), 11.60 (1H, br s).

Production Example 732-2

N6-Methoxy-4-(4-amino-3-chlorophenoxy)-7-benzyloxy-6-quinolinecarboxamide

[1495] After dissolving 4-amino-3-chlorophenol (408 mg, 2.84 mmol) in dimethylsulfoxide (10 ml), sodium hydride (114 mg, 2.84 mmol) was gradually added at room temperature and the mixture was stirred for 30 minutes. N6-Methoxy-7-benzyloxy-4-chloro-6-quinolinecarboxamide (388 mg, 1.14 mmol) was added, and the mixture was heated at 100°C for 18 hours while stirring. Upon cooling to room temperature, the reaction solution was distributed between ethyl acetate and water, and the organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate. After distilling off the solvent, it was subjected to silica gel column chromatography, the target fraction was concentrated under reduced pressure, the obtained crude product was suspended in ethyl acetate, the suspension was diluted with hexane, and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (81.0 mg, 0.180 mmol, 16%) as light red crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 3.81 (3H, s), 4.22 (2H, br s), 5.43 (2H, s), 6.68 (1H, d, J = 6.2 Hz), 6.88 (1H, d, J = 8.8 Hz), 6.94 (1H, dd, J = 2.8, 8.8 Hz), 7.16 (1H, d, J = 2.8 Hz), 7.41-7.58 (5H, m), 8.14 (1H, s), 8.66 (1H, d, J = 6.2 Hz), 9.35 (1H, s), 10.19 (1H, s).

Example 733

N6-Methoxy-4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

[1496] The title compound (43.3 mg, 0.101 mmol, 77%) was obtained as yellow crystals from N6-methoxy-7-benzyloxy-4-(3-chloro-4-((ethylamino)carbonyl)amino)phenoxy)-6-quinolinecarboxamide (68.3 mg, 0.131 mmol), by the same procedure as in Example 83.

¹H-NMR Spectrum (DMSO-d₆)δ(ppm) : 1.08 (3H, t, J = 7.2 Hz), 3.14 (2H, m), 3.76 (3H, s), 6.43 (1H, d, J = 5.2 Hz), 7.00 (1H, t, J = 5.2 Hz), 7.25 (1H, dd, J = 2.8, 9.2 Hz), 7.34 (1H, brs), 7.48 (1H, d, J = 2.8 Hz), 8.07 (1H, s), 8.27 (1H, d, J = 9.2 Hz), 8.60 (1H, d, J = 5.2 Hz), 8.64 (1H, s).

Example 734N6-Methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[1497] The target substance was obtained using a methylamine-containing methanol solution, in the same manner as Example 249.

¹H-NMR(DMSO-d₆) δ(ppm): 0.38-0.44 (2H, m), 2.62-2.68 (2H, m), 2.50-2.60 (1H, m), 2.85 (3H, d, J= 4.8Hz), 3.37 (3H, s), 3.79 (2H, t, J= 4.4Hz), 4.39 (2H, t, J= 4.4Hz), 6.52 (1H, d, J= 5.2Hz), 7.18 (1H, d, J= 2.4Hz), 7.23 (1H, dd, J= 8.8Hz, 2.4Hz), 7.48 (1H, d, J= 2.4Hz), 7.55 (1H, s), 7.96 (1H, s), 8.26 (1H, d, J= 8.8Hz), 8.35 (1H, q, J= 4.8Hz), 8.65 (1H, d, J= 5.2Hz), 8.66 (1H, s).

Example 735N6-Ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide

[1498] The target substance was obtained using an ethylamine-containing tetrahydrofuran solution, in the same manner as Example 249.

¹H-NMR (DMSO-d₆) δ(ppm): 0.38-0.44 (2H, m), 2.62-2.68 (2H, m), 1.15 (3H, t, J= 7.2Hz), 2.50-2.60 (1H, m), 3.27-3.40 (2H, m), 3.36 (3H, s), 3.79 (2H, t, J= 4.4Hz), 4.39 (2H, t, J= 4.4Hz), 6.51 (1H, d, J= 5.6Hz), 7.18 (1H, d, J= 2.8Hz), 7.23 (1H, dd, J= 8.8Hz, 2.8Hz), 7.48 (1H, d, J= 2.8Hz), 7.54 (1H, s), 7.96 (1H, s), 8.26 (1H, d, J= 8.8Hz), 8.34 (1H, t, J= 4.8Hz), 8.65 (1H, d, J= 5.6Hz), 8.68 (1H, s).

Example 736N-(2-Chloro-4-(6-cyano-7-(3-(1-piperidino)propoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylurea

[1499] The title compound (102.2 mg, 0.197 mmol, 12.3%) was obtained as light yellow crystals from N-(4-(6-cyano-7-hydroxy-4-quinolyl)oxy-2-chlorophenyl)-N'-cyclopropylurea (500 mg, 1.60 mmol) and 1-(3-chloropropyl)piperidine hydrochloride, by the same procedure as in Example 7.

¹H-NMR Spectrum (DMSO-d₆) δ(ppm) : 0.42 (2H, m), 0.65 (2H, m), 1.37 (2H, m), 1.48 (2H, m), 1.96 (2H, m), 2.34 (4H, m), 2.43-2.49 (4H, m), 2.56 (1H, m), 4.31 (2H, m), 6.57 (1H, d, J=5.2Hz), 7.19 (1H, d, J=2.8Hz), 7.25 (1H, dd, J=2.8, 8.8Hz), 7.49 (1H, d, J=2.8Hz), 7.59 (1H, s), 7.98 (1H, s), 8.27 (1H, d, J=8.8Hz), 8.71-8.74 (2H, m).

Example 737N-(3-Fluorophenyl)-N'-(4-(thieno[2,3-d]pyrimidin-4-yloxy)phenyl)urea

[1500] After adding 370 mg of iron powder, 750 mg of ammonium chloride, 30 ml of ethanol and 3 ml of water to 250 mg of 4-(4-nitrophenoxy)thieno[2,3-d]pyrimidine, the mixture was stirred at 80-85°C for 2.5 hours. After returning the mixture to room temperature, tetrahydrofuran was added, the mixture was filtered with celite, and ethyl acetate and water were added to the filtrate for liquid separation and extraction. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with plug cotton and concentrated to dryness to obtain 182 mg of an amino compound. A 70 mg portion of this compound was refluxed to dissolution in 4 ml of toluene and 4 ml of acetonitrile, and after adding 3-fluorophenylisocyanate (90 μl), the mixture was stirred for 1 hour. Upon returning the mixture to room temperature, the precipitated crystals were filtered out and dried to obtain 73 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 6.72-6.80 (1H, m), 7.12 (1H, d, J=7.7Hz), 7.22 (2H, d, J=7.7Hz), 7.28 (1H, dd, J=14.2Hz, 7.1Hz), 7.49 (1H, d, J=14.2Hz), 7.52 (2H, d, J=7.7Hz), 7.64 (1H, dd, J=6.5Hz, 1.5Hz), 7.84 (1H, d, J=6.5Hz), 8.60(1H, s.), 9.00(1H, s.), 9.10(1H, s.)

[1501] The intermediate was synthesized in the following manner.

Production Example 737-14-(4-Nitrophenoxy)thieno[2,3-d]pyrimidine

[1502] After adding 600 mg of 4-nitrophenol, 1.2 g of potassium carbonate and 2 ml of dimethylformamide to 302 mg of the 4-chlorothieno[2,3-d]pyrimidine described in Seans Acad. Sci., Ser, C(1967)264(2)207, and stirring the mixture for 30 hours at 130°C, the mixture was returned to room temperature, water was added, liquid separation and

extraction were performed with an ethyl acetate-tetrahydrofuran mixed solvent, and the solid obtained by concentration to dryness was washed with ether to obtain 250 mg of the title compound.

¹H-NMR Spectrum: (DMSO-d₆) 7.63(2H, d, J=8.7Hz), 7.68 (1H, d, J=6.1Hz), 8.00(1H, d, J=6.1Hz), 8.35(2H, d, J=8.7Hz), 8.65(1H, s,)

Example 738

N-(4-Fluorophenyl)-N'-(4-(thieno[2,3-d]pyrimidin-4-yloxy)phenyl)urea

[1503] The title compound (92 mg) was obtained from 90 mg of the amino compound described in Example 737, using 4-fluorophenyl isocyanate (90 μl), by the same procedure as in Example 737.

¹H-NMR Spectrum: (DMSO-d₆) 7.12 (2H, t, J=9.6Hz), 7.20(2H, d, J=8.6Hz), 7.46 (2H, dd, J=9.6Hz, 5.2Hz), 7.52 (2H, d, J=8.6Hz), 7.63 (1H, d, J=6.2Hz), 7.94 (1H, d, J=6.2Hz), 8.59(1H, s), 8.89(1H, s), 8.94(1H, s)

Example 739

N-(3-Fluorophenyl)-N'-(4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl)urea

[1504] An amino compound (310 mg) was obtained from 4-(4-nitrophenoxy)thieno[3,2-d]pyrimidine (375 mg) by the method described in Example 737. The title compound (250 mg) was obtained from 135 mg of the amino compound using 3-fluorophenyl isocyanate (90 μl), by the method described in Example 737.

¹H-NMR Spectrum: (DMSO-d₆) 6.72-7.56 (8H, m), 7.65 (1H, d, J=6.2Hz), 8.44 (1H, d, J=6.2Hz), 8.68(1H, s,), 8.86(1H, s,), 8.95(1H, s)

[1505] The intermediate was synthesized in the following manner.

Production Example 739-1

4-(4-Nitrophenoxy)thieno[3,2-d]pyrimidine

[1506] The title compound (382 mg) was obtained from 315 mg of the 4-chlorothieno[3,2-d]pyrimidine described in Seans Acad. Sci., Ser, C(1967) 264(1)100, by the method described in Production Example 737-1.

¹H-NMR Spectrum: (DMSO-d₆) 7.63-7.69(2H, m), 7.70 (1H, d, J=6.1Hz), 8.32-8.38(2H, m), 8.51 (1H, d, J=6.1Hz), 8.73 (1H, s,)

Example 740

N-(4-Fluorophenyl)-N'-(4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl)urea

[1507] The title compound (135 mg) was obtained from 150 mg of the amino compound described in Example 739 using 4-fluorophenyl isocyanate (94 μl), by the same procedure as in Example 737.

¹H-NMR Spectrum: (DMSO-d₆) 7.00-7.56 (8H, m), 7.65 (1H, d, J=6.1Hz), 8.44 (1H, d, J=6.1Hz), 8.67(1H, s), 8.73(1H, s), 8.78(1H, s)

Example 741

N-(4-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-N'-(3-methanesulfonylphenyl)urea

[1508] The 4-(6,7-dimethoxyquinolin-4-yloxy)phenylamine (296 mg, 1.00 mmol) obtained by the method described in WO97/17329 and (3-methanesulfonylphenyl)carbamic acid phenyl ester (291 mg, 1.00 mmol) were heated and stirred in dimethylsulfoxide (3 ml) at 85°C for 2 hours. The reaction solution was distributed between ethyl acetate and water, the organic layer was washed with 1N aqueous sodium hydroxide, water and saturated brine and dried over anhydrous magnesium sulfate, the drying agent was filtered off and the filtrate was distilled off under reduced pressure. The obtained crude product was subjected to silica gel column chromatography (eluent - ethyl acetate:methanol = 30:1), the fraction containing the target substance was concentrated and suspended in ethyl acetate, the suspension was diluted with hexane and the crystals were filtered out, washed with hexane and blow-dried to obtain the title compound (430 mg, 0.871 mmol, 87%) as colorless crystals.

¹H-NMR Spectrum (CDCl₃)δ(ppm) : 3.16 (3H, s), 4.03 (3H, s), 4.05 (3H, s), 6.46 (1H, d, J = 5.2 Hz), 7.12-7.18 (2H, m), 7.41 (1H, s), 7.50-7.62 (6H, m), 7.81 (1H, s), 7.93 (1H, s), 8.11-8.15 (1H, m), 8.48 (1H, d, J = 5.2 Hz).

Example 742N-(2-Chloro-4-((6-cyano-7-(4-piperidylmethoxy)-4-quinolyl)oxy)phenyl)-N'-methylurea

[1509] N-(2-chloro-4-((6-cyano-7-hydroxyquinolin-4-yloxy)phenyl)-N'-methylurea (125 mg) was added to dimethylformamide (1.5 ml), and then tert-butyl 4-(bromomethyl)-1-piperidinecarboxylate (141 mg) and potassium carbonate (93 mg) were added thereto and the mixture was heated at 60°C for 3 hours. Water was added to the reaction solution, extraction was performed with ethyl acetate, the organic layer was washed with water and saturated brine in that order and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained crude product was recrystallized with ethyl acetate to obtain tert-butyl 4-(((4-(3-chloro-4-((methylamino)carbonyl)aminophenoxy)-6-cyano-7-quinolyl)oxy)methyl)-1-piperidinecarboxylate (21 mg) as light yellow crystals. These were dissolved in trifluoroacetic acid (1.0 ml), and the solution was stirred for 10 minutes at room temperature. Water (2 ml) was added, the mixture was neutralized with sodium bicarbonate, and the precipitated crystals were filtered out to obtain the title compound (16 mg).

H-NMR(DMSO-d₆) δ(ppm) : 1.20-1.35 (4H, m), 1.70-1.80(2H, m), 1.90-2.01 (1H, m), 2.66 (3H, d, J=4.4Hz), 2.95-3.05 (2H, m), 4.12 (2H, d, J=6.0Hz), 6.58 (1H, d, J=5.2Hz), 6.84-6.92(1H, m), 7.21-7.26 (1H, m), 7.48 (1H, d, J=2.4Hz), 7.59 (1H, s), 8.12 (1H, s), 8.22-8.28 (1H, m), 8.71-8.78 (2H, m).





























































Example 743N-(2-Chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N'-methylurea

[1510] After dissolving N-(2-chloro-4-((6-cyano-7-(4-piperidylmethoxy)-4-quinolyl)oxy)phenyl)-N'-methylurea (15 mg) in tetrahydrofuran (0.5 ml) and methanol (0.5 ml), there were added 37% aqueous formaldehyde (0.03 ml), acetic acid (0.06 ml) and sodium cyanoborohydride (5.0 mg) at room temperature, and the mixture was stirred for 1 hour. Water was added to the reaction solution, saturated aqueous sodium bicarbonate was added for neutralization, and extraction was performed with ethyl acetate. The organic layer was washed with water and the solvent was distilled off to obtain a crude product. This was recrystallized with ethyl acetate to obtain the title compound (10 mg) as white crystals.

H-NMR(DMSO-d₆) δ(ppm): 1.13-1.47 (2H, m), 1.75-1.95 (5H, m), 2.17 (3H, s), 2.68 (3H, s), 2.78-2.87(2H, m), 4.17 (2H, d, J=6.0Hz), 6.59 (1H, d, J=5.2Hz), 6.95(1H, brs), 7.22-7.28 (1H, m), 7.48 (1H, d, J=2.4Hz), 7.61 (1H, s), 8.18 (1H, brs), 8.22-8.29 (1H, m), 8.72-8.77 (2H, m).

[1511] The structural formulas for the compounds obtained in the preceding Production Examples and Examples are shown below in Tables 4 to 51.

[Table 4]

5						
10						
15						
20						
25						
30						
35						
40						
45						
50						



















[Table 5]

5				
10				
15				
20				
25				
30				
35				
40				
45				
50				

[Table 6]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			

[Table 7]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			
55			

[Table 8']
















5			
10			
15			
20			
25			
30			
35			
40			
45			
50			

[Table 9]






















[Table 10]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			
55			






















[Table 11]

5
10			
15
20			
25
30			
35
40			
45
50			
55

[Table 12]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			
55			
























[Table 13]

[Table 14]

























5			
10			
15			
20			
25			
30			
35			
40			
45			
50			
55			

[Table 15]


5			
10			
15			
20			
25			
30			
35			
40			
45			
50			

[Table 16]


[Table 17]

[Table 18]



[Table 19]




[Table 20]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			

[Table 21]

5
10
15
20
25
30
35
40
45
50

[Table 22]



[Table 23]

5
10			
15
20			
25
30			
35
40			
45
50			


[Table 24]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			


[Table 25]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			

[Table 26]



[Table 27]



























[Table 28]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			

[Table 29]

5
10			
15
20			
25
30			
35
40			
45
50			
55

[Table 30]

5
10			
15			
20			
25
30			
35			
40			
45			
50			
55

[Table 31]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			


[Table 32]

5		
10
15		
20
25		
30
35		
40
45		
50
55		


[Table 33]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			


[Table 34]



[Table 35]




[Table 36]




[Table 37]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			

[Table 38]




[Table 39]




[Table 40]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			
55			































[Table 41]




[Table 42]




[Table 43]

5			
10			
15			
20			
25			
30			
35			
40			
45			
50			


[Table 44]




[Table 45]




[Table 46]




[Table 47]




[Table 48]




[Table 49]



[Table 50]




[Table 51]




Claims

1. A compound represented by the following general formula:




[wherein A^g is an optionally substituted C_{6-14} aryl group or an optionally substituted 5- to 14-membered heterocyclic group; X^g is a single bond, $-O-$, $-S-$, a C_{1-6} alkylene group, $-SO-$, $-SO_2-$ or $-N(R^{g3})-$ (wherein R^{g3} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{2-7} acyl group); Y^g is an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted C_{1-8} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl- C_{1-6} alkyl group, an optionally substituted 5- to 14-membered heteroaryl- C_{1-6} alkyl group, $-(CH_2)_gSO_2-$ (wherein g is an integer of 1 to 8), $-(CH_2)_{fa}-CH=CH-(CH_2)_{fb}-$ (wherein fa and fb each represent 0, 1, 2 or 3), $-(CH_2)_{fa}-CH=CH-(CH_2)_{fb}-SO_2-$ (wherein fa and fb each represent 0, 1, 2 or 3), $-(CH_2)_{fa}-C\equiv C-(CH_2)_{fb}-$ (wherein fa and fb each represent 0, 1, 2 or 3) or $-(CH_2)_{fa}-C\equiv C-(CH_2)_{fb}-SO_2-$ (wherein fa and fb each represent 0, 1, 2 or 3); and T^{g1} is (1) a group represented by the following general formula:




{wherein E^g is a single bond or $-N(R^{g2})-$ (wherein R^{g2} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{2-7} acyl group or an optionally substituted C_{2-7} alkoxy carbonyl group); R^{g1} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{2-7} acyl group or an optionally substituted C_{2-7} alkoxy carbonyl group; and Z^g is a hydrogen atom, an optionally substituted C_{1-8} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted C_{6-14} aryl- C_{1-6} alkyl group, $-OR^{200}$, $-SR^{200}$, $-COR^{200}$, $-SO_2R^{200}$ (wherein R^{200} is a hydrogen atom, an optionally substituted C_{1-8} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted C_{6-14} aryl- C_{1-6}

alkyl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered heterocyclic-C₁₋₆ alkyl group), an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered heterocyclic-C₁₋₆ alkyl group}, or (2) a group represented by the following general formula:




{wherein R⁹¹ and Z⁹ have the same definitions as R⁹¹ and Z⁹ above; and Z⁹¹ and Z⁹² may be the same or different and each is (1) a single bond, (2) an optionally oxo-substituted C₁₋₆ alkylene group also optionally having one or more atoms selected from -O-, -S- and a nitrogen atom within or at the end of the chain, or (3) an optionally substituted C₂₋₆ alkenyl group}},
a salt thereof or a hydrate of the foregoing.

2. A compound represented by the following general formula:




[wherein A is an optionally substituted 5- to 14-membered aromatic heterocyclic group; X is an oxygen atom, a sulfur atom, -SO- or -SO₂; Y is an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C₁₋₆ alkylene group; E is a single bond or -NR²-; R¹ and R² are each independently a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and Z is a group represented by the formula -Z¹¹-Z¹² (wherein Z¹¹ is a single bond, an oxygen atom, a sulfur atom, -CO-, -SO₂- or an optionally substituted C₁₋₆ alkylene group and Z¹² is a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or a group represented by the formula:



(wherein Z³¹, Z³³ and Z³⁴ are each independently a methylene group, -CO-, -NH- or -O-, and Z³² is a single bond, a methylene group, -CO-, -NH- or -O-), with the proviso that A may be an optionally substituted with 1 to 6 groups, each selected from the group consisting of (1) a cyano group, (2) a halogen atom, (3) a nitro group and (4) the formula -V^{X1}-V^{X2}-V^{X22}-V^{X3} (wherein V^{X1}, V^{X2} and V^{X22} are each independently a single bond, an oxygen atom, a sulfur atom, -CO-, -SO-, -SO₂-, -NR^{X1}-, -CONR^{X1}-, -NR^{X1}CO-, -SO₂NR^{X1}-, -NR^{X1}SO₂-, -O-CO-, -C(O)O-, -NR^{X1}C(O)O-, -NR^{X1}C(O)NR^{X2}-, -O-C(O)NR^{X1}-, -O-C(O)O-, an optionally substituted C₁₋₆ alkylene group, an op-


tionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and V^{X3}, R^{X1} and R^{X2} are each independently a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C₁₋₆ alkoxy group)], a salt thereof or a hydrate of the foregoing.

3. A compound according to claim 2, a salt of the compound or a hydrate of the foregoing, wherein X is an oxygen atom or a sulfur atom.
4. A compound according to claim 2 or 3, a salt of the compound or a hydrate of the foregoing, wherein Z is an optionally substituted cyclopropyl group, an optionally substituted 2-thiazolyl group or a group represented by the formula:




(wherein Z¹³ is a nitrile group, a methylsulfonyl group or a -NHCOCH₃ group).

5. A compound according to any one of claims 2 to 4, a salt of the compound or a hydrate of the foregoing, wherein E is a group represented by the formula -NR²- (wherein R² has the same definition as R² in claim 2), and Y is an optionally substituted phenyl group, an optionally substituted pyridyl group or a group represented by the formula:




(wherein W¹¹ and W¹² are each independently an optionally substituted carbon atom or a nitrogen atom).

6. A compound according to any one of claims 2 to 4, a salt of the compound or a hydrate of the foregoing, wherein E is a single bond, and Y is a further optionally substituted group represented by the formula:





(wherein W¹³ is an optionally substituted carbon atom or a nitrogen atom).


7. A compound according to any one of claims 2 to 6, a salt of the compound or a hydrate of the foregoing, wherein A is a group represented by the formula:



[wherein W is an optionally substituted carbon atom or a nitrogen atom; R^{a13} is a hydrogen atom, a halogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{1-6} alkoxy group, an amino group or a nitro group; R^{a12} is a cyano group or a group represented by the formula:




(wherein V^{a11} is $-CO-$ or $-SO_2-$; and V^{a12} , V^{a13} and V^{a14} are each independently a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group); and R^{a11} is a group represented by the formula $-V^{a21}-V^{a22}-V^{a23}$ (wherein V^{a21} is an optionally substituted C_{1-6} alkylene group, a single bond or a group represented by the formula:




; V^{a22} is a single bond, an oxygen atom, a sulfur atom, $-CO-$, $-SO-$, $-SO_2-$, $-CONR^{a14}-$, $-SO_2NR^{a14}-$, $-NR^{a14}SO_2-$, $-NR^{a14}CO-$ or $-NR^{a14}-$ (wherein R^{a14} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{3-8} alicyclic hydrocarbon group); and V^{a23} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group)].

8. A compound according to any one of claims 2 to 6, a salt of the compound or a hydrate of the foregoing, wherein A is a group represented by the formula:




(wherein W is an optionally substituted carbon or a nitrogen atom; and R^{a11} , R^{a12} and R^{a13} have the same definitions as R^{a11} , R^{a12} and R^{a13} in claim 7).

9. A compound according to any one of claims 2 to 6, a salt of the compound or a hydrate of the foregoing, wherein A is a further optionally substituted group represented by the formula:




[wherein W is an optionally substituted carbon atom or a nitrogen atom; and A^{b11} is (1) an optionally substituted 5- to 14-membered heterocyclic group or (2) a group represented by the formula:




(wherein V^{b11} and V^{b12} are each independently a single bond, $-SO_2-$, $-NHCO-$ or a group represented by the formula $-(CH_2)_b-CO-$ (wherein b is an integer of 0 to 6); R^{b13} is a single bond, an optionally substituted C_{1-6} alkylene group, an optionally substituted C_{3-8} alicyclic hydrocarbon group or an optionally substituted 5- to 14-membered heterocyclic group; and R^{b11} and R^{b12} are each independently a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted 5- to 14-membered heterocyclic group)].

10. A compound according to any one of claims 2 to 6, a salt of the compound or a hydrate of the foregoing, wherein A is a group represented by the formula:




[wherein W is an optionally substituted carbon or a nitrogen atom; R^{c13} is (1) a hydrogen atom, (2) a cyano group, (3) a halogen atom, (4) a formyl group, (5) an optionally substituted C_{1-6} alkyl group, (6) a group represented by the formula:




(wherein V^{c21} is $-CO-$ or a methylene group; V^{c22} and V^{c23} are each independently a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C_{6-14} aryl group), or (7) a group represented by the formula $-V^{c21}-O-V^{c22}$ (wherein V^{c21} and V^{c22} have the same definitions as V^{c21} and V^{c22} above); R^{c12} is a hydrogen atom, an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{3-8} alicyclic hydrocarbon group; and R^{c11} is a group represented by the formula $-V^{c11}-V^{c12}-V^{c13}$ (wherein V^{c11} is a single bond, an oxygen atom, an optionally substituted benzene ring, an optionally substituted 5- to 14-membered aromatic heterocyclic group or $-CO-$; V^{c12} is a single bond, an oxygen atom or an optionally substituted C_{1-6} alkylene group; and V^{c13} is (1) an optionally substituted C_{1-6} alkyl group, (2) an optionally substituted C_{2-6} alkenyl group, (3) an optionally substituted C_{2-6} alkynyl group, (4) an optionally substituted C_{3-8} alicyclic hydrocarbon group, (5) a hydroxyl group, (6) a carboxyl group, (7) an optionally substituted C_{2-7} alkoxy-carbonyl group, (8) an optionally substituted 5- to 14-membered heterocyclic group, (9) an optionally substituted 5- to 14-membered aromatic heterocyclic group, (10) an optionally substituted C_{6-14} aryl group, (11) a group represented by the formula $-NR^{c21}R^{c22}$ (wherein R^{c21} and R^{c22} are each independently a hydrogen atom or an optionally substituted C_{1-6} alkyl group), or (12) a hydrogen atom)].


11. A compound represented by the following general formula:



[wherein R^1 , R^2 and Z^{12} have the same definitions as R^1 , R^2 and Z^{12} in claim 2, but Z^{12} is not a pyrazolyl group; Y^{a1} is a group represented by the formula:




(wherein W^{31} and W^{32} are each independently an optionally substituted carbon atom or a nitrogen atom; R^{300} and R^{301} are each independently a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{1-6} alkoxy group, an optionally substituted C_{2-7} alkoxycarbonyl group, a formyl group, a group represented by the formula



(wherein V^{300} and V^{301} are each independently a hydrogen atom or an optionally substituted C_{1-6} alkyl group), or an optionally substituted C_{2-7} acyl group); and R^{a11} and R^{a12} have the same definitions as R^{a11} and R^{a12} in claim 7, with the exception of the following compounds (1) and (2): (1) a compound wherein R^{a12} is a group represented by the formula:



(wherein V^{a12} and V^{a13} have the same definitions as V^{a12} and V^{a13} in claim 7), R^1 and R^2 are hydrogen atoms and Z^{12} is a C_{6-14} aryl group, a 6- to 14-membered heterocyclic group or a 6- to 14-membered aromatic heterocyclic group; (2) a compound wherein R^{a12} is a group selected from the group consisting of the formulas:



(wherein V^{a11} , V^{a12} , V^{a13} and V^{a14} have the same definitions as V^{a11} , V^{a12} , V^{a13} and V^{a14} in claim 7), R^2 is a hydrogen atom and Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a 5- to 14-membered aromatic heterocyclic group, (d) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (e) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (f) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (g) a C_{3-8} alicyclic hydrocarbon group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group], a salt thereof or a hydrate of the foregoing.

12. A compound according to claim 11, a salt of the compound or a hydrate of the foregoing, wherein R^{a11} is a methyl group, a 2-methoxyethyl group or a group represented by the formula:



20

- 25




35

- 40





50






(wherein Va^{15} is an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group or an optionally substituted C_{3-8} alicyclic hydrocarbon group, and Va^{11} , Va^{12} , Va^{13} and Va^{14} have the same definitions as Va^{11} , Va^{12} , Va^{13} and Va^{14} in claim 7); R^{300} and R^{301} have the same definitions as R^{300} and R^{301} in claim 11; and Ra^{11} has the same definition as Ra^{11} in claim 7, with the exception of a compound wherein Ra^{120} is a group selected from the group consisting of the formulas:




(wherein Va^{11} , Va^{12} , Va^{13} and Va^{14} have the same definitions as Va^{11} , Va^{12} , Va^{13} and Va^{14} in claim 7, and Va^{15} is as defined above), and Z^{21} is (a) a C_{3-8} alicyclic hydrocarbon group, (b) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (c) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (d) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group], a salt thereof or a hydrate of the foregoing.


17. A compound represented by the following general formula:



[wherein Z^{22} is an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group; R^{300} and R^{301} have the same definitions as R^{300} and R^{301} in claim 11; Vd^{13} is a group selected from the group consisting of the formulas:




(wherein Va^{12} and Va^{13} have the same definitions as Va^{12} and Va^{13} in claim 7); Vd^{11} is an optionally substituted C_{1-6} alkylene group or a group represented by the formula:



; and V^{d12} is (1) a group represented by the formula $-NR^{d11}R^{d12}$ (wherein R^{d11} and R^{d12} are each a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group), or (2) an optionally substituted 5- to 14-membered heterocyclic group], a salt thereof or a hydrate of the foregoing.


18. A compound represented by the following general formula:



[wherein R^1 , R^2 and Z^{12} have the same definitions as R^1 , R^2 and Z^{12} in claim 2; W^{11} is an optionally substituted carbon atom or a nitrogen atom; R^{300} has the same definition as R^{300} in claim 11; R^{a11} has the same definition as R^{11} in claim 7; and R^{a120} has the same definition as R^{a120} in claim 16, with the exception of the following compounds (1) and (2): (1) a compound wherein R^{a120} is a group represented by the formula:




(wherein Va^{12} and Va^{13} have the same definitions as Va^{12} and Va^{13} in claim 7), R^1 and R^2 are hydrogen atoms and Z^{12} is a C_{6-14} aryl group, a 6- to 14-membered heterocyclic group or a 6- to 14-membered aromatic heterocyclic group; (2) a compound wherein R^{a120} is a group selected from the group consisting of the formulas:




(wherein Va^{11} , Va^{12} , Va^{13} and Va^{14} have the same definitions as Va^{11} , Va^{12} , Va^{13} and Va^{14} in claim 7, and Va^{15} has the same definition as Va^{15} in claim 16), R^2 is a hydrogen atom and Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a 5- to 14-membered aromatic heterocyclic group, (d) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (e) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (f) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (g) a C_{3-8} alicyclic hydrocarbon group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group], a salt thereof or a hydrate of the foregoing.

19. A compound represented by the following general formula:




[wherein W^{41} and W are each independently an optionally substituted carbon atom or a nitrogen atom, but W^{41} and W are not both nitrogen atoms; X^{y1} is an optionally substituted group selected from the group consisting of the following formulas:




(wherein Z^{12} has the same definition as Z^{12} in claim 2, and W^{11} is an optionally substituted carbon atom or a nitrogen atom); and A^{b11} has the same definition as A^{b11} in claim 9], a salt thereof or a hydrate of the foregoing.


20. A compound represented by the following general formula:



[wherein R^{c13} has the same definition as R^{c13} in claim 10; X^{y2} is an optionally substituted group selected from the group consisting of the following formulas:




(wherein Z^{12} , R^1 and R^2 have the same definitions as Z^{12} , R^1 and R^2 in claim 2, and W^{11} is an optionally substituted carbon atom or a nitrogen atom); and R^{c11} and R^{c12} have the same definitions as R^{c11} and R^{c12} in claim 10, with the exception of the following compounds (1) and (2): (1) a compound wherein R^1 and R^2 are hydrogen atoms and Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a C_{1-6} alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group, a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (d) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (e) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (f) a C_{3-8} alicyclic hydrocarbon group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group; (2) a compound wherein X^{y2} is a group represented by the formula:




(wherein Z^{12} is (a) a C_{6-14} aryl group, (b) a 5- to 14-membered heterocyclic group, (c) a 5- to 14-membered aromatic heterocyclic group, (d) a C_{1-6} alkyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (e) a C_{2-6} alkenyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, (f) a C_{2-6} alkynyl group substituted with a 5- to 10-membered heterocyclic group or a C_{5-10} alicyclic hydrocarbon group, or (g) a C_{3-8} alicyclic hydrocarbon group)],
a salt thereof or a hydrate of the foregoing.

21. A compound according to claim 10 or 20, a salt of the compound or a hydrate of the foregoing, wherein R^{c11} is a group represented by the formula:




[wherein V^{f11} is a single bond, an optionally substituted C_{1-6} alkylene group or a group represented by the formula:



; and V^{f12} is (1) a hydrogen atom, (2) a hydroxyl group, (3) an optionally substituted 5- to 14-membered heterocyclic group, (4) an optionally substituted 5- to 14-membered aromatic heterocyclic group, (5) an optionally substituted C_{6-14} aryl group or (6) a group represented by the formula $-NR^{f21}R^{f22}$ (wherein R^{f21} and R^{f22} are each independently a hydrogen atom or an optionally substituted C_{1-6} alkyl group)].

22. A compound represented by the following general formula:



[wherein X has the same definition as X in claim 2; R^{300} and R^{301} have the same definitions as R^{300} and R^{301} in claim 11; and A^{31} is a group selected from the group consisting of the formulas:



15



25

30



40



55

366

N-(4-(6-cyano-7-(2-(1,2,3-triazol-2-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-(1,2,3-triazol-1-yl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(2,4-difluorophenyl) urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(1,3-thiazol-2-yl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-cyanophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(2-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylurea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(1,3-thiazol-2-yl) urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-cyclopropylurea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-cyclopropylmethylurea, N-(4-(6-cyano-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yloxy)-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyloxy)phenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(3-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(3-(1-(4-ethylpiperazino))propoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(3-cyanopropoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-(methylsulfonyl)ethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-(methylsulfonyl)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-phenylurea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(3-methoxycarbonylpropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(3-carboxypropoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(2-(2-hydroxyethoxy)ethoxy)-4-quinolyl)oxyphenyl)-N'-(4-methoxyphenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyloxy)phenyl)-N'-(3-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(3-(methylsulfonyl)phenyl)urea, N-(4-(6-cyano-7-(3-(diethylamino)propoxy)-4-quinolyloxy)phenyl)-N'-phenylurea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-phenylurea, N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N'-(2-oxo-1,2,3,4-tetrahydro-6-quinolyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxyphenyl)-N'-(3-acetamidophenyl)urea, N-(4-(6-cyano-7-benzoyloxy-4-quinolyl)oxy-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea, N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-phenylurea, 4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 7-(2-methoxyethoxy)-4-(4-((1,3-thiazol-2-ylamino)carbonyl)aminophenoxy)-6-quinolinecarboxamide, 4-(4-((anilinocarbonyl)amino)-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 7-methoxy-4-(4-((1,3-thiazol-2-ylamino)carbonyl)aminophenoxy)-6-quinolinecarboxamide, 4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(5-((anilinocarbonyl)amino)-2-pyridyloxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-(anilinocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(4-(anilinocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(4-((2,4-difluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(4-((4-fluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 7-(2-methoxyethoxy)-4-(4-((1,3-thiazol-2-ylamino)carbonyl)amino-3-fluorophenoxy)-6-quinolinecarboxamide and 4-(4-((4-fluoroanilino)carbonyl)amino-3-fluorophenoxy)-7-methoxy-6-quinolinecarboxamide.

25. A compound according to claim 1 or 2, a pharmacologically acceptable salt of the compound or a hydrate of the foregoing, wherein said compound is a compound selected from N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N'-(4-fluorophenyl)urea, N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N'-cyclopropylurea, N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(4-fluorophenyl)urea, N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N'-(4-fluorophenyl)urea, N-[4-[6-cyano-7-(2-hydroxy-3-pyrrolidin-1-yl-propoxy)-quinolin-4-yloxy]-2-methylphenyl]-N'-cyclopropyl-urea, 4-(4-(4-fluoroanilino)carbonyl)-4-methylaminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-(2-pyridyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, 6-carbamoyl-4-(1-ethylcarbamoyl-1H-indol-5-yloxy)-7-methoxyquinoline, 6-carbamoyl-7-methoxy-4-(1-propyl-


carbamoyl-1H-indol-5-yloxy)quinoline, 6-carbamoyl-7-methoxy-4-[1-(1-methyl)ethylcarbamoyl-1H-indol-5-yloxy]quinoline, N4-(4-{4-[(anilino)carbonyl]amino}-3-chlorophenoxy)-2-pyridyl)-1-methyl-4-piperidinecarboxamide, N1-phenyl-3-chloro-5-[(2-{[(1-methyl-4-piperidyl)carbonyl]amino}-4-pyridyl)oxy]-1H-1-indolecarboxamide, N4-[4-(3-chloro-4-{[(4-fluoroanilino)carbonyl]amino}phenoxy)-2-pyridyl)-1-methyl-4-piperidinecarboxamide, 1-(2-chloro-4-{6-[4-(2-diethylaminoethoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}phenyl)-3-cyclopropylurea, 1-(2-chloro-4-[6-[4-((2R)-2-hydroxy-3-diethylaminopropoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-phenyl)-3-cyclopropylurea, 1-(2-chloro-4-[6-[4-((2R)-2-hydroxy-3-pyrrolidinopropoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-phenyl)-3-cyclopropylurea and 1-(2-chloro-4-[6-[4-(2-diethylaminopropoxy)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenyl)-3-cyclopropylurea.

26. A compound according to claim 1 or 2, a pharmacologically acceptable salt of the compound or a hydrate of the foregoing, wherein said compound is a compound selected from 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide.


27. A medicament comprising as an active ingredient, a compound according to any one of claims 1 to 6, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.

28. An angiogenesis inhibiting activity-based medicament comprising as an active ingredient, a compound according to any one of claims 1 to 6, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.

29. A pharmaceutical composition comprising a compound represented by the general formula:



[wherein A is an optionally substituted 5- to 14-membered aromatic heterocyclic group; X is an oxygen atom, a sulfur atom, -SO- or -SO₂; Y is an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C₁₋₆ alkylene group; E is a single bond or -NR²; R¹ and R² are each independently a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and Z is a group represented by the formula -Z¹¹-Z¹² (wherein Z¹¹ is a single bond, an oxygen atom, a sulfur atom, -CO-, -SO₂- or an optionally substituted C₁₋₆ alkylene group and Z¹² is a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ alicyclic hydrocarbon group, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or a group represented by the formula:



(wherein Z³¹, Z³³ and Z³⁴ are each independently a methylene group, -CO-, -NH- or -O-, and Z³² is a single bond, a methylene group, -CO-, -NH- or -O-), with the proviso that A may be optionally substituted with 1 to 6 groups,

each selected from the group consisting of (1) a cyano group, (2) a halogen atom, (3) a nitro group and (4) the formula $-V^{X1}-V^{X2}-V^{X22}-V^{X3}$ (wherein V^{X1} , V^{X2} and V^{X22} are each independently a single bond, an oxygen atom, a sulfur atom, $-\text{CO}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{NR}^{X1}-$, $-\text{CONR}^{X1}-$, $-\text{NR}^{X1}\text{CO}-$, $-\text{SO}_2\text{NR}^{X1}-$, $-\text{NR}^{X1}\text{SO}_2-$, $-\text{O}-\text{CO}-$, $-\text{C}(\text{O})\text{O}-$, $-\text{NR}^{X1}\text{C}(\text{O})\text{O}-$, $-\text{NR}^{X1}\text{C}(\text{O})\text{NR}^{X2}-$, $-\text{O}-\text{C}(\text{O})\text{NR}^{X1}-$, $-\text{O}-\text{C}(\text{O})\text{O}-$, an optionally substituted C_{1-6} alkylene group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and V^{X3} , R^{X1} and R^{X2} are each independently a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group, an optionally substituted C_{2-6} alkynyl group, an optionally substituted C_{3-8} alicyclic hydrocarbon group, an optionally substituted C_{6-14} aryl group, an optionally substituted 5- to 14-membered heterocyclic group, an optionally substituted 5- to 14-membered aromatic heterocyclic group or an optionally substituted C_{1-6} alkoxy group)], a pharmacologically acceptable salt thereof or a hydrate of the foregoing, together with a pharmacologically acceptable carrier.

30. A prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective, comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
31. An angiogenesis inhibitor comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
32. An antitumor agent comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
33. A therapeutic agent for angioma comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
34. A cancer metastasis inhibitor comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
35. A therapeutic agent for retinal neovascularization or diabetic retinopathy comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
36. A therapeutic agent for an inflammatory disease comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
37. A therapeutic agent for an inflammatory disease selected from deformant arthritis, rheumatoid arthritis, psoriasis and delayed hypersensitivity reaction comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
38. A therapeutic agent for atherosclerosis comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
39. A therapeutic agent for a pancreatic cancer, a gastric cancer, a colon cancer, a breast cancer, a prostate cancer, a lung cancer, a renal cancer, a brain tumor, a blood cancer or an ovarian cancer comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
40. An angiogenesis inhibition-based antitumor agent comprising as an active ingredient, a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
41. A prophylactic or therapeutic method for a disease for which angiogenesis inhibition is effective, comprising administering to a patient, a pharmacologically effective dose of a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing.
42. The use of a compound according to claim 1 or 2, a pharmacologically acceptable salt thereof or a hydrate of the foregoing for the manufacture of a prophylactic or a therapeutic agent for a disease for which angiogenesis inhibition is effective.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09221

A. CLASSIFICATION OF SUBJECT MATTER		
Int.Cl. ⁷ C07D213/74, 75, 215/48, 239/47, 401/12, 14, 413/12, 405/12, 409/12, 413/12, 417/12, 14, 471/14, 491/048, 495/04, A61K31/4709, 47, 5377, 496, 4545, 519, 44, 437, 4439, 505, A61P9/00, 10, 35/00, 27/02, 29/00, 19/02		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Int.Cl. ⁷ C07D213/00-75, 215/00-48, 239/00-47, 401/00-14, 413/00-12, 405/00-12, 409/00-12, 413/00-12, 417/00-14, 471/00-14, 491/00-048, 495/00-04, A61K31/00-5377, A61P9/00-10, 35/00, 27/00-02, 29/00, 19/00-02		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) REGISTRY (STN), CAPLUS (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 11-158149 A (Kirin Brewery Company, Limited), 15 June, 1999 (15.06.99), Full text (Family: none)	1-5, 27-40, 42
A		6-26
X	WO 00/43366 A1 (Kirin Brewery Company, Limited), 27 July, 2000 (27.07.00), Full text (Family: none)	1-5, 27-40, 42
A		6-26
X, Y	WO 97/17329 A1 (Kirin Brewery Company, Limited), 15 May, 1997 (15.05.97), Full text	1-5, 27-40, 42
A	& EP 860433 A1 & US 6143764 A	6-26
PX, PY	WO 01/47931 A1 (Kyowa Hakko Kogyo Co., Ltd.), 05 July, 2001 (05.07.01), Full text (Family: none)	1-5, 27-40, 42
PA		6-26
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 21 December, 2001 (21.12.01)		Date of mailing of the international search report 15 January, 2002 (15.01.02)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09221

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX, PY	WO 01/47890 A1 (Kirin Brewery Company, Limited), 05 July, 2001 (05.07.01), Full text (Family: none)	1-5, 27-40, 42
PA		6-26
Y	SPACEY, G. D., UINGS, I. J., SLATER, M., HIRST, S., BONSER, R. W., "Indolocarbazoles: Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Autophosphorylation", Biochemical Pharmacology, (1998), Vol.55, No.3, pages 261 to 271	1-5, 27-40, 42
A		6-26
Y	FOLKMAN, A. J., "New Perspectives in Clinical Oncology from Angiogenesis Research", European Journal of Cancer, (1996), Vol.32, No.14, pages 2534 to 2539	1-5, 27-40, 42
A		6-26
T	DEPLANQUE, G., HARRIS, A. L., "Anti-angiogenic agents: clinical trial design and therapies in development", European Journal of Cancer, August, 2000, Vol. 36, No.13, pages 1713 to 1724	1-40, 42
X	KOTVA, R., CERNY, A., SEMONSKY, M., "Substances with antineoplastic activity. LIII. N. (.delta.- (4-pyrrolo [2,3-d]pyrimidinylthio)valeryl) amino acids and analogous derivatives of di- and triglycine", Czech. Chem. Commun., (1973), Vol.38, No.5, pages 1438 to 1444 entire description; especially, from page 1440, compound II	1-3, 10, 27-34, 39, 40, 42
A		9-26
X, Y	WO 98/37079 A1 (Berlex Laboratories, Inc., Pharmacoepia, Inc., et al.), 27 August, 1998 (27.08.98), entire description; especially, Claims; description, pages 46 to 49, etc.	1-4, 9, 27-40, 42
A	& EP 968206 A1	9-26
Y	BUSSOLINO, F., ALBINI, A., CAMUSSI, G., PRESTA, M., VIGLIETTO, G., ZICHE, M., PERSICO, G., "Role of Soluble Mediators in Angiogenesis", European Journal of Cancer, (1996), Vol.32, No.14, pages 2401 to 2412	1-40, 42
X	WANG, F., SCHWABACHER, A. W., "A convenient set of bidentate pyridine ligands for combinatorial synthesis", Tetrahedron Letters, (1999), Vol.40, No.26, pages 4779 to 4782; especially, pages 4780, 4781, chemical compounds in series c	1-3, 9
X	US 4764454 A (Fuji Photo Film Co., Ltd.), 16 August, 1988 (16.08.88), especially, columns 15, 16, chemical compound (17) JP 62-168137 A2	1-3, 9

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09221

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 41
because they relate to subject matter not required to be searched by this Authority, namely:

Claim 41 relates to a method for treatment of the human body by therapy which does not require an international search in accordance with Rule 39.1(iv) of the Regulations under the PCT.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

(See extra sheet.)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☒ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09221

Continuation of Box No. II of continuation of first sheet (1)

This international application relates to compounds having neovascularization inhibiting effect and use of the same.

As a prior art relating to neovascularization inhibitors, JP, 11-158149, A, the laying-open of which has been carried out before the priority date of this international application, discloses quinolyloxyphenyl urea derivatives having neo-vascularization inhibiting effect. Thus, there have been publicly known compounds characterized by both neo-vascularization inhibiting effect and a structure bearing a two rings connected by an ether linkage and an amide analogue group. In the sight of the prior art, therefore, such characteristics are not special technical features linking compounds of claim 1 together.

This International Searching Authority finds that this international application relates to the following three inventions, with the result of partial international search about the group (1) being attached to this order:

1. a group of inventions relating to compounds set forth in claims 7, 8, and 11-18 and use of the same,
2. a group of inventions relating to compounds set forth in claims 9 and 19 and use of the same, and
3. a group of inventions relating to compounds set forth in claims 10, 20 and 21 and use of the same.

<About the subject of prior art search>

Although compounds are represented by the general formula in claims 1-6, most of the constituent moieties of the formula are represented by variable groups including many practical choices, and only some of the compounds set forth in these claims are supported by the description in the sense of Article 6 of the PCT and disclosed in the sense of Article 5 of the PCT to such an extent that a meaningful international search can be carried out. The same applies to claims 27-40 and 42 relating to use of the compounds.

In this international search report, therefore, prior art search has been made only about compounds which are supported by the description in the sense of Article 6 of the PCT and disclosed in the sense of Article 5 of the PCT to such an extent that a meaningful search can be carried out, that is, compounds wherein A is one of the groups set forth in claims 7-10, and the results of the search are given. The same applies to use of the compounds.